%PDF-1.6%‚„œ”
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 8364/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-05-21T06:39:33-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-05-21T06:39:34-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-05-21T06:39:34-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.4 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:b7d057fa-d028-b949-a375-afe06dd56743</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:6d344d5b-79aa-4918-a565-1501a7a8fd1f</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:27ecfd10-d87b-45c2-8283-f74195d413a8</stRef:instanceID>
            <stRef:documentID>xmp.did:c7c909c9-c228-44e9-82ad-1781f5cf7544</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.4 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-05-21T06:39:33-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2162960759</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2162960759</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1117836794</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1117836794</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.010</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 11/Kids[14 0 R 15 0 R]/Type/Pages>>endobj14 0 obj<</Count 5/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R]/Parent 3 0 R/Type/Pages>>endobj15 0 obj<</Count 6/Kids[10 0 R 11 0 R 12 0 R 13 0 R 16 0 R 17 0 R]/Parent 3 0 R/Type/Pages>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 18 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</T1_0 21 0 R/T1_1 22 0 R/T1_2 23 0 R/T1_3 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 837>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 26 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 21 0 R/T1_1 24 0 R/T1_2 22 0 R/T1_3 23 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 889>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 28 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 27 0 R/GS2 20 0 R>>/Font<</T1_0 23 0 R/T1_1 21 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 1046>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 29 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 21 0 R/T1_1 23 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 34588>>/PageWidthList<</0 612.0>>>>>>>>endobj16 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</C2_0 31 0 R/TT0 32 0 R/TT1 33 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 34 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -345.646 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 15792>>/PageWidthList<</0 612.0>>>>>>>>endobj17 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 35 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R>>/Font<</C2_0 31 0 R/C2_1 36 0 R/TT0 33 0 R/TT1 32 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 37 0 R>>/XObject<</Fm0 34 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -345.646 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 11429>>/PageWidthList<</0 612.0>>>>>>>>endobj35 0 obj<</Length 22978>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 359.6458 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 311.7658 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 69.8567 714.5277 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.004 Tc 0.004 Tw 1.8 0 Td
[<0056005800470047004800510003>-129 <005100580050004500510048005600560003>-128.9 <005200550003>-129 <005A00480044004E00510048005600560003>-128.9 <0057004B004400570003>-129 <0044005500480003>-129 <004500520057004B0003>-128.9 <0056004B005200550057001000570048005500500003>-128.9 <005200550003>-128.9 <0046005200510057004C0051005800480003>-128.9 <005700520003>-128.9 <004B004400530053004800510003>-128.9 <00520059004800550003>-128.9 <00440003>-128.9 <004F00520051004A0003>-128.9 <005300480055004C005200470003>-128.9 <005200490003>-129 <0057004C00500048000F>-3.9 <0003>]TJ
/TT0 1 Tf
-0.018 Tc 0.055 Tw 0 -1.05 Td
[(especially on one side of)0.5 ( t)0.5 (he body)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(severe headache or conf)0.5 (usion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0056005800470047004800510003>-55.1 <0053005500520045004F0048005000560003>-55.1 <005A004C0057>0.5 <004B0003>-55 <0059004C0056004C00520051000F>0.5 <0003>-55.1 <00560053004800480046004B000F>0.5 <0003>-55.1 <005200550003>-55.1 <00450044004F00440051004600480003>-55.1 <000B005600580046004B0003>-55.1 <004400560003>-55 <0057>0.5 <0055005200580045004F00480003>-55.1 <0056005300480044004E004C0051004A000F>0.5 <0003>-55.1 <0047004C0049>0.5 <00BF00460058004F0057005C0003>-55.1 <005A0044004F004E004C0051004A000F0003>-55 <005200550003>-55.1 <0047004C005D005D004C0051004800560056000C>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.014 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/C2_1 1 Tf
-0.008 Tc 0.008 Tw 1.8 0 Td
[<002B004C004A004B0003>-107.4 <0045004F0052005200470003>-107.5 <0053005500480056005600580055004800110BD8>]TJ
/C2_0 1 Tf
[<0BD80003>-107.5 <003500280025002F0032003D003C002F>36.9 <0003>-107.4 <00500044005C0003>-107.4 <004600440058005600480003>-107.5 <004400510003>-107.4 <004C00510046005500480044005600480003>-107.4 <004C00510003>-107.4 <005C0052005800550003>-107.4 <0045004F0052005200470003>-107.4 <0053005500480056005600580055004800110003>-89.3 <003C>91.7 <0052005800550003>-107.5 <004B00480044004F0057004B00460044005500480003>-107.4 <0053005500520059004C0047004800550003>-107.4 <005A004C004F004F>-8.1 <0003>]TJ
/TT0 1 Tf
-0.012 Tc 0.086 Tw 0 -1.05 Td
[(check )0.5 (your )0.5 (blood )0.6 (pressure )0.6 (bef)0.5 (ore )0.5 (you )0.5 (receive )0.5 (your )0.6 (REBLO)0.5 (ZYL)37.2 ( )0.6 (dose.)0.5 ( )18.6 (Y)92 (our )0.5 (healthcare )0.6 (provider )0.5 (may )0.5 (prescribe )0.5 (you)-12.1 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.05 Td
[(medicine t)0.5 (o t)0.5 (reat)0.5 ( high blood pressure or increase t)0.5 (he dose of)0.5 ( medicine you already t)0.5 (ake t)0.5 (o t)0.5 (reat)0.5 ( high blood pressure)-18.2 ( )]TJ
0 -1.05 Td
[(if)0.5 ( you develop high blood pressure during t)0.5 (reat)0.5 (ment)0.5 ( with REBLO)0.5 (Z)0.5 (YL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.006 Tc 0.115 Tw 1.8 0 Td
[(Extramed)0.5 (u)0.5 (l)0.5 (l)0.5 (ary Hemato)0.5 (p)0.5 (o)0.5 (i)0.5 (eti)0.5 (c \(EMH\) Masses.)]TJ
/C2_0 1 Tf
0.006 Tw 21.81 0 Td
[<0BD80003>-115 <00280030002B0003>-115.1 <0050004400560056004800560003>-115.1 <004B0044005900480003>-115 <004B00440053005300480051004800470003>-115 <004C00510003>-115.1 <0053004800520053004F00480003>-115.1 <005A004C0057>0.5 <004B0003>-115.1 <00450048005700440003>-115.1 <0057>0.6 <004B0044004F00440056005600480050004C0044>-6.1 <0003>]TJ
/TT0 1 Tf
-0.015 Tc 0.072 Tw -21.81 -1.05 Td
[(during )0.5 (treatment )0.6 (with )0.6 (REBLOZYL. )18.6 (Y)91.9 (ou )0.5 (may )0.6 (have )0.6 (a )0.6 (higher )0.6 (risk )0.5 (for )0.6 (developing )0.6 (EMH )0.5 (masses )0.6 (if )0.5 (you )0.6 (have )0.6 (a )0.5 (history )0.6 (of)-14.8 ( )]TJ
/C2_0 1 Tf
-0.02 Tc 0.02 Tw 0 -1.05 Td
[<0028>0.5 <0030>0.5 <002B0003>-41 <005000440056>0.5 <0056>0.5 <00480056>0.5 <000F>0.7 <0003>-41 <004B00440059>0.5 <00480003>-41 <004B004400470003>-41.1 <005C>0.5 <005200580055>0.5 <0003>-41.1 <0056>0.5 <0053004F0048004800510003>-41 <0055>0.5 <00480050>0.5 <00520059>0.5 <00480047000F>0.6 <0003>-41 <004B0044005900480003>-41.1 <005200550003>-41 <004B0044005900480003>-41 <004B004400470003>-41 <004400510003>-41 <00480051004F00440055>0.5 <004A004800470003>-41 <0056>0.5 <0053004F0048004800510003>-41 <00520055>0.5 <0003>-41.1 <004F004C0059>0.5 <00480055>55.6 <000F>0.7 <0003>-41 <00520055>0.5 <0003>-41.1 <004B00440059>0.5 <00480003>-41 <004F0052005A0003>-41 <004B004800500052004A004F00520045004C0051>-20.2 <0003>]TJ
/TT0 1 Tf
-0.011 Tc 0.093 Tw 0 -1.05 Td
[(levels. )18 (Y)91.6 (our healthcare provider will monitor you before you start and during tre\atment with REBLOZYL. Call your)-11 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.05 Td
[(healt)0.5 (hcare provider or get)0.5 ( medical help right away if)0.5 ( you get)0.5 ( any of)0.5 ( t)0.5 (hese sympt)0.5 (oms:)]TJ
/Span<</ActualText<FEFF2005>>> BDC 
36.553 0 Td
( )Tj
EMC 
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-35.967 -1.338 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(severe pain in t)0.5 (he back)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00510058005000450051004800560056000F>0.5 <0003>-55.1 <005A00480044004E0051004800560056000F0003>-55 <005200550003>-55.1 <004F0052005600560003>-55.1 <00520049>0.5 <0003>-55.1 <00590052004F005800510057>0.5 <00440055005C0003>-55.1 <00500052005900480050004800510057>0.5 <0003>-55.1 <004C00510003>-55.1 <0049>0.5 <004800480057>0.5 <000F>0.5 <0003>-55.1 <004F0048004A0056000F>0.5 <0003>-55 <004B0044005100470056000F>0.5 <0003>-55.1 <005200550003>-55 <0044005500500056>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.266 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(loss of)0.5 ( bowel and bladder cont)0.5 (rol)]TJ
/TT1 1 Tf
-3.6 -1.41 Td
[(T)0.5 (h)0.5 (e mo)0.5 (st co)0.5 (mmo)0.5 (n si)0.5 (d)0.5 (e effects o)0.5 (f REBL)0.5 (O)0.5 (Z)0.5 (YL)18.5 ( i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (e:)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
2.386 -1.596 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(st)0.5 (omach \(abdominal\) pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004500440046004E000F>0.5 <0003>-55.1 <004D0052004C00510057>0.5 <000F>0.5 <0003>-55.1 <0050005800560046004F0048000F>0.5 <0003>-55 <005200550003>-55.1 <00450052005100480003>-55.1 <00530044004C0051>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(t)0.5 (rouble breat)0.5 (hing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004D0052004C00510057>0.5 <0003>-55.1 <00530044004C0051>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0056005A0048004F004F004C0051004A0003>-55.1 <00520049>0.5 <0003>-55 <005C0052005800550003>-55.1 <004B0044005100470056000F>0.5 <0003>-55 <004F0048004A0056000F>0.5 <0003>-55.1 <005200550003>-55.1 <0049>0.6 <004800480057>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
<0047004C005D005D004C0051004800560056>Tj
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
(high blood pressure)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.886 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(allergic react)0.5 (ions)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.314 -1.448 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(diarrhea)Tj
-0.004 Tc 0.125 Tw -3.6 -1.676 Td
[(RE)0.5 (BLO)0.7 (Z)0.6 (Y)0.5 (L)37.4 ( )0.7 (may)0.5 ( )0.7 (c)0.5 (ause )0.7 (f)0.6 (ert)0.7 (ilit)0.7 (y )0.7 (pr)0.5 (oblem)0.5 (s )0.7 (in )0.7 (f)0.6 (em)0.5 (ales)0.5 (.)0.6 ( )18.7 (T)0.7 (his )0.7 (c)0.5 (ould )0.7 (af)18.7 (f)0.6 (ec)0.5 (t)0.6 ( )0.7 (y)0.5 (our)0.5 ( )0.7 (abilit)0.7 (y)0.5 ( )0.6 (t)0.7 (o )0.7 (becom)0.5 (e )0.7 (pr)0.5 (egnant)0.7 (.)0.6 ( )18.7 (T)111.5 (alk)0.5 ( )0.6 (t)0.7 (o )0.7 (your)-4 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.05 Td
[(healt)0.5 (hcare provider if)0.5 ( t)0.6 (his is a concern f)0.5 (or you.)]TJ
0 -1.446 Td
[(T)0.5 (hese are not)0.5 ( all of)0.6 ( t)0.5 (he possible side ef)18.6 (f)0.5 (ect)0.5 (s of)0.5 ( REBLO)0.5 (Z)0.5 (YL.)]TJ
0 -1.338 Td
[(Call your doct)0.5 (or f)0.5 (or medical advice about)0.5 ( side ef)18.6 (f)0.5 (ect)0.5 (s.)0.5 ( )18 (Y)92.1 (ou may report side ef)18.6 (f)0.5 (ect)0.5 (s t)0.5 (o F)0.5 (DA)55.5 ( at)0.5 ( 1-800-F)0.5 (DA-1088.)]TJ
/TT1 1 Tf
0 -2.4 Td
[(G)0.5 (en)0.5 (eral)0.5 ( i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( ab)0.5 (o)0.5 (u)0.5 (t the safe an)0.5 (d)0.5 ( effecti)0.5 (ve u)0.5 (se o)0.5 (f REBLO)0.5 (Z)0.5 (YL.)]TJ
/C2_0 1 Tf
-0.022 Tc 0.022 Tw 0 -1.338 Td
[<003000480047004C0046004C0051004800560003>-41.3 <0044005500480003>-41.3 <00560052005000480057004C0050004800560003>-41.3 <005300550048005600460055004C0045004800470003>-41.3 <0049005200550003>-41.2 <005300580055005300520056004800560003>-41.3 <00520057004B004800550003>-41.3 <0057004B004400510003>-41.3 <0057004B0052005600480003>-41.3 <004F004C00560057004800470003>-41.2 <004C00510003>-41.3 <00440003>-41.2 <003300440057004C0048005100570003>-41.2 <002C0051004900520055005000440057004C005200510003>-41.3 <004F0048004400C00048005700110003>-23.2 <003C>92 <005200580003>-41.3 <0046004400510003>-41.3 <00440056004E0003>-41.3 <005C005200580055>-22 <0003>]TJ
/TT0 1 Tf
-0.018 Tc 0.055 Tw 0 -1.05 Td
[(healt)0.5 (hcare provider or pharmacist)0.5 ( f)0.5 (or inf)0.5 (ormat)0.5 (ion about)0.5 ( REBLO)0.5 (Z)0.5 (YL)37.3 ( t)0.5 (hat)0.5 ( is writ)0.5 (t)0.5 (en f)0.5 (or healt)0.5 (h prof)0.5 (essionals.)]TJ
/TT1 1 Tf
0 -2.4 Td
[(W)0.5 (h)0.5 (at are th)0.5 (e i)0.5 (ng)0.5 (red)0.5 (i)0.5 (en)0.5 (ts in)0.6 ( REBL)0.5 (O)0.5 (Z)0.5 (YL?)]TJ
/C2_1 1 Tf
0.018 Tw 0 -1.446 Td
[<002400460057004C>0.5 <005900480003>-55.1 <004C>0.5 <0051>0.5 <004A>0.5 <005500480047>0.5 <004C00480051>0.5 <0057001D0BD8>]TJ
/TT0 1 Tf
0.055 Tw [( luspat)0.5 (ercept)0.5 (-aamt)]TJ
/C2_1 1 Tf
0.018 Tw 0 -1.446 Td
[<002C>0.5 <0051>0.5 <004400460057004C>0.5 <005900480003>-55.1 <004C>0.5 <0051>0.5 <004A>0.5 <005500480047>0.5 <004C00480051>0.5 <00570056001D0BD8>]TJ
/C2_0 1 Tf
[<0003>-55.1 <0046004C0057>0.5 <0055004C00460003>-55.1 <00440046004C00470003>-55.1 <0050005200510052004B005C0047005500440057>0.5 <0048000F>0.5 <0003>-55 <00530052004F005C005600520055004500440057>0.5 <00480003>-55.1 <001B0013000F>0.5 <0003>-55 <0056005800460055005200560048000F>0.5 <0003>-55.1 <0044005100470003>-55.1 <0057>0.5 <0055004C0010005600520047004C005800500003>-55.1 <0046004C0057>0.5 <005500440057>0.5 <00480003>-55.1 <0047004C004B005C0047005500440057>0.5 <00480011>]TJ
0 -1.446 Td
[<0029>0.5 <005200550003>-55.1 <00500052005500480003>-55 <004C00510049>0.5 <00520055005000440057>0.5 <004C00520051000F>0.5 <0003>-55.1 <004A00520003>-55.1 <0057>0.5 <00520003>-55.1 <005A005A005A>55.4 <0011>0.5 <003500280025002F0032>0.5 <003D>0.5 <003C002F0011>0.5 <0046005200500003>-55.1 <005200550003>-55.1 <00460044004F004F0003>-55.1 <00140010001B001B001B0010001700150016001000180017001600190011>]TJ
9 0 0 9 46 235.7858 Tm
[<00300044005100580049>0.5 <004400460057>0.5 <00580055004800470003>-55.1 <0045005C001D0003>-55 <00260048004F004A0048005100480003>-55.1 <00260052005500530052005500440057>0.5 <004C00520051000F0003>-55 <00440003>-55.1 <00250055004C00560057>0.5 <0052004F00100030005C0048005500560003>-55.1 <003600540058004C004500450003>-55.1 <002600520050005300440051005C>74.6 <000F>0.5 <0003>-55.1 <001B00190003>-55.1 <0030005200550055004C005600030024>18.4 <00590048005100580048000F>0.5 <0003>-55.1 <0036005800500050004C0057>0.5 <000F>0.5 <0003>-55 <0031002D0003>-55 <0013001A001C00130014>]TJ
/TT0 1 Tf
0 -1.491 Td
[(REBLO)0.5 (Z)0.5 (YL)]TJ
0 Tc 0 Tw 6.3 0 0 6.3 91.697 225.3128 Tm
(\256)Tj
/C2_0 1 Tf
-0.018 Tc 0.018 Tw 9 0 0 9 96.2234 222.3658 Tm
[<0003>-55.1 <004C00560003>-55 <00440003>-55 <00550048004A004C00560057>0.5 <00480055004800470003>-55.1 <0057>0.5 <0055004400470048005000440055004E0003>-55.1 <00520049>0.5 <0003>-55 <00260048004F004A0048005100480003>-55.1 <00260052005500530052005500440057>0.5 <004C00520051000F>0.5 <0003>-55 <00440003>-55 <00250055004C00560057>0.5 <0052004F00100030005C0048005500560003>-55.1 <003600540058004C004500450003>-55.1 <002600520050005300440051005C>74.5 <0011>]TJ
-5.58 -1.231 Td
[<00350028002500330033002C>0.5 <0003>-55.1 <003900180003>-55.1 <001B0012>0.5 <0015001300150016>]TJ
ET
4 M 
36.5 201.786 539 529.522 re
S
q 1 0 0 1 36 162.6329 cm
0 0 m
540 0 l
S
Q
BT
/TT0 1 Tf
0.055 Tw 9 0 0 9 36 185.7329 Tm
[(T)0.5 (his Pat)0.5 (ient)0.5 ( I)0.5 (nf)0.5 (ormat)0.5 (ion has been approved by t)0.6 (he U.)0.5 (S.)0.5 ( F)0.5 (ood and Drug )55.1 (Administ)0.5 (rat)0.5 (ion.)]TJ
0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -2.111 Td
( )Tj
EMC 
50.568 0 Td
[(Revised:)0.5 ( August)0.5 ( )-55.1 (20)60.2 (23)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-50.568 -1.671 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.018 Tc 0.018 Tw 49.103 0 Td
[<001500130013001A>60.2 <001000380036001000150016001300130017001B00180003>-55.1 <0003>-55 <001300180012>0.5 <00150017>]TJ
ET
/PlacedPDF /MC0 BDC 
q
236.563 132.651 138.874 19.075 re
W n
/GS0 gs
q 1 0 0 1 241.8615 133.0932 cm
0 0 m
-0.143 -0.296 -0.449 -0.487 -0.778 -0.487 c
-0.909 -0.487 -1.036 -0.458 -1.155 -0.401 c
-3.866 0.914 -5.299 3.23 -5.299 6.299 c
-5.299 9.764 l
-5.299 10.241 -4.911 10.628 -4.434 10.628 c
-3.958 10.628 -3.57 10.241 -3.57 9.764 c
-3.57 6.299 l
-3.57 3.905 -2.503 2.175 -0.4 1.155 c
0.028 0.947 0.208 0.429 0 0 c
-2.556 8.032 m
-2.556 7.542 -2.16 7.145 -1.67 7.145 c
-1.18 7.145 -0.783 7.542 -0.783 8.032 c
-0.783 15.104 l
-0.783 15.594 -1.18 15.991 -1.67 15.991 c
-2.16 15.991 -2.556 15.594 -2.556 15.104 c
h
0.187 8.237 m
0.187 7.748 0.584 7.351 1.074 7.351 c
1.564 7.351 1.961 7.748 1.961 8.237 c
1.961 17.746 l
1.961 18.236 1.564 18.632 1.074 18.632 c
0.584 18.632 0.187 18.236 0.187 17.746 c
h
2.93 7.583 m
2.93 7.094 3.327 6.697 3.817 6.697 c
4.307 6.697 4.704 7.094 4.704 7.583 c
4.704 16.119 l
4.704 16.609 4.307 17.006 3.817 17.006 c
3.327 17.006 2.93 16.609 2.93 16.119 c
h
5.674 6.454 m
5.674 5.979 6.059 5.594 6.534 5.594 c
7.009 5.594 7.394 5.979 7.394 6.454 c
7.394 12.222 l
7.394 12.697 7.009 13.082 6.534 13.082 c
6.059 13.082 5.674 12.697 5.674 12.222 c
h
f
Q
q 1 0 0 1 258.4387 141.176 cm
0 0 m
0.002 0.053 l
1.118 0.437 1.809 1.108 1.809 2.307 c
1.809 2.49 l
1.809 3.866 0.691 4.998 -1.59 4.998 c
-4.746 4.998 l
-4.746 -5.739 l
-1.361 -5.739 l
0.856 -5.739 2.378 -4.625 2.378 -2.841 c
2.378 -2.733 l
2.378 -1.341 1.558 -0.322 0 0 c
-3.365 3.786 m
-1.787 3.786 l
-0.283 3.786 0.484 3.216 0.484 2.197 c
0.484 2.089 l
0.484 0.858 -0.581 0.463 -1.979 0.463 c
-3.365 0.463 l
h
0.964 -2.717 m
0.964 -4.046 -0.083 -4.543 -1.61 -4.543 c
-3.365 -4.543 l
-3.365 -0.672 l
-1.586 -0.672 l
-0.082 -0.672 0.964 -1.172 0.964 -2.548 c
h
6.89 2.39 m
7.288 2.39 l
7.288 1.132 l
6.966 1.132 l
5.678 1.132 4.834 0.488 4.834 -1.215 c
4.834 -5.739 l
3.546 -5.739 l
3.546 2.39 l
4.834 2.39 l
4.834 0.933 l
4.896 0.933 l
5.126 1.669 5.724 2.39 6.89 2.39 c
8.435 2.39 1.289 -8.129 re
9.865 4.214 m
9.865 3.586 9.579 3.292 9.079 3.292 c
8.578 3.292 8.293 3.586 8.293 4.214 c
8.293 4.842 8.578 5.154 9.079 5.154 c
9.579 5.154 9.865 4.842 9.865 4.214 c
16.87 -3.5 m
16.87 -5.065 15.705 -5.892 14.002 -5.892 c
12.284 -5.892 11.149 -5.156 11.057 -3.5 c
12.345 -3.5 l
12.391 -4.497 13.128 -4.819 14.002 -4.819 c
14.876 -4.819 15.582 -4.436 15.582 -3.592 c
15.582 -1.613 11.149 -2.978 11.149 0.227 c
11.149 1.562 12.13 2.543 13.925 2.543 c
15.567 2.543 16.656 1.731 16.778 0.151 c
15.49 0.151 l
15.413 1.102 14.754 1.47 13.925 1.47 c
12.99 1.47 12.407 1.04 12.407 0.227 c
12.407 -1.69 16.87 -0.509 16.87 -3.5 c
19.843 2.39 m
21.592 2.39 l
21.592 1.255 l
19.843 1.255 l
19.843 -3.239 l
19.843 -4.42 20.15 -4.665 20.932 -4.665 c
21.147 -4.665 21.392 -4.635 21.592 -4.619 c
21.592 -5.724 l
21.346 -5.77 21.024 -5.801 20.794 -5.801 c
19.199 -5.801 18.555 -5.172 18.555 -3.438 c
18.555 1.255 l
17.189 1.255 l
17.189 2.39 l
18.555 2.39 l
18.555 4.998 l
19.843 4.998 l
h
25.398 2.543 m
23.388 2.543 22.315 1.163 22.315 -1.076 c
22.315 -2.273 l
22.315 -4.512 23.388 -5.892 25.398 -5.892 c
27.407 -5.892 28.481 -4.512 28.481 -2.273 c
28.481 -1.076 l
28.481 1.163 27.407 2.543 25.398 2.543 c
27.177 -2.197 m
27.177 -4.129 26.502 -4.758 25.398 -4.758 c
24.293 -4.758 23.619 -4.129 23.619 -2.197 c
23.619 -1.153 l
23.619 0.78 24.293 1.409 25.398 1.409 c
26.502 1.409 27.177 0.78 27.177 -1.153 c
h
29.843 4.998 1.289 -10.737 re
43.559 4.998 m
45.746 4.998 l
45.746 -5.739 l
44.381 -5.739 l
44.381 3.51 l
44.304 3.51 l
41.558 -3.962 l
39.886 -3.962 l
37.172 3.51 l
37.095 3.51 l
37.095 -5.739 l
35.745 -5.739 l
35.745 4.998 l
38.039 4.998 l
40.745 -2.46 l
40.822 -2.46 l
h
52.011 2.39 m
53.315 2.39 l
49.711 -8.347 l
48.377 -8.347 l
49.282 -5.801 l
46.643 2.39 l
48.008 2.39 l
49.956 -3.945 l
50.018 -3.945 l
h
56.777 2.543 m
54.768 2.543 53.694 1.102 53.694 -1.076 c
53.694 -2.273 l
53.694 -4.512 54.768 -5.892 56.777 -5.892 c
58.388 -5.892 59.339 -5.003 59.661 -3.484 c
58.342 -3.484 l
58.111 -4.42 57.59 -4.758 56.777 -4.758 c
55.673 -4.758 54.997 -4.129 54.997 -2.197 c
54.997 -2.089 l
59.706 -2.089 l
59.706 -1.076 l
59.706 1.102 58.787 2.543 56.777 2.543 c
56.777 1.409 m
57.82 1.409 58.386 0.794 58.401 -1.076 c
54.999 -1.076 l
55.017 0.794 55.688 1.409 56.777 1.409 c
64.483 2.39 m
64.882 2.39 l
64.882 1.132 l
64.56 1.132 l
63.272 1.132 62.428 0.488 62.428 -1.215 c
62.428 -5.739 l
61.14 -5.739 l
61.14 2.39 l
62.428 2.39 l
62.428 0.933 l
62.49 0.933 l
62.719 1.669 63.318 2.39 64.483 2.39 c
71.385 -3.5 m
71.385 -5.065 70.22 -5.892 68.517 -5.892 c
66.799 -5.892 65.664 -5.156 65.572 -3.5 c
66.861 -3.5 l
66.907 -4.497 67.643 -4.819 68.517 -4.819 c
69.391 -4.819 70.097 -4.436 70.097 -3.592 c
70.097 -1.613 65.664 -2.978 65.664 0.227 c
65.664 1.562 66.646 2.543 68.441 2.543 c
70.081 2.543 71.171 1.731 71.294 0.151 c
70.005 0.151 l
69.928 1.102 69.269 1.47 68.441 1.47 c
67.505 1.47 66.922 1.04 66.922 0.227 c
66.922 -1.69 71.385 -0.509 71.385 -3.5 c
81.626 -2.901 m
81.626 -4.819 80.307 -5.892 78.282 -5.892 c
76.38 -5.892 74.815 -4.972 74.616 -2.917 c
76.042 -2.917 l
76.211 -4.129 77.07 -4.696 78.267 -4.696 c
79.632 -4.696 80.245 -3.883 80.245 -2.978 c
80.245 0.074 74.785 -1.69 74.785 2.314 c
74.785 4.031 76.15 5.151 78.052 5.151 c
79.892 5.151 81.426 4.246 81.518 2.13 c
80.092 2.13 l
79.969 3.433 79.141 3.955 78.037 3.955 c
76.732 3.955 76.165 3.187 76.165 2.375 c
76.165 -0.325 81.626 1.27 81.626 -2.901 c
87.447 1.409 m
87.384 1.409 l
87.036 2.126 86.375 2.543 85.53 2.543 c
83.52 2.543 82.6 1.163 82.6 -1.076 c
82.6 -2.273 l
82.6 -4.512 83.52 -5.892 85.53 -5.892 c
86.375 -5.892 87.036 -5.475 87.384 -4.758 c
87.447 -4.758 l
87.447 -5.739 l
87.447 -8.347 l
88.736 -8.347 l
88.736 2.39 l
87.447 2.39 l
h
85.683 -4.758 m
84.579 -4.758 83.904 -4.129 83.904 -2.197 c
83.904 -1.153 l
83.904 0.78 84.579 1.409 85.683 1.409 c
86.788 1.409 87.463 0.78 87.463 -1.153 c
87.463 -2.197 l
87.463 -4.129 86.788 -4.758 85.683 -4.758 c
94.653 2.39 m
95.942 2.39 l
95.942 -5.739 l
94.653 -5.739 l
94.653 -4.696 l
94.592 -4.696 l
94.285 -5.355 93.626 -5.892 92.598 -5.892 c
91.08 -5.892 90.144 -5.033 90.144 -3.116 c
90.144 2.39 l
91.448 2.39 l
91.448 -2.932 l
91.448 -4.236 91.985 -4.804 92.951 -4.804 c
93.887 -4.804 94.653 -4.175 94.653 -2.595 c
h
97.596 2.39 1.288 -8.129 re
103.818 2.543 m
102.961 2.543 102.308 2.126 101.963 1.409 c
101.901 1.409 l
101.901 2.39 l
101.901 4.998 l
100.613 4.998 l
100.613 -5.739 l
101.901 -5.739 l
101.901 -4.758 l
101.963 -4.758 l
102.308 -5.475 102.961 -5.892 103.818 -5.892 c
105.828 -5.892 106.748 -4.512 106.748 -2.273 c
106.748 -1.076 l
106.748 1.163 105.828 2.543 103.818 2.543 c
105.444 -2.197 m
105.444 -4.129 104.769 -4.758 103.665 -4.758 c
102.561 -4.758 101.886 -4.129 101.886 -2.197 c
101.886 -1.153 l
101.886 0.78 102.561 1.409 103.665 1.409 c
104.769 1.409 105.444 0.78 105.444 -1.153 c
h
111.218 2.543 m
110.36 2.543 109.707 2.126 109.362 1.409 c
109.3 1.409 l
109.3 2.39 l
109.3 4.998 l
108.012 4.998 l
108.012 -5.739 l
109.3 -5.739 l
109.3 -4.758 l
109.362 -4.758 l
109.707 -5.475 110.36 -5.892 111.218 -5.892 c
113.227 -5.892 114.147 -4.512 114.147 -2.273 c
114.147 -1.076 l
114.147 1.163 113.227 2.543 111.218 2.543 c
112.844 -2.197 m
112.844 -4.129 112.169 -4.758 111.064 -4.758 c
109.96 -4.758 109.285 -4.129 109.285 -2.197 c
109.285 -1.153 l
109.285 0.78 109.96 1.409 111.064 1.409 c
112.169 1.409 112.844 0.78 112.844 -1.153 c
h
99.027 4.214 m
99.027 3.586 98.741 3.292 98.241 3.292 c
97.74 3.292 97.455 3.586 97.455 4.214 c
97.455 4.842 97.74 5.154 98.241 5.154 c
98.741 5.154 99.027 4.842 99.027 4.214 c
f
Q
q 1 0 0 1 373.928 146.2062 cm
0 0 m
-0.73 0 -1.323 -0.594 -1.323 -1.323 c
-1.323 -2.053 -0.73 -2.646 0 -2.646 c
0.73 -2.646 1.323 -2.053 1.323 -1.323 c
1.323 -0.594 0.73 0 0 0 c
0 -2.832 m
-0.832 -2.832 -1.509 -2.155 -1.509 -1.323 c
-1.509 -0.491 -0.832 0.186 0 0.186 c
0.832 0.186 1.509 -0.491 1.509 -1.323 c
1.509 -2.155 0.832 -2.832 0 -2.832 c
f
Q
q 1 0 0 1 373.6636 144.9224 cm
0 0 m
0.284 0 l
0.377 0 0.45 0.024 0.502 0.07 c
0.554 0.118 0.581 0.182 0.581 0.263 c
0.581 0.348 0.557 0.414 0.508 0.461 c
0.46 0.507 0.387 0.531 0.292 0.533 c
0 0.533 l
h
0.308 -0.223 m
0 -0.223 l
0 -0.834 l
-0.276 -0.834 l
-0.276 0.755 l
0.283 0.755 l
0.466 0.755 0.608 0.714 0.708 0.632 c
0.807 0.55 0.857 0.431 0.857 0.275 c
0.857 0.168 0.831 0.079 0.78 0.008 c
0.729 -0.064 0.657 -0.119 0.566 -0.158 c
0.923 -0.82 l
0.923 -0.834 l
0.627 -0.834 l
h
f
Q
EMC 
Q
endstreamendobj34 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 333/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 20 0 R>>/Font<</TT0 38 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6949 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc 0.018 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.3099 Tm
[(REBL)0.5 (OZ)0.5 (YL)]TJ
0 Tc 0 Tw 7.56 0 0 7.56 97.8239 750.8563 Tm
(\256)Tj
-0.018 Tc 0.055 Tw 12 0 0 12 103.2556 747.3099 Tm
[( \(l)0.6 (usp)0.5 (atercep)0.5 (t-aamt\))]TJ
ET
endstreamendobj38 0 obj<</BaseFont/BADDLA+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 39 0 R/LastChar 174/Subtype/TrueType/ToUnicode 40 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 667 0 0 0 0 0 0 611 0 0 778 0 0 722 0 0 0 0 0 0 667 611 0 0 0 0 0 0 556 0 556 0 556 0 0 0 0 0 0 278 889 0 0 611 0 389 556 333 611 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj39 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 41 0 R/FontName/BADDLA+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj40 0 obj<</Filter/FlateDecode/Length 333>>stream
Hâ\íœnÉ0∆Ôy
◊CEK¥BBtï8Ïè∆ˆ 41“Q†ﬁ~v\u“"ˇ¢ÿ_>ŸDU}™m?CÙÓG›‡]oç«iºyçp¡ko’6”Î˘~
_=¥NET‹,”åCmªQÂ9Dt9Õ~Åß“å\©ËÕÙΩΩ¬”W’¨ jnŒ˝‡ÄvÜÏHË•uØÌÄÖ≤umËæüó5’¸e|.!Á≠ò—£¡…µ}kØ®Ú≠Ú3≠B°5ˇÓ„X .ù˛nΩ cNﬁl(ÑÃG·#ÛI¯DºèS NÑÊJ∏b>ìÅ<ë¸ÑÛ—LX3)ÖK‚tòÒNx«,˙)Îß¢ü≤~*~Rˆìâˇå˝gÚV∆oe¢ì±N∂ﬁ3ãf∆öÂs`
‹®{G∏e4YxÃCﬂºßQÑÒáp˜{ãè?ƒç®ä∑˙` ¨
†Ôendstreamendobj41 0 obj<</Filter/FlateDecode/Length 20441/Length1 47536>>stream
Hâåï	XWÄ´¶ª´aF‰g∫g†'ë∞∆(kÇKÒZ7ª*âÓè à"*ûâJ6ËPÉﬁ °Ç˜-ääÒ¬ã√ùqœ®„™q˝Ã∫Ãæ>6˚Ìó/˚Ê´Ízı™æ7ÔÔW’Èìß∆Åd ëCÜæ€ZÜôItlJLZ_˛ √ <?èùñ.∑,{-G∆ß%§¥Ã;±aBBÚÃ¯¨ü<êF0_]b\Ã∏:Ø7C BﬂcAΩô£%>4Å©¿ƒîÙ≠ÛÄê´…©±188ÑÌ1qõ◊•ƒÃHkY/zü)ybLJ‹ãº7Ûÿ|8 üêñ:%›7 äÀùÎiì„Z„ã-Ïˇ÷ «]U\Ñ’BOv
ˇñ'WÒ*/A•yïsVrúÄ}Y™´3ÿ†æ2∞ü£A®m˙{ä·∏7–·p∞}çBôs7‡ôV6oË√¯1;3!hu≤ßJÂå˘Ô¡9^ —≈U≠iÁ÷ﬁ›√”À€«∑É_«Nù˝ªhuí¨7*∆∑ﬁÓÙNo∫Ω€˝Ω=C~€Î˝B{ˇ.Ï√è">Ó”∑_ˇø¯áO˛¯ßAÉáD~˙Ÿ–a˛ÀœGå5˙ã®1—106v\\|B‚¯§	…)S”&Mûí>u⁄Ù3g}˘’Ï9s3æ˛Î7ôÛÊˇ-Î€Ïú}óªx…“eÀÛV¨\µ÷Æ[ø!ø†∞h„¶Õ≈%[∂n„∂Ôÿπk˜ûΩ˚ˆ8XzËpŸë£« èü8	ß*Nü9{Ó|ÂÖãó._©ÇÍö⁄´◊ÆﬂÄõ∑LÊ€ñz‡=¬ŸACÿQEÅ9ËP…™™\ 7ÑKÂ¶rs∏lnW¿]Ê^Ûn¸~æ‡-úûØà#_Ú'âzS9ƒmívÇˆî∂RÎ–Õ’≠—˝®{#˘JZ©ø4H.çêFI_H≥•˝RÖT+ô§Á“+©Ivó≤QÓ&wóC‰ﬁrò.˜ì£‰TyÆºL>†Ùﬁz?ΩAo‘w”÷”GÈ3ıÀı%ïÅÓ/ÉØ°≥A2t5ºchà1ƒ®<Ù
(*•ù‚°¯(ï.J†¨Ñ(aJ≤í°d*Y e©R†lWˆ*e Q•Bπ®\Qn*ça∆cc¥1÷oú`LNûﬁÕØ∏s±ﬁÆ≤˜≤áŸ√Ì€˚Ÿ˜ÿ€c?j|Ÿÿ––‘‡hpﬁ3v√ÚU†“´F™vrÅ\$óŒÕ‚2µE\W≈˝ƒ∑Á#˘,a±P%º  £¶#=EP¥©F-Y[°m“Å.CóØ{)Å‘Qí•ÅRd+µ1RÜtP:#]ónK/•◊Ï≤{1jAåZ9¥çZ£ñ+Á7SÎ–Jmê~®~£ñ€FÕìQÎd–µRã6åk¶&ˇµ»6jπJæ≤µçZ%£V«®ın£gLb‘¢É”5øbŸév≠˝F-¬ﬁ◊>¿^kohàjo¶&7e8©9Ó±˙|Œ§Üı£ôtu\”xßÊ´ò‘RÇUÑˆ¨˘OY>Îú>¿6‡!´nõØÕ€Êis∑πŸ⁄Ÿ46µÕ’&⁄»&ÿ8õ OúÔ¨¨Yó3…¥æπSbù˛4âŸ•OCôŒ∂Œ®O™üi-≥]∫l]d[Y_Rüg…≥ZXø≥lvÊ◊˚Y&YX∑≥t∑DXzZÕÃ˝ÕaÊPs/sOswsW≥¡Ïoˆ1£Èô…fzdz`∫ÎÃ2ù17ïõJôu⁄¥…¥À‘ﬂ‘«Ù±)–d0ÈM∫˚´¨«¨-G‚˝‚Ω÷≈µ‚qµ∏™ÂúÙò¬›nπU∑{" €‹µX◊ÁXÁG3b˝òdYL/±ËvLzQ°x®%€E«§ªKóq.˘Æ¨À™;8ΩjØV ø2‘!Íœòf}Z=ÌgﬁÊæ›‚QØ˝≈‹˘NQgµŒ2mØüeéVGµŸ#ˇè¯∞6+^¶I¸ü ä ÊqQêa>,ÇX[`#x@6C˙,Ö#,ÑêÖ»æßœa=lÖ¿KxÖ∞Œ¡ÿc!raTBúÖÛp.¿E∏?@<T√®Çùê œ`1\Ö®ÖDx6¯í`<LÄHÜâê©0	“`2LÅ©ê”`:<Ç0f¬ó0æÇR(Äπ0á}ÂøÜ'cÆ@r»£ vh¿ï∏
W„hÑ&$—∏◊·z‹Ä˘XÄÆ®F∂√B,Ç◊nƒM∏ã±∑‡V‹Ü€qÓƒ]∏˜‡^‹ˇÑkòç9∏‡A,≈CËÜÌÒ0ñ°;z†'zÅÓ†7˙‡<äæÿ‡1,«„xO‚˜ËáaÏ∆NÿOa˙c‘¢O„xˇÇªp%îQè<ãÁ<V‚ºàó2` *hƒ+XÖ’XÉµx -|ªb‹áxç≤)á–BZDﬂQ.-¶%¥îñ—r £¥R§U¥6”ZKÎh=m†|*†B*¢ç¥â6S1üƒO†⁄B[imß¥ìv—n⁄C{iÌÁì˘:@©î—a*£#tîéQ9ßtíæßSTAßÈù•stû*È]§KtôÆPﬂ¿7ÚMºC ï¿	º $àÇã‡*®US’“5∫N7®én“-2ëônìÖÍ…JwË.›£˚ÙÄ“Ùà’˙≤—S˙;=√ÎxÎ&ﬁBì∆KÙ=E/—[Ù}≈¢üÿQÏ$˙ã]D≠®%Qı¢A„≠Ò—¯j‹5ı´ÊŒøiÆÔ‡.ã4‡Ô>˚{vüÁ}ˆ°∑ êû@°(E∫HÔ]@Eë≥RfQzÔ]lw'"Œâz )`°#Ω˜ﬁ!!í€ªˇx˛⁄ŸŸôùœÏ~ørFŒ 99/‰¢\r˜]éÀu\û{ËÚ›#˜ÿ∏¬hUQ∞Um5õ`míM∂)6’¶aÇîñ2ˆ=;∆éµ„Ïx;¡N¥ìÏd;≈Nµ”Ït;√Œ¥≥Ïl;«ŒµÛÏ|ª 8ú¥ÉCvë]ló¯◊k©≈>¥ŸèÌ'ˆoˆÔˆˆ”‡pp$8ú	∏]f?≥ÀÌ
ª“~nWŸ’vç˝¬Æµ_⁄uˆ+ªﬁn∞•¨îìÚRAb•¢ƒI%©,U$^™J5IêDIí‰»‹»<jIÕ®9µ†ñÙtd(µ¢g®5µ°∂‘é⁄SÍHù®3u°Æ‘ç∫SÍIΩ®7ı°æÙ,ı£˛4 ≤@R$U“$]2§∫‘êLπ,W‰™\ìÎí%5•Õ†ô4ãf”öKÛh>-†Ö¥à”züñ“ÙqTG#Q‚‘MuK›V«‘uW›S9*W=PyÍ°JS˘Íëz¨
T∫œV¯†	"Ä`¿C®2@¿Aä@QàÅbPJ@IUJAiUCeB(Â†<TÄX®qP…g¥È>oƒ´,U™™ZP í R “$[jÀQ9&«ÂÜ‹î[rõ∂A:d@u®ôê5°dCm®uÈ˙F¬€0
ﬁÅ—.ºc`,åÉÒ0Å~Éâ0â~ßÌ¥Év“.⁄M{h/Ì£?h?†Étà”:J«Ë8ù†ìtäN”:KÁË<]†ãtâÆ–U∫F◊È›§[tõÓ–]∫G˜)árÈÂ—CòS0ãQ>=¬‚XÇSñƒRXÀP!¨∞,ñcÕF6lôò9daáÂ±∆bEå√JÂ"\îc∞2V¡x¨ ≈∏8ó‡í\äKs.ÀÂ∏<W‡XÆ»q\â+séÁ™Q√	ú»IúÃ)ú iúé’0Å3∏:◊‡LŒ‚ö\ã≥π6◊·∫\èü‡'1ì∏>7‡Ü‹àü‚∆‹Ñõr3nŒ-∏•‹ëª¸4∑ä⁄(E9F%Í¯nÕm∏-∑„ˆ‹Å;r'ÓÃ]∏+w„Ó‹É{F£—"—¢—Ó≈Ωπ˜Âgπ˜Á¸?œ/@~ë_‚ø ~YÓÒ`~Öá_˘U~ç_Á7¯M~ãáÚ03`&ÃÇŸ0Ê¬<ò`°‹áE∞ñ¿˚∞>Ä·#¯òGHé‰ …ÉkÚô,ìÂ≤BV Á≤JVc-y7‡¶£«È	zíû¢gËYzû^†óË}X¶WÍUzç^´◊Èç˙˝Ωﬁ¨∑Ë_ı∏•˜Ë˝˙∞>ÆOÎÛ˙≤æÆoÍ€pÓ¿]∏˜!r·÷√'IY#_»Z…óGÚX
§–ê!¡c(ÄBh•AkÅk1”±>6¿FÿÿÔnäÕ±%∂¬÷ÿ;cwÏ≠+a?|_¬¡¯*æâ√uéƒ—>ç≈Ò8'„Túé3q∂œHÛq!.ˆΩÚùÜ·'¯)Æ¿’¯%n¿Øq~ã?‡OæŸ¸éªpèŒ¿}xè‚I<´≥"^≈õxs1}Ô±>√5≈L	SF_5ÂLEﬂÇ*˚Do™ôDìlRM∫©n2umS”dõzæ!5Úiø©iÆ…¥0-Õ”¶ïy∆¥6mL[”Œ¥7LG”…t6]LW”Õt7=LO”ÀÙˆ+}dù¨ˇÛ~t®EªˇﬂèÈkòÅfêyY6:p∆ÖÆà+ÓJªÚ.Œ≈ªDóÏR]∫ÀtŸÆûk‡ªÊÆïkÎ:∫ÆÆßÎÎ∏ÅnêÏÜ»âhŸh9u\ùP'’)uZù·¬0U°#!Ü&¥!ÖÜ°Ñ.åÜE¬¢aLX,,ñK™≥Í\$'íy…ã<å‰ÀNŸ%ªeèÏï}ÚáÏórP…a∏ó·
\ï-¡∫‡+òj∂®Ï`cuì:¨6?À÷`l∞9ò§€˚ﬁŸŸw®NjÜö)€t7›]˜–=u›5,%Ó´ã¢T]—Å#£ÉÔƒ∑b%Fäπùnó€Ìˆ¿49,	Æˇñs’S¡,’DWs‘\5Oç˛©F	õ°fò[ÂŸ$ﬂ wÚΩ¸K~êe3lÉ_‡W¯~áÌ∞v¬.ÿ{`/ÏÉpN¡i8g·úáp—ÎlË5v¡ÆÿMW“ïuÔMæÄÒEÔ¥vƒN^iÄœyπm∞-∂Û÷~∆-∏’{€é;pß∑˚≈a^Òk¯:æ°ìt≤N—©^Û€8
ﬂÒíßxœìºÁiﬁ˜ª:Mß{’stÜÆÆkËLù•kÍZ:€+Ωá˜1«ãΩÜ◊ÒÜw„•ˇÔôﬁiúÏ≠æbÜË´˙äükﬁe/≥ôó~
O„Ø7≈NÚÜ”∞•…4YﬁtÇ˜ú·◊7LCL¡][◊—wı=‹ƒ˛oñ±ëƒ 6
œ˝9ˇ·ªjÄ£™Æ9˜››Ñ`˘…?–∑y$“lÜ
Ñ`Iv4‹`wC“IêJ,àÖ*·w`¥Ç"£©•E˛¸πÅT;tÖR
R§®äí*•PÑ}˝ﬁ&ƒ§3Úﬁ˛ú{œΩ˜¸ü{NçıÖç≥ˇ≈UÙ.}Zæ≠œT÷ˇ@•ß”^æCItd.ç#I∑P≥øÖ˙ˆEÍESh#*–~îHSij‡ˆ–Zﬁd-∞Æ–zû∂Z˚xôµ¯ÁP•ﬂüJ¶°4Îß¢Rø¢]¢†ı[ä•U‘ôÜ”dN§0*ñ3t<º@Ë0?c›’^øÁ©ÄF”hÎàuó≤h≠\Á8€ÈO®Ë≤”öe’P_J'Sx¨3÷gîIAtØÉ'7…±‰Fïøí^‚Ì/Ä^D·x1S+rºJ„hÍˇß…DgÒ˜‡R«Y«uÎW÷erROÍûjË
ÊÒbõå∑FZÁh:Ìß˜!Ø˝6…Èrªczdîıäı%–>‘¯Ô« «oÓ-µ~oΩIÒ‡'ô :Ëié†C˘}#Í¨:Ke†|UπéZª?üA-±X,÷N— H;‹>Eø#ã†Ét∫˘'j˛K®¯”¯«\Åò˘’I•8°m“¥”íÂNË€†Ëh>¢ÎÌhtÇ8ˇa.ÂŸ<=À+|A(qM‹í±rπ¸VﬁsdF.Dæµ&X7)ôRÈ'ËzÍ†€?D„ˇØÙ˙≠ÙÙy\ç>F!]Cuî.&äZ±Qlo 7¨◊é»¡≤P>.èÀsàá51·ò»›◊"/Dﬁàú¥ˆY'·;]q~&C£K·€Ë]tc°˝Ñ.⁄˛ÉÛás9?*Ûx5o@?t›«UHI—7]>Pù+~=-ãﬁ¶€êÏpN|"æ75áñéxw¢“µøi_JóÃîdÆú(À—¬;aác∑„=«uƒM•≥÷˘jÍ±«Óe›˚4BëÍàäÏÖÔ∆¬ìA[–mæ]Dèy˘V¯7¨êäﬁÈ!=åãπÑ«Û£<É´xØB.{â7°”{@‘ìÈ¬#Fã2U®ﬂV°*h¿{ πÏå8+ö¡yíf w‰j„¥rm∫ˆdòØ-÷V@≥Îµ]⁄	ÌîvY˚JkÜ’íd_˘î\$_ñ€eÉ<âÚsº[qO69N:Ó:Ó:Ö3’Ÿ€99eáÛbå3fHL)˙Ñ”17bk—fÅsù⁄="1ÿWÏΩd7c¢KÍ…=∞C¢‚ç“"∞KWﬁDäÏiÔtz•¬˛˘|êÛQ™s
çâ‰⁄√Á≈˘g1]làS‰vÌ	«¬Mªëç÷âwƒA.§Q ¶âÕÒ%ﬁAó‡Ôø§¸8œ£›‹Ã˘¸,Â::-µ2^A÷V!πè„Îh©¨§«ËÅ£Ût%≤Evëœ ?5“FXÙu˙åw“vX◊ê›4d£0≤ÃZ¯˚J≤≥ﬁLƒY‚1déÛ5∞ì(f®s§\D◊Èøt≈q UàLz9R#∑»œ≠°V"QF;w’4s	^rc{4ëá\2Q]JÂTIœ"Î≠∑îµŸZn-¥Ê“áÿ{}»~—àÙ>ﬁÁËc^É8Û`9øÔâTR]ÂdŒ‡Aàáf«‹LªPWvwÊB€+h<˙"º9Ã¢ìtïnq,lìBŸÙ¯ÕÔö#Ç⁄!*‚T™EÃˆG/lïdNYÌmF<Bl\GûòAáÈ,NÇD≥@?Áî@œ?≈Í◊`¡Âº3ï»⁄YÙ5‰Ó yb>Ëyq“Fd≠&tûæÑ∂≠(_Ÿ»>ûÜ≥n—£T	
C®îÎaÅ∑i2´O;}˜cr:ˇ˚Bà–Æ‘áÜ9>gAŸë	Vû®—·é±0ˇ*nØ4¡OÇãnê„%DôN±&ˇ= ≈À¢ Z•=ôC“Nÿƒ+ƒ¯º£ßxGçQ0<Xﬁ–¡è¸hPÓ√‰d{≤~ÿˇ°Ãå~F∫[ˇAﬂ>Ω”RSíìzıÏ—›’≠kó¯Œqùbcú©	¶løQ“UfH…LcÏÿ{lÑ1n7R:¶ä;ÆQz(∫LÔ∏“ãï?˚øïﬁñïﬁ∂ïÏ“® '[˜∫:Ó3ÙF.ü ¸kü‘UsÖ◊E·.Ä›nl–˝…’>]qH˜´‚’¶?‰√qıù„äå¢™∏úl™èÎ∞3 ïd‘÷s“Hé"…ü_/(∂òR©ÜœØRüÕÅ“2¸·JU:)‡˜•π›¡úl≈E≥å
EF°ÍÊâ.°¢(Â,R1Q2zç-≠—Î≥õÃµç.™y‚+ç åÄ“¬AõFwË˙T“¢/íø‚EÅUÌ±iöÈOÆ—Ì°iÆ“U”§@{¨€˛qˆäå‚êY“k°ƒí2‘ƒ `@ÒJê‘mIl©Z‰´2¸ˆLh∂Æ:ÖFµ9;”§öä&/tÔIMıÓ∑.P™_7ß∑ïf√æﬁıΩ»úºpoäWOÈà……ÆwuoQl}◊n≠@|óˆ@U.
Eó€P…‰6Õ≤Õë1°ÙY:8	ê)œ˛© #sVñ·	2v©JX§Fu*
ôÆ|{ﬁﬁØ.C7o<¿hæ÷q&‹:„Ãp›$¥˝§Õ’Äø+èGeeŸ.SõÇ«ë—Ò‡úÏçbàQÎ“ÒıQ)tÊÑ˙›n€¿kΩTÅÅZ2)–2÷©"myzÇJÑlL”}L¬T≥‰>¶m{»Ä'7.'JP±ômünÆƒû˛Í|≈â@Wµ‡K åíIÂ›oÜZu[2•√®ü◊ÜkÖTœ¢Äñ&Z!ë¶E±p mãÌA ^…|úQßÆTú2:¡z±rÖ∆∂¸„‹ÓÔ›”€nS£u›ﬁ˝˚n[+ó*ﬂ”q<º√∏wÒ¶~e¶(ôRnöqp≈H@¶YlË≈f»7ZK*›eò˚≈v±›¨ıáÓ¥—:∞&MØBàjŒá≥
*¨7xı§z/Ø.+Ïw˝èÌjn‚∏√ª{èΩ;ùNß«…ñÏÉ;À≤dÑlÀ& |±)\å	PÉOImB:≈Œî‡¸A‚…$~Ù¶Mxî“∫ oäÕ#qRövÚWô$M:ôL<-¡Õtú2çú¡:ıwÇ¥d¶c›ÓÍnÂ˝ˆ˚}ﬂ˛~gÆﬂ4B0iÈhŒf"‚ƒÉÉ?H”5ü!ÿÊÈi≤¸àcmIîµ1
	<gÊ"ÆB"Tß•®4Æﬁ»‰3mÍLfu>Éö`¨ŒASõ4Ω¶7
Üå?g0sán!ÉùÄZ=aØ%[πwêäñ[JµÁC#QE>·Æ@"¬–"Úí%âüÀ6…våÏız¬Y17ùüôVßQSìöQa-ú√ë*“†˙◊¢|%AÚ≠7ˆoyË˘â°Æ%{Ì˛˜ßPCí…Kˆ{„gø±_9–È i$V…J´4FbRÈíˆ£Ø(TTüÍ`B∞„"¶3¬Á‹ŸA„€÷‚†ôŒ_˝*ˇR¶!Eò˙†OP¬|m›≤˚ ;á^ﬂ{§πıòΩv‰µŸèw|ÜãΩoœõΩÚ/{∆æÂ πê«…0_gôIlAV_—PﬁlYfß"%·qà=ÙÌ“xõz5∑ZΩñCã¶sµI?∞}?©Üz8dO91‹—¸&ºz˙·G5Ë´iÁºUÈ]pçΩ¡≤¢©â|uç˙Êkk4í‘NjD”ëä®œ/Å(F§,÷Õ˜Au€Z;)cy¨01*∫R∞Ô ∫ÑïhOt$∫}â›â·Ñ`$í	íT»'˝ƒ?Fæ?∫∞vùÉr&Á(cµöÎπÔY==ìõ.™ƒπºÈEπ0÷8“
}#zZÉEF¬N◊w⁄üé«„YòÑΩæ4Çàm=ÂZ◊z :-˜fqÂ¸f›<8OÉP <§}{ÎÎ766§™bU∆kﬁ˘RŸCVù8:çÌèˆÔŒ˝Ú©Uˆ'∂Wøy|¡◊7∂Æ™πÚ*ˆ«õ◊YOøÕù◊7Ô¥ÎX<vÒŸ«.ı∏¬æeÁƒç,€ r˘qªWîsmÕõ8Q{JÎ¿≥Ì∂ñKÖ(Ôõœ·$wí#'2lL&âQÇ¢§ï!+$‰¬Æ∞·N∫-7„fE;a%»·Læõ≥65w3ôôÃˇ°åÆÙ4\e‹W(c85B¨˜ööyÁzômö˚îLÊ¶û;?k_∏i˜‹Ù˝!Óÿ~ânß 9¬2Q	,ÂﬁçØøöÌ`ZÌÄrK¡"q5ô‰N‹Zy|Ç≤Ö)n
úÂÅW÷ÜΩ‹^aüºOaL¡CKc•Ω‚N›ÈÌ’˙Ÿ!aHÓW^µ¡í¡“˛∞L}BÄÜ5_8.’¬‘ø–-ÜR&;)a$©í!1í£F#©[záﬁ≠˜È√:oË◊u¢´±aÑ=h~—/0i¥¸ôﬂﬂF,j—†¶È¶i~Æîîù,n¨7êWE¶Åp¿W_Á'R¡g[ÍéwçBe¸Ç˝å}…∑ü¡µ◊Nü˛˚GÁŒMíw'˜uèƒÔ≥øcˇ‘>ho«/‚≠_ÿÖBanˆñ√É„ƒã†ôh÷z.ÌYÈŸH∑π∂…ØäGî·»ÔîDâx©DJç reπá
™Ë(O@mT=xv(O´ÔHÆ^±7Ùî>(Ü˙u^DŸ£¨Sv(œ+/)øV8≈pÀ∑[ˆ»öª$ı´‹ê@ ¶£B∑¢hHP∆E+Ü‹™õ∏ﬂ-ãÛß¯	˛œ<ÀtG∞IFHƒ‘Óé|EÌñˇEæ»›√qÁh“ÁhÚéS”âxNŸ•^∆ﬁ;ÆE9‹ìsRW¥(µƒo2	âx¡®_˙Ãπ˝üÔıΩ˘F«Æm£ˆœˇÚ‰˙G:3æ∑-≥fEÂô)Ó¸ö∑ü;Ù~˘Ω˝GÌø·¶£Y3ˇ3¶≠rSÛ™áe»X∏êé7«˙√8bØYK]fñc(Ø‹Ì±ApÄ\ºc‘910K^†,f#≤àì¸$æ.À≈Û«0äjÈ)ÅˇÕìí≥î
"c§‰˛/Eù£‚#[äy)RØñ™˘€›UH	''®7Æ:‹¯“'%iØØ$=¿%‚–}iq 1œÍeGé(nz!W¡«KÇ˘)¸0Œ‚ÒÜ¸'bµ6ë,õ;ûﬂÓÇ{/¡ÆE‹9éh·˙YOöÏ;Õìñıõ,ôPc^`XóÑù„€à•†ü¥ Dw
3î∑‡o¿“Kî%4
{K‰k<^l∞É’	kô•ûRì ∆Ñ_¿8&XÇ«HïÂÅì-*"(V›"a-+* )1lπ⁄].∆≈&ãig:`ùã∂$($Õ˚RUp9g]ºxÿ›Æ!Æ€iá¶Å]ó≥µ…8Ú0l¢Ãp61aEL ﬂÁm∞
æ?Ü∑Û›¯Yæƒ0´S‘Çyd¨pxƒ€‡r¶7®°TÕ—-‰q˙$ŸEHœíT‘âJÉ6ë$m#›L⁄È˜HüÙ¢kñ\ßP.©q‰¥ên‚ıñS√¶dH~[;˜”å]ÃπŸksëõ∞´ïÖ∞	v)ä†:‹cm•a°ú”É·Ue+ WF?T?ˆäç°Â°çUù°Æ™˛™á~>/˚c¯Oe2œªµ 
∆¯{¥lh'È'á˘≥¸[º¸zÍØ*—+ÎjΩ5ÓJ+ûHUZ’–ÑÙ‘ˆ πJRπ\wvòT<©%:F∫™ü“ø–Y]Ø¡ı»Çª∑	ﬂ`ZÂﬁ&”*S°)ßÃ1Ú›≥,ï›Rç#xVÏ·q±á50√≤ÆyµU¬=bµ;;_˛ÖLÊÀ∏ ıÄ•SrxM
ß:@â?Jb¸¶´>6jÛå˚ı◊}Ÿ˜·ª≥Ô+óÿπúsq‡2Œóêr›9%\)_	%…rå[≤R2*ÖP1Ë$J‘µ@E;∆Z–n0Ü⁄Mkö M`¨me”4Å∫©€˛ÿË∂T(–hùîe¥"ó=Ø§Yg?~ﬂ˜9€ÔÔ˘˙=(ìí{$t[BmRè4 QR8”ﬂ≤òuwAÂú)Yf6GSò.Œ ∞˘\~ƒlIõ23âf˘ÔX∫g¨¡$ëX∏ˆ^¥BÔHlMê%≠à-~Iπ°“·
4\`©ççúf®Ä(…êVTñ≠VíY'ˆ&+ï#LÇsÑ¶∆,⁄∂†}xÛk©hM˘ÆÀk£Vü+ùª⁄ı∆˜ΩÆ}`m˙Z„›DSwÎ∫UØã¸«“SØ_~Ø<Ò KÎbMa{°0vhÛ´kc5U±ç´Vî?ñÖ‘‹äÆe…¶ƒ6@•º!ﬁ&˛nlÏˆÖ¢∏›”/Ùã˚BœÖá…aÓÔ°?y?
M≥”ˆiˇt>Î_Ó_\#¨°"◊œŸöƒ¶µáŸ„9»º>/åàì¬%—·6≠’±º(twÜ«3·∏nJèOÁ/#öpÇüã0@ï0@è»|lu/á•*…Ü,íâ4èoxπÕç‹ë®MÑ#›ñ˘÷œlÄ‹∂~Fõù—à¸¸li
¨6?´i qÇ¯ìƒö»661x\H¡Ùó ˜‹OµıÔ€ø£Ω/à⁄ÏÔßÀ˜ê8s˝Ú”eõ:éæ}ıÕØ§y%çl®fWÕ¿NÏD˝xí.‹7
ÆÊìéS¸qÔyfƒy≈qÖüàÿÌ¥ö|ú-8€‚Á˘KÏ•»Áo∏èúÊÓ€˛ÀÛ1O,hÄ◊∑O˜ﬂﬁRAùxﬁîn	$˘™ÖThw˜∫IwH¿ÈÂR8™£å@`ùä*›îJ í⁄KÜb¶4<bgp;ÎÖœÓàöq⁄%ÑpÙ$\6BFÈ†j:ﬁàüé”qèl7xènW,FàÜ1.aêg1-ÜgBFm 2‚∏@XÜp¸‚tTÃœõPÄè (	ã·ãÂÿCU=,5Û, ô∆Î£„ÁóÕaãú◊¨?Ö£™dæﬁm Jn¸R7~Ω€ ∞Û°ÈÏ.MÉäü¡ı
ÿìÜ∞…´‘d€ú†d˚Å˚Ñçï»/P®q˙ùÚΩó˙Q‡3H`ÁÍÖØ?∂Y•ˆvm…Âz2}ÍGè˛ŸëVæQæ∫ÔjÙÃ∑˜Ø\˘,ÊÿØ¡ÂgPÁ(bì…{çîœô7òvÜbFôkÃ-Ê_S…Ù2˚ô30¡@/+I%ëi áú–°i Á,§’ºï6viòªæÜ¬ÃÂ/
ÆÁ	Ç=~ß¢ìD
˛]Çw¡ﬁ∏ +r:•€ıê^›JÆ≤Ø
µVsUT:µ…—õJùNùcGl?·.≤π—‘≠‘«)7ëJß⁄a·˝‘Ìõ2"1=„!së±…¥-R!Çìå9m8q⁄Êı˘‘h,ñTÅ·≤oRõ≥Ω>4‡Cæ	≤`x"—dEÊb®7Üb0w°&ôT—JçÑj∫∂#è•—ﬂ≠Ç™j¥¿ôÉ3°Í™Ò»£zZΩ©ﬁV)èZ©©°V©ÍÇJ´·⁄Ê¶kÕ:†oõ:lYÉz<Â0∑ûElròAˇ_á∂K√âi~9à3±dÊcIƒ∫äÛkﬁ&ﬁ>è®√◊˙é7ŒnŸ}∂∂¢|ßB›∏b˚“Úùxæ±e˚íÚ:yÙ≠éŒŒéû-≠'ÊãdœóÊV>^&…¬õÎ/ûú Aw∏¸=6Û1‚î±tπµüt™ôoˆÎ—VÍ	˛	kÙÛ®£ãÌrÖ.±+TåÕŸ>è⁄Â∂ c`à.ó◊„ñd{dg≈})∑€ìÙz1∏Ük'1ÑYKEﬁäWËr åwjÉwpw&V3 ¨Ï6¯>∂œŸ/Ùâ}°˛[*‚^5àÒ¿i™íÍìëô,≠∫t±ôüsëÂì›G⁄ wê¯›æoºp‡©ß—…7€∑ñˇVû/œïˇRËúü¶&«˙ÉÒë≥ß¡_’dÓ˝ºQ;Ã ámb˙ò›ï∫›€›;⁄ÈpïyÑ[‡»<◊∆ë‹π«HŸl–FQ$Î¨%^GÉcßÉvDˆß≤Gÿ/º#‹h¡K$eÓü$á–Ë√æ¸$äãÓ±¡l
¬Îßàvç¸8PÛ2äAbÌ®¥iÌhv„ÊÓwùÀñ2Ó1íÕÙ:€eVÓhÌ-~ÂÒGW<ô¶ì√;Z≥ˇY⁄Úv˘ﬂ∞«®^ÿcy›∏∆˙ÿjª*˘§Í¬â¿∞z¨Œa§pÖütﬂê?©æœœ)läÔ‰∑Ò«\√¬à2…ŸZ™çDkÚiekÚ†p0p@˘N¬—î\≈\k¯6OA~L±)	5ŸƒeÂ¨í≠Œ&l¨ìÒ9‰Ørä¢T€äQˇ,∑7\[©›uáÇ/÷ù
´ª†\®Êá–Èï–…∫∑ÍFÎYIπZçX•^)¢€"3vπΩÊHYcÑ*Ùö&WÜ±Ÿ^èÍQ∫’«Â/Úf†/∆Ø)A≈ ^@–â∞∂wC˛ b“dRÚ]⁄ú6àG≠3ƒ"ÎœbŒèDîTÂÇ‹Åä“V‘/Õ!'íH:"+d≠üÁ»⁄HçËB≠´=Ç"ø-?_ÇüEˆ≠≥4ù$îÖﬂç◊÷U¥§›√x<Å«èW&¨q8béç(‹Ï‡Q£RPNØ+øR˛®∞≤¬Ò4¡˚∏ï»ò}à¥$èãè9Vj,J_í@»@ÌàÓECË3D»£^ X”/Ç&B∆zÇF=Ùg4â∑ h1#\…ÄáJF∂Ió0Sñåö\‡π©“$•¥‘1îÑÓâ†ˆ»BÑ\‹¸ ¶üÊ1•··¨∂òq=ƒ`XãEãi¬Q*ô%5±[√·ÚûZ∏ ü^‚õπ ◊åo«∏f@ËÓªÆf≥l˛èÛ*ççÍ∫¬Áæeﬁÿ€cﬁ,vå=å1©˜ûbú†,6[î&,vS®†BIî§P‚` vÿ∑í°¥Çí™ìF∏†&N	"-Ö†@* ®Êı;wfê„ˆO;“ßsÁÓÁ‹Ô,O`=Ω4ΩW¶KüEà@:Tß#ıH™tönóÜÄir·ö+“R~¸√K2MÁ”·”ñ_∫~È„@¯æc∆‰˘πﬁtøx ‰ª_˙H‰dèØ	§Áxù¶£zXÌ∆_º˜ÊÍºa√˚∫|}úÈ≥GUøæÓ/á·E}≠ Z}+™—∂`ñóº¬üï48qT‚î$#’I’Â$wJ/S∏SëÁQ„åx£ááÕùDÓÓ√nu&Du˝1°A!«Ö9máŒƒ	q9Ò9D9b¢f’ÔN©qVò€ÕC¶:”\a6ôÃ€¶Nf≤È5sM%ÊOvƒRNı·ƒâ!à«…¥B•S G?D∂¡«aÚ›T-∑‰7!¶~éd„(H¬ècåp˙¶¥©õçÜ≤ø»·+*( t(KC	“åÚÃ˙È3KÀ‚^~Y§i˛+·âØdßÁ“¿ÇqUyÕ‚¸ïèváW¡>çà24?πhK–=…1«—¢´q∂T[πRÓ®V™_(F´Í–\Ô4Õ¯8[/”Ôt»DW–õQx»%,¯|öá˘Ïœö<;< œmèÚµGx‚¸qvY3bÓª∏mˆTw¥0·∏4âz6I1$s-GU.µ≈Ù~EÚ£Jˆã®]\ÃMuÃ‡ﬂœ´o}F§ˆ_1r·@ë∫Ωf÷s≠- é∞Á C∆.˙\Ñ\"“¨˚÷e˝é~ë¯≥∞î*Ö;∏§¨œ±œÿ∑'I/K)vß©c∆*ŒÅØ˘˜®{ÙΩ	{{ ˛,€æÿø§`Y°:∑˜™¬-Íú^sús”‘b◊‘¬9nµ8•,≠¨èöUX¶'™πÖŸjﬁ‡≤™‚íí“·ïU˝Ù˝&Ø$ëóü_˙3ØÙ¨¥'cvı‹áÁ®ÅÍ|ÓâØ»[ê∑"Ø)OÀ;¶¯ÉÒÈ+W Z•UUñbÙ∑˝÷x∑{/F~cÆÏë:‚π„bT$ç~ÙÕÙr∂ Íh4oÅ*»Ã‹…å: PΩñãd7WÆ’á@π$I9øu•täò˘°¢ù.Úµß©hæ˛JQaJÜªø¶8Õ≠ ?#•®P…@ÒõÔÓÉ.õ·Bç„v˚¿á}á|Æq| Ωì¢Ó¸ŸpÛÈ”·Ê≥ÁE›ü∂Öˇ∂Áó"c«N·€Ω'¸YÿxÁF˙¯iCÊf|q3œç®öZï]π¶*0`dc•~Òd∏È/=+ÍOüN∂l_‹µ3|y˜në±sól{VüPåÇy¡…Àí˚}∑«§›ØæV>"˛Ï*Òı/rsıL§+kû¸ÚÚß3í ÔŸSÌƒø]◊ {≥¸@[∞Æ≥Û·£d≤;17‡Ä1,<Ü*ì©≥≥sirdü.øûE∂hóRE+Sœ“≠ÅRÄ'çﬁ4E?ES≈Ù,∆ÍÅJµ7•k®Û·‰z•ÃzÑ˘µ¿.† ¯Åi¿§(& ﬂ√ö3@+ˆò¡˚HyçÍå6ä≥h~ º•◊R3∆ﬁ∂ï—,Ó«Yo`⁄—ø’÷Jk—ﬁÄÒ)<WJ^_K£0>Ìız≠eçd†è–~Ñ~Œ_«wÜÙ„¸≠¡∫Öˆ@Ï˝4∆Y91z_èl_„5RW÷q∑aüÂË_åV”`^üãu}ÒøÌ‹+≤ê®ı«úre(Ü|ÁWFı&©7Ùx¨Ó/ÔÙﬂQ√˜Î
‹âı∫	¥∫‹≠;øÖ°»˜cù{Cî6ªÑY/˝∫uüﬁ]Ñ^' ]{ûÚÏdµ‚û˙Q⁄Äˇ˘@πD	mÕWÔ‚é“R[ÌD?)y¿7î©|Ei∂L*Å˝&cˇI¿ÿÛ…áÁ˘÷Wê}µÎîÜΩfu8˚LÃNl¸âwùåπŸ`◊WÅy∞¡`!ﬂÁÁ∞ÕÒÓ˜EmxÊ^¡9’úŸW∫Gﬁïa˝KÿK»s"Ôë ∆Î`”É¿Ä˜˘1HûE!˜j%UiµÓ@ˆ“Ä6`-Ûò	îÒúè˘ÒíØ‡sì˘¡‹–OIÆN‡ªGtêæ∞:Í3/b˝4 ÿ–≥Q0óÌ3ã9À˛€õπ≈úâI…Èz…˚”¨'s™ã|K—8æÉ<‹äIˆ;ÏªÑ•Íîw⁄§∂Ssñ˘ìlÊ˚#˚DT~øãÆÉ¢>2Î˚HÆÉã1≥≈cyû6aœZ€Z¥É∆hóhåzé∆ËK ◊Aø„ËÉ>Z;bX6çµá(o9k7vìFª®√Yk¥˝∞E;mïvmW˙kÌB◊˜[7ugÙ˝ rŸ˛Ÿ"c…Ë:ˆøˆˇ?P>—˜”l¥ø‘€-˙¨cü0:D.‡çIÙV ÌŸbÉΩ^3j(ŸFtòØi∞§-DöìÇ∞S&˙klO…∏€Ñ˝Oâjƒ{Ωn8…ßﬁDlƒY '» Ô9∫èæ≈πÓ\ä…_ªKÊ«]H2~˜;‡p)ä W¡«ë¿Sú8>À¸Ä4F¯j›zÃœ3¥ÚÕ?ªÒt`7~›yŸ]rn·¯.s¸˜håÈœÒëc«Hésú˚bÛªÀ.Îõ;˛*„pMç˙uê‰`è˜¢q‰ÑzÃ∫Ωa˚»:aTX'‘≠∂ç÷ØåzÎ¥Ì®µzg=Œ©°H,cäÂR∂Á≈X’˝4;œ6…π8_Ê—Z»∂˛WG≥∞Ô9Œ´ÏáÍ¯Ïâ˝^—ˆ“è¥´‘Ñª'©á"˝⁄√1Q[å6˙”y<Amí„„µ;¥XÀB{/‰frÿZl˚#Ø±⁄dﬂµ»˜ÈSÈm.G[Eªıwi2øÎ°YÚ€√Á”Ï+h´A‡U⁄§uBÁt<%Âf…'^˚k´ìı3Üê[W°œxæÆºQ{¥H[Ñ§çö%áaﬁ”ˆ±¨7¯&};-≥«”&˚ ƒß{îf ñ»≥ﬁ•Iˆ†¥ª&Ûı?·‡X≠‘MÎ_íˇ,KÌÑu¿øcNJ’;h3|i•¥ODÆfˇQ;»…Å~e=—éøCm˚È[ºkG.h«ªu@óz*E{≠∂ﬂzÄπUÿÉ¯lÙèìı	Á©†uÅ˝≈ë«‚|Ã·;»˙Á™◊qﬂıÙoÓÀ>∏ã‚å„œÔw˜ªK"¥Ç!î∑ÇlbhäPA(°≠8iàF-L}AÉ„¿`K’Qh©¢Çà )≈-/jµ±be
 ÄScµ÷p®ï*•¿…ÀıÛÏÌ˝r^¯@˝ß7Ûôgwo_û€€›Áªµú%√Û»„^ÈGxT—ÿæbÚ3`:‘Öò≤°Mı§è˚¥<}ãl√ã¥Hê“Ω‡˛äΩ∑LÜ;OJÅ;˝°ÃLó lg4ÎÓ#bÜ#˜iﬁ-ñ>ŒG2 9f‚œÏLÅ4ı:«?ê1n5Ì7ÀÕÓo‰f' ]≥ióy^ÆÀ‹ÑŒO?ñÙ ⁄‰ÀoÈ“`≠÷3c:)Ó›Rf⁄≈0æF®œ+c>?ÃW˝åı†˛íé˚´æf˝¥>û»?Ûù⁄/ÌLùø…pÊÈ∏ ¥Õc”»Xë~æY¶ßô◊ë	æœª”Sµ0\w∫‘cK∞¬nx6¡«Ó%2ãæ_∆>£˜%˝Œ.,ÔüÄ·›Ë]ÁDÂq‹˝¡∆x>S&ó*ÈbŒÙ‚Oø3ıÎ•ø{Ápø`£‚Lì≈;[˙˙y“7ΩóÚ*⁄%Úô>Úà;ô∫‚¥Â”…‡Èõ«aÒoå˛∂”)NÃˆPÀ˛*—¯¸Y¸;¯ø3‡V3ˇ+‰b≥Ü>@ì˚¡+©M2>ı^púÛ‹S¬ºô˘¨ós¢ˇDy≠)O¸?÷  ùÛd9ÈÀî(ü¸ØmÂÈ∑&N¥"¸2¶∏ÔRíy‚¡0≈”5V‹:ü7ï“üyÈV‚Àﬁ÷yØÉî*È)‰ó~ø|M…Ê+•Ø¢uÊ∂ó¬\oT“{•ß‚TÆ¬‘™ƒÊıZùWg≥∂5ÌÕˇâ÷yÚˇ–V‹-úGÔ£ô+•(i„{6πoìe—Yr¢:âΩ—/WüˇO∞w^É≠ß/t÷yJX´–A–tAo¨G´>Œsª< “T+“≤H„Œ!bp„: ∆ëæ{
)´¡çﬁ#=Öwª`¨pª»]VWv&?"l€¥ ˆwAÿ^€GÌ4€7ÃÜe§w´¨·Ï"ÏQÍØß]5–8€ü¸`=4˛ô¸P Ó7Ç~6"cKi_”Tèú‡˙˘⁄˜èSµ¯8	~`4'˛&Ôßl£ˇŸÜMﬁ5¢ˇﬂñçÓ≠¨ù4ﬂkJÏÓs“;Nd˘üüXé¿AwN–Ñ¶ÙçéFÀÕ≠˙—Z£∑w=ô2ö“ZÊS˝hß⁄Yı+ˆ1sœ{Óî´´ ¯≈ëÿŸö.ñ[†ìÖsO ©Û˛¸õ≥ß=Òı(⁄ræ"·3>$ÿNÏjœô˚RjSpªÉ|WbY~”¢≥µ’€:¶}°˘”çëgSØ∂‘$à 'ZíÔK-_Uí±¯ti+vüq,œ£„q˙≥Ê£8ë?T ~k≠Kì:†≠|[:˜tÛI›ÀoPNÚﬁ‰ì∫$ 'iıæı⁄ıL˚-"±ÔNˆÈÂÓ‰‡≠høF>$˜qvøŸº7CÆÄëM=%}8G˙BùΩwı"MÓ—¯ñ◊(eyÎ§å¸≥\xÊ’aÏÍRøEKˇWèúÊY‰}wá©{≠•∫≠ıú\∑™œç>dŒåÔÛ˘G§√π∞Ó»˛kÓêåΩÕ!ÚÍ=◊y?8J_Gsi¡\ñ{ﬁTΩÔëoOæ=gqoÉtÀlñe§gc∞úÔ5CŒÏqô≠Aì˜å©sÔ*›∑e4Á¸ƒå#ì›}¡ZŒÙ3Ö\5¶ C;¡ßÌ£¥ùC∫∂ΩP”œ:⁄?®1¿/$ñqﬁpÈFŸ<ç√p3uobnØKÔënúÛ›yWhmâ7âqàW^_cŒ¶¨ì+|◊>’Ó π.Â›7·zÁ8}Ø4mÁ•á»zßA÷ªÎ§ä˛û/X-ãÚ∑ ¢<æ'øJñ˚_ëÂÓTYX0Hñp[B~Å∆´(Æ2˜ÕQÌ∂⁄Ô*◊Íw”wok+£oNj„ﬂ Œ’KÉïÒq£vyÂÃMﬂøUñê_–ñ∂°üÅPG`r<çÕN◊`GhÂß6∆ﬂöç˘Ur%˝Ù#]lÊ∂^.v˚öÒõXMÃŒ¥£üv∆w3«I_¢±òó¶\Z(“&0¬¨õ}2S◊˘˛pû-´4∫`∏\≈ˇ∫
3≥•–ù+È’¡ñl4ìÆ#wßY≥s’OE◊ó]s”O±GﬂíÛ4ÌÓíÖ¸£YñÈ¨”U:∑Ó©3>ÆÅ?≤é©`Æˆ∑¿ﬁ Ïw◊0ñ¬|©?ñeÓX≥>;€µŸ≈=&ﬂsü2kÊ\æ?ﬂ¯∫ tÓ¶∞FXÓ‰<cOE÷Ã’Ê}Æ\mæMÂ¨a›2?N=˙jü\’Õ˚∂T˙sXØO≥vf2ÓHÈÓ-Å#RË]Ç>úÀwè†ÌL©Mí2%ı`∞7Ìí∆≈)sQÊú=í˙á‹‡ló)Ã◊¯1,‚{+Zœ‘]+,)È’©ûº¢Ùó√¥){Õrÿ≤*ıÇ=–ê˛à±{“ø>}r:∞V–ÊFã]qø∆ΩÜπ˙4ÂIh´∂4	Âj/HbÀãíPÆˆÚ$î_~?r’ÀÂGÆÚìP~·Á‡GÆ~{%°º◊I¸ïÑÚQß·GÆyÓùÑÚﬁ'Òct G'˝‡|z^‚é˙¨∆Obı]ÿÿ!ÿ…k“‹{Éâ6øÕ÷ª≠}ÇÓñ+`uà«¡ø‡1€Çét€D„∑ì˛ˆ;·X⁄∂˘ÖplÉ≥yïııw˚X^}gÏÊΩ·xfl¸hﬁÍò`©≠?ÿé˚dËwÛ˘ÿÖııΩ~£i˜d€/‡o“o˚~Í{Ûz“ø5SÛÛv.WÜ„6qO:Câ}_€r.»6ÓâÛ9ßi¨ŒKã®’≥÷úπ5r^,VçA˙=Ô<ºq/ìÆé>
T7ËnÓìú˚Ê>˘&˙≠`ËMŸE~}¨`ûÕπyøÙ—1‹CË˙÷∏´ö√Ÿ%c£56õX=\„A¡©ˆ·”)¢ˇ.˛N©Û∆sûÜwŸ≥¸€»ﬂäÓ∏[™<_¶Â’KùˇWﬁ;2íxUïGw[oVdäÂ¨»û5H™Û_§¸~¥Tëå“Ò¸Kds60;;kıûk˛ªŒˇjX'“¯u∏ ¯åøÿs∞]L,VÌ§sÚ™‘‚O±∆OÊÌ7%_ÚŒg_5J?}Òú‘ÊßÂQıt¨_®ÆÀŒ}âs@:zoHqÊÁ“—Ãı2’{õyΩ-m-Ò°Œ,Ág÷Ú]Àe©ªçæñKèLGÈl¥√n”wh£>V£g»2÷DQR◊D:*´o^gM†≤cÿÔQ´±3ˆ˝∆∆ÙÜô˜Ãπ∆Ω]æÂ∑˙0a#ü¸›≤‹€m÷¿x£øÜ xˇbÎ:ÈmëÚL9:˝J)œ+í˛“Yıô?ëµ©zçÌıêíÃ2aèÂ¸üW±?ÅıvWŸ=˜&¨µgGEXnˆ&eMKm˘$∏j¬˜˙.ò¶õÜ˝õw˜ÜıõÙ¨bØ•ÿQÕ-Mâ›≥«4õÁ≈F”∑∂V◊À"´[On˙3ó’=Ã.åÈ·PO∂∂£±É£<˚Ûç’r¡ŒHG'-uómglp¿⁄ø[ª]◊öjΩ§çÈÍ⁄\˙µE«⁄}ŸPWœŒa´#}›ñÕÍÔ6´◊€≤UA†ÁTd˝ƒWY{éµk±Vó∑‹üíˆ!t⁄ªV«™~ˇ˚eUu≈Ò≥ÔÓæM"….Ç…æK°î$>êVk1R∆Ñç÷q,çdÅï∏õŸ,k+ôJ-	mp$»TqwÜj@-∂•S°Œ‘÷Z@Fîèé≠4q⁄∂y˝ü˚ÓB¥e:”ŒMÊ∑Á‹{œ˝x˜„‹sk0Ô´qÊnﬁwåŸ„tõ=}%|$ø¬}	Ãÿï˘w9›˛]Á%ø¬\ÉzkpøÑúÓúP_IÖ∆º÷≈ŸˆÉ£‡=ê]¬„t˙YÁt#VÔ#qw¨ìÔì⁄KanBøõ–O˙É˜¿x·¯æƒÏ‰ÔEΩ{Â7ˆ]8 —¢ÖúG–œ#®s˝úï≤á…Œ{v≥ÛÇo;)◊+;Êlˇ™›ˇt—Ê£—ˇ∫8=Ãï˙ÓÅ∆Ó˚πÛ8¬:Œ“aı.Åtzò∆‹&«}ﬂ¸w∫yÜm∑¢Û˙.¯˚(≈À`/8≈{K`0ËGÅ~.‹=
ïÊ≥»ò'ú7¸∑9G¯àÁúé•.5?˛®Ûˆ‡ˇcêQÁ>˘F‚ÿÎ0Œj˚wF˘æ“‹Wq¡@∑¯ÆœŸçΩM?/—¸è∆|ŒÂÉ€—¡_13ΩtßŸÅ∑Ì ¯§ﬂ:'Ùµ\q@±Œç˝úW¿O›yñ˘;˙" ®ÑÅ~˙C/Œ&osõtÈ=ÈÊüW÷˜z	„≠K¯∂z¨w@∆/1∂çTåòÁQé‰†ÔjCLY¿Ò«Ú,4”DƒÖµäRÃKƒªq„qö#9ªÁCÜc"πN«i∂yÕˆØ“/¬Oä∑@7Íæáò≥éV†l«>‹«Éâ„òG¯—é7."g±≤Œ≈+ øI∂'âı(Ù›†˘üÇ¸:X
}4‰7¿›`ß êl_!⁄ÚAgJa∑«ï√≈8‰",ÙÅ|„ó∞[Nçn‰›
Ú@çÇmˆ!∆„≤*igß—«t ≈JüÇ≤7A"nœ∫UY÷¶ÍºçÔO45ob™°`•”È;ùû”T‚çPkö∞íΩ¸˙±ä£pZùô`3“gå)∆à%”Âtä'Äíæ_–çæıdõEÙmﬂ54oÅ∞¿=¸ˇ3±tù˚&ÍÂ∑›Bo≥Û¨€rÒ:∆qLÚ¨íùÊØ©,w9ﬁΩà≤0t J£@zÍ‰›Iÿ[‰·Ë≠√ç»|Ô:„≥ñçs˝_£’˛≠à%∑“› q¨≈w…`æ◊°ﬂ»{«7ñ™–nß çÒ>s‡¯¸∆‘éyW“Sº∑T,»ˆ;E}ÚÛ∆Ã√ó®D’Ω‘Äá‘ﬁÜv7˚lÃ0>á;@øôÅﬁ…Ù)ø"iÔfúØ•-–+.Nc=g*>≤∂~õ*ÔQÿ1ö(∫áGPÁÌÀßÕ ï3F“.ë.†±˛+Îﬁq˘¥Ò6ï2¢s\{q˝OfŒ}˜e“‚	≈d˜€π=›ﬂ˜w^‚ö˝®$ÎŒÎ‡ù¡^vPˆ&ˆR)Ï6Œ‡Ã∆˝!Ö\x˚ÓiwπˇæÎ∂á¯¸”yàßa”ƒw«¿Ï[ªŒÁ∏Tt:˚Ÿœq¨(„Aƒ\WÇ8>v¶|óM¶Ÿ“◊¬ßb,˚9ÂwöÙAyì˝˚ œ ƒ~∆¯“)§K]øƒ∫±ß°˙,î◊∏~ä}êòã:sëw÷ıY“g≤o„s%*¡Wë˛£>»xà›qß»∆YXÔ¬wNÔæõ§Ô4‹vç?£Ë¸vëÁˆ*·3ªÂ‚%_fcÃ˝¶/¬Ê@_.,Ô`"4˜Mböb\EÀü{w5”(æ≥Õ	ÚΩ"˝÷≤¯\úœwﬂìºNº^+i0|JÒEÔA	^[ﬂ&≤¯Ó¬<˝¸¶èúÎ"Ôiû«ì“WzËŸ|ú⁄w¶åk¯}«oá9Øˆy˚eﬂrEjoç¡∑=Ü{pÖÔy∫]›˜˚–vØ‚)Ü«Ìz\j¸¸ª§Â^yƒ§>|–?ﬁYÁ¡-us_ˇ¯”Dπ’˝sU≠À†6óÇ«˚'`;œ3xèÀî;F4S6¸‘ˇ◊º°—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—\<D˘7P7›Lk»$ÉÇTNuDÊY„eÚ!MT@ª+àˇÓìø¨˚©)π7xÆS∫†°ûªîÓÖﬁ®t˙2•˚ÈœzXzºπ‹¶Á}•{h¥qó“*0ñ)] µ“Ω–3J7°ˇ^Èè·–≤»¶
¸OÇ°ÖÖúA	äÉ=@M2g
RIË¸[è¸ò¥(CIòÒoQ-Ú†~äöe*
Öı¸6¿2=Ü∫lì6ı %€kÄÕ˝êIZÑºÕˇ7∆¬≠∆eãnΩ:§bHqÔÕÅV/Snœq‰ñÀ,ŸˆB9VãÊ!µ•)9Z∂.€aŸì¨»¬®5#O§häZS…¶D≤>KƒÀ¨pc£U[∞0’l’Fõ£…%—Ü≤™puıÙ∏p2Vﬂ8æ*—ÿ0#ÚÒ≤§n≈ö≠z+ï¨oàﬁ_ü\d%Ê˜€Ωã[)î’≈c©hÉ5'Uüä¢rº°<ë¥(IZÛã„©d,⁄\ˆ_\Ó*XV„:‰∏>ã?%	»Ùëı`¬Â‚º:W“ÍvS*˜BŒgËwtâøg#-·|±ìûQ¯µ¿ì@P•ÿôÒÁ€ïœA)î2]4Œ~ﬁÈÇr”ô?˛˚vÀ>—Asi≤;“uú›ë©¨∂•úEWñ_/e:«-ˆ⁄°T+î6¨[¿OÄâu–[¿B<-⁄”SCha;
Ñ≈vx∂J¸˝v|Àvz_Âx1™mô‹A‹˝6Y´XlC≠ ~É†<%ª8@@kGY;¢]lMC¡pûÿLÀÄ!ßÄ«C!¥æ!îs≥1jWÜÉ‚4¥[Ã†.`†Ÿu®∂éòOKèø^N·¥L^ÅÑ˝*z≤
]>â_èLW∂_ïZƒÕ?úñıLWLtïLj{fa)yDTƒiÖƒCê%êÛ GBﬁ+(_é≥2⁄-ËÔòﬂ"Ü—XáEŒyHTãT,Õß‹~ß«|÷∆OWKìÄ»ßâê9¬ü∂C÷^Q)'E&˜*ﬂätpò˝Ç¯éS!¨Z`5<xA‰aeÛ‰óD2π˘ˆ⁄ ¡gF0-!å—ÉYéÀÜ‚i4,æ,Æ•"î-#i‰TQ"Â≈Vö
π)3˙⁄P◊^Ò=Yk=7äÓ'ª[kr&ø¿Ó
Áä…(›-⁄∞ m≤Ûµô—_∞)<Zå°
``éóA[&7}+¥V¨Z+V™+’äAµb˜ëX˘/“À8∂©„é„wg„Áí8ÅóêﬁKÃ≥â]'#5ÑﬂsÌV´ˇ¿ZŸÖ™Ü.R˚ñl7mC@B™†ë&Mö*-n•Eh¨Õ˘y§6	"]V©⁄‘amöñNöÊ?ÿ_£¢L˚o æwvÄi˘ß⁄Kæ˜Ωw˜˚‹ÔﬁΩÛ≥zÆ"f‘qÅ‰”döG]n´ßl,h]UˆÌØ;ûvx±0ûe,%EÎûjG∑úô◊Ó€©¬º’›„±;éˆycöébu∑w¸¸≤#®.ÂŸ™w@y€ıécwÎ÷ Ïó∑‰éc/B.Ã†„˚).,ésπë9°Ï∑¨!â˝ë˝IﬁnvÁ“◊ˆØ⁄˛˚ño¨≤FÎC¡˛ ΩiÌe«`Ø≥øíy‘[fkx¯sˆVì≥`_≥:â¡◊q˛x˛=¯m{ËK^cµ*sˇ–ÓÍóÀ÷Ï–hª¬çve˜@ª“◊?nÏ◊Ïs≤C¸æ˛9[%√ªp/|ï…ó[lÇÅˇ™Ìøa+rã≥œÿ9Ø⁄›r
¬÷§-⁄.iü⁄§uñÂ+ÏSvìÏAË'∂ZoT˝˚xœ2∆£ÏÁ¨hÚ>´ì}D3Ùü*ìuÈ§è}lGÂ sˆäŒÎléÕôﬁ®iòas¡1"·»ÇC7Ù∞’tÀ√Æ„2œ˘eÔ£åùa˜@&4«Æ⁄Œ®∞˛çkí◊≈», ≤™ÂPÊUç†Ù<Í˝V’bÏ
91å1]Ñf°K¯¡6«.@Ô@ÔBÔ©ñ"TÇ¶Ò4…É»É»É»+""""Øàº ^Ç$ëëëëSDDDDNræ99E§A§A§A§ëëëëVDDDZ&Ñ	¬TÑ	¬aÇ0aÇ0AòäàÄàÄàÄà(""""¢àààà"t:ÑÆÑB°+B°É–····QÑÑÑÑGuJê$ö ö ö öähÇhÇhÇh*¢	¢	¢…¶+éÜıêêêÜB@@@
i i i¥/Ω®Éa€Ã@°YH≤´`W¡ÆÇ]UÏ™⁄^%H≤Ñ !@EÑ !!@BeeeeEîAîAîAîQV∑I‚ªo Ô|kÿ%öq„ªñÕ“Â…Â3d]˘{§¢¸]≤†¸rY˘U>M¸ 1ûÚ"·njÛhè’èG¿qËuË<4-Bw!M’ÓAÉ6ÿÑ9ÏÏ—ékÛ⁄¢vW€∂®55÷„:Óöw-∫Ó∫∂-∫ö.¶[¨K=GÒh!®Ú" áæDP∆T-∆"ÔA<g'wê4{ø—ÈΩ Ω§ãA˙AêZÏEÍTO:ùD&N3Êˇ1æE˝Åcx2]_z∞õ€˛ÁxçÆ¥lƒ¡@h∫E°q(WmAƒgÃ·ˆê+P ÇtôÇÙ˜„b_Ø€¨≥.∫P˝¢ãt»<Å˝‡ñÌ@V≥«aüŸÅs‹Í†K$ —[∏s7·ã6øèÓOZˆKõ/√nÿ¸ Ï5;p v⁄|≈≠.˙2·Nâûj˚$Æ[˙IõøÇ∞6ÅÖÏÄ_Fë»@ÔÕê˚p£MÌkeÚŸ¸lÿÊáe¥õ‰çß.V”€IwT1°áuöqRs;ˇÜˇò? ˛,,∂«◊zÕ	ªg‘Ë+f'_	ˇ¡∑≠NèÔáJ€ÖÙ[|¡∏ ?ƒX‘X‚?Â¯ıpÕçÊkò˜Uï¬ÊóıªiÓ‰≥<¬ã·˚º¿_‚g˘I˛öÅvõü·+rö$K3ÏÊOc¿Ô„*õøh‘‘_‡?‰&√˙ä\_r®5n4º"WÄå∑≤?ãı5π«_é÷hØ‘æ’Ê¥”Z\;¢˘¥aÌmP€ÂÓs{‹›ÓÓN∑€Ìr;›ÃM‹ªjM3D∞mwπ<“\NY:U›√dâ%a‘Õ»KDÏt§Xj2NSbıí:ßãM˙j¥Ûƒ´bõ/NE_ä§N≈≈°P™¶mú—PJhÈ”ô
•◊≥hÏG5JNejtC6]}œ£ì\π6P'î>}ÂZ6Kº˝o«º±æcΩá_HlQ‰⁄eËÒ·}≤:(~íöÃà_f≈∏¨lfS‚“§~&Sg=¨+ô®≥niŸL›ôg=…ì≤›ôOdv_Öa7w#å§!Ã'∫√Û$.√pèZq~‡àíÜ∏Œ.‚Wq˛Œ.Á§2Æ≤Æ']W1!Î*f› Oƒ`«ÄMT¸~Â”iFF—åOWQqéê0W!øÎ‘@ú™dbÙqà—ôx2°r9Ë„ﬁäŸµ3f◊~ƒÑ˛œc*¢’±“ÃZr óÃ˘íSPNºˇˆõ^1{N◊+3%Ÿ°á?wÓç7•üù%ﬂTBÃ¯zelmãÓ5Ÿ=ÊKT»ZÚT¶≤fN%Ï1s,È;õ»VcG3÷Â∫˙(WÊËÉïÉedÆòµE∑%ªc2ó%sY2WÃå©\…∑‰æOg*nœ>¶ÂU∂Ω{870îç˜{Ú«‰ÜÆÚŒ‹vzÉle≈_\tA≤+lÖ-ŸÖœôÏÍFsOªÀ;sdh‡6Ω—ÓÚ†π◊'õKKdPJLúHâ°…W3r´ÛÏ÷˜¨ ’Ì%…∑¯«yQ	OFí¬ñGq´£T*dQ
Iâ‡dJ<w3—4§ %≤h;∞ŸÊp®∂JGG≤∂±äŒ&Aã2ù¨Öh+hv‚≠KceWYcÚU°X›38~˛æ¡/Bxèc”ˆËòzãòÆÚ˝•Xùh9^W•€{Ü∆ë°*›hπŸFeŒòœEÀF9\é∫–∫¥ÄFæ øJÌ—)Ü
õÅj1ã≈∆¥dæèÏΩÉ*qYVB°l®@’z˝Ôb”ÕE¥∞Öˆ®5|qÛÜ¥⁄ÌAp'ZŸKõX©©ŒíÇZÉ¥Œèú˝GÄ ûó˛)endstreamendobj20 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj37 0 obj<</Metadata 42 0 R>>endobj42 0 obj<</Length 5767/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 27.9 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2023-09-25T13:28:08-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2023-09-25T13:28:08-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-09-25T13:28:08-04:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e9ccb478-a5e7-984e-a54c-e534a8c2b689</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Dark Gray (CMYK)</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>11.000000</xmpG:magenta>
                           <xmpG:yellow>7.000000</xmpG:yellow>
                           <xmpG:black>77.999997</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj31 0 obj<</BaseFont/BADDLA+ArialMT/DescendantFonts 43 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 44 0 R/Type/Font>>endobj36 0 obj<</BaseFont/BADDLA+Arial-BoldMT/DescendantFonts 45 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 46 0 R/Type/Font>>endobj33 0 obj<</BaseFont/BADDLA+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 47 0 R/LastChar 174/Subtype/TrueType/ToUnicode 48 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 333 278 278 556 556 556 556 0 0 0 0 556 0 278 0 0 0 0 0 0 667 667 722 722 667 611 0 722 278 0 0 556 833 722 778 667 0 722 667 611 722 0 0 0 667 611 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 0 333 500 278 556 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj32 0 obj<</BaseFont/BADDLA+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 49 0 R/LastChar 174/Subtype/TrueType/ToUnicode 50 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 611 0 0 722 0 0 667 611 778 722 278 0 0 611 833 0 778 667 0 722 0 611 0 0 944 0 667 611 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 278 556 278 889 611 611 611 0 389 556 333 611 556 778 556 556 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj49 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 51 0 R/FontName/BADDLA+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj50 0 obj<</Filter/FlateDecode/Length 452>>stream
Hâ\ìÀj„@E˜˙ä^&ã ?∫´b«N¿ãy0û˘ Yj;ÇXmy·øü∫}CF`˜RWù+™ÀÌ~∑Ôª…ï?”–‚‰N]ﬂ¶xn©âÓœ]_ÃÆÌöÈÛ.ˇ7óz,J€|∏_ßxŸ˜ß°®*W˛≤á◊)››√¶éÒ±(§6¶Æ?ªá?€√£+∑q¸àóÿOnÊ÷k◊∆ì˙VèﬂÎKteﬁˆ¥oÌy7›ülœø7~ﬂ«Ë˘~Nôfh„u¨õòÍ˛ãjf◊⁄Uov≠ãÿ∑ˇ=˜+n;ûö˜:’/œf∂?ìü¡+Ú
º%o¡;Ú¸J~5^n2€b¸F6Å /2€b»,d+Y¡tptptptpÏÂ—+0K@ñ¿æ}É'{0{Ù
¨P?–?¿_Êôm1fAYíó`÷‘Ê‰Ê‰ˆÙÊ‰ˆÙˆï‹˜Ö¸f^A^a^A^·7|savAvevEv•≥¬YÈ¨pV:+úïŒ
g•≥¬YÈ¨pV:+úïŒ
g•≥¬yC[0lüSÖ±≥”·æf∫π•d„úèPûcLp◊«ØS6£≥]¯ "È‡Ùendstreamendobj51 0 obj<</Filter/FlateDecode/Length 26123/Length1 55236>>stream
Hâåï	XWÄ´¶ª´a Âg∫g†'ë∞∆UñDó<◊›¨ëDwçGD9Ô®dEó ºV¿ºoQT‘®xqxœ8åg‘q’∏~f›&oÄèÕ~˚ÂÀæ˘™∫ÍΩ™ÔÕ˚˚Uu⁄‰©±‡È¿Aƒê°Ô˜ÄñabìùöÕó=¿P è/b¶•…-ÀûÀƒëq©„ì[¸N,FHü43næ›§ <ãèçw”ÛÌÄ·XPH<õhâ>õ©Ä¯‰¥≠˛FÄ‡´I)1—™∫ËtÄú)Ãøô=#µe˝Ù'L…£ìc_ÊΩ]¿¸D ~|j î4{ ‹ ®®u¨ßNémçØx≈˛o-p‹U’q¿IX#Ùdßkyr5ßÚtT."ØrﬁÅˆS0£Kuv‰‹Oˆ≥7uMüaO1˜á⁄Ìv∂ØA(uÏ<”*¿ÊΩ?fag&≠ìÏ©R9b˛{∞EéHtrVª∏∫µkÔÓ·ÈÂÌ”¡∑cßŒ~]4ZI÷È˝√;Ôv|/Ë7›ﬁÔ˛€=ÉÚ¡áΩzˇ>Ù£∞è√˚ÙÌ◊¿¿?˙„ü>˘Û‡OáD|ˆ˘–a˘Î/Få5˙À»1Q—06f\l‹¯¯		âI…SR'Mûí6u⁄Ù3gÕ˛jŒ‹yÈ_ˇm~∆ÇÖœ¸&+;g—‚osó,]∂|Eﬁ U´◊¿∫ı6Ên⁄ºekQÒ∂Ì;∏ùªvÔŸªoˇÅÉáó9ZzÏ¯â≤ìßN√ôÚä ≥ÁŒW]∏xÈÚïj®©≠ªzÌ˙∏u€h∫cÆﬁ=å4òUÑ`òãvï¨°⁄≈˘sC∏n*7óÀ‚r∏Ó2˜Üw„á/·¨TxM˘êI‘õ"….&k4âö3ö*ç];OªV˚Éˆ≠‰#i§“`i∏4B%})ÕëJÂRùdî^HØ•&πΩ¨ór7πª,˜ñCÂ0πø)ß»Û‰ÂÚ!ù†Û“˘ÍÙ:ÉÆõÓS›0]§.C∑BW¨WÈIﬂ^Ô©˜—w÷K˙Æ˙˜ÙÉÙ—˙XïøªøNE•∏*Óä∑“QÈ¢(AJ∞™$)ÈJÜí©‰(Àîeß≤_)Ué+Â EÂärKyd5Ñ˙¢1Ü8C¢!%()hz7ﬂ¢ŒE:õ bµÖŸ˙ÿ˙€ˆŸûÿÏc?n|’ÿ–‰ﬂ‘`op‹3v√ÚU†“©F™vs\ó∆Õ‚2µ≈‹&Æö˚ëo«Gô¬°ZxI@.åöñtNQbÑµ$Mπ¶I⁄tmæˆïRGIñI≠‘∆HÈ“a©R∫.›ë^Ioÿe˜d‘µrØ6j	åZÆúﬂL≠C+µ¡∫°∫QåZn5F≠ì^€J-J?Æôö¸‘"⁄®Â*˘ ˆ6jUå⁄MF≠wµXC£î∆®˘…6¥il2j·∂~∂Å∂:[CCdcX35π)›AÕ~ü’Á&¨1ÈÍ(∏¶	ÕW3+∞•™.ÏY˚ü≤|Ç1¿:‡´n´è’ÀÍamou≥∫Z]¨j´≥U¥íU∞rVïû:ﬁXX7≤¨`íay{∑ÿ2˝Y≥Kûıb:À2†>°~¶•‘zÈ~êe±uU}q}û9œ\hŒ0ou‰◊˚ö'ô«0Øª9‹‹”`h`
5ı2Öòzö∫õ∫öÙ&?ì∑	çœçV„c„C„=Gñ±“x“Xf,aVÖqãqèqÄ±Ø±è1¿®7Íå⁄´-',áÕ«‚|„<Ö2VÇÎƒµ‚quÀ9È	Öπ›v´q}* ”‹µX◊ÁXÁG3b˝ô§ôL/é∞hW&!T(i…v“2ÈÓ‘√iúSæ≥@›¡1´ˆlïÅ+C¨˛úi÷ß’”~6€‹∑[f‘Î~1w°C‘ô≠^∆ØÌı≥Ã—Í»6{‰ˇ⁄f≈πÑ∫ƒˇO õ pëêè`!,ÜlX€`3∏CC:ñ¡K¯¡J»Ddﬂ”∞∂√?·ºÜBÿ	Á†v¡XàÅ\Ug·<\Üp.¡˜5p™a7åáÁ∞ÆB-‘A<<+|	0!í`"‰C
LÇTòS`*§¡4òèaÃÇô0Ê¿WP0Ê≤Ø¸◊û¡QÃ√ï®By¿∏
W„\ç–ÑÑ":Å◊·z‹Ä1–’ËÇÆXàõ‡¸àõqn≈",∆m∏w‡N‹ÖªqÓ≈}∏¿ø‡fa6ƒCxK∫a;<ä•ÿ›—=¡w—ΩÒGÏÄ9xÀ$û¬”¯˙bGÿ{±v∆3Xé~ÿ5®≈
¨Ñ∑o∏˜QBu®«≥xœc^¿ãx	/£?†ÇºÇ’XÉµXáW°ﬂ¡w±+¬xà◊(ã≤)á—b˙ñri	-•e¥úVP≠§UB ≠¶5∞ï÷“:ZOh#ÂS“&⁄L[h+Ò	|"”6⁄N;h'Ì¢›¥áˆ“>⁄OË üƒ'”!:L%tÑéR)£„tÇ Ë$ù¢”Ùù°r™†J:KÁË<U—∫HóË2]°jæÅo‰õxª 
*ÅxAH'¡YP.TCµTG◊Ë:›†õtãnìëLtáÃTO∫K˜Ë>=†áÙàæß«¨÷üíïû—?Ë9^«xo·m4∫xäÓ¢áË)zâﬁ¢èÿAÙ;äùD?±ã®µ¢$ ¢N‘ªxπxª¯¸Ds}wY§q ˜Ÿﬂ≥˚<Ô≥?°Ü êû@°(EöÙNËà®Ë!zV "

àHÔ¢‡›âäÄàÄs¢ûz
XËHBo	HÄ‹z7˜«˛µ≥≥3œ|f˜˚ï≤í'«ÂÑúîSrZŒ»Y9'Á›-WËä‹mw«ªw◊›s˜]i4à™(ÿ:∂ÆM¥I6Ÿ¶ÿTõf”1Q*Ie˚∫ùh'Ÿ7Ïõv≤ùbß⁄∑Ï4˚∂ùnﬂ±3ÏL;ÀŒ∂sÏ\;œŒ∑Ç˝Aû]¥ãÏbªƒø^K˝+ˆæ]fó€ÏﬂÏﬂÌ?Ïá¡°‡pp$8Ê‡Qª¬~d?∂üÿïˆSª Æ∂kÏgv≠˝‹Æ≥_ÿıvÉ›(U$N™J5©.5$^jJ-©-	RGÍJ¢$I≤§DÊFÊQõ»8jKÌËajO"£®#u¢Œ‘Ö∫R7ÍN=®'ı¢ﬁ‘ár©/ı£˛4Ä“ LCËJè“∞»Iï4Ió…îzR_≤‰Ç\î|)êKí-§!Õ†ô4ãf”öKÛh>-†Ö¥à”zóñ“{¥<™£ë(ÒÍä∫™Æ©?‘uuC›TÖ™H›VwT±JW%ÍÆ∫ßÓ´ü≠A4D ¡ÄÜPeÇÄÉ(îÅ≤Â  CU*B%U_eAe®qP™Au®ÒP”g¥w|ﬁHPŸ™‘Q°.$B$C
§B§Ké4í#ÚáïÀrEÆ 5⁄
ê	ı†>dA64ÄÜêç†14°üÈØ¿xx&¿k:LÑIº	ìÈWòSÈ7⁄F€iÌ§]¥õˆ–^˙ùˆ—~:@È¶#Ù•cîG«Èù§StöŒ–Y:GÁÈ"ÂS]¢ÀtÖÆ“5∫N7Ë&›¢B*¢€táä·-òÜ1XéJË.∆by∫G˜±VƒJXôJ9`≈ÄU0é5GŸ∞ebÊêÖV≈jXk`<÷‰(ó·≤Éµ∞6&`.«±\û+pEÆƒïπ
«qUÆ∆’π«sMÆ≈µ9ÅÎD'r's
ßrßs÷≈DŒ‰z\ü≥8õpCŒ·F‹òõpS~Äƒ$LÊf‹ú[pK~à[qkn√mπ?ÃÌÂ∫‹‡‹1j£Âhï®„N‹ôªpWÓ∆›π˜‰^‹õ˚p.˜Â~‹üD£—2—≤—»Éx0·Gx(? √¯1~úü‡·¸$?≈·¸¥‹‰ë¸?ÀÂÁ¯y~Å_‰ó¯e≈£yÃÄô0f√òÛ`>,ÄÖr¡bXÔ¬Rxﬁáe∞ú«J°…mπÚë¨êèÂY)ü *Yç•.√=Qø°'Î©zöû°gÈyzÅ^¢ﬂ˜`Ö^©WÈ5z≠^ß7ÍØÙ∑˙ΩYˇ¢∑√UΩ[Ô”áÙQ}Bü—Ù%}E_Ékpn¿M∏ÖP∑±)>Ä ˘L÷Jâ‹ï{r_J] w†J‡.‹É˚P™≠4h≠#P†S0õaslâ≠¸È6ÿ€cGÏå›±7ˆ√A∫&≈«Ò)âœ·K8F'„8ú‡s—$|ß‡[¯6æÉ3q∂œHÛq!.ˆΩÚ=ùéÀ¸?¡’¯9n¿/q~çﬂ·èæŸ¸Ü;q∑ŒƒΩx è`û“ŸxÛÒ
ﬁ¿",¡Rﬂ{¨œeM9SﬁT÷˘&Œ‘-®ñOÙ	¶ÆI2)&Õdòz&K72LéiÍRKüˆ€òvöÃ√¶ΩÈ`:öN¶≥Èb∫ön¶ªÈazö^¶∑ÈcrM_”œÙ7Ã@3»Ôñu≤˛ˇÛ—°Ì˛73ƒ3√ÕÛ¥lt‡å]Î*π™.ﬁ%∏$ó‚“\ÜÀr9Æ©kÓZπvÆ£ÎÍz∫\7¿q√‹p7¬çtœ ±hïhú:™é©<u\ùP'π4BB®√Hà°	mH!áa(°£aô∞lñc√ÚauJùéFä"∑#w"≈ëŸ!;eóÏñ=≤W~ó}≤_»A9Á·\Ñ|Ÿ¨æÄ∑Õfïlæ~TgÇı¡Ü‡'ŸL
~¶ÍÓæwˆˆ™óö°f V›W˜”˝ı ›GÁÜ˜√R	Ç[Íú(’D¥D‡˚»Ñ‡Òﬂ≠Xâërná€Èvπ›0]KÇK¡øÉ¡\ıP0KµVc‘5WÕScÉ™Ò¬fîm∆¬˘J6…◊Úç|+ˇíÔ‰{˘∂¬œ¸
ø¡6ÿ;`'ÏÇ›∞ˆ¬1»É„pN¬)8g‡,úÛ:[xç}0˚Íö∫ñÆ≠º…'p8>Èùˆ¿ûÿÀ+}á·c^nÏä›ºµüp3nÒﬁ∂·v‹·Ìæå£p¥W¸<æÄ/Ídù¢Suö◊¸
é«WΩ‰iﬁÛTÔy∫˜˝öN◊^ıù©ÎÈ˙:KgÎ∫°ŒÒJo‚-,Ùb^ˆNcº‘ÿ?ÔÙN„ÕHoıÛ¨Œ◊˝*.[{ômΩÙ„xOzΩ©ﬁp≤7úéÌMñ…ˆ¶ΩÁLØ∏ôinZ`*¶ÍF∫±æ°o‚¶†˙◊«AıH“¯Æ‡®™+|Œ}w7!≤¸Ü$@ﬂÊëH≥	!¿íÏh
$p7Ä›ÕO'A*± ™ÑﬂâÛ†-H--ÚÁœ§@0ÿ°„(îRê"EeDêÃ§R
Eÿ◊ÔmB$ùë˜ˆÁ‹{ÓΩÁˇ‹s®/ëuÒﬁ7Rm]¥qˆø∏äﬁ•_Î∑ÌŸç ˙®Ùt⁄√∑)ën°ÇBI“M‘Ïo£æ}âz“4⁄Ä
t ı¶È45p{ho¥ZWh4Ω@[¨Ωº‹⁄	¸Û®“oÅÉœ$”öåı”Q©_—.Q–˙-≈Ru¶Q4ï{SÀi∫^§ıtàü±nÅjO¯ﬂîK„húuÿ∫C¥FÆuúÈÙ'TÙÿiï[’‘üR…Î¥ı9•Sù≈‡…√MrπQÂØ¢ó9I˚†ó–_D8^Ã÷ÚÔÅ“DöÅ˙ˇi2—Y|»›π»q∆—b˝ ∫LNÍA¡S5]·a<IlïÒ÷Î,Õ§}Ù‰µﬂ&9SnsÃååµ^µﬁß^¥5˛ª|ÿ1‘ÒõªÀ¨ﬂ[oQ<¯çLù2Ù4á—°¸ãæµV-M†P>Ç™\G≠=êO£ñX"ñh'i§ùnü¢ﬂëÇEˆ”:›¸5ˇ%T¸)¸c.CÃ|ÉÍ§B◊6j⁄)…rÙmPt¥ —ıN¥:Œúˇ0ÒûáûÂU>/î∏&n XπB~+Ô:“#Á#ﬂZì≠‘áíÈ'Ëzj°€?D„ˇØÙ1˙≠ÎÙÙŸ\Ö>F!]Cuî*¶à±Alo"7¨”Àa2O>.è…≥àá’1·ò»ù◊#/Fﬁåú∞ˆZ'‡;]q~:@£À‡[È=tc£˝î.ÿ˛ÉÛGq)?*Û˘9^è~Ë∫è´êí¢o™%|†:O¸zZΩM∑"ÿ9‡¨¯T|-nh-$ÓD•5j”æî.ô.…!rä,EO0ÔxdÑÌé]é˜-àõ
gçÛ+‘‘+cèﬁÕ∏˚YÑ"UŸﬂçÖ'-Ü&6£€|∫8ÄÛ(4Ú	¨oX!Ω”C‡{$p!O‚GyWÚrÆC.{ô7¢”{@‘ì©¬#∆âï®ﬂÍP4‡›è\vZúÕ‡<Q3ê;ÜhµRm¶ˆdX†-—VB≥Î¥ù⁄qÌ§vY˚JkÜ’e˘î\,_ë€dÉ<ÅÚsº[pO69N8Ó8Ó8Ö3ŸŸ◊99eªÛBå3fxL˙ÑS1◊ck–fÄsùÓ{Db∞øÿ)z Zn∆D?ñî …=∞C	¢‚:ç’"∞KWﬁzâ$Ÿ√ﬁÈÙJÖ˝¯ „#TÎ…Û¥õœâÛÚœb4∫ÿ'…m⁄éÖõv!≠ÔäúG"WÃõ4‚Kºù.¡ﬂIÎ˘qûOª∏ôs¯Y¡µtJÙ÷Jx%ÂZ[Ñ‰N<ë[–2YAè—IÁËJd≥Ï"üA~j§∞ËÙ9Ô†€Ï∞Æ!ªi»Fadô5˜UdgΩŸà≥Zƒc2»\Áqj`'QÃÁπòZËøt≈±ïáLz9R-7À/¨V"QF€wU4s	^rc{4ëá\2Q]D•TAœ"Î≠≥îµ…Za-≤Ê—Gÿ{}»m~—àπÙﬁÁÈ^ç8ˇ`9øÔâTP]Â>ú∆CÕéÖ∏ôv¢Æ:‰8ÊmØ§çËÊ8HPN'Ë*›‰Xÿ&â2Èõﬁ4WµÉîœ…TÉòà<û◊&…|ú≤⁄€Ñx>àÿhAûòEáËNÑDÂ†ãs
°ÁübıÎ∞‡
ﬁÉô
dÌ˙rwÂl± Ùº8i≤Vx:G_B€VîØL‰œ¿Y7ÈQ™ Ö·Tƒı∞¿;4ô’ßÖæ∞ãÚ8ïˇà}!DhWÍG#_∞†Ã»d+[Tkq«Xò∑W
çÊ'¡E‰∏KΩx
ãL'YìäˇÂ‚Qi’iOGÊ“G¥6Ò Ö1>Ô∏iﬁ±cFÁé ô=bÿ#?:‰·¡É≤2=?¯Pz⁄ #’≠ˇ†øæ)…I}{˜ÍŸ£{7WB◊.Òù„:≈∆8RLô~£ §´ÙêíÈ∆Ñ	Yˆÿc"|ﬂDHÈò*Ë∏FÈ°Ë2Ω„J/V˛ÏˇVz[Wz€W≤Kœ•‹¨L›oËÍòœ–π¥8 ¯◊>#®´Ê(<)
Øç¬] ª›ÿ†˚˚T˘t≈!›Ø
Vô˛ê«’wéÀ7Ú+„≤2©>Æ3¿ŒÄT¢QSœâc8
àDNΩ†ÿ.`J%>øJ2|6JKÛá+TQq¿ÔKqªÉYôäÛÀç2EFûJDóP~îårÊ´ò(Ω⁄ñÜVÎıôMÊöFïÖ<ÒFExV@i·†M£õt}*qÒ≈>ﬂqx˜¸@›˝ÿÕÙ˜©÷Ì°i÷È™©8p?÷mˇÉ8{EZA», È5PbaâjbU0†xHÍ∂$∂T≠ÚU~{&4GWùå<£ úÇiíMESπw''{˜YÁ)ŸØõ”Ü[çM1Ça_ﬂ˙ûdN]¥'…´'uƒde÷ª∫µ*∂ækBﬂÂ~†≤Ö¢Àm®pjªfŸÊ»òáPzπNd ∂*≥…,œ∆2<A∆.UãT´N˘!”ïcœ€˚ï#ÕeËÊÇÕ◊:ŒÑ€fúiÆdÉ∂ü¥ª˜`ÂÒ®å€EbÚaS8&:ñïπ∞Q7j\:˛†>*Çn√¡ú¡Pø€mxu£ó 0PKã≠cù Rvìw∞'®D»∆4›√Ùöncñﬁ√¥o‰¬ÂDΩTlz˚'¡’ªáø*GqÔ†+[ÒÖ%Faqi@˜õ°6›NÎ0j≈g∑„⁄ ’#?†•à6H§hQ,úrV˚b{àW2g‘©+îßåN∞^†\°	≠ø¡8∑˚{˜4∆ƒﬁ∑©—j±wEˇæ€÷∆• ÒtèÍ0Ó¿]º©Å_ô.
ßïöf\\êizÅ2√ç÷“2CwÊ>±Ml3k¸°{m¥ˆØNQkÇ¢äs‡¨ÇÚÍ~Æ∏ﬁÀˇcª⁄c£8Œ¯ÃÏŒÓŒﬁ√Î=ﬂŸgﬂûÕŸ'úœˆ˘Go¡.\Û~∫YÅ(`Q¡àWhì∏Ç$†8™+P
Æä
Ü»v†8˘ÉñHUKS“ÇZI’K"∞n›oŒ&Çäª€ô€’›ÃÔ˚}øÔ1{µ.–2ˆ.^~ñ`“∏j∆äì·˛†Ü2-£Á∂%πü$M¢¢- Umå¸äDm"\¿•àAwöáÚ"⁄H"ùò´'Z“	îÑÔ⁄c*c¡Ï`vˇ±!=6)zÑqz¥—^@÷”œêÜföÓp÷˚QFLC∫r#Ü0åà¸ TŸ=Á!CåâDÏ'˙≤{6Ú≠Tz8••P2©%4ÿ[∏§î‘hû⁄∫jBº9zÆè¨˝¯›Ó/›3¥ØmZMâΩ‡æ˚Ùê‰∆E˚™ΩÏÎ£ˆ±CÎ8íF@bfêÃ6Û Hô⁄F⁄‘É¿Ë1∑Ã¡G◊8&g0ùSÓ—CNéFﬂ–»—§“7ü„˘ûP'BµO˜Ê»D¯˛¢¶)ÖÎˆ]:¯˛åÊìˆÇ≥x≈∂ØÒÔq≈5ªË¡’oÏa˚G≤Õ¿=ò∑á…ÛLqH™‹èãÃÈ0Æw®Í\*OÃBd†0Íw∂mœã ÌVÀÕ4Ï›íN„Ïî›–PÛΩ9í$ó’÷÷ïtb˘∂÷∫%≥»^Ïø≤ÎÌÕ∆÷¬’K¯~”Òõ‰E“˛Æ2É1lBQﬁ◊Cà	¢–DµÃ^Úã=/ÒΩnZ-⁄mU§,ÿº;ùÑ°ˇˆ€w¯j˚a8	Ë4—Ùíz§í“ß–äﬂ°Ms¨ï±j¯ˇ~~Æ„ˇ&pPC¯_–ÆrÌEÕ°KRΩ®≤^Å©4F	ÌU˛|"„}.≤ƒJ¶í©1$Æ+|-8y∫¯¸¯ﬁìï7@ã¸ΩMH Ì6À%ÕÌâSM”„SÚ¶¯M∫ƒª.ˇÑ,1üô˛@úC&®µ®æ0´üÏ?´˝¸º’,ˆ‡Bµ»i,®˘ÒÂ≥ÇöÜ5ø—”8n\j.†kIÈ)ÆêDz¯¶ñæmEtÓdE" ‘ö88¶∂&^ZR,…°⁄â’U"¯Kñ$Ã ﬂå‚Ö#y°›õ6vÿ∂‹æãã^<π"í∫v’9÷˝ß@Â‘Ö€vΩbÙ=L≥~˜ã9≠∂û1WÄñ—’tyÄ¯IË∫ô‹Qé◊ªwñﬂGDëΩL
O
Ü|z¿;œKbﬁ^/ÒzsJäC∫G1rBëÇ≤ÕRúiö√eΩNÏÏÍcé8∞–	âö—˘—U—Õ—éhW¥;™—XîDsädxb‚È'oıMÆ\4Fœ-ö’>iqZ©Ln‡WvCÖ’Èt yG;ŒNh¬&gÛ˘‘q∆”âDV¿èp∂b÷Å4‹|⁄±®˘t‰Õ3™Qø[»Ú´äÁÃÁÀ(]¢Aú]]UWÀY-+-"«oJKê9ßNºŸ∫iÂ]÷o∂œ±oŸ.˛‰ÉÚ.kû3ÈÍq¨wGf,2_˛îNx·›ïm'#e^[s±›•Ò≤˝eÀ~–¥Ñ—ÙÄΩì9≠π3^(ÁjTı-Ï@]Ê4Öä≤íÙ ≈1⁄B•LCêZUr hEõ2KEÏ»7\1óÈ\"30Ç8gŒß9õ´Y†ñ·ƒp‚9îQ‡jBÆÄ2˙e’âLdyÉ„◊;bÚÒW‰F⁄™È‡˚£˚v˚}@–ÔÙm1ìÄ^¢!ŸPb %ÂE¨P∫¢(hÃ¯ì“<PƒBj…71q<ã_}~ã√Á‡u˛y¯
©ÙT≤&}òcÎyê˛%gvıËzÚ±ÍùY_‘\¥TﬁÆlwæÆÏqæûªßÄIπRÅû´Ñ≥√y·¸pë2ÀÒ#q1kul*Ó €öˇ°˚CÌèÆÀ⁄5ÌéÊ
%ÅæÃ@~Ñ/ì∞Øp≤ƒt”≠«ıÊyÏ1ΩyqO?õÂæ…YT√øóÈKI¿00π8VLä˝e›*ŒRjLTàáæ‡´G∆¨nÁqoçp„µ·T;®∂lOG¨õëd
|óH∑G1#[Æ	fKbIÒDR◊Îj´1óñÚd‡’ÙÍ™⁄∫!I^µÏ#Áo€«Oº˝7úç´'ŸˇúË¯‰÷ó¨èI¡˝tÎæèq€g∑öï≥o}Z˜“+#wÌGˆ£ŸÒA∞ìÁÅÚå>kÜòHUÅ05$ÍΩ$Q
Æî‘IC˙ãå°‘øeõÆ˘ÆU.a≥´√E∏Tª]C.—EcŒÇ3&◊mœÜ¯ñkº˙C“À‹ÁΩ
Ω
c!Œßˇ”ÎI|˜>Ä√§	áÌÎÈt0}âL8ì¸<˝ÿ‘	Ú86	hS&˙™‚q TI(3õ…ú‹8¢&ùO;ËJt›Lø•bÖ“F§·sËrN√ÅUÇì+·F˝ÓDÙ±Úâ3∑åõíÃîÚˆ-Äñ„Îƒa:¯p&‡x¢ßáûÇViöô?_ÊkãBà"E§˘PÌü©r‡È¿∞˘∫-ÈÒ•3V{ﬂ{o–SèfﬂÁÍáê¸`£ì‰ôáP™î:†c Æ√dÖS‚™1ejúıèﬁËüÕ£ÖQx
ÉƒıﬂÏø*‰yUıêBQcµÑLVMÕzq-€†Ó ;≈£Ï∏zû™#Ï°Í;"v±#ÍevEΩFÆãˇ`ü´w»ó‚-ˆ’µÉÌTwìNq7ÎTªàº‹±ñl€ÿzu;yYîõH≥ÿƒö’e 2∂\ïÛ‘
wúL„l™ötÀqäc™ó‰ãπL>#ë∆≈ÀÕ •2ÍîÂ*…Ì¨ 4DôØ∏‚>d¨t;\q≈tó≈|ÄGáMçq(tí†Z)\hI®\.%xYÍÌﬂS¸AAˇËTs2Ïbà
cU¬ˇ®Æ÷‡&Æ3∫˜Ó„ÓK´ïΩz{À
…6D`[6êq√&«0èÒ$º‘V¶	Ù‡aäM“§y4–÷C:í!`\ÀÄ[BIH˙ßùñê∂‘Ö&§t‹Ú#SL±V˝ÓJ<bY˜Ó]›ŸΩﬂwœwŒπú¡≤ˇ‘¿b∏ƒVÂ0VeYíà8ECZy@A∏‡Z(¨VgKp
._ëÊàMvàHŸª0¢XääÛxé]8≤a"c√$¶a
ïJxåáVÜ˛Mn<ô‘[˛≠∑D¬z!W»µDBz!ôÑ˙XØªe´Ì„Îí}€Œˆ’ÖhóÃ∏jWπÍF,^>™Xs®‹π.ìL2GaÉ≠p≥æü†ìHFùr∆ùQÁKÁÔ¸â…˚ıˇZπù∑∂”/ 1åz’Ë†Ωr/øW‹ßÓ”8MÙíPmh´¥•ÇlÒmı˜r{ƒ=jØ∂´bè±€ø;∏;‘QIÖhêàø"bDB˛©úÈë¬3	®="#F÷e´ƒá∂ï2m≥”Ï6{Ã~S∞ÃÎ&6ı⁄~QSïrπ„≈Å™ÌøΩCöÆ;†e'°Ê@€”≥©=j¥üŒƒ,îKn)3ø·˝{–¥ÀŸÓå8√Œv4Î —£_é]∆Á/ÔÎ>ñºﬂ˘ûÛ¶Û3ßΩå6ﬁtä≈‚‰ƒ-Í©fO@m—<l±´~ÿ±èhÅ«æjè¶1Qù™ûó!< ä%ˇCh|Å)f™oÍﬁ{ÎºÍ€¶ß‰yÓ ü{b≤9∑Ê≠‡m”èá1ÑVˆ,o†ãH[∂˝›ß˜∂o˛Ù√ÉGûüø¶≠©ü?àçÈÀoÚ˘üsgúŒ∫ßÏÿËë·≈î„Å#?c&ÏùsΩΩOêÕ fı]ÈóZ¸W⁄ü%Y9(‰f≠UkıQó|ÜfxΩYkˆ>‚}N˚Å˛'YŸ*m?oÓñvá{M∞¬Ü§zµÂ⁄s⁄µ◊µ∑4^≥<™·Ò®^’Ô	™+uu˝6∆ä—tA‚¸åÖt Æe<∫{ŒGk˚ÖÑ”¬NËÎé#+ûä„xÃo÷¶ŒzÊn÷\,î}¢[wçıÇs˚ÍíYmõ~÷=‰î•4ó•	mpÛ	V0XcÎp<ÓÛ›Õ*ÿøÆ}÷sÊ√Œmõúü_xv≈öı-?€‹≤¥-q¸*bÈÔvæÛy’úﬁ√Œhﬁ·L¨pÄmO¨zË—’*O˘x`frL¿)≈Î•ó‚;§n©GzE"‚q5«b¬àR0·vàœ£ô∂,•ò4J˙X≠w„¸
ÊpX,ºWäy—c´éb{N∆uJÖh^∑`¨åôW †»õ®OBóú%‹KN;wfb‚÷∞*¬0‰™®hW$Ÿ§`)ç
«H±#˜ß†—ËŸ{˙c·&Pã´∂1”rıˆà°#û*I&`¶9ƒ-®∆/Mg™%ÚO˘™zC∫)ﬂP˘s¸ßÚ9ıØÃy–âÍ5Ê+I:ÃΩ≈ñﬂQOr¸IyP˝ÑìÍ∏©|Ωl©˚π◊¯˝Ú™X¢ˇ„"“<≠(-Fu⁄ñ‡h>Fó|`†§ l?’Éµt§`«Á∫P73˜pæäËÒ3
«[˘bj@  œÏ'YFµ86Zà1òùE6Eñ6W2DQ‚U-ãºÑU¡⁄r*ÀÀ
ëDA$ÑÁ9	Tí	Ä6Ïo=®@•lŸFîªû™2U6<@ÿ≥¶åÊHxI!	
ëp!jámΩráÛıÚ«]=¸˚‹ñÒQ)XrØ|ª£é…ÂG`»R¯mrŸäUÇTBèZÁDı£HEù˝›Áp>v˛ÊåÇ&¯ÿˇLÇÕ]hªïgP± ‹±
$23\Ò◊ˆJ”iq,«≥Ñ„9ñ/][ê˜é%J[à#,§àC,f%é·e=¸∏¡VH5H,fD˘$¬≥$D¥–Ã‡∫S˙Î$ö,lcXm,uÄ˛rÜ˛;FT1◊Á¶∆WVJ ˙ê{\÷“'ÍgiZò§´ÜTq†p≠F¥≠,|Ö7±èN·ìÔ~
uÄj°Á¥~ò!≈ÎÉﬁπ£ä≤;Q1î4DÄÑå(L≠⁄4¢Öï<iƒ¡ÜÇ<Y5áI5ÖÂ¯º¨5ôtD◊Í"”ˆc
7ÑÑX∏è«`9åÚ∏∆u!’Ä*Åoª%$—R®ñ‘¥±ï•Sa.≈⁄l€	ÔYÊ 'f¬Ú‰{∑ŸæÙ¿ëtèâÓ!Qø‚∂„eC`ô&AQãq⁄é«`Ò=æ&µ	h-Í∫—°âÿäMKÊ·|Ò–1_ìBß7È·t;…íg&Ú,ﬁF^"É¯$ëL¨ìôÿ"Ûpä¥cõ<â;»èpè¸≤2ÅØ/0≤N⁄Çs„å(Ö°ò?¿‚¬Jn÷‰(˚Rÿ°â+ìÒ’¬‚◊\˜ gPŒﬁH"bo"èF€™V_‘/˘§Êpk¯âöı·5Ω5ØÜ_ãäGœE>â™Ç‡ÒÑp†VòÓœÑ∑‡^|H>‘ﬂ§ˇ¢c3—0À7√ì∞ìuÈÑ=u4a3›ïòL‡D´I#LiﬁÙwMƒò∫˘Åy”‰Lsjdl∏[J¯ ò]Âõ≥£:4°H:ñ«ﬂ‰àÍëgPp¿on?ª=Ãò3l€Pæ3´Fú.MÛd¶®øP1x√"ÿC[§’»“4JwúÇrmú{*à.—“‡S¡Æ 7nzˆ)d…8ÿ»liõ›—=ïÄ±LÇôL~ìMéπ
ô,·˜XΩârôÒ“`òIOEÕÙäƒ⁄Œ&3tG ó¨¶óƒ%ó•~§∂ππë 'kÇ1êÀZAàO≠iJS6ªdπu*~#–ÿ ∑öõ–∫bÚèø?ï_ƒF´ùkäNÿ∂∑≥oè<æˇ’èwt-ZÅ÷4_KÃ^µ`Ò√ç∫Çø®{ÛıÃû!'ˇ‚Æ≈U≥√bkÎˇπÆÿ&Œ3|ﬂ˝˙Ó|æÛ˘Ó|Á$N‹$Œèã“`áí‚ÉÑ@…B»Ë≤ÍÜt#‡≤—@’ù≤F@˘QÅïçA√Äm÷v¢°≠≠TM´®∆&$ˆ'Z—®—ñ∂È;{ø≥°€,ŸÔŸ˛Ï{ø˜{ﬁÁ}û°Ω´˜∑‰óÂ∑/©œ‹TÁöeıs√µ%Î†‰{ áÖñO%‘Ÿ)ªZ¨´Õ[öG™lá–atòâ¸œ9∂ÜÆóÍ}5yKË©≈∑$Ô0wî‹†a" á0ƒp>ü( Ñ‡πΩAT*H*,è†
€çzâ~‹SÒlΩ77¥éß>Z -´€@èbìFlN¢dcß-ˆ∞=Bè—c¶ÚôdÇH:éJßÇDÖÇïÈ>Õo<T©{êµcËF&ì]sﬁVcOlOÓ‹µ~›n∞≥á3˜2_d&2∑◊$… ”mΩ'ﬁ>u+çØ¡ﬁ„–	ÒwªΩSN®	cÉúRSFüπ›:Bqø≠ºm˛Iπeé±cÆ1ﬂò>≈˙Ê˚ÊÎÀ’ÂF≥ôpß‹‹µ÷®5©≠ÃVy≥[ﬁgùUœ£Í∞¡{ÑÊ≈pº®j1OT¬üX¡òeoL∫åhBÄö©^ë∞a)a√:"zpz∆(_˘9Ñ?E!¢J¬R®¸S èiV†3[ ÷Ò¿Î≠„ë…ÒOO&Ôb”ìëƒ¨Üö2a\'UÛj:,ˆätuÊæÁm©æó6ÆÏ—ëô¸˝XÊ>2∆o|H~<w’ìá^ø:∏Êπ™ﬂ‹@aDÉÔ)=Éï˝ìPªÓn⁄s‘õj-?hLÒ|o∞?H.†bÓzÃZN5πóÎM÷Qû◊∏à5`=9èG!¯+<Ra§»2¿ÿ	π¨ÇŒÜá;‹¸Y1é*…∫GèV§õRj-l2
’‰6>∆ÊÌø°Bwg¶ù_})3ùπ1¥Yiµ™È≈ÓΩª÷sœ‡ö*C†ôêuòTfz_ˇ ¶”?øtÍÏwÏ∑∞¢˘Ëg£Ñ}“,÷ÂèI?RŒ2gÑ+¸i$‡rihπîm⁄Çg•av8éÆ˚ñg˜˜π$ÂÀ˘∫°€oL÷ØÈ–)›AC0ÓDè"πﬂ3†ÆÙ¨ıêS≈£dÿ ã°®J‡5E1'>Rëçë9ŸhÊ;—ñÅN¡Ñiw©*î˘-™&.wâ»!T•gATÏ
><§Ér»eKr
ûc√ÆxÉj[≈∆ß:mÕ¥Àµ∏iex
61W„—ìàß·{Ã◊/¿
'ã‘U„8Ù`ÈdNL9? ‡µ'=‰«·≠º∞–yª(w‰V‚.f–§s{èUÚ‡õzÌ=6Àëd	0{ë»ñH$^kp¥Ñ!^TÆ¡'®êÅ‡√=¿±~Úﬂ»ú7v.sˇÂ“>G*õ∂©›ãWóQ€:ûjh@Ë´U«N]<t∞…ºìπ⁄˜ 2Ù≠_jl|ÛÜ	Ûhõ{Ó<U“EJë7A˜õåãæfí∫·%5’z|2°x|àPHçw…"ÍgERƒ!∞»+h÷@~T‡'‡ØYü&—∏´Õµ“Eπ ï*oóóÙé ⁄ñ<æ0©u'çÎi`LÄ|1,ˇ∂Q2Edœ(u$…L¨çuó0°M∞ôÉg^ÍÊ »Õ!_OhŒa=™ΩõÉuG_ÿˆ|∏q·„57ofÓ“·ïªw≠*˘≠R◊ﬁrgÊıÑ”˚ôvz≠£ ™–
˚ô≠{
H’-ıVÔñ˙´È"ÆìzE…(e£F≤ëZ#'¥DiGE’Fy ;ÂSÎ•®Q_}¥Ej2Z õùpß˝¬òŸ¢[+›Rô«Îs$∑ﬂ†Õ‹ùpÄÓÒ: π ∫≥±º2€ ≈•ŸXÀ6ØÁ9Éøã¡ÑS(ó·‡Ê‡Çã:gZleÖòòtxÀ
™Q5P–à-—íêj=ˆê}&s¸£å+ÈªÜUzrK÷<òˇÑìúsÛ!8æé:%∞<≈O¨†s#n≥√[rJKïÆØËâ§™X<Â¸å·0˜kÄ¬r ˆ◊Ñºöá,.°‡”æ‰≤Ìhë´†ºcSm©O˙ﬁı[}œ tÌw˝à[ÿ{e ÛœÃÏ\ª˛¿ﬁÎv6óÕ◊É!£∫¯È◊ﬁº8G$¢¿Ø~8≥Ù◊óüm=‡!w˛Ú¯©üú>yäı–Î	‡uÉ≤#2*Du¯ ï≈h±˜/Ëƒså¡îêùﬁ^D∂OÛ™>J#ëåãZ@qº h∫ ¢_¬.ﬁ.*âù„—,n(3âÒHIÏ†y“${Õ	ì¸ƒD&°Ö›°-X{RG:“-<[¯Õ["≠i,º·Í≥‹ª¨+g75ı;Ú ’‡Xí$¬!HÍ Âò3ÓX|âﬁÿ{µ{∞≠ sØ®˝ÒÊM—Ã=êûX÷ªw }à¨>≥∫¶iﬂÓÙ«∞i¿ˆ´–ào¬%Epƒ÷QÇáÃ‚^!nÛ+y≤üãøŒøœ¬3Ö¸Z˛%˛$|¿P,GÄWÉ)fÔÉ_&A±À—…¡Ãt∞*â—ñ+∑Ø/˜w⁄ìbº£¨H‹Ò·§·˘*≤2˜êE#:33ΩúOﬂ&»Ÿüf⁄—/úu‚ª’‡¬\ë7Ïb˙˝$°kí‚V¯ˇœà÷Ÿ.)xiaRa¿:˘•®ùgÜˇ2πëëœûá4Mlµﬁ5qı¡5:è'§hˆFˇ'oúµÓ’9[VÎÌºÔ~d’y°≤{~µV,Gj’ÏfNOøwÊiYû†ô“ÿÍSÃ™˚ y]∞/ë¯◊(AÕﬁπ y„Æ]ü5'∆Q
ÂcÀ¯ˆúpMxóO∏-´¿≠ëgÚÕÏ◊]ﬂaôa˛ØÙ8=C 2+∏Æ∂è˛>˝=»cèq«\B!≠≤:¬T≤ï\•´Jj°[¥6/.Åxä•EÜf°VÑ(∫8Åë!ømò*W]!á∏u)ÜQ?Å
!aÀˇnŒ:‡ÍX ¯Æ‡(™;æoø˜nÔ{Ôˆæ¬e˜í›ª\‰¢π#¢Y$\ÅH	AíìAPZ ¥Xj-Fç ƒJqö(ö„îHôÏ$∂ù¶’)ulGZu¶“2Sú`Gò¡P;d”ˇ€K¯®c/∑Ô›€}ªõˇˇ˝ﬂÔc≤-H·Üå˘
Ö?ÿ˝¯ÔªﬂÊ´fQÇö˛˝ê†dàT.⁄&`´›‡∞∫E
Ç/Á9àBhj4ª–≥ÊüÃœûaﬁº9â3üòz˝˝†y^}ªJ◊å‰(âkî©c»vfêcŒ1W&∆¥0O2˝pÇÅê(êöîÜàŸj$BÙ™q¶˛ Ûµ«º˘üºkA∞ΩÄˆ:Z8J$·Ó&x∞´ËgbÜ ô`&^C.·ók‚b!ïNÆZíÌ…æ‰+ÏIÓ'‚Ï‚`Ú\r<È$íÈd\¯uÚBíM·h¶∆Ì÷EÜSh.\ÄÈp»∆)+“ú€„—#—®¶€`Kπ‹ö◊c4f[<h'lê2g∏¬≠ 
ÁvFQKE·‹ôbM”±í"›WB5ÓçyÎ0U7¡QGëû—ç˜g“˙{˙ùrÈ1Ω]ßΩP/”ßuZ%˛Y5kÛPü s@’$Ë†⁄…∂&‹ÕBí€Ç•ÍÀ ˙ÊC>wß0›¢îOÒcﬂ'[ÓOX•ﬂÇ®€hµQùc≠›eπˆúH fË´nùkNÃ©û∑hÎ=Ê≠yum}˝⁄Ê5ΩSdÛÀs´ñvvõ$ô˚qciÆ„Ë‘MX≥#≈aÕDü‰|≤Øëﬂ ”#4Ç’r◊5ÆO‹kA∂ás:X—n	N"-@XêM†ix»óA∂ÕÆâNú_áCºÖ‹"∫ä1‰.‰∂2ıŒoåYıÆ‹’Ví ¿Ès¢hUÂ≤oß  ôŒ˜õé≠åësNoû_◊1d∆hÌ¯ô≈[;æáÒz5ËÚc©\\è±Ùö‡o¯n¯È≥‰%ÜÙÜòê@6∏◊˘÷Ç=d/€À˜à#¬á‰_ôø	äÃ{…·>…øK˛Å}ãˇù»Ï·≤<Â±™–.„I4'Ur·ñ»Æq*ƒ]∂+o^Ûfdñ’ÖmÓV"€Ç4¬îéö|/Ñ∏∆µH+æÉøWö:~eÃw>}—ºqvÔÿ—’µcG7©>èÿCÊŸ+◊Ã∑:¶^Ë?>0Ä„Ì4øA˜@ºn]«åπÛ}K}§7CU:*}ôHµÃ±ÃW˘<"¨c◊›Úcì‹ÁˆOÿ2^ˆ_F¿nwªú≤¬áwÅ◊Ú$ùNóÊv[Ãæãhá7Ö
™Ûq∂≠∏\Èæ8n^˛Ãr.÷1≠lÎù˛Ù%¨$é,&¶l¡nG›âÿÚü}}ëÊÕ—ıáW¬^h›¯Ù˛G∑<K[∑…¸á9eNöÂÍß>°Fá˙“…}PêÇ™∞b0=úh” Ïa®¥wΩs´sóó∂	.1&íá≈ië¨Wä§8B~«Hr‘7E≤∂!∏Ö2aó@·'Ω}^≤Ÿ˚§˜5Ô9/Ìu¢¨¯I≤ı#Ö<’£(ö◊mwîÛ$ÊEK^C&†∫+ÔÀß¢ç®î◊‘fW5Æ›vﬂ|»Éb’Ù-°ÕzP?ÆË≈€kZ˛ ˝Wßi≠g{Mˆ≥πãNô◊ ∆2®g7ƒXB˛÷c=lú◊eèÔıˆJ=zWâ¿I9âÙ˛¬1Í<´|ˇ∑cReìéz«fGóΩ«{RπEq£®F€¢n“xH˚’gäÑ
m	õ≥/w¨tÂîUN-“µ
1´d’l<[ƒ±6∆#(Aá.™™ÁäT£Ù[‚^Èª˛«í{JûÛwîÛwïúQœƒÌË∞¸|h…´%É•¨¨%û	—X&@¿ îÛJ]Ò·b≤ÿdä√•d@›∫RTVä“•®téR§)ƒ2[=L…Ûí‡ ^JÌ¡)ø	h ªÌÚÇ§⁄p¯2ëßR#À"ƒ¢ “‘yJNYã‰Mhõ<âlH&È∞¢í	üC$·f—πÑΩ.å¬9^æXñœMmëQBù~;	e$ﬂ´#”„√säx|8Vîá¬÷ÿà¿èÌ4OÕ©Ωé©o´®¨¢äö3^Ö(«ÆeXæßÕ[k¨gpo ˜®®—-®]EÅ‹0jA¥5”Äô+5”Wiá0‡—ÅrŸÄÁ <T6≤ŸHÕÖ¶8	<◊%«‰fyßLÀıa–€Fu·È09|[ÍzSûÀ.¶zjÜ›.¶Ú…»_l»;≈6¯45-ﬁ ¬•h˙C∞{´]	h ü˛‹Q)Jb%˛9$VBÜ˛ı∫Ωí¿7#∏–W∞ÃL®Ná¢œâŸè¡Äœ±~	‹P°Ñc
{w<˙Õäb…øÃ<˝µ}Á?>ˇA¬º·i^ø≥¨0™°ﬂ4¨ø~Â£)îN≠ÆOD”Ö~…S˚¿∫£á~˘BÁΩ<ƒÁ¯£≠Àk˜ø¯ÁAÿE±ÈK‰Ê%‡Ñ?…B,©-ÈZ‡\Ólpq!?§~Bˆ˙$${I	)Å≥qbß€E»˝Ú†Lµ@7&SÚ¢á¸CÊ0·g9ùN—.§miÇH£f@	òa$Çî&{Î˝’RüÙöDµHÌ“•s“Uâ!$∑T(ïI¥
ÔÌüµÉÄ'F	izl~C’äõ†#Æ7UπØá0¥ º‚¬‘ãñ–v¡cÚ«=íïS'MÉîz‚ŸÚl±á||ÃÆGıÂ¡çO<Ùx•]xÍ)¶µqsÌ”©h‰|I˘™%˜v°˜∆ﬂ≈<˘˘†ÃZ}p‹êˆlÒt3î¿Üÿ*≤ SK÷z&HŒrt⁄ l~I≤	¨O“¸~§3`©Ñ öÜ=ˇTÇ¿ﬂí<∫ #˛Àç]ûb˛G4)YÀM@êJ>lÏ(ı’ø⁄∂˝‘C([]Ωtw	
ı’o|‰T7Ÿo«7/\πÁ"´q⁄A5Búv1¸L"úŒp∏aq√„∆_Ü°∑LZaxAÊçX ŒÛ6—NîÙRˇeªZc£∏ÆΩwÓÃÏ‹ôŸù›ı>1fÌ5ÎcØwºˆZûƒ¿ê§§`“M*‚%*Jq⁄"Û£ëç¢÷Ùë»R+(î y)cbC˚#j ‡RïTPß±‘¶H®V
∆v∂ÁŒö∂?:⁄sŒ}ÏåfŒ„ªﬂâ*QVÖj’ã™µ=c∆LÜDµE‘≈hâj¢u )%HcX◊úg©J»§)XBµµÒ~)≈ianÅÂS£*SB∞c%ßÛ;¬ÂIS’Èı∫•S=ä¨ç≠É&dÇ‘[*%9ï∂—uT†ÁH=¥ÉñGkD8"‡àvr+¬ì+Ó∫ùáì*Y€±u˘ﬂúπ√O99ıÂ0ºÇS⁄)8∞xù¬Uâ+˝°lS∂…»∏Ω◊\j	In„∑∏“Ô˛z¶#X[K*J>U†hüj§∆JÉgíìEe
í
Í£rôR¡ºöÊK	))ÆÊÑú‘)tJ√¬∞§∏˘óˆ=æ\®R*REeT[Ä¢4(ñ)–¥8J“±VI≤-çöƒe 
¥í¨;Âßï˝®èÓ˚î>∂_@Ét@TŸÄv]ßW≈´ uvUªÖn—õ‚MÂª©›G˜È¨8'œ*˜Ÿ¨V+Nˇh)ZLö •Lo83∆g⁄£=ƒgG‡HOè∆¡™®˘ª00fæMú”ü`†Z|¶J ‚2dê¬ÉŒ{é®ù»è˝F•bl¢ÿuZb
ÿ5VÉÄ¥‹%hà`™	"Se≈%πdY)Â˘°1HƒÍ‹mn‚Ü§p=©`7äÅœw#ƒBvè≈pD?GK\%È*D√ÖB4Róí ï¬ﬂ6ﬂ£≠Œ¡œÎh‰uﬁÚï¿€¡p8	G˛1’“s≈s£z>x`_µ4æ2∞/îÃ¶GU>õ~t8ßÁE<ø¸¸á+w€ß∞˜‚8ˆºwÏ∑Ì/∆« «:…ó/oê∑œCñiPπõù ∂^M ó(ñœ‚)|Uû—Eó•a))5°fW'Ó∆ﬂ≈˚dñ¿)9ã[‰xï<¨ŒIs≤≤ò&‰%Ã§-¨ùÆeR◊∂ûv≥Ø”›¨`?°ØÀÁÿU:≈2]†≤¨∞ ç—%,C€ÿ
™hÑµ∞µl°„tíÕREÜØ=Ìsº∏v:‚v⁄
h^S&SD0.§∏Óâ˜´5ãÊCÀ¨6ÖQ QDIUÁ∑gTÃáV∂’À%QÆÍRâd˜®îQ¿X™kÎ:˝®>≠∫¿óIFÂÀæpp‚™Gm˝/ÙBÂﬂπÈ2Ú≥Œ’ï–‘Ä∏4ïÍM8?∞4<?¬<WW•D?√bê”¸G¡¢ˇ§Gæ∑wÊ*Éù∏bU˜€?ƒ~˝^e„Cˆ»µ$N{
W€J·¯i{úcá€~ñ>QıcsÃó±üzXÛòÆ†Ó1eÆ$Æƒ ¨^\ã ìEI¢∫ÍñÇ¸ı
YÌå3P…	| ’£◊πì(®l3 ‹◊Jò‹ZæÚ
3 •CsÇéò˝< ∏∆Rà3#òôÁêUû5π°˜);?Vß∫
–WN-Å∑ˆtwnB◊óØ+`™ó{ÆTP≤€hÂû*ïQ~ı)é˙8ÍG©ÅŒ!Z≈ô˜7√’Ì+±¯πÂ÷Ωm~√Â∑â<Õ`¬Ì(ÃKœÍ.ëÏ‚U55¸8lr„î=á„ˆ°ˆ≈Ì˙üyvm‰©∆-/F††‹‰ãá‰l~ÀUﬁ)}o7˜~ÙOÔ∏kÃ7I1Ã¢ï6º&√†dÏb‰ûc§I]…VjÒF≤Ô ˝>◊ßÙcÌütZ£¨éìEæâ\à·ı¿◊¨pùvÃ!√@là™K,ÖÃ¡©1Öeœ<’Á÷ZÃπæ«ƒ<ıÀ”Ôë<Q˝–ÅüÏ †É⁄aﬁ¥AZ(YÒNçB¿ˇ«†A«‡Ì˚Œ£éÅ∑i˘‘„êãﬁ=≥yærßıvjá¿¬›õ†osã{KY~¬Ò±ÂV¬&ˆ Vñ….ÀóÓ˘∆–∞◊	¿‘újh ∫És›(”à≥Mí,6V∞úÕT™∂‘•ü±	ﬂ∞wÌ+«ßˇå'{ÍL˛q—~¸ßÚ= ∑‚Ω‚î¯/ÒÚ†E®µ„êırÆbø)ø©åxƒú/ÃFÖuôu&	,y%1"åào®oË'Sü§\ﬂJºú9`
€2ñ∂˘∑∂GÖlpìπ-$d}πhÆBxÃÃë¨[®7SB∫%◊ëmjj~™Ω£™0¯]c·tCCs«ﬁ∫‘eú˘ÍGì¯dÚJÚ”§ê\›¿WX[∫'}0}8M”$a±Ú¡É–IE;⁄õa˜˝ °ÿ—â¡Œô≤A-≤¸≈≥xUÈ¸È*ÃÊ[9ªõÕÛ·mÄ"† |ë„Oi”õ´ççP\º˙î
5‚qËp¢8›ßFÈÍE˘<n†æ@°Ò™j“h˙™CUî |4”PÌk4I5ˆfB∞$…¡`(
≈k†øà{Ω]4˘ò‹ΩÄw^πløvÈí˝⁄Â+xÁGGÏøå¸Wˇ¸éü±?±Â_~^˛‹OÏ›æ8W2õ∑ºcSG™}®#Y”˘˝vÒ⁄˚$øı2ﬁui˜\x˝à}Ì¯1{Íƒ	\}Ï8N˘“jâúŸam<‡qW.’6ú¯ﬁ+ˆ(˛}∞)^’‚’¿NÜ÷º#á^Ú¥ﬁuE\à_«?k]»Ìá¥ÁG<,»p8vÓ ëóŸkQªÅ<xm£ÙúˇπÙFi~â‰ÊÂ-4!\F=t/ÚÅ¨ê¢nÒ"⁄Ñˇéæ{ª@⁄ÖÖ®úæÉûáˇÔÉ˘^∞?&πb˛ˇUê„ ê.ê» ÊÂ+ O¬=ì o¡3^‚œqÏghß¸oÓÀ5∏™Í
¿ÎﬁÛ∏óh	∂ÖÜ0Ñ	Ü"By•µÂeyX™tÄ:X2eƒÇejÅÅÿÄ<B(’jë@B;hΩîNyh™≠∆∂‘qƒ"µ§h8˝÷æÁd.'ƒ Íüûôo÷~Ôµ˜^{≠}™es	¨Öá`µS(k®[ÁíiZŒ\+£;Èıîop∑»J“e‘O“∂FjˇB˘&ıŸ§üv
=/V"1 ÑÙE ;0ˇ*’Ÿì˘ãÏ"Ô,Èﬁå˝Íó ê˘ææ&}B˚òµÍóiö˝)¶|%LÄÂ0Ö˝—˛}È◊Ö|	È–´ÚFhkãt£Õ–Ë0ŸéÏ√¸w˙Î≥n÷—¥&Ù7:]ô’/t“uùÜjx-E∑0%óQ$wY∑ôÛ”5ÜD´ÂˆÂíÆÀ9È]P∞ª∞ÆΩ‡ÿ”•_\º-Ë9¬Ÿ%e‰sa®°H"v•ÃµŒsª‰qw≠¸úrâˆÉˇJèË˚íÈˆêÅÏﬂD∆øf0Êc”UÔ}d˚$Ø˚"yf3˜·`üto»èÊ\'“∂QÔ˚˙cò≈î¡<’è˘stœ9˜ë¬K/–ˆÛ‹´0gkOû´¸ê˛?`¨àô'yI	‘œfO/¡~’!¿ÿôèkãX—-ﬁ9‰ó ™a•⁄<É¥Ûß—>Õÿ+6£∂©ˆ°∂·4∂züÍû\ÉπÀ˝;Û˝ß@GËÂnï|z—V˜gö⁄¨ﬁó`lµ-µô@õûcÏ˛êÆSm*EÆv2^u0Ûb[Å‘{«∏TZÌçNÂVçî™Õ™ΩR˜EmMÔ£ﬁ	_éKYk∂G≤ÈﬂŸÿ:∂»`/ö‰´RŒòÖÓJÏ¥V∆ÿGeåıäåq W±æﬂQ∆zÏ|ÿ≠26ûê,Œr,}◊ádô´âÃfÆü⁄UÏEçl0˚ZÌf◊Dß ;ÌH‰∞S-6Èf2L$ë¨S©§÷]k˘ı}”©íô§œ85û«zVÈùà’F˙B◊@R˛"<Ω„∑F ‚s"ªc“Œ9sÌ<Ï‰…@;!#Ïˆí«>ı†º¿Ω«¯›R∆?©ïŒÎ'±ˆ“›:çodÆËõƒ–ÒëﬂN±£Àl.lKÅÏ5,’f‘Ô"dGÓ›ÿG}ﬁÅ„ÿ„h∏GcÉ˙g—Pí¥WÔlì}ñJ‰SÅ}ÜÏ¥w»>caªKç-ÍﬂMl·û¢GI∞~ıèÍ„‘G™ü”ÿ¥Àî˛k7~∏Z&˚˜:˙BcÏÛ˝»^~œsGOπØ{{c#ºΩ÷oØªﬁ{>6«;‰ÓÚ*YwVSLM$}ôﬁß ñÍ>i\‚®”Sf˙˛¨‹¥e~Gçw˜o∂Lc‹W4ÆÍ=¥*πwÏ'„-∂7À˜Ì„RäÓÈ÷ØìÂˆ}2F}¢=ü4Â¯t≠ø¡*5ıÏs2ﬂŒ"ΩY!7π1ôÔ˛Q˚x’¶ÏD≤NÀú…≤ªÀ±ó…/ú2QœJ◊Ω›;¢gœùœå?!bÇórªû5'X„A#+å=iﬂù^ΩÆ/6Dæ‚X¨O€Äˆq6HW?÷öΩHò=ZclòΩ–1›7Ã{CxÅó;?ìÖÒ4)èﬂÇ™ìÃæƒÃµCÓèÁô}∑Mº˛ê˚Qãç»RÁÀﬁ«∆˛∑zûUœ™Â~)Í⁄KGßV*∏KKÕ˛$ÂrΩ?V≠¥Wa}˘Ê=Qãç?'Û‹*Y·&∞ªbAÁVÀZÊ»◊IØ¥´º⁄éb—π)oﬁ'ßÚº◊ÙæƒíÀc~⁄®Ê˝«º÷IÙ}Zñ‚KF∆kÂYWˇp%¢è∆Œ–/â…/ÇbXëƒîµK »Õå±PÀ£3‰ZDEºàﬁ˚Ó^Öå¥~)iˆLﬁgdq4GñXc∞ª≥ƒKjﬁŒñ^÷Yπ◊˙»ƒü%Nö4Ì:«O…8{˝2›~Q¶[ÈXÉ=“œŸ-ìùáygMeüË ˙¥ëqÓr“9ﬁVmgÊ¯»Î†ÿ$◊ÙK¡Ë†:?ì¢ÛVı#ÏAı%ù™ØÍ⁄§ßØ„ïÙ3Î‘qÈg⁄¸KF≤OoAè§º4>Z"U∞)zîwxBä#kΩ=ÏÎ›!FßÊÌ‚»R∂],ë}êg†*a¸€æ]ûdÏ˝»ù˙_†DˇÄÔBRˇ¸ﬁÍR—yÆTûä˝û∑'5Ô‰  %öçOœæºŒ¥ﬂ(˝Ì«√}Ω=ä5_“∑≠d≈‚í=Ny!˝Byßó¨≥Á“vÇX≠ÈÙIıMŸ«º‘5ÁÅÏpºï"ª™‰~ı—¯¸iÙª8ﬂE=≥ˇõ‰k∆ÜNÒ&èy"˚dj‰òWè?wïd^2Õ~nîõÇs¢|©)ù∂2@˜<\Nz®‰√Á⁄Zûqg•ÿA@,WÚ˚m⁄C8O<»S\µ±ÏÊ˘¶y["_˙≥Ow€˘Ërºyﬁm'9JÙQÚe‘ø'∑(M˘|…R¥≠¬ﬁvWÿÎ=JÙ∏‹¨X®õ`⁄WRˆu¢Ó´ï–æ¶ø9ü¿Œ√ÁC_±ˇÑ?zó7sædÜeÍùﬂ€pY‡KÆ‘&t7˙∂4Êˇ‹ù#p˛¸πŒÉùG[Öv¬õÓuﬁ€y´>À?ÊÀR"rq©H√~ë∆Ô‚áà¡ç€(+ ›˘!dP6I4j8F˙QÍﬁÄjÿdwí«¸weGÚ£í}/>Ôè◊#Ÿ_˚’Û⁄iêÏﬂ∞*Hˇ∞≤Ü»’»:⁄oßﬂ$$oÄ∆≈»˛‰«ˆ–¯WÚ√Å∏ﬂ8Nz6ÚåiÃ°ˇFòØÔë+¸á~∂≤Öˇè´ïË8æcﬁúË˛á∏júg+2¸Øúk2¯óh&˝}‡ÕwDI˘˜˘ƒú@rû˚úáÏeﬁEﬁî1ÛéÊ-kﬁ‹˙~Ù•yo◊ò˜dƒº)}…~™7Í€YﬂØ»JÛü˜*˙…∑–´–ËƒëﬂÕñ–¡ø'w“ÊoËÛ|O:Òµé∑e©"…ojÔebW:>˜•»>ØYM˛´ƒ≤6AL|k3€<¶}Æ˘kçë◊S«˙Ã
îœÙ	◊Á¯tS¬±¯Zi-v_w,o!Fß∆ÈOõ‚|@õ·í´ƒÚ–;Ø˘ª4¸h-ﬂ⁄;˜ZÛ·wGJ~áÚ	ı&~ó˘0ÕÍõ€^Ú=ì…}›ªkÖ{zá=◊˚gp_¬˜∏Èæ˘ywë‹£Ÿ,Ω#Y∞¬ˇÔÍNöË=ÆÒ-ﬁ(πÒmíK˛7€§œÒ&%cü∑"≤ã∑Ùu9óû$≥´M€â>ìZ≥Á∞›Í˚‹ºŸ3£{)gq^r`|v¿#MgÕ?$s≤àº˙ükΩÎ’1V]Ko¡ñ$ˇyÛÙè|:˘t|q'wátvRAz	2ôÜü·≥úÉﬁEwßiÛ u˘ˆQÉüüÈX2◊>·m≈ßOs2¯’ò'´4vBåæÎÈªåt'dzÏYÀ8€Ëˇî∆ÄXqú∏#•3eÀ5√t⁄>ÃﬁNéæ#ùÒÛ]®Àew6ÛØ‹,c⁄R÷¡÷uB√${ÄÙÜA‘›S¨z∆~∆Ù]&€≠ŸnoìB∆€ù∂EV∑9(´„¨ßM°¸èı≤Å±™∏‚¯y˜ﬁwÔ≤‚»˜ñÖ-H†$[‘jÖ≠T>eY@B≠I4ç,ZKmÉ®@]Ö≈B+RbÍ«j-Z¨†´Åj≠Pe¥¯πKRÓõ˛Œ‹πoüv7My…?gfﬁ‹9gŒú9Á?5—W§&ò/˜ójﬁo’ÙWiΩJÍ*æœ%m∏€ñ®ß\≠˚fÌæNV%{Nskﬂ≈‰’afc°ﬁ‰ª¢
|S…˛_îj˙´⁄‚6¨s	éÉ#i}Zõ˝ûfo,ÂóÆ∆_õØ˘Se,Î°=–˙vΩX}kl≠¶fg€≥N{kªıq⁄ñD~ijâ%‹\i„¶^kå—
:π±*ÀF xŒk"ËñΩS∫À•“€bvÂÁ¿ô4éÇ}6fó´ù
ç/s˜zõπ£óN⁄ˆÀΩú—Ì∑ßõ‘∑¡1Yam¨œ«F*Ò’ëfp∑Ú0GÇZt)ó⁄„∞6òd„≥ªãÕí‡sl∂1”ë˝∑≥∂ÆÍªyƒË≈»g‹©DZ_√ÔÀe¢›#ú Ø%nÒèø~U/3íπEﬂí™hÒ˙(±≥Ω£•WXéK∑"¯·rˆ}%ﬂ.ñ•ﬁgRÆ»¨4áΩÄ6Ü(|ëÚ fNÓëÃQ˘ûˇ≤Ã√_’‡'‡>ˆ”®–yvÓVôÂ5Ö∑%S∆ˇOÉ§}~‹∂c/94:l* ÛÃ;‡§˜∫ÀXﬂ√Æècõ¸Ûà’¯ÊÙƒ¸π¡4|ıeT§¡∑*/LÉqï§·∆{§¡∏ Qi0>Í4v¥4Ø%;ZÔó„˝ŒÄ-≠€'∆˚¥bﬂ∏4˜?ÿ—íü˚¶¡xﬂVÏòê„“vêü‰ç˙{≠ü‘Íõë;êó!o €hÛÓ5≥]∑õ7ß˙3Ωæf1ázl>Î¿§f®.”9˛&—cÆß›Ä¸N¨KøÕ=Î∂p:sõú≠OÄß
˙j;∫sác}V7v‰ÍbcpÛG8Ω«vÁ∫"oåÁÎˇ∫G˚›√Õ0\?Co“ΩMnÜ⁄û€N{CÃôrO:_nåı6ÒN4›¡ ˜ˇ“Êº ªy'ﬁC>\®µ∫»Q©π÷Ê‹π“©†VYéA˚WöÔB¨	.ïû!é5äï7h∑ÔIÚæ}Oæ?Å+XÙ•éÏßˇk¸ö8<áºπD˙´é‡3¯
kk›UŒ·ÔóI
À5v⁄Z=RÎAÒe2=éM«•ÎóD˚dE8ì|øeœäÊ–øﬁÒSôF≤∞hΩ¨àﬁ‡_FSØ*íÒ‰mﬁnLv†úï»≥ÜÀÙv`|	\™áåS}—E2ü]íËŒ˚a´æsÌπ´ˇ∑ÄGDæ¯:om∆^ddâ≠≈ ù‘'{d)ˆ‘˙âﬂ:9;Ï Ω˙B˙GÌ‡èÀ“vû‹ÕbûÍzPy]ﬁ˜É¸c“9|MfoìŒ÷◊…¸M¸˙c∏¥ì‘á—Èö› æj‰Å`7k’HÔlgÈnπ√ªv,ì5∂¿gé…Zb¢Gö◊$<*œo^!&‡yn?*µvÏﬂ æa˝û›!”ÇÎÂõ¡	«S2±): 5·3-ˇ∫\fF∑P[ë—·.©»V¿”«JEQÈ=$›ïüE≥âMÂk‘Ë∞∑ ÆÓ∏©‡|ˆ o€›˝ûÍÓ‹Î`´ÀïÒ∏Ωõå5=‡∆Øã¿‹¯˝œ¸"n7}Øoˇ[œo“\≈]Àp£rü84Åˇ∏;˚π∂¸º∆r˙S•„ırü„≠≠ÀˇlIÍÊúª·òOû*' G$}ÓÁk1îÀô}	èNKÊ÷Xng•9Ê‰A'_÷XSÆóñº˙¥≤%˛⁄Ãc›=KdÃ´ÔlANO¯u[2œø[êyæﬁñújåÊ©DFwI§4ë.èµoñéó7øü“r5<Ìê„± ﬂ«‡˜ª∏sZÉ∆ù"l4ac°$Gˇ/‘Ë” ,e^©H¥Õ4D€ö•æ[Cx7ﬂ›M}ÈeäzJÈ§¿Ê{bò«¡.p|;˝åi3ËYe‡Íí⁄± æO*Oá∞Ω5ËôÇ>≤x¥{…ZÔZú]¢ﬂ]c˜ÿ®µ∞UÏCl°ËÙ‹¡7'–s¬ FE‚˜ƒèâ_ÿ€Q{^âÕâ~∑Óˇ{é¨π¢5¥|.¶Qq¶ˆ›öÌŸÕ´‡†∂πKoπw	“4*R6Ø¥vaè öCÔ3sÒÎ{‡ö£ûOÉ˜5∂|b@ÅÙ§„†—¡ıı.*¬#Êçh¨9®˜¿“W(ó:ù¢ôWâ¡É—‰>æπŒæëî{Ω≈]-÷¸ÆpπØ¨›^ÍπÄvo≠ıE€âm!ˇ<'≥øÃ˘ÃdóÉ7≤éê/:ÜèIïüìia-o€ˆ‰§øô#
t-qÿ„∞*Ê~Êßÿœv¸wÖK©ÇˆpÙ°≈‘8æ≠<v~å‹—xºŸÆ$˜0aﬁ∫¬ﬁ~»yük˘À˝ÿvøî¿yV(_∞5‚\,îïp sî(_∞waÅÖV:î·ó™`5º±^&[|¿ºZsR°ú»ûSΩL
˚ §‡m@~µyë<Èˇ4ÌápŒ)≤îˇ:*˜—5î*/ÚÎÒ#9≈ﬂ»ÊÏˇ9%F‡#Iyf>ıÌÌ†îÒØ"o7”ÓáºÃ [›¯œ§<€âµ≤¥eÃ{<ñ^Ôï~ot0ÓΩƒº%2‘k`Ï*P∆8Ëúg‡x˙ﬂ(;Ø‹˚ „•ÿ/qÌ
˛{¡@tΩ 4∏ˇí9£öÁd?í—≈’p™Û¡2SóiÍ2HiP%Áq¶gN2ßÔ°'è‚∂öâ`=˝OΩgeÆ¬_àäù¶Œ_úÃÓñaŸ’Rvë≈ŸÓ2é∑¿»\Í’“ü¸3.=%~ÂÙm7'X`æ‡‹ñ¯∞„mãN÷Öï¡ÌñÓÖea∫$“´»Ã[;Öÿíå≤∑⁄òëeﬂ3ˇ÷ªñ‹ËrW¥.πAf∏\§\KkI≠Î¥áiÏd»(V¢˙òQ1«7z&ìÙ˛Œuwxn∞L~´±Â∏†ŒﬂÍwëü#/Ò™Ò√eRÍæΩ
å∑:ée›ıŸr|ºÅ‘@@˚RÌ:E¡ˇg§¨Á~›LnB{»©}Œs¢√óŒ6*ó+¡!Ê)™d®ø^≈7á€ÓáÁ…Ö
o˝Í”ÙœëQë∞ﬂNmªÔñ2Ö_âè+OÌ£ˇrE~ﬂmÙ˝u“Gëƒ[>¶[⁄ΩyN9¥Ê—®ß∂ÕÇO[A,˛{ìX*cﬁmﬁß‹Ÿ∑®'•Wú√…áıƒ›fπçø;„ı‡ÁêÛ‡”Ãôß5B9∞ÊV∏ÎlÂ•~ùŸ•yNπ¢ÂÉ?˝÷ûOéùhﬂeóÀ$õk…©ÿ≤Kπ®æ”l*∂5œh |*≈@4œxü—øë~Yúó¥Ì-‰6¨§˝]˛Á)ÕA˛,æô≈ÿâ8gŸú©πMÔ!˘ øÃ§ˇ/rê˜.¯œ∆vxÔK9wau≠9πµ6Ÿ‹È≈Îz£á∂æ]ÏΩù*•zô7≤-æ‰¯e¬1w•˚mÒBÊÏ)D˙ˇ]Œ†JzPoÜ¿iö∞´ãr˘¸ªkÅÙ—ö~√æWlﬁ·,KÚ<_kû÷I='=Øe“ÅúRr ª¿óÙl≥5“[k~˙3ÿ_ g≈∞uZ˝x‘Ê å|ﬂÍ «π∏-Ø—˜ùæ∂òΩoø‰-◊≈≈Vˆ∂Ü:∏4˚îLpı˛÷Œ9¸ó˝≤çç‚8„¯≥3ÊüÔ0ÊÏÿÜùP¸ÇçÌc±9‘Tˆ.∏ÙCÇ|"F"*Œ¡∏‚‹ùŒÁê ¡N⁄H¡®‡§≠‘µ>†∏IIÒ±õ˘Ú&E}„‘™©TÂT©_**™™Íá™ï˚ﬂπSÉ‘F
UT)“¯ÙõÁŸŸ˘ÕÃŒé«ÁÔª∏Û.ù∏4z¸ªdÚ.∞Y8yè¸Ê?·o»™≠wÒG|Cqøµ˛A≤DïmwÒ¢˚nï®*˘r%¸µe~¯!koó®˘=QmÊ£	‚øä:ú˘ı◊âÓá◊xç®	lƒ^◊ÅË¡QÖ•ﬁ	∞ñõ5„oN~'ZªJ¥’u†~ÎSDùQ¢Æ◊à∂5XØûQÔ?>}Ño+
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(üëØó˛Bü£s‰!FÍ¶˝Dûø≥7iÆâ™È
JNÓœódÈÊ^∫é+çJ?Ω⁄ÊrŒiùˆh9Ø@>ZŒ=»' πóæ®ΩÑñZE•€ßvßúk‘¬-Áå™ŸD9Á®ˇj9Ø@ÓîsÚ˜À9Ê√VËdPü»ÜË≈˜Rí COSJ÷Ï∆Uπ[£>.[t·éE£¯⁄á∫√34&Øbà1¥~ÂZZ»„p›∂qŸfdd#hÛböé¢.Ièˇsq{M»Kﬁ~\≈qÂé.Ëd√Ú™4rµ›≤!˚>"Á*ËÆ∆q7#gÎ∂ÓzE°–1t$&ˆ&…Ã”©òÿùLßíÈ·L<ôË÷Ë®ÿ?|$3&ˆ≈∆bÈ'c#]ª¨ÅÅá≠+Ì‹ïŸ;ÙÒ™d.‚cbXd“√#±'Ü”GEÚÒè^ƒ"É{˚ÒLlD<íŒƒ 'F∫ìiëƒù¥8îOd“ÒÿX◊ˇÒuÔBÀ|FÏ∏ÎÂw‚Nq£IÔ0|Tæ¸èÁ|í≠>µõ≤|º–J+ΩGˇÂÁÍ–§Â„Ø“¿ÖRÄ,‡dÚWØœ0Ákje¥É∆¬J…g∑À˙ŒØìK¸2§Ì®ælÔw´/;ÊÄ!„ˆK±{õåˆÍ“mo≠°[–∫#9Á¿XLË2} V Á/Ûˆ=\BG~´ñ_¬…f¢º	V «Ï/·Y.—ùrMfu—©¨ráø(≠F~ñe LÇ9p¨¢$ ∞8≤∏wÅø¿œ€=`≠·ﬂ£	¿¯∑…Øi§£˜o:π6ﬂr¸Î”
oP0 ÒΩî›æÌEbh˛ê›πM.·CŒöj#Äˆg0È3ò»ôE©…k∏Ìœ8ÎÇn˜_∂˝k•w¬ıî'PoD∞
Oë∆c<Aü!ùüB‹àxq‚c|Ñ|rû¶„ìØÕ˚˘z⁄Ç€‚˜\ÁºÅe≥qª∫4Œ∏›÷n‡âwÛzŸƒœ}‘É∏ö{mCã‹îãˇÇSyü;øÏ¿z„û{©≠&—™N˜ﬂ‡kf◊»'r*}∆¥U≈áòCXs‘∞ 	ŸQ¬FG÷Z˛yﬁDA‹; 7–zƒ=|£å?‡Ái‚wùñ&=ø»ø&≠ó‹N1|_ikı9æj#oUÚ>‹ÕÒ≥xgÂ‡”NÀNÉ¨ﬁF!¿∞∆»&‰¶üB6Ö∑6Ö75Ö75ÖIMa˜?ç;ß—¶õß?F”`πª≠÷€X–ôln3¯˝ºXƒRj®mp*´›ô’€5Îd≥zß™⁄Ëø¡«∞œ«–ß…3N]Ωë\‰ÌÚQ∂:ıçÆê≤±]o∫“´Åt_…ﬁÑÖpfﬂhØ◊sñékw#Î§±ü∞ÇªHÏWÏ◊ÓÎf7qÌ∆üñ„œÀÒ•∏ígÖ“/˚•ãV˚:;»~G3»[do·◊ŸoŸº;ˆ>[†~ƒ[∏A\@‹éx›~‡]}ûÕ;ò˚wl_–}Xˆñ›—]NÙÊrR◊XNjÇÜ’ÃﬁdoP∫xq3‚,OõóÎÛ,CÔ"˛òı“ÉàØï„€l…›‚Ïuvçv":vµ;ÖúÌu√úÌq√õJWën}â]aó©Md∑4†ˆeße≥Ó_Dªƒ2ˆΩ∆Z√Œk¥ø¢Qñnπëjÿ;Ïv2m/	}ÅM≥i≥>l6õùÊ,5á:C≥\4ãN≥¬
∞≥8@f~Ÿîaªò`öù∂+¬9Îüx&˜πM¢Ã ,ä2%3B¯˜›?À¨ü=OÉÄ°èS`LÇgÒÖmö'¿Iå¨…ÄqpßI
F
F
FJ))))i§‰Ë„¿5¢0¢0¢0¢“à¬à¬à¬àJ√ùoFTiD`D`D`D§ÅÅëÜ	√Ña¬0•a¬0aò0Liò0L¶4B0B0B0B“¡¡¡I###$C¿0Ñ4C¿“0!ç å å åÄ4000“»˜3\££££(ç"å"å"å¢4ä0ä0äÏÿU^∞ﬁÅRÄRÄRêJJJJA*((ÖÚ£g‰b0lõS`L◊Õ√Õ√Õ√ÕK7/∑◊8p›åååú4r0r0r0r“»¡»¡»I####+ç,å,å,å¨4≤r„é◊∏˜MyœØÜ=´XçøµlR€"„›ñÒ›íÒ∫*„IöïÒ='„q
ÀxåZdD2fH_≠ŸzÿoqÇÉ 	f¿X^ô›Ä÷kn™{Ω3ﬁ9Ô≤w’ú∑Ëe~œ†g∆3ÁYˆ¨öÛ=LXçÃ'œQ-tNñ(Ô ¸AŸ/≥~÷Éq{pŒˆ‚”√zÃµw⁄µõÌ⁄rª6◊Æùk◊¨Jˆ≠BûtÇ¬◊òU-}˙-niÌ√…tˆ⁄Ì:›nŸ°œkK•∞≈Ï@ºÆÇYtÇf†À∫v¥?`n*wπZ¡@∏CP0à/à5kWõÃßÕ:Ô¯®“ßµﬁ¢›Bò∑[^∑[˚ÈU”∆Ög÷ªòπ°Ó¨ŸÆÿjTÍ P¸ìu™f/ÄI¥àdà,%ß"ŸN‘M+!UDHï*Uï*˜ÇP”™„µÇ÷	ï"qÆz•∑∏µU{Íïæ7kU}Î¿Ã7˚ﬁ7Ôøy∞ñÌ¶˚$éﬂäËs8πgÄ?∏Ï‹ﬂ˚ùÀ^ÏπÏÄ{n|`Ÿçˇƒ≤ΩÙ6aA\∫‘¬|nƒEó›⁄ÇÀ∆ 7Cˆ8È‡£69‘[´ﬁÙï4óÕå∫lŸ
â„¡”.í€ª 1–Ä˝Ÿ§vêfzÿÏsˆ;,ˇÂÒãÍ~÷=z'bâØÅúen6Ñ|x?‘[»ü≥]}ã}±®æœædÏi¬S¿º˚ﬁ.˚Dı§gôKÏ	{õU«¨Ãn±U∂»ÓÈ`wŸ
;¿má⁄“≥}6ﬂáO°ªÏ=›[º…>dg3ÍÊó\Û„¶ò2Â´ø˘◊=¨Ò€)èf∆Âø‰yYŒ…≥≤&è o»yXRî>Â¢R•K	*íBîaÔ‰◊åA†láª∫Ç8≈|@¬âDâ‹"¸R¿í¨BéZ¸’}b≠©¸ÔÇÊ—–¬]~AÀQ>dk)«Øñ'ü,Úîaqy~ŸÆS˙‘+ó>ı(Y≤=zÇ¶Õ>túds{§I(}ms€qH¯Ú£t8=t}pÊ¶Ÿa(∂F„¨ÖœO#¸´`Ûo#ü¬…Iƒ±¯«u≈nJ˝RoﬁlJ}é›ÆK˝˘E¥◊Mh«Ç’‹4G öí#*“‡ˇIipF>/ÀÅE ^®óƒ/Íº E^˝HÕõuUùê#¡9“…9T¨5Î±ò`i*µëEmMÅJÇ	
ÖÔu"£BåOûQÙe˙î2-¥Ùå√|Œ’6g¯*påˇŸJ9É6í’ç√|IÀµ|	zëˆËAò?YS’˙F*ƒäk˜ ÆñxU+ô|C3’zÚ∞É˚›IÕ¨ì√¸í]?ÃîL7ôIÊµU”i§ÁÏÏø¥∂NµÏπ¡Ê0òçZÈlw›i‘ ¢Vµ“ô¥– ?ƒ∫ü∑Î
…97V|lH=!®·‚H‘…]Xøé›úçÜ7F^	›#=Ü√/j9ﬁ]âl"ã.¯;CWò˚[Æ∆lt‰›kπ¿<®ÂH;µIü^∞x¥p◊∆R·ô’ŒgV∆&‹aíh¬/<WDáüÛLRÓÿ*ùZµZ-„P5 ÑX|º`Òw`'≤RE”€D€[Ωª;Ôùºßõ†î√ôA»`&∑.Y™u’d	Ø
ï∆ï»‘?¬¸#ËpèìªìIqãx‹’Ò˛RiLN˚◊UD˜Jt
)Xä®˚òL¿dGﬂIÏ§jz-QKuÅuål_•Ó‰nÄTår;0≠8êlÿÍ}„æ¬5úÜcî©»◊ìM€I?Mlπµ,¬W⁄‚€À≠ pæzµΩ¨⁄Z$úU±»‚?ùgû˛` ˘Ωëendstreamendobj47 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 52 0 R/FontName/BADDLA+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj48 0 obj<</Filter/FlateDecode/Length 473>>stream
Hâ\ìAj„@E˜:E/ìEê-uU% éùÄìÑÒÃd©Ìå%—ñæ˝Ù◊	å¿÷RU˝]˘f∑›ı›‰Úè84˚0πc◊∑1\ÜklÇ;ÑS◊gÀ¬µ]3}>ÕˇÕπ≥<Ôoó)úw˝q»™ Â?”ÀÀoÓn›ápüÂÔ±±ÎOÓÓ˜fÔÚ˝uˇÜsË'∑p´ïk√15˙Qèoı9∏|.{ÿµÈ}7›RÕ˜øncp≈¸ºdòfh√e¨õÎ˛≤jëÆï´^”µ Bﬂ˛˜^ÑeácÛßéYU‡„≈"›?í¡O‰'ñºøê_¿Ø‰4®*ŸßDürI^Çr.…%ò≥JÃ*◊‰ubœZèZœZèZœZèZÔ…,d+Y¡ÏÔ—ﬂ”≈√≈o»0Ω<º<Ω<º<Ω<ºÑ^/aAaAaAaA·\¡\°£¿QÈ®pTˆTÙTˆTÙTˆTÙTˆTÙT:*’»¶Ø¬W9W1Wü…œ`∫+‹ïÓ
w•ª¬]ÈÆp7∫‹ç99ç99ç99ç99ç99ç99ç99ç99◊Ãên8¥üß«7mô˚⁄çÊcZãyÁ}¿&t}¯⁄÷q]™¬/˚'¿ úxÓeendstreamendobj52 0 obj<</Filter/FlateDecode/Length 29807/Length1 61168>>stream
Hâåï	TTW@´˙ˇ_hê}QÏ˛ø~'FeúËÇÎ8ãëD3qÇ*Ç†‚ö®dÇ5∏·ÆÄ∏Ô¢†∏·é ‚ﬁmÉ‚JLèßÅŒk‡0ô3''ÛŒ©zUÔUùwﬁ˝øÍ•Nù.êD⁄≠;¥ìËÿ§òî,æ¥ √ ‹á«ŒHï[∑=V –∞¯îÒI≠æﬂ3 °a|‚Ï¯Ô∫t–ﬁ¯Ù…Ñ∏òq∑/>*H=ŒÇzN`≠Ò©Øò
úêî:´’üÓz#196Üﬁ\∞Ωû˘wíbf•¥Óõœ0%OéIä{∫≈u5Û!)…”RmAêPÁaﬂOô◊_«Ó°.éÀ¿l¿AX+Ù`∑oùπJàWy8*5Ò*˚‡k!»v
fıc©éˆ¸aÉ˚…≤≠Q®n˛{à·x –f≥±sBâ˝4‡ôV∂Ë≈¯1;1!h[d≥Jeè˘Ô¡69^ —¡—IÌÏ“¡’Õ›√”À€«◊Øc'ˇŒ≠$ÎÙÅä·ùwªΩ¸õÆ›B~€ΩGËÔz˛˛˝^ΩˇˆA¯á}˙ˆÎ?`‡˝Èœ˘Î‡èÜD~¸…–aü˛Ì≥·#Fé˝y‘òË;..~¸Ñâ	ìì&'ßLô:-u˙åô≥fœ˘‚ÀπÛÊß}ı˜Ø”,¸G∆7ôYã/˘6{È≤Â+VÊ¨ZΩf-¨ﬂ∞qSn^˛Ê-[∑nﬂ±ì€µ{œﬁ}˚<t¯H——c≈%«Oîû<uŒñù;·‚•ÀW Ø^ª^ïU’7nﬁ∫wÔM˜Õ5¿ªÖ≥ãÜ≤´ä
Û–¶íU#Tªπ nóÃMÁÊqô‹".èª∆Ω·]¯!¸B¡S∏ ‘Øâ#oÚ'âzSŸƒ$MÇfíÊ¨Ê≤∆¶ùØ]ß˝A˚VÚñ4“ i∞Ùô4B%}.ÕïIeRµdî^JØ•fŸU÷Àπ´"á ΩÂ09\Ó/G……Ú|yÖ|X'Ë<uæ:ΩŒ†Î™˚H7L•K◊≠‘ÍUz“ªÍ=Ùﬁ˙NzIﬂEˇû~ê>F†
p–)†®g≈MÒR¸îŒJ†¨Ñ*aJ¢í¶§+ "eπíßÏR(≈ q•L)WÆ+wï'Ü0CÑ°Ø!⁄kà7L2$'œÏÍ[–©@gUY{Z√¨·÷>÷˛÷˝÷ÁV[„ÿ¶õ^55647⁄Ìˇ˚√rU†“©F™ˆpÅ\$ó Õ·“µ%‹fÆÇ˚ëÔ¿GÚ¬R°B¯ûÄ‘åöñtA—b§µDMô¶Y⁄4mÆˆïíü$KÉ§»6jc§4Èàt^∫%›ó^Iodê=µ F≠ª‹´ùZ£ñ-Á∂PÛi£6X7T7äQÀnßÊŒ®u‘k€®EÎ«µPìÅZd;µl%WŸ—NÌ2£váQÎ›N-Œê¿®Eß2jæ≤≠Î˚åZÑµüu†µ⁄⁄ÿ’ﬁBMnN≥S≥’±˙|…§äı£òt±\ÛDªÊ+ò‘ZÇççWÑ<6W˝ß,zº‰_∞Ãx¬™€‚mÒ¥∏[\-.gã⁄‚dq¥à≤Œ¢≤@Ω˝AÌ&+ô§◊æ}PX;ÛE≥ã^Ùb:≥v.@MBÕÏ⁄bÀ’∫‡⁄%ñ’5Ö59Êsæ9ãı∞mˆ¸_ÛÛÊÖò#Ã=ÃÅ¶Å¶¶0S/SOSSà©ãIoÚ7yô–ÿ`¥ü⁄≥åÁç'ç•∆"fù3n5Ó50ˆ5ˆ1ıFùQ˚hMÌâ⁄#Êíxﬂx°îï‡zqù∏V\”zOzN·.˜\*ùÎ‡b[∫ÎñÎÚ¸hF¨?ì4!ÉÈe¬QÌÃ§'ÂãG[≥¥LB∫;ås»u48˘ÿWù<⁄d ¸ p
u˙Ñi÷ßùf¸lµ•o∑Æ8≠ˇ≈‹Övq hÛ“Ì¨üeéväj∑G˛ÒaÌVº:L=·8ÿÈ∞ÄãbØœXK 6¿vÿnê…ê~À·{¯√*»@dÔÈKÿ;‡ü
^C>ÏÇãpv√XàÖló!.¿%∏W†Æ¬SàáJ∏∞∆C,ÖP’0ûÉæÅòì 	a2‰B2LÅò
”`:§¬ò	œ`ÃÅŸÃÖ/°Ú`>ÃcØ¸WP/‡Ê‡*T!á<
`ÖF\çkp-ÆÉ&hFB¿ÜÎqnƒMòãyËàN®FgÃ«Õ~ƒ-∏∑a‚v‹Å;qÓ∆=∏˜·~<Ä·_p31·a<ÇEx]∞√btE7tG®ÖËâ^XÇ«—}pû¿R<âß4ûA_ÙÉΩ∞;b'<ãeËèùQÉZ<áÁ·-¸BJ(£ıx/‚%ºåW∞Ø‚5¿@T–Ä◊±+±
´Ò„;¯.v¡ xèÒ&eR-¢≈¥Ñæ•lZJÀh9≠†ïîC´hµHkh-l£u¥û6–F⁄DπîG˘¥ô∂–V⁄F|?â
i;Ì†ù¥ãv”⁄K˚h?†ÉtàO‰ìË0°":J«®òJË8ù†R:IßË4ù°≥TFÁË<]†ãtâ.”*ß´tçÆSﬂ»7ÒÕºM ï¿	º $àÇÉ‡(8	j™§*™¶õtãn”∫K˜»H&∫Of™°Zz@©é—czBOÈ´ız≤–˙éﬁ∆;xÔ°QÌ!∫âÓ¢áË)zâﬁ¢èË+˙âE±≥®µ¢$ ¢N‘´=’?—\ﬂ¡]i¿ﬂ}ˆ˜Ï>œ˚Ïèj(È	$!(*®t§˜.¢¢ßËYQgJÔ	 ®Äw'
*
Œâz )6jD•	°äí@ÄÑ$HnonÓè˝kgggû˘ÃÓ˜€@JåÀ19.'‰§úí”Úªúë?‹eWÈ™\µª‚Æ∫wÕ]wµÆ.DUl€÷&€õj”l∫Õ∞ôò,ç§±}…ælßŸWÏ´v∫ùag⁄Yv∂ùcÁ⁄yvæ]`⁄Ev±-∞Övâ]¸€e¡˚ö]nW¯◊Îˇä≠¥´Ïj˚ñ˝õ˝ª˝á};8
GÉ˝¡ª∆æcﬂµkÌ:˚û]o7ÿçˆ}˚Å˝–n≤ŸèÌfªEöHÇ4ïf“\ZH¢¥îV“Zí§ç¥ïdIëTIãD
©[‰YÍN=®'ı¢ﬁë)‘áÓ†æ‘è˙” HÉh0°°4åÜ”I£h4ç°±4é∆”ù4ÅÓ¢âë•í.í)Yí-Ì§Ω‰»ürVJ§TŒIÆ‰IöOh!-¢≈T@Ö¥Ññ“2zçñ”
zùﬁ†7iuTG#QUô∫†.™ﬂ‘%UÆ*T•™R’Íä∫™2Uç∫¶Æ´ZïÂ≥U >hÇÜ ∞@¿™lpÖz±ÒP®v–©ˆ*CHÄ¶–öCHÑñ>£ÕÛy#IÂ™<h£:@[HÜHÖ4Há»î|È(áÂ79"Á•L.»E˙≤ ⁄A{»Å\»Éê·∏ëæß‡Yx¶¬Ûº/¡À0^ÅWa:˝3`&Ì†ù¥ãv”⁄KEÙÌ£üÈ˙ïˆ”:HáË0˝FGË(”1:N'Ë$ù¢”Ù;ù°?Ë,ïP)ù£ÛTFË"]¢r™†ÀTIUTMWË*ÃÇŸãqTC◊0Î”u™≈ÿac™„Ä6¡÷ad√ñâôCvÿõaslÅâÿí£\èc8[akL¬6«Ò\üpCnƒçπ	'pSn∆Õπ'rKn≈≠9â€D's
ßrßsgr∂≈dŒÊv‹ûs8óÛ∏ÁsGæÅo‰N|ﬂå)ò ∑pgÓ¬∑Úm|;wÂn‹ù{pOÓ%ó§ú{sü®çRî£aT¢éÔ‡æ‹è˚Û »Éx0·°<åáÛ…£xt4≠çâ∆ÚÀ„x<ﬂ…¯.û»wÛ=|/O‚˚¯~˛?¿JOÊá¯a˛+?¬èÚc¸8?¡OÚ~äüÜ˘∞ ¬"XPK`),ìÀ,á:ºo¬JX´˘©î*©ñ+P*Ô»yW÷ :yO÷ÀÏ W·<îÈóı+z∫û©gÎ˘z°.‘Kı
Ω“wÄ5zù^Ø7ÍÙ&ΩE™ø–€Ùv˝Éﬁtë˛E‘GÙq}Zˇ©œÈ2}.¬%(á
∏ïP’ÿ	o¬õe£º/Hç\ìÎR+u.Ä+pj‡\áZ®”ÅV¥÷(’àiòÖ∑`gºo˜ßªaÏÖ}∞/ƒ°8«Íñ8Ô¡˚q2>ÇO‡”:ü≈|.öÜØ‚úÖsp.¿E>#-¡e∏‹˜ 7u&Æ¬∑m\ãC‹åü‡V¸øƒØ}≥ŸÅ{∞Hg„>‹èá±OÍ\<É%XÜÂXÖ5XÁ{èı>∆ƒô˙¶±.1	¶ÖoA≠|¢O2mMäI3&À¥39∫£…3˘¶ìoH∑˙¥ﬂÕÙ–dzö^¶∑ÈcÓ0}M?”ﬂ0Õ 3ÿ1CÕ03‹å0#Õ(3⁄å1c˝Œ8Ÿ$ˇ>:‘¢›ˇÊc∆õâfíy¿<([8„BWœ≈ªFÆ©KtI.≈•πóÂr\æÎ‰:ª€]◊«ıwÉ›p7⁄çw›$˜ÄõÏñ£—&—uDU≈Íò:ÆNp]Ñ*ÑPáëC⁄êB√PBF√zaL∆ÖÒa˝∞Å:©NE*#UëÍ»ï»’HçÏñ=≤Wä‰'Ÿ'?À/Ú´Ïór˛Ä?·,î»ˆ`SÃ1€U~∞%¯$¯Zù>6ﬂ»∑¡¥`[0SÙΩs®ÔPC‘|µ@æ”#ÙH=Jè÷√Ù∞6¨ì ∏¨ŒàP7äñ|y!¯\¸w+Vb%ŒÌv{‹^WsÂP∞"8¸;X®€ÇÖ™´zZ-V™P=¸SM6SÃSÊ¯V>ï≠Úô|._»ø‰K˘J∂¡w=¸ ?¬ÿ	ª`7ÏÅΩP?¡>8
≈pé√	8	ß‡4¸gºŒ.^„0é#tK›J∑÷Iﬁ‰Ω8	ÔÛN·`‚ïﬁÖÒn/∑ˆ«ﬁ⁄7∏øıﬁv‚.‹ÌÌ>âS)Ø¯Q|◊©:MßÎØ˘9úäœ{…≥ΩÁôﬁÛ\Ô˚Eù©≥ºÍ≈:[∑”ÌuéŒ’y∫ÉŒ˜J+2Vz±•xœ{ß±^j¸ÔÙNÕdoı!Û∞.—g˝*ı.ªzô›ΩÙcxOxΩÈﬁp™7úâΩLé…ı¶ìΩÁlØ¯”Ÿt¡tL◊ı∫\W‡÷ ¡Øˇ0^ı—QW¸Œ«€KñèêèEyÀ3©d≥"°îbX≤Ÿ‰Kw” ª!)	∂T$*àê¯–rê
•⁄îñæ§Å*m§Í±GC(ÿVl jAèH˙µÿ◊ﬂ€ÑòÙèûÓÏ{ÔŒ‹;3wÓ‹πÛª >JóYîFd^ƒs…˙∆ÕKﬂ˙ÚœÄƒ;˚¢˝Ù÷L˝;:Œz…¬èG‡oS*”†‡‘B6™FÀ&*GQ–æÉ•õ4	¯X‡ÈÜÏ=¿…Gi,K3?fﬁ N£◊J¢	4ãioeÛÃïTCÁ‰zöFÛÄøõÿZ3dn3∑õ/¬+éà∑Õ4ú2ÄÏóP∑˘ÖÚæ˘7Ú¢«≥úsl˚∞C‰√,k!˘c`ˆ›bëdÊRÛ+h‡rÔ&I•‘Õ∫∏£◊”Eñ∆öÖ£Ï5ÛHç£E»v”Ne≥π[©1KÕnã9Va‘]‘ép69F∞D•◊|—Ï•t °πXOù`]"vc]l&,¶¿Ji:8ÀÈ∑»?N;øŒó+âJ.‚‚£Ê{4Ü&S¥›áûg_‚&«].ﬁíA≥àíaóX÷¶7ÅÂ3Ä)∞ªÅñÛÁ≈îÄ'£‘!SŸDœaÙ≥@-áÅHzƒ^y@^≥›;o&cG≤ËG»ù^GÜêDˇ {Hı#ÓÁãqø\;‰+Úî=äUﬂã|g+@ˆ1äÂ±2ˆ÷¿öYNﬂ.‡˛ìÏü≈+˘}∏iƒ
qL°T»Âzx¯f€•X(ˆFÏè±/Õ\s#ï¡÷A˚gëïu¿OzÄ%œ–9∫¿‰9…(VnQ≈÷†<éòÒ≥x¶”ÅYN≤ÏS‡±´Ïpoπ,ÃÑ¢Ò¯#∏#˜‡\['˚s˛oë*&‡LM",ñC´Ò !Ò°Ãê=@˘π(;ïpgPé+Ω∂D˚ì	îÓıΩ7≤oúçQ¨5∂3÷Î0?§Ïa¨0û
†}eˆ{'<ÓótôYv õ≤y∞Ãb∂å≠`´`…ßê’Ω◊˝ Ú¨nd W†sü•Û¿jE| ΩºûØ¿=øùw?ÛØÑw¬ë"≤≈l±H‘ãáƒj±S‚]‹≈ƒ?≈uS:‰x9AfIèú-ÀïÚyyQ^Tj}>±9lﬂ∑mD˛Û˚∑ÏÖˆÖˆ2˚" ¸√ˆ˜"VÑFú˛5˙±Û¿qà∂Ò)2±Ò¸y1’âROÂ˚Y+åu€îU∂|õOΩ2∂~ãø 0Cî≤VAÀ¯‰æ—lc‰´¯»ﬂ”e˘÷v#Ø≤%≤«˘["µ3‚”1Áõ‚NÈÔ–‚≥Àü“_•ôÁeæO,ÑìÖJà‹b+ÿctàà◊∂¿èÁ≥W*Y.˚ó0I˘¢i‚#ZO˜Ò˜q?<B≠ÙCV'ó“6ö¬öÈ"ΩåS1Qπ0Ö˝Å7JùèfƒÂ+X›td¨BCO±Eb∑Ì
?C+©G:Ë¨¯9¥Ô·E©ÏU YN¿c¥ëVòÎhµíßÿR\€wS¶<èË÷,r•ﬂ'Uj”„tEò%J—íœôø®BÑÿçÚ‚ÑÑ5‚åﬂÉ(vÇ:lïºìñ*…QáHæ+ßjÛe⁄e.•˚ÕÌ‰E<h1õ1‚~˙Ñû¶˝lCl5—≠89gŸ<%»{î†ÈÂ:?√+¯Œ°˚kg≤4˙Â *Ö oHó°
öin1ˇÔæv’“∑Èc¨ÚÃ0Gt—îÿ|ﬁfE÷{é Ã}ÊxÊ†Û{¥Ä^£óÏ
EÌÏ±¡NaΩk®ûóõâ˙X#Ï4¨‡ÉµV"˛lÚ˘´*g˘fﬁU0#zﬁ¥©ﬂúí;˘ŒIwxs<ŸoˇFVÊm⁄∑:˛÷[∆π2“”R«¶å=j§sDrR‚p«∞ªMëÇ3 	h¡àjdEô•Õô„µÍZ—ACESp®å°F‚bÍPI$ø˚_íæ>IﬂÄ$s™T‡ÕQöjtkj'´.ÅﬁZ¨ÖU„rú.ç”œƒÈ$–n7:®Å¥Üb’`5`n–ëb◊6‹·◊¸ıoµ9ÜÉ H’ö⁄Xj!ã<5êﬂ∆)!	JZq¿H◊ä-ëà÷ÀBÅbó€ˆÊÃøD´5H+2Fx‚"‰èOcÿ¸Ü=>ç⁄h≠Ü6´m9]˙ñN'’F<âuZ]¥&dàhÿöc§Û©è~úˆuÉèÚáZs]B§5™VU◊[T„'e°¡\∑ıá1˙ÚÃ`DbÍ-0bIÖäŸ¯Üp»`0•j≠ƒZUﬂ˙ÍµÄ’Y¶√¥"≠A_¡÷dËïØv∑gd¯éòÁ)#†Íï!ÕmÃti·hÒ∏∂1§óØ˛U∫OM ÒÊ¥9Gˆ∂-yD?ëò4ò®‡≈©∏∏EïîXñYis·Ü∫DÖ&!k ≥^ıy§/…É~aÜ^Fv§—ÊèËŒ|´›Ío(ôNM’Ø<@ª¸˘–ñhã-”yï,“ÚìWˇ&mx<Fv∂Â"v?ˆ:∆ÎSΩ9wrMkr™¯¿|¥∂çÜÛ'¡¸n∑µ¡õ;}Tãä±∂,‘WW©÷’NæIû∞¡#ßÎ&'• ‚¨Ω…Ë—‡…ƒ4RåÑ¨ÅˇÁÿ—ÅÜ|Éç˝Ï˙>~IÖVRVRz§ﬂ∂%ïCj}¸º^?eåˆáÑã˜S‹%‚\8eÕÄ∞U	%2[‹©Î:Ì	 xSÉÜ32ßÔv∏›ˇgßN≥◊Íˇ|›≠_M#ﬂ3¥>cH}àzâ∫Ä¬∏*K*´u›1ÑWÎõpnˇOï!∑Í7®
'3ˇN≥+œz¬.√ì˘-¯__Suà†´ü„gyß7'à@ßÎAMÍ=⁄iÆ≠’Tß¶·«˘qΩ)πÈ8ùÊ—Õ.#∏%[5∞|
NEmk-kÛ±÷äÍ–'ë⁄ZjÁå˚#EaÀê‹_º{Ò#ˆgqx´≤ù»=“=2/Ü+Ô∫*∫Æ˚∫F™Ï¬µDÕ±2QNììÓ˙€’≈qÜgfw{∑{7{/ﬂŸóı⁄Ü3÷€‡ws‘K*‘≈Mì`öC\ú
ƒ&
é	é	±ClC†òV·QëbRZ Ç ∆¿˘ë‡¥™õ∂éê†R†∏≈◊Bﬂıüµœn⁄ÓﬁŒŒŒÓÕˇ¯æ˘ˇ[Æ#Í≤X)ç„¢ìhü√
wCµÏs<è8
ª0é;¢æø’¶c±Ò±:6Ç*#ïë9Ö8ÜCD-.+-+-pz)∆◊ﬁ˚C’í˛ÊıπÛr¬8úx∫ﬂ«é;W«¸1∫egﬂ«âÃÑ˛˘?6‰Yd%íçb‰íò∂}Ü{7⁄«=Ô >tSJ™°sø€È4;7∫≈Ï|i8m6RÌtd:à„àkR«0ˇ•ß;©≈π!8ã|êÈ(o∆·pˆº‹∆Ê˛%Uü%û∆◊Ò_˚{vnYÚÁ„WÔ$æNXAÀ˘8Nj…À‡œŸF`Y√ë*\EŒA$]X¯5€¸·Ô”1:å
™FÊ¢zVíÂùOÚp¸‘)ÊÎ^h⁄`è√°ôÜüDêçDj`Û±äXæﬁwÚ˚wõz«@_ò¢®§»€;88»˛ª?R~‚–≥=àK~—Â© Ò‰ÜÓ©ÿ≈a¬Ì„éqÑ[á∞æp»∆›B‰¯Ô0ÁO6¬Ã::B'|—&‰ácË9Êìpÿãã0>‹ëx. |˘/òÅ†Í‰ﬂyU \¡’'£öaK◊x¡£)JöOﬁ21`#¿@êT$≥‰ìehe6Ü
 ÄAh¡fQ∆	ÒgÖôD6”0†ivÓª]dSR6Ç®,≥ñçMM9=g∑®hË—Et˚'ê™|pπ‡r&Ø/Úbi∑∑;/:…b˜ìÓ'ΩOæì±»Ω‘ª4LFù•ŒæÃΩ⁄[x!c=˘â∏ŒﬁËlw[v“ã˛´‰≤xŸ˛g˙î∫íëïS\(a$QâHôjÇo8`TáÇã†Ì¬ª‰ﬁ≈Í√#ìj‚X=l]ÀŸÅ·äF›‘UZ4◊Ás	≈úÏ‹êõ˙äÊñ™4îìm´ÎÜ:◊u≠}ºvhˇÁÎwÙnj:|¯Õ¶'bdÛxﬁëöìâ‰’D"Òª£ªœ‡˜ªæ∫˚¡⁄;/µ2Æ\  v6tÃ–9CQãÎ¯çd;ŸcÂèXB¢@8I¿2¡ól¶ˆ6f¬l=∆ì◊ÕUù€Üj4uòÄÇóç É+ÖââO∫,ä≥XHy¢P¿∫`Dÿ{qøÉ&ñF}¸û8‡!R5AïïiX≠`˛A±pVé*äñíRà#‰A˜¸°Eª˛V∞ñ„€Mô}˜R≥-\∂Ämæ0…%I•äﬂÌ´F%U5;wâRËiAcMch{´FìôÊZúÙ2±••ÈôT%DœT]ü≤vå0M+Y{n.#/ô(ª\ƒhHNï§‰\7Ï.7©÷<låÕ›S≥•b∑ìÍ4•L/˛?iåœLìf
3J˚Ñ≥büÂÇıb–≤Pé ãuÚrG£´—ΩŸ’Ô∫ô~3„n∫|÷~∆M2hê>B5*~íºã,@~+‹%@+]≥Q´(^
¶{Ç¡tk0¢Ö5=»)çì'üR±«˛SÃd∫√ââlkHo3Æ„>“åtDqπ!´ß*IyÖl$<È%3P&ﬁ~bÇÏW∆¬,º@pèTéå«n®.Ü,4mé¸∞B< Œ(µ Q«^çFgz≥BeÄxiiI1P_¥‰ñ≤u·ı ‡«[ñë¥ôø˙≈Wáˆº—≤˜∏ÔˇihÏ{˚¡RÌË—˘ëeoûªπ¢ÓÁ{∑∏?ªr˚Ësˆhˇ—` ‚‰0Ô¶Ñqt8{¿o0ˇ˚É3™Üex¿y96≈);5õ-œ´y-/(‰)9äÏ@“)#øn	1ŸÁ°}ÿâ\ïï"*‡7rûûwU–s·πÏb¯Õü≤@iU¯Í’u‹3æ’¥÷≥‹˜ö≤ﬁ”™lÒlŒ¯µbtŒ‰ç]VºÉ\Ã`1¿Ä>ÿ2Ê!ótÀ≤ó˜˜í(@Vπ†• j*ÆÜ˝ùË~∆d˝-KC»åM!åB4D@„—3ÏM®„QówÜp/.áD2`ÿß£’Ï8˛ŸâT¿2Qd1k4õà[„79G®âÁú∞T@X≠∏>Í.Û±òeg)õÍ¶0d ZXãr≤Cãª3ﬂ´€xÏÉEOz\ˆÜxkÌK[=›Y∑?z˝R›äÂ-â[ó?M‚∑˝{⁄é∑4Ì˜¸íºæaYÀ¶M˙©+ªñ◊ÏÕ◊>˛È@‚ü√,Bn
 ≤i(4Ån∑å2¥|+¨uRùüÔ “DañÊR4If ≤Ls⁄ÃTa'´%Xls¶'Îò/ù~.Uhp©Ø8∂ŒÕ$«Õ ÏsØ9£◊LrﬁÈåÙÕt«VıHE≈T÷;c*"¶'πaf?÷1«&Â≥1Ë<4≤Ÿ À˛È5Éñ◊¥t⁄æî0êÖ&H]åàe%>úÁ[Ë[ñˇQ(HÖx⁄Äõ¯µ÷z˚´ÚkJc⁄ªhﬁ ∑ZõÌõ‰Ve[⁄Ô’ÛnW6≤+®ß≥õÆ∞€£zàëUÀ”e§˘ëjtÊ„ˇt√Y	Kq≤“†·ß°°¢tR'q∆Òé”s˝«9Ã¡˚Æﬁ©¥È5ºƒ€1g*mé∆FË®…¬I∫*b¶q¿¿	ˆM=ÍQ}4äC°í‚…êëbÇ∑göêúgö®"Æ]≥z¯Ï¿Ì∫ó€∂%∆Æ\IåÌx±µn’;õW¨lˇ÷¬égõmŸxêÀ»€]€yıZÁä]y≥œµ˜'∆€?≈ãVmzªfY€¶á…™éß~ÛVÀááXΩ‘·≤ïôwπ°Û-#<¡"ï^™DÑeÿ˝V≥ ¡∫Jà¶]¶in(¯8∏z†Ë„¢ÉÉBÒGí„PÕGÖ^òŸÅWû∆'êäøØª';˜Õ∫â0ñFMÇôdÃ∂Ä“ï÷U“¥ùÎ†ÖÛ‚ ΩKÌV!äì–Uˆ„Ùû|OπÁêxôWxg∑IœˇõÙjèmÍ:„Áq«æ_;∂„ÿ±sç!ÑF^\“q5⁄t¿B#ÜR∏eC•€:∂ [7uÑä‘áÄ°fºÑ£ƒ"^!M4Ccù`]K7m¥V§ÖnmDIÃæsÆ¸É4'˜úÔ>|˝=ﬂÔ4bä™Í 3EWÅ¬œ8>¡lU¬-B)ø‚◊®-ÈA¯ñ'!À,°P•ã4;ƒÙÎÃ+§k‡<Õ	Ë6zN•Û§Û“eâní∞‘Ö±£5Ëß’À:›§cùü[>ıºJ÷®-*Q∑¯.~‰z´¯èÄ«¢EV?äÃ®çˆœË´µ˙·üÛŸ44ô_àà]8’ü…l∞Œú1œúŸ ª;§œú√⁄WÁN¿–‘!˘(S{†Q¢;∑xF5·ï+≤.?I#N—$-H““ÒäJIı»ÇKáw¸¸œ¯ﬂ€Í∆WÀ=∑Î…‹„d!nÌ˛˛õØÛi´ÿ…uàî≈Q9.ËFƒ‰IŒ[%©.’òZñZÂYÁQæ˝û‹ÏY•Ω"ø¢)„√_û«=ûÇ@¢º|¬TOÄﬂJÄ∞ )UtG
dßö„ë‡∏£(‹Û
„oWD¨ï œe˛∏RΩòC˜ÚÁtû!˛îùOÿÇÊŸyéwS úÚ¸Óvá≤+(.„Û
ñóMO_πÀ‡≤–ÁÁäìzhÓ'ﬂ˝· 8™µÜk3ì˝ﬁ7‹∂¡^µ?9™/ò$ÖìUnÎ/M¡åZ5ıãƒï[Ii€πUÀû_øÒÈñwﬂ»m¡è≠ù6{N›OvÂ˛Çó?S:s·£Ûﬂz#◊.˜4u?˜ÃæÍÒ'[û?≤§íŒÛáó’œ˙ÓÑ¡›™>ÌÖ∫y/Ur÷∏ÏŒ?‰’0=≈—è/%ﬂäÏø∞ÔcÁY.Ÿ® Xäö—ãÒ¥.æ	mó“∑çn⁄aú5.†æ¯gqøà˚„qZÆî˘ÀãÌí'ç∆‡”°∆¢o»/ƒx=∞ùn3∑∑·Ω§Õˇ°YÄÇ(j≠®ƒµ£e¡9&ïe,¬R¨ °”XBÚX•æŸ®‘∆GK
KmÜôŒµaEâ•ã9mÜV\ﬂéÜu¿ÖCøp&DÄOÈ4^â)5f,8.0∂∫J*TK9 ëP0¿1OÍË},˜Î´˝πèv¬3{ˇä'N?U›ªÂ¿ﬂ/øˆÍ/˛FHÂ'ÉÔ‚ÔºÊº+Á&Ì˛Èû‹'õO‰Æøví„⁄.¿ûÖê—>›Ug≤]Çg27;˝V¬á®Ï¡%ÇVyDRyºb.åà+"ı$EK‚÷CßﬁÁ#©wk$ı˜ß^^ŒﬁKπ äô/9ShLe
ìôƒ$•(çEÛBx©
√a™ƒhaLX"¨8â√^Å”Èr¯¨≈Yû°Ö·BòÀÇÚs\≤*œM«CVÓ¬ˇ9∏«M/Æö˚√Õø_ü;Ç3õﬂÆ|¢˛gﬂû€û{OÓ	≈øÚı‹˘3˚sπ_´jüR˘ƒı}◊>/OÄ’{ >?jË-'§»	∆TQâ;“ÎIhà©<;‚V†FùOg€^€ ﬁ®!y˛èr’ß/r(Ô¥zQ∞Ÿ˙ÅæÙ˝uZYVáí˘cè4vhM}H◊…=ÌπøÃÌºä†—IÎ¡z”I6™¯Æ`¬N`£!QÌ!Ùv4°∏û/¬‹Í{ß/•˛(˝˚†m∫™gÔ◊Ωç^∫J7pΩm^:ÏÖ#<ˇßndÄì£°â&<ﬁ›ﬁ^‚ï	—då≠™ ±7Ñ¶ |Íhe≈ †p⁄Hã“f[lÕµíGŒ/}sYﬁ‹QŒGÀ6∞m4KåfCöﬁ>íÔ˘åœ∫ß‹fàﬂåZ`E"Ì1Ä*∏ é¨{{…ÌﬁﬁaEÓﬁGﬁÆ#«ÜÎA«S¿µ‡äﬁ;ŒcEd–˙ÿ¥«jƒ^]„Óì*‹ΩlÇªß∆π{<·Óë®ÿùr√™±ÂMÚ!ôR»¡F¥F“dò)–eÙ/$l∏∏	QÒ∏$ä‰ΩÛœÔ‹ÒŒM«rôÖŒÈb”®büπx¡—†Ÿ¶+ká≥#.Ã‡°ØˆüÍÂ≠l‰›∑lî—rG«b,#fsíAˆ;>ï–á.¶õ êÚ  ]À∫U‰*ëµˆí˜Aëœ⁄·'∂"§¯@ãÙπ”I7b`•»f~A€¿|¿A7ú2.È~[ˆÈ‘É0aÕDÃCºö¬ı’,Æ£:vÚß4îª÷ë∑‰÷à%CÆ%˜Üp“È”÷Öß˘‰ñNãæëF˘Åƒ)QÖ«±R±Jbï≈ x§∏DDôRÖ{Öò˜8¶W¨Íe‹a%bËî±n{5>±»:EÿêcÄv‹p˛6!àóú ç( æjtå<(#ÓØE|¨IL(â_Îìu≠$÷ò≥íìVÎØÍøWÍ≥ÙY>:AgL4–E“j„ÊÉiDfcä˘ôCWVo|…Ùn%€h´⁄ ⁄Ë~U	üiV»$(ÀÑ¡‡U!3ô>œ7;@jÛx5»l”¥xúñZ$–C⁄êÅ+è 6Î¬ïéW˜xmG_£a≠å4±wHPaF∂ØŸ¬Vi|«ñó»-2i;ÊÁ≈_åw [Å<l‰Ë›ìæ,p_pÉ5Í/
åòs‡/
[e∫GuÖÙ;ÉêÉaú∏(òÓú√:‹+É{o1Ω¸*?˝†3ô1'&3FàS3f’T!üW'e\ó7WF+≤PóMê˛8\8e*N·ˆo≈cÒ¢äp—#¯Y,ü»5 -ê{?›¸ÂÜtËvùtnÈ  /∆ùÄŒ%ºß‡óè¥$e=SÁfI.16lï¡ÿ¡àJ)ÛHÑxT&Q[Q‰DëÔÇ∂ÏV¿¨Èúµ5lk⁄≠Yk—dçA∞m¿è=\£íDÓªçj\•≥iÅ’+˛´||ÖiDrÀØ—;Wﬁ—˝5ÃÜ2∏©≤ÇàAsÍ2`˛ÈŒ∫s™\±*£é) p2ŸYbï+Ú´)!:Z*£öA8
¯˘@gàqWåÉ‚‚≠#°|¸“xTÈ@´1Ô ÿøÛ,%=gár∞µ“VÀ`gÇKÅC_í?@&ä°ﬂ9QZ¡`¨0ì$K
jÖZL:Pÿi˛∆§ÖÖë±„éˇ©ÇˇR^-∞Múw¸æÔŒÁ{¯ûÒ€é„KÏ≥'¡çS)¥,<„„˝*§)’`e£jyˆAG7*∂vB´x,*4$DaZµ(“†≠@Zß“jkß!V`k’FùhgˇÔlßH’§-…}˜œùüˇﬂÔˇ{,Y¡•é•¸µC[Y∂‹∑“ø8∏$ÙåÔ8Vö÷#"Ô1£`#à!'õ‡,Èü⁄|≈ﬂm∆Äbƒ&'Ÿ√¶û‡ﬁrTÆòdŸ˚®#.πÁÇ}ŒïòªΩ‡°I˜∫L•åzÜò=€C7´TC=•e0Xhj:àöﬁF≠g/‰˚ﬂºñ<uï_ˇ
Ì∫Û„´˘Î¯-¥Ω2îˇ’üˇíˇeﬂe¥¸∑˘ÁØ°
ı"Ò≈¸ﬂ
ÓôtKîüz√ö¥N€‚∆Û‘yÓÍ
7#∫"¿0îœ_pO∫…ŸyçSã‹;bÖ»g·Ç— Çü†_˙M’7=a‡~+f∏Æ\!≈Mÿ™Ç´Ä¥f[·	l‘.ßé∂o=∫Ï_˘+˘ÉËø˘En˛îßÛáÉ≤æÆ€•¸ÿÿØiÙÏè:üÚH9'`∆!®A*—®eË¢åÙ¶Úäı‹∂
@∂rÿ´”^c v{„%≤ﬂ§pï
±TË„7zı`ŒüˆV&2˘Ω<ëQãg•xÜ˚Ô˜ñõÖ˚zµx&˜≠πPƒÂ∂p[tëÿﬁ~îˇæºKŸ'T^íN+ m˘ñ¢Ç⁄E5≈≠iä¶∏x=Ñç†W`uMï\?œ{}¡@ƒG®$@öÓÛQF•Ωü~ø¢»\ƒî_f	¥ãÆ≤∞U∂ù¨¥ç%K>1õã∆vƒˆ∆ËX•ˇ›cˆøÚQUÀ©oÁ‚ n˙I`"ÇQ‹Î4‹õû≠AEê+»ì”é=Í0Ÿ˛Ù˝_T—âYg)YEù¶È”m†.[1d`ü` ´?Èp»V8´V∫·®ÄcÇpàN‘{Ω7ÎÑ|Â+´¢'cÄSï-Ç≠*„><¸ŒÓ∑ﬁmOvÃÍxdIç1ÔØËƒæcæt2_Á\py◊ÀÔï«cÓÃw°)O?;UtéÌ§öwÕﬁ∏üdîŒÒ[Ã?ÔRuÿc%÷–kòn˙1Üâ'Èl¯€Ù\Á¸ÚY3c≠âEÙ2gg˘í‰°2π
t√¶ûX©àó
≥T$JEïΩÖäx©0KEÇ8⁄VR%%3Üct"ﬁ§d™f∆g’.è.ÆÍào7K[‰ıÓu˛]‚ni∑≤G›ÎéÔßãá§√ sÍæÿSÒ£“1Âò'Rtj5Ü©áÃ o¶êIQ©†Œ‘O1©u0\RÕÆ–°≈ΩRM$Gqá◊A∏√vféHâxiõÛ“öûÕ¡Q<Â±Qµwﬂ!´&ì%—aÑÀ#!Œ…24fQ<V	◊ ÍÖjÇÅ›‡°ª^™ƒ€*´¢(ZàV°Ëƒ¢tŒ*´!oIﬁû∏ç7©J
óe‹ë"è&ëøKÎ·3!S'ÚMnÈ%êÎÀä=Âﬂ!≥ò≤¶d!˙äÓ™¿Á_ÿT>R sR¡M≤åêO0÷à‹B	ÇJÂ∫æF1p~Ys7–ñ0c	”lÃ455 *}N(üı∏}^∆gÉî=0;/J+/ÔŸ~f—¬Œñ¸÷á6m¯·g?9yoøcPÈ9}ÓDv*˙`Èﬁ›˚øzÂ˜˘œè£ÎÍ#œ-y†{Ê¨Uæ’ÈÊìÎ∂ˇnÌ¶wûîüy˛…∂$[˙ﬂy≠˚±;©u†É¿äNÍê%9pNAﬂ?Äª{ÌÿÇ–E6äp-çh®˚P1mﬁ∂Dõ∏"7|Vä-7J$1Z"Ö|¡@ìˇ»ıø?¡@;¡ù‹Ã}L»†@˝SÍÕh4<ÜÜÀÚÂÃ·|»!ıÙ|˘9y⁄†˛ï¥nÍK0ï•ÃRÓ
«x	º‡°2L◊ ¥qè+Ø9n+NÖµ|ÈÀªM\Úgx¬üa;Óa¬Ça;^‰¢^ı.Ù‚UﬁﬁΩ^⁄+ôQ	%;(ÿt(îËP(!Eò†CÅ)Fä
t(‰<ƒû}MáÈ‹›vtﬂnD¡ÿjó¶r®A+∫ÄF∞BnØÄ¢1´Ü÷Êø˙„’¸ó;Üf˜ÏyØﬂ18z˛√¸Ë…Áëtá^0˙∆õ}ﬂBn“#tÆz‰Bõ˚9~Õ¥„∑zu_‘¸ñ%C¡`°…¬eÚ‰÷˚VL›dR\µP+3—Fv£¯À8öf9'œ≤<KÛÇ:¡G—-@2§Yû&d„%WÈ(FnåÎY`B‚ Xº 4h…ÿoÒ.˛aKÿ+@C}ñ$äÆ(E?º ¡ì+<Bîª§=ñhÃU’ç"Ã∞ø_íáåU†2È/
.w$CX8}L∞ŸdƒNiHœòúNs†)íKÏÍÄ<<|@Öeﬁ9dê0dêúãw1É„#‡âG–TíP»Ï"[sx4ÖÉÉó{>@‰dŸƒLj(Ñ0∞∏eÏÌ"c·¨æã¬7∆.‚mt{æıâ'∫_@ØèˆéΩHv)swŒﬁ%◊y]&S$-3ÕÊÊ¥¿â<.rÆÏ¢d	â«9",¶fåMü16åπÑ¨ÙYzå√'fπëI
ËÄ6ä7\íb8É»Bv∏ŒŸÈ2r˛ƒq≤X".ä.°>x.⁄¢úuú≈aÆÕ52cPFîÉ}à
Hdv√Ì#0¨¿~†È#]”’õÍ(Eó”µ¨mËIŒÉî!ìN´√√ËQË%Í •Ì^‚J#ã¸F˜QƒâJªü†Õç®©ôL?rû˛d·ú—´LpÙ 2˙‘˙Ï⁄∂ûûQÁÜú∂Ò€Lò˘ï§öqç5âó¯ÍÄ¨NI’’Y©…”öV=∑:'Â™7Kõ™W’ñˆß~Ê˝y¥‰I#DÊ4A8ÃˆKØŒ$˚óí√Åk…?x>Lr3Ω(B4B#c¨Î∂àŸR÷Hÿ¢ÉTæ
zRu&Àd'ÕeÊLZÃ-KØÁ6•wp]q›ìÓ•µÊååµ6ñÒ’nˇ ‘ˆNÖkÂÚ˘Uy\vº*ø."”≤ã \&‚D0/ì7ˆ®*€!ªw»¨¢¿*áiﬂ >”Ôˇ©;vR‰EAõ^g%Ñ˙0-¶V´´)÷í∏#l˜Æ´=∏â„ÔﬁI:Kß”›I'ùN>˘lK≤RCÿå¿ƒÜ`Êa^A©xÉI 9@MS
ÖBíôd“–ßJ©M <¥∏Ö·è∆ŒòâÖiÏñ§ò∏©ÉÌÓÆlp;ñ|{ßùª€˝~ﬂ„7&Ód‘Œo¿ºAÁ›hÒdÄÏ\«JéF‰A˛a›ˆJ=´€Ç:(
räZ
åÂ8cóD!„⁄«dPRNÿ_¥∏ºΩúj.áÂ2~∑I¯ér¿ù_‰?gÍ0Qö©¬Dôl$Ä*õ‹$yZÒÀòH´`≤ë*‡áõJ ûÙ)d±!‘Ãbû'“è%4ﬁÍÈ¡ Ÿ™H˜wã8GÕOeF9	ò¬ƒwQÒÖ@*Ä-ïÓ8Úã±Â2¡âq`ó”)πd_mbl®È¿Úã&—ÒgÍ[ŒN}qZl]◊j©‹≥}´∑’ΩæsÔû„µÇYŒ?´ À.lXR˙¬⁄5ø+Ó¨´z◊Ã3%ÁÒ,Îüö∞(ÂNÌ´÷óN”xˇá] ‡çBU(úQ4-˘Ï¨	?FΩU¥ÜA ^ÿ§ÑF+Ô7∆åïFcÖ÷™QöñØF‘…ÍFÌÄfÔàª‚ûWç'ëï‡Ú	◊sû˙¨Áπ5¸z◊zOªˆ•µKÓR˛Ó∏#ﬂQæˆﬁ“5%◊XƒI≈∆
^7÷µ∆U∆.ÔCCü`ú6“ïl’ƒ@ãSµ±n'Vgìlk–tåKjîuì16æ°>Ë>©!“·‚AÉ[§xΩ„…nÇbê‚"tÄ¢⁄!JjÕ∞ﬁáV¿YêÜ8(‡¢EÉG∫ó$•âQC;.HJÕ¯˛4Æ02’Ö›¯πP¬èÄJŒ‘qˇc∑∏*‚3Ñ~tÖ¥'âı¢èàÎ%#ˆ©ê Û!ÔEâµùÂi»"§ÛD•ü˙˝ÈÜìÀZR˙¿w<ªéä÷Ω∫Âƒªõ∑ú0∂ı?|e÷+üΩ8po‡⁄€çsu˚.ˇµÛ‚e§´µÉ∑È4“+\|í"¬µmÁ!œB‘ÇçÄª 2n’¿Bõì…¬´g»Í+^=#‡’3§¬/_πòIú•¯[Rú≠O5[°¶NqLëÁ:Ê IGR>H§ﬂ‚éG<÷,N±‘SkÈz„fÎFÆâ;j˝»¸±Â#´’e›m˝ö¢m˘?‚7€yöáHbÙ≠≈ øTΩ÷–nÅ˚¿xûOﬁQEØÓ∑e} œFÎÛ≥!π6ÑP' Èùi¡‰’ÈÔ`†∆T0c√ìûƒyeJ≤£Üí!B%C˛DCı\_52Ê3 ∂ó-J7<•»⁄Ÿ≈Ú"!—ç>$_#‹AsàQ;”è≥4FééüÙﬁ˚C◊¿øæŸ˚¡u≠EŸæxœÒ#?´ˇ‹%“Ω–rR;Zﬁ…^˜¸˘/Æ˝Âß 1≤
av1RDå¨”èX(‡¢‹”ú1&≈‘‘<ÀiÆ∫öZa\i^.%’vÌäÒ™„Ü“„ËëÓ…ˇRzÛ\öÚ`∫V{0wô1îü„O≈∏j™í´íûQXÊs´π”?]}ÅMÄN⁄∆
<b$Àà Qíf›"ÑN
¢.&≈&Q◊DÜ†¢3G$¶Ö©*öpâÑ∞"âºx«Eﬁqt~ó∞Tƒu2FG‹d˜üc:òõÃ c¿Õbh&áî—i&'Sä6bKqF…â÷é`Z"5#›?ítqg≤npÒ˜	œR	D≥÷b$∆¿Á†ÙÑgtŸ €ØnÆø≤3˘F—©˛‹õ∑º{Ï'çÔÏ˛Ì˛ÇÙ/fO¢l}Uî˝“gæÿuÈ∆¨©h‚ôa6Wó5†:Q&MÊ:v%ΩŒ∏¡ºíÕrb$ÀF}yU¸?hˇ“ÿ'ız%ˆÒJâ:…>√3Iùm_¢ÃQó⁄_,UMçŒ^™◊- ‰9YÆu·^Åv©¸°Y†¡ê≠Z–F«;¨fÌàhﬂƒé◊à=≤Œ!◊%Õá±¿èÊ∞ˇ„-Â|spt¥ïÉúGCgßQ|‘'aõ’†Êä~F˜èé#ï;)ï ï!òJ0rºR#51ö—ﬂ=S@}ioÍqÇ∫◊P7!W"ﬁüäìîâ·Ç	b°0’0L1DJÅ(1y§?ÅyƒDÈÁ⁄¬wœ|3pJ◊ØB|t€Ú·ÆÂ˚˚ª®Ÿ÷≤˘{_~ŒóüÜ{+,¯€¿Ñ‹ñ∂5ı›S÷E*‚@6ø 2‰Ù…y•H)Vte£r–˙Ó=.À√r≠JªbP~z¥®7ã£≠ºjÅN*$9¥	XIPtË9` 4ıƒ›j˚©í≤(>Í!Uã P—1MùC4j6
I£ëèâ¬CÌ∆wôŒHx?A&£ë¡?à·°Aﬂ'$Üv+ga»Ω–Ü{íaêÓÖÊ¥êN'2≠	 ÀÈrÌÌî≠∫$à&3c B	I0€≥Åh‚≥aÜFÔÿCà'—ãƒ¢„∆"ö Y√™Êå8}‚áá9<;∑‘,….+ùÛtG˝÷˛‘∫h’˚€ñ™‰≤˝èV!FLòMãëF√zíeçRòH5l•d2{oò-ê¬ærv¨4ù≠íÊ3Ÿ5lüÂ°”6∆NÙM÷Ñõ√Ãÿº±£*¬UlU^Â®yyÛF≠eñÁ-ï7ÖªÇ∑ÛÓ˙ÓEŸer~Jù<]®:‚$B.(&>“⁄A'@±ï⁄¶óUï∑TÊ´VãÀ	D,∑ªSÜÇ¨ÀIπI6Ñ—ñSua"k2ë5˘±¨…D÷d˘°ëë5<ÀÑœ3≤&„P0ΩºâáêØ˘œÒ¸M~ê7h|?aÔ¡ÿÚ˘¯nºäÔƒm„â∂ÒJ(º)À[hÊy{ê˛O·˙ª{„à<›ò?›¯«åI!Síeóú	êAƒ*£sr,"J$Ñ:Fà›™∂t ¶m{‹6∏•ı´˚Î?ˇÂŸóéÆ¸™˘Oﬂ˛˙Ë∂óè}R„±ÖûŸÅ“ã«µÓÉÒoB∏ˇÕ¶Gıﬂw4æOè˛º˝‹•Ûœ„ŒÚÁ –∑ëkIpÈ‡BÖÔî£4n[Hºbt%›∆»•Ò≤ï≥ƒˇ“]Ì¡U\e|œÓŸ≥{ˆ>ÿΩèΩõ‹Ñ‹pπ°ˆ⁄
‰Måfµ–T(Åñ∂CÄ+ïÅ*/'ÅB©ˆ¥äë±CuT@Í‘BÜ¨c˛†uZ ≠ıQá◊êb;òNFôHÅ$~ﬂ∑7p°ö«û≥ÁÓûª˚˝æﬂÔ˚}a'°ÈLW•âêŒIø~zaT≤>…\™1Æè0»;Ëò@$6Ní∑ìïx¨ê»B"±¿Ñ{•Öt¡œcle´ã\L¶∫›AWmw˜∫›Ó®À]5ë#æ˙6<√ ºèíÅÃ9ßp§	*N¸±4∞ï&~µ¬KΩ¯AE%Z™d9[ì-ÛKÊ¢ÑtMÿRî9DZl
Ï`ãÏåä®ëãäpöEL‡•ƒÃoWÄ‘,_∏D◊M:Yá`Iß≥wkﬂ∆_œÈ›∞z˛˜ö¿˛kWqˇOÜó™˚:7/ÿπe¯7¿… |ÆœPN˙_ñ”ÒÊ….πWvÀ>yVJCë5≤]nì{JKÁ‰®¥j$x,É´ö⁄V¶]pK9]·{¯^ﬁÕ˚¯9.˙¯ Wû·ß‡åÛ¿+´èq„7n·∑rR6>¶lM8∆å#â,å!o5oèﬁ:à XÛ ï¸«î_◊ëèO´OjïΩΩΩ¸“€o_KÚ∫kÔa^¬;kW‡ùCÍW¸¥<ÑxT,í⁄∏»øı!°…0>•¿^œõ»±	§Ïæç7>¢=i©1ëâ◊LhB≈&$6#0∆tZ®•ˇXúÎ\Ãê-\œâª¨Ö÷ì⁄Î=ÌÇ0ñuFŒl˜»Ê»ºHoç6πÖ?•ˇHæ.˛»ˇ,˙≈á∆ƒ«f2fY∫¶qUCJN§iÊë0°qû”≠ÑÆ[ √M·◊ÖaBf*?¬∆˘RÁK}Çâgµr¡‘Íï]PËC9EÕAO§∞fed¿‡O°∑©Q§bJå2ùl≥B\©GŒ◊∂<^¶T(Ls¡{@â A∂(µm¯ÿöúTCß~wûo±è√ËÂ£01l≥…l“ËxPPèô#Yç|FS•q
êÛmÄÛΩK˙ñ¸tuÉ4´´õ ∞3=’0¸©'C√¡⁄zÑ6px‡Ûî|Ó8™à—æû⁄ ±Ø«≈·Lè› ÇÅŒ¬47Á€Äfx£;Õôôp·€â&:¿]C=ﬁ¸œÉÈ‡rVl#ãÇ≥‚%´g,À»DˆÚá#´ÿÔŒåÏ˚¶~Ï˙´¨{d„rµÊ#ã1/üÜ√‚‚Ö√:QGª0„ûçÖi¡8yJ0N»—ËÁ@V«È5˙˝¨ŒÁ¡aP◊jÙv}õ>™sP-K’!√ùH–íP¡˜(¨⁄)µ\’Æ‹TµÍ2U∞|áY25a2JÖNπ¡Q•ïﬂ Q$i>–î™—∫`#ÛtØ~ÏÍ}•Z!Í¿dŸÔè*†no)MÄAıÁÜ"ÖÔÁ˝Ú|Í˝å˛Æ>îQSf&+ΩtFjZv|ïHbÈ4ò»VVÿ÷©Î ÌÕ©πT™2öÎrò√©3Ò®+¡™¢Œ$Å/È £S¯¢éJ˝Iò˙ÅÓ†ﬁèu)%∑Œä~ÿÀu•Yö∂Kﬂÿ.M€¡˘GæÉ€•©§©¡L#ó®•√∏1ú_ßç”∏ü´®ıŸ;•0Ïu’˘ßˇ™?¡ø0a‚ñ*Õı1/xŸOP…	†àîúò;¬6™m)˜%ÒÁmó≠î°‚pÎ¨3/v@ó&$ñHtE°+H·Dº.v“,Ié§íE|ì”©ô¬CPñ»/ñ®}S¨⁄∏ªfÎõ?{˘Pv…Á€ÿªp˘€y›≠Kó-<ˆ ··IÍO◊,m|aˇnµg”¶˘?˛¡ﬂ∆º≈E»ómÒ„∫&‚Í/Ì#ˆÌÒAm(.8Jn$ÃS6{—>ÂùÛF=û1—Ño¡Ñ±"—pt¢G~¬#o"W"W∫·*BDÇ–∫#LÆ"DÆŒ? ë´°Î 9ëq	1¯µzH∫Jtﬁ†ß∂{{ΩnØœ„û¶÷']‚ÊPØ„Ã˚ﬂ∆¬∫ÕX8e∆ÇóòÿÁ«n7*≠){®ÿqS`·e2∑¨¬œ ®1˙çÊÅõn√é¥LÀ∞4a◊9"öf„¨X	‰;∑£≠Ñ"î—w§nÅ∏ÛÁN?∂oæmıﬁπ˙˛ı/Ò∫›ØÃjü;uÀzıπØØ˝¬Æ∑Ü_ÖKô9˙ü(Fî
∂˙p“√7ââd„êíÎqVAƒ´"‹"Ó7mÊW≈J”,ÿç±Fwö7Àûõ„ŒÚñËK‰Cv1VtÚ÷ÍkÂr{ml≠ª‹{í%•–#ãµáıá≠≈·5⁄
}Öµ&l•™∏·Äd$&¶…„ß)tÛ‰Òè:Xª¥:ÿK≠,N»3‡q†	P!>1Wòl0≈∞çå°SŒÇF‡˙ó∆gìaù®Ñ£ÿﬁ≈àŒa¬∑äçækIóˆaKîUôRYòÅ‚Zºâú›ë/ãeXB–< R˝Zñ-π@_ óÈÀ$«⁄ÑóƒÌ öí$ÛØîõˇô˚ø˝⁄ﬂôª˘“ÛgGéˆt>◊sËŸŒ5Œ&Ì‹8r~¯‰•o±Ò,Ú÷â∑˛⁄â7·Å:GVÚZ@0¶ågÀ¸ùa˚.˚sˆõ7g∫3jMÊS·lı‘‰‘Í/V∑g∫2fc™1=;5;›f./I-IØ2WáW⁄kS´”}ôwßΩ”ïÔåÔOÙè?óÕ∏Yû∑Û…iº—æèœ∂ŸÔá.Uèÿ!'™πUU®ÚnU4§D+&û≤òm˘÷c÷6ãg¬¡	æÌ¢B -Øt~uÃ–}DXí≥C-Ãµ,€zÇ≈Î’˙XNQ˙¿±Ω¨õ2^√öŸ<¶1¨s§∆å‘òë3 ∆-í±£K©`a‹$pe5-3<ñoµob{¯rˇÕvÆÿ(å»G§£Rƒ¬©tƒ«D’M&Tl‹&9Zzù˚w}m«©UŒn^Ù˝ªù7˝Í•'÷Y©ˇˆ;>¯›—1rÌ˘áØi˚O?ÒÓâ7ˇÇZ˙,PÒu¿–Qﬁ?˚ô8≥9ÀÚøó/‡èÛ'∏êé)Mâ;2¢h&QKﬁ—e2sB&Œ‚ÍÁˇ˜J7\≈ﬂ)ì4A)KÌ
⁄%Qf'[c-«?—.ı€≈ÀÎ˙!>hè®"5(ˆù—-«1VÎXq¨˙¸óÏ™èë¢<„Ô;;_Ôª3;ªÏÏÏﬁ«≤∑_Ïúwx∑«yÄÓ†òCËqî
‹Q“
Ñì á¶@Åz$‘C£X%öÿ®hƒZ”Ç‹…ajKZ5ıèãóFâöIJ,!^bÂèº>œªw€›ôwûôùwÁùÁ„˜˚=ûÜ~— í~y¸∂≠µınª˝ˆEMrÒ•ùÀû(ı÷6Ó∫ˆz°6})r
º0?‚Ö˚‰\"∑ê-gKÛkrõr˚Ÿv(ˇj¸w≠âòÃKßº˘+Zœ{JF∫WíÏ S˙ ‡—c¿“áÿäCÊhq¥dïä˘R~ﬁÇ¸:æ6zÒ˛Ú√-ÁáÛG˘Û∆3Âc≠øûˇ
ˇ≠ÒrÈïÚÈ‚{≈dyVÛ‰fçñY#?kîÎ}»Ã=h¥Ã˘Y£lË6ı¨”KÉÀÈlqémkLèKØá9øùﬂÏ◊¸~ˇG˛¸}’Úõ˝Ì˛æ‹Ï?ÂK˛;õ9êØ
QM‡Ì6©d”Ih)®M%ää2ë¨RˆòS•¥m†q[£‘ÿ0Gìq¢©ÉúmÁæ„`π°-⁄ú¶Èº∆S’úﬁéEÍßÍ#÷ïüƒÒ≥8”œ‚,_¥(~R¡∏¥˛M-_Å©c=ìZ¡ß‡å
í˛ç0póﬂ¬Iï¥x‘‹R•∫±„\áTÎÓê:lJiû§Í J§\∂Óe 4phÑ>."õ∑D©[byVo≥êè≥¯L+Ü¥DCiÂæòm†¸õ≥°‡wˆÕ˝Ï6v≠dåóv}7®Ø)P]xSmjß€”^◊– ‚ …‰ºWÁÈ∞tSSãíh-:∂k«Ìàö3≥¬ ZÜ*7¡–îÄ”π±ñ…µòÜ>èghπƒ∏»“l7"£ÿç’ÏuÇJp‡Ar@—¡];„›…:‘îä•6©´∫†ªEPcÇı® ØI™”J±ˆ¶ıÿæ˝{∫
GﬂÆ…-ïßWxgùs“xhÎ˛°d≤=sËœ«÷l}ˇ¿áü“[ÿµiÈ≠-©B«]WˆÓ-7ÀˆmI≠X’›“–Á˘Œ%˚÷Ω√7∞NÛ”ﬂHÂ9‚ëOŒ9ÿR¨2åÏ0Ü}J®ar!IõíàD-;Gr‘tù÷Ù;Ÿùµ⁄∞ˆ+M&¿—/j'µs⁄§¶jHàUZùÑÒÕ(bñVW˛3_´kµ:˚#ÀÄ•ŒàÄ∫~—ﬁñÜHä.8µ˘⁄! ˙)Pbˆ≈+ãë™¡Dêw:;Ì∞A
ÇÇá˛+v9-]ùN7 Yãì@◊Kv˙ãº≠ı–°”ccÒ†‹Ù“ˆmõéK?yÇj€æ{ÚâkG˚Z”¢ì,ª ·È˝gI|√†Gî≤Òd’¬’v∫âjßy=û4h<0w¿M§3YHy(\”B{B{.:¿z¿Ì]W¬ûP¬¬ªP¬ûhm<T¬&˙c⁄£Á<Í≠LãŒEp˙Î¥¥#˝b˙dz:-ßçªNåñeìÏìŸ,q∞Îƒ¡ƒì«ß2¸¡L®`&â>q•ˇΩÊäkÍˇÂ.0˙Ω∂∏Œ¢à“≤3-SR5]’$Øldà©;ÇÇ∑R9sÁvâ–î 8ù$<ƒ¥#µ˝oxπﬂééFùÔæ˚»¢—ÁGó˝¥øÎ!Èôkßüºπ˜Ó’Oñzæ˝¢!ä\ÇËpz˘î$›qœ}°ßËÑÎ*U9QòÆPI…c˙)Ì¡ÁˆÁê»v∏‘Ãô.Öíú”√ﬂMßáACS’qê ÈN√ëŒ·éOB÷4∑J 0Ö√rÖ*I¬ güÖø(∑UIÀòG ¨»{H_Fz˘∫FZ´ﬂ«6”Õ“V}+€Cv”›“^}€ÕGËàÙh‰1Ì∞˛8˚yñ=Õﬂ «˘;‰åvä@ﬁ„üëè˘W‰¸[rÖ∑¬ÎIÚ2)ÚnﬁOBŒî–MVHïÍ)Uº;É˜¡W'(∆B√»â¿PÙ^¬	Ω"ÆJäbD!lÌü‡ÿ'ÇâÄ¥◊j"îô∞õk∫^`<¡'Iaí†¬A≤Ë∫$QU„,B®“nP#ßáa»Üôƒ∆if,TÜI+dY)§πËÂøc6M•˝kÉ◊”©©ãÉ(5Pm‘#\÷†tGî∂`‰¿ª#m)<¨†ΩolØ»‡⁄π¥3ûÙt«;)˝˝w€˛t±–ú
æ:˚›ÉrÒ⁄°-€Ô˘ôtí≤C%D9Ÿ· çıÏ8K\pÇËE5Uï:£f?5LA±ó¬(ZN÷®ˇpn4fãÄZ—rBqŒù%®!™Z‡”P±†áJ2óé'Œ,–9¿:ˆ˘	˚£`≥åå3CX®¿≠»Û∏¥‹YÔq"NVƒo|˙ÇÄ@y÷pvXÛ‹™›–XB∏˛:<”úØ ™¡‚jÜ˘Æ"Yç≤hLwmè$¥=mÑ^©†UÙ V%]⁄B}Qli§Wµ>}EÙ´◊YÓÆ∑Vπh˜Î[‹ΩÍœµáı≥Í€÷[Óø‘oY9ÍîIŸ,≈ V…mO‹B∫››˙£˙≥ëc∆	˙öÙZÙUcåº•æ˚õ|^˝î]í/YˇtØ®ˇfQWlà—cLåñ›ô¥Õò%ªƒ—5Ω†YÖ61-bR£`éOüª•L»æäË
Löà´<Íy‡‹#Ø‚Œ6gøÛ∏√.C.b8ÍÅ˘Ø´Ö¨mÆ¿ÜÁˆE¸÷Ÿ∂Lòà(
 ñ¶0Œı®ap€q ﬂWúVàöÂÆp3∑bŸø:öû’◊-°(Z‚\0c	”åÈ–Â\O¿t¢\Ø"QÕïuÀ1b¶Xû8ÆÎöÜ•„ZV,Fx‚™m“çÊsÿåò„ÙD»≥˝únÁèpâèK˜Ü¨ﬂ°€ùG…¡≥®≠–ç (Æ◊â1z5~u≥êD~ﬂï¡¡Ëÿ∞»S_^Ø,{ÊØNg™Œ„Hﬂç˜˝dÂHÃ~WãŸãqG˜'õWﬂ7jfç¨Ù«È†i/êÿÙ‰(ôoe]»QzÀÃgÌäì’’Pq˙Ù‰)m>˛Cvµ 7qú·›Ω”Y“ù|ßìd[≤íl˘Ÿñå_òX<R^·ÉÉ‹$ÑàC!M'á«@B§43Ñ`öb33Ã08í@¡J€Rf†§dÄñ45igù@,˜€≥‰∏©=ü˛›Ω›ˇ˝˜€ˇﬂ÷M›_>kûŸzÌ@Z`†UGÎ0≥ä∫pÑnD´?Lãqç…Hvt`¶AÂÉ„2ÕqŒ˛kùˆÄ ¸¬?ﬂ‘v±K7H1Ä~¿e`E©g"%¸Æà◊†PÃx‚ ‰A%W(Ë‘ƒ±£µby«ëÌïc∫ˆ%Î(∫Ñ ÛÀŒ≥Ï'}[ŒùgãÓ_f-áø˚"çä<ÙoDç˛%ôá<*ï%ëŸ$&9¿H’ºë´—àIJg¶ôTù™!Ø!Ò¸3”kÃS7ãõ≠≠È[’ñ“â¥s™Mçg>¡eÛ8|Z%%Ø°?ó≠Q˝Q±!≠Aûõ˛.›bﬂ"¿∫ï3ÚŸÙﬂióÖœlü:Æh7ÌzÍp…
—ùjñâG∑t^R%¬ƒng8#<Ç	C\d«IíêfµŸ®$Ÿ,¢Ä+üä|Ó†™Í–d\*òCÕ.©Lµkß…i”¬ƒÊ&ƒ&0«iuÑ¡≠(Ç›f&·%†(ƒ>Cß˙d«J%dWüêl+„vdÜ‚“Liµ$H›l|<= ¨d°Âdgã˘Pmº3ê,ê+¥õ⁄ùﬁø5˛üyÆhL≤µÒeÌ·Ê´Íz´…“Å_N›kMíá“≥rô˚[Œ1îP¶! º~0hh<∆€=[‹o§2NC„rAQêp 3yÍ©F	4°*]óh˝¢Ω‘_ÓºîxõæyıÚ®ƒó¨ê&æùW~?°Ù˝ûNiH4b]¡ƒ,·68‚£ˇIr$«ÓVY{U]í%W\Wr\	$π‚çF|W}YÁ}^çNú^3mdw™~™ÚE,ıÖÓzuü]à;‚ÿê@a¨B„?iäMœpdÈrÅR‡®R™ïÈ≠NπP/tM h–\û%˙◊œK“ãéóúÕÓfœ+é7úÙÆ◊›[ÏªÂµcŒ£ÓÿˇÓ˛∆—ß}ÎÓ˜K1*√%˚≥EuÇ∫NTÔ†˘¶}ÿÉ∆$è™UU—+qs∫]Æ∞nw£¢*ÜaŸÓñeªK◊Eñ∏‚◊¸,Í?Óg˛nV{XÖ/‚Ón6;.◊Íqù=¶◊ôﬁM«u©4D ∂ÛO¶∑‚%¶ÃPÑôJø¬ÙËå™´=îhA`ÑÛ˙ñ„π°ÿõ•›π·’n4.ÔıeiΩfâdÒáCäQV0	2+íû§‘zì?àzÈà6Yà6«à“ã»˝∑Ë–X„Óˇº´⁄∞á™çtú≤√√ÚIˆ “‡˙∏
¯∑öˇÖA™¬=xï{tqÕ§LgæEN,˝Õ’Hhx‰˙°ƒ≥cÛb-ıâß;¥¬ºÏ&5G,Ïk˝ÈöñY”˝3˚∆5‘"°ˇ∂ÂñÂb–pRE‚tmºj´æ)cìoÎ∞+˙≈åãæ+√¨«ãèî∞¸Ç¢í¢X§ló∞[ÓptENG˛±?eçïEF_à≤(Bng~IE¥õ-à/-vóñóG(≤î∆ FU±≤¬r^∑Fãä*—Ápuu ØÂΩ˝A⁄b°M§4≠ö†j‡π¿™¿◊…õ≤–·†U÷∏ ¬h.ÚgGè≤§îftâÒÍ ™`’G®Ë¢?[–)˙∆π˘äwlg≥ô‹¶ıN◊ÓNÎE¿>’‘@ﬁÈÂè^lmﬂº;ç¸Ìá´lü5≥\¶±æûÔ$≈±…¬€dJÕÉ4úìØá”ÛYxX~Fæ=,Â˚¬Êé.¶N’$√©?H3m(y”P™	◊SóC“?9+H≤-¯!Éw∑°k÷PP™ëéuèõâπ°<VY°ÁeÜDÊqÎb˘à<Ω≤ÇÂQgpDFÜ«-•e ûdÊ‡îõÎtÇï˘(≤ª”gŒˆ$ZOùJ¥û9Gü˘x{‚¬û]¥∏Ωùˇ™#ÒßÇW?ºjIƒW6Ò…ìÊT‰=4m˚ÛuÖ«r·d‚ùON&∂ÙÙ–≈'?°M'_nO|∫≥=ÒŸÆ]4“æìF€Ô)ó,´mXg’Ω±Â€WøõÔOÏ¢øù02œ#V·‚Ã6æﬁ¸î˚1µÊk∂ïø∂ÎpyR\ˆã{˚˙û÷àUA’Ü˛|êˆ`b:Øë{˚Ó5kfÀ–?G•îlb∆ ˆ≥K‰«‚
‚&ßÂêüYÍ…\∫ûÃc{HáêC‚‚^Ú<˙ÓA},‰Q>˝Á jÄz¿ólõ<‘Ò:˙·c°c◊c dûu8yŒRﬂﬂá˘6[z»"` m‚u≤[2»R‘wb‹qëêjﬁc6K{»¥øáÔO¢m‰\‘ﬂGy>∆≈íe[⁄[ƒÀ% °ΩzﬁLÆ∑@¯5©WÙÅµ4@Á‡UÃ1ÚG¿TÙqAé÷”ÚÌÈo√wH≤ÛØÁÌ¿Ñ§ú=Ø‡{-∆Â°æeÏê U ≤Ωƒ`nÚ!dÎt`›@YÃ◊<∏&ÿü¥Èˇ1`„‘°¿úπÃËø	ib€±ˆò,îì’êM@60ãù'K≈á	ÖøZ-7â¿ﬁq?}åíÈ®SÿYg9D∂Ú:0Õƒä˛>Ò=≤C∏CF‚[≥¥ÎXówIî˝ìîHa≤
¸ö ˝kÄm–yÀ‰√B2ÛóBñã7MΩ
l¿\_ß¸ƒ}É˙ÏÎ#òÎ;~0æòà}Y<ÀÌ¡¸QÓsæÔ¥>a†ÔÙôœÅˆLX;Á$√«CW8…√∂Ô%iCü∑‡◊kê"‡·6§`Ú,	|;=^@rÄR‡&–4£Ä©@!Ê&òW0˘
Œpnö¸ 7,=!l39;∞ÜmÊ~úô˜ì∫¯<Ai/iJ"»uÚÛ¬9[§tÛ3≈9ìí&øõLﬁﬂÊÎ‰úî8{‚Wd"∑¡<É‡VJÚsõ˘yÿÃÊê◊ ∑Ç«k9gπ})…˝¬πf˙g")kÜ¨5fûHÅê‹$◊◊¶d Ér1Ÿ	ùèKSvêI‚dí6Y ˛ãLäH©%Ü6¨}˜≥Ø»#÷§{9„ø‹ókpU’Ä◊=è{// È@ÒyäB®TjRÑ¡¢ì–HEKJ[¯™v,ƒÇÑßcyöËÄ(S±„£`Å©”†V⁄ô˝Ù1e¿é∆‰Ù[˚û.;ÑjˇÙŒ|≥Œ^wÔ≥◊Ÿ{Ìµ÷¶˝º%W)â⁄ÿC˛~æ≥Üı¨ïX”GΩZÁzØ6Ê˚5¡)_b¸gñyn"mb˚Sˇ©T“ˇk≠˛Jpé˙5ƒÃö‡¥_|œR=â3±pm$—ˇ*°o≤_lU≤"∂;Q,ôqës∞W _Û‰´ﬁ~ˆ'õ8œY@_ÏˇEﬁpó»Ø6¯(V)ïN≠ÃKdÀÉŒJbs9Geé¢ÔG>íÊG˘úÌKëå¸’ñÛCüÍÅås˛áú˘Œ„Gc…Æö4>õ¸@åÜy)>kÙœÚrQ‰üñüVX˛ŸﬁˆK[ö‹B|èŒ)v,àæ_„£∆8çëÁ4ŒD˝mô6~°Sçk>$e·πæ>§èágü8Ã~óAº0ÿﬂlu;[„y<~∞ÖÔûŸòS'a>ÌÂ“î^⁄Ey‘$”¬x∂…ƒõ≥≤‹‰—c_õ¯6ôÌ◊±Ôƒ@cÔ˙≤ûÿ]·=¿öØñ≈|GW∑äÛà&ÍöòΩÈ¢yAs¢ªÇu÷\¥DÊ∏S/ËÿA“—‰ã|)≈ˆFGNU©:øT6∆œHûWL¨›/Â∫W˙jèÓ}Ú	ÈêÃ&N‘ @ÔÙ…ñ∂Ù[o÷†@∂ø–±T¨Eb≤$Ÿ±Ù—˜m0c
§S∏õÃZòÒ‘"Í√∫º3û-ﬂ2ıƒy—/ñRŒ–ÜD•làsÊ≤e+Ôxâq≈j„rLæ^!˜qæÊõÊsƒ¯YPÁ÷=3âÎ‡V≤F5“≈Ød+Ã∑èR1∂Jœè[-=’G‚+à√ZO¨êÖ^?Øê%Ëñ¯ƒIÊ]Ñn.Áw gw„{Ñq[ò{zõØµå÷z^“9^iÍ 16hù¬¸Ó)Ÿ‡…|¸¯…¨√3“ó÷¢Òò¬¥gÖ,Natô)ªŒÕîü®ﬁ$Ô3C;ë@sËÔi˘°W"yÓ@ŒnGÈÔ˝û≥˙©¨q3díwP÷xªe±∂ΩŒ“€›Œ˜Ô§∂T˝πGıŒ˚¥WIô7åÒÛe∫7Iw_≈˜˛ mΩ)Ï5„¸gÒì\∆üÂΩ!±RÊñp∂ÊÒ¸i≤ˆ3sÏJoîÙ7„“0∂FX6;c¯™"ˆ{ı˘"{±µ—Œ»∆KÿgæSﬂÀ8Ì„≠ëa¨”1∏1%∆9K§÷;î;‹o ì±≠¡^÷µ–bTz€{
nˆÀÎ4œ7!€Rmj∑¡Ú1<√ªﬂDÓ–{Å‚ó!*—≠ÉU^Ù_::œ•ÙÈ¯›ÇΩµwëk v.ÿ´ÿ˝YÁ!Ã7ƒ˚z∞W¡ãî¯l…JÃê,∑˙kgµ˝núß]íÎJÔñl∫¸§≠cA˙7F˚Å¸ ‡XöºVeòÆÿ∂+Ö˝ùﬂ1Î˚…N˘ê\;CñƒéJ¶˚>¥˚”Ó≠g¥OËóΩµ¯äËö€zªmÔkKmgáLJ'ÚÉFX*∑+^>˝¡n'»ÌJ¸m˛{ªi€€“e“◊]≠6·ÉΩö∂„wK/≈…≈÷√ôÉ∆ˆbh_3æÉ‹©ËŸUúù‹◊†Òˇ¡2RI[◊!∫ÆÓÍ‘ˇ—˛D˚bÔˆxáe4≤'r(r<≤(íÈg÷>∑∂.ä%óÍcùçÕΩÛˇ	ŒŒAxﬁ˘_œ|2!~å:$ü:≤ñ˙‰>ô#RO,˘¸ÿL∫˘:≤wCË¿sGtﬂGæ RwûÁ«–◊¶Øõ¨Î ÆË^«&√˜çOçØ˚≠»gÁ`[j|]5<ƒÛøÄ|^˜'‰õ»UÙ?Õ∏π»ﬂ§˛ØüD{Ï£}ÜˆTò¿Ûs»l‰M–:1~•¢ıHì{Ëó./}ˇ¯¢íöe2vˆ@ÓE>eﬂ!æ∞åˆ≥iﬂ5¢˝oI˙·]¢©L≠w¶„‘}€”Ô>óª„Dí˝lH«+Í©)€k≠µ¨÷œ¶~•πøô:ñyE≤"â=m¥~’⁄YÎW§æø*Ó{ä±ÎcWò7“ckÏú¨ÉLË 
˙|ÍÙ
{2ÔÛ‹ç6)¥ØÇí¡rWπÓ‚Óy‰!⁄›ëÁ£ú≈÷&1∂Öúˆe∑[õ#Ø ßÊÖL≤hNqk»h≈Œ≈≠••‹}≈πºôùûßˇ€vîÁ#⁄‹.yJ¢ ÿ´ÿuiì:†ÖvKunk€v›—Í∂UóDmõ&ˇ€æ’39í”àuÓZãﬁ-º]jˇ»˚7û∑∞ÕçLá8–;Ã°â‘ˇAw GK—ÕJ~.y…W$èˆ. o6¸YÆˇ!_å-q>	Íiˇîv¶w»ÙùRﬁí?€~´ıπ©Y3üS˚Â∏:¡´0-⁄kΩC2˜GYWÔπ^Ypﬁ;Vÿ¢,è¬+¥3hgã≥‚â€≤ÖÁy»∂»∂ƒ˜q0ÖX~èˇnPˇ±ÈSƒÖﬁèdq~∫WÀ;Oo”ßyíëh/U‰Œ9‰–¸øí±Ûig#ª$ÆïMºg7„iàü%ñí€hÓ`ﬁYÙΩ€;+À›v2Ç˜‰z'$+î¸:yPÛU¸f∆êÛ–ıAˆ6ÚÑÙ& »Á}√4◊∏5¯»_K˛q≤dü;Vˆy/Àcºo{€jY◊Ê]Yó,ó¬‰lYØñïÓZôÉnm‚YYÔ'U˙é(ØjNåû)¶bâÓ&ÁO£ù ·—7€5Å±o¢‹E^ﬁò>o4.YH.=À˜3∑⁄⁄RmCé_Â|áá¸ƒûO◊»©~óíÚÉ0«œhÃ˘%2;ÛuMÕ⁄NîqÓ,Ó}ö”u˛Õ»£rø7¬5∂mâÊb]Íõ´Ö¢⁄ÑÁR•˚lÈ¨~e|)E± Ï◊h›3øg8C˜?ÿ£ÎcòIG∫zˇ|HÌTØÆ∞@q÷qFßsVAo5SµÃ°o∞Ÿåõj∆çàèá|Ïö¬<’¡…»3Nz≈≤–¿zÈ˛9Y¡‰cŒ{Ã5T2Ã˙=éMãŸÁ®áDrXG˝Ó.^oÙÍü˜˚O“Œ5ﬂJ≥VåÀ‡^ßﬂHMÂﬁ,¬I˜6≠ØX∑∞o‚u)L‡ØÌ§–ﬂ!πÓ√‘/˚âuW≥wEÏkÜÃqèÀ5ﬁ≠2ŸÌ(ÂJ¨08;É§RWú”Ë?B˛åvïî9»˝¨W%LÖÖ|wù· µp^	˘û‚T«Æ„ˇ?√∑√ÁÓ©gtCÂ5CÙéjŸú˝Ç„PÁ,gÓ·RÓÏféıÿ¬<n&ÁœÇ1ﬂÈŒsßW ªò;l´ÚÙ*o¥	ı96ËU∑A?¸v4◊Ø9;ö”˜¥AﬂÛK∞£π˜ﬁ`É˛ÜÀÿ7∆˝òVÿ—‹:Á⁄†œΩåcm–èµÌ >qèmxáªÈÀ»√|
yÔkxãgÓ¡î∞˝aÿÔÁ∞
ûás0<ÑòL¢OÚo∞∆]†· Új1øhû`ÙÖí‘\:∂·W©π·ú;R„Î_	ÌMk7¸á˝rèÕ≤∫„¯˜}Æ¥ÿr≠i;(o&§≥B8¶≠X∞ÉY(%äs§„miZ÷æ2oÒä7ÅÕ8ºÊLÊtVìn3^pùë,ŸåÚ«Ä(Y ìÂ“gﬂﬂ9Áy˚∂•4õ¸≥‰¥˘ºøsûÁúÛúÎÔ˜=í√˙{Í€‚{;i/"[M˘uÊª/ËæwoÈ)/Ôeå™ﬁ=D.Y»˜„hk{Ë˛ù&zùˆyÚyãºm“%f>dÃ/K[=~'Ω≠ÿ(˛Pbuÿ®ò}Ê)ü˚^ØX•4„Ã.ÂÔ"˙æô(Ú®CûB•ËÒ·~É*ø¡O16Å˙ÑZAÈÖÉΩ7P‰¬RØ≥›ó®ãÁ–ﬂÚﬁ/qì¥-~[4áªÛIçƒ0˙MâÖﬂßœ]õ˚¢“/√Yf¥wÑ˝˝∫xg[ÁﬂÄ°‚œ√2ÊÂX∂„vˇ.‹9d%∫Ç„ÏÎ42^çñbÜˇ Ê∆w€`%r¸®åö¿≤ú1|ﬁ¡∏{≥s÷R◊ΩèŒŸÂÒ∑3Ûb4üÀöQÈusÊ∫πˆßK…<’gˆó:ÃÛJ©«®ôTºæôsíR˝˘ÅƒOo7<˜>¿?∆ÿ}&Ö9‘^ób]N!∂_pøU*∫.3˜S‹Lóc™ø¸:ÆQ)uÛ?8œãê[˙ˆÆpBItä⁄mª◊§Ù‚Ho
ïv`Ï ÿ∏ç<Óﬂáç‹e}uM¨£2ö¬Wk\#3ZâüôÒõ•7‘ºÛyµWÄRøÄ{á∫£ü5}
∞ãe7ƒz6ÏBuË“>á∆‡a‘˙Û9/£Pæéë·ä>C•ÎVJåˆø¢≠≈Ó˝kÃyˇ)ë≥4«úÒ4üˇïÏ’ÁQŒó<WgìœŒl5œo!wìf˝^ﬁE˜ÍÙôc∫}ıÓn]˛œa¥ë”Êà5|¢Q˜êd∂NUzTkÎﬁ6£Î’˛©‘ˆ—üY9√‹#£2z8÷ì˝Ì⁄¶8Où˜	œËf÷Mí ÷—}-À>Fçrè∂Jä›iÏ≥≤◊DÎıµ]=ÄHøfÈX}Œb´uıC}ÏèåùÎÎ¡lF˜≤QdÚ˘Ω>ò]å•;ç°?§ç≠y>,À˝ÓOŸV≠	\£cEøWãæˆ∂QãûŸwB ˜@oÓ&¸¯lå$B∏¢7FÁHs÷#C∆ı%˙\`üÔ◊DOéû‹ xõ˙}Æêª€Yû‚w…êK4·>ç“ˇÁÄsÄê'x»HeâÖÁÑ*Cè6ƒDëœ{<èÒºplá9Ó¶Lü„ÔõvøÓ:~›u9_„>Wﬂ≥·ô<DbgÌ7◊GÒπF¸Àé2ú◊W…Úéaã¿≥RÃs˚o∑Å˚âd◊È∑·›T0y9ãB@eÍs¿;“g‹x∂˘	Ù˛'ÍyÚO°ﬁhØCGû¯w¡¯æÒ95ÿÆ|¡båﬂ¬∏+Á|ä˜G4ˆ÷|Q-˜Mëú∆IüÂG¯iT9éûıÔ§O8ΩÌﬂK-@¯≠5Ü}ÜmZ˚Eø°ΩBÕÛºBª;ﬁmK)√ÔµìùFoãém”t—œ{˙˚^˜Ké„äD7xW£HÈóf¨%EÓQæß^‡÷πı®êò·Nß∂¢˛Ω†Œ0 ˚òVì«y©qweùÔR¨ÒÍ8OD4ëZß7§¸õ™~±Òãì‰[Ó≠Ù„«8Á(ÀÒÎ≠ì6¸qßË"ó7
ˇzÓã,ª ˙ã˚8Ì\√ó§Ö˝]åfg.qQÓºOΩS¿Á?!≠L“#7í'…jLUœOqüúdy‚zÃøKÎ#E ùØ5Ú>QâîÛR‘ƒ)∂ßÀPu4Râ?©o•‹J∂«roJ.Ö[`“ﬂ?ƒz]T l/qT∑•ﬁ≈erz ¯ˇDUn#™ÇQd}‘ÈWDùâO1”[Ç\”<2çkΩﬂ‹DGΩG8[—”Ãø„¸K˜ST+∂FùÓDb¨ˇk4˚≥pâÜ˙‡#ÓÉÉòÈÅ'¸´0)®a€ŸKWπ€5zÌ—iÓªZÁ@¥?±ã}…"∏9o`◊<à≠≥á–&ÍT<˜4¢ﬁˆhE∆{ákŒö“π·l<»s\E¥/“Zk4ÎÊ Ÿc˙zcwb¨÷qráÍÊlErjÈrYgÅ9√∏ü∂Àﬁ2ZêU£ΩŒrØç.wä£Nß%¶ÓM˙^›C~A™ŸÓìº«\!$NDè	Y˘N·|ÁΩ˚1›õFf1=´ûÎYnËµ∂¡f|OÆb9a	&ª[•Æ^Î¡Ú¡ıò(8„˘ç‚≥‰ÔÂΩn5ÔÜR∑dºÛ".‘~õÿ?œ1]+d∆=X>è{ãƒ˚-≥ß{$πäq•+Ëà0ˇ2ŸDˇ∫CE|˜ä—kÎ›°<€iﬁAØ√xÌ√È€QBˇU‚m‰ﬁ£Ó◊Ìa}S•¯F˙˘”#L¸[ÀvOâ.uÈˇ≈óQ+öˆÂû4WÍãŒßﬂªN|üˇ‘âØü™bµ®‹”ËoR‚[ú}∏Ã9≠}P‚Ä‚ã‹ÙïÏc•≤*ÌL6>•9ŒeÀç;,⁄ß|RæˆY.ÿﬁÔ≈ü1˛j5÷-÷˛À˘P˚ Ácñâ9A>C9œ¬kâ9›ªUl:©˝§ÚÖÙ”íñªãπ?ì3HQ1ò^2⁄rO˚jl”Ö¶ŒSß˘%®ıˆsül„⁄IL~˚7`hÊﬁ\&ÛÔV˜ïπ|/§GÁKÃì8©÷âkTGMtâæ˜Ô jem˝´1RbÁÈMÚañ]™QqZÊÒuY.„Ó<ı˙8∂_¿}z¬ÙSÓ'E‹ß2wø¯.ﬂ5Ä+Ωß±√]N-4sMº-Î~ªCê}¶=.&ˇtpW’ÙÅæ3Ògà~◊e˚ﬁﬂ®§ÿç!˜ghõaˇ¿‰›Œ©ßø¡›7r1ß‚Õh*˝—_ÙPpP»>/æ¡Òå˘ô¶‰$óâ„¸ÊB‡¢’Ω˘÷`¬Ê‚2†îﬂ˙ˆÄ≤4e˜˙‘áπ%XwZ10=_Û›ÁÄœp∫9ˆYèÛò/*J4ï„Åkﬂ™ésŸüÍΩSWj7ˇRwÿb±X,ã≈b±X,ã≈b±X,ã≈b±X,ã≈b±X,ã≈b±X,ã≈b9/$Äºi¯f‚)Ñp0ób1‡5yc·3‰„y˛∫êø[‘Ø§Ct2óÄ˛õño“.Ú7ö¥«ÙrìòæÕ§C‹úxê%^é¥ô8h“	åq™M⁄Aæ”h“.üßM⁄c˙Qìòﬁk“ÏèÛ6v#ârL·ˇt¶°	¥Û—äí∆X•û\√\”Ú[œÁÕ™DﬂT`ˇìX»gÀY?çvïk†m`È’¸M±d”Õ¨+eõUôzíVÌ•Xf%mnÂ≥V4˛}ëV[Tã∫^sÕÃ…◊ì®e™^ÂÙó[¯ÙR’BRµ›§˙öƒ2Ên„€¥Í≠î.€ù,ü2ezrQSCr~kKk˙éU…kZ€Vµ∂’ßõ[[ í+V$6/oJ∑'6¥7¥≠nHïUVÃû=Ø¢¥¢≠π~≈¸Eˇ°æ|cõ8Ô8˛<œπˆÏx‡ÑÊ‚ªƒÒQrÄ©°3üçΩ–zUIôùe$!x#¿¬Hìá4§°Æ§Í$∂1iA}1U´*.Á)s§0eÎ‘¨hÎòDˇ•›^¨/∫îæX«+Ô˚‹ôP4ZM{1iw˘¸~øÁ˘}ü{û{û«wóœ+ŸN)(CJÒƒ–¡¸7áNQFø˛ô˝)#«î"rœ)Ê*=≈°bçèååûPFë9°èé+û…6˝◊7	e
Áó·µO≠ˆ”Ëï´øÅy=jØÒÁ)ˇ€‹ˇÌÓ™>'HeπHpLì^·—í⁄ ﬂ∏*¨'ãÄ	Î-≠Iû÷	MVª¨óÖP…ø&ÍMl<"∂U`G¡0\d@¢ﬁ{‡
ò7Ä¢†ùU¿(ò ã<#4	í•»æƒ:a-⁄Æ≈ì∆+‘ì%Pëa#†Äq0‹∂é◊åÇ3`|dgt°ﬁza∆^o=kª“·£Qª8‰˚øfK_…9˛È=éO=È»v8≤«∂:’õíé_∑¡Ò˛p‘‡~EmÙZ" pì¸8,eø"^JâL.kà	ò‡Æ÷ËÇø‘™F'Ê°(RÆ\®U[M¨`∂D¸Dfg:ˆaiU]t"Ò{ü\s@`Ô„|èΩGŒ∞E>Á∞q0Ê¿u∞‹lÁª8ﬂaÔ/{õD@Ä	0ñÄáΩÎcoÒ˜ÅmyåΩÎco‚∂ﬁÑı≤[àn±[⁄≠ÿˆË¥hëj á´A}c5¢eˆÎŒzÏ(+ç5+¥ê≤Eh±¬è…e°¡⁄9"óŸ_Jä&_Nlfo‡MÎ
ËÉ‡8p#∫âË&1¿Û‡20v¨(lºníÕ@›@d7,tSf◊-5)'Ï˜Ï7§3˛;º¨∏ùΩj˚ﬂ≤_€˛5¯ ¸{’
 $±yÇ6>x|˘áÿ/K≠~πí®csò;6‚†Äq‡fs¨≈:(˚qëY≤ (-ÚÅÌJ^â~X÷’]ÿÄ
7Íé'¡L(*”’ã?Bëı¬à∏QøÛ=D‹®ﬂ:ãàıËID‹®#‚FÌ@ƒç⁄’ã¶Ã~Úã÷ur¨ÎU^v
≥t
≥t
≥tä∏ÿ)~í;.>∂[mmò±K∫∂æM6f®qï{©Ò"5Ú‘8Mç≥‘ÿIç˝‘–®!Q#Hù≥t¶¬†˙œÔ+n◊®±@çW®Q†ÜJç05Z©°–ò^fÕ÷ì[ló∂])¡tOt‡È„eÕò—fÏ˘f<Ê`ØÉä]“!RZÒ⁄ ˜-•∂∏Sﬁ¥#:öÿÕÊ—pÀ0Oﬁ.,–<∂—<.2èxa„` \K†‹P∑`‡„∂ı¬F@Ä3`	∏Ì·,FF´Cºb,Rt/±yú-8õY≥ﬁ‰ì|öo∑0.Qoêv+A#Å û»˛:±ÆLkß>©˝Á'µ§&Q√.∞q“ÑÖxæÍ«≠;Mrô˛–RgÂƒ˙ta◊—ÌD•a¯m§`ó'í»˝V|ïΩµ§}hÊµ‘Ú]≈[M…w§ø HeÜo“¨¸g•Ï¢ñ¸'‘º<%ø!ùó_ãîE‘\UÀnF±•”“6˘ï[zâKñ|öª)˘€Rß|D≤y'±øÄíÓï˜™}Ún\/%êıÆ9%«•˝ÚNGı8o3%o∆4'l√`◊Kvß°†}¡gbezHﬂ‡πË…z∫<_ÙD=<ÕŸ”‰iÙ¨˝¢O\%>,ÆE—-∫D&quπ≤®kK∑⁄Ì„ŒÌ‚÷e«>∆-ˇ†Ê=*2Ú1ø dX¶'I3Êµaí9†òˇË	ïÈä=}ÊC°$5˝íÈMö€¥LŸSŸk∆¥åÈÈ˛jví“9‘öÏªeJz≥eZ·UÁMˇÆÏ4°¥Ó‹sç‹?zÓπ\é4N∆‚˛é∫Ì_J=¿V≠vÔh∏/n2/fz≤Êœörfîï¶\∆¸~è“üù¶”è“©izõª\vZË†ß˜Úz°#ïÀe tü≠#
ΩvÃm['‚≈ÃuDÉéÓí££=t≠‹AWSC¬∂.\ScÎ\îÎ&≠È‘dk´≠©WH¡÷ÍïOk¬–Ñ√∂&`ê[≥0∏∆Ï∞%íIP≤%Ù"Ÿâ>bKˆ›ìD™íÛÀíÛvOΩßëMÌ‚]MÌ"4⁄z‰ìöFKÌπ·˛t>î•Û`–|ˆ‰°”8†(ì√9ûPLA<0|à˚°ºôÂSÊp(•L∂˜? ›œ”Ì°‘$ÈO˜f'˚ı| j◊€”°°TÆ‘ŸΩ5v__Áó˚⁄⁄˝ÄãuÛãmÂ}u∆êéÒt'Ô+∆˚äÒæ:ıNª/bÔÒÓÏ§Híπ]˝é/±ï+∞_õs…ÄÔxáΩy€õN7Œ‡kÂ%≤RÀôáíf-‡©çâç	û¬oäßV°⁄[M5únonú°/US>T◊ÖíD+é∆HCz$Â¸p†™8∆'‹±Z·≥‰“¶>î*	…òm=3æß/;ÈÒ†vêﬂíπ„n› ïÈrÂöSπ	ï;x• ,y›N^WSS˛˚˙èU˝.˛+0ÿlâÍAäNrÇÃÙ2<
z˚pØ˝}Ÿ|KÒ◊C!á,PçÓ^£:lM#Nô{æKq¨UÁ¢XıNK4)‹ùíÂÉOñ∂<cEM˚ó  ˝ÚG2endstreamendobj45 0 obj[53 0 R]endobj46 0 obj<</Filter/FlateDecode/Length 343>>stream
Hâ\“]kÉ0‡{E.◊ã¢¶F[¡⁄ºÿs˚69v¬å!⁄ˇ˝bﬁ“¡Öáúcﬁ|ÑU}™u?≥›é≤°ôuΩVñ¶Òf%±]{ƒú©^Œw˘ØZÑÆπY¶ôÜZwcêÁ,¸pÉ”lˆT™ÒBõ |≥älØØÏÈ´j6,ln∆¸–@zf+
¶®s?ziÕk;}€∂Vnºüó≠Î˘´¯\1Ó#åM¶ïd[}• è‹S∞¸Ïû" ≠˛çÛmóN~∑÷óÔ\yÒ®X«–3tÚ⁄ï^<ÒJbËÌ°
:x%®LQôàC)¥É2(ÅˆêÄJ(É0_ä˘ÃóﬁÁ;Cïó¿R¨ApËaµV+ê,C2Ådí	$ÀêL YÜd‚ •´éßuåGQÈ7¸æ≥Î÷ª¬Á*o÷∫#ı◊»üÂzäΩ¶«M3£aÆk}É_ yÆåendstreamendobj53 0 obj<</BaseFont/BADDLA+Arial-BoldMT/CIDSystemInfo 54 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 55 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]17[278]29[333]36[722]43[722 278]68[556 611 556 611 556]74 75 611 76[278]79[278]81 83 611 85[389 556 333 611 556]3032[83]]>>endobj54 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj55 0 obj<</Ascent 1010/CIDSet 56 0 R/CapHeight 716/Descent -376/Flags 4/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 57 0 R/FontName/BADDLA+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj56 0 obj<</Filter/FlateDecode/Length 28>>stream
Hâö¿‡¿¬!¡¿¿ø≥¸ √(†'h 0 MÈtendstreamendobj57 0 obj<</Filter/FlateDecode/Length 16423/Length1 42930>>stream
Hâ|U	tT’˛˛{Ôõô,@Å¨–óöHÿ!@HfÅ@ì vÜ$ê∞F®ö†©+ë•*HEv˚© k∞è"à§ë¢¶"HŒâP b2ØˇL∞≈ûSÔ=ÔΩ˚ﬂ˚ﬂˇˇ˛ıï,XTÄ ¸Ω«gıJFÎ8¬è+Ø¥Do%)
∞ÊŒ(û9∑ï∂ï⁄ÏôsñÃÿ>∏À˜@õ ·
‹˘ı¡˜«›≥ò©!o¥Úwû_]Áñ,~HÔ˙ûü3?œM£7Só1]?◊Ω∏∏ıº*á_˙<˜‹Ç¶˜W2ΩP3ã<<_ﬂ ¥ˇRûG†¡¶Ω™ıaîë≠_Yá"ÿ¶â ´ﬁ°g÷bq:_ıÛﬁü46]O≥Y;Áô@}¨√h_*»4M÷´Újá‚oîÔŸé(ˆÅyÂ««Sd^Òûyø‚ÎÓ‹˙<˚∞£§c?=@(ÓQ8%a4Ó≤ßˇå¨G&a£+:·qå&≈<ÒXMÕRÛ:Ü‚%l5Pππãœ_ƒ˚∏«æTÑ«¸è£ ◊ÂU‰òØ¬Ü
é·L§Np„œ;åa-÷·=cﬁc≠!(gy)ÅÊ	≥qX≠÷hı~Aì≈Ã3ã–1®ÒÊÛ+ƒ"o`cäßZ5
—òçïxô¬Â˚ºZè7·°@1M¶k«Y”hL∆<<çJÏ¬)
¶L≠^k2c^É–É1·:ı£±bõ
4áô1Ô‚∂◊;k’µ]õ‚næfæáé8@˛tÑNh…⁄Zñô[Ã∑»xíÿ#„Xœt,«	|àÔqKîôeÖ,÷|í:ìN±ÏÒ"\<'ûìÁ–ì≠ù∆h·O08"ápGŸ7GÆRE“Øh:U—-(Ú≈YπQ÷»Ûä‘Nˆ∑›ÿG%ÿÜwpgpñ4ñﬂõ2iÕß?“k‘ qS‹U6µ\˝†Z¥XOÉÁsúyaà¿cXä2ˆÌÿè|åœp∑Ò/
¢ÅTH[»†∫)¸Då/ä≈±MÏï„dï<°˙©45[ùQµﬂi´¨n´ß˘-œZœ^Oùy¿¨„‹iÀÚcë¡]∆Y±«qé•é/pŸõ?,Â“ì¨e!˝û÷—^:IutÉ≠Ño∆à!¬¡ZÁãÏßr±V¨cÌgy~".ä/ƒw‚é‘dåÏ/üí[§! O‰7*H≈™û*IçWπ ‰»$k#µ,má∂[{Ok≤§XÚ-≈ño≠Â÷∂”-q-_z‡)Ùû˝úª6Œ§•ÏâÕÿ y_√18≈˝ò7‡üÖä¶Óå{e–KO–T*†r™†óËe⁄H[Èm∂ÄmV∆/Fà,·bÖ®/àûáƒá‚Ç®çå<T⁄eºLí£eÆú"Á±%Ú9πÇ=[%w…≥Úúº&øïçµP’E-RK’+jª™Qu⁄c⁄\û[µ„Z≠Vß5kÕaâ∞DYzYfYvX.[-÷˛÷LÎÛ÷Û÷€∂bä¢8FÆ„ë!¬πªà]"DïQ#ot&Övly<«!ã´‚6ÜK«•≠˜ú±u·™É˜¶%U|øÑ£ùDôEH‚>‘Ä}tI4®øä°¯å\Æ∂Ày⁄)ç›‹ç÷à#‚0•°F§à…bì]•∏ ˘æÎh6-ƒnj§¡Ù,†2úùd≠@äπU(Ú£—‘FÄe*O‚g¬%\˜lVm‘3‹übGtæ¢ùx@öyìªõ‰n‰Ê.≥öÛ}%º]o◊Y◊c8wê9ñ≥®!ˇAXÜ©•h¬}\◊qF•q'ΩÊ)Rõ’◊Ê 3ë+å´;∏Ó
1í+Ê*g…Q¶Ω‘TÆtÓ%…\’ô»E>ûÂÆWeÊ&sππƒúèè¯ÓJ†Ù:WƒAæëÇxæàœi◊·»ü∑ÛˇO>jqÉ¬®%s=4j•⁄móV£”ŒXíÿ€+∞ë3˙2g≥?[êá:‹¿]≤ql¬ëÄæåw cœ∆ë#è"ù"PÃ5€É˚x⁄CK≤îrˆﬁ&ÆÁ£\M‹'¶‚ÍIP([î«˙m,g˚˘◊Ã˝Gp9ÌÁù|Ó⁄q¯éÌnKE	ÎKeI∏k’2¶K¯ÜΩm˙p%p_p–dñuO ü5ÙG&Usﬁ¡ Ó¨yö˝›ïÇêF1Ù&ﬂsqÖ∂Eg“æ&Åœ8s†(íG˘cÚ˛Î¸˜äƒPzäQ¥c;Z–ë∆£üg"c8GRÙ©≈+¢¿¨êO{Ê‡#Ï‰ò§™R´#uƒ§‘·√Ü¶<h‡Ä~}˚$'ıÓ’31!>Óó=∫«vÎjèâ÷—•sTdDxXhßé!Ç€µk€&0¿ﬂœfµhJ
BÇ”û·“çXó°bÌ£F%ziªõ7‹èl∏ù∑2~ cË.õ˛SŒTÊúÒ?ú©≠ú©ˇ·§ =)â	∫”Ægv˝ ÂN»Êı{én4˙÷c}Î5æu^GGÛ›VË–rÈN#£¥∞“Èr∞∏Í ˇt{zÅb™˝x¿+#‘^\M°√»∑°Œ¡’∂6 à∞;úF∏›·E`»nNwæë9!€ÈàåéŒIL0(=œ>›Ä=ÕhÔcA∫OçaI7¨>5zë◊¨“´j+W¬tW|`æ=ﬂ=5€êÓØéˆÒ¨◊aÑ.Ωˆ_íÖßgW<z)+ùaE∫ó¨¨¨–ç⁄	ŸèûF{ﬂ99,ÉÔänÆ VΩöù8&KgmbeN∂A+Y•ÓµƒkU´}vßw«5K7¸Ïiˆ¬ Y.MD•ÅâK¢˜ED§æk6 ¬©WN ∂G√#Ì9nGTu»ø˘Æ“ÿ6é+<3{qyÆx/)J§yË†l]´õ5◊ñ≈⁄¢eÀ±¨ävô»ád+j1Hc¯áı≤⁄-“ƒHö6Å[4çã¶Ä)˘%8±`∏Ó)Ú£u⁄I7âì0PEuRëÏRR£Ì.93oﬁÃÏ{ﬂ|3Û•:yYVΩÚzÕ∆Ü©¢Ïå—¥R–æ\[”ïJ•Ê¥hYL-ÚÔ BdºáΩ`…à|Í§…X'JÓÑf$0Ù Åô»àΩ£i©õ÷”˛.(˘ΩÈœ0¿ü˚t}Õ¡ï>(}ÜhëÚdçj†_-g¬·L}=•à–s
6n.…mû»ívˇ§‰Ö‡CÉÄÌ¡Dw#¿ÔÛ—	>õU—!2S{F ≤rœ"µ1ú»êQ™YX’ÿˆQÕ‘™f≠˚®ò|¡·ÑlMhÌgíÏñæc›lˇ?Í±≤>æ◊ﬂ≥ƒ€ó]¡6>¥N*Î;◊t+•å•wÑqìïq3%-êÚÎkç©0¢œ∞A¯Ò%R…0@ Rˆ∆2“Ëˆrö–˙|ˇ≥OV–|©S∂xüˆ*eˇÌ∂be¶;º^ÓY'Ø≥Nüf¿^6D‚C˚”iÌ:]6†t:Ê˜∆“£ÈÉŸ‚‘!øWÚßÁ»Er1=Ÿ7∫:°Ÿ‚¸Yw&v.N√›@VÇ∂Œ¯Òô=3*>≥wˇ»ú7ó3C#≥ìﬁ—≠âƒFDË|p¬1-†≠W.BñDU‚ÿÉ¥[¿H÷\Å0◊qâù:ë3,-EÚë]“bd AQ(KÀê47˘*|AH0ú¯À^faYÂ–øëó]ÄX.ˇÀ≠Äj#ùHKB&T∑©&h-≥GüpÜa»‰@ErÕM≠0÷≥ÙP¯" Î~ÇjÈ&’ÕtbûÔdµ‚%Ü>ÑΩ\G∏Kö7_•÷%©Ië%ÕEa$åÑ·ˇ:‹S4_˛ÁÍ»ÉpaêoôCBÒé*vt)|-$B∂∏†äµm
ØB“u–W:HÍP=[œ’jıù®ÉãÍEèí1fú;¶9™˝à1ıÛòhDÃhEëDà`Ö@áY÷ÀÒVé„5Z’ÂŸ¨•ü–π<ä6HÜg≈,æÆyÅp,‹Ë4zá√Ö≤‰†™´∆•{∆fpñT±ZƒM‚îHƒy@,¥ΩÊd›√áWÅîóí©≈d ôﬂ’7∂Ìò( %»Uòª#˘p82Õm
Oü∫5Ω…I3AäD¶o›ö·IÔ–»Q

'öõp<£€œTãÁS,ÃjXÌ|± H-œl'}8ïóüèÅ˚,√›(º1ïøv≤põÙ‡Æ˙?ﬁ∆ÖÀ‹¸röxÛÔQF<»◊Ú:Ù5(≤úñ!¢6»ö/1òaœq@UA£—!ßÒÚo	»yV›†£f“0e ^Cì·gÜk :/¶\Z ä@≥À˙Êoïq†$êí©«ñí+|-¡ 	¿êÑ5NùZòıt10≥ÆR6cÈ_@#Üìh”Hôê´Ôs∏ñl√µÖ;˘Î‹|˛ŸÚEå|;ˇ$¯tª>1Ë¯‚äó[ÖÉ/˚É•\çZ
‚Tnêõ‚ﬁ„∏jnîõ‰ÓsÏ!aêÜ0Ô¿∫Ã@à≈,@¨E®SâEﬂdõ/î}J=∂‚J√ Çµ‘æs∏ñõˇ"¨ﬁQ¸Æeõ·∫⁄ÇSÍ1¡•©‰<vWø{{Âé‡ﬂ§w+ƒv9&-4.ù=#?Îz≈5Á˛ùÎ˜n=œlv^∂◊u∂Ñ|Çú&ØW˘€º˛ÜÚéD<ÅñÊäC@oRÍÜZHdèr<∞ Åòázÿd4)_Ò`‰ë<œÁ÷„i¿≠HÖZ∫ﬁ	⁄ÁS++¢>’-A‚t)æ,y¸*+Ë⁄
ËJ9®K9¥hÄ™j’U5á4ub≠!Q≠ø†'’z\‘cΩj¥+z◊n+£Äˇõ0∆≠uæG¯]ﬁÌxƒq‹¡8‰÷â-´»‰Sπ‰.)π.Kw)í9@‡ÑU^LÜÔRj§¬Â•0€Ë¡©DÆ,Ã°@q·5∑G
	êd8Ayä1IËd§í(ô¬5ÌÌ≠-vªç±⁄æPM®ÜÁ˝BmJ{{G;Ñµ!ˇ60Å∑YÌ≠-P’ﬁÜ«ä·∑ﬂ∫ûç3Ó`·cù$0€_Næ¸˙Oü˘ÌŒ¡„Ò!¸p˚«Åéëm;˚Z%y”OŒ'ûz≠ê=˜˝ùï≤&õ=≥ˇÒ †∑rO_O·msã≥&“3‹Íå‰”¿ÜÛ¿J™D/Õ!sÒÅ⁄¨ÎÍp’MÃ√¸∞vÿ>ÏLT˛K‡€ÿCè•Õ›«∆qKü˚ºÇ®’Åö»ì0À	V:ùŒÑ¥ü∆5YÖ´§:¬ÑLY\ßÍÒ$öÇÔ…ûhÔl7˘»ª§‘“@éÚvd YîJ‚dÔà™Á«µ„ˆqÁD%óL†dâ≈ Ñı ´±Y¨@®ΩŸ4ñø3{≥P»œòQÕ éì…Ô~ÔËÿiXÇ˜œ>,|^∏_¯ÎÅƒã§˛óª'/ºzÌÁ/—]f¯Öï £ø´{FL	s¬~Ã4aû∞ürûîü'œÎoK∑ùë˛Ïº«ﬂ”‹≥‹≥=‡-ùñN[øπﬂs&Ùz°€‹aÔp2'∏¶iÓ¥È)˘WÊãˆ9Û5ªh,1‘≠–¸™Ÿ™[¥FÆRJπ©B1ÃcŒ∫«UsÖ©–©–µ><ù«pRÇ Î0≠≈>‘h†Éo∑]n¡gï]#e(rª‡d»ÖsaÕ/&ÔcÛã·0‰ (ê0ÂBß´⁄;8J:HŸÊ¬'∆√ª'N=˘ç¡q∂ÜﬂºW¯€s7ˇA>mŸ;Ù£_ø˛‚Å„ço‹ƒ!Ãb/“≥q∞;∏¬õß’çÊü–&Ãe∂¸®Ò@'´¶™H7£Ëªmä‹œl”˜€∂…/à¢µDeçj‘	FLÖ÷Ò∫´∏âÎäÓ[ÌG+ÌÆ§’g%ŸñΩ+Y˛€H<êxç]°â4.&u1îüC∆µìRH:)û‡Ä).iåâ±iõ¡˘¥86ª4&iK;ÈLôI…Ùõf:d”xÄ5P¨uÔ{í¯îÈåÂßg=kﬂΩ˜‹sŒ-ë•(¬Hq8®`/∆éf‰≠^t;¬ŒÈ4b∑•ıõjÅ» +R◊fkS“h·Z`xJdTbsUpwCÖYgﬁ™}gÕªÊ-ÛÉ—ÁQ •T‘?ªÆß{ÛÜ=áoFE»ädxÖvŒtº˘Âˆ◊ÚÓ—Aà∑‚-¨x®\Ù„	 	}í¥Wø*Hù√Ï1€i·¥4¥Z=h)ΩÑK⁄B√“)ÓT¨Ì7‚'∂?ä7¯ÎíîÎ»ı¿^Cv≈ﬁ˜Ωø˜Zº°≤ *¨Ù˜—!+çr´LÀ~¡ß9qS(|&Ø NVΩ$ΩñÕIØ˛\≤†”!l®ùpÌµäicÏäß;bÁ)Ux” ™≠}34bBÕjHé8$<√Üe8„-T◊†9ß@èﬂ(ˆ‘¯çê~˚1WcaoÆI≠T‡pB¡óÅCJÜ™Ò:ö=
4KÃ ˘
>P™Ò•GUºåå	∂á»∂V´)£˘òA[»„e≤$„á ¯Ò≤…¢»óÀB∑πbDÙÄ-ÜxAQ4Å1NY4Ä˜ œ©Ùêﬁ•„Ê?_hCûèßê¬•ÀÛÎØ)≤Ïh˙⁄¢E≠¨8zÚ¿ﬂ eÊYÛΩÁˆ-EO>ª≥ÆÓiÇ}s”J¥=j¨ﬂû∑'èVD©£j∑‘U≈†0∂T¢≥®éÆ≥<Óhˆ46ï4¡U∑:n∏n∏ïÖRÃ∑∞8Væ\™˜-/Æ/ø"¶T€~–,ª(ŸKE©Hˆ©ﬁ9í®˙#‡$A )¥Ï"I≥ãÈµ∏4 d≠äßÅ xsà≠eq√Â;ä"€Ê` ÿΩº?¿ïñÿ£A?n:!{´P¥‡∏a£bM	TﬁÓækô˛sN9S≤dù∫ˆT⁄Ÿeıè"ó#ƒ8)r)P[(b5~ÒVgñ‚;Iﬂ:⁄<mÖõK6ïµUpòÂU÷ßfu/-ú)†ö–\ôÄP∫=wz˘TkÕ+njü_Ëñæ{ÊìÁ÷#Ù˛Ø∫ˇP«È^Û_ˇòŸ’∫yœñçªíEº!ÕW˛˙ﬂ>Ÿ{ŸQß}3K~ÒÛ'MÏóÈ]o9˙⁄ÎCG Y/S”ºÊ£Fç2 G’∏êŒ≈h±ÎSt	<Îc#Ùj◊ãÌˆ∏∑≈C#NjûÖl6è◊Ê£(ª-jåÇH¸∏Äf$@ö°$>=ˇæ»Ow¯Ø¯ÈÀ~òô<Qüó¥-úÚ¢+^‰®5ÈƒÉ{√nÓQÏQÀ¶3;¬ÿ®NANUb/¨ƒÎbÅ—^P 8°{øEoıº∑ÓpCû9Y∞‚¡d{ÃúY¸|piGOoÍ ]ulM¢˛≈›©/ h¿6ô≈àKÂ©ÌîÄ}©ÀVcç›%ågÑs¬eÅÕZÖù¬¸Åµp<Ö`qÉ∏Q’ûÄc9û±—<h¡¢â3k&Æ;q¿àÿ“yóï>™,;ñ˝ =ñ1ßcŒ‹zòâﬁ˙svZ$7\E|¥QÇÔÆôÓbGÿ3Ï9ˆr⁄<Ôdá‡0*¿Q¯DeoCÂ}7…<;3\Øå®–È>j–Ûn’Ω∆∫≈ å3(nç;Î≠ıéKNñ#•wÒ≤ƒâv;Hç¢>äîûB≥%ˇØÙ6{Tî°˘F%Iºç ]∏∏ÎÓôUn´†vO…5oL≥9YQΩÏ[eêHvﬂ«-˘tËÌçªGÕ|&z¯D›ñÓÔ‡∫Ø}ÄH%pC˝∆“ãh“z›}›Àú•/≤¥`›Ïlr7˘ö˝˝Ù!Óêµ_Œ”aˇ*ú'ŸIÓ¢‰<f˝à˛˜°ı◊"ªÕ˙"◊mµ∏0ÂÿÏ*Nëá·=’|∞5ß#áŒë5Í˚í6ÅiQœ≤É–Ê‹öﬁÊg¶‘‚é+ÂıÄåDÔ‚Åï{SáØ¢∏˘€/^6ØÔE€€˚˙⁄€“˙Kà€kûΩ|’¸∞{v¯µ··°√√√8ﬁ}ÊìL?ƒÎˇ2`<∞¿Ω‘M+qKµTÌéÁ‘[ñIÀ‹ı97sÏÅ≥æföøôchﬂÌw}vª”!g˝Æ´DñQßì˚ˇ:ﬁG¶A!ùÓÛº§w1bœ{óè°Z‹PIs∆Ùb+s'Í}àã˝Ïâ	Dõ3´{†ƒæ˝õ÷?ø˚õ{†¥çÃOÕî9m˛)˘XÍíebÏ≠#c«~4Ä‹CQñ˘$ˆa£∏üEÇåV±õÿm¨•BY-oë;∆&8ƒ|ëÓgE∫Fliqúﬁnî<‡€Bs∂bJp
ïBá¿¡ù †BØUv*«ïs
£8©(≤ê¯i∫¡Äp’L†\*k˚o√y∫%» üˆsÄÓÍπÈTtRÀG‘UÀG+÷¨~«6w‰A#òÜL®<πaD◊m≠om˛ÍíÆ¨`¢˝[Îˇ~†ˆMÛ*ƒX	xvBå•Ù∆Œ≈Ö≠E™KRy˙ã˙JﬁìÙ– iiB>´}æ!MÎ\âÙò¥QÍ≥˜+«Ù	ëØë˙Ëf}Ctè≤«≥[ﬂÊGøƒ%ÌKé§∂XÁıHQtæò–z"úàúçu	ö_*u]Û›(Z‹·y∆˚Ìím•=ﬁÓ“o_È	˝DXÍBΩÍK˛WKﬂ()ÁTÕgh·∏œ»ÕèÁ˚–ﬂ}»≥jçÖΩÖt°·œãÒ∞k®¿rçÂ®≤Uî£ÚêVÈDŒåƒ>
5dÖ#ié$‡∏≤„8Â3†–d≤Õ0HY'ﬁÅtOQi·6BÚ°®>OKj_AÕÍ‘¶N#Ri&®Èt±[È‚‡Z1…b{cìnæ&’?Xﬁ≥ØñŒú	Jü˝;m<ΩÍ„≥üçÖ"xˇŸX~$Ω…ﬁ»Å7[%4OOÍá§WÙ_Í–9M%Ü	RœC≈∞˚SÁ‘†åA${Ω0éW#/ÆU"5"¶u°ˇr^ÌAQ^W¸‹Ôπæ›è]Q@À[Y$≤∆ÿQåP4k£ùHS£åNu™5ôL‘*âh4ä:⁄4mp5∂5!ùnöŒ¯hò8MH≠YçäNÕÑ‘)æ˛Œ›]á–«LÛ€sø˚8˜ûÛ˝ŒπÁª#T©xZäèûô¿L!"≥IÕ⁄Ma®îŸËµ#PjG**ÀÌHÒWÒì[àËM±≥Ïf{ï≠Ÿı°≤wJH<rBJ‹¯’≈˝M±˙Áj1?ˆ≥{ÂcÃ±¡Fy±–j¸55…≤˜+ŒŸà€õVìRÄ¯·÷/ì√IVRòõ'í¬–Õ„ﬁ∞,m÷#¶ÁdQTQûüó“Uî#∂+g˝¯∫—ÏÄﬂBΩîW*Biﬂ˝÷”ïπñˇ±°£K6]ºvÒ„Ç°ªæÊE´J≥3Ûƒ{çã˙ˇ˙ßAQR<Øæ ≥$€o˘jß4Ïˇ·ª/nü4Â·¨¿¯±˛Ã3k_ÿıácà¢,Á∫“Æ¬ù–)Ã&î∂û¬î™Q3G5¶òA?e®?ŸiÈñ∞”Kd®n”c&e∞ªS»>b≥’•Q[µO	Ì>.˘cÑ¸Ü)ø˝íºÓO	°änFñ¿åHAÜögß’˚k¨√÷õñ∫‘⁄lÌ¥Œ[w,ù¨T+€*µ4|ˆ~ÔàL%pwÌ±J‰â…»oìÂDl¨û}Øz∞∫ø©:µ?»©ÈSØ¢¸Ùï•‡èsåè˜Y“ß6;-.ıçØ(´»ı)¢ﬁ¸Ã¸ôÀæ?kCÿÎ~ˆY“Ú.-xÆ8sÙ≈¢≤π”'Ì^˙Ëµ°mO≤Ã|-ı¡¡àΩ–˜mﬂ^]uA£Z©ˆ’*µæOSVÜ>Õ èﬂ≤<n#› Û˚â‰®Ä¨¬AÃˇó*¡Ì∫_∏ƒóp˝Á1v≈å®ör*ifJiˆpS≠´˙ıS-ù≥D0k^Õå5E"x∏~Ÿ7:˜*GÜ2.-ü<gÌUE…;Ω®É√NØÒÎ°írì˛qÒèz π§,ˆ≤CUÂö0TØÀÂIÚ¢¢U“‘ê;‰GΩßΩIàÌ;ë æc=§{-
zs©»[NUﬁ-‰é•§ìëú$uy›vπ&»-ÚPMM5^#SÑ√£#i^Úh^è€≠(¬@€NÊôÂﬁ‰¨‰“‰H≤ñl€°TOçgéGıúRJ#^M	{µmé¶jÔ(•(–6GRí*Hd#Ö®"òÙ;p+»‰*Œò}ª	7US∞n˙ÚG˛"üe°òäˇ¥∞¿dh7Ò◊¶ıëìn„À•2=Gà_-˘g™lcTÍ9ë3Ô^˛≈Ù¿ƒâ ÿòOá˝Mä=Î KüÕ∫>©9•˙W–%G^ΩR=ÜÂ˚⁄3ªÓ¶íÀèπnÄW Êî°:öñJRGË%JÆ0‚]J8éN:•˛ûû—Z)¯∫9Üı”¥X|JO`¨ò¶é°LÌ(’c˛Z<∑BÓV¬Œ Ê7 Øe¿l X,åc>0kŒù–—Ãz§ºB+Õz{∞¯&≤ﬁ@{0ˆä¶e‹èΩv@«x¥˜£ˇê—IÌhÔ√x#œïí◊7–LåO@{∑ﬁ‡8fôË#¥—¿˛ª¯ÃêyÿøUkun£]›èa|d=‰Ç¯y3d˚
Øë∂≤ç€∏ˇlB;0ÿ,Åx})÷e·πm/ŒÂÜLFiD„0ßZyàéANƒ˛”‚vì¥v‹∑	Áóg˙˜®ÁÛŒƒv› zÄÛ√Œ6m_B+=¢ñ…˜«6'ìïz~bªÙkŒ]xwvu∫ˆ$Mrë”âs÷Ë'iûøTK¥í–“*µÔ‡$m0ˆ“è–O
»¨¸çrï[2r©˛[˝ÅÂ–˘æ‰√ì|ÁdñvçB–µXâΩœ&¸ƒæ¡Ûº◊Eò{è„~}x
>ÿ¨·Ûaˇˆ9ﬁ˚]—0ÙÊ^¬>µÏô%€cÔï÷b˝jËrüÿ{àI „+·”üøﬁ„3$ yá‘’I™“È|ôÑÄ†ù˘,¬<˚{0ﬂ#˘
Œ07ôÃ˝¥‰Í|>{Ã€„1Û4÷/Ç@Åqîûà£ sŸ?Àò≥/	›Ã-ÊLBJN∑Hﬁüa;ôS√‰ÀzîÊÚ‰æ‡VBr‹AÔzñ™_û©CÌ•ùÃYÊ[B≤_òkèq˘¯0['ƒcd÷èï\2·ã˚ÚCÍÄŒ£<Ì£:Ì"’©PùærÏ{}∞GÎE+¶9Æ(‚]Œ¡⁄˝#‰>ÜŸ+VbØó¥.¯¢óIøˆ*„¥^°Î]ŒùƒYΩKŸ$€ˇ"GBDcc,√«˛◊˛ˇ 'z≠@˚¶ﬁÎ8∞g«ÑŸ'JÅÏÑDˇ	`3P‰*˚\-‚îYO©Q?∞JãPï°J-J5öü"S.˙ÎçGeﬁ›	˝ßEµ·}Ω`˙iºzπ{)ü‡~ X?‰Ïa<˙ÁFr)!|)ô3úw!u» ‚Ó†∏«üÅÀ‡„‡Qæ8?À˚9hãÒ’π}üügÈ ‰ã	~é‡i—~ö#y9RÚ›¬˘]ﬁ-àSú£-a?ÁGŒqú#9œÒ›óò?R[øπ„è2˜–‚x\•@	tºœ#›®¨˙£◊çèún≥∆ÈVœ9›∆~Áßfãs∆8ÈÑ›Ö˜Ô‘h,óq<%ÓRˆﬂãâ{Tœ£Ò|÷!Ábyè6»<@∆zƒﬂJZΩΩ q®D‹¡ü–˜úˆ:}GªL;qˆıÕXø6üÍ8'jÎ–F?r:è{’ùr|ûˆ9≠”
—~Ú ˘ì÷øÂ5NèÏª„>}1Ωﬁïh€Ë5˝8-‚w≈v(Œ9~˜à˘êk32	æL⁄ lé¬∆”Rê|‚µo9lü9ôl]Ö}<‡5¯¢…é˚cØÙET˙hè‰0|¡:çèeΩA˙Ã?L]ÍpÂ#?}A!πDÓuú∫"“ÔöºØ?C|ÙÅcı¥U∑úøK˛uu 1‘á¯bå˘)®˜—ƒ“VÈüò‹ŒÒ£ˆëü9˚»z¢ˇ	≠1∫háÔzqÙ‚Ωı¡ñzÌv≠À˘ÊNá‚Ω—?W÷'|OEúÛ/fî2Ãˆ«>É¨ˇ∞ØzÁ›M[ëK¶∫˙Ë«F6ï‚z‰¢ql¨4ïÂ)?ˇ ÿÏàAˆ•∆§»Åéç‹Ø,ß38ÖB‰éÌƒﬁö™˛’˙
‘7È9•Ñ∂®u‡›m‹*m‰gm˝ì˚≤Ó¢8„¯Û˚›˝ÓíH-`Â≈l"LäXA)°UÑ4D£¶J—Ë80ÿRul©AA$•tDáÖZ)E≠XôÇPpja¨÷2
µE•Ú2EÚr˝<{{øúó¸@˝ß7Ûôgwo_û€€›Áª}ùèdîs¬ƒüŸôπƒ‘ÎLˇ@∆∫U¥ﬂ"ì‹ﬂ»$' ]è≤ióŸ$◊gnFgM†KzmÚe¨˜ È˛¡Z≠g∆8tV‹ª•‘¥ãa|çPüW∆|~îØ˙9ÎA˝%˜W}Õ˙i}l…?Ûù⁄/ÌLùøÀpÊÈË⁄∆qÈ˘≤V§ﬂFáoë©≈¡fÊudÇÔ≈ÛÓåTå◊ù!µÿÏøa/</¬«Ó≈2ãæ_¡>ß˜%˝Œ.,ÔüÑó`_Ù.éé”Ry˜`∞9ûœî •J∫ò3Ω¯≥ÔL˝ZËﬁ≈9< ÿ¨8”•@ÒŒñ~~ûÙKÔßºívâ|¶Ø<ÊN°nπ8m˘‘<bÛ8,˛ç—ˇ¿v>ﬁâŸûjŸ_%ü?ègˇ˜>∏≈Ãˇ
π»¨°–‰~jÍEôêz78…yÓ)a^äÃ|÷ 9—¢º∆î'˛keêŒy≤úÙeJîO˛◊∂ÚÙ['Z~©S‹}‘ádûx0LÒtç7œg«ÕEÖdûF∫¯≤øyﬁÎ ˝ïÙTÚKxPæ°dÛ“O—∫
s€KaÆ7+È˝ræ‚îÛÆ‹‘™ƒÊı:ùWgã∂5ÌÕˇâ÷yÚˇ–V‹≠úGÔ£ô+§(i„{6πoìe—Y“Rùƒﬁê´œˇ'ÿ;;`¸ÈKáuû÷*t4›_—Î—™øÊéπSÊã4‘à‘Ω"R?ësà\øé≤Ò§/¿~ÖîUcâFuÔíû ª=∞V∏]Â.´+ªê∂mXe˚Î∂◊v'Q;uÉ¬ˆu≥aÈ›¿*´{ª{ú˙ÎiWÖE‘œƒ$?Xı!?à˚ıÉ·_Äüı»ò˙˛¥ØÖÈ™GZ∏á~±6«˝„T->ﬁ?0öìwàS∂—ˇl√&Ô—ˇoÀFwâf÷Œöoáª˚¥z«â,ˇÛSÀ18ÏŒ	–îæ——hY£πU?ZkÙˆ^£'SFSZÀ|™ÌT;´~≈>aÓyØ„œù2ø*ç_Qâù≠Èb˘t∂pÓIuﬁ¿üˇpˆ¥'æG[.P$|&Ñ;â]Ì9s_NΩ«Ó"ﬂçXñ≈¥Ëlmv∆6èi_j˛tc‰ƒ‘k,’	¢Ú…ñ‰˚˛ñØ+…X|∫¥ªœ8ñÁà—Ò8˝yÛQúè»*•ä?øá5◊•I–Væ-ù{∫˘§ÓàÂ7(≠º7˘§.âÚIöΩoæˆB=Sƒ~ãHÏª”Ö}zÖ;%x+⁄Øë…}ú›o6Ô›'W¬à»¶ûñæú#˝`ûΩwı"MÓ—¯ñW/•yÎ§î¸Û∞1<sÇ™0ˆÛRøEKˇWèú∆Y‰}wó©{ù•™≠ıú\∑™œç>dŒåÔ¯«§?Åsa‹ë˝◊‹!{ªC‰’{ÆÛ~púæéÁ“Çπ,˜ºizﬂ#ﬂû|{Œ‚ÆﬁÈûŸ"ÀHœ∆`8ﬂ´·áúŸ„3€ÇÔ9SÁFﬁU∏oÀŒ˘…G¶∏ÇµúÈ7e
πjLìá5vÇO€«i;átWl{ˇ∞,¶üu¥PcÄ_H<*„Ω·“ù≤4√$ÍﬁÃ‹^ü~O∫sŒ˜‡]°µ%ﬁmåCºÚ˙ôs6eù]·ª»`®r…Öp)Ôæ78'È{•i˚@˙rYÔ‘…zwùT“ﬂ¶Ç’≤(õ, „{Ú+eπˇ5YÓNìG
ÀÓoK»/‘x≈UÊæ1J£›V˚›‰:˝n˙ÓmmEÙÕIM`¸ƒπzi∞2>n‘.Øåπ)Á˚∑…Ú€“6Ùs	î¿18òOc≥”-ÿZ˘ôçÒ∑dc~•\M?Hõπ≠ïã‹~fº≈&V≥3ÌËßùÒ›Ãq“óh,Ê•!óä¥	å0ÎÊÄÃ‘5F~ t¥eFó—¸Øk†03[
›πRû^lÕ÷A3È:rwõ5;W˝Tt}Ÿ5˜H˙iˆË[“Q”ÓyÑ4À2Éu∫JÁ÷=$Ûåèk‡è¨„@ ô´ÉM∞∑≤›5å•0_Íèeô;Œ¨œ.vmvuO»UÓ”fÕúÀ˜Á_ÇŒ›T÷Ë ÀùúgÏ©»öπ:ƒºœïkÃ7¢©ú5¨[Ê«©E_ê¢∫yﬂë
ÎıY÷ŒL∆)=º%pL
Ωã—ás˘Ó¥ù)5ÈO§TI=ÏOª§qDqDJ]î9gè§˛)7:;e*Ûµ~ã¯û£ä÷3u◊ DÀÖJzuÍ|ﬁø Q˙´a⁄îÌ∞µ¨äAΩ‡=®KƒÿÁ”ø>}r:∞V–Ê&ã›pø⁄Ωñπ˙,eIh´∂ ’ˆIbÀãíPÆˆä$î_—ÇπÍÂÚ#W˘I(ø‡#WøΩíPﬁ´ˇF%°|‘i¯ëkû{'°ºw+~åIB˘ò§úOœ¬À‹Qü◊¯I¨æª{9v
<Cö{o0ŸÊ∑€z∑6°O–√r%L§Ò8¯ûÄqMËXAß∞M4Np;È#ÿÔÜci€∆¬±vÃ∆U÷◊ﬂ¡Ôcyıù±˜á„ô±Ò£qs®cÇ•∂˛;ÓS°ﬂçÁa÷◊˜˙ç¶›SMløÄsºAøÌ˚M®ÔçÎIˇ*‘LçõÏ\Æ«m‡ûtÅ˚æ¶È\êÌ‹pN◊XùóQ´g≠9s´•c,VçA˙1=Ô<ºq/ìné>
T7ËnÓìú˚Ê>˘&˙≠`ËMŸC˛=˙X¡:<õsÛ~È´c∏ü†WË[„ÆjgèåSå÷ÿbbıpçóKï7üéI˝wıwÀ<oÁixó=Àøï¸-Ëéª•“Ûez^≠ÃÛˇ∆{GFØ ¢ÚËnÎÕ
ÇL±úŸ≥KU˛Kîﬂèñ*íQ:û±ågŒ.â∆ŒŒ√ZΩÁöˇÆÛø÷â‘FüÒ{∂´â≈™ùtN^ì¸)÷¯…ºù„¶‰+ﬁyÏ´zÈÎÁ£/6JM~Z˜'RO«˙•Í∫Ï‹ó8á§ì˜Üg~!ùÃ\?)”º∑ô◊;–“÷Ê˘C‰ºÃZækπ,u∑”◊rÈôÈ$]åvÿk˙m‘«jÙÃ!Y∆ö(JÍöHGeıÕÎ¨	¥@v˚=j5v∆æﬂÿòﬁ0ÛûŸ ◊∫∑À∑›ìV&l‰ìøWñ{{Õò`Ù◊Pô‡ﬂCl]'#Ω≠Rñ)Cß_-eyE“”R∫®>Û'≥6UØ£ΩûRíY&ÏÒ†åˇÛˆß∞ﬁÓÔJªÁﬁÑµˆÏ(ÀÕﬁ§¨a©-øÓÖÍΩæÓ”á√˛Õª{√˙zV±◊RÏ®∆√ñ¯‘ÓŸöéÕÛb£Èõ[´Îeë’≠≠€Ñ˛ÃeuÛücz8‘ìÕÌÏê(œ˛|#Dµ\∞;“—IK›ÂF€≤ˆ÷Ó‘µ¶Z/ic∫∫EõKø6ÈXªœ"ÍÍŸ9lU§Ø€≤Y˝ù√fız[∂2Ùúä¨?_|’†ëµÁXª&kuy”˝)iFßÌ≥:Vı˚UÃ˚|ˆ‹ò÷–ußxGÉ#ﬁ—∏ÂåÁœƒË∫SØªàˇLpƒ¶…Í]±5ºáh˜Ò•Gp$ØG‹JGüÑa+ÏÉ·9ÿ‚§Ç#NäqG˛«~Ÿ GU]q¸ºw˜#âdw˘
Å@ˆEhDí¯@[≠Ö›@(6Z«±4êV‚nf≥ jLEAhu¿ê S1L≈›ôVÿh±-ùQÍLÌ¥î‰£”VJ:S€º˛œ}w!Úi[Í¥37ôﬂûsÔ=˜„›èsœE¨ﬁC‚ÓX+ﬂ'uó¬∑˝nD?ıË^‹ø„Ö‡˚ÓJ f'7ÍÕñﬂÿ≈w·y˝ Z(x˝<é:g—œY)ªò¸ºÁÁ1?/¯∂rΩÚcŒ˜Ø⁄˝O◊m>q%.ø.Ns≠æ˚Jc˜˛‹yfgÈêzó@:]Ãc^-«}ﬂ¸wªyÜÌEÊıC{ˆQä7¿npí˜ñ¿`–è˝\∏∫*ÕgëÒw~Îø”9ÃÁ@ºÍ¸ï·XÍRÛ„è;Ô`ˆ?˘6Í‹/ﬂH{¬Y-bˇŒ(ﬂWQ¯Ó/¯Ëﬂı;±∑	˛Áuö˚Èòœô©|p⁄!¯ã>æ≈D7›Ìk«€∂|“oú„˙ZÆÿØXÎ∆~Œõ‡ßÓ<À¸Ì=UTŒ@ø˝°g£ä∑9éMªtüpÛœè+Ô{=àÑÒ÷%|[÷;(„ó€*CÃÛ«Úé“$œ"Zçò2¿Ò«Ú,¥–ƒÖuä
ÃKÃ≥q„Qö)9ªvÁÜc"πNGiÜoÕØ“/¬Oä˜¡‘˝#bŒzZÅ≤>˚pr\$éb·SDﬁ∏àú≈V»zèÄ¸ŸF1Í{–wÇr‰_˘ XΩÚap/ÿ°Ú!€€my°3∞˚ë+%¶ãy¿EXË˘Ê/a∑ú∆ògêw(ìl≥1ó’J;€<Ö>¶Pë(S˙xîà@∏=8£ Ú6µÁmº¢âEÎSı+ùo‘È0NQπ'F!¨i1¿JvÛ{Ë«*é¬iu¶ÅMHü6_£#aLß”!ûJzA∑z◊ëÌ+°Ôx“dº¢æ Ó·Ø”p¯üQà•Î›7Q7øÌÊ{Zúøc›ñãw1é#íWîÏ˝ä™
ó„›ã(Cßº4€§Q/ÔN¬ﬁ"É£∑v7"Û~Ë¸çœZ>ŒıìûÙoA,πÖÓUæàc-æKzÛΩ˝Vﬁ;ﬁTãñp˚8µnåÔyò	ﬂ¿Á7°Œp¬≥í^‡Ω•bA∂ﬂ!JË€ê_4◊cæBÂ™Ó`X¢ÊN¥ª…kcéÄy#Ó@ ˝vz”£¸ö§=õpæ√∑‘@Øπ8çıú¶¯‘⁄˙mä0û˜`«ƒhåËDCùÆûˆÖ®ö1õë^âtÄF¯hÑ¨{◊’”ÊT¡à:Ãq›≈iÙ?ñ9˜›WIãÁh(ìﬂoÁˆÙÂæˇ®Û:«–ÏG˝CXwﬁo
Ëˆ≤É≤ÉÿK∞{‘<ç3{˜√'v}8¸·QÏª¡«rˇ}◊mÒ˘‡ÛO√¶ôÔéÅŸ∑"vùÀq©Ëpˆ±ü„XQ∆Éàˇ∏Æq>|Ï4˘.K3§ØÖO≈Xˆq, Ô4ÈÉä$>ˆ3ÏÉå”Tà˝å˘§3HW∏~âusN√jË”Q>…ıSÏÉƒ,‘ôÖº≥Æœí>ì}üC¯+ﬂ@˙
¯ Û$Øπ„0Oíç≥∞ŒÖÔúÓÕ|7Iﬂi∫ÌöF?–˘Ì"œÌ]TŒgv—´≈K*æÃ«ò˚.L_-.ÑÕ˛û\X.éab4˜Mbö`\%Àü{wµ–Pæ≥}£Â{E˙¨eŸπ8üÔ<æ'yùxΩVRo¯î≤ãﬁÇRº∂ﬁçdÒ›Öy˙¯u9ÀEﬁ”<è'§Ø4Ë>Ÿ|ú⁄w>◊˚éﬂ/9oıx˚Âﬂr%jo«∑=É{pÖw}M›˜{–v∑‚Ü«Ìz\j∫ºÙØax.èπ‰Úà:pøã˜$"¢c∏≠,¢B‹´◊vÈı1Q1<{û†OÅì:B‘˚êKüN¢‰®$*ú≠—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4öˇy“çF£˘ú0àäo¶3t;=E>2)D’TO‰;kæA^§âÙC¸
‚ø˚Â/Î~Í@  ˜Ôfcò“ı5ÓQ∫zì“}–ó*›O˜Î`ix
πM„#•Tiﬁ£tìÊR•‰?©tÙú“}–ßtå«th;YdS˛oÅ£˘áúJ)JÇ=DÕ2g<RiË¸€Ä¸Ñ¥®BIîöoQÚÊ°~ÜZd*áı"¸6¬2
=Å∫lõê6 #€kÑÕêiZÄºÕ˝7∆¬≠&eãnΩz§HqÔÕÑ÷ SnœI‰VÀ,Ÿˆ|9VãÊ µ•9Z∂Æ⁄nŸ55∑X±˘qkj*ô <‘∑∆ß“Õ©tC&ëJVY—¶&´.1o~¶≈™ã∑ƒ”ã‚çUµ—	¶DGF”âÜ¶Qµ©¶∆©±œñ%u+—b5XôtCc¸ÅÜÙ+5˜≤›[â§ïAY}2ëâ7Z33ô8*'´Si+Öí¥5'µ0ôI'‚-Uü„r◊¬r˛ß@éÏ±¯£PíÇlDØ1Yo&ºI.˛g´s-≠˛o7Â+±e—b±É^A¯µ¿Û@PDÏ»˘ãÌ»´ê}˙Iô-iÔr:°‹6ZÊè˙æΩlèhßY4ŸÌŸzŒnœE&ÿRé˛≤+´oí2[‡˚˚Ÿ·Ë T´&ï6<6Éü ‘NÔÒ¢hÀN£Ömh(Ì'∂¡sE{ 8@`Ù€-€Ë#ï„¡®∂Ê
{q˜[e≠2±µÇ¯Åe‡ep x)ÖﬂÕ¿Z ⁄»mbK6Eãƒ&Z
LÒ,É¬h}}.$ÁfC.ÿ◊éDC‚iöL⁄)¶R'0—ÏZT[K&Ã'gG›$ßprÆ(`á`ø
É^ÖÅ¨Bóœ„◊êÈ`˚Uπæ%‹¸£Ÿ`oYÔëlÕW…ÖJÌÈòÖ≈dà∏H“P
ã%êÂês á@ŒçT,«…Cˆ2Ù7Ê„DÅ‚®(¡9ã	bïI≥ÖŸÄ€œ¬Ïl|ÒxQ*MÇ¢ò∆@÷[ªEDN˛ä\·u<æŸP{ØxL¯©¨ñ¡j@8∏Waeã‰óƒrÖ≈ˆöh/√g∆0-aå—¿,'eC…,äˆ_É©eƒÍ9QîK˘±Ö&BnÃUwÓﬂìµ÷q£Ë~¨ªµ∆Êävg¥PåEÈN±∞Zvæ&W˘%õ¢ïb8’ sº⁄RπÈ[°µb’Z±R≠X©V™ªèƒJî¨ÑMµxòö≈É¥lÜŒ€™∫K*√Ü€ªƒ@Qäâ	Ì∆T»î+»J≥}˙J≥“\ØÄ=nØh¡>oAõë…(µSª≈ÚSnÃïñqÖÊ,∂Î?I/ﬂò6è;éﬂù?Ü0îBÔÁ±É=√†ND?èk∑Z˝'§ï›§™ì©}UK∂ã÷?@"EZT%Eö4i™4‹IC—≤ñÛ„ÖöÑZZ©⁄‘≈⁄4çNöÊŸ´•J_L{7±Ôù…4ﬁT{‡{ﬂ{Ó~ü˚›sœ˘±üªéÉç[∞Gﬁíªé√Xπ0˝é'ÌÔpaqúÀçÃ	eøe5πHÏèÏOÚv≥{8ó˛ª¶ŸÙﬂ7|{É’
ˆÈuÎ0˚;{ô˝ï,¢∆ÿ∂âá;gaU9ˆ[%Q¯Œ_Ö~€¯ÇWYµ√‹ﬂ∑€z‰≈≤M;8‹¨p£Y9ÿ◊¨tıåZ˚î}Bcà?√è¿?adæÔÖo∞˘~ãçì	¯oö˛[ì[ú}ÃV»qx≈nóS∂&mŸvI˚»&ç≥‘0_c±õ‰B?¥}á–z£‚;¬;Ó`< ~…
v?Ô≤ZŸ4Mˇâ†ŸíN∫ÿ/Ïàd¡^”˘*[`foƒ4Ãêπ‰·Px…°zHèËK∫Âa◊Ò Yd¯¸≤wQFàŒ∞{ Z`WmgDXˇ∆5…ÎbdeI’≤(s™FPzv{øQµ(ªB&!Ü1f°9h∫ÑdÏMË-ËmË’RÄä–û&9999E‰@‰@‰@‰ëSŸãê$≤ ≤ ≤ ≤ä»Ç»Ç»Ç»*BŒ7"´ààààî"R R R RäHÅHÅH)¬aÇ0Aòä0Aò L¶"L&SaaaaEÑAÑAÑAÑVÑB°É–°É–AË tEË t∫"< < < <äÄÄÄ(¬£ÓOíDDDD]uuuuE‘A‘A‘ŸLŸQ≥>RRRSHHHHM!5 5 µÊ•‘b0lõYhöá$ªvÏÿ≈n®ÌUÑ$+@ÑPÑ !@BÑ !QQQQRD	D	D	DI%µqãê$æ˝¶¸÷∑Ü]¢i7ækŸ<R>G(ü%[ ﬂ!eÂoì%ÂoëÀ ﬂ$Â3ƒß„)/Ó¶6ètX=xLB/CØCã–2¥i™v˙¥Õ∆ÕAgá6©-jÀ⁄∫∂oY´k¨√5ÈZt-ª÷]˚ñ]u”≠>÷¶û£x¥ê˜T9áÚ!Ñ/îQUã≤1‰√svclÃÏ¸Z†˜t=@óÙΩ µZÿ≥‘©ût:â0Lú¶ÕæS|ä¯¸ßd∫æÚ‡ ∑}OÒ*]kÿêÑ?Ä –tä@£P2 Æ⁄àOõÉÕ!◊ ?4 È2ÈÈ¡KbWß€\emt©Úyiëy¸G¡›±˝aX’ˆO¬>∂˝π’BWà_˛*¢∑pÁn¬óm~›6Ï◊6øªaÛ1ÿK∂ˇÏúÌˇí[mÙy¬ù=€Ù)\∑Ù36aßm>⁄~üå ëÅﬁ!ö&˜·Fì:“»‰µ˘l–Ê'd¥õ¯Âçß.R”€IwT0°á´4Ì§Ê~˛5ˇ	 ¸XXlèØÙ™vœ®“ÃVæ˙9Ç-n[≠2ﬂÂ¶È∑¯íqïøè±®±¬∆èÒÎ°™Õ◊0Ô´*ÖÕ/ÎUv”|ÇœÛ0/ÑÓÛ<é_‡g¯K⁄m~ûØ…iíM≥õ+<ÖÄ´0l˛¨QUS|Üˇàõ‹œOËkr}…Ò∆∏ë–ö\2⁄»˛=¨o¿® =˛|§J;ÕÄˆç∂†ù”b⁄ÑÊ’µ'µ~≠€›Âˆ∏€›‹≠n∑€Âv∫ôõ∏ª´€u3H∞mª]i.ß,ù™Óa≤DÅí0Íf‰9"ûp$Yr*Fìb„íº®ãMy´¥ıÙãbü7FEWí$œ∆ƒÒ`≤™müë`Rh©sÈ2•◊3hÏ«UJŒ¶´t[6]È]O£ì\π÷∑J(˝ÓïkôÈÌy#⁄Ì:’y‚ô¯E∂YΩèW˚≈OìSiÒ´˛åïïÌ˛LR\ö“œßWYkKƒWYª¥Lz’ôcâ3≤›ôãgv_Öa7∑#å¯•!Ã#∫√Û$&√pèq>‡àêÜ∏÷6‚Sqæ÷6Á§2Æº•'‚e]W1![*fÀ è≈`«Äçó}>Â’iZF—¥WWRqéêW!øÎ‘@ú™db¯Qà—ﬂWπÙQoƒt›âÈ>äò‡ˇyL«Ç¥2Rú›LL{Yob äwﬂxµWÃ_‘ıÚlQvË¬·À^|ÂUÈ¶E—;≥ﬁ∏^Ÿ‹£{Svèx„e≤ô8õ.oö”q{ƒIx/ƒ3ïË…¥ı_πÆÓÊJü‹c∞ìr∞¥ÃµˆË∂dwTÊ≤d.KÊäöQï+Òö‹˜©tŸMbôßœ7º¬ˆ∑bg˚2±OÓî‹–´Ω≥}∑ùÑﬁ ˚Éq¿mêÏ
Y!Kv·s&ª⁄—‹—ÏÍùùËªMo4ª<hÓÙ∆»Œ“î„ßìb`Í≈¥‹*¬º∞˜=ÀÀCu˜íƒkq¸„º†Ñø«#I~œ£∞◊Q,Û≤(ÛÑ$E`*)û:çôhRe„¥€is8T[π•%Q›ﬁ@gì†ôN÷Ç4à4[Ò÷•±í´§1˘™P®Í}˝.æ¡Á º«±{xDΩEÃT˘˛R®è7Ø´“ÌC£»Pâ ïn4‹Ï°≤`,Ñ"%£*E\h]YB#_í_•ˆíÉÇ˘ùÖ@µê¡bcZ2ﬂˆ·~ï∏$+¡`&òßjΩ˛w±ÈŒ¢Ô.læ9j^_ÿπ!çˆ|s‹âFˆ‚VlB™≥®†∆ ç≥›‚—Å≥ˇ0 £“GŒendstreamendobj43 0 obj[58 0 R]endobj44 0 obj<</Filter/FlateDecode/Length 529>>stream
Hâ\î›ä‚0Üœ{9ú9⁄&_í§†uˆáuˆj›¬⁄ñZº˚≠yƒÅ-(<¶Ò˝	˘“r∑ŸuÌ§“üc_Ô√§ém◊å·“_«:®C8µ]ík’¥ıÙ†¯]ü´!IÁÕ˚€e
Á]wÏìÂR•øÊ≈À4ﬁ‘À™È·5IåM€Ó§^~ó˚WïÓØ√7úC7©LÖj¬q˛£o’Ω:ï∆moªf^oß€€ºÁÎçœ€îéúc¶Óõp™:åUw
…2õüB-∑ÛS$°k˛[wûmác˝ß„Îf~=ÀtVDZCÔP	-†-TF 3hÂ–§°-ÑÇA!(á,§!»CΩCZ@ZA"É!CNCÜ|≠"iº^4^//Çç∫†ÆQ‘5zÇûFO–”Ë…CèÖ
44(4hh–“†¡ß≈ß¡ß≈ß¡ß≈ß¡ß≈ß¡ô≈ô¡ô≈ô–Ñ£	A¡° (8ÑSqúä†Á–Ùz¬©8NEh…—í‡≈·E‚^>†5DgéŒ,ù9:≥tÊËÃ“ô£3KgûŒ,˘<˘,˘<˘,˘<˘,˘<˘,˘<˘,˘<˘,˘<˘,â<â,â|Lî˚˚ö∂eLî/¬Á˙ëœ=€(≥Ø_bÍıÊÓBgŸ*^È«›Ω_Óy©Á‰®Ø„8ç8®‚¥∏œâ∂œY6ÙÉöw›?…? 6h%ªendstreamendobj58 0 obj<</BaseFont/BADDLA+ArialMT/CIDSystemInfo 59 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 60 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278 333]17 18 278 19 28 556 29[278]36 37 667 38[722]40[667 611]43[722 278 500]47[556 833 722 778 667]53[722 667]56[722 667]60[667 611]68 69 556 70[500]71 72 556 73[278]74 75 556 76 77 222 78[500 222 833]81 84 556 85[333 500 278 556 500 722]92 93 500 191 192 500 380[604]404[604]3032[83]]>>endobj59 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj60 0 obj<</Ascent 1006/CIDSet 61 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 62 0 R/FontName/BADDLA+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj61 0 obj<</Filter/FlateDecode/Length 38>>stream
Hâö ˘ˇﬂ›og¯ˇˇ√Ä åXçjÄÄ  Ê0	\endstreamendobj62 0 obj<</Filter/FlateDecode/Length 28282/Length1 59820>>stream
Hâ\UxMW˛◊ﬁ˚‹y	E^‘πéd*è"©ze"$7tÚPâÒ∏Wr%QëP⁄®WUâﬁz’ßÜTu*j™'&L(F_∆|öD1EgÍUùhø"”ÔS3≈=≥nbs÷wŒ^{Ìı^kØ3gˆ\Ç2$˙å…ÌùÑ∂ÁøÆ¬ÊËm[Í
ÿÚ¶UóµÌÌÄv£x∆ºi›JœÑ!ìÅ©ÉJ<Ó¢≥«Ø~îod¶ßKò–∆_ﬁ»üû%es*ÔÔû:3£º–≠nØM ∂„˝π2weE€˘˘-¸—g∫À<Õ€€≥ÆÛG ’ßb∂Á˛˘◊7Ä†#êr≠ÖÜ ≠ZKf/£€V˘¶âéö≤)·‘%ƒYGQôŒ¢Ì¸ÚyYÈ:“†[wµ”ælJ∂ß“ﬁ4êeYl'V˚–oJ;àH~£¥ùàT±à ¨f~Ø˘W_©uÕÓ_≈˜Ã_ˇj>ï‚}¸	SK}Ä®√qÑ#õ± ÎQ&0Â5‰0hL_OëVzc+◊a+òw<· ∫PÑıcô<ÕRÀÇä±(«*eÕ≈D\TK—£0Ù≤ïo≠∂÷Y€±‰qÎW6
Ö÷Ìúıw$≤ƒõÿÑã¥Æ›>Œ¿xÆ¸˘6f£ZNRd[?≥º»>(d°Åéäx÷ÓA3E–ôŒZ∂Y¶ı)su≈$î†©m¢ïe5†€®d≠õ∞˚Íq_Q∞÷bm∑Zâ<√Ò‘°ëéJﬂΩ%æ!ú1ç≥‘˘§Ggú$É>ÂZ∞ñ§•i/Yg–	}1éΩ›…íˇ†€b√byLeZ√ yy√üm|ÜÀEΩi=+zâr±EŒF [ÏÀPÑRŒ˜F÷~Å‚iøMrõ⁄≠Óÿ∫˘.Y°\ëXºÖ∑ÒÖp§:=OØ–óÙçHSƒ[‚ä\Øv©Sv7G=eXÖ›∏Mi e”Ø©ÑPΩAõ®ÅN“51T‰âÁƒMY"g…√jCÆz^-’ñkØ€Æ˘Ú}ü˙æ›∂í¨Â»Ê~X¬ﬁøâ-Ÿ4·<√E\!çÇ(îA'ç£˘ãh˝éjh’±ïìtÖæ£È›`∞âh·=1[º(÷ãÕ¢â·§¯A¸[ÜÀ2^ˆì)≤@ñ≥WUr-√>yYE©&eqûì¥⁄;Zç∂[˚Xk±€_	@¿Áw∑›ãªw¡ﬂ
ﬂﬂ^_ùuùπÜQúÖÓHaÔ›”πﬁ∏„>¿i
Ê‹EQ•“(ŒÃöN≥®í3˘*U”éVﬂ˜–!Œ“Y∫…>áàÆ≠>?)˙âab√d·≥ƒZ±N‘â/≈œ“.Éd{ŸY∆…·ríÙ»9rû‹ M˘π¸Z^ë?…ªñ
T›U´‚’p5EÕU[T≥j÷&j'¥omÅ∂2€r[ΩÌüˆßÌ©ˆ±ˆl˚$˚˚~˚ô wÁ'ÿá?‚°á.…%“)˜aµHVë¢Q4r?OAëÃ‹©¢ÜVàÖT'zjï∂¡b0çFãäÂ\Ôàüƒ`ôE#)”Eﬂ6m∂NÍ=^R‘'∏Æqlç¨π“LãƒM[0ˆƒ@∂˘ôÏ£‚Â	|%/í]m≈ﬂT Ö”u±SéÂ.8¨Rµ|8‰fÏë≥h!ˆ	'x'`%˜ÒhzèÁB%—ø§)Fsıóﬂ`)ûÁpùÔÒ
¸ÜäT1V#ô†ÔÚ≠Ë•Õ¥≈Ÿ:”_D©Úä«®BÌ‚ËROíZ'ºJìdµÌ¶8èπhRÅ∏ œﬁ7â=2Kµh9T¬7`!ñcñµÛ¥|uää!ÈYƒ†]è2I9x]ÃSe"œ¥˝|ªÚ*≥ò¡ù3ä˚bOàjÜç<'wP)ﬂÒÒ<≈QgÀı(÷Bâßœ„æL∞ﬁ≈&´3≠uH‰yPe-`ç5¯kPCÀ|ÛQÅ«˘Ê\†QZ¶h“2≠D·ÁEÆÿh}9€1ÅÔˆ&ïgΩWùE.ÜX+≠ørw?¡v¶‚W∏ Qﬁ`#‰Q$˚FãZ+SVpºëmÌ¥∫S J¨√ˇ vn{<◊ÿ§SÔ|xDé5Gz|•úá5úÖ4Œ÷\û?Ø••èÀö6$ıó)É–øﬂS…I}˚Ù~21!>Æ◊øàçÈiÙpË›Ô÷5:*2"ºKÁNèuÏ÷>4$8(∞]Ä›¶))	N#”•õ±.S≈#F$˙˜Üõ	Óá.SgRÊ£<¶Óje”ÂLcŒiˇ«ô÷∆ôˆÄì¬Ù§$&ËNC72Ωû&dÁ3æ*√(–ÕÎ≠xV+æ∂a‹·`›Qí°õ‰“ùfÊ%^ß+É’’¶Èû¿ƒ‘1ƒònT‘Rx*µ""‹9®V  Ñù2£åßid¯=0eå”]déÕŒwfD;â	&•SM√ÃˆÒ≠,Ho5c⁄“M{´Ω‘^◊kézW÷áa™+>∏»(rOÃ7•ª¿o£C<€Õ0√_∫Òø-+Ôòû_ıi¥Ù:#Juˇ÷Î≠“ÕﬂfÁ?|Í
XÀäòLó7ìMØ‰$éÃ’ŸöXVêo“26©˚#ÒG’ü«p˙)ÆÈ∫ŸŒfîxßª∏4Q^9Û{£¢“XóÂ‘Ωy˘Ü√m∏3∫÷vÇ7gﬁ"”Ù»GOj√:¥%∂6¥˝}$8‰aƒÛ‡¨ke˜c#sdñ¸œpCòz°Œû‰” ˇ«3 ﬁ¬Ã∆O±îYƒ)5€•ªºaÉ¸tøº©≈Ñ∫˜∏åÎ?<Jqﬂßÿb¬n¡è˙˚‰A´Ò˘q3>ﬁåã˚„U‹ƒqÖw˜˛,ÈN⁄ìdY≤˘Ñjè ˛xLìÄvbQÃORÇ”¡ÆSà	?I∞#hC¬OÜHÈ¥N!ÿ∆aúƒ•Lòq”÷fJgÌ eòà0◊√,ıÌ…6u€ÈÙ§€€›∑∑ÔÌ˚æ˜ˆñQD™L¡∆GçvÈÙi$l¶<¿}h	¯vUtN∏?` ÔJËh54∫∂-m»¥5¥⁄€ÉÙ¢p¥ã42…¿∏$ªûI∂çK&^oì{Ü§ë›ïö¯€®ÀQ≥nNv˝ÒÛ˘¢e¡EKó7h5Ò∆1ﬂ.™õ‘ »+&dcµ.GuÁ%c5‚Â)êr≈ƒ`÷hêª¯|¯ã©◊&§,`•—ÉµÖ]¥Ò±L5ˇÁKâÙ]ˆñÒx¯⁄òô]s¬ì€s'µ'ô'«90∂ EuÀ„qÛ$P-£Ò±0’5¥Í.TëôˇDz†Ç›Qoó.´fÄôÆ±Ê§Åﬁ±z.∆ŒÈ”B¢ã«µÖÒ∆¯™Dz€Í†FÉÒ3‰9oÆi'N"›∑À€µpw|µœÅ† hAww,Ì÷q«≤Âg(ú:Íz&’ç¢Ãë§∫Æ·_—3B":l|ﬁ
p(AB5†ÊCÅaÀ{†qt›G? €jK-%ç¬¢hûn.∞aDÌR•	\|≤f¡SW•C÷ÁG9ç„∏cÍ{ª›a:I“ë$™äTEfÕƒ1"jIyYy±(¡/õb¸≈;ø≠]ﬁø}S¡º`áSK˚Ò=lΩseÙ˛Ô¢ÒΩg?JÂ•¥I˙ü◊Â©d*%&3≈»nbòqûΩË˜ú¯–K)©á Ω^õÕ®\ÔU£Ú•n3õIΩÕög%÷cˆ1√p˝õùé RK
B+v¡NG…ËvOôW∞y{ˇÚ⁄œ‡\vˇπˇÃﬁ¯Ú?‹Ωr'ı∑TX˘AÍ*~N'fÙ‰)38ıób/—CòãÇÕ8ÇÃÑÉ+§9O¡ó€¯9 ∂Ÿñ«ÜØ”dÑFP+iíé&±jØú5≥∏¥8€)JeeÂø\ÚÏÏ 2np∞eW®÷≥Í†w>Nêı‰[Ä„4›”Lö9RãkAeë\°x¯ÊÔπ√O“Î1z’&gÕD-∞»“@ˆ|RàßN1å˚†hÎ9îØª	36í1Ò‚É¸0oX9ãÅüí£˙ŸªpÍ$ïÄáñùA\˙jè≥í$“WuÕYπè√Ñ;ƒù‡∑a'å‚q»Ã›B‰‡÷	 ˘ìõaÊN“Ì¬åpl=œ∞á≥q1∆ù{R·À¿’ßˇ ´¬ ·\ﬂM≈usÆüú~E…1%“∑ÏYE˜0M*íYr…2î2ÎCE ¸ É∞∂"o∑¯ü3√L"õÈ&∞»®‹—=ã»¶§¨QYf%ÎõòÚ·úΩ¢Ê°>†e—,√ÈÇ€∑-}M_ÕãÌ§√“aªhLí≈Mjã≥üT{Î+≤Wxûˆ6IMñ5éó≤õ<çﬁM‰ª‚FÀf[ª∏_⁄K/∫ØêÀ‚eÀülπÊ∂öÙ@∞d¶	#5”û<µA¶—≠–´¡áA{¸veH|èµÑìcf‚Xä°
va∏£QµóœvπÏ@~18• ‰†Æ‚Ÿe*ßHb}”–·ç=//X?t‰ÛM?8”Ÿ÷÷Ÿ˘Z€12Ñy<Ôÿ ì©ÙïT*ıõ„˚O„˜R˚æ∫Á–ıw^‹…∏Ú x∞3£∫∆ÈäZ“ƒo%oìY¸1õê(Œ$`ô‡Kf√z3[¬,$“◊åËÜ m]5 ıÄZ@¡À∫á¡5éâÅOÆ,Ëä≠D˜ƒLkÇ.¡cÈ√¸& ÑFK¸Œ\–à‘éB VÂTbµí˘≈¬Å†*äR)Da1πﬂ;®nﬂ_ä^Ê_}¥-Ô√Ø_Z…÷.K∞6?æ0∆%ìJ∑√!÷+åJ™jTÓË&J°Êw
~F—6¿ÔgRøœ
øÃ,˜'»Y]&Êú-è™Ñhyêä>dÂ *J2K´Xy~6#/ôP(€ÌƒP®õl*◊sM∑ÿ§ﬁÔd}lÓòöÖä≈BÍsXv4º¯ﬂ¥1>3}Lõ°L/õ+Ãœ
üàg•Y}“„rTÆ≥6…k≠õÌõoŸ˚Ì7roxÔÊ üXN;àó˙Ë#‘O≈è”wë‰œÇß	– ıõiñ(^ÚÂ:}æ‹,_.dã¨\ß¯iÇ=˘îä’vüb+@Ü;lò»Ê÷ú!6„:>K∂#Q\°ÀÍ©*≤íl [	O˙»◊P~ª;Cv»+#añ^ πåF™í£±Î™ù!EªuFÿ
©&ìi—xT†é};ÕœÑ Ò≤≤“†æëÑ!. √&JºÙ†ú‰‰ˇÙ›Ø~q‡’Ò«Ωﬂç<ˆÛsÔØ?>?≤f‡µÛ7^h˙—¡∏„≥?ﬁ>ﬁAˇ—éU≥Ä)œ§oÚ.`JG«Ä≥x‹:Ûø€á0£jXÜ.öõlÛõÕÖŸ~Ô/Ù	ÖJPë›ÿ˛4 »ØI!Ü"*bŸg∞à˝êΩ≤™
6ë$‡ó¸î~jØ§Á√≥ŸÕõ*(.•FŸ©5Í≥ÍF/˜¥Î%∫ﬁπ÷ıeìsßwæÂ˝ôb4Œ‡çEV¨ºÑA/f∞Ë∞Ä≥pT-D
.ÌïÂlﬁ›Gé"YßÄïò©ÿ[Wj4¢πìµmRk»»M!åB4D¿‚·”L⁄3›ù¿=û!‹á+`#–-≥’¥˛a˜x¬2Pd9k8À‰≠—Îåú∞O2<3pB®Ä≠∏%Í(w±úe 'ïOT«1d J¨D¡)°gzÛﬁi⁄z‚˝-≈ãùvKkbÁ˙w;{∑?|ÂR”kwÏI›∫¸Î4~›}†ΩkG€ÁO»+[÷Ïx„Ì‘Öoˆ¨]ypÜˇ£Ô§˛~åŒÖ@Ö>»o
Èeˆyù¸Æ‹)_îÖ≈‹bÂ«<gé#Y‰$¡l·$$C∞_‚x'«ÒúÇà¨“?ÈÆÿ(Æ+˙ﬁÃÏÃ~fwfˆÔµ={¡ø5∆≈6∞‘	Qvk YöïCB1≈PlMK†‚`>&EPB>T¬ßqÇå16PAZ⁄¥VöÇhHähUD≠#ñ{ÈΩowç©⁄’ŒŒ€y3Û>˜úsœÂœpgà,⁄~”Nn!ŸÖn…)ã≈nfÁTÿ”JhO&&÷¯Çe({ùb:%3/\!mÃ≠î⁄·‰pz+ßr«s¯0>ç›¯w“’C€ÿNˇ‘è	·  KïzSe:®VUiQ‹‰h¥µ4" eEÅÌüﬁKúêÛ›QêúÀ¶£< ÁMàÚBvvæ"¡Ä{LØl:¢Ú∆ö®lÊGÂº,8Oà2µçÅÌ¨§ÂZπ/¨ÒÂˆå¥poΩv·BW¢í÷‚ªáø}(q HΩ{§Äáπ?◊ÚhÏÇ$sz	Öı9qA4Àe◊}æ,7JÖC=ÀÈ¢D
Bæ`éÄ5ÀP”ê%à# —H0âQ‰f⁄´∞ﬂŸ°üdoÀﬁ„9Ï˘µ|E˛<”jÛ]≈!ﬁVf)sú„Å™«Ós{<πØÀ„u)N†àÈ¡âòÆ˝`4]äÈ£©IùRz	È™f8=≠N]©nPw™Ç
$	2í)	™A.ò&I∞›pü•ïD°ªTS;]'ˇYr%ÀC∫ƒ—QGÿB„ 7Z≠•Dë0·cöGõ¿m=B‡ä'◊óÀ_àœ+Å»üˇKﬂÎÀ7uu¥=’VxÙUÓÍ»©Íñ]Á©uıé¡ﬂå–çÍ∂Ì}˜uVO˜swﬂM¸Ëôƒ–'wu˛]€àú4/õ”ÍîÍÂ(4á÷QûfÍ¶ì:ùê™2-y∫◊i◊)ØbcN’*F0¿4/¿\ e∑˙/˜´¶#P˚‚…	tÜd˙fdÃ0∫Á¸bi±uô{±±⁄∫&ÎÎÊ¨+÷À~M2pãíúÁáô‡a+óuHÿQ`Ñç\Ï–pñ5NÊôI/’a AÙlÈ9Éüùj∫……ÒÕ*$‘(*∞VqÁ:µΩƒéë”i‘ÙO‘V6ÑÄ˚~.–√ç;Iö4`‚¿hSä«î÷òä“’.F%®V–öâäõT8èhÍî:ÍR˛Î¡íYüˇ˜¯Ÿ˙Æë˛–Ú◊ƒç∑∂˛£„⁄»îÍWÁÆ˙˘¡◊j]À Êî=ˆ≈üü6ÒÔ?n¯)ùM◊—£˘’µ¯±Xœ€{ﬂ6`Ëùﬂrò8I£ÈÍsRæúU∞Åñ!À8*ÿdg3œs∏%’,EÛ\H±6€˛I™!ˆu?N+È0èÆäÁB=‘T5gp`Æ:Ñn+ÃﬁQ-öL’ V¨`D¬ãRx≤€=e≤-10{≤“Ào∫∑U∏ﬂ—∂;·N|›ÛyΩM/æâun- 0 aR∆ë$ªdí©ó¢FÇ„Êóñ∫su—R®ªù∫MF∞a–Õ™ààÇı%¬PI'l∞N%»ßãO>}?
_~úO∆€}Ïç>_ﬂ√j·—R◊@4:Zëúb”ìπ¡*%≠·©ÒÒ4ÜÕ<ºà√‚ì>&g>∂“áÎKc—â©	§d–îJ?-ÚœÚœ ø)ﬂ*≥ÿ Ëz≤ûÆV[õ´‰5ŒµÅÌdm6[_r¥»õù;ø◊.x‹y¿îŒ,#Ñ'√òàß	F>“G/2d¢â”ÿ_J«ÏtÛ9µıpı¶iVL∏£P¢®
ßÙ–]›ìÇÕ«y CÁ∏fﬂhI„3}úØ˝£%Õ p0)y©µ≈Ÿ‚0i•√t.æ™â4≈b4?ø≤"eÁ“NÄ¿èw[∆Rá.k\~Û‹˘€+Zw$ÜÆ^MÌzns√“W∂.©ﬂ2mV{ÌKG:6m8ÃgÌ]∂ˇ≥Î˚ó¸¨®§oÀŸÑ“Û;?†Ûñ∂º\˜|kÀÉ9Ì’Ôl‹tÏH∫ñELÍ†äÔ•‚Ì»Å0^É0ƒäôÄ©SKúBåhPc!’X•£µíà£PW\9ÆjÔryI•ÃF:U®*(fö<4—∏+}ë¯$&"ìÿ∆@¥~*™ËµG+â1ìxò;Õbñ<5Ü‚ˇ3Í£c˝◊P«dVL=È7√ﬂÛ?^¬/˜Ø’á◊Ü÷Îm°Ì˙>ˇ—–Ÿ–mˇMc»|Àˇ∂ø√œO+Z,ròw√ ¶`Æ!Özµ´ìlI/’$%π'ësöFâY{4≠∂ó†Nw°Lk£X“Lç”⁄#«∫MÑ“¿ÿ‹ôñ]o¢ÒX*S>∆UV†⁄¬ô ò‹ö a¢§2>Ü•∆ˇ∫EµÎk&”…gVtSÈ¬ŒÅ◊ﬁ=¯Óg‹Ô≠˛qÁ—uÎ–ZuÌü‹i£\–@≠ü^ßÍæƒﬂ_&˛û8Òﬁ9æ‚çÓæ7€@r3ΩP˛lÚA—$2|ÑÖàíç´æääÇù´_C8ˆ‚Äı¿^X∞ı™FOeπèá£∑øøüèı˜ÓÔ'‹ÉB,1Øq—˙nÍRTføÏJ5æb@‰PŸbLîò¿XÿÔDµL≠∑.µ=´n·€’ﬂZ.àÁ’;™√jâ—\ç∫‘q\Ω'ﬂsﬁsŸYp
.ﬁa∑Y™´(I2¥≠¢,QB`SAåCíΩ–≈Ò<^Û·5ﬁd/<e”-´.Úb◊h⁄àUæerî„NSŒa∫eÉ|_‚ø[#|,\¯vÅ
=îöé˘ºt]Ê€e*„Uë>ñ∏“Fâì^SÆ¸)π[p¿7; P¡ÈU°ÅÈ7™‘¯∂ZJ#N≠•Avfõ
Ó∏UÌÎsııµZíg@ÀÏ„é⁄Ÿ«ıÔ,|∫KPx´t
_Ú‡+QåÆBøÖü0-ßa>ó˜‰Ú˘¢ƒsÂüpO_˚≈»Æ“ªØœÃÀ*∑úæ?ìûMÃ‡“=Ω/ÏÿéŸldﬁ[)ç9*O/ &O8‚|Aò^^n∂µÿƒÑ÷XmÕéó-/;ƒøçÎ˛lõÕ„÷ãããäHV∂˚ñ£Î±ÛESòuÖYé¥›HyQƒù≠¯vë≈ZÙ"ƒy„ÛÂ,|B∂„}2‚¬áw…°íl›†B˚IRÃRº˜ªXêìwL;æóƒ#ﬂ|&iÇáÃ?ó˝ô30òº@√U<ÄöUP¶¸áÙjçç‚∫¬˜ﬁôŸô›yÏÃÏ⁄Î›ıÆg1,Ü·W0@ï -∏Mope‘-&)
JSL
	M®x)E.%âQÇxÿ8∆–ÆT(¥ "Ö$(Âï™D¨a{Ëπwv¡Ö?TµΩ˜ûôYçœÎ~Á˚“å4’ÅÆVî™0√tûFäq¢ºj"Ûd1àéÚ*zv©ΩÖ$;Œ<≥p—öı≥€N¨s6„©´&Õ®©~qßÛ	ny:9mÓ„Oæ∂ŒŸ+Ù6^Ùõ£è∂-:–T∆Õ2Ú÷NˇŸòÅvQô¥§z÷ä28òh·›´¬r·® áö…‚¡.Y`Ò]≥ÁSÀBÂj3Zäûçµ°’±hª6˜ÜzòÎRO™g—•ÿ◊1C3cF,∆çıîc≠¢Ô©ı¡Ÿyı·KbœõØö€πm⁄ˆ¬ºõtiD=®Gx8ôü,I3_í÷˝Û—@\·¢qﬁ´'˝3P“îéÖíñÑ%Öz#Ö„Õçås•2µîq¡öeúK&T ”
	M·e8‰·ãGåÑƒô#+ ˘êò§0GÚÇ&:æ´o™ÛÁÀ◊ùÛØÔ√”˙.‡qìèUÙmﬁÛœ∆ñ+/˝·B æ8Å˙˛e¸‘Åãg∆∑o⁄Â|µÒàÛÂ+GiÊvAG_Ééñ—kvûGàKí("éßÌÈÛ∆e$â4™ònVäOr3,ü•_DÂΩˇGõ)ìÁπÅg˚¨ñ5Z¶∂ˇRÍ¡˛*+Ö~ Kd?ª¯ëÉ;π‘‡G‹j°wØÛƒ;é∫ó∆ Cù_1x—oÏãaΩàÔÖ!Ï∞à%ë¡o[fé+ŸÊqrﬂ7πqò˚√¸ø‰“e:µÙΩÉ˚t2Ÿ?TG˝~|Ô–Ba7†˛ñ˘è#í	‰UÚ\‹Îk˜ùıü@à,IÇdâ"@√Ê)∑®Tãâ2•x!0CàL(:"ªQ“ ˘‡•èÆî˜€\∏∑Ì¸lµ,[ ¿ö‘•*?π° ¥Q"\ê–3Ó%çÍ˜ƒ`ÄSh¯¿ R übXw˜ë;}}C°wËM2˜N5È™èAWA8Ù∑C¥VD Ø;'M≠d{E•ªè/u˜í1Ó^< ›cqw/à∞∏í^i	Ñ}«Y0‘÷£v¥ÒêçÍ–ÁË&Lnn@˚:À$07;ˇŒeÁF.;ﬂÿ∫;YvvÒÁÜ·„¥∆9€`ÏeZóM ‰R9xÇñæ¬8÷GGƒXu˜*˜#65ˆÿ˙≤»Û,˘πg≠∫÷x)PÔí!Á@ê"∂Ã«˝^o“Áìí2%Å‘3fPád∑ô·ÇΩc3)+g¨ ∂v†.–‡8Iq/wˇï+ÍÖl◊ò›πHÆÎôV7":eÆß¿}îqâ 7¬ÑmrÚ>qiÛÙ≈%}'^<Òw‹^–Òãiœ¸íª5Ó9Ω¯3zÈtq
®≈V0Å^êdQ@ﬁ≤˝"·4æπﬂÜŸSÁyp6ÈW2.Z∏…N‰mÈ#ÔC¬øﬁˇb+B?x¢ìK.µ>å$®&ÎuISF´†Ã`@#‹∞K®•òÙ±‡W8/¬DÚ íºƒ'{XÙl	Ót≥Ë‡‹ïÆl$∑së∫ë‹ò–«èÎgœ7`D¶R◊S(+2Ì"ëuñá≠[y∂
lïËi/¶apƒyhVàvü˙ÿ*Ê(¢DVD≠§ÄÀgV˙Ÿ"(¬Äπ®Nßoc{…RèL»UΩ≠fqœìK?{-¢R5’? è)n07ˆÉÿµW"‚óÇ$*ÒÀïóîSêJe∫2›œç·G©„¥9‹<~π˙úˆ≤*…Dê“ÍDm&©·æ+⁄R≠˙Õ∑ïl„∂à[§Ó-—cø¶ï
$(DÂU*H`J ,ˇ,lÈî$ØOÜ¨i:≠SìŸf≥ót ó,©óŸ>≈Î≥le•åÂ^R√2<!=@UΩ v-ˇRÎ=§˛]Kh⁄ “—iPê#ÌœL)Ä>clÏ»ΩãK‡¶ê}ÿo+Â®/ø¿(*lpäÓS—?"ÂÓ Ù‡9†˚Á≠ŸØ¿≥xF—ˇˆÕGÔ®–Àªim\"≠ˆÄYï÷ ´òyh<‹üvSﬁ \µf®*Çˆ«˘°âU8Pãã±±èƒÛJÛ√è·˘X8‚‘ÔsÊΩ∑6~øÓunN5f‡1˛‚ =å;`
—Ÿâ_8` πâ!(˘¿˙)wJPK1`â»âà'yyBº¢ƒsñ«#‰êS∏7ú˜$¡8±#¨ù3ñå-πNníó m≤ K0áŸxR·ü=⁄@ÊûP˜Ú0XNeRl&µˆˇ◊L±Ä©Z‡YÖ‹„wqw/æ´ïítpCY)–≠‘†K≤´”˛ÒÓÍ¥dóªfyZNS≤◊≥‹5È›bf⁄rqZ‘Ç	–Î˛Ó ò1◊åÅôGÕ€Ú≤ıK·aGJXÅÈ§ƒ∆éìÈ=9Ë@¡VÒ+°XmmTÅ6«˝T¯i(äN€u?Í¡`4çÚºŒÂêÂ˜Ñ∫µøh\(T%VÃ6ffÜÏ»aéw∂˛î1?074ø†>2;˙jh—√qé3„≤7/i]¢ÛÇAÃÕ?0n2<È°Ÿ£üÇHÀí`–iã·ò?IkË·¬ªuÈm&á‹µ.«•jÿ-P‹ÄéÂºô$å„VÈ®¢ï(.j∆kÒƒ3∏˙Ì.ß˚ÿ{No«);ˇ	éÆ¯r„?úÛ‰4n¡øÎsﬁ∏π”~Ëû˚'Á[Á=\â£ùXﬁÏ\ÜúÌÑâ4›≠¢t–∑¿X$5zMpû>/»ÀJÖ
\ñh&%¶ß$=ãΩ˝vî∆"E¨ÜøHÅ˙øí«áπox¯Àj¨÷å´≤Ó—Gó=Åö¢b*¢O	l*£FÉv⁄I∆l™˝…¶ÜŒ_ùµ¯˘£;3?([Ì¸ZË’Ã›-Gú°°w8ºne„ØÚT⁄9øá3B
r0⁄	S÷∞9±pn—B©•
õlŸ:íRáJÎM%g»9√Ïπ˚Eß©Ñ˝fÁà—ïΩéçÆ‘≥ª?ª√Ûè;cI˜9|_œÓÙπ=åQ⁄å¬÷Â∆¬ñ¬eﬁÁ¥˛5æµ˛ﬂ™{¸=˛k⁄Uø”Œ2¸A√~≈kFI"íÔÛòÜÆ*BÅ◊õäÑ„!
%aöÙP%˛√xµ¿6uù·{Œ}¯ﬁÎ{ØØçüâ„ÿâ}m«òºúáI ∑	!H€•êÅG(P^-ê•0@eÍÑ>@{0uÌƒREAàgBï ¢hÉ≠-S;—uïV•£hç ∂®%è˝Áÿì¶I≥uŒ˝}}ÌsÔˇÁ˚æøÑ÷”ÎµŸ41`ho⁄9˜ú-µÕ%‘@‰âÖL0º=‹f√%ﬁˇ∑∆¬ˇ‰£“Üìˇ’ ‰6Äo‘e¶Çë´uækLóÉ†"Ë˚hs¸^}Ñî?Òü/&Á8MY4miõ>◊ÓòKhuS≈–Ä}
|i;ìÜf˙”zâF1å¬!:QÂvªúÇ≈Ìq{fï≤s0¿©îBã`´4tywœÔ>\Îxlz|∏cÎÚdhÒ_—Ò˝Gó˛ÙƒTeŸı›o‹*äÑóÓòÍFï?xπﬁjô‹¡V◊Ì^∏±èx¿U”w∏øÛ2ÿeF◊≤kπˆyéãDkÿ¥ˇÏ"ÀcEÕ≈¬-—'ŸNÀ™¢Â±˛YZ)Ë•ûp>à‰#DÛA)-Eˆ‚l…F>àÁﬁB¢òjÑqòçFjm©“ëÊÚoü*Ìà<k›¨n—ûqÆ˜Ó∂ÓQ˜ÿˆÍ;¬=ë>ˆêµ_=d{Eﬂ~1ÚCı®Ì®+êsj…ê·(4
$#÷öâ8∏™JÉYõKMÓ.Ï/ƒÖ∑öD#(¬ªy¬‘ôÒÅ§∏Y y	ª#ùÅë;d±QÂcŸw°ôåÑ5’ á¸EÅB—"p,P$\Á†•-LòváÅá∆‹Lí¥&UYQ;ÍB€—$@qŒúï$Kí•·é€$Éâ£8°pM√qrk*˘]º†
û	"ﬂ‰+G‰Çe›Âﬂ${¡Wπv%4¥∏¥c >ˇäR˘xñÃuË~F…4Nû`l'ra'È$∫¢8V] Wg—5¬Q√®I’÷V*=(_p9=nŒCA
MGÿXuY]}}Ô∂SO∂ØjòzˆÒMæ˜œü∏ﬂ«_±ùyÎ‹Òt=˙xEÔûæ?ˇÌ‘ø^CÈ[_Y˛hœÇÊ•û5â∫Î∑˝z›¶w˜i/Ω∫oÂ≤ÍÍ-±ÜÅù;nˆ<ó ı8Ëi	∞¢ì˘ÿî€
nÖxC‰‹$±np%)ÆAl·⁄ƒù∂7˘œmÖ¡ˆ!|ıí 9úw<x∆Ò`⁄(b¬+~jÿ3A7
∫€›∏ÀΩ››Îf›™îëú7X2%9O0r>˜Ú¡»\Œ§g	Fû!9„"ÜÁ!¡$2cKÙLÆçÀÍ+’èìA–ºeuïˆq¥•≥s]√Î¶¸Ò˝©Ø∑/<≥˜÷ e‚¸Ì©âØ"ı.ªl‚¬;O#'…ë —9í—¸le:xƒàT/eÜóDaæ¸ˆ{˙Ì˜Ï’’ `MP˙ äB3\Œ£2&∆F‰r•BÈR˙≈~ÈàrMπßXÉJªÇ9lqvo]ñê≠	¸eS"»Å_Àíyß(ÚBAÃ;1Ê%XÍnPØø^DÎ±HRiç•€E‘+·3B¶äÕXz5FáÒ1å19cÚÌ<Æ Ñø∆ﬂ„y¯/ZªNf=~˜(‡ìØ∏j.çyõâì&N(Î„ù‡’/06®ƒ?.HD–ÍÄ]™ß/bÈcpY-µÙÃÙµ˙ŒNjs@»;C®:Î–´~dÚ˙hÔú‚í$z˘7ì√‡Û>Í›ækˇ∫Ö‰\»Â\AõEi.À5HC”w.:<)x‰;¶ÁÉâ%ìDÙ’"_˝…lÄÄã¡‰0∏∏X&ók‹F¥Qÿh˝D‡xée—"	Ç$∞í¨ ˙§†lu –ﬂ≤Çƒ tì≥l#H7´ÄXÃ Îˆôí,K,Ü™kCÿkJäÙÑ)˜ –L¢SµZï √>±¶I0%Ñg^AM+ïP%ßüüRˇ¿¿ﬂ™⁄pà"ÒU÷´ègÄJ≤áø3÷8Ì5ë#}`N"!B-xR–FFË0->ÁÅ¥˚!ÌóDER∏+”„‡Ï«-
a DïSí@ExıÛ>"äù3Ã≤?,ê7L˛˛jo~Ù€»ˇÈ‰e¸ªd™ÂÖzé†≥'D™gyéVI9Ô–m™=’ää≠+ãV)ánSSME÷Ä` Ú…∆¶…ë–ß9»1Bú$s¢,E°TLF˜Å(Çàs¬y9fıßôHÖ/¬ë#ïûEŒ¬O¯ÄE¿V9†¿vºä‡æ8H!c©MÿmJìY4ƒ¬„åO|çÚ∆íq¿·‡L∆ªıQ}Ç!nÑåF{ö∂%d¿ÆÄ^I#ô÷GF–wöª3	öK\J#o(¯˚d ö¢öOp5®∂.Tr!K»«_∂∑NºœL‹ËdO^bOØk;sf¬≤·»f€ÙÁúüõœƒò:ú4gK™TÊS ‚jYYZ≠u’Œ-[TñQ3eõ’Me]á‘æ¯œ‹Øº•∫bƒŒnåíˆî∫æ7}ßbÉæ´±ﬂÕÿÆ€1qÅà“Ÿ	u:Tä© ◊ÜÓ Q±ßÿõò]ñJsÈŸã∏÷ŸOâùâgƒMâù ÂÜr_Ωü∞◊•4ƒÈÂ·îß*‰ÙÆéoã„∏ø\k“k«¥iç?¶ù’æ‘XM! ◊àƒÃkdaóÆöB¯Zl6ò5?Î¬ßΩ?q˙˝Ü\T@ùcsTÆÚ≥÷¯}#–M	Öâ¬‰,—YÖ	sdﬂ¿ÁQxxå”,@”Jñ”Ö‡ÛUå^ijQì1t#hTg>Mú=—z∞J∑iPIŒôj†4Uëæñ∆øH£¥á‹€#‰=oIy¯·¶ÄãÖ&µ—t+^Íür3mxçziù,.T÷?Ïr∫¡($tÄqc3≤’8ô¯Ï3¢V£â¶±…Q;q√πÎª≥6)M-Ÿ¬‘= ¯LwÑjÍËª&%∆¡ùè©èpª\N∑ß‘`ã≠ë<∏àm\˜´Õgﬂ^ÿ”Z≥ÂœPuÛ¡ÔÔ.:Á›˙á˛Éß⁄u…SÚ∂ﬂÛÙ»∂UUœm⁄¯K£Ë≈éñ”˚óÓ[Í‘‘ÇpDﬁöú◊ŸÌÌ~i±π¶mŒÆ{ˆœ´G∑c~=∂§ºµkÂ≤yﬂD˜¢ãÅt¶ıöØ#^±˝õÎÚé¢<„¯˚ÓÓ›ﬁﬁﬁﬁÓﬁÌÌf/õl~	‹ï@Ó~Ãç,`B5·WÉb∞ê§ê¡H®
XQSgt¨h§hQÇF≠)-◊¬áÖ	é‡åQK¶Ü≠Åå©MI“Á}/H⁄ôÀ›ﬁﬁNvﬂ˜˚|æœ˜)rïª*]Æ9vßÕÿvÅ∑ÊYçvõÌûLÍ…pç^NyR“*9•Ø	7xí6 õıÕ·¥˝ôØ◊Ë5ˇ¸÷¯÷¸*ßœ≥Õ<W©\™MsÕëWç\Î⁄‡ÍÕπ¡+>%‰Á¿W≤-7èΩ!À/fù±":bΩÿ*r∂C‘içäYÙòÑçÒinê÷ÎHÒ¿A-r∆)%zä[±G¥¯Gú8aò4ÜºŸÅ;Ò Êl</∆,tƒQZ¥pp”…!ÂÖi©`épÄî
¶•W|ﬂE*å^™ì[„,r_¨ë[`3w¡åˇâ8§*öìï8QÛˆIw‡•Œ¢…Éò}S3j /Ñºπ2ó	)®∞†òÖX	Ö@fú7˛—o∫öèﬂw¨…˝Ó'61âÂøl9˙˙∂ñ£ÆÓëœ/~˛£üç^˝Ù5¸“…Âœú˚À˘3Á¿Wk«Æ∞‡Waºz<	%¸;e,ãÿAµ®±àX"üeq"ˆáxY=OWœ˚»ÍyÖ¨ûß~Ó¬ôLn>ù*#$0-|ÿ∂ÊÁu¡:£>XoÏgˆ≥ØHáîCaüG2ΩÃÉlÉkõØQjï˚ﬁﬁ˜æÁÛÈæ›æØ÷_pØºEﬁ)≥2ãqûÜ»C’√cµ°‘á!»…≤àn?£è^‰˜P*»ÜıâQ∫6Ü»Dr®:?¶öÑ©&wY°¢€¸û·˝‰"ﬁK.‚©ΩÚ”≥ß≥¢zP%™π∫Æ∞öÊ!LÚ–@ÛıË@3];¿ÆŒ*UR˝¢SËˆl∂ëöêë‡áâÄ(«&èÁ\{ªwÙ_Õ_?˝÷ˆ1sÁÍΩoz≤·9¸îÒAŒ¡ﬁ£òŸuÏ@ˆ¶áN}ÚÈüéÄ»*–Ï©ëÀùC^Üì"RB∫SrïkÂ÷Jfôw©Vg=¿‹ÔZ/¨”Í≠¥}¡u1¯•y9xYªf¸”ºL…”m;&∏Vá	ª¸T¶Hö™œf •j¶R™“Ó≤VzWHHó›ˇ–áÒuøÇC¨_Td R‰UH≤bV£à*GÂºä’QÎ’V–$5ëTrT⁄¥™™õTêJÅUÈòAv\ıìáÔW)•*
Êu‘≠Å¢ì|â„9"—bûÂsi…QüÊs3•He£mâß›á7sµHK5-ô]R!ô¨ü‰Ô6gêkõÚÀâÉgÊ∞võ3vÊ˙”;/nk∏D˝K•Ôé‰›÷Ú˙ëG∑ÿ˝Î}ˇ9ÿéŸ_,ôÀ¯á´ò¿Ÿè˛t¶˜Ïi¢Y5∏h.pÕÍ√FV2i ïñãÎŸMÆ-¬z—"]ê.ú•‰(«"Ô≈Åœ\√⁄PòõòmN∑ÊÜÁZK˜òK≠µÅüÜ◊Z€›€CCÃPñÇt,KÜQ´ì˘å’-πMÈPE·≤-/è∫ô7I≈ﬁr≥4– ˚Æ /Å√ë†Î“ÅM"Zê[K§ˇì-ï»ıBÒîDßÑ•∞ﬂﬁçLJêOg.i≥6∂ı∏Rƒ;ES∑î õ†îEï  fQçt™(5—S—Ö#˝ãî&HœM?~#–!˚)\©‰HSí¶L"N—äõöo!¶†xR5>üŒÑ8m¢ÏöÓÿ’øΩÜµ/.b?æy≈˚ŒSÎˆçÙ2K|3W<˝ÿxÖq∞€`ˆ>\2˙◊—+y«∫7‚wœﬂx\$∂∫>Añú\M¿≤YjN3≥—‹Ô{UzCÚÑ•©”LõúIˆ£$l'r<Îì-/1Q-»±n‰m◊∞6t8#¬!ñylâl‚Ùô	ÚÈD-;—Ü∞ÈLLGL∆áç:hpPl|‹ phÎ“»~¢LF£ßÜ?†1Ï`ñyw£|4ÑΩË÷Lr:ù@hÜq ïM /ÃRaoÁ?ÏhäÍx∑í"≤ëÍñ≥qGßÏ⁄Ö£¿Is\-,èó'fT &`kƒ’BÒP°˙N{{0¸DKÕ=Ÿ3ÀñﬁŸ”√æ≤ØiS¢je‡5oU˝}˚nn "Êç.aø"r—º≈©Eó#ZçX©πÖ3'&N“bÖ≥ƒ
Ìn±J[¡Ø7ä√ﬁ!ˇ‘¬XÒÖw◊∑≈:b|E~≈‰9±*±*ørÚ≤¸eì‰◊ÂØõ\kçı_…øZx≠X5twËwÃÒÆ+»”N¢‰°i¥è¥¢4:è ∂2;ú2óe…ﬁ ÀÁ’CÒH‹… :o`≈påz£’‡b∞ÂÃÚµ5É⁄öÒÉ≠‘÷ù˛jdlç\Â&ﬂ3∂fêPp7)zc´å#®¿.:)˜»ó‰1ô≥Â9Úbhtî9L¥ï»ì-ÚüdÍm2ı6Ÿå∆∂Ê{ã.ö`o◊îˇs∏ë˛°$¿”O¯È'üIBL4%√–çLÄ,jòåœÂqU£!48¡Ï6ÀÊo›±7Àè[:?‹¸Ò≥'9º˛Ûé?~Û´√;;Ú÷#€è¨
/âî›øzFÁ38˘ÂÀÔ{πıf√˜=€ÀN˘8}ÚÏ©3ß»dπ!ˆ
t-Ø˝ÈP¯!#¡í±Ö∆ÎWŒV≤›GOÕ6ÃÑ·Q}™∆∫0í-Øâ^_Dp‚â1ß¨”£;D°ÑækDÅ*Ÿ8Åf;!LÆÉ≥CIçH"ê#í˚
^Ç˘˝}≤∑¬"ù∞h$*ù˙†Œ4Ízß>¶s:£E(Øéœ0ÎAyP9}à#®QC%éA)ÕƒJπ5‚∆	Œ‰AƒP,9Ö‘éáãq’`zHíëbBB§ß¡ìô882t˙›~>‚w˚≤±‰.Ä›Ö jçgR¢Æá‘Bï Ë©{∫O∑º]›µmSÌ≥IàÑﬂΩê:ÙÍ»ΩÃÅ=è÷=∑c‰˜¿‰^
~Ç‘«£sŒ°Ç¨`±–&tùBZ∏$
<l°Qh⁄«Oı	cÇ◊ cÒ√
nˆqå‹.7ÁuÛ‚⁄πÆìKs}ú;Õr‚Ú˛Àvµ«Fq‹·ù›Ÿ˜ﬁ›Ó=ˆˆºˆ›ŸÁ3
◊DÄ;nÔ“Úv∞CH">Öhc¿ÊM-iú6qQ#íJmLäHï™
JˇAZ	à0MhõDºÑCC©#§"7<|Óo~kõÉ‘èùŸπ›±gæ˘æﬂ˜—∏£‘Û ¸Stbﬂ(Ó’ÿ_•®lt\Ÿ(3·lœ(#ë∆ˆê6+˜Ôﬁ:ÿ=&cπ!,Ïó˘uùô–Ù⁄à ªÚr__Ωv˙ÙÌ≠π˝»˙Ë€≈Ö§◊‰ŒÊgQ1->Bk≈ù¢UDQ¶îßbà#>ù¬µD]f+‘%π‹
tÉ¢G£¿J_Z”∫uí–szã.ËlEulE∫â…ÉÇéôRèc21ÿ¢t3	r[èÖ¬¨úS jd1dÉ∆fs÷ ôW:π‹ñ	`U¡˙âıYµµ]¶“Ëù≈‘(¶Ê’/ªúw"HÅ≠ù‘!•a¬2P|g_Òπ™â∫}µèÓôGØû9ss€õ˛yªi€Ìû„V0æ¬YæÜ}—˘ÔÁ]…ÛV“”“U¯˛#KÇj0Ù$ñ±ÿÚ¥Òé:ﬁ*ô7ŸãO	õ5>(%CïY¬Ÿ°‡§¨ B¥A*q ˇ"åHîäT™SÁ “É⁄bm≥∞Q˚L∏,…˚%ííj‰¥R/=¨Ê|-æV⁄*-ñ[’Ìt´¯¶˙gÈØÙo“†tU˛ØtSâ5M Kí¨™
‹®äíñ•∞,K•iQã¢¶¡Å•
Åc)J≤åÂ4zÑÚ™H6bï¬Ó*ìòL¥-e›`ÄÙ4«ß!+r$«µ s‡xÊß"˜qÁ$sAT åF.f¯.UŒ˘A)÷5‘a∞>√ô»9RﬁÑo8ŒçV¥æK|(C∑õ«°u2~Ë» ª“(‡ı†ÑŸÕ◊§íÑ˙¢¿´éœ Çt∂¬˘ˇ^€‚º¶~´¢^U**∞ÛΩı–|“õƒÊ`e=˛≠‡|¡ˇrôºqîìF˚{+Îƒ˛^õ5Á{Õz…kŒ¿Ê†ÓΩúiÖ√∆^ÃœQ¢Ñm¯k·p#^‡≠·^áΩ¸ÔÉÆ˜8)¥¢ucΩN‘+RKHä»¿PÚÓ’‚*Ú¡˘‚ﬁüä«ÓºO7ç¨‡?..eÁÚ∏‘!_/Q†Df£ÍŒbõùÓµS¶zmU€| M@LàoâD⁄óÎ¢ê◊ä;ƒQëÇökº‡	<õ	Ö>ŒÊ-éÙCÃ‰K’˛Îªj_Q¢ˆ÷ûS∆Ãò'Y–E¿Mh◊LÔ’.&^ôå'_X•◊y√lg^Ëè›ö=VC•L)Úó£úh∆¶WéåuÄAˇ»/–}Ÿ4§ÉÍ•ËIÒ¨8ú‰£J2•:nRÑTº\ä0K!)U3µÅ4ÈN˜§˘4Ëò?›mãbbs0≠±j™cb≥EZå—Q∂Pã«‹Ü2∂0ÄôÂ÷DzK1§ê7út∑K\úŒùòŒ≈È‡˛´º≈¶s±J∫õŒe\¬‚Ïlb∏øÉªl>õ„kSi2¿˜z8>¡1˛	»øäoó≥«*ùqè|#∆RÏA·˜(Yù>B∂∫_Å±®@"1KFÜJäsa§µy«Ã3î$1–ï†L{≤lÑC5a√rI–/‘c—çÃ¿ê….^πF]Z∏˜N€øj”ûƒON¸ˆ›C©∂Ô¨˝Uﬂ‚è=ﬂ@k^o~f˘‚cÔôƒˇfÕ3ØÔŸ√˜nŸÚ¯Ø9ÚÈ∏Á∫Á≈&€Û!QêB¸ÔÕ#Êe·ü°Î¬pH¢Lr·¿l5…ÊÄs—uhR	˚√v<ëlüÊÛ˛j}ñÉûKG∑•£€“'‹ñé$–´	∂√Ë∂tt[p”TG∑•37Ür®£°”	¸ËÕ#]s^Œuá_ÎÙ8ú~á:_±ëõ√}ñÂ1Ôˇ.Ì>√eï.:∆ƒ˛|~◊5áùw1ﬁ@vœ(|Å35x¬ÖŸí•jä&kÇd÷Xíﬂ%-8Ú‰Áô›Ü#Ñ(3?Ω‚Æ∑7û[∂˜qSÎõºzÓ˙whÕû˜f≠]0m˚»z~Áè:›}j‰}p(‹Ã—/È$@—«≈»Í√á≠$LDí%◊≥^? ZÃò#ÕUûñZïJÌäí5ÇˆtgñŸl≤g9mbõ˙ÑYÏ'ú±C]av;ÏŒfQ%—∑TxR|R[j¨Vä+µ5Ü-ß≤íÆv1˚∏xdñr0˚»ïÕ±—Î}lˇ±ÉûÅuÿ¡ @Uß≥Sd¬…¶úîyÍ–6>/û NÅæøö3¸,ˆëŒ‚[é¯˙_èµ®?úçÁaJ&<7µ,[«ƒµp9≥3S.J∞Ñdî©Ö€… ñ∫H\§.ó´î’&ˆH»¨–∏Ü"Æ4Õ‹˜Û?'ˆ∂kØ\(ÌÌ⁄Ÿ{Ë•Æ^>D&Ì⁄Tº4Ú—µüë8Òù:yÍÃá'O¿?‘UlßïÄ`êãìÂ˘]Ü˘†˘m≥…§π‰Å$üH>`§*¶E¶U|∑bm≤;©4D‹˘—˘n´≤‘hã∂π´î’FªŸ]Ìˆ'?üsŒï}∆/&GìväfÃLd:m0g”˘ÊÛ˝ZE—‘-ø`óó3ï∑À˝:ÁèUhƒ‘Ú⁄2máFìa·ﬂv%Ø3 5gÏ˛÷∏°˚
±Dg« ‘ÿYK±Õ÷6êP-_Ls\?∏ “CêÎÑ&Hé¥Å∞:ájLPç	™1¡B6%adfÿ·£åà¡&â\I,1ßŒ!ôfÛ>!6GnﬁçπÖN@1áûµñ+∞¬…uÜ∆E’éÑyh'YB	z]˚v?˜Ú¿™ç∂-yÌ!kˇ¶-xg√˙É≈vÒOøX∏’—7~Wº˝ c#∑Ö}?yˆ‰âø3Œ-∂Cì+'3Úªt>√Ov·õ¯≠Üîã‰bM±ÓxO\ÃÜ≤n.>34”]Z‰>z÷]ﬂˇD:º"]5˛ÂòUF&RœO7ÊÒ≥ç%|;ˇ©ÒπsŸæª‚ﬁ·Ñ˙¬eÂ∫Ïó¬ÂÄã˙kπ¥ià»ñvh<Ø√v∆Ω@ê)aÄ).í1 ±mÿ¯R∂ıõÌ5ì
d >ûCıÿ`U üñ/»£2MÄ…m2V#ìÀÿãrr€ˆå/Ú9VﬂPô-©íÖŒC#ôú•∆o√uôde8—ˇë]Ì±Qg|fo_3∑{∑ªw‹ﬁﬁ˘qæ7∑éMÏ3éÅ‰ñ@d≈è– 6E-Ÿ°!†ò»($&QB("ëRÖ@D“î6ÃS¢EêÚá‘î ° ’jä’(¢R≤›oÊlÍ§Úzˆ€ªù€ŸÔ˚Ê˜hÕ7©*æ⁄¬˛'Œç˛k„ﬂûª∏È‡HÕëmõÚÏØçv	ÍÃ6\áï£œﬁ{wéÔ˜ÉÉü}~ı⁄Áå·^Ä“\Ç™òË≤7≥>Ñßƒ¢8G\"Æ∑à21U¢=d˘TÏÁ[Qí]≈j2¬!!iñÖüg¸ò&iΩˇxÊ$¢ë9˝@QFÚ$ëﬂfµ^¯°=f2:ÔÙArXjZ‡‡Fó˚;/∞Dı‡Œ	M`+,/
≈È*≠\ı»£èŒ\Æ≥Ôoö7„√\kiuœ»UñÖ“ÿ-ﬂ1»¬4üÌÌì·‰2üÃM/KÆMˆíΩdw˙pËwµˆÈƒéEÌijØŸR\xBåL£jÈ†˛≠CÔVªI7Ìˆwk›˙@v Ãe”πÙ‘ÈÈtπMvM~KjK∫/Ωèæ´Ωôﬂ_˚÷¥ËoµCπÚ«≥≥ë¸ÑMN©â =‰ÀÓp¸§&ÇÙDP	æ¬≥™ZV®πåF≈X";EÙ◊U∆N{Ißñ%ø⁄)9ÌŒœúOú/9ËT;ùo±⁄yÕúsPõ)–#U≥€Ïa¡¿W¿ËaòÈ¸p§àyŸf„∫é ïBe≈EdÀ`ì ¯/0º+∞XQÁØé·X⁄ÒB—bõ^œ∂ù-èl∑8÷#NÇÕtlñ√ç£·,}ZX˘©í.¿‘-W
∏¿û¬fÿˆd?Sòÿß‹>…&b¸Q5πBqu√˘°‘–◊ 4„4äñı.oπD9À Ì,``ÅÁ∞E$“A¿Aæº`b!Óz	éÖ‰7∂÷yê1)¿0lÚq(ÜN=m\"±è6π'i‚a–¬Ï¶“&´•æÏl ¥˘	öËyª¨ûº‹U))\õ5À>9©'‚à‰ï8ñÄ°*ó5ÅT%S∫¶N•qúœ*ªbUïLgπ®≤Ú¿®[pwÌ⁄Ö&¡ÓÏŸ‘jéî°&óÕ’	M≈ÈÕeÇÄ=∆µXÿmfW	e≤œñ>æ¥£w[Sfﬂ•w⁄g?Txc…Œs+Ã£⁄ÊÆﬁÓH§>æ˚O˚óu]⁄˘≈◊¯·äßz÷Œ}8Õ4<æ´≠u{æ⁄ù∑c}tq«‚ÊTEeà¶g˜v¨xÔßGÿ>Mè}/§wêçæ:É(Ù`*[$¨≤≥!Ës0¬öN±E‚)P∑œ4í(âu+£·1E}å<∂ZyFÈS^WD ÈÄrT9Ø\QdÖë5√*•L÷<¯~ÄañRˆc„Gı≤Ç.k2∆˝…„“¨¨*ï≥B7ä‚È«÷˝»§˝É>6Ü¬ó do66óômu›åÕÚóm2SÄÔÕÄd)3ÃR/±üÃ˙˘Ü⁄›ªèü8rÛUÔøg<≤ˆ†ãW∞≤aÙ’WFˆ-¨ç±=XvSÃ¬”€œ†‰ÜL±ãB")Ÿj≠p—·¥äh8Òòõê&‘…Dmf'b‹´ÿ‹•ÿKÄÕm'ÀÄÕ·€æÔOlÓOlÔ‹üÿ‹p⁄ÃüË,c6>ocª-∆j4ÖYìÿw1·ôÿÅÿ—ÿXLåirü8F$AÆêõD$ƒAÓ·O&î=ï∞ﬂÁ|A∏7!{6isò˜ºümÿ\√ˇoBÄAXﬁK≥ Ã¡7QL4zPdEïUI#"jq§´f1R(Ï˛Öπ5Mº49(N£	œ6ƒt˚JΩ_Æ:‘n¯¸Ê”ãÌù9Ó¿º_∂7mﬁ9˛ÍÉ≠ãñº∂Ghπw™%Ú›ÇÍP|˚ò ÃY˙§gK*¢™åeä$¢JXê“¨˝§z˜∆†qcZÉ±[j¸TìÑQ“l°ﬂu≥ÖÄÕ,™l Èé√èü·éØ<RUSDy∏Ó$…LE`Ä´Îﬁs˘∫"J¿‘¶¢<…“‘DÁ°V∫/ñ´Oíuxù–•vëmh+ﬁ*lW∑ë≠¥˜/˙^Rˆ®/ìﬂ†∑…Ù:Hœ°S 1z]§◊—óÙ[Ùwz›°µ:4ä"4è≤¥ô∂#è…≥"E	Z•xLÊÔN‡}ÿ´#&ëΩ +#ECY.ÿg\Œ≤¨OI“¸P∂˙.‰˛›A’óJºîqØô*™ö!4LE>A a∆BA≤®™ `Y°ƒá∞TØa-©zûG˙à@N„¯	OÍì	"è$'˝∑ˇ ∫i8Êåtét∆¢√CùLj0µQö≈‡≤[∑_™s˚w^ËØã≤”r Æéh≤ÈEùÀkpc(bOo5b¸á— TG›oœå>-fGvØﬂ∏ÙYa4táåêt
∫√+À›qYLôrÙë9Q…„„ÍÄ¶säΩ"3°ïø8?0¯@≠,2=~MMF®!,!∫&≥•ôX©hRvaN ù	¨38h\4Æ∫É¨˚XÇ„å”€qÿÅa\ßRaæπ“‹k˙ÃØﬂÈ±õ≈â¿d∞C™käFEeé¡ıwﬁ©ÍtQî5í„ƒ±$â≤ü¯™e†ê/¨T®q%8ÿåRP›@5)3‘ôÅπæVŸS™¸sÇ≠Ê|kep±ıî≤F]omó≠lQœ»gÉ'≠À˜HﬁoÊQ^œÚ¡úU~5[[’’∑}˚µÒG¬G˛√⁄	tR>¯ãxM˛ö‹oˇi›ëÔí
øÃV¨Ò—‡cÄèA>Z„mßÅ†h!SU‘åÃòç(>k˝Ùÿ5Øô°î›W‡^M«·êL˝fñ∫ÊRq1Ì07òΩÊÀ&5©Ω» Q.ÃˇR›…emΩ{vm±ø2˚√˜¬>I¿R$B©
Ö¶	¯æ‡∏Ñ,–,è{Îh0ê¯ÃT‘ÑbZñ+)aIRPÁåÎz@ª„R5”ëtß +ñ®M-_÷´=8 Íäﬂ{ø›oø˝ˆÒ}˚Ìn≤O…Úp—§‰Åk£¨ä(∆lbJ(A^!`ê(VL(:uÏ‡c3t«1Ä!âƒ£uJ„c∆f:£•C“2"∂ ŸÌÔ‹›Ñg˙Gßª˚€süÁﬁ{Ó9Áû„ë€≥‡«5Õ· ”±√Îez‡≤È·À<<[=ägÄøë“uﬁ°o—Ö> ÓO9}º√∑≈'|TsôvæÃæ∆•¿∏ﬁ8Œ/˚/?(C¢p√•∂∂‚¸»»⁄Bü∞,3˜≈—yŒÍ|ÚG√dÉ˚.ÅVÓö:ºfÅ Ñ˙#”öız
‹‚ΩÃYƒ¥gô7Ûi/´4
,Ë(ø)˜i≠?R›ã”2üuTrŸPÿT§Íæ≈≤ıÏQGA∂’BÎu≤å˙
Ç7º’ß«ïƒÒªIú»Æ4¡|b^æúÁÀú}G/∞0ÍÄ€‡w,ë‹Ü˙¨$õ	¿¿è˙ì8QkÓ1€HÆÑbE§Ç“°H‚œ'ßR¨î*º>=x‚[’·w_´π•Ø'›;x∏¸Ã+√æ?äá«ˆ˝È#Ò‡ïøàÆ„W?Åß)Lﬂß|O·ˇŒΩCq=`(.%6,’•˙SñQ‡Jπô·äD‰ÛHË£Hÿ$"0È¢Ô1n–É¥>ñ,¥=∫íÚ§aîUVõÙÁp;≠<O»*uï∫K=µÓZOç˜%ü´Ã*Ûﬂù◊jµ˙[Ék¨5˛5¡'‘Mû'|õõÉœx~·{ŒzŒø+∞O?‰zœÙù|©ˇ#çgÃ¸6êâ]7näy~W,j3ÊOäûÿ~6A¥rvÑá¡0‹&Ï ØB8‡˜œ∞Ù *Üä>√•#≈—˝ñÂvªTb¿bfLTƒN∆Dl@Ã9n@©¿ÄhNπÊX)K<`ù¥Ñ5¿oÔ3xª3™SóîV™¿]Ènt+›∑pcƒ;d#ÊÙF∫†Ùﬁÿ#Hò†x1d^õ√mè\åÑÃã≤ƒBíÊ”À¢˝lár{Q`8	‘πÆNÉF{°I!h“ sgŒ3WÊ<ü¨GÅÃ}≥ìz—Ï§Ô√Ò`“W$]J¥R,ƒ>Aá¸•øÃ¶ÔµÁ	n1Œñ¿g÷›ùÔ+±ª“Î?¯<Q4-qÆ7ΩÓ∂Èï]-’È’áÕ≤È—v#n+{È±m]õD˚ïﬂ˜‹ﬁ⁄D/X‚õ!Ëïó˜§<÷Ä¯É&,>À ØÜ}|úr¢¿oEDÇ⁄©{P(eŒ
3…ì˙|>OÃ”Ê;Õ%ºY4kãùÕu|•X©≠u>…’ûtÓÊœhªúﬂÚK"÷Jxπñp&µ_kg∏√ƒk◊o´LÃP™Ií∏Ÿ©M◊gp◊&8|û*ñ€8¢æ‹√<^8•ßNxu1¿ç^8:ª:(~¬s†3è:Eû^Œº)Ô2ÔVÔøºv/ÕõN]ﬁGô˛Á=å7≤ña
Q3Ê£Ö]Üâó`πuÊEså
√	Û]Ó%xuÊ¬ˇ˘Û\az?L‡•ïÀß∑yºúóhÇèKO#Y¢ˆA?IëD)ÚGZyõº{-Û≈1ÉÑê#Á˚£IßñΩÖﬁc˘IRÎyI "y…Ò0•µ™Ü´≈Ö5ÖAÓ®≠*ñâÉùã“ç ™±˜;ûXÀ/º®hÍãèè-}“˘
ÆS≥∆Ç,Ã‚<ñ∫!Osy¬∫~*ƒ<1ç˚EBâYñœg≥)j$®#ZéF#©x(é≈‚Ÿ¥	aI‹§x#ûçbÇƒ›îP†˛e™‹Ö–˛µ¯…x&Æƒ#”^–è‡})≥,ˇ†/¶ò›f√Éı¢ @fX∆<(|%„ÖR7bßP¢ÊrMt©≤+•k%|]◊B˘Â2ÉÜÏÂ‡zá‚p€Ûr6wêÌ≤√DﬁvÌÅ´ÉΩ^îo≤L%º^Cuxfî!bàrDJ€∂UQ*WS][5+ﬂQR\§Éî‘Òö™†Ç‹°ˇ¿ÅùøZŸ´ôŸ6˜„èyKooØÚ Ó’˚ÂÔsﬁÛ≥;w_˝©Ì¬'ü\	⁄J"
)˜Œ¨‹y<u=I]—µP(ü˘§Â	%'s∫Ñp^#—ß¬·êÃŸH‰!/â(4!ÚêyàD>Sä<t2î	)°Htí»/˛ORè¸©„;E$túÇÇúcÃDÙ˝øàΩ˚"oû*p˚â—yàÑÿ1∂ÀV¨å2C"»gÂÂ¨∏àÅgm~ë™‰@k™KJƒ⁄é°MÈt_:Ωi®£ÌÌß˜Ó˝Ûä∑ï—çC—∆EÁgÔ]zdÈﬁ”ß˜Ç¿O^„=Ö≥h¯ØÔr ˇ:ÈÛÉl›.~i™{÷>`‘}£E5Ÿ”}ÆÙz¢øµmxa¥glµ…47™NåßÄ„÷Ùvá…F{F7õS¯2Ê©QsM"9Å#‚[jÎdA`æ#Œ∑∑∞E|[,ﬁd]%ŒR∂∑ÿFå}ı€@O–\åø¯+P¥ ë\[∞h¢:∆æKs¡cÒë¥ì-÷¶±{KfÎÌ±üb˚QÓ∂ùcá‘$[è˙AÃ;icl6ç¡ú=Íõl⁄_EˇJ¥Ì]Ñ˙Î(/¡º \ŸÈxûÖâ*⁄À¡gwÓº• ˚¨÷÷ô˘Œ“
û˜ œbçÖ†ÛÄzåÒÉﬁÏ‡ßÿN~*”ç~P∂ÎÔ†v`néﬁ>œ†ÊMG}; ÏC5ÄB†Lº≈‡ôŸ{†8ˇè≥ÁN±áËÃg¬˛s{˙>≤{¨ü¨˘†X$3#†ŒI{õäÌS0_©b[A€Å(pü¯à≠∑›À8‰ıí}Ñ)Ë…È‡€*∂ ué}6Ÿ{ŸÀT$:3c∂WŸÂª	}õ’=8«*» ,.≥
ÒªAù¡∂@øÊÇˇ6`?xûó˙∞ä5c˝A´l#Ráûû√Zˇó…ım∏◊a≠´dòﬂ‹Ö{Ÿ
¨£˝`˝
í9›;oI'1vcñ–û/Å≥ìN“ö^3rzÿ}ç≤nåyr=jÇ¥áqH=À}øü0†q‡F`Ë⁄ÅõÅz†k3¨´H}ÖŒênJ˝ÄnÿOAÜÿõ‘ŸÏˆÀ˚Ã⁄ÃÎ9^¥N°˙kœ°êxíΩêŒb/G«yìMëŒåS©ﬂÌRÔø¶síNMPÿûÌªãˆ m∫5N…Ó∞g≤á=‚~∂ÙeËÒv“Y⁄ﬂ8%πêÆIô¿&r¥n“Y+•çÄ*åÁt}˚8ó≈}àœeÍ
¯îˇ·æ\É´™Æ ºÓ9˚‹{yô IBy®ëá
b®TJRƒà¡¢àIl§‚#•≠®v,ƒÚ 8æ†¯BphÇ#VPdúäE+Nùµ“ŒÏ§OË`$ßﬂ⁄˜úpŸ!ƒ ˝”;ÛÕ:{›Ωœ^gÔµ◊Z[&òªeÇˇ∞‹d˛%„˝!2,ééÔ°Ô&oø\ùﬁ.#ÿÀ+i?Ó»ïJ™1qK∞ùÔl`=Âi÷ÙN”ËùeA–Ó$±#hÊÿÁV“%±=ÛüJ%˚øéÍOoW–@Ãl?√êÔyDœDjb8à%˙_A-úõ>/±2]ìÿö*ó‹§»A∏›î»∑É˘ñŸŒ˛‰Á9ËÀÉø»Î˛2rYc¯I¢VjΩFYò óΩƒ4ÊÚv…<Eﬂèº#ÀèéÛ9◊ób˚´+5ÊG>’ô‰¸Ìå¯,‚0¬è&‚ìΩ57h|∂˘Å3˛~—‚ü;‰9‰±:~Z„¯gW◊/]isÒ=>ßÿ±8˛~çè„4Fjú”8˜we÷¯%^=~¨q¯}©äŒıYeÿ∏':˚ƒaˆª2ì•·˙‰ÊpÉﬂ#‹ê,‚˘c¬ı|˜ÏñúzmÿÂ”!q.ÕË•KúGÉ2#ägkmº9 èŸ<ZaÌÎî|AÊMÏ;1–⁄ª::É¨'v◊òXÛ'd)ﬂ—€Ø„<¢á©∫&v/Dzi^–úË/gù5-ìy˛ß‘:vÑt∑˘¢X*±}á’ëSU™.®îgì˚•»îk∑KµÓï~á⁄£{üæG∫•Ûâçr°˘%}Ú•3˝V€5(ëı÷/tlkë∫YR¯Ï$˙Ë˚÷ÿ1%“#Zèµv-Ïxjıa]ﬁôÃó´m=±_û	 •í3¥&U+k∏
ÁbÔxéqÂj„
læ^.◊qæõsƒ˙Uÿ‰7=≥âÎ‡◊≤F“+®ekÏ∑è7ô[ßÁ«ØóÅÍ#…Âƒa≠'ñÀsû\ö¨ëeËñƒIÊ} ›|ŒÔpŒÓb∆˜è‚∂0˜bÙ:∂Xk≠Ùº§J§g≤÷÷bm–:Ö˘˝}≤∆/ìE¯Òw”ÀYá2ó÷¢±_¶4µÂ©∂ÁD,Õ`uπô8”œïü©ﬁ!2CëPsË´Ê~˘â©ê"ˇBŒnwj~œY="O˙92Õº+Oö≠≤T€¶ßˆ7Ò˝õ©-UˇÅ\•zÔC⁄+• åa¸"πÕLìª¸ÒΩ?Hg3ùΩf\ ~R»¯º7"±W™¸
Œ÷BûèÑµüùcsX©ò	2‘éÀ¬⁄„ÿÏM‰´ ÿSÏ’Á„Ï≈÷;cO`ü˝N}/„¥èyR∆∞Nª·úålûÏ-ìXÌ˝Q.Òø'˜&6Ñ€X◊Rá	Ÿm32q3#Â∏üÁÛëøÜ2mj∑ëÚ),‡›o _“{Å‚çìQ*—≠Çï^¸_6:œâÙŸ}¬m«µ∑êk q0‹¶∏˝YÁQÃ7 |'‹¶‡ãeJrÆ‰•fIû?}?∆9Ì†Áiã˙˛ß=õNø·YÎXí˝çÒ~ øÒÿù%®år√)€v™∞øs·v}ˇ!˘í3ª¬›»äƒ.…ıÔ¡ÅˆP⁄=„ıå˜	˝£VÔÏæ"∫ÊÆﬁmª˚⁄^€{I¶e˚Aã?<"cSLp€È2VIæ≈oµnõıÌP%Á˙O®M¯‡†÷Ì‰ï2HÒ
±µ@«pÊ†•˝1¥ØﬂM.SÙÏ*ﬁfÓk–ÚˇHπT…Z◊Q∫Æ˛ôˇ„˝â˜≈›Ï+1;Âr‰@‰h‰dY,≥œ¨{n]]KN‘«9√€zÁˇúùw·x˚=WBU»Ö‰nÍêbÍ»FÍìÎdû»Qb…ó¿:‚–5»è–ëΩõá@7ûª£˚Úië¶C<œDﬂò!ÙLY’ïΩ—ΩçMGÔõíﬂÙ[ë/¬ôÒMıpœˇÚy”üêo W“ˇs∆ÕG˛&Ûˇ—i¥g¡k¥˜”æÆÂ˘!d>Ú|Ë	=øB—z§’=Ù¥Àﬂ?æ™§fπ;˚#∑!ÔsÔ_Y∆˚ŸétÔÒ˛∑'ÉË.—Zf÷Å;”ÍæMŸwüì›qb…~6gc √£‘î]µé÷ZVÎg[?F“ﬁﬂlÀº"y±ƒûNZøjÌ¨ı+Rﬂ_ó¨=ÂÿuÉµ+ Ÿ±5qPVA.Ùâd}éxÉ¬ùƒû¸˚w£µ
Ì3†"C¯π+á\˜:q˜Ú}⁄}ëá‚ú«÷V1∂ùúv∫€ÕëßêSã"¶9¥•èπ(‚r≈Õ≈•Ω‹} πºçùùßøn;ŒÛ1ù∆Jëí*	∑)n]⁄™hß›^ù€—∂[wt∏Ì‘%q€•’ˇÆÔ≈ıLÅ¥‡úªé¢w≥ÂXÌ€‡û„ñÛµY£K≥!érË≥ƒÍˇ∞/ê£¬G–ÕI)EÈÁ•àˆ o6ˇY≠ˇ!üI,ÒáGiˇúvÆyﬂˆΩ6¢∫=v˝VÎs[≤f6>§ˆÀp1ÙÄaFº◊zádÓO<≤ÆﬁsMUx»ÏßlWéî;·y⁄9¥sà≈y…ÓƒÌYœÛBdgdg‚˚dòN,ø*x'<ö¸©ÌS∆•Ênô@úøÕ4ÚŒΩ·õƒÙ¶YrR]•é‹9è⁄üˇW0vÌ|dØ‘ YÀ{∂2˛Õ…‰¡JÚa'ÕÃ[!´†ÜæWöÚòﬂE∆ÛûB≥WÚ"9<hí5_%á1Üúánr∞ï{ÂB3U∆C1Ô£π∆o¿G˛ XÚèó'Ø˘ì‰5≥QfÚæMùÎeUßwdU∫ZJ”seE≤^V¯O…<tO•îßíÁIùæ#Œ´ö„gä©D™ØÕ˘3hDr\¸ÕnM`Ìõ*WêóüÕû7ó.%ó‡˚ô[mmØ∂!«/Åjæ√ ªÛÈyı·Ô2R~Â¯Y-9øB¶bg±Æ©]€©2Ÿü√ΩOs∫ŒøπKÆ7!Zc◊ñx.÷Âh[µP\õ\	tü-"=’Ø¨/e(ˆŸ˝∫\˜,Ë∆Œ—˝_’ı±Ã¶ø'ΩÕ?R;¸´7,VºUú—€8+¯†yîö©^ÊG–7\g«›j«çONÅbÏöŒ<ı·g«ê«?3Â≤ƒ¬zÈ˛yy·´»ôﬁ{Ã5ZrÏ˙›ÖMKŸÁ®áD
XG˝Ó^f0zıœkÄ˝á{i⁄oè§]´∆ÂpØ”o§¶Úáâ_⁄øXÎ+÷-ÍõzEJS%¯k)^íBˇvÍóÌƒ∫o≤weÏkéÃÛ˜H?së‹Ïwój%QÓLÏGR©+ﬁÁË?A>LªN™ºè‰z÷´nÖ%|wìÂ]j‡º‹ÒC≈´Oú…ˇÜÔGœ}3œËFÀÀñ¯ı≤.˙Ö{†…{åπ«Iµ∑ï9VcÛ¯πú?∆‹18öÁ2S…;ûK\´ÚÙ*œqâÙ.ËUésA?Óv¥’Ø-;⁄“tA?4ÿ—÷{œvAˆIÏõËÇ~bÏhkù]–ûƒéI.Ë'πvü∏«6øÕ›t#Ú„(ﬂÔC^Åƒ˚öﬂ‰ô˚E8=jı˚¨Ñ«· åã ÊÖ”ËSá¸¨É…ˇeøÏcª™Œ8˛˝›WZhJ][°4BÄ—ÒV&ëÇ:Ö⁄p¬*miUäÉ 6$‚
Ñö	lÑ°ò∞¶#ì·,&›fD`∫≈få Y"d¡ # KÔæœ9Á˛˙kKi6›≤e∑ÕÁ˜úsÔyªÁÂyæßÖÊ£¥Ω°˛¬~Ççd0)”}I›ÊC∫oÖÈ≥˘M]ˇ∆Îfº	˘Ê€…›üÍ[|om?≤≈î_c˙›Ø«ﬁº±•ººóoTıˆ∑ÿdﬂ˜•-i°˘Wö‡]⁄7»	Ú>9b“Ÿf>‰õﬂí∂Z¸Æ:[P/˛PbµøP1˚ILS>˜ÉV±Ji∆ô] ﬂÙ}˘»ÛR®C∂¢@tÉ¯p∑Rï_ÁV06Å˙ÑZAÈÖSpù˜êÈû∆|ßìÏÉ‘≈ìÈoŸáÛ<(mãﬂÕaØ≈tR,1å~Sb·∑ËsW'P˙Â6ñÈÂúÂxäFﬁŸ÷∏≥—U¸π?î˘ó¯-€Ò˜I,Ô≤çﬁgk™Ø˙zÛq∑˚,¶Ñw[oí‹n‘∆vçaARo>ﬂ√∏{ìíVS◊}àbŒŸò∞Ô¯<¯Ë≈Á≤fTzÕúπfÆ˝ı\2Mçô„•sú\Í1j&Ø‚úT®Ò|[‚ß≥é˝4‡^`ÏûäA~µ◊0¨I ¿6Ô
ø√c_π¢Î‚s?‹ﬁÉ˛BåpWcÄ[ 5 •n˛ÑÛ¸ íCKﬂﬁË/ÄÔŒÆQªmw™ï^ÏÈÏEÜ“å]q∂±õ›ßQœ=1¥≠Æ	uT\S∏jçK√>‚ﬂC+Ò3˛˝∆&Ë5Ô|^‰§#◊MÁﬁ°ÓhgÕò¸tÏbŸu°ûıQ‰€¥?Gï˜J‹Èúó4î¯Ô¢ß?¢œ|_È∫E£›/®EK0Ä{¢9Ôﬂ'rñ&õ3^«Á&˚ÙyîÛ%œ’Ÿ‰≥[ÃÛG»
R£ﬂÀª`•Nﬂ∏†€WÔVËÚ7xÉzNõ%z‘±F›Cru™“£Z[∑∂q]ØˆOaß∂ç˛Ï» ÊIãÎ·PO∂∑i´√<uﬁ«<£X7áx°énkYv5 S⁄*m(vß±Ø…^≠◊÷∆uu∂#˝ö†cı9≠÷’œ∑±ÛåÍÎŒl\∑≤A`Ú©qΩﬁô-Cí“ù∆˙/“RÉÜ÷<Ôû`Ωv˜ßD´÷∂—±¢ﬂãD_;€®EoÅÏ;¡{ñ{†5eÇΩﬂèëDkç—˘‚˝àıHóæm	.	Û3ö‡e√y√œ;Œ˙∂órwª	ﬁVˆK∫—¯G5JˇﬂŒ|û‡.=ïı$ﬁ™¡ø`XB8Ô·<ÜÛ¬o;√ÔÆéè9Ïﬂ¥˚e◊ÒÀÆÀWı›∑{"<ìßIh=·¶„Ê˙(.iƒ?±lö¡„º"{…1√FÅg%ãÁˆÔv%˜I¨”nº»ª©`Úrè Œœ–ÁÄw§sÃπŸ¸¯ïzˇ˘ı<π◊Pn¥◊i~Gä¯w¡¯æ˛I≈ÿÆ|A˙äoa‹ïs>‹˘-™Zkæ†Ñ˚&SŒ„§ÀÚ=‹:Zø^só”'|qWRˆµ p‘∞Mkø‡¥c’<ﬂç∑iw'¬ªm∂ eÿﬂR≤”Ëm—±K4ÕgıÛñqÖæ◊˛úﬂqô¢ú˚ê©ÙKVìL˚<ﬂS/÷ÿÂò 1√MmE˝!zAù Õ9I´I·º€ªŒw.V9•ú'"öH≠”a∆ )X’œ2~qêÙe?J?˛ÙµŒ≥ﬂ±ﬁi√=ÄÂ¢ãlﬁ(‹‹3YvfG{3Ì√Á§ñ„-Cçµ
CÏ*‰YRÔ§Û˘˜»b¶3hªì9‰≤#‘Ûk‹'WYûÿÛ†uQAÚ¨/ıy+@Öu‘ƒlOókRu4*bøS}UÿlèÂ,ﬁîl*
;›§=æûı©@ÿ^ÏºnKΩÀ$µîqˇÜ¬‰*zidm–‡Nbü"ﬂôã\”2äk}‹‹DG}@8[¡´Ã≥ﬁƒ|¡˛Eä-AÉ=êÎæéwÜ∏7®NpúBæ{/ª„1»+f€ŸK˜π€U9KÉÎ‹w%VSp<∂ãcI¿õçÙ§˜0ôkûÑ÷⁄Khc•*Å{1Qo{µ"„Ω√6gMÈ\û„9.$⁄i≠’ãuìÂÏ1=C≈ÿùË£uú‹°ö9[Åúá˙Üd÷ôiŒLÓßÌ≤∑åd’`üı'π◊c¨¨†¡*F∂©˚†æóOëì"∂˚
Ô1cÖÿÂ`ìêêoæÍºÛF;£»8¶«µœs=Û≠÷÷€Ä{g<À	s1ÿﬁ"uıZwñ˜f`†`ıgY7…Ø‰ΩnÔÜR7ªÛºu ˝µﬂ∂œÛõÓ‚ﬂ›Y>Ö{ãÑ˚-æß;˙˛•Åh‰B∆ïFoO–ƒ¸[d=˝Î¡A›€FØ≠µªÚl◊Ò:˝µßo\äl˙Ølßû{è∫_∑á4˙¶ÒçÙÛ◊%Fò¯∑öÌ^]jg–ˇã/£V4ÌÀ=iä‘ùOø7U|ü{J≈◊äOU1ÉZTÓiÙ7‚[¨£i]◊>(÷§Ä¯"ª}G«X†¨J[ÉçO)@í5íﬂ≤Qcwé*üî™}ñ∂˜kÒgåø⁄_ı±≥¥ˇ≤>“>»:…2!ó…9‰Ò,º£ëò”º[≈¶´⁄O*_H?-iπªò˚Sw9ÉÙ:”KF[ÓmcÖ∂3]hÍÏ5u⁄óüãÁ8˜…6Æùƒ‰˜Òuw6∫∆Ô]¿Hô˜å∫ØL·{— -:_bûƒIµN\£Rj¢ÛàµΩ8M(ëµuÔCOâ]úß√‰£;_£‚¥Ã„YÍ≤d∆›i™˙8∂üŒ}zŸåSÓ'ô‹ßÎ‚wø.ﬁ5Ä{úW±√^H-4SLº'·~ªCê}¶=.ˇÏ·Æ*N‡g&ï–7ZÙËÀË¡gQI≠ í Ä‰É@∑«Å‘BrËÒ?ãÂz›ﬁ1Èøæ6»ÿ†…d;Y›4wPÈﬂqË}R”ß»aô;ÛÅ~Ïßˇ2ÕÄøRí’kÔæ—øÖ!«Äa…3‚óücUåπ¯Ê)`Ï]@>Îé„˜ﬁÀπœµ+‡çj"˚ø30y0ïëΩË`⁄r`˙”¿ÃA¿¨i@…9†å°oÓÕwÿˇº_F¸7]ÓÈÚMˇG\¸˜Ú‡ààààààààààààààààààààààààààààààààààààààààˇq∆FDDDD¸áà)£p˘ÿ
n√0îNµ”.Û@*ﬁ‡Ø˘{D˝J⁄Gs1ËøQ±˛&m#56«§¶ö¥«Ù&Ì„°ÿs,sí§Õÿ)ìé°∑Ud“R≠*ì∂˘ºŒ§¶_2ièÈ}&ÕÒXG∞9»√p˛èfÍT£ív:£ñ‘·áx\=ô»‹¶Â∑úœkTâ°|3èÒ?≥¯l!Î◊a© U“V≤Ù2˛V∞‰¶kXW ÷®2Â§NµW¡2ãhó‡Q>[å™a,“j≠jQ◊+eÆÜ9È=%Lï´úÓπñOá©rT€’j¨9X¿‹ˇ†æ|cõ8Ô8˛<œ•∂v<pB„¯.q|îƒ‘–çœéΩ–∫(!Iôùe$!ÒJ ãQÏÄ6ipHC*ÍJ™Nbì‘S∑™‚rû2'A
S∂NÕ∫Å∂éIÙ_⁄Ì≈˙¢KÈãuºÚæœùÅ¢—j⁄ãIªÀÁ˜˚=œÔ˚‹Û‹Û<wæ õ7GÀ’-?ïB€∂=&ıŒH˚≤„Ÿ¸7èe§ˆÏƒ±ÏƒP~4;ﬁ"E«∆§Ó—gÁsRw&óô8ûiâE„Òß¢Jtbthl_ÔïL'çÊ§!)?14í˘∆–ƒQ)˚ıœÌOóÚ»==>öœåH=˘°|ç«GÇŸ	)ãÃÑ4úùœOåfr-ˇ√ıçA«˘ºÚô’ﬁá^π˙ÃÎòπ∆_§¸osˇ∑ªkéÙ
‰ZÒ⁄ea3YLÿl(ı‚ú∞I®7ZEµ(¯Ó!gt´ ·âöVÇÕÇK`Tê¡ázÏ)†ÅK`\6ºh|fVY0VxF®ºÜ$∫¢õÑçhªoßPCVA	DÑÇN0 ¶¿4∞ô:^ìß¿"¯ÿÃ®BçÒ‚våΩ∆xŒtÖ#c!≥8d˚øf_I[~ﬂ~À«ü∞dª-Ÿ#;¨ÍñòÂ7m±º;“∏_S∫ı‹§?KŸØàìR"íã¬¢&ÿ 5™‡.4…°ÈE°ÇPÅ	%ñÆ‘®™E◊∞[%n"≤ø≥è¨˚®∞Æ:4}í}@.ÅE ∞pæœﬁ'ßÿ
üsÿòã‡*X6∂ÇÛ=úÔ≤wâìΩCÇ ¿4X´¿ŒﬁÅu±∑˘˚ﬁ¥<é ∆ﬁÜu±∑p[o¡:ŸD7ÿÌèFxWhŒî`9Â†¶Æ∏=°"˚Éqk3vîåï∆éZIŸ.4ÅGƒ¢PkÏãÏ/I/F∑±7âKÎËÉ‡∞!∫éË:—¿‡"–v¨HlºÆìm@]¿¡ÆË¶»ÆrLåzÿÔŸoHf¸w¯1‚˛ˆöÈÀ~m˙◊·}ÀÏ5√'íËZ‰	⁄∏‡]A‰`ø,4π≈R¥ö-bÓDÿ àÄN0 ¶Äç-≤FcDt„"dŸA†4»á¶ˇ	y…A‘#¢*∑cJ‹»ªG3-MÀLïœˇEn‰s/"‚F˛Œwq#Î4"n‰±„à∏ëGé ‚FÓ@ƒç‹Ÿã¶»~¸ã¶Mb∏Û(ï¢Nv≥t≥t≥tÇT∞¸$∑*¯ÿ~d47c∆.® ÊfQõß⁄e™uSÌ%™e®víjß©∂áj©¶PÕK5’T™-–ùò
ç™?øß∏K≠•⁄2’^•Zéj2’Tk¢öD√jë5Ol7]¬tÖ(Ë‡o√€«…0£ÿÛx',¬^%≥§B$5Z‚ç>ÓÕ´‹≤;îçÓeKh∏ÑeX"ÔÅ
,–∂—.≤Ñ8a#` \´†lP7b‡S¶u¬AÄS`ÿÃ·¨F≤Â!^2,∫ìóÿŒFú¨A≠wy]äkØ0Â•NÌÙï|,L<|^π´’EZ5˚i’??≠"ï—JvéMëz,ƒe?e‹™ãÙÜº F7–Ô_v›EdÄﬂIrf˘Q‚upø_]Ø¿áÔ4sÚqûÆ„≠f≈[ﬁøäzã·ﬂº‚ü•b5ƒ?°ÊïYÒMÔYÒı`—ÅöÀrë¬ÕK¶tŒªS|uŸîûF‚Ç!û‰nV¸∂∑C<Í5+q0áíÍªÂ>q/Æ˜’Æ9+Fº≈=ñÍQﬁfV‹Ü!(Vÿå¡nˆöù˙}ÊüÈauã˝º=eÔ¥?fŸ∑ÿÏ¢Ωﬁ^g_Ôp;\éuékáÕQ·`‚X_,≠®
¡“≠∑π∏≥Up[a∆.∆-ˇ`Ê/=Í`‰I¢IH≤dOå&ı+√$yH“ˇ—„/“5˚˚Ù¸1™ªì$Ÿ”w*…¢Ω‘≠áï§nÔ˙jjÜ“si‘ÍÏŸ"%Ω©"-Ò™3u∫ª=5G(≠>Û|˜üy>ù&µû„ë⁄àª≠z◊ó„˜1Ée´‹=jÔâÎıÛ…ûî˛≥˙¥‚A©>ù‘ø◊#ıßÊË'Ù„D|éﬁ‰.ùö⁄Ë'ân^/¥≈”Èdë0uD¢7°√éπiÍ¯aÊ:"9|ñÓÇ•†=tM‹AWYI¶.PYiÍ*(◊Õ‰öÒô¶&SS#ëú©…’Hü’,†	LçG#À¶fŸ£qçﬁfJº^H|^SB"^S‚•ôíw%¡≤‰Ï…Y≥'Åﬁ’x-M’ mM’
4 zdbäB≠È·˛D∆üÙ'2`PÓ¯·Z];$I3√iûêtA<4|ò˚°åûˆg‚˙∞?.Õ¥ˆﬂ'›œ”≠˛¯ÈOÙ¶f˙’L‹hU[˛°x∫–—µ#|O_gÔÙµ£Î>Î‚€¡˚Íﬂ'ÊÈﬁWò˜Ê}u®f_ƒ‹„]©â•€˚-_`k◊`ø÷5§c◊±6sÛ∂6‘û¨õ«◊ Àd≠í÷Ù«Ù*¿S[£[£<Ögäß÷°⁄YN’ûlm®õß/óS.TW˚cD…OÊ&Imb4n˝Âp†*?…'‹≤JÓÛ‰∫:œÂ	IÍÕ=I=≤ø/5c∑£vêﬂíæ˚v›⁄µâbÈäUŸÇ ›ºRÓy›^WYY˛˚˙Oñ};
4∂P†™è‚üè¥†˚íΩØÇﬁ>‹k_jﬂR¸Á!ó∆Ê®Bs∑ØQ∂¢´L¯=ﬂ&?Yé së/{´%ö‰nO…ùÉOñrg∆ÚäÚ/ îeÊTendstreamendobj19 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj30 0 obj<</Length 13874>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 36.5 670.859 cm
0 0 m
539 0 l
S
Q
q 1 0 0 1 36.5 534.5167 cm
0 0 m
539 0 l
S
Q
q 1 0 0 1 36.5 288.7683 cm
0 0 m
539 0 l
S
Q
q 1 0 0 1 36.5 170.9023 cm
0 0 m
539 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc 0.055 Tw 10 0 0 10 261.8157 715.0277 Tm
[(Pati)0.5 (en)0.5 (t I)0.5 (n)0.5 (formati)0.5 (o)0.5 (n)]TJ
0.018 Tw 9.5 0 0 10 249.2253 700.4715 Tm
[(REBL)0.5 (OZ)0.5 (YL)]TJ
0 Tc 0 Tw 5.95 0 0 5.95 299.0243 704.052 Tm
(\256)Tj
-0.018 Tc 0.055 Tw 9.5 0 0 10 303.2993 700.4715 Tm
[( \(REB-l)0.5 (o)0.5 (w)0.5 (-zi)0.5 (l)0.5 (\))]TJ
0 Tc 0 Tw 6.261 0 Td
( )Tj
-0.018 Tc 0.018 Tw -10.451 -1.006 Td
[(\(l)0.5 (u)0.5 (sp)0.5 (atercep)0.5 (t-aamt\))]TJ
0 Tc 0 Tw 8.95 0 Td
( )Tj
-0.018 Tc 0.055 Tw -12.609 -1.006 Td
[(fo)0.5 (r i)0.5 (n)0.5 (j)0.5 (ecti)0.5 (o)0.5 (n,)0.5 ( fo)0.5 (r su)0.5 (b)0.5 (cu)0.5 (tan)0.5 (eo)0.5 (u)0.5 (s u)0.5 (se)]TJ
10 0 0 10 45.5001 656.3028 Tm
[(W)0.5 (h)0.5 (at i)0.5 (s REBLO)0.5 (Z)0.5 (YL)0.5 (?)]TJ
/TT1 1 Tf
0 -1.452 Td
[(REBLO)0.5 (Z)0.5 (YL)37.3 ( is a prescript)0.5 (ion medicine used t)0.5 (o t)0.5 (reat)0.5 ( anemia \(low red blood cells\) in adult)0.5 (s wit)0.5 (h:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.344 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(bet)0.5 (a t)0.5 (halassemia who need regular red blood cell \(RBC\) t)0.5 (ransf)0.5 (usions.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.007 Tc 0.112 Tw 1.8 0 Td
[(myelodysplastic syndromes who may need regular RBC transfusions and have\ never received an erythropoiesis)-7 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(st)0.5 (imulat)0.5 (ing agent)0.5 ( \(ESA\).)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.01 Tc 0.097 Tw 1.8 0 Td
[(myelodysplastic syndromes with ring sideroblasts \(MDS-RS\) or myelodysp\lastic/myeloproliferative neoplasms with)-10.1 ( )]TJ
-0.015 Tc 0.069 Tw 0 -1.056 Td
[(r)0.5 (ing s)0.5 (ider)0.5 (oblas)0.5 (t)0.7 (s)0.5 ( and t)0.6 (hr)0.5 (om)0.6 (boc)0.5 (y)0.5 (t)0.7 (os)0.5 (is)0.5 ( \()0.5 (M)0.5 (DS)0.5 (/)0.7 (M)0.5 (P)0.5 (N-)0.5 (RS)0.5 (-)0.5 (T)0.6 (\))0.5 ( who need 2 or)0.5 ( m)0.5 (or)0.5 (e RB)0.5 (C unit)0.7 (s)0.5 ( ov)0.5 (er)0.5 ( 8 week)0.5 (s)0.5 ( and hav)0.5 (e not)-14.8 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(responded well t)0.5 (o an ESA.)]TJ
-1.8 -1.38 Td
[(REBLO)0.5 (Z)0.5 (YL)37.3 ( is not)0.5 ( f)0.5 (or use as a subst)0.5 (it)0.5 (ute for RBC t)0.5 (ransf)0.6 (usions in people who need immediat)0.5 (e t)0.5 (reat)0.5 (ment)0.5 ( f)0.5 (or anemia.)]TJ
0 -1.344 Td
[(I)0.5 (t)0.5 ( is not)0.5 ( known if)0.5 ( REBLO)0.6 (ZYL)37.3 ( is saf)0.5 (e and ef)18.6 (f)0.5 (ect)0.5 (ive in children.)]TJ
/TT0 1 Tf
0 -2.406 Td
[(Befo)0.5 (re recei)0.5 (vi)0.5 (n)0.5 (g)0.5 ( REBL)0.5 (OZ)0.5 (YL)0.5 (,)0.5 ( tel)0.5 (l)0.5 ( yo)0.5 (u)0.5 (r h)0.5 (eal)0.5 (th)0.5 (care p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er ab)0.5 (o)0.5 (u)0.5 (t al)0.5 (l)0.5 ( o)0.5 (f yo)0.5 (u)0.5 (r med)0.5 (i)0.5 (cal)0.5 ( co)0.5 (n)0.5 (di)0.5 (ti)0.5 (o)0.5 (ns,)0.5 ( i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 ( i)0.5 (f yo)0.5 (u)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.344 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(have or have had blood clot)0.5 (s)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(t)0.5 (ake hormone replacement)0.5 ( t)0.5 (herapy or birt)0.5 (h cont)0.5 (rol pills \(oral cont)0.5 (racept)0.5 (ives\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(have had your spleen removed \(splenect)0.6 (omy\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(smoke)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(have or have had high blood pressure \(hypert)0.5 (ension\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(have a hist)0.5 (ory of)0.5 ( ext)0.5 (ramedullary hemat)0.5 (opoiet)0.5 (ic \(EMH\) masses)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
(have or have had enlarged spleen or liver)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.021 Tc 0.041 Tw 1.8 0 Td
[(are pregnant or plan to become pregnant)0.5 (. REBLOZ)0.5 (YL)37.2 ( may harm your unborn baby)74.5 (.)0.5 ( )17.8 (T)111.3 (ell your healt)0.5 (hcare provider right)-20.9 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(away if)0.5 ( you become pregnant)0.5 ( or t)0.5 (hink you may be pregnant)0.5 ( during t)0.5 (reat)0.5 (ment)0.5 ( wit)0.5 (h REBLO)0.5 (Z)0.5 (YL.)]TJ
/TT0 1 Tf
0 -1.308 Td
[(F)0.5 (emal)0.5 (es w)0.5 (h)0.5 (o)0.5 ( are ab)0.5 (l)0.5 (e to)0.5 ( b)0.5 (eco)0.5 (me p)0.5 (reg)0.5 (n)0.5 (an)0.5 (t:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.308 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(Y)92.1 (our healt)0.5 (hcare provider should do a pregnancy t)0.5 (est)0.5 ( bef)0.5 (ore you st)0.5 (art)0.5 ( t)0.5 (reat)0.5 (ment)0.5 ( wit)0.5 (h REBLO)0.5 (Z)0.5 (YL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.057 Tw 1.8 0 Td
[(Y)92.1 (ou should use ef)18.5 (f)0.5 (ect)0.5 (ive birt)0.5 (h cont)0.6 (rol \(cont)0.5 (racept)0.5 (ion\) during t)0.5 (reat)0.5 (ment)0.5 ( wit)0.5 (h REBLO)0.5 (Z)0.5 (YL)37.3 ( and f)0.5 (or at)0.5 ( least)0.5 ( 3 mont)0.5 (hs)-18 ( )]TJ
0.055 Tw 0 -1.056 Td
[(af)0.5 (t)0.5 (er t)0.5 (he last)0.5 ( dose.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.014 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(are breast)0.5 (f)0.5 (eeding or plan t)0.5 (o breast)0.5 (f)0.5 (eed.)0.5 ( I)0.5 (t)0.5 ( is not)0.5 ( known if)0.5 ( REBLO)0.5 (Z)0.5 (YL)37.3 ( passes int)0.5 (o your breast)0.5 ( milk.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.048 Tw 1.8 0 Td
[(Do )0.8 (not)0.5 ( )0.7 (breast)0.5 (f)0.5 (eed )0.7 (during )0.7 (t)0.5 (reat)0.5 (ment)0.5 ( )0.7 (wit)0.5 (h )0.7 (REBLO)0.5 (Z)0.5 (YL)37.3 ( )0.7 (and )0.7 (f)0.5 (or )0.7 (3 )0.7 (mont)0.5 (hs )0.7 (af)0.5 (t)0.5 (er )0.7 (t)0.5 (he )0.7 (last)0.5 ( )0.7 (dose.)0.5 ( )18.7 (T)111.4 (alk )0.8 (t)0.5 (o )0.7 (your )0.8 (healt)0.5 (hcare)-18.1 ( )]TJ
0.055 Tw 0 -1.056 Td
[(provider about)0.5 ( t)0.5 (he best way t)0.5 (o f)0.5 (eed your baby during t)0.6 (his t)0.5 (ime.)]TJ
/TT0 1 Tf
-0.021 Tc 0.042 Tw -3.6 -1.272 Td
[(T)74.2 (ell your healthcare provider about all the medicines you take,)]TJ
/C2_0 1 Tf
0.021 Tw [<0BD8>-0.7 <0003>-41.7 <004C00510046004F00580047004C0051004A0003>-41.6 <005300550048005600460055004C00530057004C005200510003>-41.7 <0044005100470003>-41.7 <005200590048005500100057004B0048001000460052005800510057004800550003>-41.6 <005000480047004C0046004C005100480056000F>-20.9 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.056 Td
[<0059004C0057>0.5 <00440050004C00510056000F0003>-55 <0044005100470003>-55.1 <004B0048005500450044004F0003>-55 <0056005800530053004F00480050004800510057>0.5 <00560011>]TJ
/TT0 1 Tf
0.055 Tw 0 -2.406 Td
[(Ho)0.5 (w)0.5 ( w)0.5 (i)0.5 (l)0.5 (l)0.5 ( I)0.5 ( recei)0.5 (ve REBL)0.5 (O)0.5 (Z)0.5 (YL)0.5 (?)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.344 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.069 Tw 1.8 0 Td
[(Y)91.9 (our healthcare provider will prescribe REBLOZYL)37.1 ( in a dose that is right for you. Depending on how you respond to)-18.2 ( )]TJ
/C2_0 1 Tf
0.018 Tw 0 -1.056 Td
[<003500280025002F0032>0.5 <003D>0.5 <003C002F000F>0.5 <0003>-55.1 <005C0052005800550003>-55.1 <004B00480044004F0057>0.5 <004B00460044005500480003>-55.1 <0053005500520059004C0047004800550003>-55 <00500044005C0003>-55.1 <00440047004D005800560057>0.5 <0003>-55 <005C0052005800550003>-55.1 <00470052005600480003>-55.1 <005200550003>-55.1 <00560057>0.5 <005200530003>-55.1 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.015 Tc 0.015 Tw 1.8 0 Td
[<003500280025002F0032003D003C002F>37 <0003>-72 <004C00560003>-71.9 <004A004C0059004800510003>-71.9 <004400560003>-71.9 <004400510003>-72 <004C0051004D004800460057004C005200510003>-71.9 <005800510047004800550003>-72 <005C0052005800550003>-71.9 <0056004E004C00510003>-72 <000B005600580045004600580057004400510048005200580056000C0003>-71.9 <004C00510003>-71.9 <0057004B00480003>-71.9 <005800530053004800550003>-72 <004400550050000F0003>-71.9 <0057004B004C004A004B000F0003>-71.9 <005200550003>-71.9 <005600570052005000440046004B0003>-72 <000B0044004500470052005000480051000C>-15 <0003>]TJ
/TT1 1 Tf
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(by your healt)0.6 (hcare provider)55.5 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.01 Tc 0.098 Tw 1.8 0 Td
[(Y)91.7 (our healthcare provider will do regular blood tests to check your hemogl\obin to monitor if your anemia is getting)-10.1 ( )]TJ
/C2_0 1 Tf
-0.018 Tc 0.018 Tw 0 -1.056 Td
[<004500480057>0.5 <0057>0.5 <004800550003>-55.1 <004500480049>0.5 <0052005500480003>-55.1 <004800440046004B0003>-55.1 <004C0051004D004800460057>0.5 <004C005200510003>-55.1 <0044005100470003>-55.1 <004700580055004C0051004A0003>-55 <005C0052005800550003>-55.1 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0003>-55.1 <005A004C0057>0.5 <004B0003>-55.1 <003500280025002F0032>0.5 <003D>0.5 <003C002F0011>]TJ
-0.016 Tc 0.016 Tw -1.8 -1.272 Td
[<002C00490003>-69.5 <005C0052005800550003>-69.5 <00560046004B004800470058004F004800470003>-69.5 <003500280025002F0032003D003C002F>36.7 <0003>-69.5 <00470052005600480003>-69.5 <004C00560003>-69.5 <00470048004F0044005C004800470003>-69.5 <005200550003>-69.5 <0050004C0056005600480047000F0003>-69.5 <005C0052005800550003>-69.5 <004B00480044004F0057004B00460044005500480003>-69.5 <0053005500520059004C0047004800550003>-69.6 <005A004C004F004F0003>-69.5 <004A004C005900480003>-69.5 <005C0052005800550003>-69.5 <00470052005600480003>-69.5 <005200490003>-69.5 <003500280025002F0032003D003C002F>36.7 <0003>-69.5 <00440056>-16 <0003>]TJ
/TT1 1 Tf
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(soon as possible and cont)0.5 (inue your t)0.5 (reat)0.5 (ment)0.5 ( as prescribed wit)0.5 (h at)0.5 ( least 3 weeks bet)0.5 (ween doses.)]TJ
/TT0 1 Tf
0 -2.406 Td
[(W)0.5 (h)0.5 (at are th)0.5 (e po)0.5 (ssi)0.5 (b)0.5 (l)0.5 (e si)0.6 (de effects o)0.5 (f REBL)0.5 (O)0.5 (Z)0.5 (YL?)]TJ
0 -1.488 Td
[(REBL)0.5 (OZ)0.5 (YL)18.5 ( may cau)0.6 (se serio)0.5 (u)0.5 (s si)0.5 (d)0.5 (e effects,)0.5 ( i)0.5 (n)0.5 (cl)0.6 (ud)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.344 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.024 Tc 0.042 Tw 1.8 0 Td
[(B)-0.6 (lood clots)-0.6 (.)]TJ
/C2_0 1 Tf
0.024 Tw [<0BD8>-0.9 <0003>-41.9 <0025004F0052>-0.6 <00520047>-0.6 <0003>-41.9 <0046004F0052>-0.6 <005700560003>-41.9 <004C>-0.6 <00510003>-41.9 <0057004B>-0.6 <00480003>-41.9 <0044>-0.6 <005500570048>-0.6 <0055004C0048>-0.6 <0056000F0003>-41.9 <00590048>-0.6 <004C0051>-0.6 <0056000F0003>-41.9 <004500550044>-0.6 <004C0051>-0.6 <000F0003>-41.9 <0044>-0.6 <00510047>-0.6 <0003>-41.9 <004F0058>-0.6 <0051004A>-0.6 <00560003>-41.9 <004B0044>-0.6 <005900480003>-41.9 <004B>-0.6 <00440053>-0.6 <005300480051>-0.6 <00480047>-0.6 <0003>-41.9 <004C0051>-0.6 <0003>-41.9 <0053>-0.6 <004800520053>-0.6 <004F>-0.6 <00480003>-41.9 <005A>-0.6 <004C0057004B0003>-41.9 <0045>-0.6 <004800570044>-0.6 <0003>-41.9 <0057004B>-0.6 <0044004F>-0.6 <0044005600560048>-0.6 <0050004C0044>-0.6 <0003>-41.9 <00470058>-0.6 <0055004C0051>-0.6 <004A>-24.1 <0003>]TJ
/TT1 1 Tf
-0.014 Tc 0.079 Tw 0 -1.056 Td
[(treatment with REBLOZYL. )18.3 (The risk of blood clots may be higher in people who have had their splee\n removed or)-14 ( )]TJ
-0.009 Tc 0.101 Tw 0 -1.056 Td
[(who take hormone replacement therapy or birth control \(oral contracepti\ves\). Call your healthcare provider or get)-8.8 ( )]TJ
-0.018 Tc 0.055 Tw 0 -1.056 Td
[(medical help right)0.5 ( away if)0.5 ( you get)0.5 ( any of)0.5 ( these sympt)0.5 (oms:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(chest)0.5 ( pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
[(t)0.5 (rouble breat)0.5 (hing or short)0.5 (ness of)0.5 ( breat)0.5 (h)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00530044004C00510003>-55.1 <004C00510003>-55.1 <005C0052005800550003>-55.1 <004F0048004A000F>0.5 <0003>-55 <005A004C0057>0.5 <004B0003>-55.1 <005200550003>-55.1 <005A004C0057>0.5 <004B005200580057>0.5 <0003>-55.1 <0056005A0048004F004F004C0051004A>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.272 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.055 Tw 1.8 0 Td
(a cold or pale arm or leg)Tj
ET
4 M 
36 36 540 695.808 re
S
endstreamendobj29 0 obj<</Length 32775>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.011 Tc 0.04 Tw 8 0 0 8 36 727.2481 Tm
[(A)0.5 (ll p)0.5 (a)-9.6 (t)0.5 (ie)0.5 (nt)0.5 (s r)0.5 (ec)0.5 (ei)0.5 (ve)0.5 (d b)0.5 (es)0.5 (t s)0.5 (upp)0.5 (or)0.5 (t)0.5 (iv)0.5 (e ca)0.5 (r)0.5 (e,)37.4 ( w)0.5 (hi)0.5 (ch)0.5 ( i)0.5 (nc)20.5 (lu)0.5 (de)0.5 (d RB)0.5 (C t)0.5 (ra)0.5 (ns)0.5 (fu)0.5 (si)0.5 (on)0.5 (s a)0.5 (s ne)0.5 (e)0.5 (de)0.5 (d.)26 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.062 Td
[(The primar)-17.9 (y ef\037cac)20.1 (y assessment was conducted after completion of 24 weeks on stud)-9.8 (y)-15 ( )]TJ
-0.02 Tc 0 Tw 0 -1.062 Td
[(drug.)36.6 ( P)17.7 (a)-10.4 (tients with a decrease in transfusion requirement or increase in hemoglo\bin could)-20 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.062 Td
[(continue )0.5 (on )0.5 (blinded )0.6 (stud)-9.7 (y )0.6 (drug )0.5 (thereafter )0.5 (until )0.5 (unacceptable )0.6 (toxicity)55.2 (,)37.3 ( )0.6 (loss )0.6 (of )0.6 (ef\037cac)20.2 (y)55.3 (,)37.3 ( )0.5 (or)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(disease progression.)Tj
-0.01 Tc 0.047 Tw 0 -1.602 Td
[(The median a)-9.9 (ge of the 229 stud)-9.9 (y participants was 71 years \(range:)37.1 ( 26,)37.1 ( 95 years\).)37.2 ( )36.6 (The)-10 ( )]TJ
0.001 Tc 0.106 Tw 0 -1.062 Td
[(trial )0.5 (popula)-10.4 (tion was )0.5 (63% male )0.5 (and )0.5 (69% )37.5 (White.)36.6 ( )37.5 (T)73.6 (able )0.5 (16 )0.5 (summarizes )0.5 (the )0.5 (baseline)1.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(disease-rela)-9.8 (ted characteristics in the MEDALIST stud)-9.8 (y)55.2 (.)]TJ
ET
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 213.12 622.7643 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 623.0143 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 213.12 623.0143 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 36 622.7643 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 622.7643 cm
0 0 m
74.88 0 l
S
Q
1 w 
q 1 0 0 1 36 643.4562 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 643.4562 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 643.4562 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 138.24 600.6465 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 213.12 600.6465 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 36 533.293 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 533.293 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 522.1091 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 533.293 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 522.1091 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 138.24 510.9252 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 213.12 510.9252 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 138.24 499.9912 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 499.9912 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 36 499.7412 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 499.7412 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 499.7412 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 444.0717 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 444.0717 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 36 443.8217 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 443.8217 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 443.8217 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 432.6378 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 432.6378 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 421.4539 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 432.6378 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 421.4539 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 138.24 410.5199 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 410.5199 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 36 410.2699 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 410.2699 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 399.586 cm
0 0 m
0 10.434 l
S
Q
q 1 0 0 1 213.12 410.2699 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 399.586 cm
0 0 m
0 10.434 l
S
Q
q 1 0 0 1 36 600.3965 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 600.3965 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 600.3965 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 488.5573 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 488.5573 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 477.3734 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 488.5573 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 477.3734 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 138.24 466.1895 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 213.12 466.1895 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 138.24 455.0056 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 213.12 455.0056 cm
0 0 m
0 11.184 l
S
Q
1 w 
q 1 0 0 1 36 399.086 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 399.086 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 399.086 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 36 322.1741 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 322.1741 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 322.1741 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 611.5804 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 611.5804 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 611.5804 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 589.2126 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 589.2126 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 578.0286 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 589.2126 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 578.0286 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 138.24 566.8447 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 213.12 566.8447 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 138.24 555.6608 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 213.12 555.6608 cm
0 0 m
0 11.184 l
S
Q
q 1 0 0 1 138.24 544.7269 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 213.12 544.7269 cm
0 0 m
0 10.934 l
S
Q
q 1 0 0 1 36 544.4769 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 544.4769 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 544.4769 cm
0 0 m
74.88 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 647.0562 Tm
[(T)74.2 (able 16:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
(Baseline Disea)Tj
[(se Characteristics of P)24.2 (atients in MED)34.2 (ALIST)]TJ
-0.017 Tc -4.737 -2.1 Td
(Disease Characteristic)Tj
0.017 Tw 16.401 0.531 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 190.7111 634.5042 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 163.7036 626.0042 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(153\))Tj
0.017 Tw 8.456 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 262.2475 634.5042 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 240.4673 626.0042 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(76\))Tj
0.048 Tw -28.371 -1.461 Td
[(T)18.2 (ime Since Original MDS Diagnosis)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 138.924 616.9304 Tm
(a)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 141.3913 614.3163 Tm
[(\036)-47.8 (\(months\))]TJ
/T1_0 1 Tf
-0.223 Tw /Span<</ActualText<FEFF0007>>> BDC 
-13.867 -1.398 Td
( )Tj
EMC 
[(Median )-270.8 (\(range\))-17 (\036)]TJ
0.048 Tw 16.052 0 Td
[(44.0 \(3,)37.2 ( 421\))]TJ
9.869 0 Td
[(36.1 \(4,)37.2 ( 193\))]TJ
/T1_1 1 Tf
8 0 0 8 36 591.9485 Tm
(Serum EPO \(U/L\) Categories)Tj
0 Tc 0 Tw 5.6 0 0 5.6 121.661 594.5625 Tm
(b)Tj
-0.017 Tc 0.048 Tw 8 0 0 8 124.3646 591.9485 Tm
[(,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 36 580.7646 Tm
( )Tj
EMC 
0.789 0 Td
(<)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(200)Tj
0.048 Tw 15.346 0 Td
(88 \(57.5\))Tj
9.869 0 Td
(50 \(65.8\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(200 to 500)Tj
15.953 0 Td
(43 \(28.1\))Tj
9.869 0 Td
(15 \(19.7\))Tj
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(>)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
0.632 0 Td
(500)Tj
0.048 Tw 15.322 0 Td
(21 \(13.7\))Tj
9.869 0 Td
(11 \(14.5\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(Missing)Tj
0.048 Tw 16.416 0 Td
(1 \(0.7\))Tj
0 Tc 0 Tw 10.802 0 Td
(0)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw -28.008 -1.398 Td
[(Diagnosis per WHO Criteria,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(MDS-RS)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 65.0112 527.459 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 161.4865 524.845 Tm
(135 \(88.2\))Tj
10.1 0 Td
(65 \(85.5\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(MDS/MPN-RS-T)Tj
0.048 Tw 16.185 0 Td
(14 \(9.2\))Tj
9.869 0 Td
(9 \(11.8\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.843 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(Other)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 56.6829 505.0912 Tm
( )Tj
EMC 
0.024 0 Td
[(d )-228.6 (\036)]TJ
-0.017 Tc 0.048 Tw 7.6 0 0 8 166.7623 502.4772 Tm
(4 \(2.6\))Tj
9.869 0 Td
(2 \(2.6\))Tj
/T1_1 1 Tf
-27.075 -1.398 Td
[(IPSS-R Classification Risk Categor)-17.7 (y)55.2 (,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.398 Td
( )Tj
EMC 
0.789 0 Td
[(V)18.2 (er)-17.8 (y lo)-9.8 (w)]TJ
15.953 0 Td
(18 \(11.8\))Tj
10.332 0 Td
(6 \(7.9\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.075 -1.398 Td
( )Tj
EMC 
0.789 0 Td
[(Lo)-9.8 (w)]TJ
0.048 Tw 15.722 0 Td
(109 \(71.2\))Tj
10.443 0 Td
(57 \(75\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.955 -1.398 Td
( )Tj
EMC 
0.789 0 Td
[(Intermedia)-9.8 (te)]TJ
0.048 Tw 15.953 0 Td
(25 \(16.3\))Tj
9.869 0 Td
(13 \(17.1\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(High)Tj
0.048 Tw 16.416 0 Td
(1 \(0.7\))Tj
0 Tc 0 Tw 10.802 0 Td
(0)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw -28.008 -1.398 Td
[(RBC T)74.2 (ransfusions/8 W)18.2 (eeks Over 16 W)18.2 (eeks Categories,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(<)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
[(4 )-245.8 (units)]TJ
0.048 Tw 15.346 0 Td
(46 \(30.1\))Tj
9.869 0 Td
(20 \(26.3\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(\035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.504 0 Td
(4 and <)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.93 0 Td
(6 units)Tj
12.519 0 Td
(41 \(26.8\))Tj
9.869 0 Td
(23 \(30.3\))Tj
-0.198 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.398 Td
( )Tj
EMC 
0.789 0 Td
(\035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.504 0 Td
[(6 )-245.8 (units)]TJ
0.048 Tw 15.449 0 Td
(66 \(43.1\))Tj
9.869 0 Td
(33 \(43.4\))Tj
-0.018 Tc -0.198 Tw 7.2 0 0 8 36 389.774 Tm
(EPO)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.469 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.605 0 Td
[(er)-17.8 (ythropoietin; )-233.8 (IPSS )-233.8 (R)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.726 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.605 0 Td
[(Interna)-9.8 (tional )-233.7 (Prognostic )-233.8 (Scoring )-233.8 (System-Revised; )-233.8 (ITT)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
18.812 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.605 0 Td
[(intent-to-trea)-9.7 (t;)-18 ( )]TJ
-0.021 Tc 0.036 Tw -29.822 -1 Td
(MDS)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.717 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.599 0 Td
[(myelod)-9.9 (ysplastic syndromes; RARS)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.16 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.599 0 Td
[(refractor)-17.8 (y anemia with ring sideroblasts; RBC)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
15.997 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.599 0 Td
[(red blood)-21 ( )]TJ
-0.018 Tc -31.672 -1 Td
(cell; RCMD)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.937 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.606 0 Td
[(refractor)-18.1 (y c)19.8 (ytopenia with multilinea)-10.1 (ge d)-10.1 (ysplasia; SD)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
18.444 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.606 0 Td
[(standard devia)-10.1 (tion; )36.9 (WHO)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.762 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.606 0 Td
[(W)17.9 (orld)-18 ( )]TJ
-0.017 Tc 0.048 Tw -32.961 -1 Td
[(Health Organiza)-9.8 (tion.)]TJ
0.017 Tw 5.04 0 0 5.6 36 360.3881 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.045 Tw 7.2 0 0 8 40 357.774 Tm
[(T)18.2 (ime )0.5 (since )0.5 (original )0.5 (MDS dia)-9.8 (gnosis )0.5 (was )0.5 (defined )0.5 (as )0.5 (the )0.5 (number of years )0.5 (from )0.5 (the )0.5 (da)-9.8 (te )0.5 (of )0.5 (original)-17 ( )]TJ
0.048 Tw 0 -1 Td
[(dia)-9.8 (gnosis to the da)-9.8 (te of informed consent.)]TJ
0.017 Tw 5.04 0 0 5.6 36 344.3881 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.023 Tc 0.036 Tw 7.2 0 0 8 40 341.774 Tm
[(B)-1.4 (a)-1.4 (s)-1.4 (e)-1.4 (l)-1.4 (i)-1.4 (n)-1.5 (e)-1.3 ( )-1.5 (E)-1.4 (P)-1.4 (O)-1.4 ( )-1.4 (w)-1.4 (a)-1.4 (s)-1.4 ( )-1.4 (d)-1.4 (e)-1.4 (f)-1.4 (i)-1.4 (n)-1.5 (e)-1.4 (d)-1.4 ( as the highest EPO value within 35 days of the first dose of stud)-10.4 (y drug.)]TJ
-0.018 Tc 0.018 Tw 5.04 0 0 5.6 36 336.3881 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40 333.774 Tm
[(Inc)20.2 (ludes MDS-RS-MLD a)-0.8 (n)-0.8 (d)-0.8 ( )-0.8 (M)-0.8 (D)-0.8 (S)-0.8 (-)-0.8 (R)-0.8 (S)-0.8 (-)-0.8 (S)-0.8 (L)-0.8 (D)-0.8 (.)]TJ
-0.017 Tc 0.017 Tw 5.04 0 0 5.6 36 328.3881 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40 325.774 Tm
[(Inc)20.2 (ludes MDS-EB-1,)37.2 ( MDS-EB-2,)37.2 ( and MDS-U.)]TJ
0.004 Tw 8 0 0 8 36 306.264 Tm
[(The ef\037cac)20.2 (y of REBLOZYL in adult pa)-9.8 (tients with MDS-RS and MDS-RS-T was established)-17 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.062 Td
[(based upon the proportion of pa)-9.7 (tients who were red blood cell transfusion independent)-12 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.062 Td
[(\(RBC-TI\),)37.1 ( de\037ned as the absence of an)-9.8 (y RBC transfusion during an)-9.8 (y consecutive 8-week)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(period occurring entirely within )37.2 (W)18.2 (eeks 1 through 24.)]TJ
0 -1.602 Td
[(The ef\037cac)20.2 (y results are sho)-9.8 (wn in )37.2 (T)74.2 (ables 17 and 18.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 263.624 252 -12.912 re
36 250.712 83.52 -37.692 re
119.52 250.712 42.12 -37.692 re
161.64 250.712 42.12 -37.692 re
203.76 250.712 42.12 -37.692 re
245.88 250.712 42.12 -37.692 re
36 213.02 83.52 -19.972 re
119.52 213.02 42.12 -19.972 re
161.64 213.02 42.12 -19.972 re
203.76 213.02 42.12 -19.972 re
245.88 213.02 42.12 -19.972 re
36 193.048 83.52 -19.972 re
119.52 193.048 42.12 -19.972 re
161.64 193.048 42.12 -19.972 re
203.76 193.048 42.12 -19.972 re
245.88 193.048 42.12 -19.972 re
36 173.076 83.52 -19.972 re
119.52 173.076 42.12 -19.972 re
161.64 173.076 42.12 -19.972 re
203.76 173.076 42.12 -19.972 re
245.88 173.076 42.12 -19.972 re
36 153.104 252 -20.912 re
f
1 w 
/GS2 gs
q 1 0 0 1 119.52 250.7121 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 250.7121 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 250.7121 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 250.7121 cm
0 0 m
42.12 0 l
S
Q
0.5 w 
q 1 0 0 1 161.64 213.2702 cm
0 0 m
0 36.942 l
S
Q
q 1 0 0 1 203.76 213.2702 cm
0 0 m
0 36.942 l
S
Q
q 1 0 0 1 245.88 213.2702 cm
0 0 m
0 36.942 l
S
Q
q 1 0 0 1 36 132.1925 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 119.52 132.1925 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 132.1925 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 132.1925 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 132.1925 cm
0 0 m
42.12 0 l
S
Q
1 w 
q 1 0 0 1 36 250.7121 cm
0 0 m
83.52 0 l
S
Q
0.5 w 
q 1 0 0 1 119.52 213.2702 cm
0 0 m
0 36.942 l
S
Q
q 1 0 0 1 36 213.0202 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 119.52 213.0202 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 119.52 193.2983 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 161.64 213.0202 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 193.2983 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 203.76 213.0202 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 193.2983 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 245.88 213.0202 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 193.2983 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 36 193.0483 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 119.52 193.0483 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 119.52 173.3264 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 161.64 193.0483 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 173.3264 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 203.76 193.0483 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 173.3264 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 245.88 193.0483 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 173.3264 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 36 173.0764 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 119.52 173.0764 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 119.52 153.6045 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 161.64 173.0764 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 153.6045 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 203.76 173.0764 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 153.6045 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 245.88 173.0764 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 153.6045 cm
0 0 m
0 19.222 l
S
Q
1 w 
q 1 0 0 1 36 153.1045 cm
0 0 m
83.52 0 l
S
Q
q 1 0 0 1 119.52 153.1045 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 161.64 153.1045 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 203.76 153.1045 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 153.1045 cm
0 0 m
42.12 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 39.6 254.3121 Tm
[(T)74.2 (able 17:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Efficac)10.2 (y Resul)]TJ
[(ts in MED)34.2 (ALIST)]TJ
-0.017 Tc 0.017 Tw -5.211 -3.163 Td
(Endpoint)Tj
11.783 1.594 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 155.6111 241.7602 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 128.6036 233.2602 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(153\))Tj
0 Tc 0 Tw 7.6 0 0 8 152.5564 233.2602 Tm
( )Tj
-0.054 Tc 0.085 Tw 7.6 0 0 8 134.0539 224.7602 Tm
[(n)-36.8 (, %)]TJ
0 Tc 0 Tw 7.6 0 0 8 147.1061 224.7602 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 128.0684 216.2602 Tm
(\(95% CI\))Tj
0.017 Tw 5.667 3.188 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 194.2625 241.7602 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 172.4823 233.2602 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(76\))Tj
0 Tc 0 Tw 7.6 0 0 8 192.9178 233.2602 Tm
( )Tj
-0.054 Tc 0.085 Tw 7.6 0 0 8 176.1739 224.7602 Tm
[(n)-36.8 (, %)]TJ
0 Tc 0 Tw 7.6 0 0 8 189.2261 224.7602 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 170.1884 216.2602 Tm
(\(95% CI\))Tj
0.017 Tw 5.475 3.188 Td
[(Common)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 239.7697 241.7602 Tm
( )Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 218.4042 233.2602 Tm
[(Risk)-17 ( )]TJ
-1.124 -1.062 Td
(Difference)Tj
0 Tc 0 Tw 7.6 0 0 8 239.7773 224.7602 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 212.3083 216.2602 Tm
(\(95% CI\))Tj
0.017 Tw 5.765 1.594 Td
[(p-v)16.2 (alue)]TJ
/T1_0 1 Tf
0.048 Tw -28.964 -3.073 Td
(RBC-TI \035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.248 0 Td
[(8 weeks during)-16.9 ( )]TJ
-3.248 -1.062 Td
[(W)18.2 (eeks 1-24)]TJ
12.124 1.062 Td
(58 \(37.9\))Tj
-0.456 -1.062 Td
[(\(30.2,)37.2 ( 46.1)-39.8 (\))]TJ
5.998 1.062 Td
(10 \(13.2\))Tj
-0.204 -1.062 Td
[(\(6.5,)37.2 ( 22.9\))]TJ
0.017 Tw 6.568 1.062 Td
(24.6)Tj
0.048 Tw -1.258 -1.062 Td
[(\(14.5,)37.2 ( 34.6\))]TJ
-0.198 Tw 6.05 0.531 Td
(<)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(0.0001)Tj
0.048 Tw -29.43 -1.965 Td
(RBC-TI \035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.248 0 Td
[(12 weeks during)-17 ( )]TJ
-3.248 -1.062 Td
[(W)18.2 (eeks 1-)20.2 (24)]TJ
12.124 1.062 Td
(43 \(28.1\))Tj
-0.456 -1.062 Td
[(\(21.1,)37.2 ( 35.9)-39.8 (\))]TJ
6.461 1.062 Td
(6 \(7.9\))Tj
-0.667 -1.062 Td
[(\(3.0,)37.2 ( 16.4\))]TJ
0.017 Tw 6.568 1.062 Td
(20.0)Tj
0.048 Tw -1.258 -1.062 Td
[(\(10.9,)37.2 ( 29.1\))]TJ
0.017 Tw 6.353 0.531 Td
(0.0002)Tj
0.048 Tw -29.126 -1.965 Td
(RBC-TI \035)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )246.5 ( )]TJ
EMC 
3.272 0 Td
[(12 weeks during)-17 ( )]TJ
-3.272 -1.062 Td
[(W)18.2 (eeks 1-)20.2 (48*)]TJ
12.124 1.062 Td
(51 \(33.3\))Tj
-0.456 -1.062 Td
[(\(25.9,)37.2 ( 41.)-39.8 (4\))]TJ
6.229 1.062 Td
(9 \(11.8\))Tj
-0.436 -1.062 Td
[(\(5.6,)37.2 ( 21.3\))]TJ
0.017 Tw 6.568 1.062 Td
(21.4)Tj
0.048 Tw -1.258 -1.062 Td
[(\(11.2,)37.2 ( 31.5\))]TJ
0.017 Tw 6.353 0.531 Td
(0.0003)Tj
0 Tc 0 Tw 7.84 0 0 7.84 36.0001 144.0221 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 38.6248 146.4065 Tm
( )Tj
EMC 
-0.02 Tc 0.036 Tw 7.2 0 0 8 40.0001 143.7925 Tm
[(The median \(range\) dura)-10.2 (tion of trea)-10.1 (tment was 49 weeks \(6 to 114 weeks\) on the REBLOZYL arm)-20 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1 Td
(and 24 weeks \(7 to 89 weeks\) on the placebo arm.)Tj
0.003 Tc 0.115 Tw 8 0 0 8 36.0001 119.1226 Tm
[(T)73.6 (able 1)39.6 (8 sho)-10.4 (ws the proportion of pa)-10.4 (tients who achieved RBC-TI \0358 weeks during)3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(W)18.2 (eeks 1-24 by dia)-9.8 (gnosis and baseline transfusion requirement.)]TJ
ET
0.5 w 
q 1 0 0 1 324 416.9598 cm
0 0 m
68.703 0 l
S
Q
q 1 0 0 1 324 366.1569 cm
0 0 m
73.496 0 l
S
Q
q 1 0 0 1 324 332.4351 cm
0 0 m
109.119 0 l
S
Q
q 1 0 0 1 324 281.6321 cm
0 0 m
60.639 0 l
S
Q
q 1 0 0 1 324 222.2885 cm
0 0 m
26.074 0 l
S
Q
1 w 
/GS2 gs
q 1 0 0 1 324 715.1481 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 715.1481 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 715.1481 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 470.88 715.1481 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 715.1481 cm
0 0 m
50.04 0 l
S
Q
0.5 w 
q 1 0 0 1 470.88 703.2061 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 398.27 702.9561 cm
0 0 m
36.43 0 l
S
Q
q 1 0 0 1 434.7 702.9561 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 398.52 690.7642 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 690.7642 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 324 679.2923 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 679.2923 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 679.2923 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 398.52 667.8204 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 434.7 667.8204 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 470.88 667.8204 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 398.52 645.1266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 434.7 645.1266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 470.88 645.1266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 398.52 610.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 434.7 610.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 470.88 610.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 398.52 599.4889 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 434.7 599.4889 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 470.88 599.4889 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 324 598.9889 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 598.9889 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 598.9889 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 470.88 598.9889 cm
0 0 m
55.08 0 l
S
Q
0.5 w 
q 1 0 0 1 324 570.077 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 570.077 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 570.077 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 470.88 570.077 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 570.077 cm
0 0 m
50.04 0 l
S
Q
q 1 0 0 1 525.96 667.8204 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 525.96 645.1266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 525.96 610.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 525.96 599.4889 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 525.96 598.9889 cm
0 0 m
50.04 0 l
S
Q
0.5 w 
q 1 0 0 1 470.88 679.2923 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 679.2923 cm
0 0 m
50.04 0 l
S
Q
q 1 0 0 1 398.52 621.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 434.7 621.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 470.88 621.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 525.96 621.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 398.52 656.3485 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 434.7 656.3485 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 470.88 656.3485 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 525.96 656.3485 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 398.52 703.2061 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 398.52 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 690.7642 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 434.7 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 470.88 702.9561 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 470.88 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 525.96 702.9561 cm
0 0 m
50.04 0 l
S
Q
q 1 0 0 1 525.96 691.0142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 470.88 690.7642 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 690.7642 cm
0 0 m
50.04 0 l
S
Q
q 1 0 0 1 324 644.8766 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 644.8766 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 644.8766 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 470.88 644.8766 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 644.8766 cm
0 0 m
50.04 0 l
S
Q
q 1 0 0 1 324 633.4047 cm
0 0 m
74.52 0 l
S
Q
q 1 0 0 1 398.52 633.4047 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 434.7 633.4047 cm
0 0 m
36.18 0 l
S
Q
q 1 0 0 1 470.88 633.4047 cm
0 0 m
55.08 0 l
S
Q
q 1 0 0 1 525.96 633.4047 cm
0 0 m
50.04 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 727.248 Tm
[(T)74.2 (able 18:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
(RBC-TI \037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.464 0 Td
[(8 W)18.2 (ee)]TJ
[(ks during W)18.2 (eeks 1-24 By Diagnosis and Baseline)-12 ( )]TJ
-3.464 -1.062 Td
[(T)74.2 (ransfusion Burden in MED)34.2 (ALIST)]TJ
-0.017 Tc -0.115 Tw 7.021 -1.569 Td
(Responders)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(/)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(N)Tj
0.048 Tw 10.347 0 Td
(% Response \(95% CI\))Tj
0.017 Tw -11.897 -1.524 Td
(REBLOZYL)Tj
5.217 0 Td
(Placebo)Tj
5.548 0 Td
(REBLOZYL)Tj
7.389 0 Td
(Placebo)Tj
0.048 Tw -28.361 -1.479 Td
(WHO 2016 Diagnosis)Tj
/T1_0 1 Tf
0.017 Tw 0 -1.434 Td
[(MDS-RS)-17 ( )]TJ
10.89 0 Td
(46/135)Tj
5.223 0 Td
(8/65)Tj
0.048 Tw 3.824 0 Td
[(34.1 \(26.1,)37.2 ( 42.7\))]TJ
7.164 0 Td
[(12.3 \(5.5,)37.2 ( 22.8\))]TJ
0.017 Tw -27.101 -1.434 Td
(MDS/MPN-RS-T)Tj
11.352 0 Td
(9/14)Tj
4.992 0 Td
(2/9)Tj
0.048 Tw 3.593 0 Td
[(64.3 \(35.1,)37.2 ( 87.2\))]TJ
7.164 0 Td
[(22.2 \(2.8,)37.2 ( 60.0\))]TJ
0.017 Tw -27.101 -1.434 Td
(Other)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 338.6829 650.3706 Tm
( )Tj
EMC 
0.024 0 Td
(a\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 412.0363 647.7566 Tm
(3/4)Tj
4.761 0 Td
(0/2)Tj
0.048 Tw 3.593 0 Td
[(75.0 \(19.4,)37.2 ( 99.4\))]TJ
7.395 0 Td
[(0.0 \(0.0,)37.2 ( 84.2\))]TJ
/T1_1 1 Tf
-27.332 -1.434 Td
[(Baseline RBC T)74.2 (ransfusion Burden)]TJ
/T1_0 1 Tf
-0.073 Tw 0 -1.434 Td
(2)Tj
/Span<</ActualText<FEFF2006>>> BDC 
( )Tj
EMC 
0.612 0 Td
(-)Tj
/Span<</ActualText<FEFF2006>>> BDC 
( )Tj
EMC 
0.484 0 Td
[(3 )-120.8 (units/8 )-120.8 (weeks)]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 375.949 627.4268 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 408.5191 624.8127 Tm
(37/46)Tj
4.992 0 Td
(8/20)Tj
0.048 Tw 3.824 0 Td
[(80.4 \(66.1,)37.2 ( 90.6\))]TJ
6.932 0 Td
[(40.0 \(19.1,)37.2 ( 63.9\))]TJ
-0.073 Tw -26.869 -1.434 Td
(4)Tj
/Span<</ActualText<FEFF2006>>> BDC 
( )Tj
EMC 
0.612 0 Td
(-)Tj
/Span<</ActualText<FEFF2006>>> BDC 
( )Tj
EMC 
0.484 0 Td
[(5 )-120.8 (units/8 )-120.8 (weeks)]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 375.949 615.9548 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 408.5191 613.3408 Tm
(15/41)Tj
4.992 0 Td
(1/23)Tj
0.048 Tw 3.824 0 Td
[(36.6 \(22.1,)37.2 ( 53.1\))]TJ
7.395 0 Td
[(4.3 \(0.1,)37.2 ( 21.9\))]TJ
-27.332 -1.434 Td
(\035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.504 0 Td
(6 units/8 weeks)Tj
0.017 Tw 10.848 0 Td
(6/66)Tj
4.761 0 Td
(1/33)Tj
0.048 Tw 4.287 0 Td
[(9.1 \(3.4,)37.2 ( 18.7\))]TJ
6.932 0 Td
[(3.0 \(0.1,)37.2 ( 15.8\))]TJ
0.017 Tw 5.04 0 0 5.6 324 592.291 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 328 589.677 Tm
[(Inc)20.2 (ludes MDS-EB-1,)37.2 ( MDS-EB-2,)37.2 ( and MDS-U.)]TJ
0.017 Tw 5.04 0 0 5.6 324 584.291 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 328 581.677 Tm
[(Inc)20.2 (ludes pa)-9.8 (tients who received 3.5 units.)]TJ
0.017 Tw 5.04 0 0 5.6 324 576.291 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 328 573.677 Tm
[(Inc)20.2 (ludes pa)-9.8 (tients who received 5.5 units.)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8 324 552.5464 Tm
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
0.017 Tw -3.375 -1.698 Td
(16.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(How Supplied)Tj
/T1_0 1 Tf
-0.007 Tc 0.064 Tw -3.375 -1.518 Td
[(REBLOZYL \(luspa)-10.2 (tercept-aamt\) for injection is a white to off-white lyophilized po)-10.2 (wder)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(supplied in a single-dose vial.)37.2 ( Each carton contains one vial.)]TJ
0 -1.608 Td
(REBLOZYL 25 mg/vial \(NDC 59572-711-01\))Tj
0 -1.608 Td
(REBLOZYL 75 mg/vial \(NDC 59572-775-01\))Tj
/T1_1 1 Tf
0.017 Tw 0 -1.788 Td
(16.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Storage)Tj
/T1_0 1 Tf
-0.019 Tc 0 Tw -3.375 -1.518 Td
[(Store vials refrigera)-9.8 (ted a)-9.7 (t 2\260C to 8\260C \(36\260F to 46\260F\) in original carton to protect \from light.)18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
(Do not freeze.)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.805 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION)]TJ
/T1_0 1 Tf
0.012 Tw -3.375 -1.518 Td
[(Discuss the follo)-9.8 (wing with pa)-9.8 (tients prior to and during trea)-9.8 (tment with REBLOZYL.)]TJ
0.048 Tw 0 -1.63 Td
(Thromboembolic Events)Tj
-0.014 Tc 0.025 Tw 0 -1.518 Td
[(A)0.5 (dv)0.5 (i)0.5 (s)0.5 (e)0.5 ( b)0.5 (e)0.5 (t)0.5 (a t)0.5 (h)0.5 (a)0.5 (l)0.5 (a)0.5 (ss)0.5 (e)0.5 (m)0.5 (i)0.5 (a)0.5 ( pa)-9.4 (ti)0.5 (e)0.5 (n)0.5 (t)0.5 (s o)0.5 (f t)0.5 (h)0.5 (e)0.5 ( p)0.5 (o)0.5 (te)0.5 (n)0.5 (t)0.5 (i)0.5 (a)0.5 (l)0.5 ( ri)0.5 (s)0.5 (k)0.5 ( o)0.5 (f)0.5 ( t)0.5 (hr)0.5 (o)0.5 (m)0.5 (b)0.5 (o)0.5 (e)0.5 (m)0.5 (bo)0.5 (l)0.5 (i)0.5 (c)0.5 ( ev)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 (.)37.4 ( R)0.5 (e)0.5 (v)0.5 (i)0.5 (e)0.5 (w)-14 ( )]TJ
0.029 Tw 0 -1.068 Td
[(kno)-10.2 (wn risk factors for developing thromboembolic events and advise pa)-10.1 (tients to reduce)-14 ( )]TJ
-0.004 Tc 0.08 Tw 0 -1.068 Td
[(modi\037able risk factors \(e.g.,)36.6 ( smoking,)36.6 ( use of oral contraceptives\) )]TJ
/T1_2 1 Tf
0.043 Tw [([see W)17.7 (arnings )-37.3 (and)-4 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.068 Td
(Precautio)Tj
0.012 Tw (ns \(5.1\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.63 Td
(Effects on Blood Pressure)Tj
0.024 Tw 0 -1.518 Td
[(Caution pa)-10.3 (tients tha)-10.4 (t REBLOZYL may cause an increase in blood pressure )]TJ
/T1_2 1 Tf
-0.013 Tw [([see W)17.6 (arnings)-17 ( )]TJ
0.012 Tw 0 -1.068 Td
(and Precautio)Tj
(ns \(5.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.63 Td
[(Extramedullar)-17.8 (y Hema)-9.7 (topoietic Masses)]TJ
-0.022 Tc 0 Tw 0 -1.518 Td
[(Advise pa)-9.9 (tients with beta thalassemia of the potential risk of extramedullar)-17.9 (y hema)-9.9 (topoietic)-22 ( )]TJ
0.004 Tc 0.116 Tw 0 -1.068 Td
[(masses.)37.3 ( Review possible risk factors for developing extramedullar)-17.6 (y hema)-9.7 (topoietic)4 ( )]TJ
0.005 Tc 0.125 Tw 0 -1.068 Td
[(masses.)36.7 ( Instruct pa)-10.3 (tients to report possible signs and symptoms of EMH masses)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
/T1_2 1 Tf
-0.017 Tc 0.012 Tw -31.5 -1.068 Td
[([see )37.2 (W)18.3 (arnings and Precautio)]TJ
(ns \(5.3\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw 0 -1.63 Td
[(Embr)-17.7 (yo-F)24.2 (etal T)74.2 (oxicity)]TJ
0.019 Tw 0 -1.518 Td
[(Advise )0.5 (females )0.5 (of reproductive )0.5 (potential of the potential risk )0.5 (to a )0.5 (fetus.)37.2 ( )37.4 (Advise females of)-17 ( )]TJ
0.011 Tw 0 -1.068 Td
[(reproductive potential to use effective contraception while receiving RE\BLOZYL and for a)-9.7 (t)-17 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.068 Td
[(least 3 months after the \037nal dose.)37.2 ( )37.3 (Advise females to contact their healthcare provider if)-15 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.068 Td
[(they become pregnant,)37.3 ( or if pregnanc)20.3 (y is suspected,)37.3 ( during trea)-9.7 (tment with REBLOZYL)-9 ( )]TJ
/T1_2 1 Tf
-0.017 Tc 0.012 Tw 0 -1.068 Td
[([see )37.2 (W)18.3 (arnings and Precautions \(5.4\) and Use in Speci\037c P)18.2 (opula)-9.7 (tio)]TJ
(ns \(8.1\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw 0 -1.63 Td
[(Lacta)-9.8 (tion)]TJ
0 Tw 0 -1.518 Td
[(Advise females not to breastfeed during trea)-9.8 (tment with REBLOZYL and for 3 months after)-17 ( )]TJ
0.012 Tw 0 -1.068 Td
(the \037nal dose )Tj
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.048 Tw 0 -2.525 Td
(Manufactured by:)Tj
0 Tc 0 Tw 6.305 0 Td
( )Tj
-0.012 Tc 0.048 Tw -6.305 -1.13 Td
[(Celgene Corpora)-9.8 (tion,)37.2 ( a Bristol-Myers Squibb Compan)-9.7 (y)]TJ
0 Tc 0 Tw 19.713 0 Td
( )Tj
-0.012 Tc 0.011 Tw -19.713 -1.13 Td
[(86 )-36.8 (Morris Avenue)]TJ
0 Tc 0 Tw 6.387 0 Td
( )Tj
-0.012 Tc 0.048 Tw -6.387 -1.13 Td
[(Summit,)37.2 ( NJ 07901)]TJ
0 Tc 0 Tw 6.848 0 Td
( )Tj
-0.012 Tc 0.048 Tw -6.848 -1.13 Td
[(U.S.)37.2 ( License No.)37.2 ( 2252)]TJ
-0.009 Tc 0.009 Tw 0 -1.693 Td
(REBLOZYL)Tj
0 Tc 0 Tw 5.6 0 0 5.6 354.4106 135.3177 Tm
(\256)Tj
-0.009 Tc 0.067 Tw 8 0 0 8 358.8424 132.7037 Tm
[( )0.5 (is )0.5 (a )0.5 (registered trademark )0.5 (of )0.5 (Celgene )0.5 (Corpora)-10.4 (tion,)36.6 ( )0.5 (a Bristol-Myers )0.5 (Squibb)-9 ( )]TJ
-0.012 Tc 0.012 Tw -4.355 -1.13 Td
[(Compan)-9.8 (y)55.2 (.)]TJ
-0.017 Tc 0.017 Tw 0 -1.63 Td
(REBPI.007)Tj
ET
endstreamendobj25 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 537/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 20 0 R>>/Font<</T1_0 63 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 747.7531 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
(REBLOZYL)Tj
0 Tc 0 Tw 5.6 0 0 5.6 77.8897 752.1521 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 82.323 750.2881 Tm
[( \(luspater)18.3 (cept-aamt\))]TJ
ET
q 1 0 0 1 324 747.7531 cm
0 0 m
252 0 l
S
Q
BT
0.008 Tw 8 0 0 8 453.1892 750.2881 Tm
(REBLOZYL)Tj
0 Tc 0 Tw 5.6 0 0 5.6 495.079 752.1521 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 499.5122 750.2881 Tm
[( \(luspater)18.3 (cept-aamt\))]TJ
ET
endstreamendobj63 0 obj<</BaseFont/CINJZY+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 64 0 R/LastChar 174/Subtype/Type1/ToUnicode 65 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 407 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 704 0 0 648 0 0 0 0 0 0 593 0 0 778 0 0 722 0 0 0 0 0 0 667 648 0 0 0 0 0 0 574 0 574 0 574 0 0 0 0 0 0 258 906 0 0 611 0 389 537 352 593 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj64 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/hyphen/B/E/L/O/R/Y/Z/a/c/e/l/m/p/r/s/t/u/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 66 0 R/FontName/CINJZY+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj65 0 obj<</Filter/FlateDecode/Length 333>>stream
Hâ\íœnÉ0∆Ôy
◊CEK¥BBtï8Ïè∆ˆ 41“Q†ﬁ~v\u“"ˇ¢ÿ_>ŸDU}™m?CÙÓG›‡]oç«iºyçp¡ko’6”Î˘~
_=¥NET‹,”åCmªQÂ9Dt9Õ~Åß“å\©ËÕÙΩΩ¬”W’¨ jnŒ˝‡ÄvÜÏHË•uØÌÄÖ≤umËæüó5’¸e|.!Á≠ò—£¡…µ}kØ®Ú≠Ú3≠B°5ˇÓ„X .ù˛nΩ cNﬁl(ÑÃG·#ÛI¯DºèS NÑÊJ∏b>ìÅ<ë¸ÑÛ—LX3)ÖK‚tòÒNx«,˙)Îß¢ü≤~*~Rˆìâˇå˝gÚV∆oe¢ì±N∂ﬁ3ãf∆öÂs`
‹®{G∏e4YxÃCﬂºßQÑÒáp˜{ãè?ƒç®ä∑˙` ¨
†Ôendstreamendobj66 0 obj<</Filter/FlateDecode/Length 1856/Subtype/Type1C>>stream
HâÑT}T◊üawﬂÚïXqfáı´X¿êäHDA*`‘ÍíFYewuYAçhkE?–TT4Dc?∞T(FE‡‰@ä’T”£¶äò&j,Q*GÀº˚Gﬂíòûˆ¥ßÛŒº˜Ó}˜˛Ó«ª˜±å“ÉaY64)%=u…‚Òs§¬b…i…3ßKk•¥¨Lg˛ƒô˘nΩ¨cÂ@•‚Àc⁄^]}ïßíóì∑˘wÜx.
`<‹0+Xgí}ızáeEÅS4∆Nù:ÅŒ±ëCsÙ1*22JLÃ∑ÁJbÊ˙"ßd-Slyv«jª√ÏîÚ√≈ƒ¬BqHπHtHEí£ÿÕ¸øàiõ›π~µ$Œ∂ÊŒ˘ ?≈%ZäD≥ËtòÛ%´Ÿ±J¥/ˇó~u%ú*≠∞PÁRæh±âŒIÃœÁQmN—lÀ≥~“ŒXæ‹í'1≠Êı"ÏﬂµÛ$á”LW;Öqà+◊:,E˘ñ<ß≈n+zn3[•ˇ‚Ö›!ZhÖﬁV$IˇdDrfñõàÛ•Â˝X∆ãÒf8f$3Üô»D2—L3çô…º…$3o1ÈÃ|&ì…b≤ôÖÃ	f8Ω* ú«î1mÃvªä}üΩÔë‡aı8†‡ŸääK PÂFe´*LµTuîDãÂ-Ú”ñŒ£ZÂJπlpû´å¿.Ï‡q:ÏS¡Ç"∂Ò‡&\ïj1Ìa:Rö»≠º{ánä√˚N*~5∫ÑmÉ“Ì|4jr0«i1≤£Ócà ﬁ$FY 
¢¥Q∆[&º÷ÎwÎ)1ïˇö!∆i!r1D≈B®Äﬁ‰é>ãQ•≈à4&¢HıñBpl¥+⁄†Äáv‡∞ùpOÀÅÉE0∏Ä`§ÓN¿a`‘ºÑb¯íáÚ≈ß∂ôâŸ%oÈ1û†9˙0¨F?Ã˘"ÊcΩFÓ™´ø|S#"ö©◊¯ê¿êÿXÚYkÈÏå\Gñ£	◊X¡êDçMÑ`ñZR‹í¡.û2˚®/}0Q~É“ßWJEÂª%Ø•* üÀw—H8Hÿ@è÷QÑ0 ¡ÙºxÃÖ åÖ5tA,‰B“◊–A˘X Ä1¸€¿¬ ¨}—}“%√R¶è¿Å∫¶NÉñ—π”pf»4›ú#π[ªr∆oÙ˚lO>jÚ§¥˝¸Œe∂˛yÌÌÈzV®Ôû>{ıÅò∏á(∏¯√üAn6Xìì$Î,=Œ ‹Á5≈É¶*)0T∫ë?!pDNSa°oI=NÉzŒ"pÿ5G5î,y!Ûò‹ß8$˜—ƒÑY#õT‡ÁÍƒ`¯á⁄•qôT‹ “ﬁ∏nÄﬁÄ”` 4d_X nãF≈≤‹™∂÷Ûáö˜Õ˚ZvØÒƒÙó¸g{Í?j◊µ4mIü∑+fì>zs¥Ω¥aYÚÏÍıÍãÕ∫ùvoÿÛÆ'å"õj∂^º®Öè‘‡á~«F°'˙‰·à_‘Ï <†∑`P»M-¡[P˘G‰t?}pFºDàÑêﬁ€zDè°$mãdN—EŸﬁ∫S˜›„ŒﬂŒﬂØÇ˛<ÿZ7R#8yà˛`2¸ﬂ‘°QDoå¿òÁ®Ñ)‡ıu+pÁıËOVmYV∞@ü”¯hõ˛ëÚ|≈âõèt7NIIUz˚HsEÎ√†	¥jZkäÂ)œ∆Å2Ä@Í`àÊ≤[⁄»Û?9˘h[rÜÄøßt£˙⁄°Î˜∫˜.HSJ˜©A=í≤sMV°À>ˇx™nNv·¬Â˙ÌD”}µjn7ÌJàß)y>–Nu∂“õËnßÌI˜;*»¢≥ù´ªt0˛Ì∆ŒÑ·8yn¶#À‚Üxzuj8ËäÁ#V›{†◊t?®ÎyÚ¯Ã‰XAÛtäuZ8Ì]`$x£7o-q–Tµª]/%ö⁄«Ánø®ÆŸ^V%h™ X≠©›µes≈Øt…≥L©k‹¯û¬s≥J{iï∞çTi.MN-ƒÛ∫ºL‡´onÜêÔ„Í¶’«ùVyE€tqÔÈ+M≥v†#†˘Â»TÈPÅƒÇ¡ë˜m˜◊Î˚◊vn|Gª¯Ìws3ﬂ˛∏kurﬂ˚¥ÅnÙ≤ﬂπü¶MÉ1<0b“Ñøbuß‰õìßvÓ>.ÄB]∂±t«F›/6∏§á˝/zG™π“RPé{&O
çˆ†ªäœ…› «âaÂ;”SM_pÅ“_™1∞a2åˇºÎd«9a—¨Kdo∏GÆÅ«µû{Ï·~—ë=¿ˆ+√+◊A
éÖ:R`,¨ÉLÅ1òCG
é¡°?à>‘˛@ﬂ=à £ètj–èVü˝¡Åﬂ≥[I?ŒV}ChMŒUuÌπT˜ïˆÒº3£HO*ì4\zœ¥®‡Ω•˙D¬m®4U„ ÉÛr’˚˚˜ªæ:®˛ëy¿NT˛Ω“ı∑^ﬁ`¯¿◊á|ﬂÄÀÅÚ˛ü ± endstreamendobj21 0 obj<</BaseFont/BADDLA+HelveticaNeueLTStd-Cn/Encoding 67 0 R/FirstChar 26/FontDescriptor 68 0 R/LastChar 239/Subtype/Type1/ToUnicode 69 0 R/Type/Font/Widths[463 497 463 497 240 463 240 0 0 0 0 759 0 0 241 241 352 600 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 600 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 0 519 500 463 519 462 722 0 462 463 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 240 407 407 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800 0 400 0 0 0 0 463 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 204]>>endobj23 0 obj<</BaseFont/BADDLA+HelveticaNeueLTStd-BdCn/Encoding 70 0 R/FirstChar 29/FontDescriptor 71 0 R/LastChar 239/Subtype/Type1/ToUnicode 72 0 R/Type/Font/Widths[500 240 487 240 0 0 0 0 778 0 0 296 296 390 0 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 600 0 0 556 556 537 574 481 463 556 556 258 463 537 463 740 574 556 519 0 556 519 480 538 519 760 537 520 481 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 426 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 240]>>endobj22 0 obj<</BaseFont/BADDLA+HelveticaNeueLTStd-CnO/Encoding 73 0 R/FirstChar 31/FontDescriptor 74 0 R/LastChar 121/Subtype/Type1/ToUnicode 75 0 R/Type/Font/Widths[463 240 0 0 0 0 0 0 0 241 241 0 0 240 352 240 0 0 480 480 480 480 480 0 0 480 0 0 0 0 0 0 0 0 500 519 519 556 463 444 0 0 204 0 0 444 704 556 0 481 0 519 500 463 519 0 722 0 0 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 0 204 722 463 444 463 0 296 407 259 463 406 0 406 406]>>endobj73 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/fi]/Type/Encoding>>endobj74 0 obj<</Ascent 932/CapHeight 714/CharSet(/fi/space/parenleft/parenright/comma/hyphen/period/one/two/three/four/five/eight/A/B/C/D/E/F/I/L/M/N/P/R/S/T/U/W/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/l/m/n/o/p/r/s/t/u/v/x/y)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 76 0 R/FontName/BADDLA+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj75 0 obj<</Filter/FlateDecode/Length 472>>stream
Hâ\ìÕn£0Ö˜~
/€E!◊◊≠Ñê¶I+e1?ötÄÄìAö r»"o?>>QG$‡C∂œ9◊\õ›v7ã-~ƒ©€á≈á±è·2]cÏ!úÜ—¨*€›rˇ œÓ‹Œ¶Hã˜∑ÀŒªÒ8ô∫∂≈œ4xY‚Õ>|ÈßCx4≈˜ÿá8å'˚k≥¥≈˛:œ¬9åã-m”ÿ>ì–◊v˛÷ûÉ-Ú≤ß]ü∆áÂˆî÷¸õÒqõÉ≠Ú˜äa∫©óπÌBl«S0uôÆ∆÷ÔÈjL˚ˇ∆]≈eác˜ªç¶^Ωß…e©öÓó∆‘Uôø”+Ò3˘¸BŒs6‰xKﬁÇﬂ»oâ◊´ÃÈï∏"W‡5y≤ÄŸÅÈªÜØPG†#‘Ëu:BÅéPG†#JV0ÛÚÛÚÛÚÛÚ;ÓÉ√>8˙:¯:˙:¯:˙:¯:˙:¯:Oˆ‡WÚ+ò^^ ∫u)ı˙J}ÖæR_°Ø‘WË´ﬁˇò^
/Âæ)ˆMYo˛ß zı*3hŒ¿zıÍΩR”‘ûµ{‘ÓôÕ#õg6èlûŸ<≤yfÛ»ÊôÕ#õgè<ûy“MyÔ>¥g:Eˆ≥˜ªkå©ÌÛQÀ˝éN∆yÁi∂inÛWÄ ÄÀÁ–endstreamendobj76 0 obj<</Filter/FlateDecode/Length 3641/Subtype/Type1C>>stream
HâtT{TŸü!ôKDàH«uf’tPP¡‚]+*†(∆0B\H4	A^J]_òjWÂTêßÆ´tèvµ∫¢V≈ZYwYAkä≠©ˆpN¡o‚çµ7a˚¯ßgŒúπø;ﬂÔªø˘~ﬂ74%˜†hö1;vÓ‹ÑÿO„ƒ,≥h“j‘Kƒ1ay¢)}¸›gÆàëGKÅÚmﬁ“po«‡„ÔÆøãb†mê4xè√}´˝(ö~Òè9˙MymF¶Iò"Lü(ƒ¶Î◊ãBbû—$fÖxùFoÿ§7®Mbz®õï%,så¬2—(ÃÆÕˇË¥FA-òÍt1[m¯\–o Ô¥Èb÷z—ê!ÑπÜÕÁŸj£&S´uBÏÇA‹¢… 1jÕbVûê•’à:£ò.ò2˙úåL!A´”õÚ6âd±ﬁ†6‰	≤◊«Öj]∫ê≠ŒàJÉò°%:Ñ§’	—`RìÁ∆É÷òÆ’ò¥zù14l~‚rWíH!]‹@Q4π®4Â„A˘…©@ä…P„(jº5Å¢"dTEMß®ô5[A-ñSâr*Ö¶≤)j©=O%P{®õ‘+íEEœ¢À==Vz‘Àñ»v…^ÀgÀw»ÎÂvπì∆ldé3v¥˝Ÿ<áxfxÓ˜º†X¨®‡5`ÛÄ?{˘zïyŸºﬁdnx›;¿ªÿ˚ÜOêèﬁÁúœeÄrïÚ¸¬rUz}ïÜ`ièc©sÇ˝∏ë≈3·]¯:.‡<ËÈDk›kòâ	FRÎZaRbΩÎÛ;ˇ\˙âMØkY<˚O∆ëZ±O¨ƒì[0´¯JÉQª`Ùiò|
¬ö`x@†‚ø\Xﬁ&+√	,ˇøB‰)à8Û`r<∞ä’Ëu èŒƒì7‚∞<	”ÿ≈’[˙Ë0F÷Í_èv∑k∂Êä˘ÅøLÌ<V{ß‚A`ıs&)(±—}P.ÎÉˆ†JÉ˜†~n+xÓKt¨œY[kñÍnÅÇhâÉ„2àìÍX¯a∆Y«<E0ŒëÃ|ÜASä'ÏR(k-6ÈÜïñ“^»§’6ﬂD5óø=È|>¥ÎŒÕõ«ÄR¸Xˆ+P·(2+”ÛË‹°¿ Õ=(ã_≤ï/òë∫.n’ÇUC«/ù†«Cí@T5√ÈÊùf8÷Ï˜óP‹©∂´⁄‡◊åU=æà:Íí¢ÚxÏmà€úƒM-∏ªúè@%€ô¨F<ñq0¸i'∞'y’ïö7ök1ä}û∂™+MGÓ)Tmmï€zq0áb£∞œf¢¶·7'ûuqw V.,‚Á¶≠ò≈•π´ 1VIÃ•õ•U2i¨‘¬ÓCÛÒ#«°YŸ¸Èî¢CJÚ-ƒ0èPÖïôÜﬁH"3•_¸Îfµ—≠vÿkó¡x >ÿÕTÓø⁄g?=#üüS®¡Ú n¸ÅÆ3áà¯e€vc¶s‹2zíá±ﬂ¨x˙1∑:9/3É/Ÿg5˚‹∂›Ì?‡b36˚YÌ_⁄!∏ÉTß◊IlËñj¨Ä"ÓÇ¢´öØÌ÷?˝‰√∫Ô.U<P®∫}µºÀ9,èä«»»ƒ]s[ßPıÜÎìñöC\◊§DˆßÍUqE||ë&e∑0ˇjs9ﬂR~ˆ mN’ãEÁRˆI’•¶vÆΩ&Åxï∑&!öãŒmzR≈+œì¢%[·Mè%◊Ô©Lı“U›êÃ¿TäìôóH„XÀ`/§Í:=Ü‘≥
øar§ºe±Bm3[˝§ÖØVw´z@]l/zxCkÊÁ≠IÂ∞7=áÖï∆vü¸ñØÓ0¥D’gÔV_ø]~[°ÍænZ=â‘#ÎˆÔËŸ…u±Ö<ˆ0N⁄æÅCN)≤J›V∫Á‹{E∫ïÃA§yCê¿aeÉËﬂÒ‰Æ'+%˜‚¸©Ö¸K¬ÒuÌxáSbq"éyr·DH„ º|Å;√+_[¨RôÄ“n‘;¸Y¬äÃ¡¡xÑé«CÙ)8ápanÈ©íü¿<à;ÀC w 8úàîî⁄¿d£•*Y£ø4ÿÌÚ%ÙG(e† ™–e01p⁄úRíB?ˇN∫œˇ_0>Tkv¨Õ•aá;Bà	$â≈Ê%€Ô:UÈÊ^@¿9|]o°ƒ¡Xev»;˝>–A≈‘jQ1•⁄tÀï!–!gˆ°„ÔÂınÄ˚ë+9F™3∏“Ÿƒî†©…ÖIù¿kúKá_£dWmr$›'Ã>Á}|˛-ãUŒ.Bƒ¥‘≈`ÑîG…«ﬁ BälÓv¡OpÉ¸>¯Ù¥B u=é∞,Ê¬~„üüH&íª(m7í¯N¯˜¨%ÈÆè^˙õ™«ï‚‹c` ∫ÿ∞slüèe;3wØ<\ÿáÚ ∂◊îµ’ÄrhÈ∆kKíÎ®©oØ¥)T0_-sèOÅÎ†^‘~6mÈ∞∫KâîÁ˚;¨•Z;eR£Ù5_ßﬁ¡√9üà‚ã¯D|˛	÷·µäòÇÖ)Û8Ãñ?{TI~ 8d„7ì`◊ó]Õ¯'(«∞˜X£xP—pÆï{Zë4´ÄW/}m4åí“eR®√óÖ8∑œâ(Êﬁ˚\ÕÓùK?≥À∫!ì≈AYW¶√(ª>™„ﬂJ{I©Á^&»¨Y1ûã4]È=˙ÛÆ*,‡èi≥tÜìAÜ∞‘äb

€U©0Œˇ-ReÅŸmúÅ˜ACøoï∏»˘ò¯vLzÃ|åpé!Ä§ƒ©ˇ¢ºZÉ™™¢0◊Î9¢1è€⁄:>'F†|\ë˘
¯@P4TT.pQÈ E∫\E‚!àqM¡«XbæBÑ∫Ü›DIl[áŸ4”⁄W"gÍG˝83{ŒY{ÌoØµæo≠√º-ã™L’eºΩyâ&ã0LMáAx∆◊ÃÎ≥`4É&ﬁBΩƒ∏ôh¿4–◊∏”AgÒ©Ñ'—–√‚tπ¶ﬁó a•“GN€/‰Ë7="W¬óËËéÄ›€gme}CﬁúΩ¬?ˆ#{◊Ûºvr°¢¯¸Iö&J⁄èO•ñê‹|˝ætöU)ÏŸïú¢#õˆÁÊÌß’pQ∏jÃ˝ïiÎ7{!sÿD!ÑE»Rπ_Ç˜2?≤@WzŸH3ø>ú˚EˆŸ¸ZC©Ÿﬁ!ŒÍS°å≥¬8ök!ËZñ/‰ œÛNøh%ui„YøäûVèÚ$ÔÈ€°G>ï¥l ÀïÎE©cê&}ZTA¿Ò.8Ék	Öûáq∆J._NSƒo â7òP‘ˇ_¢AmQYÇˆÅZŸ†Ùñ´≤R°W´ÒÛô;sA˝Ò^}¬ú	∏X†◊É™}‚√&M%√äa‡ÕÉüæVxë|ó1ﬂ_G_ß
˚ƒ˝äJÍHÎÆAÉ£8ˆêQnƒ3•_S≈QY kƒ≈,	˝’éÄ‚•Ñπ.ƒq®Áf <◊0$Rqı‘©[∞1wı∂‘¡*å∂®]£ñ¿YˇπPb0É]π•ü6/û&á∑f Ü„Ù:rÛŸ·wVo}kƒ;%Ök&í!Ö‡ÿÄ-à-√Ò%‘¢UU˜’ı˝≈v%;Ü◊]Ã™Nf‰öNê2Ò†Uò+NX±r¬6Ô-xÚ“™√
Ù∂@´ÚnÖè’©¨1∞¥ÖR-‹V"ÂÆÙÿ<∆Éh2A’úCªÇ#˝K+‰â¢T´ı¬PúIYs á∞^Ïm6t=éal	xêKWãŒa$¥”ÈnŒ∏qÃéÜ‰îß„òK»©fvM0˙8gπ…s°RF∂™Ø‡%Ó*¢PwËácÁ»ÌÑ´íËù"é˜G°:+ˇwˆY:s}‡˙ø+Ñãæbé˘≠MU	:u%z Q1„óÏπQÃm˚ÀÜ7ÜnÆ¿. ¸xeD|ÿ*ù´ÓB–ò}£†å‘ºÇ‡ﬂﬂv„D¸|◊,°◊wáÃ!˛s6~Ü•;òàâ¢C˜1#[•ìˇ·ñÉ˛ˆPÛ“ñì2Õ¢˙±í[‘MXØÃ5,ì9É;∑]r-IgÊNò€Êåﬂ)eÎÂ1H@˚#ü≤ˆ§u˜pfIÒY=¸}‚¿‹£a¨U«¡Å[$¥H˜lTá¬„-èm\Ó…ïÕx‰Ú˛œÛ(õå£Q£xë«ÀîÖü'@≠¯ø‡PHqäﬂìàèoP–Véˇ)÷#‚gåAÕÈç…1NW §b+<Ê‹.=CäÏŸõA•¨√ÇT¨O“•m'ÛV≠Xºé{∏û]œìÂˇ2óõ!u`ëÚÜ\mÃ;ÊA‹F-E∑0uı÷ ® ®j≠v*o:Òd¸ÆkﬂgaŸ˘È"ÅY§˝¡lm4Ô≈‹¸yysÛf≥™ÌkUä»ıÃ`Ø8Œ™d´2¬¢j{§ÜEäYÓ¢Oœt≠im3˘2_üˆ=X#ÏMLLŸFwfü=@Çß¬cN<7—¨Md"cúÍ0ﬂJ:“ÿ|x∆zm ìå7NgP^qBß£‡øe "´éñópâ@û¢Ç,J}1ñó∂8*˝•pÔﬂ&Çk€ùœæùSêÇ;î)¸Wfv˛K—ê£JWR’∞Jd∂äï†¿XW≈÷·jîÄ?d¢9£Ã◊|mŸ4KáKå*U1®aÇNﬁ¥Lèç⁄≤öD«ÓKK†x˘Ω&Säô<;aπÖs„1•ÜÔüc;[˚Úlõ5¥Õ∂:’+•;ˇSàÄvÜ ›úïø¬⁄8SGÄâ˘ô`àIÑBC≥°ÛJFØÌŸŸ,‘hèo⁄ùOåΩ-}_´LOO?⁄∑oeÅ^ﬂ˜u%®ü(ˇ)¿ §°·endstreamendobj70 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[29/uni03BC/uni00A0/greaterequal]/Type/Encoding>>endobj71 0 obj<</Ascent 961/CapHeight 714/CharSet(/uni03BC/uni00A0/greaterequal/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/R/S/T/U/V/W/X/Y/Z/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r\/s/t/u/v/w/x/y/z/endash/registered/idieresis)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 77 0 R/FontName/BADDLA+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj72 0 obj<</Filter/FlateDecode/Length 578>>stream
Hâ\‘Kã‚@‡}~E-ªMuÎﬁD	.Ê¡8Û4)ù¿Cåˇ˝‘…iz`ıò§r?¶Úı~≥Ô⁄—Âﬂá[}à£;∑]3ƒ˚Ì1‘—ù‚•Ì≤≤rM[èø¶œ˙zÏ≥<-><ÔcºÓªÛ-õœ]˛#ùºè√”Ω,õ€)æf˘∑°âC€]‹ÀØı·’ÂáGﬂˇâ◊ÿçÆpãÖk‚9›ËÀ±ˇzºFóOÀﬁˆM:ﬂéœ∑¥Êﬂ?ü}t’Ùª$¶æ5ÒﬁÎ8ªKÃÊEz-‹|ó^ã,vÕÁm∆eßs˝˚8dÛrì..¸jΩHyã\,‰] U•!Â™òéW8^ÊÈ¯;Û;ÚåyÜºd^"Øôqˇj√ºAÊ¨ÙïÚé9ÅÁû≥<f˘íπDÆò+dœÏëÖYêiÛ∞yeVdc6dö=Ãûf≥ßŸ√ÏÈÙpz:=úBè¿#Ù<Bè¿#Ù<Bè¿#Ù<Bè¿#Ù<Bè¿#Ù<≤b^!≥OAüBß¿)t ‰düÇ>˚Ë3–`4òÕÊ@sÄ9–`4òÕÊ@sÄ9–`Vv•ËJ9W1W9W1W9W1W9w˙ø)Á*Ê*Á*Ê*Á*Ê*Á*Ê*ÁÍ4ó])∫Rv•ËJŸï¢+eWäÆî])∫2veË Ë7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉÜµUQ‚˛ÀèÁŒ-ù[>‘O/Ô¥πœΩ£~C⁄6¶≠j⁄/∞S¥]¸‹Õ˙[Ô“*º≥ø S'yendstreamendobj77 0 obj<</Filter/FlateDecode/Length 4835/Subtype/Type1C>>stream
HâtT}PT◊è›}àèeè"»€ß“2≤Ó∫¡‘BÑ0( ê/iHÇ¥ÀÓcYYX‹Â#†('%à5SÜ‘†»8VM?Q¸$*j1ZC4”ô8©V›úáávz”v¶ù˛ÒÓ=˜›sŒ˝ùﬂ˘†)•E”¥nqRrrfí>Mr‘J’vãyôT#e.œØ∂[óTN©»-+e] è±X˝‚Ùã`†,›ö≤_K©à# ó
§¬iäû^Si7-XºƒªôíL6ódÆñ\“™≥câ≥™ﬁe∑ïUãØƒ≈ôÊâ1&SåòduñHb~ΩªZ™pãÈïß´ È"6V£ò‰pày^∑ò'π%W≠˜ÁøÅäv∑h´]f´TavïãŒRrg∑Jé…eì\b≤´∆R^av[ ÏïR•ò¥tû(Ωkq‘∏Ìµí£^tÿ-R•[≤ä’e.gç≠LÃ¥W:´Î´$"î∏ÃÆzqiEI⁄<—\i+Ãı"AÈílv∑7´hØ-í´⁄Lˆï5.ª€j∑T€ùïn„¸‘¸Â^'ØäV©î"ƒ–≈Pîü5ù•ööH-•œ†úµõ¢nSt≥ï„e0ãZF=†#Ëz#Ωü†Ô“œ|},>'Ø(úäae¶r≠J≠™SmSùP›g¬ô5ÃuÄ:N˝+ıyıc_∆7ﬁ◊Â€Ê{’˝í˝÷˘=ˆó¸??„?6-fZ˘¥Ì”“∫Fß'OÔò~á-b∑≤GŸøF.
Ï—Ã—ºßπÙA–ZÌ<mÉˆ∞÷√	‹Ó2˜è‡Ï‡ú‡∆M≠˝Úx?M÷»~E´Rnô»ôla`~¡„Îë
FÒ,ﬁ√‰ı$S<%√ÎHŒå|Ü˜JË=±,ÏoÜÜa≥wÈ¨”ˆxæıÄÜ,‹±&n∏I>È¸ÕˆﬁﬁﬁvKr|≥≈biÓf5Û»ÔŒhv¸™A‘†fUÚ±õåá—ˇØ‡iˇ_á‹ÁM[&OÒ9z¢E√∞∏Q˚"§éÓáP‰MÛs—dFäa(A√˜h<L,Ëƒ{B$Ï˛–ˇ1ÜXN+øA˝^‰1!»«¢ûÿ}¶#` 1D3ÊÇI`E˘x,#f∆˚
0í˜0XçlØ+XK‚ú°wÓ<ª3gËd‚3 ˇæB÷¢Ç`5€
&˙yÊòx4ùY≠.m∞ïΩ/§®¯m˜OÑ®Y‰†¸Ècp@qûË¿ˇø-!LD5nKÌDC›-ç<( g*∂°qLﬁ;F
ë`ÇH,îx»ÿ~· ‡'%ò*ºÆ∆å5˘ôY´C™Äë{yl?mÑD∞mÖtx⁄G1mMòÅÖ€Y≠‹2â5√Îk$d¢pñ:°1◊f_kÄY§îÿÜVP Ω
Mî‰∑A…„fKœÆCG~};Ùﬁ≠=ó˛l Múç˙‘$¸âPÇ˙Œá[Æ¸)¸xweŒ‚¶ÚÃ<]nÅjvt·´®ì”¶¢Äucıµ–2¶›ì∏gì]ë‹»∞-jøw
A¿£eWM∫65wth˚·É†ƒ∆∞§‘	 m=9ÿ◊Uï.p#π5ŸBëÅ·æ:…åt‰ffΩ˜fJf„Ò˚tﬁà!äTPGwÄDoI˝∂Ò(2$æ.UÉõ'ÉxÿåQQ‘uP.ïp.ÉÎ&≥UıcpÉ≤Ë1P†‘z1ºß‰Ñâ~R≈p˜VMÚ*‡ÓTÔÊÆÓ√·◊>]â~ÛW≠»ÕZˇeüÖwô¯=$Ìiêq¸ò R`p¶¿›[f^]Z•€¿láü´†„%;=0éi;HöÑéºÛúìÂπõáà∆£?«µÕòèEò‘ç1∂é{17¬B‡ä∆PõU‰.uÎ6`ûm8˘dgyÅÜó˘Ô∫‹Û]í~—˙Ï'ß5]º∑qäy4tóú¶Ë"°N´Qá9Ÿh´¡D_–3;°Ë:8¡‚|¡G=ìîO·Lí:Å˘2Ö„‹”(‚_€É3H—Ωµf‹{`π±ËÅ‰o|x«Ókß√@Å4#üè∫¬›√u¬5˜t—jKJL7Nj˚uÁæææù+ﬂHwÆ4õù˚˛(pO◊·u˛zÁπk◊:ñ¶5,œ»h8?$L1z†Á%é 1LÒ5æ‚xúŸ6˙ÎøÖ√⁄v»Éê‰ÇÙ“Ö1…&\à\ü¥É}ª>ﬂ•k≥3s÷%&
‹¯;ø?KTö`êˇ˙£K7Ü∂Êºˆ°†ØëÚÚk~'x[§µmà∑e1îI˘£ƒ>Ωö1BeüºI—gyyh&71¯H˘£ƒ>˝∏ˆÂÌzÔ•UÂQOz7‘®·!F ˘TÏER´zá€†i≠”∂ gπª≠JàfˆÅ^yÃ>$[4Éπ≈*Le∏—oQ√∑1_‚m©fˆb´ C∂G€ˇrTêãÊ‰˛hfH≠ƒüÂ£¬KÒ[Ω=%ﬂ‹Òáãw√ b·1Ù}"gÒgòõ˚\K”lUÒ∫&J9HÃÆÙπccã\©∫|ÜÌmÙ»=Ì‚=ôx„£‹πYÆ‡ü≠=ñ†£
çXÅ=há¿çBÓAòFF2hî™ﬁÃ™8(ÓºuK‡û\˚¨xééΩ€Íë7zË‚4ìõÅ®c ˇô‡øÅRD`ëõ¶–]f¿Á„Xí¿_÷eFÈﬁ`ÿ’≠Ñ´Â‰ã'Cñƒ¨Ë'£˚Ô≈≤¸Òü|W}XîUÒ}_h›Yö◊°Y∆ﬁ…D4”@RD◊≤]‰S\0ET0æŸg@pƒƒàA@M‘%æD@ÖÒPÒ#A≤ÇG©µ∂V06ü›u<óΩ„ÛÏπÔÄ⁄ÌÛÃ‹π˜‹˚ªøs~Áú[Ç;Ò{'NÓcI7πΩˆÏZ{<Ò⁄≥kÃ”ëCΩ…S«MÅIŸÇ|@z≈$∂°‚Hû
f¸yê∫Rﬂ ˙∫ìÓ™ßjíƒ∂ûˆ Æ:m/f,3’OªÔ!àmooåuœƒºÒxWﬂÍìƒˆKï>°ZŸ…}X´X}sƒ£«∞Ù¡⁄é£k®#≠¢K†
IS–Ï2›Ëö4Fè5D⁄≥…«k2z”Ëƒ4´bø)l¶/éµ~i÷¶∞∞¨œ˙•r™éË§ì≥a8›º
s$r@Pú≤Ïıî)<5F∏03i+n<ç#s .s‘Ö«r—»†ëWƒ"Àd»bFBÏëØ}d»>í3à£’PVr/†4HO¢πác5L$=\Åπ‘à<ñw4Ás~…ÁËf^10G—víö‰‡iŒÂ¿ç‘fΩÅßDœ1ﬂ`¯Y±[çXÍaT5iwÛr<ƒ'¡k4n,
1<Ì!»¯ı›ª∆∑1mÎ=‹‹Ù_A∞§(G4ò ﬁ$;`˛∏xò˙èòı(¸u““=r‘uÛ∑™◊{yD«≤êcŒÎ| Qçπ£
^B%U‚√^˛ã˙ÕÀﬁåé˜÷˙Û‘—Ï§¬EùºH¯KGbÉ
¥ªÈã˘âÖI∆¥?ÇÀ^>…¯Qcﬁ7xuk«+üÿ†(n∏~+Î;Wô(?ÂÂ…ï„A2VVfãCÂê™J®˙˙RX(â_ÅÀΩ^xıáƒN:´éıŒØj€—”ÕáõæêƒÅŒäh-H•<º¯Z'V–©nûòÂw9¶º'â?ﬁﬂ|"uπÉˇ∫ƒ˜ñ¶∑ÙHeÇ\ÜP'rpd˝–s‡bG¸◊Öâ©…McÒ€ƒ¬/G†A`çµ¬¨œ¿râ‰ 9ÇgF®èO∆Ö/q,0Íôœ…~ÎB4˜«k8X¡3WsXtßôèpπº9¬)‡–.£ãÿrÂæ—≠"vˆ∞ÄøCä±dﬂ1s8 {f&Ò‚…%hh‡¢! É%ñ¡x‘Ô%Â÷òa´®7}ÃÅ+ˇ/»˘7Õë„ﬁ√b0qtÔB3ù!ì£ØÛä
ã!‡e∞+Ã^≠√;◊	∞Çx1ôÃ§5x‘\®·‰lDRêµJ‚e]iOºP)ï<îíL¨ÃŒH°A†áÃY∏R?†#íÓÓ∞≤‘T¿dÄ›êò!Í‡b´*öÀ´õ[KR¢6È3£∂KoË8±mNrTîì√;uã~æ—hÏ:.a∂—Ìﬁ≤[WîaÉ≠ê˛Xn≈Y¯LâÎ•Ó”›÷Q;iÊ Ïj6™˛í∫q„÷∫¶3ÂGªJáwW}j¥QÍMŒ˜‡ë	‹“î≠X?gÄ$nEÇ U`{∞˚J˜AjKm≥¸˝˝≤∫¡V¢≈56:Ñ⁄]á∏ÛﬂADÑ}Gπ∞›⁄≠tåÒXlXmXU·Æ”Pÿdå®@\6HE*∫¨†…4ÆÛ*8]æ”$¨ûÛu—ë+≤:±RÿËÓ=ø?(L˙ºO‡-É◊}eûüø´Éá	C¢:ﬂíS¶AXÓX>ƒvqﬁ∏éÜ≤≥µH√KæÖ)√œBÃW`—&ò@PøDÍÄYÿa&ó∞ÔÓÉÁ˜H‘é_ñù©Yïqıö∂E¯vRôpˆ–≈Œã˚#≤∑ä&`¯ßπi ~;‘o	∏3¸ß6˛òÒ`cQ—Æº"„?q® %5?E„¸˛l≠ü◊‹>AQH}ˇ˛:8∂ö‡á{Œ¨¬JÙLã”1*ö°è‘´ƒ:É–ïQ≤ACgß”YTI√;ﬂÇâß[™NUk<˘‡¥uAíx*#so—6≠ò∫≠(€X‚Ä‹äßúoÑ°"\ª	/Kdü 6”⁄à•Ï@˚ïŒ√´È.æ+WnøÒ5ré7då[±ÄPÉd›äwÄQæª™¶≠©D"ôº”t¡¥™m¡ àøF&K»dG√˙¥Ô1ˆœ°—9vÒz¸˚∆$¥~éÕSœ‰øOÏW‰$≠Œﬁπ´`ß4S»+-Õ;§ª∫ˆü¥‰ïÑßvÖÚ∆∞*Õbg©Ã⁄ØÉ@ì9ò√ƒ{;Îé‚o-ç‰‰˜ìÓ8ºåÏ~å_v=•Â3e™ÿ.ﬂÚµ∫ˆtcq …<ôçÖ_çâF¯œ⁄ã.À√uíÅÔ‹yÃW≥rm⁄ÍÏ‚≈¡N™,¸çÔèÙâø¡ü¯πÃ`xjhÓ%\c÷Ïôß∂™FãYàªCù˙∑ŒÇ≈Ö∏v¸Ç“Ùè¸Ö.Œ’R◊êY‘WÀÚ·ƒΩ∑{ªJÇ1Z∂Ω˚·mòàn§Œ:p3¡£q(L;#ˇO⁄Êï*\¶+‡◊÷‘ÎŒè	[+Z¥≤Aœpé\îo˘Ïˆ'ûlì·}"»ß"≈Õ'…¿X4g„7îÖåI”¢ÀÛıe-5ÿ>)®;ËjΩúëƒìå=^º	˝¬≠é#gå≈yyF‰U»œﬁëü≠	åéKd‹üº≈PÖ Ï)+¿éNFÓïñoÒ«
T•é-Ôbåÿ¸≠∏¡˜OœØA◊∏Wsë≈˙Ú*áÜ⁄“˙œ%ÖH`WŒèt—ÁÈÀAÆK#˙ì∞:éƒpG?®»åqXõ®[ër¨M*PÏ>`ró•û‘è
E”+àÜZïnÜ	«´k•üÖº€Û∂k÷Ô8‹¨Ö”ò∞?ëKr#ÅiO%æaùäÜéÚ˛…	Q[ :$"†kX¥L;Ò˝•≥ïjXˆ
ï5aµáx[C:ÃU¯7âä√f¥ÊzÊÛ†!ırÂÉı¯l°QÇæ'>ıWÅù=.czàÎËóf%Ûx∞aË†Oñ„ﬁ'ÈlﬁG¯≤Óc9˜clôd≤ÍmpìO}âÒôYÀÅ#<ÔPOˆã:A-æçlÖ"‘"r+˝’U⁄DÖi3ª„∫∑”C+±,û<‘⁄"öÇÇx§’ÖÄ`ÑûDA©&ÿ(lä,•∑B±Eƒ
‚•≈õ.ÑÙ†=öCçÇΩæ)oæmPëÔf√õæ˜æ7yµib‡≈2ÆºÀbP?IÇO≈iﬁÈåNÔG<¡˜∏QΩ7sm∏R©?≠dÌ¸<"ñV;ëVÇä&äÿ2∫± ORë∂˚ ºj^◊R(]Éàk¸õÂ.JÕüÕè›æd∂1‘Ó@§∏È?©⁄_5;4n¸0èc“ÿh¨ø˙4¥}˝ÌàÀÚﬁûRÃµ7èoﬁöô+d/ö›U‰!G9xåˆ-œr‰1ÿOû1»9—cå~≤hîëÿ1F‚u{sô√≥∏Á€ﬂ¬È¸:ﬂR|“q}é2∆Ω‹ÀÔú*≠îÙÎÙYr"ŒøKÍ?Ê$ïR:K8+ùóUˇy5^[g
%ˇîËrèl“∂<lıi+JΩ◊ﬂ’Ñƒ6ù6∏M˘Bì∆Ñ‘Gp€¯,ÎÒQ’äG.HªÓMát5ƒ±–ƒr„k#ﬁXê˜˜¶ÈNêfœn#Ó∫∏õA‡˚~∞jYªl˝ﬂ∑’-s˙ë˙-¿ ’6Ôendstreamendobj67 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[26/uni03BC/lessequal/fl/greaterequal/uni00A0/fi]/Type/Encoding>>endobj68 0 obj<</Ascent 932/CapHeight 714/CharSet(/uni03BC/lessequal/fl/greaterequal/uni00A0/fi/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/R/S/T/U/V/W/Y/Z/b\racketleft/bracketright/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/quoteright/quotedblleft/quotedblright/bullet/endash/registered/degree/mu/multiply/idieresis)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 78 0 R/FontName/BADDLA+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj69 0 obj<</Filter/FlateDecode/Length 640>>stream
Hâ\‘Õn‚0‡}û¬ÀvQ%ÿ◊◊çÑê¥ã˘—–y HL'“¢ê.x˚ÒÒA≠4Hêì8∆üØí[nv€›–œ¶¸9]⁄}úÕ©∫)^/SÕ1æ˜C±∞¶Î€˘~ñ€Ûa, 4yªŒÒºNóbπ4ÂØ4xùßõyXwóc|, Sß~x7ø7˚GSÓ?∆Òo<«a6ïY≠LOÈèæ∆Ôás4eûˆ¥Î“x?ﬂû“úØ;ﬁnc46ü/ài/]ºéá6Ná·=À*}Vf˘ö>´"›„µ„¥„©˝sòäÂbùnÆ\≥Y•‹§l≠
Ú◊+’ÙÕc[éy‰ó<∂Æê_øÓ´”π≠Úπ≈òıÃòcüôüëkÊ|ˇöyç‹07»\ﬂbmªeﬁ"sÌtHôkßC±t\◊a]∑`^ [fãÏò≤0cØéNßSfEÃô~ø£ﬂ¡ÔËw;˙¸é~ø£ﬂ¡ÔËwùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)Ÿ…:ÍÏYgè:{ö=Ãûf≥ßŸ√Ïiˆ0{ö=Ãûf≥ß”√ÈÈÙpz:=úû6õ≤nä∫)
É“†0(˘YVÚ≥´z^ëiPîuS‘MÈ…œ≥“£(=
èﬁﬂ‘Mi”lc›u”˚ªÅ∫÷-†nÅ˛ †?¿Ë˙¸Å˛ †?¿Ë˙¸Å˛ †?¿_c-[-pΩvÃ◊¬Ìs∂‘ Î¨ÔÔ<ˆ’p/ˆ“–÷¿∂•gœ˜˛¬&tÔ6hG©köœ^◊~LSjsπµÊ˛ÜŒ÷Ò≥˚éó—§Y¯ˇ yÔJùendstreamendobj78 0 obj<</Filter/FlateDecode/Length 5116/Subtype/Type1C>>stream
HâlT}TWü!ôIíqS…LA∂Å(¸¿"∏‘èƒV[4êÇê`@D∂¯U±,x¥jı∏∂~Wˆ‘∂àVî.†K©´K‘5J+r0j–É´´xÓ‡ÀûÓ{∂=ß˛ÒÓª˜›èw˜›˚pLÏÉ·8≤@õöö©}'ù+.ÁÏ¶<√ÆåÀ\°∑£SÃ^Ügp~≤òg˝iîà
_mzïH‚ ~v‡ï)¡K‰)Ñ¡§X ÇÖ„„†2≥I•^êRÃŸl‹˙2CqÅï3ÿ9ÎÔ’©¥™Ki•’TPhg„4’t6^•ägµFK.«Í+mvÆƒ∆fòÛ,÷RãUp5∆∞⁄‚bVÁu∞±:Œ∆YÀΩáˇœò5ŸXk∑å\â¡∫éµ‰:ìë+ŒÂ¨úïMµñÂ≠+1ÿÚ
MfŒÃjMgπy≈e6S9W\…õÚ8≥ç3≤ˆB´•¨†êÕ4ô-ˆ RN`r≠k%ª®$7}:k0ŸC%+diÂ
L6/(#k2≥yú’nˆ¢2´…f4ÂŸM≥-&6Mø¬dk‰Ú1°F8Üë&ùÑÖ`jKÚ¡ÊaÿÇ…ò	√J|0;ÜU`ÿ;äa'0¨√z0|áÀÒñ˜]l÷è˝àœ¬-¯QºøáÉÈ√¯î˙Ùy, 5àÓäóä?$ƒÑùÿEú'Óí!≥…Ø%2I¶ƒ"Ÿ%·•oKgHç“è•ë∫∆Ω5Æh‹qﬂqæ•æÙm˜}Ï7”/«oõﬂø6ˇ4ˇO˝]„ì∆4˛ú,Zñ+´ñµ Üe?dÏ
∏=!v¬Œ	ùÅSWÓlóãÂ˘F˘1˘ J≠°¨‘™{"5qÒƒ˚Ù$:Ö˛àn°Ô”Ó]um¸p.–6QùòØ]Ê©%°u—h|L¿âXtëØ‡Ÿ#Òê9c<ÃCÇLÚ¥óC^IÜˆ ‡Pı%hºÙæó»/8¡◊	a^Ju¿B^FÎk;˚˚:;;ÙM≠^œÏıL°ˇI¬’—|b!I˛Wık™√M4¯}‚~˙Ù7ÚC~ƒFF~~5¿G°áo÷	˘#/Ò∑®á°[ldﬁñä¬ç ˜$É«v_ø•∏+ë	ôœ*TÅü¡Ú—z:
 F3êZÅ‚;P¬#D+ø!µV ·ê†ÄÿFòy&+ˆr@‘Å2È«‘3@≠Ä¯,HàZπöÏAa_°pî†@±f43	y˝¬˘≥†¸".ã Çw”ÏŸ≤Â@òí£€ÚùˇqNmkJ~ƒe]l.~K%≤G °‘Å√g|‰ÄRAB…@•®4JIe›kêAoÜ;˚KP+∫;i®ÌCµøÙqøåDÛûÚ—ç¯fhmÆ¶$l›Hdê≤™jœÅüv¡ó∂U”†ﬂF¯,®“#}2"ö≥È@œ ^—†⁄°Ä∂Ö
™®Ì(a€a•îU)Á//ÖT9ò®◊¯FﬁÒ4êT”hˆR	ucG§¶&˛C©¨™Æèˇõoq¡:óà_‹G£o…}≠'œ6üzz/¯˚ÎÁøLqe=P¬ü7UØB
•ã<” ‡∑˛ú±dn˛Z›*ÂÚUƒúE⁄8¨‡Ÿ1(Öc{9s»õ]Û\_C–QW∫ãÍ≠Åt§œìÆ3Yâ»…˙,Üj≠IZ◊€Õ®∑ê≈˚QË`J˜†üd∑œ>§¨óP-Xœ·ØÆﬁT|oA”–$]"/\ﬂ±wpË˙Òïãï‘-,µËwÛïBË5§1$;yNxÛf°…ö¯kt=˙•ì…{Ë9∞%@ÚŒŸ<7K2ñ„∞b˙3.∞ªD]0@ﬂ⁄A¸©π„Ô˜5sS™ê82∫z®I©&u's`Zà ¢Rﬁ^˝^e°Yπ≥˛$®ÔC7^cæ„ùC˛•ÃÆ5BÒºñˇí>U!HÉõë%†»Éh9d+©æ>!0˘›á(`Ó⁄ïÎ´ôùùd”H_%≈_>ï≥åºóÓ9¸‡ë`˛ËpúVkãS3Ø∂=Ëa∆û◊”áüÊßâNÛnìiq∫HCÿöP3Ú˘+}BÄ©Õ0·<‡-/;õ€•ˇÚL{ç˚º69‰MÆ,ıº	≤Ëò$5®[@:Ù8ÔªÑìJj¯f„Án)ÄLs 1ße 2˘Û˜oöï‘ÛKﬁ≤È
j÷z˙ç´“3ÃøˇÌbKõ„⁄…øv3‘s$Ò,£Ôû∫⁄ﬂ*31±(S£)∫zW9vªŒ	wºUJÒ÷I®“p;®Ë¢É(4`ÿvHÄàj°ÂΩEB¡ãBQö|E}Á.û8»‘Î…Çmh!ä4º¥ËB#ÃH/=ø2>Z0èÆºﬂ€{¸æã°Ü]«„Á3c√≠?}L·¥w=‚◊É¯’«Z_æ8Pé∑Ú¢V∞—|™"œ|»‚ÖÂeΩ'≤‡Î •„'ª^¡Œ·i —1ÒkÊÁ[Tó?aÀêÛQñGXÑló–ºŸNxÚ¨ÆBæï?@›ﬁ‰&/B6»vîM∏I¥b4á@æ$5‘A◊ì—≠ e«Íúpƒ5Nyó¨Ó4∑–[0Dèê∑ØrQiÎ2c‰O™ShXIBTˇw0’eº¶>¬”≈w⁄‹›≠ &Æ%Fâ,§+Ö˛79ÿ¥Vã|fm…g"Ñ‡’N˛±S˛çˆπg∫©g‘)¸m3j7E≤o!Y(ÑW”6C={x"-©ûqì¿Ó¯›U≈uÖ]wÁ1uC*kg§àB≈vE$⁄ ¬Z5(Uc˝ç¸ƒ„œ≤Ÿí‡O–ÇÇiê(V5+¢&•Æ±Y1é@«∞RhÇ—&Íù=o9ßwbœÈ9ú3º}{ﬂ~˜æÔ˚Óù˘=4@O”V°s≈“ÿZöY7 S>O–Ô¥mfª|≈Æ∫‚Ä}˝jq˙Ë0,l7äúßﬁÖËf¡BàtÅT+D£s§≠Ö0∫A†IDka∑oä™VTÆè¸sëûÖ›P%“*‰œ1—≈m
÷≥˜Èw–˚Ï˛©ÕˆƒVÿfáÜGÈm\◊,oñ+t'J∑C]˙ˇ¢zÛ—¨ƒœœ∑,Ñ+údìY∫>
¸YÆ)¯@µœVÉÁö{œõ]&hO!êA¨yLË∞±˘ÖR+5Å5t(”É`¢Éd§µ:◊ôô˜Ø33îh£7€ùÚT5ºäÅ%È4ÒÌîào6∂ÚÿiÁ^ÅÁ!h?pºB¢ß'¿“yíÈ sá–-r¨ÜÃDBÕÙ{∆ﬂ„Ò)f—È˘ËÎ≤V§gúû¯),√S4}™6áÏP∑!çÖ¿‘!„¿áS√XÜ4èæDËxWc¬á‹¡‡/FM ïØ√X$1f[È‡2·VÀ◊-,∏Æ30ZIå´tòXZ,0î`úõe*ºÜ:$√Áj›Ê‘#s“ ≠íê±´ â¶	Q–˛ô˙°©ÜøÖèˇ©º†-¬ä∑†(ÏJ≈7ˆªk—*£ou¬XJCÕÒù7L˜ﬁ©ë¡…Yø~Öl«¿ØÏû[J˘
·Ô+±_¡ÛÑì≠ümõX.ºO’ñÂã˜çy@r+∂‹qsh±£}≈Ö¯rî‘˝¨Ì˝ÄôÉû…”∑îπOzö≤¢)lN¬à∂lXSG3˚°¿’œ]„n»…ÚG:5≈I«Í©q-ı5
‹5∫˙‡9öÈ7+9-öÁnS›ˆo∫ÑPBÉõßAƒ=›·<wˆ—>˙3X‚˜ı'çù<wC™MAÔ√KÙUêÄ”ƒaßßbEWR$ƒy:‹≤Vxu9‚Püá:hõâc√∏‹Ü_Úri®´î\õ¸Î∞ïÕ˜ï%´]iæ°pÀÀ$ÁpÎ`∂hƒ¢!Ö‡<A«πú
∆…N\k!◊>TıòªúãπTò‰Ûêp+~êØ3râê@ Ü#*® ’ç·r7„O‹ˇS.êã+á	ÌŒ"Íu¥ﬁı,$ sÒá®?Ì•c°óô§8Ç‹"™aE˚’á|‰i"	t ônó	óX⁄È˙«Êgsñ€T¢®qñÑ[Ä≥¸ûç∆êß{?àj0¢‘håÒﬁPyÄp3e≥-±˛ù#m^uéŸDI‹íGÈﬁcòøÈøÙÒö¥Ls·¸|û2+ÆinÓ)≥˝ÇŒ&‹=±Ó\-èñë;∑¨—|T_]SˆÓ˚Bªs«vS±~Ωπ∫FÄãÏ%Ûj†ﬁ)…TÀ√tùékZ¥8c—¬¸ÜœöˆU◊VÚá:Àè‘{h◊íß€azûWãK\3ræZ˜c’É>Ò`8ı¶⁄º–»óÓ¬Hû+öI´u]Ñk∂YÿÏΩMŸ≠zº æö|ïx19uÕí|¡[ä”ÿ‡€\P€TG∞PRÀº¸úÓoÄEk_OCPgq-S0ÿÔ4∞∑xI|kVT@)2R?˝Ë‚ﬂ´§?áS–	¡ΩÄ‡¿˚`èÿWÂ?ûjãB'GÊıÄ7ÚBùÅn5ë≥˘©uÈzTÄo6yé2¿µ656ÓU|∂»ÿ≈*≈á◊mfSùp¿bdÇ7‹–dèÓÅéŒs¯5¨√®;∆[„qJ}o¿1Û9‚Õ.6DL0Égæî‡Ï¥ ƒÆÍí‘]>íº™ﬂ“ANTÌ;Œü¥œ'3V,ù!ƒEEúÈ„l¯N%OjM¥cNØJXÓ&¨ó7Ë‹	ç,ò6≈∞TΩÓÓ[Hh’EÓfåâ=]ú—ò®ßcó·Û‚ú=4ªﬂ˘Zkï`â&9e”È[≥ñhﬁ!ı€:sΩFt∂Bò"^yÉRG^rº§nAåÑàÌ[ø˛SÏÎºãH≤'€a~H˘Ù´≥6Ò√w®4π>Ô?ﬂ©⁄$ÙmIÆ7êçÙù{ã∆Ÿ”sùKq◊´M‚¨0AÆ◊\-$ÕúùRRly∑ÑÁÚ£XŒZZQa™–ˇÎƒ'¡YÆ1IÓVä«¬k
5TBØê©¥í‘Ãò‰H√P¶FrUÇâ¥
ªÕìV6å√ôiPLA…I)cá≥ï?Ô±\sá;1©˝√ìW'Fÿgñ√y˙/J_û±ëo/Ã˘0^üí¥ˆµMÇâp›¨ˆÒ±ÓJq÷ˇ[*wèa7î0$ï<«¶™s@éC]á,•A‘B`ÚI∑DÇñÉ/“hÚ2ÍKÉxÏ;´u”
ÔÇxT›Ω’WH=®GA‡Tú1Cr·7vy˙#(…n∑$Aªﬂ1†hrÂÛ¬Qì~‰g‚T,AâÖ,9`]sN¬qx¥öÂ3≤≥ãï¥màÔß«ã©zÿÒ˛/+‚a2n`(:∆vÂXåsfD∞\∑—ƒ6SèKß•«i Á¨ugïŸEK3∞d9“Êº√äápÌX1Ë'∑øl8]ªggÈ.û´Ëaπˆ≤≠o[
ı	o¸>u£Ç©Æ_ö¶∫kÊıÈ∑ÃêÊHÓŒ≈»/Ë:J∑¡:E?92=ê™Ø‰_ﬁ$p∑/o≤E˘Õäﬂ≤.º‡ãÀ(¡E™áywØµ Û¿xh^∂*cçÒÉøÎmÂµÌU91ä4∑ŸÂóln]"AQÇ.B¢´ˇ–˚◊ö2À^˛*[˙Nâ©@üU\yFÄ¡€dòÇ∏‹æ≥!Ô1‰`7∑	âúˇ«ÃY;Øú‚ebpy≤qÊˇ≤^˛!MDq Á∏ÓÆ&°›µõJ¶´l-ZƒÊ*J®≠Å†í˝ÊH0¸£øƒ~HÙÀh∂ÖÕíXbQ&FAÂ†≤-+¨™i3∆Ñ0±•dˆ}„]–˜NÉ 	Ç¯r˜}Ô{Ô›{ÔÓ˚æüÔÀÖº–≥Ó˛.5vbh1y¶7™Œù—Ntà5£núárK£Z°≤ITH∂iL[„Inn$é$≠=5Åñ≠K"–>mLq`ÇôÿS⁄&¨∂ÎÒQøN+õ±å83i;âÒâÖbËEÏ“^Ï¯|ß‘ø z!⁄qD≠XÍ–&Z*ß≤18EJNàM{πÉ'è6‘f76yœ◊€Ös~À≠Ï….˘mßå‰v*÷Êû73˜\Ãµs¢\eÔíZöxzV…ÁÏêà“S4â{Mﬂ·Ô%5”Ptày?˙”∞a˜]„Ô]Íº›!=Ãgvl…⁄0*P”Ùúˆt-®~ﬂÕà≈¡à˛˙◊»
ßïzQQôügÉ‘lT~ÒOoP›æ}†ºQ∆C‹,xÁwTqc¢;Ä0Q lR¢!fM&c±d“3¨VÉÑÎ˝6˝k±»{cﬁ«@jôÀ<ª9w∫·9ùÓ«ﬁ∏Ä,≈]y¬ﬂÈæö≠yü
∂~’˚VìµP>¿’;$œDsƒôHD"âÑ3b6;ùfi@
B°@MUUçzBR:<?ÜaX37e0…ÄîZ.≥p$Q«“®Éìy∫ 8π-xg0+QuµDKxôVä∞Ï£‡Qsπc∑ªLOïë∫¿B-‡B±Ä¶±f°.¥SóÑáù"µa∂•á≠(™∂°‰P=›ä¢jõ>}™áî3É§ú%=b†è⁄Aìö>5ï«⁄NóÏTì>,¡NÓ¥`·d∆ë!O‹3î˘i]ôﬂlIqh“∆√∆ïö˛_ü›{%»<≤§rJtJ9<úL¿v.,(˘¥é€#ê˙D*Ü=3çI~êë∑bô _h)á'ó/t;W&ê<®„Ç¬y:Öçã∞1Ωî~Ãü™ˆ”J?¨ÛpΩm§MyzQ8⁄ë™Ó†ıóÁ£e¢Mªº@^_ˆ˘|›ii·k≠≠iã…˛•§Y¸)¿ ß¥5∑endstreamendobj27 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj28 0 obj<</Length 38944>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 36 723.6481 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 723.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 723.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 723.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 723.6481 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 138.24 694.7062 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 175.68 694.7062 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 36 694.4562 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 694.4562 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 658.4543 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 175.68 694.4562 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 658.4543 cm
0 0 m
0 35.752 l
S
Q
1 w 
q 1 0 0 1 36 544.9447 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 544.9447 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 544.9447 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 544.9447 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 544.9447 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 213.12 658.4543 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 250.56 658.4543 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 213.12 694.7062 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 250.56 694.7062 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 213.12 694.4562 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 694.4562 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 658.2043 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 658.2043 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 639.2024 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 175.68 658.2043 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 639.2024 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 213.12 658.2043 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 639.2024 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 250.56 658.2043 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 639.2024 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 138.24 619.9504 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 175.68 619.9504 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 213.12 619.9504 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 250.56 619.9504 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 36 583.4485 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 583.4485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 564.4467 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 175.68 583.4485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 564.4467 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 213.12 583.4485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 564.4467 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 250.56 583.4485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 564.4467 cm
0 0 m
0 18.752 l
S
Q
q 1 0 0 1 138.24 545.4447 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 175.68 545.4447 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 213.12 545.4447 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 250.56 545.4447 cm
0 0 m
0 18.502 l
S
Q
q 1 0 0 1 36 638.9524 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 638.9524 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 638.9524 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 638.9524 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 638.9524 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 619.7004 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 619.7004 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 583.6985 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 175.68 619.7004 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 583.6985 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 213.12 619.7004 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 583.6985 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 250.56 619.7004 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 583.6985 cm
0 0 m
0 35.752 l
S
Q
q 1 0 0 1 36 564.1967 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 564.1967 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 564.1967 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 564.1967 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 564.1967 cm
0 0 m
37.44 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 727.248 Tm
[(T)74.2 (able 13:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Efficac)10.2 (y Results in Beta Thalassemia - BELIEVE)-12 ( )]TJ
-0.017 Tc 0.017 Tw -4.737 -2.631 Td
(Endpoint)Tj
13.938 0 Td
(REBLOZYL)Tj
-0.198 Tw 0.402 -1.062 Td
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(224\))Tj
0.017 Tw 3.513 1.062 Td
(Placebo)Tj
-0.198 Tw -0.054 -1.062 Td
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(112\))Tj
0.017 Tw 4.191 2.125 Td
[(Risk)-17 ( )]TJ
-1.124 -1.062 Td
(Difference)Tj
0.048 Tw 0.322 -1.062 Td
(\(95% CI\))Tj
0.017 Tw 5.15 1.062 Td
[(p-v)16.2 (alue)]TJ
0.048 Tw -29.272 -2.496 Td
(\037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.494 0 Td
[(33% Reduction from baseline in)-17 ( )]TJ
-0.494 -1.062 Td
[(RBC transfusion burden with a)-16.9 ( )]TJ
0 -1.062 Td
[(reduction of at least 2 units for)-16.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 129.1145 669.2242 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 36 660.7242 Tm
(12 consecutive weeks)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF00090007>>> BDC 
0 -1.344 Td
[( )-518.5 ( )]TJ
EMC 
0.789 0 Td
[(Primar)-17.8 (y endpoint \226 )37.2 (W)18.2 (eek 13 to)-17 ( )]TJ
0 -1.062 Td
[(W)18.2 (eek 24)]TJ
13.49 0.531 Td
(47 \(21.0\))Tj
5.389 0 Td
(5 \(4.5\))Tj
0.017 Tw 5.285 0.531 Td
(16.5)Tj
0 Tc 0 Tw 7.6 0 0 8 238.0278 649.9723 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 217.8524 641.4723 Tm
[(\(9.9,)37.2 ( 23.1\))]TJ
-0.198 Tw 5.203 0.531 Td
(<)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(0.0001)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.738 -2.406 Td
( )Tj
EMC 
0.789 0 Td
[(W)18.2 (eek 37 to )37.2 (W)18.3 (eek 48)]TJ
13.49 0 Td
(44 \(19.6\))Tj
5.389 0 Td
(4 \(3.6\))Tj
0.017 Tw 5.286 0.531 Td
(16.1)Tj
0.048 Tw -1.026 -1.062 Td
[(\(9.8,)37.2 ( 22.4\))]TJ
-0.198 Tw 5.203 0.531 Td
(<)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(0.0001)Tj
/T1_0 1 Tf
0.048 Tw -29.738 -1.875 Td
(\037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.494 0 Td
[(50% Reduction from baseline in)-17 ( )]TJ
-0.494 -1.062 Td
[(RBC transfusion burden with a)-16.9 ( )]TJ
0 -1.062 Td
[(reduction of at least 2 units for)-16.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 129.1145 594.4685 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 36 585.9685 Tm
(12 consecutive weeks)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF00090007>>> BDC 
0 -1.875 Td
[( )-518.5 ( )]TJ
EMC 
0.789 0 Td
[(W)18.2 (eek 13 to )37.1 (W)18.3 (eek 24)]TJ
13.722 0 Td
(16 \(7.1\))Tj
5.158 0 Td
(2 \(1.8\))Tj
0.017 Tw 5.517 0.531 Td
(5.4)Tj
0.048 Tw -1.026 -1.062 Td
[(\(1.2,)37.2 ( 9.5\))]TJ
0.017 Tw 5.275 0.531 Td
(0.0402)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.434 -2.406 Td
( )Tj
EMC 
0.789 0 Td
[(W)18.2 (eek 37 to )37.1 (W)18.3 (eek 48)]TJ
13.49 0 Td
(23 \(10.3\))Tj
5.389 0 Td
(1 \(0.9\))Tj
0.017 Tw 5.517 0.531 Td
(9.4)Tj
0.048 Tw -0.915 -1.062 Td
[(\(5,)37.2 ( 13.7\))]TJ
0.017 Tw 5.163 0.531 Td
(0.0017)Tj
/T1_0 1 Tf
8 0 0 8 36 527.3291 Tm
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tc 0.136 Tw 3.375 0 Td
[(T)73.7 (reatment of Myelodysplastic Syndromes with Associated Anemia in )]TJ
-0.017 Tc 0.048 Tw 0 -1.064 Td
[(ESA-na\357ve P)24.2 (atients)]TJ
/T1_1 1 Tf
-0.003 Tc 0.081 Tw -3.375 -1.514 Td
[(The ef\037cac)20.3 (y of REBLOZYL was evalua)-9.7 (ted in the COMMANDS trial \(NCT03682536\),)37.3 ( a)-3 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.064 Td
[(multi-center)74 (,)37.1 ( open-label,)37.1 ( randomized active-controlled trial comparing REBLOZYL\036)]TJ
/T1_2 1 Tf
0.015 Tw 29.152 0 Td
(versus)Tj
/T1_1 1 Tf
0 Tc -0.24 Tw /Span<</ActualText<FEFF200A>>> BDC 
2.348 0 Td
( )Tj
EMC 
( )Tj
-0.007 Tc 0.06 Tw -31.5 -1.064 Td
[(e)0.5 (p)0.5 (o)0.5 (et)0.6 (in)0.5 ( a)0.5 (l)0.5 (f)0.5 (a)0.5 ( in)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h a)0.5 (n)0.5 (e)0.5 (m)0.5 (i)0.5 (a)0.5 ( du)0.5 (e)0.5 ( t)0.5 (o)0.5 ( I)0.5 (P)0.5 (SS)0.5 (-)0.5 (R)0.5 ( v)0.5 (e)0.5 (r)-17.6 (y)0.5 ( l)0.5 (o)-9.5 (w)37.5 (,)37.4 ( l)0.5 (o)-9.5 (w)37.5 (,)37.5 ( o)0.5 (r i)0.5 (n)0.5 (t)0.5 (e)0.5 (r)0.5 (m)0.5 (e)0.5 (di)0.5 (a)-9.5 (t)0.5 (e)0.5 (-)0.5 (r)0.5 (is)0.5 (k)-7 ( )]TJ
0.064 Tw 0 -1.064 Td
[(myelod)-10.1 (ysplastic syndromes or with myelod)-10.2 (ysplastic/myeloprolifera)-10.1 (tive neoplasm with)-7 ( )]TJ
0.002 Tc 0.11 Tw 0 -1.064 Td
[(ring sideroblasts and thromboc)19.6 (ytosis \(MDS/MPN-RS-T\) in ESA-na\357ve pa)-10.4 (tients \(with)2 ( )]TJ
-0.009 Tc 0.053 Tw 0 -1.064 Td
[(endogenous sEPO levels of <500 U/L\) who require regular red blood cell \transfusions.)28 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.017 Tw -31.5 -1.064 Td
[(F)20.2 (or eligibility)55.2 (,)37.2 ( pa)-9.8 (tients were required to ha)-9.8 (ve had 2 to 6 RBC units/8 weeks con\037rmed for)-17 ( )]TJ
0.012 Tw 0 -1.064 Td
[(a minimum of 8 weeks immedia)-9.8 (tely preceding randomiza)-9.8 (tion.)]TJ
-0.008 Tc 0.057 Tw 0 -1.604 Td
[(The COMMANDS trial inc)20.2 (luded 356 pa)-9.7 (tients randomized 1:1 to REBLOZYL \(N)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
28.206 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.625 0 Td
[(178\) or)-8 ( )]TJ
-0.018 Tc 0 Tw -28.831 -1.064 Td
(epoetin alfa \(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.1 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.605 0 Td
[(178\).)37.1 ( Randomiza)-9.8 (tion was stra)-9.8 (ti\037ed by RBC transfusion burden,)37.2 ( RS sta)-9.8 (tus,)19 ( )]TJ
-0.008 Tc 0.059 Tw -5.706 -1.064 Td
[(and endogenous serum er)-18.2 (ythropoietin \(sEPO\) level a)-10.2 (t baseline.)36.8 ( )36.9 (T)73.7 (rea)-10.2 (tment was started)-8 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.064 Td
[(a)-9.6 (t 1 mg/k)0.5 (g subcuta)0.5 (neously ever)-17.6 (y 3 wee)0.5 (ks.)37.4 ( )37.4 (T)74.4 (wo)0.5 ( dose)0.5 ( level increases wer)0.5 (e allo)-9.6 (wed \(to)-9 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.064 Td
[(1.33 mg/kg and to 1.75 mg/kg\).)36.7 ( Doses were held and subsequently reduced for adverse)-16.9 ( )]TJ
-0.016 Tc 0 -1.064 Td
[(reactions,)37.3 ( reduced if the hemoglobin increased by \0352 g/dL from the prior c)20.3 (yc)20.3 (le,)37.2 ( and held)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
(if the predose hemoglobin was \03512 g/dL.)Tj
-0.011 Tc 0.04 Tw 0 -1.604 Td
[(A)0.5 (ll p)0.5 (a)-9.6 (t)0.5 (ie)0.5 (nt)0.5 (s r)0.5 (ec)0.5 (ei)0.5 (ve)0.5 (d b)0.5 (es)0.5 (t s)0.5 (upp)0.5 (or)0.5 (t)0.5 (iv)0.5 (e ca)0.5 (r)0.5 (e,)37.4 ( w)0.5 (hi)0.5 (ch)0.5 ( i)0.5 (nc)20.5 (lu)0.5 (de)0.5 (d RB)0.5 (C t)0.5 (ra)0.5 (ns)0.5 (fu)0.5 (si)0.5 (on)0.5 (s a)0.5 (s ne)0.5 (e)0.5 (de)0.5 (d.)26 ( )]TJ
-0.008 Tc 0.056 Tw 0 -1.064 Td
[(P)18.3 (a)-9.7 (tients were trea)-9.7 (ted for 24 weeks and were assessed for ef\037cac)20.2 (y a)-9.7 (t tha)-9.7 (t time point.)29 ( )]TJ
-0.021 Tc 0 Tw 0 -1.064 Td
[(T)74.3 (rea)-9.6 (tment beyond 24 weeks was optional based upon response to trea)-9.6 (tment and absence)-21 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
(of disease progression.)Tj
0.001 Tc 0.1 Tw 0 -1.604 Td
[(T)0.5 (h)0.5 (e)0.5 ( m)0.5 (e)0.5 (d)0.5 (i)0.5 (a)0.5 (n)0.6 ( a)-9.5 (g)0.5 (e)0.5 ( o)0.6 (f)0.5 ( t)0.5 (h)0.5 (e)0.5 ( 3)0.5 (5)0.5 (6)0.5 ( s)0.5 (t)0.5 (u)0.5 (d)-9.4 (y)0.5 ( p)0.5 (a)0.5 (r)0.5 (t)0.6 (i)0.5 (c)0.5 (i)0.5 (p)0.5 (a)0.5 (n)0.5 (t)0.6 (s w)0.5 (a)0.5 (s)0.5 ( 7)0.5 (4)0.6 ( y)0.5 (e)0.5 (a)0.5 (r)0.6 (s)0.5 ( \()0.5 (r)0.5 (a)0.5 (n)0.5 (g)0.5 (e)0.6 (:)37.5 ( 3)0.5 (3)0.5 (,)37.5 ( 9)0.5 (3)0.5 ( y)0.5 (e)0.5 (a)0.5 (r)0.5 (s)0.5 (\))0.5 (.)38 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.013 Tc 0.031 Tw -31.5 -1.064 Td
[(The)0.5 ( )0.5 (tria)0.5 (l )0.5 (po)0.5 (pula)-9.6 (t)0.5 (ion )0.5 (w)0.5 (as )0.5 (56%)0.5 ( )0.5 (mal)0.5 (e )0.5 (and)0.5 ( )0.5 (44% )0.5 (f)0.5 (ema)0.5 (le; )0.5 (79)0.5 (.5% )0.6 (were)0.5 ( )37.4 (W)0.5 (hite)0.5 (,)37.4 ( )0.5 (0.6)0.5 (% )0.5 (Bla)0.5 (ck )0.5 (or)-13 ( )]TJ
-0.017 Tc 0 Tw 0 -1.064 Td
[(Af)0.5 (ri)0.5 (ca)0.5 (n )37.4 (A)0.5 (me)0.5 (ri)0.5 (ca)0.5 (n,)37.4 ( )0.5 (12)0.5 (.1)0.5 (% )37.4 (A)0.5 (si)0.5 (an)0.5 (,)37.4 ( a)0.5 (nd)0.5 ( r)0.5 (ace)0.5 ( )0.5 (was)0.5 ( n)0.5 (ot)0.5 ( r)0.5 (ep)0.5 (or)0.5 (te)0.5 (d )0.5 (in )0.5 (7.)0.5 (9%)0.5 ( o)0.5 (f )0.5 (pa)-9.6 (t)0.5 (ie)0.5 (nt)0.5 (s.)37.5 ( E)0.5 (thn)0.5 (ic)0.5 (it)0.5 (ie)0.5 (s)-17.1 ( )]TJ
0.003 Tc 0.114 Tw 0 -1.064 Td
[(were reported as 85.4% for Not Hispanic or La)-10.2 (tino pa)-10.2 (tients,)36.9 ( 6.5% for Hispanic or)3.1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.011 Tc 0.043 Tw -31.5 -1.064 Td
[(La)-10 (tino pa)-10.1 (tients,)37 ( 7.6% for pa)-10.1 (tients with no ethnicity reported,)37 ( and 0.6% were unkno)-10.1 (wn.)26 ( )]TJ
-0.018 Tc 0 Tw 0 -1.064 Td
[(IPSS-R risk c)20.2 (lassi\037ca)-9.8 (tion a)-9.8 (t baseline was 9.3% ver)-17.8 (y lo)-9.7 (w)37.2 (,)37.2 ( 72.2% lo)-9.8 (w)37.2 (,)37.2 ( 17.4% intermedia)-9.8 (te,)19 ( )]TJ
0.005 Tc 0.123 Tw 0 -1.064 Td
[(0.3% high,)37 ( and 0.8% missing.)37 ( )37 (T)73.9 (able 14 summarizes the baseline disease-rela)-9.9 (ted)5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(characteristics in the COMMANDS stud)-9.7 (y)55.2 (.)]TJ
ET
/GS1 gs
q 1 0 0 1 213.12 230.0344 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 79.5076 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 230.2844 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 213.12 230.2844 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 36 230.0344 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 230.0344 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 79.5076 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 79.5076 cm
0 0 m
74.88 0 l
S
Q
1 w 
q 1 0 0 1 36 250.0063 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 250.0063 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 250.0063 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 138.24 208.7806 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 213.12 208.7806 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 36 187.0268 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 187.0268 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 187.0268 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 122.7653 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 213.12 122.7653 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 36 122.5153 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 122.5153 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 122.5153 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 111.7634 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 111.7634 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 101.0114 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 213.12 111.7634 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 101.0114 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 138.24 90.2595 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 213.12 90.2595 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 138.24 79.7576 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 213.12 79.7576 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 36 68.7557 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 68.7557 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 58.0038 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 213.12 68.7557 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 58.0038 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 138.24 37 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 213.12 37 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 36 208.5306 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 208.5306 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 208.5306 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 176.2748 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 176.2748 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 165.5229 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 213.12 176.2748 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 165.5229 cm
0 0 m
0 10.502 l
S
Q
q 1 0 0 1 138.24 154.771 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 213.12 154.771 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 138.24 144.0191 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 213.12 144.0191 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 138.24 133.2672 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 213.12 133.2672 cm
0 0 m
0 10.752 l
S
Q
1 w 
q 1 0 0 1 36 36.5 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 36.5 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 36.5 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 36 219.2825 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 219.2825 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 219.2825 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 36 197.7787 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 197.7787 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 138.24 187.2768 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 213.12 197.7787 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 213.12 187.2768 cm
0 0 m
0 10.252 l
S
Q
q 1 0 0 1 138.24 47.2519 cm
0 0 m
0 10.752 l
S
Q
q 1 0 0 1 213.12 47.2519 cm
0 0 m
0 10.752 l
S
Q
BT
/GS2 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 253.6063 Tm
[(T)74.2 (able 14:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Baseline Disease Characteristics of P)24.2 (atients in COMMANDS)]TJ
-0.017 Tc -4.737 -2.055 Td
(Disease Characteristic)Tj
0.017 Tw 16.401 0.531 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 190.7111 241.4144 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 163.7036 232.9144 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(178\))Tj
0.048 Tw 7.672 1.062 Td
[(Epoetin Alf)20.2 (a)]TJ
0 Tc 0 Tw 7.6 0 0 8 268.2095 241.4144 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 238.7086 232.9144 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(178\))Tj
0.048 Tw -28.139 -1.389 Td
(Hemoglobin \(g/dL\) \226 n \(%\))Tj
/T1_1 1 Tf
0 -1.344 Td
[(Median \(min,)37.2 ( max\))]TJ
15.829 0 Td
[(7.80 \(4.7,)37.2 ( 9.2\))]TJ
9.638 0 Td
[(7.80 \(4.5,)37.2 ( 10.2\))]TJ
/T1_0 1 Tf
8 0 0 8 36 200.2987 Tm
(Serum EPO \(U/L\) \226 n \(%\))Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 36 189.5468 Tm
( )Tj
EMC 
0.789 0 Td
[(Median \(min,)37.2 ( max\))]TJ
14.577 0 Td
[(78.7 \(7.8,)37.2 ( 495.8\))]TJ
9.869 0 Td
[(85.9 \(4.6,)37.2 ( 462.5\))]TJ
/T1_0 1 Tf
-25.235 -1.344 Td
[(IPSS-R risk c)20.2 (lassification at baseline \226 n \(%\))]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(V)18.2 (er)-17.8 (y lo)-9.8 (w)]TJ
16.185 0 Td
(16 \(9.0\))Tj
9.869 0 Td
(17 \(9.6\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.843 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(Lo)-9.8 (w)]TJ
0.048 Tw 15.722 0 Td
(126 \(70.8\))Tj
9.869 0 Td
(131 \(73.6\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.38 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(Intermedia)-9.8 (te)]TJ
0.048 Tw 15.953 0 Td
(34 \(19.1\))Tj
9.869 0 Td
(28 \(15.7\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.344 Td
( )Tj
EMC 
0.789 0 Td
(High)Tj
0.048 Tw 16.416 0 Td
(1 \(0.6\))Tj
10.212 0 Td
(0 \(0\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.417 -1.344 Td
( )Tj
EMC 
0.789 0 Td
(Missing)Tj
0.048 Tw 16.416 0 Td
(1 \(0.6\))Tj
9.869 0 Td
(2 \(1.1\))Tj
/T1_0 1 Tf
-27.075 -1.344 Td
(Ring sideroblast status \(per WHO criteria\) \226 n \(%\))Tj
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(RS+)-17 (\036)]TJ
0.048 Tw 15.722 0 Td
(130 \(73.0\))Tj
9.869 0 Td
(128 \(71.9\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.38 -1.344 Td
( )Tj
EMC 
0.789 0 Td
(RS-)Tj
0.048 Tw 15.953 0 Td
(48 \(27.0\))Tj
9.869 0 Td
(49 \(27.5\))Tj
0.031 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(Missing)-17 ( )0.5 (\036)]TJ
0.048 Tw 16.759 0 Td
(0 \(0\))Tj
9.526 0 Td
(1 \(0.6\))Tj
/T1_0 1 Tf
-27.075 -1.344 Td
(SF3B1 mutation status \226 n \(%\))Tj
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(Muta)-9.8 (ted)]TJ
0.048 Tw 15.722 0 Td
(111 \(62.4\))Tj
10.1 0 Td
(99 \(55.6\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.344 Td
( )Tj
EMC 
0.789 0 Td
[(Non-muta)-9.8 (ted)]TJ
0.048 Tw 15.953 0 Td
(65 \(36.5\))Tj
9.869 0 Td
(72 \(40.4\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.344 Td
( )Tj
EMC 
0.789 0 Td
(Missing)Tj
0.048 Tw 16.416 0 Td
(2 \(1.1\))Tj
9.869 0 Td
(7 \(3.9\))Tj
0.004 Tc 0.119 Tw 8 0 0 8 324 727.2481 Tm
[(The efficac)19.8 (y of REBLOZYL in the trea)-10 (tment of anemia in ESA-na\357ve adult pa)-10.1 (tients)4 ( )]TJ
-0.008 Tc 0.055 Tw 0 -1.07 Td
[(wi)0.5 (th)0.5 ( M)0.5 (DS wa)0.5 (s e)0.5 (st)0.5 (ab)0.5 (li)0.5 (sh)0.5 (ed)0.5 ( a)-9.6 (t)0.5 ( t)0.5 (he)0.5 ( t)0.5 (im)0.5 (e o)0.5 (f th)0.5 (e i)0.5 (nt)0.5 (er)0.5 (im)0.5 ( e)0.5 (f\037)0.5 (ca)0.5 (c)20.4 (y)0.5 ( an)0.5 (al)0.5 (ys)0.5 (is)0.5 ( ba)0.5 (se)0.5 (d u)0.5 (po)0.5 (n t)0.5 (he)-7.9 ( )]TJ
-0.006 Tc 0.068 Tw 0 -1.07 Td
[(proportion of pa)-10 (tients who experienced both red blood cell transfusion independence)-6 ( )]TJ
-0.019 Tc 0 Tw 0 -1.07 Td
[(\(RBC-TI\) [de\037ned as the absence of an)-10 (y RBC transfusion during an)-10 (y consecutive 12-week)-19 ( )]TJ
-0.002 Tc 0.088 Tw 0 -1.07 Td
[(period] and an associa)-10 (ted concurrent mean improvement in hemoglobin by a)-10 (t least)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
[(1.5 g/dL for an)-9.8 (y consecutive 12 week period during )37.2 (W)18.2 (eeks 1-24.)]TJ
-0.009 Tc 0.052 Tw 0 -1.61 Td
[(At the time of the interim ef\037cac)20.1 (y analysis,)37.1 ( 301 subjects were inc)20.1 (luded in the ef\037cac)20.1 (y)-9 ( )]TJ
0.056 Tw 0 -1.07 Td
[(analysis,)36.6 ( of which 147 )0.5 (were in the )0.5 (luspa)-10.4 (tercept arm and )0.5 (154 were )0.5 (in )0.5 (the epoetin alfa)-8.9 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.07 Td
[(arm,)37.4 ( which is about)0.5 ( 85% o)0.5 (f the total inform)0.5 (a)-9.6 (tion.)37.4 ( )37.3 (The key ef\037cac)20.4 (y results are sho)-9.6 (wn)-6 ( )]TJ
-0.017 Tc -0.025 Tw 0 -1.07 Td
[(in T)74.2 (able )-36.7 (15.)]TJ
ET
/GS1 gs
q 1 0 0 1 501.12 605.1306 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 605.3806 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 501.12 605.3806 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 324 605.1306 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 605.1306 cm
0 0 m
74.88 0 l
S
Q
1 w 
q 1 0 0 1 324 625.8225 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 625.8225 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 625.8225 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 324 543.3949 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 543.3949 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 543.3949 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 448.1075 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 448.1075 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 448.1075 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 394.8719 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 394.8719 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 394.8719 cm
0 0 m
74.88 0 l
S
Q
1 w 
q 1 0 0 1 324 341.6362 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 341.6362 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 341.6362 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 324 248.7243 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 248.7243 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 248.7243 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 566.0128 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 501.12 566.0128 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 426.24 543.6449 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 426.24 512.7771 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 501.12 512.7771 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 324 501.3432 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 448.3575 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 426.24 395.1219 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 426.24 342.1362 cm
0 0 m
0 10.434 l
S
Q
q 1 0 0 1 324 490.1592 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 490.1592 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 470.7253 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 501.12 490.1592 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 470.7253 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 324 436.9236 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 436.9236 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 417.4897 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 501.12 436.9236 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 417.4897 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 324 383.6879 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 383.6879 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 364.254 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 501.12 383.6879 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 364.254 cm
0 0 m
0 19.184 l
S
Q
q 1 0 0 1 324 585.4467 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 585.4467 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 585.4467 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 532.211 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 532.211 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 532.211 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 565.7628 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 426.24 554.8289 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 501.12 565.7628 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 554.5789 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 501.12 554.5789 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 512.5271 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 426.24 501.5932 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 501.12 512.5271 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 501.3432 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 501.3432 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 470.4753 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 426.24 459.5414 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 501.12 470.4753 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 459.2914 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 501.12 459.2914 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 417.2397 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 426.24 406.3058 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 501.12 417.2397 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 406.0558 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 501.12 406.0558 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 364.004 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 426.24 353.0701 cm
0 0 m
0 10.684 l
S
Q
q 1 0 0 1 501.12 364.004 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 425.99 352.8201 cm
0 0 m
75.13 0 l
S
Q
q 1 0 0 1 501.12 352.8201 cm
0 0 m
74.88 0 l
S
Q
BT
/GS2 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 629.4225 Tm
[(T)74.2 (able 15:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Key Efficac)10.2 (y Results in COMMANDS)]TJ
-0.017 Tc 0.017 Tw -4.737 -2.1 Td
(Endpoint)Tj
16.401 0.531 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 616.8705 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 451.7036 608.3705 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(147\))Tj
0.048 Tw 7.5 1.062 Td
[(Epoetin Alf)20.2 (a)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 554.9577 619.4846 Tm
(a)Tj
7.6 0 0 8 557.5165 616.8705 Tm
(\036)Tj
7.6 0 0 8 559.483 616.8705 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 526.7086 608.3705 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(154\))Tj
0.048 Tw -28.139 -1.461 Td
(RBC-TI for \037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
4.747 0 Td
(12 weeks with associated concurrent mean Hgb increase of \037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
23.923 0 Td
[(1.5 g/dL)-17 ( )]TJ
-28.67 -1.062 Td
[(\(W)18.2 (eeks 1-24\))]TJ
/T1_1 1 Tf
0 -1.398 Td
[(Response ra)-9.8 (te,)37.2 ( n \(%\))]TJ
0 Tc 0 Tw 7.6 0 0 8 380.9089 576.9987 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 568.4987 Tm
(\(95% CI\))Tj
16.743 1.062 Td
(86 \(58.5\))Tj
0 Tc 0 Tw 7.6 0 0 8 476.1149 576.9987 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 447.9338 568.4987 Tm
[(\(50.1,)37.2 ( 66.6\))]TJ
10.305 1.062 Td
(48 \(31.2\))Tj
0 Tc 0 Tw 7.6 0 0 8 551.1199 576.9987 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 522.9388 568.4987 Tm
[(\(24.0,)37.2 ( 39.1\))]TJ
-26.176 -1.398 Td
[(Common Ra)-9.8 (te Difference \(95% CI\))]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 417.6889 559.9288 Tm
( )Tj
EMC 
0.024 0 Td
(b)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 478.3473 557.3148 Tm
[(26.6 \(15.8,)37.2 ( 37.4\))]TJ
0.017 Tw -20.309 -1.398 Td
(p-value)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 344.182 548.7449 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 489.3253 546.1309 Tm
(<0.0001)Tj
0.048 Tw -21.753 -1.398 Td
[(Mean Hgb increase \0351.5 g/dL \(W)18.2 (eeks 1-24\))]TJ
0 -1.398 Td
[(Response ra)-9.8 (te,)37.2 ( n \(%\))]TJ
0 Tc 0 Tw 7.6 0 0 8 380.9089 523.7631 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 515.2631 Tm
(\(95% CI\))Tj
16.511 1.062 Td
(106 \(72.1\))Tj
0 Tc 0 Tw 7.6 0 0 8 477.8735 523.7631 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 447.9338 515.2631 Tm
[(\(64.1,)37.2 ( 79.2\))]TJ
10.305 1.062 Td
(75 \(48.7\))Tj
0 Tc 0 Tw 7.6 0 0 8 551.1199 523.7631 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 522.9388 515.2631 Tm
[(\(40.6,)37.2 ( 56.9\))]TJ
-26.176 -1.398 Td
[(Common Ra)-9.8 (te Difference \(95% CI\))]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 417.6889 506.6932 Tm
( )Tj
EMC 
0.024 0 Td
(b)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 478.3473 504.0792 Tm
[(23.2 \(12.2,)37.2 ( 34.1\))]TJ
/T1_0 1 Tf
-20.309 -1.398 Td
(HI-E per IWG \037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.67 0 Td
[(8 weeks \(W)18.2 (eeks 1-24\))]TJ
/T1_1 1 Tf
-5.67 -1.398 Td
[(Response ra)-9.8 (te,)37.2 ( n \(%\))]TJ
0 Tc 0 Tw 7.6 0 0 8 380.9089 481.7114 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 473.2114 Tm
(\(95% CI\))Tj
16.511 1.062 Td
(109 \(74.1\))Tj
0 Tc 0 Tw 7.6 0 0 8 477.8735 481.7114 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 447.9338 473.2114 Tm
[(\(66.3,)37.2 ( 81.0\))]TJ
10.305 1.062 Td
(79 \(51.3\))Tj
0 Tc 0 Tw 7.6 0 0 8 551.1199 481.7114 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 522.9388 473.2114 Tm
[(\(43.1,)37.2 ( 59.4\))]TJ
-26.176 -1.398 Td
[(Common Ra)-9.8 (te Difference \(95% CI\))]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 417.6889 464.6414 Tm
( )Tj
EMC 
0.024 0 Td
(b)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 478.3473 462.0274 Tm
[(22.3 \(11.8,)37.2 ( 32.8\))]TJ
0.017 Tw -20.309 -1.398 Td
(p-value)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 344.182 453.4575 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 489.3253 450.8435 Tm
(<0.0001)Tj
/T1_0 1 Tf
0.048 Tw -21.753 -1.398 Td
[(RBC-TI for 24 weeks \(W)18.2 (eeks 1-24\))]TJ
/T1_1 1 Tf
0 -1.398 Td
[(Response ra)-9.8 (te,)37.2 ( n \(%\))]TJ
0 Tc 0 Tw 7.6 0 0 8 380.9089 428.4757 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 419.9757 Tm
(\(95% CI\))Tj
16.743 1.062 Td
(70 \(47.6\))Tj
0 Tc 0 Tw 7.6 0 0 8 476.1149 428.4757 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 447.9338 419.9757 Tm
[(\(39.3,)37.2 ( 56.0\))]TJ
10.305 1.062 Td
(45 \(29.2\))Tj
0 Tc 0 Tw 7.6 0 0 8 551.1199 428.4757 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 522.9388 419.9757 Tm
[(\(22.2,)37.2 ( 37.1\))]TJ
-26.176 -1.398 Td
[(Common Ra)-9.8 (te Difference \(95% CI\))]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 417.6889 411.4058 Tm
( )Tj
EMC 
0.024 0 Td
(b)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 480.1059 408.7918 Tm
[(17.0 \(6.7,)37.2 ( 27.2\))]TJ
0.017 Tw -20.54 -1.398 Td
(p-value)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 344.182 400.2219 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 491.5399 397.6078 Tm
(0.0012)Tj
/T1_0 1 Tf
0.048 Tw -22.045 -1.398 Td
(RBC-TI for \037)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
4.747 0 Td
[(12 weeks \(W)18.2 (eeks 1-24\))]TJ
/T1_1 1 Tf
-4.747 -1.398 Td
[(Response ra)-9.8 (te,)37.2 ( n \(%\))]TJ
0 Tc 0 Tw 7.6 0 0 8 380.9089 375.2401 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 366.7401 Tm
(\(95% CI\))Tj
16.743 1.062 Td
(98 \(66.7\))Tj
0 Tc 0 Tw 7.6 0 0 8 476.1149 375.2401 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 447.9338 366.7401 Tm
[(\(58.4,)37.2 ( 74.2\))]TJ
10.305 1.062 Td
(71 \(46.1\))Tj
0 Tc 0 Tw 7.6 0 0 8 551.1199 375.2401 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 522.9388 366.7401 Tm
[(\(38.1,)37.2 ( 54.3\))]TJ
-26.176 -1.398 Td
[(Common Ra)-9.8 (te Difference \(95% CI\))]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 417.6889 358.1701 Tm
( )Tj
EMC 
0.024 0 Td
(b)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 480.1059 355.5561 Tm
[(19.1 \(8.6,)37.2 ( 29.6\))]TJ
0.017 Tw -20.54 -1.398 Td
(p-value)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 344.182 346.9862 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 491.5399 344.3722 Tm
(0.0003)Tj
-0.015 Tc -0.198 Tw 7.2 0 0 8 324 332.3243 Tm
(EOT)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.463 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.611 0 Td
[(End )-257.8 (of )-257.8 (trea)-9.9 (tment; )-257.9 (HI-E)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.08 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.611 0 Td
[(Hema)-9.8 (tologic )-257.9 (Improvement)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.445 0 Td
(\226)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.511 0 Td
[(Er)-17.8 (ythroid )-257.9 (Response; )-257.8 (NE)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.454 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.611 0 Td
[(Not )-257.8 (Estimable;)-15 ( )]TJ
-0.017 Tc 0.048 Tw -29.788 -1 Td
(RBC-TI)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.497 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(red blood cell transfusion independence)Tj
0.017 Tw 5.04 0 0 5.6 324 318.9383 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.086 Tw 7.2 0 0 8 328 316.3243 Tm
[(The majority of stud)-10.3 (y participants \(>)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.619 0 Td
[(90%\) were outside of the United Sta)-10.3 (tes and a non-U.S.-)]TJ
-0.017 Tc 0.06 Tw -13.619 -1 Td
[(licensed )0.5 (epoetin )0.6 (alfa )0.6 (product )0.5 (was )0.6 (used )0.6 (in )0.6 (the )0.6 (control )0.6 (arm )0.5 (for )0.5 (such )0.6 (pa)-9.8 (tients.)37.2 ( )0.6 (Direct )0.6 (comparisons)-17 ( )]TJ
0.001 Tc 0.141 Tw 0 -1 Td
[(ha)-10.4 (ve not been established between REBLOZYL and U.S.)36.6 ( licensed epoetin alfa product for)1 ( )]TJ
0.004 Tc 0.155 Tw 0 -1 Td
[(the trea)-10.1 (tment of pa)-10.1 (tients with anemia due to IPSS-R ver)-18.1 (y lo)-10.1 (w)36.9 (,)36.8 ( lo)-10.1 (w)36.8 (,)36.9 ( or intermedia)-10.1 (te-risk)4 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1 Td
[(myelod)-9.8 (ysplastic syndromes or MDS/MPN-RS-T in ESA-na\357ve pa)-9.8 (tients.)]TJ
0.017 Tw 5.04 0 0 5.6 324 278.9383 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 328 276.3243 Tm
[(Common ra)-9.8 (te difference is based on the Mantel-Haenszel stra)-9.8 (tum weights.)]TJ
5.04 0 0 5.6 324 270.9383 Tm
(c )Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.005 Tc 0.161 Tw 7.2 0 0 8 328 268.3243 Tm
[(Based on CMH test stra)-10.4 (tified by baseline RBC transfusion burden \(<)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
27.099 0 Td
[(4,)36.6 ( \035)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
1.733 0 Td
[(4 pRBC units\),)42 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 268.3243 Tm
( )Tj
0.008 Tc 0.175 Tw 7.2 0 0 8 328 260.3243 Tm
[(RS sta)-10.2 (tus \(RS+,)36.8 ( RS-\) and sEPO level \(\033)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
16.008 0 Td
[(200,)36.8 ( >)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
2.84 0 Td
[(200 U/L\).)36.9 ( 2-sided p-value is presented.)45 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 260.3243 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.2 0 0 8 328 252.3243 Tm
[(The sta)-9.8 (tistical significance level a)-9.8 (t the second interim analysis is two-sided p-value 0.03.)]TJ
-0.016 Tc 0.024 Tw 8 0 0 8 324 230.4109 Tm
[(No major outliers were obser)-18.4 (ved in c)19.6 (linically relevant baseline demogra)-10.4 (phic and disease)-15.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
(characteristic subgroups.)Tj
/T1_0 1 Tf
0.017 Tw 0 -1.903 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.081 Tw 3.375 0 Td
[(M)0.5 (y)0.5 (e)0.6 (l)0.5 (o)0.5 (d)0.5 (y)0.5 (s)0.5 (p)0.5 (l)0.5 (a)0.6 (s)0.5 (t)0.5 (i)0.5 (c)0.5 ( S)0.5 (y)0.5 (n)0.6 (d)0.5 (r)0.5 (o)0.5 (m)0.5 (e)0.5 (s)0.5 ( w)0.5 (i)0.6 (t)0.5 (h)0.5 ( R)0.5 (i)0.5 (n)0.5 (g)0.5 ( S)0.5 (i)0.5 (d)0.6 (e)0.5 (r)0.5 (o)0.5 (b)0.5 (l)0.5 (a)0.5 (s)0.5 (t)0.5 (s)0.6 ( o)0.5 (r)0.5 ( M)0.5 (y)0.5 (e)0.5 (l)0.6 (o)0.5 (d)0.5 (y)0.5 (s)0.5 (p)0.5 (l)0.5 (a)0.6 (s)0.5 (t)0.5 (i)0.5 (c)0.5 (/)]TJ
-0.016 Tc 0.06 Tw 0 -1.07 Td
[(Myeloproliferative Neoplasm with Ring Sideroblasts and Thromboc)9.8 (ytosis)-16 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.07 Td
[(Associated Anemia in ESA-refractor)-17.8 (y or -intolerant P)24.2 (atients)]TJ
/T1_1 1 Tf
0.003 Tc 0.11 Tw -3.375 -1.52 Td
[(T)0.5 (h)0.5 (e)0.5 ( e)0.5 (f)0.5 (f)0.5 (i)0.5 (c)0.5 (a)0.5 (c)20.5 (y)0.5 ( of)0.5 ( R)0.5 (E)0.5 (B)0.5 (L)0.5 (O)0.5 (ZY)0.5 (L)0.5 ( w)0.5 (a)0.5 (s)0.5 ( ev)0.5 (a)0.5 (l)0.5 (u)0.5 (a)-9.5 (t)0.5 (e)0.5 (d)0.5 ( i)0.5 (n t)0.5 (h)0.5 (e)0.5 ( M)0.5 (ED)0.5 (A)0.5 (L)0.5 (I)0.5 (S)0.5 (T)0.5 ( t)0.5 (r)0.5 (i)0.5 (a)0.5 (l)0.5 ( \()0.5 (NC)0.5 (T)0.5 (0)0.5 (2)0.5 (6)0.5 (3)0.5 (10)0.5 (7)0.5 (0)0.5 (\))0.5 (,)37.5 ( a)3.1 ( )]TJ
-0.01 Tc 0.048 Tw 0 -1.07 Td
[(multi-center)74.2 (,)37 ( )0.5 (randomized,)37.1 ( )0.5 (double-blind,)37.1 ( )0.5 (placebo-controlled )0.5 (trial )0.5 (in )0.5 (pa)-9.9 (tients )0.5 (with )0.5 (IPSS-R)-10 ( )]TJ
-0.019 Tc 0 Tw 0 -1.07 Td
[(ver)-17.8 (y lo)-9.8 (w)37.1 (,)37.2 ( lo)-9.8 (w)37.2 (,)37.1 ( or intermedia)-9.8 (te-risk myelod)-9.8 (ysplastic syndromes who ha)-9.8 (ve ring sideroblasts)-19 ( )]TJ
-0.017 Tc 0.018 Tw 0 -1.07 Td
[(and require red blood cell transfusions \(2 or more RBC units over 8 wee\ks\).)37.2 ( F)20.2 (or eligibility)55.2 (,)20 ( )]TJ
-0.001 Tc 0.09 Tw 0 -1.07 Td
[(p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.5 ( r)0.5 (e)0.5 (q)0.5 (u)0.5 (i)0.5 (r)0.5 (e)0.5 (d)0.5 ( t)0.5 (o)0.5 ( h)0.5 (a)-9.5 (v)0.5 (e)0.5 ( h)0.5 (a)0.5 (d a)0.5 (n)0.5 ( i)0.5 (na)0.5 (d)0.5 (e)0.5 (q)0.5 (u)0.5 (a)-9.5 (t)0.5 (e)0.5 ( r)0.5 (e)0.5 (s)0.5 (p)0.5 (o)0.5 (n)0.5 (se)0.6 ( t)0.5 (o)0.5 ( p)0.5 (r)0.5 (i)0.5 (o)0.5 (r)0.5 ( t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (m)0.5 (e)0.6 (nt)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)-1 ( )]TJ
0.004 Tc 0.118 Tw 0 -1.07 Td
[(an er)-18 (ythropoiesis-stimula)-10 (ting a)-10 (gent \(ESA\),)36.9 ( be intolerant of ESAs,)36.9 ( or ha)-10 (ve a serum)4 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.07 Td
[(er)-18.3 (ythropoietin >200 U/L.)36.6 ( )36.6 (The MEDALIST trial exc)19.6 (luded pa)-10.4 (tients with deletion 5q \(del 5q\),)22 ( )]TJ
-0.011 Tc 0.041 Tw 0 -1.07 Td
[(white blood cell count >13 Gi/L,)37.3 ( neutrophils <0.5 Gi/L,)37.3 ( pla)-9.7 (telets <50 Gi/L,)37.3 ( or with prior)-11 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
[(use of a disease modifying a)-9.7 (gent for trea)-9.8 (tment of MDS.)]TJ
-0.002 Tc 0.089 Tw 0 -1.61 Td
[(The MEDALIST trial inc)19.9 (luded 229 pa)-10.2 (tients randomized 2:1 to REBLOZYL \(n)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
28.123 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.638 0 Td
[(153\) or)-1.9 ( )]TJ
-0.01 Tc 0.047 Tw -28.761 -1.07 Td
(placebo \(n)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.809 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.621 0 Td
[(76\).)37.1 ( Randomiza)-9.9 (tion was stra)-9.8 (ti\037ed by baseline RBC transfusion burden and)-10 ( )]TJ
-0.002 Tc 0.089 Tw -4.431 -1.07 Td
[(baseline )0.5 (IPSS-R.)36.9 ( )37.4 (T)73.9 (rea)-10.1 (tment was started )0.5 (a)-10.1 (t )0.5 (1 mg/kg subcutaneously ever)-18.1 (y )0.5 (3 )0.5 (weeks;)-2 ( )]TJ
-0.008 Tc 0.055 Tw 0 -1.07 Td
[(t)0.5 (h)0.5 (e)0.5 ( do)0.6 (se)0.6 ( c)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( b)0.5 (e)0.6 ( i)0.5 (n)0.5 (c)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 (d)0.5 ( a)0.5 (f)0.5 (t)0.5 (e)0.5 (r)0.5 ( c)0.5 (o)0.5 (m)0.5 (p)0.5 (l)0.5 (e)0.6 (t)0.5 (io)0.6 (n)0.5 ( o)0.5 (f)0.5 ( t)0.6 (h)0.5 (e)0.5 ( \037)0.5 (r)0.5 (s)0.5 (t)0.5 ( 2)0.5 ( c)20.5 (y)0.5 (c)20.5 (l)0.5 (e)0.5 (s)0.5 ( i)0.5 (f)0.5 ( t)0.5 (h)0.5 (e)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.6 ( h)0.5 (a)0.5 (d)0.5 ( a)-9.4 (t)-8 ( )]TJ
-0.011 Tc 0.041 Tw 0 -1.07 Td
[(least one RBC transfusion in the prior 6 weeks.)37.3 ( )37 (T)74.3 (wo dose level increases were allo)-9.7 (wed)-11 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.003 Tc 0.085 Tw -31.5 -1.07 Td
[(\(to 1.33 mg/kg and to 1.75 mg/kg\).)36.6 ( Doses were held and subsequently reduced for)-3 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.07 Td
[(adverse reactions,)36.7 ( reduced if the hemoglobin increased by \0352 g/dL from the prior c)19.7 (yc)19.7 (le,)23 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
(and held if the predose hemoglobin was \03511.5 g/dL.)Tj
ET
endstreamendobj26 0 obj<</Length 28234>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 726.248 cm
0 0 m
57.378 0 l
S
Q
q 1 0 0 1 36 590.5969 cm
0 0 m
68.834 0 l
S
Q
q 1 0 0 1 36 299.5301 cm
0 0 m
136.829 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(Speci\037c P)18.2 (opula)-9.8 (tions)]TJ
0.024 Tw 0 -1.517 Td
[(No c)19.7 (linically signi\037cant differences in the luspa)-10.3 (tercept-aamt PK were obser)-18.3 (ved based on)-17 ( )]TJ
0.012 Tw 0 -1.067 Td
[(a)-9.8 (ge \(18 to 95 years\),)37.2 ( sex,)37.2 ( race/ethnicity \(Asian,)37.2 ( )37.3 (White\),)37.2 ( mild to severe hepa)-9.8 (tic impairment)-17 ( )]TJ
-0.012 Tc 0.039 Tw 0 -1.067 Td
[(\(total bilirubin \033 upper limit of normal [ULN] and asparta)-10.1 (te aminotransaminase [AST] )0.5 (or)-12 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.067 Td
[(alanine transaminase [AL)94.3 (T] >)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
10.78 0 Td
[(ULN,)37.3 ( or total bilirubin >)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
8.639 0 Td
[(ULN and an)-9.7 (y )36.7 (AST or )36.8 (AL)94.4 (T\),)37.2 ( mild to)-10 ( )]TJ
-0.017 Tc 0 Tw -19.419 -1.067 Td
[(modera)-9.8 (te renal impairment \(estima)-9.8 (ted glomerular \037ltra)-9.8 (tion ra)-9.8 (te [eGFR] 30 to 89 mL/min\),)20.1 ( )]TJ
-0.006 Tc 0.068 Tw 0 -1.067 Td
[(baseline albumin \(30 to 56 g/L\),)37 ( baseline serum er)-18 (ythropoietin \(2.4 to 2920 U/L\),)37 ( red)-6 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.067 Td
[(blood cell \(RBC\) transfusion burden \(0 to 43 units/24 weeks\),)37.2 ( beta thalassemia genotype)-16 ( )]TJ
0 Tc 0 Tw 0 -1.067 Td
(\()Tj
/T1_1 1 Tf
0.231 0 Td
(\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0.539 0 Td
[(0)0.5 (/)]TJ
/T1_1 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.045 Tw 1.276 0 Td
[(0)0.5 ( vs)0.5 (.)37.4 ( no)0.5 (n)0.5 (-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 4.224 0 Td
(0/)Tj
/T1_1 1 Tf
0 Tc 0 Tw 0.737 0 Td
(\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.045 Tw 0.539 0 Td
[(0\))0.5 (,)37.4 ( s)0.5 (pl)0.5 (en)0.5 (ec)0.5 (to)0.5 (my)55.5 (,)37.4 ( a)0.5 (nd)0.5 ( ri)0.5 (ng)0.5 ( si)0.5 (de)0.5 (ro)0.5 (bl)0.5 (as)0.5 (ts)0.5 ( st)0.5 (a)-9.6 (t)0.5 (us)0.5 ( in)0.5 ( MD)0.5 (S \()0.5 (ne)0.5 (ga)-9.5 (ti)0.5 (ve)0.5 ( vs)0.5 (.)27 ( )]TJ
0.05 Tw -7.544 -1.067 Td
[(positive\).)36.7 ( )37.2 (The effect of )37.1 (AST or )37.2 (AL)93.7 (T >3 x ULN and the effect of severe renal impairment)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(\(eGFR <30 mL/min\) on luspa)-9.8 (tercept-aamt PK is unkno)-9.7 (wn.)]TJ
/T1_2 1 Tf
0.011 Tw 0 -1.629 Td
[(Bod)-9.8 (y W)18.2 (eight)]TJ
/T1_0 1 Tf
-0.016 Tc 0.024 Tw 0 -1.517 Td
[(The a)-10 (pparent CL/F and )37 (V)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 106.5945 612.6713 Tm
(d)Tj
-0.016 Tc 0.024 Tw 8 0 0 8 109.0978 613.1613 Tm
[(/F of luspa)-10 (tercept-aamt increased with increasing bod)-10 (y weight)-16 ( )]TJ
-0.017 Tc 0.012 Tw -9.137 -1.067 Td
[(in pa)-9.8 (tients with beta thalassemia \(34 to 97 kg\) and in pa)-9.8 (tients with MDS \(33 to 124 kg\).)]TJ
0.048 Tw 0 -1.629 Td
(Drug Interaction Studies)Tj
/T1_2 1 Tf
0 -1.539 Td
[(Effect of Iron-chela)-9.8 (ting )37.2 (Agents on Luspa)-9.8 (tercept-aamt)]TJ
/T1_0 1 Tf
-0.011 Tc 0.045 Tw 0 -1.517 Td
[(No c)19.6 (linically signi\037cant differences in luspa)-10.3 (tercept-aamt PK were obser)-18.3 (ved when used)-11.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(concomitantly with iron-chela)-9.8 (ting a)-9.8 (gents.)]TJ
/T1_3 1 Tf
0.017 Tw 0 -1.899 Td
(12.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Immunogenicity)Tj
/T1_0 1 Tf
0.006 Tc 0.126 Tw -3.375 -1.517 Td
[(The obser)-17.7 (ved incidence of anti-drug antibodies \(ADA\) is highly dependent on the\)6 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.067 Td
[(sensitivity and speci\037city of the assay)55.2 (.)37.2 ( Differences in assay methods prec)20.2 (lude meaningful)-17 ( )]TJ
0.017 Tw 0 -1.067 Td
[(comparisons of the incidence of anti-drug antibodies in the studies desc\ribed belo)-9.8 (w with)-17 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.067 Td
[(the incidence of anti-drug antibodies in other studies,)37.1 ( inc)20.1 (luding those of REBLOZYL or of)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(other luspa)-9.8 (tercept products.)]TJ
-0.003 Tc 0.08 Tw 0 -1.607 Td
[(I)0.5 (n)0.5 ( t)0.5 (h)0.5 (e B)0.5 (EL)0.5 (I)0.5 (E)0.5 (V)0.5 (E t)0.5 (ri)0.5 (a)0.5 (l)0.5 (,)37.4 ( t)0.5 (h)0.5 (e)0.5 ( m)0.5 (e)0.5 (d)0.5 (ia)0.5 (n)0.5 ( d)0.5 (u)0.5 (r)0.5 (a)-9.5 (ti)0.5 (o)0.5 (n)0.5 ( o)0.5 (f)0.5 ( e)0.5 (x)0.5 (p)0.5 (o)0.5 (su)0.5 (r)0.5 (e)0.5 ( w)0.5 (a)0.5 (s)0.5 ( 6)0.5 (4)0.5 ( w)0.5 (e)0.5 (e)0.5 (ks)0.5 (,)37.5 ( wi)0.5 (t)0.5 (h)0.5 ( a)0.5 ( me)0.5 (d)0.5 (i)0.5 (a)0.5 (n)-3.1 ( )]TJ
-0.006 Tc 0.07 Tw 0 -1.067 Td
[(ADA sampling period of 50 weeks.)36.6 ( Of the 220 pa)-10.3 (tients in the BELIEVE trial with beta)-6 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.067 Td
[(thalassemia who require regular RBC transfusions trea)-10.4 (ted with REBLOZYL and evaluable)-16.9 ( )]TJ
-0.016 Tc 0 -1.067 Td
[(for the presence of anti-luspa)-10.4 (tercept-aamt antibodies,)36.7 ( 4 pa)-10.3 (tients \(1.81%\) tested positive)-16 ( )]TJ
-0.009 Tc 0.053 Tw 0 -1.067 Td
[(for )0.5 (trea)-9.9 (tment-emergent )0.6 (anti-luspa)-9.9 (tercept-aamt )0.5 (antibodies,)37.1 ( )0.5 (inc)20.1 (luding )0.5 (2 )0.5 (pa)-9.9 (tients )0.5 (\(0.9%\))-9 ( )]TJ
0.007 Tc 0.133 Tw 0 -1.067 Td
[(who had neutralizing antibodies detected.)37 ( )36.8 (The majority of anti-luspa)-10 (tercept-aamt)7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(antibodies were of lo)-9.8 (w titers.)]TJ
0.002 Tc 0.107 Tw 0 -1.607 Td
[(In the COMMANDS trial,)37.2 ( the median dura)-9.8 (tion of exposure was 42 weeks,)37.2 ( with the)2.1 ( )]TJ
-0.009 Tc 0.053 Tw 0 -1.067 Td
[(median )37.2 (ADA sampling period of 27 weeks.)37 ( In the MEDALIST trial,)37.1 ( the median dura)-9.9 (tion)-9 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.067 Td
[(of exposure was 49 weeks,)37.3 ( with the median )37.1 (ADA sampling period of 46 weeks.)37.4 ( Of the)-10 ( )]TJ
-0.002 Tc 0.085 Tw 0 -1.067 Td
[(3)0.5 (3)0.5 (1 E)0.5 (S)0.5 (A-)0.5 (n)0.5 (a)0.5 (\357)0.5 (v)0.5 (e)0.5 ( \()0.5 (C)0.5 (O)0.5 (MM)0.5 (A)0.5 (N)0.5 (D)0.5 (S t)0.5 (r)0.5 (i)0.5 (a)0.5 (l\))0.5 ( a)0.5 (nd)0.5 ( E)0.5 (S)0.5 (A-)0.5 (r)0.5 (e)0.5 (f)0.5 (r)0.5 (a)0.5 (ct)0.5 (o)0.5 (r)-17.5 (y)0.5 ( o)0.5 (r)0.5 ( -)0.5 (i)0.5 (n)0.5 (t)0.5 (ol)0.5 (e)0.5 (r)0.5 (a)0.5 (n)0.5 (t)0.5 ( \()0.5 (M)0.5 (E)0.5 (DA)0.5 (L)0.5 (I)0.5 (S)0.5 (T)0.5 ( t)0.5 (r)0.5 (i)0.5 (a)0.5 (l)0.5 (\))-2.1 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.067 Td
[(pa)-10.3 (tients with MDS who were trea)-10.4 (ted with REBLOZYL,)36.7 ( 21 pa)-10.3 (tients \(6.3%\) tested positive)-14 ( )]TJ
-0.013 Tc 0.033 Tw 0 -1.067 Td
[(for trea)-10 (tment-emergent anti-luspa)-10 (tercept-aamt antibodies,)37 ( inc)20 (luding 14 pa)-10 (tients \(4.2%\))-13 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.067 Td
[(who had neutralizing antibodies.)36.7 ( )37.3 (The majority of anti-luspa)-10.2 (tercept-aamt antibodies were)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(of lo)-9.7 (w titers.)]TJ
-0.005 Tc 0.073 Tw 0 -1.607 Td
[(There were no severe acute systemic hypersensitivity reactions reported \for pa)-10 (tients)-5 ( )]TJ
0.022 Tc 0.206 Tw 0 -1.067 Td
[(with anti-luspa)-9.7 (tercept-aamt antibodies in REBLOZYL c)20.3 (linical trials,)37.3 ( and there)22 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.096 Tw -31.5 -1.067 Td
[(was no associa)-9.7 (tion between hypersensitivity type reaction or injection site reaction )]TJ
-0.003 Tc 0.082 Tw 0 -1.067 Td
[(and presence of anti-luspa)-9.8 (tercept-aamt antibodies.)37.2 ( )37.3 (There was no a)-9.8 (pparent effect of)-3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(anti-luspa)-9.8 (tercept-aamt antibodies on c)20.2 (linical response.)]TJ
0.048 Tw 0 -1.629 Td
[(Anti-Drug )37.2 (Antibod)-9.8 (y Effects on Pharmacokinetics)]TJ
-0.004 Tc 0.079 Tw 0 -1.517 Td
[(Among )0.5 (pa)-10.1 (tients in the )0.5 (BELIEVE )0.5 (trial )0.5 (with luspa)-10.1 (tercept-aamt )0.5 (exposure da)-10.1 (ta a)-10 (vailable,)33 ( )]TJ
0.016 Tc 0.178 Tw 0 -1.067 Td
[(luspa)-10 (tercept-aamt mean trough concentra)-10 (tion \(C)]TJ
-0.016 Tw 5.6 0 0 5.6 191.8169 279.3756 Tm
(trough)Tj
0.178 Tw 8 0 0 8 205.7273 279.8656 Tm
[(\) was a)-9.9 (pproxima)-10 (tely 35%)16 ( )]TJ
-0.008 Tc 0.057 Tw -21.216 -1.067 Td
[(lo)-9.8 (wer in )0.5 (4 pa)-9.8 (tients with )0.5 (beta )0.5 (thalassemia who )0.5 (tested positive for )0.5 (trea)-9.7 (tment-emergent)-8 ( )]TJ
0.012 Tc 0.159 Tw 0 -1.067 Td
[(anti-luspa)-10.1 (tercept-aamt )0.5 (antibodies \(2.19 \032g/mL\) compared to pa)-10 (tients )0.5 (with beta)12 ( )]TJ
0.023 Tc 0.21 Tw 0 -1.067 Td
[(t)0.5 (ha)0.5 (la)0.5 (ss)0.5 (e)0.5 (mi)0.5 (a wh)0.5 (o di)0.5 (d no)0.5 (t de)0.5 (ve)0.5 (l)0.5 (op)0.5 ( t)0.5 (re)0.5 (a)-9.5 (tm)0.5 (e)0.5 (nt)0.5 (-e)0.5 (m)0.5 (er)0.5 (ge)0.5 (n)0.5 (t a)0.5 (n)0.5 (ti)0.5 (-l)0.5 (us)0.5 (pa)-9.5 (t)0.5 (er)0.5 (ce)0.5 (p)0.5 (t-)0.5 (aa)0.5 (m)0.5 (t)23 ( )]TJ
0.001 Tc 0.102 Tw 0 -1.067 Td
[(antibodies \(3.38 \032g/mL\).)37.2 ( )37.3 (There is insuf\037cient da)-9.7 (ta to assess whether the obser)-17.7 (ved)1 ( )]TJ
0.025 Tc 0.221 Tw 0 -1.067 Td
[(anti-lusp)0.5 (a)-9.6 (tercept-a)0.5 (amt a)0.5 (nt)0.5 (ibod)-9.6 (y asso)0.5 (cia)-9.6 (ted p)0.5 (harmacoki)0.5 (ne)0.5 (tic change)0.5 (s reduce)25 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
[(effectiveness in pa)-9.8 (tients with beta thalassemia.)]TJ
0.008 Tc 0.135 Tw 0 -1.607 Td
[(A)0.5 (mo)0.5 (ng 2)0.5 (1 ES)0.5 (A-n)0.5 (a\357)0.5 (ve)0.5 ( an)0.5 (d ES)0.5 (A-)0.5 (re)0.5 (fr)0.5 (ac)0.5 (to)0.5 (r)-17.5 (y or)0.5 ( -i)0.5 (nt)0.5 (ol)0.5 (er)0.5 (an)0.5 (t pa)-9.5 (t)0.5 (ie)0.5 (nt)0.5 (s wit)0.5 (h)0.5 ( M)0.5 (DS)0.5 ( i)0.5 (n th)0.5 (e)8 ( )]TJ
0.019 Tc 0.19 Tw 0 -1.067 Td
[(C)0.5 (O)0.5 (M)0.5 (M)0.5 (A)0.5 (N)0.5 (D)0.5 (S a)0.5 (n)0.5 (d)0.5 ( M)0.5 (E)0.5 (D)0.5 (A)0.5 (L)0.5 (I)0.5 (S)0.5 (T)0.5 ( tr)0.6 (i)0.5 (al)0.5 (s)0.5 ( w)0.5 (h)0.5 (o)0.5 ( t)0.5 (e)0.5 (s)0.5 (t)0.5 (e)0.5 (d)0.5 ( p)0.5 (o)0.5 (s)0.5 (i)0.5 (t)0.5 (i)0.5 (v)0.5 (e)0.5 ( f)0.5 (o)0.5 (r)0.5 ( t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (m)0.5 (e)0.5 (n)0.5 (t)0.5 (-)0.5 (e)0.5 (m)0.5 (e)0.5 (r)0.5 (g)0.5 (e)0.5 (n)0.5 (t)19 ( )]TJ
-0.01 Tc 0.05 Tw 0 -1.067 Td
[(anti-luspa)-10.3 (tercept-aamt antibodies,)36.7 ( )0.5 (there )0.5 (were )0.5 (no )0.5 (identi\037ed c)19.8 (linically signi\037cant effects)-10 ( )]TJ
-0.017 Tc 0.006 Tw 0 -1.067 Td
[(of )0.6 (anti-luspa)-9.7 (tercept-aamt )0.5 (antibodies )0.6 (on )0.5 (pharmacokinetics,)37.2 ( )0.5 (pharmacod)-9.8 (ynamics,)37.2 ( )0.5 (safety)55.2 (,)37.2 ( )0.5 (or)-17 ( )]TJ
0.012 Tw 0 -1.067 Td
[(effectiveness of luspa)-9.8 (tercept-aamt over the trea)-9.8 (tment dura)-9.7 (tion.)]TJ
/T1_3 1 Tf
0.017 Tw 0 -2.187 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
0.017 Tw -3.375 -1.697 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Carcinogenesis,)37.2 ( Mutagenesis,)37.2 ( Impairment of F)20.2 (ertility)]TJ
/T1_0 1 Tf
0.007 Tw -3.375 -1.517 Td
[(No carcinogenicity or muta)-9.8 (genicity studies ha)-9.8 (ve been conducted with luspa)-9.8 (tercept-aamt.)]TJ
0.003 Tc 0.115 Tw 0 -1.607 Td
[(In a repea)-10.2 (t-dose toxicity stud)-10.3 (y)54.7 (,)36.7 ( juvenile ra)-10.3 (ts were administered luspa)-10.3 (tercept-aamt)3 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.067 Td
[(subcutaneously )0.5 (a)-10.2 (t )0.5 (1,)36.7 ( )0.5 (3,)36.7 ( )0.5 (or )0.5 (10 )0.5 (mg/kg )0.5 (once )0.5 (ever)-18.2 (y )0.5 (2 )0.5 (weeks )0.5 (from )0.5 (postna)-10.2 (tal )0.5 (day )0.5 (7 )0.5 (to )0.5 (91.)29 ( )]TJ
0.001 Tc 0.1 Tw 0 -1.067 Td
[(H)0.5 (e)0.6 (m)0.5 (a)-9.4 (t)0.6 (o)0.5 (l)0.5 (o)0.6 (g)0.5 (i)0.6 (c)0.5 ( m)0.5 (a)0.6 (l)0.5 (i)0.5 (g)0.6 (n)0.5 (a)0.6 (n)0.5 (c)0.5 (i)0.6 (e)0.5 (s)0.6 ( \()0.6 (g)0.5 (r)0.5 (a)0.6 (n)0.5 (u)0.6 (l)0.5 (o)0.6 (c)20.5 (y)0.5 (t)0.6 (i)0.5 (c)0.5 ( l)0.6 (e)0.5 (u)0.6 (k)0.5 (e)0.5 (m)0.6 (i)0.5 (a)0.6 (,)37.5 ( l)0.5 (y)0.6 (m)0.5 (p)0.6 (h)0.5 (o)0.5 (c)20.6 (y)0.5 (t)0.5 (i)0.6 (c)0.5 ( l)0.5 (e)0.6 (u)0.5 (k)0.6 (e)0.5 (m)0.6 (i)0.5 (a)0.6 (,)37.5 ( m)0.5 (a)0.6 (l)0.5 (i)0.5 (g)0.6 (n)0.5 (a)0.6 (n)0.5 (t)1 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.067 Td
[(lymphoma\) were obser)-17.9 (ved a)-9.9 (t 10 mg/kg resulting in exposures \(based on area under the)-15 ( )]TJ
-0.016 Tc 0 -1.067 Td
[(cur)-18 (ve [AUC]\) a)-10 (pproxima)-9.9 (tely 4.4 times the maximum recommended human dose \(MRHD\))-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.067 Td
(of 1.75 mg/kg.)Tj
0 Tc 0.098 Tw 0 -1.607 Td
[(In )0.5 (a )0.6 (combined )0.6 (male )0.5 (and )0.6 (female )0.5 (fertility )0.5 (and )0.6 (early )0.5 (embr)-17.9 (yonic )0.5 (development )0.6 (stud)-9.9 (y )0.5 (in )]TJ
-0.008 Tc 0.06 Tw 0 -1.067 Td
[(ra)-10.2 (ts,)36.7 ( )0.6 (luspa)-10.2 (tercept-aamt )0.6 (was )0.6 (administered )0.5 (subcutaneously )0.5 (to )0.5 (animals )0.5 (a)-10.2 (t )0.5 (doses )0.6 (of )0.6 (1 )0.6 (to)-8 ( )]TJ
-0.009 Tc 0.055 Tw 0 -1.067 Td
[(15 )0.6 (mg/kg.)36.8 ( )37.5 (There )0.6 (were )0.6 (signi\037cant )0.6 (reductions )0.5 (in )0.6 (the )0.6 (a)-10.2 (vera)-10.2 (ge )0.5 (numbers )0.5 (of )0.5 (corpora )0.6 (lutea,)28 ( )]TJ
0.01 Tc 0.148 Tw 0 -1.067 Td
[(implanta)-9.9 (tions,)37 ( )0.5 (and )0.5 (viable )0.5 (embr)-17.9 (yos in luspa)-9.9 (tercept-aamt-trea)-9.9 (ted females.)37 ( )0.5 (Effects)10 ( )]TJ
-0.006 Tc 0.069 Tw 0 -1.067 Td
[(on )0.5 (female )0.5 (fertility were )0.5 (obser)-18 (ved )0.5 (a)-10.1 (t )0.5 (the )0.5 (highest dose )0.5 (with )0.5 (exposures \(based )0.5 (on )37.4 (AUC\))-6 ( )]TJ
-0.008 Tc 0.059 Tw 36 86.406 Td
[(a)-10.1 (pproxima)-10.1 (tely 7-times the MRHD of 1.75 mg/kg.)36.8 ( )37.3 (Adverse effects on fertility in female)-8 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.062 Td
[(ra)-9.6 (ts were reversible after a 14-week recover)-17.6 (y period.)37.4 ( No adverse effe)0.5 (cts were noted in)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(male ra)-9.8 (ts.)]TJ
/T1_3 1 Tf
0.017 Tw 0 -1.8 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(CLINIC)18.3 (AL STUDIES)]TJ
0.017 Tw -3.375 -1.692 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Beta Thalassemia)Tj
/T1_0 1 Tf
-0.011 Tc 0.041 Tw -3.375 -1.512 Td
[(The ef\037cac)20.3 (y of REBLOZYL was evalua)-9.6 (ted in adult pa)-9.6 (tients with beta thalassemia in the)-11 ( )]TJ
-0.003 Tc 0.084 Tw 0 -1.062 Td
[(BELIEVE trial \(NCT02604433\).)36.8 ( BELIEVE was a multicenter)73.8 (,)36.7 ( randomized,)36.8 ( double-blind,)34 ( )]TJ
-0.018 Tc 0 Tw 0 -1.062 Td
(placebo-controlled trial in which \(n)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.213 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.606 0 Td
[(336\) pa)-10.3 (tients with beta thalassemia requiring regular)-18 ( )]TJ
-0.017 Tc -12.819 -1.062 Td
[(red blood cell transfusions \(6-20 RBC units per 24 weeks\) with no tran\sfusion-free period)-17.1 ( )]TJ
-0.004 Tc 0.075 Tw 0 -1.062 Td
[(g)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (er)0.5 ( t)0.5 (h)0.5 (a)0.5 (n 3)0.5 (5)0.5 ( da)0.5 (y)0.5 (s)0.5 ( du)0.5 (r)0.5 (i)0.5 (n)0.5 (g)0.5 ( t)0.5 (h)0.5 (a)-9.5 (t)0.5 ( p)0.5 (e)0.5 (r)0.5 (i)0.5 (o)0.5 (d)0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.5 ( ra)0.5 (n)0.5 (d)0.5 (o)0.5 (m)0.5 (i)0.5 (z)0.5 (e)0.5 (d 2)0.5 (:)0.5 (1)0.5 ( t)0.5 (o)0.5 ( R)0.5 (EB)0.5 (L)0.5 (O)0.5 (Z)0.5 (Y)0.5 (L)0.5 ( \()0.5 (n)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
29.163 0 Td
( )Tj
EMC 
0.037 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
0.596 0 Td
( )Tj
EMC 
0.037 0 Td
[(2)0.5 (2)0.5 (4\))-3.9 ( )]TJ
0 Tc 0.096 Tw -29.832 -1.062 Td
(or placebo \(n)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.041 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.641 0 Td
[(112\).)37.4 ( In BELIEVE,)37.4 ( REBLOZYL was administered subcutaneously once )]TJ
-0.012 Tc 0.04 Tw -5.682 -1.062 Td
[(ever)-18.3 (y 3 weeks as long as a reduction in transfusion requirement was obser)-18.3 (ved or until)-12 ( )]TJ
-0.007 Tc 0.062 Tw 0 -1.062 Td
[(unacceptable toxicity)55.1 (.)37.1 ( )36.6 (All pa)-9.9 (tients were eligible to receive best supportive care,)37.1 ( which)-7 ( )]TJ
-0.021 Tc 0 Tw 0 -1.062 Td
[(inc)19.9 (luded RBC transfusions; iron-chela)-10.1 (ting a)-10 (gents; use of antibiotic,)36.9 ( antiviral,)36.9 ( and antifungal)-21 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(thera)-9.8 (py; and/or nutritional support,)37.2 ( as needed.)]TJ
-0.012 Tc 0.035 Tw 0 -1.602 Td
[(T)0.5 (h)0.5 (e)0.5 ( B)0.6 (EL)0.6 (I)0.5 (E)0.5 (V)0.5 (E)0.5 ( t)0.5 (r)0.5 (i)0.6 (a)0.5 (l)0.5 ( e)0.5 (x)0.5 (c)20.5 (l)0.5 (u)0.5 (d)0.5 (e)0.6 (d)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( a)0.6 ( d)0.5 (i)0.5 (a)-9.5 (g)0.5 (n)0.5 (o)0.6 (s)0.5 (i)0.5 (s)0.5 ( o)0.5 (f)0.5 ( H)0.5 (e)0.6 (m)0.5 (o)0.5 (g)0.5 (l)0.5 (o)0.5 (b)0.5 (i)0.6 (n)0.5 ( S)0.5 (/)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 25.329 0 Td
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.035 Tw 0.536 0 Td
[(-)0.5 (t)0.5 (h)0.6 (a)0.5 (l)0.5 (a)0.5 (s)0.5 (s)0.5 (e)0.5 (m)0.5 (i)0.6 (a)0.5 ( o)0.5 (r)-12 ( )]TJ
-0.007 Tc 0.065 Tw -25.866 -1.062 Td
[(isola)-10.4 (ted alpha \()]TJ
/T1_1 1 Tf
0 Tc 0 Tw (\036)Tj
/T1_0 1 Tf
-0.007 Tc 0.065 Tw 6.266 0 Td
[(\)-thalassemia \(e.g.,)36.6 ( Hemoglobin H\) or who had major organ dama)-10.3 (ge)-7 ( )]TJ
-0.015 Tc 0.025 Tw -6.266 -1.062 Td
[(\(liver disease,)36.7 ( heart disease,)36.7 ( lung disease,)36.8 ( renal insuf\037cienc)19.7 (y\).)36.7 ( P)17.8 (a)-10.3 (tients with recent deep)-15 ( )]TJ
-0.005 Tc 0.075 Tw 0 -1.062 Td
[(vein thrombosis )0.5 (or stroke )0.5 (or )0.5 (recent )0.5 (use )0.5 (of )0.5 (ESA,)36.7 ( )0.5 (immunosuppressant,)36.8 ( or )0.5 (hydroxyurea)-5 ( )]TJ
-0.015 Tc 0.026 Tw 0 -1.062 Td
[(thera)-10.4 (py were also exc)19.6 (luded.)36.6 ( )37.3 (The median a)-10.4 (ge was 30 years \(range:)36.5 ( 18-66\).)36.5 ( )37.4 (The trial was)-15 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.062 Td
[(comprised of pa)-10.2 (tients who were 42% male,)36.8 ( 54.2% )36.8 (White,)36.8 ( 34.8% )36.8 (Asian,)36.8 ( and 0.3% Black)-16 ( )]TJ
-0.019 Tc 0 Tw 0 -1.062 Td
[(o)0.6 (r)0.5 ( )37.6 (A)0.5 (f)0.6 (r)0.5 (i)0.6 (c)0.5 (a)0.6 (n)0.5 ( )37.6 (A)0.5 (m)0.6 (e)0.5 (r)0.6 (i)0.5 (c)0.6 (a)0.5 (n)0.6 (.)37.6 ( )37.5 (T)0.5 (h)0.6 (e)0.5 ( )0.6 (p)0.5 (e)0.6 (r)0.6 (c)0.5 (e)0.6 (n)0.5 (t)0.6 ( )0.5 (o)0.6 (f)0.6 ( )0.5 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.5 ( )0.6 (r)0.6 (e)0.5 (p)0.6 (o)0.5 (r)0.6 (t)0.5 (i)0.6 (n)0.5 (g)0.6 ( )0.5 (t)0.6 (h)0.5 (e)0.6 (i)0.6 (r)0.5 ( )0.6 (r)0.5 (a)0.6 (c)0.5 (e)0.6 ( )0.6 (a)0.5 (s)0.6 ( )37.5 (\223)0.6 (o)0.5 (t)0.6 (h)0.5 (e)0.6 (r)0.5 (\224)37.6 ( )0.5 (w)0.6 (a)0.5 (s)0.6 ( )0.5 (7)0.6 (.)0.5 (7)0.6 (%)0.5 (,)37.6 ( )0.5 (a)0.6 (n)0.6 (d)-19.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(race was not collected or reported for 3% of pa)-9.8 (tients.)]TJ
0 -1.602 Td
[(T)74.2 (able 12 summarizes the baseline disease-rela)-9.8 (ted characteristics in the BELIEVE stud)-9.7 (y)55.2 (.)]TJ
ET
/GS2 gs
q 1 0 0 1 501.12 459.4043 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 459.6543 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 501.12 459.6543 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 324 459.4043 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 459.4043 cm
0 0 m
74.88 0 l
S
Q
1 w 
q 1 0 0 1 324 480.0962 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 480.0962 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 480.0962 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 426.24 424.9885 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.12 424.9885 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.24 405.0166 cm
0 0 m
0 19.972 l
S
Q
q 1 0 0 1 501.12 405.0166 cm
0 0 m
0 19.972 l
S
Q
q 1 0 0 1 426.24 393.7947 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 393.7947 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.24 362.3509 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 501.12 362.3509 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 324 362.1009 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 362.1009 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 362.1009 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 350.629 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 350.629 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 338.9011 cm
0 0 m
0 11.478 l
S
Q
q 1 0 0 1 501.12 350.629 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 338.9011 cm
0 0 m
0 11.478 l
S
Q
q 1 0 0 1 426.24 327.1732 cm
0 0 m
0 11.728 l
S
Q
q 1 0 0 1 501.12 327.1732 cm
0 0 m
0 11.728 l
S
Q
q 1 0 0 1 426.24 315.9513 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 315.9513 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 324 315.7013 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 315.7013 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 315.7013 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 281.5355 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 281.5355 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 324 281.2855 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 281.2855 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 281.2855 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 269.8136 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 269.8136 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 258.3417 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 269.8136 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 258.3417 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.24 247.1198 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 247.1198 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 324 246.8698 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 246.8698 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 246.8698 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 235.3979 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 235.3979 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 224.176 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 235.3979 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 224.176 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 324 223.926 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 223.926 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 212.954 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 501.12 223.926 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 212.954 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 324 447.9324 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 447.9324 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 436.4604 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 447.9324 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 436.4604 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 324 393.5447 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 393.5447 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 393.5447 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 382.0728 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 382.0728 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 382.0728 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 324 304.2294 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 304.2294 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.24 292.7574 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 304.2294 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 292.7574 cm
0 0 m
0 11.222 l
S
Q
1 w 
q 1 0 0 1 324 212.454 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 212.454 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 212.454 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 324 191.5421 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 191.5421 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.12 191.5421 cm
0 0 m
74.88 0 l
S
Q
BT
/GS1 gs
/T1_3 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 492.1962 Tm
[(T)74.2 (able 12:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Baseline Disease Characteristics of P)24.2 (atients with Beta Thalassemia)-11.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 561.666 492.1962 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 360 483.6962 Tm
(in BELIEVE)Tj
-0.017 Tc -4.737 -2.1 Td
(Disease Characteristic)Tj
0.017 Tw 16.401 0.531 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 471.1443 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 451.7036 462.6443 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(224\))Tj
0.017 Tw 8.456 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.2475 471.1443 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 526.7086 462.6443 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(112\))Tj
0.048 Tw -28.139 -1.479 Td
[(Beta thalassemia diagnosis,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Beta-thalassemia)-17 (\036)]TJ
0.048 Tw 15.722 0 Td
(174 \(77.7\))Tj
10.1 0 Td
(83 \(74.1\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(HbE/beta thalassemia)Tj
15.953 0 Td
(31 \(13.8\))Tj
9.869 0 Td
(21 \(18.8\))Tj
0 Tc 0.888 Tw /Span<</ActualText<FEFF00090007>>> BDC 
5.32 0 0 5.6 324 415.6566 Tm
(  )Tj
EMC 
-0.017 Tc 0.048 Tw 7.6 0 0 8 330 416.3966 Tm
[(Beta thalassemia combined with)-16.9 ( )]TJ
0.017 Tw 0 -1.062 Td
(alpha-thalassemia)Tj
0.048 Tw 16.527 0.531 Td
(18 \(8\))Tj
9.758 0 Td
(8 \(7.1\))Tj
-0.223 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-27.075 -1.965 Td
[( )-789.5 ( )]TJ
EMC 
(Missing)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 350.7599 399.0387 Tm
( )Tj
EMC 
0.024 0 Td
(a\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 454.7623 396.4247 Tm
(1 \(0.4\))Tj
0 Tc 0 Tw 10.802 0 Td
(0)Tj
/T1_3 1 Tf
-0.017 Tc 0.048 Tw -28.008 -1.434 Td
(Baseline transfusion burden 12 weeks prior to randomization)Tj
/T1_0 1 Tf
/Span<</ActualText<FEFF00090007>>> BDC 
0 -1.434 Td
[( )-518.5 ( )]TJ
EMC 
0.789 0 Td
[(Median \(min,)37.2 ( max\))-17 ( )]TJ
0 -1.062 Td
(\(Units/12 weeks\))Tj
15.494 0.531 Td
[(6.12 \(3,)37.2 ( 14\))]TJ
9.869 0 Td
[(6.27 \(3,)37.2 ( 12\))]TJ
/T1_3 1 Tf
-26.152 -1.965 Td
[(Beta thalassemia gene mutation grouping,)37.3 ( n \(%\))]TJ
/T1_0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.466 Td
( )Tj
EMC 
/T1_1 1 Tf
0.789 0 Td
(\037)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0.531 0 Td
(0/)Tj
/T1_1 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
1.255 0 Td
(0)Tj
-0.017 Tc 0.048 Tw 14.167 0.032 Td
(68 \(30.4\))Tj
9.869 0 Td
(35 \(31.3\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.498 Td
( )Tj
EMC 
0.789 0 Td
(Non-)Tj
/T1_1 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 2.278 0 Td
(0/)Tj
/T1_1 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
1.255 0 Td
(0)Tj
-0.017 Tc 0.048 Tw 12.189 0.032 Td
(155 \(69.2\))Tj
10.1 0 Td
(77 \(68.8\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.612 -1.466 Td
( )Tj
EMC 
0.789 0 Td
(Missing)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A200A>>> BDC 
5.32 0 0 5.6 350.7599 321.1953 Tm
[( )0.5 ( )]TJ
EMC 
0.049 0 Td
(a\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 454.7623 318.5812 Tm
(1 \(0.4\))Tj
0 Tc 0 Tw 10.802 0 Td
(0)Tj
/T1_3 1 Tf
-0.017 Tc 0.048 Tw -28.008 -1.434 Td
(Baseline serum ferritin level \(\035g/L\))Tj
/T1_0 1 Tf
0 Tc 0.55 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(N)Tj
-0.017 Tc 0.017 Tw 16.887 0 Td
(220)Tj
9.869 0 Td
(111)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.545 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Median \(min,)37.2 ( max\))]TJ
14.105 0 Td
[(1441.25 \(88,)37.2 ( 6400\))]TJ
9.638 0 Td
[(1301.50 \(136,)37.2 ( 6400\))]TJ
/T1_3 1 Tf
-24.532 -1.434 Td
[(Splenectomy)55.2 (,)37.2 ( n \(%\))]TJ
/T1_0 1 Tf
-0.092 Tc 0.642 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Ye)-74.8 (s)]TJ
-0.017 Tc 0.048 Tw 15.722 0 Td
(129 \(57.6\))Tj
10.443 0 Td
(65 \(58\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.955 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(No)Tj
0.048 Tw 15.953 0 Td
(95 \(42.4\))Tj
10.212 0 Td
(47 \(42\))Tj
/T1_3 1 Tf
-26.955 -1.434 Td
(Age patient started regular transfusions \(years\))Tj
/T1_0 1 Tf
0 Tc 0.55 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(N)Tj
-0.017 Tc 0.017 Tw 16.887 0 Td
(169)Tj
10.1 0 Td
(85)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.777 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Median \(min,)37.2 ( max\))]TJ
16.068 0 Td
[(2 \(0,)37.2 ( 52\))]TJ
9.869 0 Td
[(2 \(0,)37.2 ( 51\))]TJ
-0.115 Tw 7.2 0 0 8 324 203.1421 Tm
(HbE)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(hemoglobin )-162.8 (E.)]TJ
0.017 Tw 5.04 0 0 5.6 324 197.7561 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.021 Tc 0.036 Tw 7.2 0 0 8 328 195.1421 Tm
[(\223Missing\224)36.9 ( ca)-10.1 (tegor)-18.1 (y inc)19.8 (ludes pa)-10.1 (tients in the popula)-10.1 (tion who had no result for the parameter listed.)]TJ
-0.017 Tc 0.023 Tw 8 0 0 8 324 175.6321 Tm
[(The ef\037cac)20.2 (y of REBLOZYL in adult pa)-9.7 (tients with beta thalassemia was established based)-17 ( )]TJ
0 Tc 0.098 Tw 0 -1.062 Td
[(upon the proportion of pa)-9.9 (tients achieving RBC transfusion burden reduction \(\03533% )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(reduction from baseline\) with a reduction of a)-9.8 (t least 2 units from )37.2 (W)18.2 (eek 13 to )37.2 (W)18.2 (eek 24.)]TJ
0 -1.602 Td
[(Ef\037cac)20.2 (y results are sho)-9.8 (wn in )37.2 (T)74.2 (able 13.)]TJ
ET
endstreamendobj24 0 obj<</BaseFont/BADDLA+SymbolStd/Encoding 79 0 R/FirstChar 30/FontDescriptor 80 0 R/LastChar 31/Subtype/Type1/ToUnicode 81 0 R/Type/Font/Widths[631 549]>>endobj79 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/alpha/beta]/Type/Encoding>>endobj80 0 obj<</Ascent 1010/CapHeight 688/CharSet(/alpha/beta)/Descent -293/Flags 32/FontBBox[-180 -293 1090 1010]/FontFamily(Symbol Std)/FontFile3 82 0 R/FontName/BADDLA+SymbolStd/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 502>>endobj81 0 obj<</Filter/FlateDecode/Length 240>>stream
Hâ\PÕjƒ æ˚s‹=,&Ÿk⁄mrËM˚ F'©–®LÃ!oﬂ—,[ËÄ:√˜√Á»K˜‘yó@æS0=&ù∑ÑKX… 89/Í¨3È6ï€Ã:
…‚~[ŒùÉh[ê.â68<ÿ0‡Q»7≤HŒOp¯∫ÙGê˝„ŒËT†XŸËE«W=#»";uñqó∂k˛ü[Dh \ÔaL∞∏Dmê¥üP¥óÇˆ •z˚?Ô™a4ﬂöD[?3∑:?÷ä˚Îﬁ7*ª4Ÿ•<ŸÂ∆œ~¸m∏á5+Á,ª)s4ÁÒææ"∞*Ò+¿ D*thendstreamendobj82 0 obj<</Filter/FlateDecode/Length 671/Subtype/Type1C>>stream
Hâbd`ab`ddtrtqÒq‘ÆÃM œ	.I	 ˝êe¸!ŒÚCéGÙ∑«ÔùøÆ˝jc˝Ó√ˇ=@p∆OE!FF6ÆÙíƒúÇåƒ§‘íDÁ¸Ç ¢ÃÙåCKSi&-A§•òä)8¶‰'•*Wó§Ê+xÊ%Á‰%ñ§¶Ë)8Ê‰(Ä*V(J-N-*
ÍªáT§*X(§§¶1 ]◊Œ»¿t:É£„Ò›{ºŸÀ$Uˆ2w≥¸Ë¯ßÉÌ{ﬂÔ£¢øÌæOf˝˛ÇÌ∑¬Ô¢ﬂAú?ìÿˇ∞≈ÅŸﬂÌ~˘l?ˆãÇXøA<æü‹ïks.˝–‹–P.¥ÂÛè¯9¬kÑÁ¸hˇQ-Í˝€çµìMxM€¶⁄Õ´K6¶Æéôú8)†!ßÃ9™ º—©Ê7À|è•qÛ3óo®:õ∑g⁄ŒYOV,º0gápÃbØŸãKÊV-l^∂pŸ¬©õzÊıì®dÎ¨Î .+À…)\⁄8•b^ÌÚÊ›ﬂŸø_î¯ùˆ˚ù®ö˙ÏÇ®Ú™“äí¶™ûÇﬁ∫â•ã7Æn[—x∏˝§CìLﬂ∂dı¬ÂsÁ´Z—¥¨pv!«“ƒi∂ì"9¯~Ï¨⁄ø˝À…Ô›kÖn‹¸>ıì·öÔFD∑Ê≠¨Ÿ⁄≤•ekﬂ⁄ÈKßú_≥‰√Ù›Ìá6ﬂMŸ‚≥r√™µÀ¶]öz:qWŸó£jS‹S8≤+≤-•˛*≥G4D∂E»=bÎ[2a…©Æüµ¢€◊Ì\7Sn—îu=ÎÛ/ÑT˝Ê( nnl¨¨Ó-ÔKöVQ›‘\^º∫jv”í	ÛzWÙMmôU≈!ºÁà˜Ïﬂ,5Œ≠95È…•ÈÂ±‚Á‰LØô[1óÉØbﬁO”Yøcg∞=Áz¿` qa2ßendstreamendobj18 0 obj<</Length 23387>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36.144 726.248 cm
0 0 m
13.291 0 l
S
Q
q 1 0 0 1 36.144 559.4205 cm
0 0 m
41.95 0 l
S
Q
q 1 0 0 1 36.144 477.2922 cm
0 0 m
51.766 0 l
S
Q
q 1 0 0 1 36.144 443.6591 cm
0 0 m
39.372 0 l
S
Q
q 1 0 0 1 36.144 380.713 cm
0 0 m
24.239 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36.144 727.248 Tm
[(Da)-9.8 (ta)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.536 Td
[(Animal Da)-9.8 (ta)]TJ
/T1_0 1 Tf
0.033 Tc 0.264 Tw 0 -1.514 Td
[(In embr)-18.1 (yo-fetal development studies,)36.9 ( luspa)-10.1 (tercept-aamt was administered)33 ( )]TJ
-0.004 Tc 0.077 Tw 0 -1.064 Td
[(subcutaneously a)-9.7 (t 5,)37.3 ( 15,)37.3 ( or 30 mg/kg on gesta)-9.8 (tion days 3 and 10 \(ra)-9.8 (ts\) or 5,)37.3 ( 20,)37.3 ( or)-4 ( )]TJ
0.007 Tc 0.132 Tw 0 -1.064 Td
[(40 mg/kg on gesta)-9.8 (tion days 4 and 11 \(rabbits\).)37.1 ( Effects in both species inc)20.1 (luded)7 ( )]TJ
-0.02 Tc 0 Tw 0 -1.064 Td
[(reductions in numbers of live fetuses and fetal bod)-9.7 (y weights,)37.4 ( and increases in resorptions,)17 ( )]TJ
-0.01 Tc 0.045 Tw 0 -1.064 Td
[(p)0.5 (os)0.5 (t-)0.5 (imp)0.5 (la)0.5 (nt)0.5 (a)-9.5 (tio)0.5 (n lo)0.5 (ss)0.5 (es)0.5 (,)37.4 ( a)0.5 (nd)0.5 ( sk)0.5 (e)0.5 (le)0.5 (ta)0.5 (l v)0.5 (ar)0.5 (ia)-9.5 (t)0.5 (io)0.5 (ns \(s)0.5 (uc)0.5 (h a)0.5 (s as)0.5 (ym)0.5 (me)0.5 (tr)0.5 (ic)0.5 ( st)0.5 (e)0.5 (rna)0.5 (l ce)0.5 (nt)0.5 (ra)0.5 ( i)0.5 (n)-10 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.064 Td
[(ra)-10.2 (ts and angula)-10.3 (ted hyoid in rabbits\).)36.7 ( Effects were obser)-18.3 (ved a)-10.3 (t exposures \(based on )36.8 (AUC\))-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(a)-9.8 (pproxima)-9.8 (tely 7-times \(ra)-9.8 (ts\) and 16-times \(rabbits\) the MRHD of 1.75 mg/kg.)]TJ
0.02 Tc 0.195 Tw 0 -1.604 Td
[(I)0.5 (n)0.5 ( a)0.5 ( p)0.5 (r)0.5 (e)0.5 (- a)0.5 (n)0.5 (d)0.5 ( p)0.5 (o)0.5 (s)0.5 (t)0.5 (n)0.5 (a)-9.5 (t)0.5 (a)0.5 (l d)0.5 (e)0.5 (v)0.5 (e)0.5 (lo)0.5 (p)0.5 (m)0.5 (e)0.5 (n)0.5 (t)0.5 ( st)0.5 (u)0.5 (d)-9.5 (y)55.5 (,)37.4 ( p)0.5 (r)0.5 (e)0.5 (g)0.5 (na)0.5 (n)0.5 (t)0.5 ( r)0.5 (a)-9.6 (t)0.5 (s)0.5 ( w)0.5 (e)0.5 (r)0.5 (e)0.5 ( a)0.5 (d)0.5 (m)0.5 (i)0.5 (n)0.5 (is)0.5 (t)0.5 (e)0.5 (r)0.5 (e)0.5 (d)20 ( )]TJ
-0.005 Tc 0.07 Tw 0 -1.064 Td
[(l)0.6 (u)0.5 (s)0.6 (p)0.5 (a)-9.4 (t)0.5 (e)0.6 (r)0.5 (c)0.6 (e)0.5 (p)0.6 (t)0.5 (-)0.6 (a)0.5 (a)0.6 (m)0.6 (t)0.5 ( s)0.6 (u)0.5 (b)0.6 (c)0.5 (u)0.6 (t)0.5 (a)0.6 (n)0.5 (e)0.6 (o)0.5 (u)0.6 (s)0.5 (l)0.6 (y)0.5 ( a)-9.4 (t)0.6 ( 3)0.5 (,)37.6 ( 1)0.5 (0)0.6 (,)37.5 ( o)0.6 (r)0.5 ( 3)0.6 (0)0.5 ( m)0.6 (g)0.6 (/)0.5 (k)0.6 (g)0.5 ( o)0.6 (n)0.5 (c)0.6 (e)0.5 ( e)0.6 (v)0.5 (e)0.6 (r)-17.4 (y)0.5 ( 2)0.6 ( w)0.5 (e)0.6 (e)0.5 (k)0.6 (s)0.5 ( d)0.5 (u)0.6 (r)0.5 (i)0.6 (n)0.5 (g)-5 ( )]TJ
0.01 Tc 0.148 Tw 0 -1.064 Td
[(organogenesis and through weaning,)37 ( gesta)-9.9 (tion day 6 through postna)-9.9 (tal day 20.)47 ( )]TJ
-0.001 Tc 0.095 Tw 0 -1.064 Td
[(At all dose levels lo)-10.3 (wer F)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 113.1553 612.9257 Tm
(1)Tj
-0.001 Tc 0.095 Tw 8 0 0 8 115.8398 613.4156 Tm
[( pup bod)-10.3 (y weights and adverse kidney \037ndings \(such as)-1 ( )]TJ
-0.018 Tc 0 Tw -9.962 -1.064 Td
[(membranoprolifera)-10.4 (tive glomerulonephritis,)36.6 ( tubular a)-10.4 (trophy/hypoplasia,)36.6 ( and vessel ectasia)-18 ( )]TJ
-0.02 Tc 0 -1.064 Td
[(occasionally associa)-9.7 (ted with hemorrha)-9.7 (ge\) were obser)-17.7 (ved.)37.3 ( )37.2 (These effects were obser)-17.8 (ved a)-9.8 (t)-20 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(exposures \(based on )37.2 (AUC\) a)-9.8 (pproxima)-9.8 (tely 1.6-times the MRHD of 1.75 mg/kg.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.896 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_0 1 Tf
0.048 Tw -3.375 -1.536 Td
[(Risk Summar)-17.8 (y)]TJ
-0.004 Tc 0.076 Tw 0 -1.514 Td
[(Luspa)-9.6 (tercept-aamt was detected in milk of lacta)-9.7 (ting ra)-9.7 (ts.)37.3 ( )36.8 (When a drug is present in)-4 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.064 Td
[(animal milk,)36.8 ( it is likely tha)-10.2 (t the drug will be present in human milk.)36.8 ( )36.8 (There are no da)-10.2 (ta)-9 ( )]TJ
-0.011 Tc 0.045 Tw 0 -1.064 Td
[(on the presence of REBLOZYL in human milk,)36.7 ( the effects on the breastfed child,)36.7 ( or the)-11 ( )]TJ
-0.013 Tc 0.032 Tw 0 -1.064 Td
[(effects on milk production.)37.1 ( Because of the potential for serious adverse reactions in the)-13 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.064 Td
[(breastfed child,)37.1 ( advise pa)-9.9 (tients tha)-9.9 (t breastfeeding is not recommended during trea)-9.9 (tment)-17 ( )]TJ
0.012 Tw 0 -1.064 Td
[(with REBLOZYL,)37.2 ( and for 3 months after the last dose.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.896 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(F)20.2 (emales and Males of Reproductive P)24.2 (otential)]TJ
/T1_0 1 Tf
0.011 Tw -3.375 -1.536 Td
[(Pregnanc)20.2 (y T)74.2 (esting)]TJ
-0.013 Tc 0.033 Tw 0 -1.514 Td
[(Pregnanc)20.1 (y )0.5 (testing )0.6 (is )0.6 (recommended )0.6 (for )0.5 (females )0.6 (of )0.6 (reproductive )0.6 (potential )0.6 (before )0.5 (starting)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(REBLOZYL trea)-9.8 (tment.)]TJ
0.017 Tw 0 -1.626 Td
(Contraception)Tj
/T1_1 1 Tf
0 -1.536 Td
[(F)24.2 (emales)]TJ
/T1_0 1 Tf
0.005 Tc 0.123 Tw 0 -1.514 Td
[(REBLOZYL may cause embr)-18 (yo-fetal harm when administered to pregnant women)5 ( )]TJ
0 Tc 0 Tw 31.482 0 Td
( )Tj
/T1_1 1 Tf
-0.017 Tc 0.014 Tw -31.482 -1.064 Td
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tions \(8.1\)])]TJ
/T1_0 1 Tf
[(.)37.2 ( )37.3 (Advise female pa)-9.8 (tients of reproductive potential to)-16.9 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.064 Td
[(use effective contraception during trea)-10.2 (tment with REBLOZYL and for a)-10.2 (t least 3 months)-11 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
(after the last dose.)Tj
0.017 Tw 0 -1.626 Td
(Infertility)Tj
/T1_1 1 Tf
0 -1.536 Td
[(F)24.2 (emales)]TJ
/T1_0 1 Tf
-0.004 Tc 0.08 Tw 0 -1.514 Td
[(Based on \037ndings in animals,)36.7 ( REBLOZYL may impair female fertility )]TJ
/T1_1 1 Tf
[([see Nonc)19.7 (linical)-4 ( )]TJ
-0.001 Tc 0.096 Tw 0 -1.064 Td
[(T)73.6 (oxicolog)-10.4 (y )0.5 (\(13.1\)])]TJ
/T1_0 1 Tf
[(.)36.6 ( )37.5 (Adverse )0.6 (effects )0.5 (on )0.6 (fertility )0.5 (in )0.6 (female )0.6 (ra)-10.4 (ts )0.5 (were )0.5 (reversible )0.6 (after )0.6 (a)-1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(14-week recover)-17.8 (y period.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.896 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(P)24.2 (ediatric Use)]TJ
/T1_0 1 Tf
0 Tc 0.1 Tw -3.375 -1.514 Td
[(Safety and effectiveness in pedia)-10.4 (tric pa)-10.3 (tients ha)-10.3 (ve not been established.)36.7 ( Based on )]TJ
-0.016 Tc 0.024 Tw 0 -1.064 Td
[(\037ndings in juvenile animals,)36.6 ( REBLOZYL is not recommended for use in pedia)-10.4 (tric pa)-10.4 (tients)-16 ( )]TJ
/T1_1 1 Tf
-0.017 Tc 0.012 Tw 0 -1.064 Td
([see No)Tj
0.017 Tw (n-C)Tj
-0.025 Tw [(linical T)74.1 (oxicolog)]TJ
0.012 Tw 9.473 0 Td
(y \(13.1\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw -9.473 -1.896 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_0 1 Tf
-0.003 Tc 0.082 Tw -3.375 -1.514 Td
[(Clinical studies of REBLOZYL in beta thalassemia did not inc)20.2 (lude suf\037cient numbers)-3 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.064 Td
[(of pa)-9.6 (tients a)-9.7 (ge 65 years and older to determine whether they respond differently from\)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(younger pa)-9.8 (tients.)]TJ
0.018 Tw 0 -1.604 Td
[(Clinical studies of REBLOZYL for trea)-9.8 (tment of anemia in ESA-na\357ve and ESA-refractor)-17.8 (y or)-17 ( )]TJ
-0.011 Tc 0.04 Tw 0 -1.064 Td
[(-)0.5 (i)0.5 (n)0.5 (t)0.5 (o)0.5 (l)0.5 (e)0.5 (r)0.5 (a)0.5 (n)0.5 (t)0.5 ( MD)0.5 (S)0.5 ( i)0.5 (n)0.5 (c)20.5 (lu)0.5 (d)0.5 (e)0.5 (d)0.5 ( 3)0.5 (4)0.5 (7)0.5 ( \()0.5 (8)0.5 (2)0.5 (%)0.5 (\))0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( \035)0.5 (6)0.5 (5)0.5 ( y)0.5 (e)0.5 (a)0.5 (r)0.5 (s)0.5 ( o)0.5 (f)0.5 ( a)-9.5 (g)0.5 (e)0.5 ( an)0.6 (d 1)0.5 (6)0.5 (7)0.5 ( \()0.5 (3)0.5 (9)0.5 (%)0.5 (\))0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)-11 ( )]TJ
-0.017 Tc 0.022 Tw 0 -1.064 Td
[(\03575\036)-21.8 (years of a)-9.8 (ge.)37.2 ( No differences in safety or effectiveness were obser)-17.7 (ved between older)-17 ( )]TJ
0.012 Tw 0 -1.064 Td
[(\(\03565 years\) and younger pa)-9.8 (tients.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.959 Td
(9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(DR)-9.8 (UG ABUSE AND DEPENDENCE)]TJ
0.017 Tw -3.375 -1.694 Td
(9.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Controlled Substance)Tj
/T1_0 1 Tf
0.012 Tw -3.375 -1.514 Td
[(REBLOZYL contains luspa)-9.8 (tercept-aamt,)37.2 ( which is not a controlled substance.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.896 Td
(9.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Abuse)Tj
/T1_0 1 Tf
-0.002 Tc 0.09 Tw -3.375 -1.514 Td
[(Abuse is the intentional,)36.6 ( non-thera)-10.4 (peutic use of a drug,)36.6 ( even once,)36.6 ( for its desirable)-2 ( )]TJ
-0.001 Tc 0.095 Tw 0 -1.064 Td
[(psychological )0.5 (or )0.5 (physiological )0.5 (effects.)36.8 ( )37.5 (Abuse )0.5 (of )0.5 (REBLOZYL )0.6 (may )0.5 (be )0.5 (seen )0.6 (in )0.6 (a)-10.3 (thletes)-1.1 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.064 Td
[(for the effects on er)-18.1 (ythropoiesis to enhance a)-10.2 (thletic performance.)36.8 ( )37 (Abuse of drugs tha)-10.1 (t)-9 ( )]TJ
-0.02 Tc 0 Tw 0 -1.064 Td
[(increase er)-17.7 (ythropoiesis,)37.3 ( such as REBLOZYL,)37.3 ( by healthy persons may lead to polyc)20.3 (ythemia,)17 ( )]TJ
-0.017 Tc 0.015 Tw 0 -1.064 Td
[(which may be associa)-9.8 (ted with life-threa)-9.8 (tening cardiovascular complica)-9.8 (tions \(e.g.,)37.2 ( stroke,)20 ( )]TJ
0.012 Tw 0 -1.064 Td
[(myocardial infarction,)37.2 ( and thromboembolism\).)]TJ
-0.013 Tc 0.032 Tw 0 -1.604 Td
[(Luspa)-9.8 (tercept-aamt and its metabolites neither selectively penetra)-9.8 (te the central ner)-17.8 (vous)-13 ( )]TJ
-0.02 Tc 0 Tw 0 -1.064 Td
[(system,)36.9 ( nor produce beha)-10.1 (vioral effects in animals tha)-10.1 (t are consistent with central ner)-18.1 (vous)-20 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
[(system activity)55.2 (.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.959 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_0 1 Tf
-0.007 Tc 0.063 Tw -3.375 -1.514 Td
[(Luspa)-9.9 (tercept-aamt is an er)-18 (ythroid ma)-10 (tura)-10 (tion a)-10 (gent.)36.9 ( Luspa)-10 (tercept-aamt is a receptor)-7 ( )]TJ
0.006 Tc 0.126 Tw 0 -1.064 Td
[(fusion protein consisting of a modified extracellular domain of the huma\n activin)6 ( )]TJ
ET
q 1 0 0 1 324 464.0828 cm
0 0 m
201.546 0 l
S
Q
q 1 0 0 1 324 218.4374 cm
0 0 m
30.305 0 l
S
Q
q 1 0 0 1 324 158.1917 cm
0 0 m
32.262 0 l
S
Q
q 1 0 0 1 324 115.0278 cm
0 0 m
31.295 0 l
S
Q
BT
-0.01 Tc 0.051 Tw 8 0 0 8 324 727.248 Tm
[(receptor type IIB linked to a human IgG1 Fc domain with a calcula)-10.4 (ted molecular mass)-10 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.068 Td
[(of a)-9.6 (pproxima)-9.7 (tely 76 kD.)37.3 ( Luspa)-9.7 (tercept is produced in Chinese hamster ovar)-17.7 (y cells by)-5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(recombinant DNA technolog)-9.8 (y)55.2 (.)]TJ
0.012 Tc 0.159 Tw 0 -1.608 Td
[(REBLOZYL \(luspa)-10.1 (tercept-aamt\) for injection is a sterile,)36.9 ( preser)-18.2 (va)-10.2 (tive-free,)36.8 ( white)12 ( )]TJ
0.011 Tc 0.154 Tw 0 -1.068 Td
[(to off-white,)36.8 ( lyophilized po)-10.1 (wder in single-dose vials for subcutaneous use after)11 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.068 Td
(reconstitution.)Tj
-0.018 Tc 0 Tw 0 -1.608 Td
[(Each 25 mg single-dose vial provides nominal 25 mg of luspa)-9.9 (tercept-aamt and citric acid)-18 ( )]TJ
-0.011 Tc 0.042 Tw 0 -1.068 Td
[(monohydra)-9.8 (te \(0.085 mg\),)37.1 ( polysorba)-9.9 (te 80 \(0.10 mg\),)37.1 ( sucrose \(45.0 mg\),)37.1 ( and tri-sodium)-11 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.068 Td
[(ci)0.5 (tra)-9.5 (te )0.6 (dih)0.5 (ydra)-9.5 (te)0.5 ( )0.5 (\(1)0.5 (.35 )0.6 (m)0.5 (g\) )0.6 (a)-9.6 (t )0.6 (pH )0.6 (6.)0.5 (5.)37.4 ( )37.5 (A)0.5 (fte)0.5 (r )0.5 (r)0.5 (eco)0.5 (nst)0.5 (itut)0.5 (io)0.5 (n )0.5 (w)0.5 (ith )0.6 (0.)0.5 (68 )0.6 (mL )0.6 (Ste)0.5 (ril)0.5 (e )37.5 (W)18.5 (a)-9.6 (te)0.5 (r )0.6 (for)-13 ( )]TJ
-0.014 Tc 0.026 Tw 0 -1.068 Td
[(Injection USP)129.3 (,)37.4 ( the resulting concentra)-9.6 (tion is 25 mg/0.5 mL of luspa)-9.6 (tercept-aamt and the)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
(nominal deliverable volume is 0.5 mL.)Tj
-0.007 Tc 0.064 Tw 0 -1.608 Td
[(Each 75 mg single-dose vial provides nominal 75 mg of luspa)-10.2 (tercept-aamt and citric)-7 ( )]TJ
0.008 Tc 0.136 Tw 0 -1.068 Td
[(acid monohydra)-9.7 (te \(0.254 mg\),)37.4 ( polysorba)-9.7 (te 80 \(0.30 mg\),)37.3 ( sucrose \(135 mg\),)37.3 ( and)8 ( )]TJ
-0.013 Tc 0.033 Tw 0 -1.068 Td
[(tri-sodium citra)-9.9 (te dihydra)-9.9 (te \(4.06 mg\) a)-9.9 (t pH 6.5.)37.1 ( )37.3 (After reconstitution with 1.6 mL Sterile)-13 ( )]TJ
-0.002 Tc 0.087 Tw 0 -1.068 Td
[(W)18.2 (a)-9.8 (ter for Injection USP)129.2 (,)37.2 ( the resulting concentra)-9.8 (tion is 75 mg/1.5 mL \(50 mg/mL\) of)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(luspa)-9.8 (tercept-aamt and the nominal deliverable volume is 1.5 mL.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.963 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(CLINIC)18.3 (AL PHARMACOLOGY)]TJ
0.017 Tw -3.375 -1.81 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_0 1 Tf
0.012 Tw -3.375 -1.518 Td
[(Luspa)-9.8 (tercept-aamt is a recombinant fusion protein tha)-9.8 (t binds several endogenous )37.1 (TGF-)]TJ
/T1_3 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
( )Tj
-0.016 Tc 0.024 Tw 0 -1.068 Td
[(superfamily ligands,)37 ( thereby diminishing Smad2/3 signaling.)36.9 ( In models of )]TJ
/T1_3 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.016 Tc 0.016 Tw 26.881 0 Td
[(-thalassemia)-16 ( )]TJ
-0.004 Tc 0.08 Tw -26.881 -1.068 Td
[(and MDS,)36.7 ( luspa)-10.3 (tercept-aamt decreased abnormally eleva)-10.3 (ted Smad2/3 signaling and)-4 ( )]TJ
-0.003 Tc 0.082 Tw 0 -1.068 Td
[(improved hema)-9.9 (tolog)-9.9 (y parameters associa)-9.8 (ted with ineffective er)-17.9 (ythropoiesis in mice.)34 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.068 Td
[(Luspa)-9.6 (tercept-aamt promoted er)-17.7 (ythroid ma)-9.7 (tura)-9.6 (tion through differentia)-9.7 (tion and increasing)-16 ( )]TJ
-0.01 Tc 0.045 Tw 0 -1.068 Td
[(t)0.5 (h)0.6 (e)0.5 ( p)0.6 (e)0.5 (r)0.5 (c)0.6 (e)0.5 (n)0.5 (t)0.6 (a)-9.5 (g)0.5 (e)0.6 ( o)0.5 (f)0.6 ( l)0.5 (a)-9.4 (t)0.5 (e)0.6 (-)0.5 (s)0.5 (t)0.6 (a)-9.5 (g)0.5 (e)0.6 ( e)0.5 (r)-17.4 (y)0.5 (t)0.6 (h)0.5 (r)0.5 (o)0.6 (i)0.5 (d)0.5 ( p)0.6 (r)0.5 (e)0.6 (c)0.5 (u)0.5 (r)0.5 (s)0.6 (o)0.5 (r)0.5 (s)0.6 ( \()0.5 (n)0.6 (o)0.5 (r)0.5 (m)0.6 (o)0.5 (b)0.5 (l)0.6 (a)0.5 (s)0.5 (t)0.6 (s)0.5 (\))0.5 ( i)0.5 (n)0.5 ( t)0.6 (h)0.5 (e)0.5 ( b)0.5 (o)0.5 (n)0.6 (e)0.5 ( m)0.6 (a)0.5 (r)0.6 (r)0.5 (o)-9.5 (w)0.6 ( o)0.5 (f)-9.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(mice and increased er)-17.8 (ythroid precursors in humans,)37.2 ( thereby increasing er)-17.7 (ythropoiesis.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.9 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
/T1_0 1 Tf
0.048 Tw -3.375 -1.54 Td
[(Increases in Hemoglobin in P)18.2 (a)-9.8 (tients with Lo)-9.7 (w RBC )37.2 (T)74.2 (ransfusion Burden)]TJ
-0.009 Tc 0.055 Tw 0 -1.518 Td
[(In pa)-10.3 (tients ha)-10.3 (ving received <4 units of RBC transfusion within 8 weeks prior to stud)-10.3 (y)54.7 (,)28 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.068 Td
[(hemoglobin increased within 7 days of initia)-10.4 (ting REBLOZYL and correla)-10.4 (ted with the time)-15 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.068 Td
[(to luspa)-9.6 (tercept-aamt maximum serum concentra)-9.7 (tion \(C)]TJ
0.006 Tw 5.6 0 0 5.6 488.28 435.3698 Tm
(max)Tj
0.066 Tw 8 0 0 8 496.9768 435.8598 Tm
[(\).)37.3 ( )37 (The grea)-9.6 (test hemoglobin)-6 ( )]TJ
-0.014 Tc 0.028 Tw -21.622 -1.068 Td
[(\(Hgb\) increase occurred after the \037rst dose; a)-10 (pproxima)-10.1 (tely 0.75 g/dL a)-10 (t a dose of 0.6\036)-28.3 (to)-14 ( )]TJ
-0.017 Tc 0 Tw 0 -1.068 Td
[(1)0.5 (.)0.5 (2)0.5 (5)0.5 ( )0.5 (t)0.5 (i)0.5 (m)0.5 (e)0.5 (s )0.5 (t)0.5 (h)0.5 (e)0.5 ( )0.5 (r)0.5 (e)0.5 (c)0.5 (o)0.5 (m)0.5 (m)0.5 (e)0.5 (n)0.5 (d)0.5 (e)0.5 (d)0.5 ( )0.5 (s)0.5 (t)0.5 (a)0.5 (r)0.5 (t)0.5 (i)0.5 (n)0.5 (g )0.5 (d)0.5 (o)0.5 (s)0.5 (e)0.5 ( )0.5 (f)0.5 (o)0.5 (r)0.5 ( )0.5 (b)0.5 (e)0.5 (t)0.5 (a)0.5 ( )0.5 (t)0.5 (h)0.5 (a)0.5 (l)0.5 (a)0.5 (s)0.5 (s)0.5 (em)0.6 (ia)0.5 (,)37.5 ( )0.5 (o)0.5 (r)0.5 ( )0.5 (a)-9.5 (p)0.5 (p)0.5 (r)0.5 (o)0.5 (x)0.5 (i)0.5 (m)0.5 (a)-9.5 (t)0.5 (e)0.5 (l)0.5 (y)0.5 ( )0.5 (1)0.5 ( )0.5 (g)0.5 (/d)0.5 (L)-17 ( )]TJ
-0.004 Tc 0.079 Tw 0 -1.068 Td
[(a)-10.2 (t a dose of 0.75 to 1.75 times the recommended starting dose for MDS.)36.8 ( )36.8 (Additional)-4 ( )]TJ
-0.008 Tc 0.059 Tw 0 -1.068 Td
[(smaller increases were obser)-18.2 (ved after subsequent doses.)36.8 ( Hemoglobin levels returned)-8 ( )]TJ
0.057 Tw 0 -1.068 Td
[(to )0.6 (baseline )0.6 (a)-9.8 (pproxima)-9.8 (tely )0.5 (6 )0.5 (to )0.5 (8 )0.5 (weeks )0.5 (from )0.6 (the )0.6 (last )0.5 (dose )0.5 (follo)-9.8 (wing )0.5 (administra)-9.7 (tion )0.5 (of)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(luspa)-9.8 (tercept-aamt \(0.6 to 1.75 mg/kg\).)]TJ
-0.008 Tc 0.057 Tw 0 -1.608 Td
[(Increasing luspa)-9.8 (tercept-aamt serum exposure \(AUC\) was associa)-9.8 (ted with grea)-9.9 (ter Hgb)-8 ( )]TJ
-0.019 Tc 0 Tw 0 -1.068 Td
[(increase in pa)-10 (tients with beta thalassemia or MDS who had a baseline transfusion burde\n)-19 ( )]TJ
-0.009 Tc 0.05 Tw 0 -1.068 Td
[(<4)0.5 ( u)0.5 (nit)0.5 (s/8 we)0.5 (ek)0.5 (s.)37.4 ( In)0.5 (cre)0.5 (asi)0.5 (ng lu)0.5 (spa)-9.5 (ter)0.5 (cep)0.5 (t-a)0.5 (amt)0.5 ( ser)0.5 (um ex)0.5 (po)0.5 (sure)0.5 ( \()0.5 (ti)0.5 (me-)0.5 (a)-9.6 (v)0.5 (era)-9.5 (ged)0.5 ( )36.5 (A)0.5 (UC\))-9 ( )]TJ
-0.005 Tc 0.074 Tw 0 -1.068 Td
[(was associa)-10.2 (ted with grea)-10.2 (ter probability of achieving transfusion independence for a)-10.2 (t)-5 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.068 Td
[(least 8 consecutive weeks in ESA-refractor)-17.6 (y or -intolerant pa)-9.6 (tients with MDS requiring)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
(transfusions \(\0352 units of RBC transfusion within 8 weeks\).)Tj
/T1_2 1 Tf
0.017 Tw 0 -1.9 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
0.005 Tc 0.126 Tw -3.375 -1.518 Td
[(Luspa)-10.4 (tercept-aamt exhibited linear )0.5 (pharmacokinetics )0.5 (\(PK\) )0.5 (over )0.5 (the )0.5 (dose )0.5 (range )0.5 (of)5.1 ( )]TJ
-0.004 Tc 0.08 Tw 0 -1.068 Td
[(0.2\036)-79.9 (to 1.25 mg/kg \(0.2 to 1.25 times the recommended starting dosa)-10.3 (ge\) in pa)-10.3 (tients)-4 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.068 Td
[(with )0.5 (beta )0.5 (thalas)0.5 (semia,)37.4 ( )0.5 (and fr)0.5 (om 0.1)0.5 (25 mg/k)0.5 (g to )0.5 (1.75 m)0.5 (g/kg \(0)0.5 (.125 to)0.5 ( 1.75 )0.5 (times )0.5 (the)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(recommended starting dosa)-9.8 (ge\) in pa)-9.8 (tients with MDS.)37.2 ( )37.2 (The geometric mean \(% coef\037cient)-17 ( )]TJ
-0.01 Tc 0.047 Tw 0 -1.068 Td
[(of varia)-9.8 (tion [%CV]\) stead)-9.7 (y-sta)-9.7 (te )37.2 (AUC a)-9.8 (t the starting dose of 1 mg/kg was 126 \(35.9%\))-10 ( )]TJ
-0.013 Tc 0.03 Tw 0 -1.068 Td
[(d)0.5 (ay)0.5 (\225)0.5 (\265g)0.5 (/)0.5 (mL)0.5 ( f)0.5 (or)0.5 ( p)0.5 (a)-9.6 (t)0.5 (i)0.5 (e)0.5 (nt)0.5 (s)0.5 ( wi)0.5 (t)0.5 (h b)0.5 (et)0.5 (a)0.5 ( th)0.5 (a)0.5 (l)0.5 (as)0.5 (se)0.5 (m)0.5 (i)0.5 (a)0.5 ( a)0.5 (n)0.5 (d 1)0.5 (5)0.5 (4 \()0.5 (37)0.5 (.)0.5 (4%)0.5 (\))0.5 ( d)0.5 (a)0.5 (y)0.5 (\225\265)0.5 (g)0.5 (/m)0.5 (L)0.5 ( f)0.5 (o)0.5 (r)0.5 ( p)0.5 (a)-9.5 (t)0.5 (ie)0.5 (n)0.5 (t)0.5 (s)-13 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.068 Td
[(with MDS.)36.8 ( Luspa)-10.2 (tercept-aamt serum concentra)-10.1 (tion reached stead)-10.1 (y sta)-10.1 (te after 3 doses)-11 ( )]TJ
-0.006 Tc 0.069 Tw 0 -1.068 Td
[(when )0.5 (administered ever)-18.1 (y )0.5 (3 weeks.)36.9 ( )37.4 (The accumula)-10.1 (tion ra)-10.1 (tio of )0.5 (luspa)-10.1 (tercept-aamt was)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(a)-9.8 (pproxima)-9.8 (tely 1.5.)]TJ
0.017 Tw 0 -1.743 Td
(Absorption)Tj
0.009 Tc 0.145 Tw 0 -1.518 Td
[(The median [range] time to maximum concentra)-10.3 (tion \(T)]TJ
-0.009 Tw 5.6 0 0 5.6 497.3483 206.8065 Tm
(max)Tj
0.145 Tw 8 0 0 8 506.3078 207.2965 Tm
[(\) of luspa)-10.3 (tercept-aamt)9 ( )]TJ
-0.005 Tc 0.074 Tw -22.788 -1.068 Td
[(was )0.5 (obser)-18 (ved )0.6 (a)-10.1 (t )0.5 (a)-10.1 (pproxima)-10 (tely )0.5 (5 )0.6 ([3 )0.6 (to )0.6 (8] )0.6 (days )0.5 (post-dose )0.5 (in )0.5 (adult )0.6 (pa)-10.1 (tients )0.5 (with )0.6 (beta)-5 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.068 Td
[(thalassemia or 6 [3 to 7] days post-dose in adult pa)-10.2 (tients with MDS.)36.8 ( )36.8 (The absorption of)-11 ( )]TJ
-0.003 Tc 0.081 Tw 0 -1.068 Td
[(luspa)-9.6 (tercept-aamt was not signi\037cantly affected by the subcutaneous inject\ion sites)-3.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(\(upper arm,)37.2 ( thigh,)37.2 ( or abdomen\).)]TJ
0.017 Tw 0 -1.743 Td
(Distribution)Tj
-0.012 Tc 0.04 Tw 0 -1.518 Td
[(The geometric mean \(%CV\) a)-10.3 (pparent volume of distribution \(V)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 503.3846 146.5607 Tm
(d)Tj
-0.012 Tc 0.04 Tw 8 0 0 8 505.9123 147.0507 Tm
[(/F\) of luspa)-10.4 (tercept-aamt)-12 ( )]TJ
-0.005 Tc 0.073 Tw -22.739 -1.068 Td
[(was 7.1 \(26.7%\) L for pa)-9.9 (tients with beta thalassemia and 9.6 \(26.7%\) L for pa)-10 (tients)-5 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.068 Td
(with MDS.)Tj
0.017 Tw 0 -1.743 Td
[(Elimina)-9.7 (tion)]TJ
-0.004 Tc 0.08 Tw 0 -1.518 Td
(The geometric mean \(%CV\) half-lives \(t)Tj
0.004 Tw 5.6 0 0 5.6 441.6967 103.3968 Tm
(1/2)Tj
0.08 Tw 8 0 0 8 448.5677 103.8868 Tm
[(\) of luspa)-10.3 (tercept-aamt were a)-10.3 (pproxima)-10.3 (tely)-4 ( )]TJ
-0.014 Tc 0.025 Tw -15.571 -1.068 Td
[(1)0.5 (1\036)-25.1 (\()0.5 (25)0.5 (.)0.5 (7%)0.5 (\))0.5 ( d)0.5 (a)0.5 (ys)0.5 ( i)0.5 (n)0.5 ( p)0.5 (a)-9.5 (t)0.5 (ie)0.5 (n)0.5 (ts)0.5 ( w)0.5 (i)0.5 (t)0.5 (h be)0.5 (t)0.5 (a)0.5 ( t)0.5 (h)0.5 (al)0.5 (a)0.5 (ss)0.5 (e)0.5 (m)0.5 (ia)0.5 ( an)0.5 (d)0.5 ( 1)0.5 (4)0.5 ( \()0.5 (31)0.5 (.)0.5 (7)0.5 (%\))0.5 ( d)0.5 (a)0.5 (ys)0.5 ( in)0.5 ( p)0.5 (a)-9.5 (t)0.5 (ie)0.5 (n)0.5 (t)0.5 (s wi)0.5 (t)0.5 (h)-14 ( )]TJ
-0.01 Tc 0.048 Tw 0 -1.068 Td
[(MDS.)37 ( )37.1 (The geometric mean \(%CV\) a)-10 (pparent total c)20 (learance \(CL/F\) of luspa)-10 (tercept-aamt)-10 ( )]TJ
-0.006 Tc 0.065 Tw 0 -1.068 Td
[(w)0.5 (a)0.5 (s)0.5 ( 0.)0.5 (4)0.6 (4 \()0.5 (3)0.5 (8)0.5 (.)0.5 (5)0.5 (%)0.5 (\))0.5 ( L)0.5 (/)0.5 (d)0.5 (a)0.5 (y)0.5 ( i)0.5 (n)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( b)0.5 (e)0.5 (t)0.5 (a)0.5 ( t)0.5 (h)0.5 (a)0.5 (l)0.5 (a)0.5 (s)0.5 (s)0.5 (e)0.5 (m)0.5 (i)0.5 (a)0.5 ( a)0.5 (n)0.5 (d)0.5 ( 0)0.5 (.)0.5 (4)0.5 (7)0.5 ( \()0.5 (4)0.5 (2)0.5 (.)0.5 (9)0.5 (%)0.5 (\))0.5 ( L)0.5 (/)0.5 (da)0.6 (y)0.5 ( i)0.5 (n)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.068 Td
[(pa)-9.8 (tients with MDS.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.63 Td
(Metabolism)Tj
/T1_0 1 Tf
0.024 Tw 0 -1.518 Td
[(Luspa)-10.1 (tercept-aamt is expected to be ca)-10.2 (tabolized into small peptides and amino acids by)-17 ( )]TJ
0.012 Tw 0 -1.068 Td
[(general ca)-9.8 (tabolic degrada)-9.7 (tion processes in multiple tissues.)]TJ
ET
endstreamendobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 83 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 20 0 R>>/Font<</T1_0 23 0 R/T1_1 21 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330033005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 474>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 84 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 23 0 R/T1_1 21 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 85 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330033005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[377.0 0.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 626>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 86 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 22 0 R/T1_1 21 0 R/T1_2 23 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 678>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 87 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 23 0 R/T1_1 21 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 730>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 88 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 19 0 R/GS1 20 0 R/GS2 27 0 R>>/Font<</T1_0 23 0 R/T1_1 21 0 R/T1_2 22 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 25 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00630037006300390030003900630039002D0063003200320038002D0034003400650039002D0038003200610064002D003100370038003100660035006300660037003500340034>/LastModified<FEFF0044003A00320030003200340030003500320031003100300033003900330034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 784>>/PageWidthList<</0 612.0>>>>>>>>endobj88 0 obj<</Length 46368>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 227.0442 cm
0 0 m
252 0 l
S
Q
q 1 0 0 1 36 218.4821 cm
0 0 m
252 0 l
S
Q
q 1 0 0 1 36 209.92 cm
0 0 m
105.242 0 l
S
Q
/GS2 gs
q 1 0 0 1 250.56 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 673.7642 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 213.12 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 674.0142 cm
0 0 m
0 20.192 l
S
Q
1 w 
q 1 0 0 1 36 715.1481 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 213.12 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 715.1481 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 138.24 694.7061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 213.12 694.7061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 137.99 694.4561 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 138.24 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 175.68 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 213.12 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 138.24 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 639.3485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 639.3485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 639.3485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 639.3485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 570.267 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 175.68 570.267 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 213.12 570.267 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 250.56 570.267 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 138.24 558.795 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 175.68 558.795 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 213.12 558.795 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 250.56 558.795 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 138.24 547.5732 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 547.5732 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 547.5732 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 547.5732 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 36 547.3232 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 547.3232 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 547.3232 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 547.3232 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 547.3232 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 535.8513 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 535.8513 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 524.6293 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 535.8513 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 524.6293 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 535.8513 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 524.6293 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 535.8513 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 524.6293 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 36 524.3793 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 524.3793 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 513.1574 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 524.3793 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 513.1574 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 524.3793 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 513.1574 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 524.3793 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 513.1574 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 501.6855 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 501.6855 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 501.6855 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 501.6855 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 478.7417 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 478.7417 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 478.7417 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 478.7417 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 467.2698 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 467.2698 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 467.2698 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 467.2698 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 444.3259 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 444.3259 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 444.3259 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 444.3259 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 432.854 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 432.854 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 432.854 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 432.854 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 410.1602 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 175.68 410.1602 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 213.12 410.1602 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 250.56 410.1602 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 36 512.9074 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 512.9074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 512.9074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 512.9074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 512.9074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 501.4355 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 501.4355 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 501.4355 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 501.4355 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 501.4355 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 489.9636 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 489.9636 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 489.9636 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 489.9636 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 489.9636 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 478.4917 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 478.4917 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 478.4917 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 478.4917 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 478.4917 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 467.0198 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 467.0198 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 467.0198 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 467.0198 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 467.0198 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 455.5479 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 455.5479 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 455.5479 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 455.5479 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 455.5479 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 604.6827 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 604.6827 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 604.6827 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 604.6827 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 604.6827 cm
0 0 m
37.44 0 l
S
Q
1 w 
q 1 0 0 1 36 409.6602 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 409.6602 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 409.6602 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 409.6602 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 409.6602 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 36 388.7483 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 388.7483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 388.7483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 388.7483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 388.7483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 444.0759 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 444.0759 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 444.0759 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 444.0759 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 444.0759 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 432.604 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 432.604 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 432.604 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 432.604 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 432.604 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 421.1321 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 421.1321 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 421.1321 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 421.1321 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 421.1321 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 639.0985 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 639.0985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 639.0985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 639.0985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 639.0985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 662.0423 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 662.0423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 650.5704 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 662.0423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 650.5704 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 662.0423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 650.5704 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 662.0423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 650.5704 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 36 627.6266 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 627.6266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 616.1547 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 627.6266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 616.1547 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 627.6266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 616.1547 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 627.6266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 616.1547 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 36 593.2108 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 593.2108 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 581.7389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 593.2108 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 581.7389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 593.2108 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 581.7389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 593.2108 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 581.7389 cm
0 0 m
0 11.222 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 727.248 Tm
[(T)74.2 (able 8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Adverse Reactions \(\0375%\) in P)24.2 (atients Receiving REBLOZYL in COMMANDS)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
[(T)74.2 (rial)]TJ
-0.017 Tc 0.048 Tw -4.737 -3.393 Td
(Body System/Adverse Reaction)Tj
0.017 Tw 16.401 1.825 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 190.7111 706.1961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 163.7036 697.6961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(178\))Tj
0.048 Tw 7.672 1.062 Td
[(Epoetin Alf)20.2 (a)]TJ
0 Tc 0 Tw 7.6 0 0 8 268.2095 706.1961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 238.7086 697.6961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(176\))Tj
0.048 Tw -14.197 -1.524 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.237 1.062 Td
(Grade \0373)Tj
0.689 -1.062 Td
(n \(%\))Tj
3.998 1.062 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.237 1.062 Td
(Grade \0373)Tj
0.689 -1.062 Td
(n \(%\))Tj
-29.65 -1.51 Td
[(Respirator)-17.8 (y)55.2 (,)37.2 ( thoracic and mediastinal disorders)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Dyspnea)Tj
0.048 Tw 14.622 0 Td
(21 \(12\))Tj
5.389 0 Td
(7 \(4\))Tj
4.695 0 Td
(13 \(7\))Tj
5.174 0 Td
(2 \(1\))Tj
-29.881 -1.434 Td
(Dyspnea exertional)Tj
15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(0 \(0\))Tj
4.926 0 Td
(1 \(1\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Ner)-17.8 (vous system disorders)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Dizziness)Tj
0.048 Tw 14.854 0 Td
(16 \(9\))Tj
5.158 0 Td
(1 \(1\))Tj
4.695 0 Td
(15 \(9\))Tj
5.174 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Headache)Tj
0.048 Tw 14.854 0 Td
(15 \(8\))Tj
5.158 0 Td
(0 \(0\))Tj
4.695 0 Td
(12 \(7\))Tj
5.174 0 Td
(1 \(1\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Musculoskeletal and connective tissue disorders)Tj
/T1_1 1 Tf
0 -1.434 Td
[(Back P)18.2 (ain)-17 (\036)]TJ
14.854 0 Td
(16 \(9\))Tj
5.158 0 Td
(2 \(1\))Tj
4.695 0 Td
(13 \(7\))Tj
5.174 0 Td
(3 \(2\))Tj
0.017 Tw -29.881 -1.434 Td
[(Arthralgia)-17 (\036)]TJ
0.048 Tw 14.854 0 Td
(10 \(6\))Tj
5.158 0 Td
(0 \(0\))Tj
4.695 0 Td
(14 \(8\))Tj
5.174 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
[(My)-9.8 (algia)]TJ
0.048 Tw 15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(0 \(0\))Tj
4.926 0 Td
(5 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Osteoarthritis)Tj
0.048 Tw 15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(1 \(1\))Tj
4.926 0 Td
(4 \(2\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Infections and infestations)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(COVID-19)Tj
0.048 Tw 14.622 0 Td
(19 \(11\))Tj
5.389 0 Td
(6 \(3\))Tj
4.464 0 Td
(17 \(10\))Tj
5.406 0 Td
(2 \(1\))Tj
-29.881 -1.434 Td
[(Urinar)-17.7 (y tract infection)]TJ
14.854 0 Td
(13 \(7\))Tj
5.158 0 Td
(0 \(0\))Tj
4.926 0 Td
(7 \(4\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Pneumonia)Tj
0.048 Tw 15.085 0 Td
(8 \(5\))Tj
4.926 0 Td
(7 \(4\))Tj
4.695 0 Td
(15 \(9\))Tj
4.943 0 Td
(11 \(6\))Tj
/T1_0 1 Tf
-29.649 -1.434 Td
(Metabolism and nutrition disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Hyperuricemia)Tj
0.048 Tw 14.854 0 Td
(12 \(7\))Tj
5.158 0 Td
(1 \(1\))Tj
4.695 0 Td
(10 \(6\))Tj
5.174 0 Td
(1 \(1\))Tj
-29.881 -1.434 Td
[(Decreased a)-9.8 (ppetite)]TJ
15.085 0 Td
(8 \(5\))Tj
4.926 0 Td
(0 \(0\))Tj
4.695 0 Td
(11 \(6\))Tj
5.174 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Blood and lymphatic system disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
[(Thromboc)20.2 (ytopenia)]TJ
0.048 Tw 14.854 0 Td
(11 \(6\))Tj
5.158 0 Td
(7 \(4\))Tj
4.926 0 Td
(3 \(2\))Tj
4.943 0 Td
(1 \(1\))Tj
0.017 Tw -29.881 -1.434 Td
(Neutropenia)Tj
0.048 Tw 15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(7 \(4\))Tj
4.695 0 Td
(13 \(7\))Tj
4.943 0 Td
(10 \(6\))Tj
/T1_0 1 Tf
-29.649 -1.434 Td
(Psychiatric disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Insomnia)Tj
0.048 Tw 15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(0 \(0\))Tj
4.926 0 Td
(6 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw 5.04 0 0 5.6 36.0004 402.9623 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40.0004 400.3483 Tm
[(Reaction inc)20.2 (ludes similar/grouped terms.)]TJ
0.017 Tw 5.04 0 0 5.6 36.0004 394.9623 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40.0004 392.3483 Tm
[(Inc)20.2 (ludes asthenic conditions.)]TJ
-0.012 Tc 0.035 Tw 8 0 0 8 36.0004 372.7762 Tm
[(O)0.5 (t)0.6 (h)0.6 (e)0.5 (r)0.6 ( c)20.5 (l)0.6 (i)0.5 (n)0.6 (i)0.6 (c)0.5 (a)0.6 (l)0.5 (l)0.6 (y)0.5 ( r)0.6 (e)0.6 (l)0.5 (e)0.6 (v)0.5 (a)0.6 (n)0.6 (t)0.5 ( a)0.6 (d)0.6 (v)0.5 (e)0.6 (r)0.5 (s)0.6 (e)0.6 ( r)0.6 (e)0.6 (a)0.5 (c)0.6 (t)0.6 (i)0.5 (o)0.6 (n)0.5 (s)0.6 ( r)0.5 (e)0.6 (p)0.6 (o)0.5 (r)0.6 (t)0.6 (e)0.5 (d)0.6 ( i)0.5 (n)0.6 ( <)0.5 (5)0.6 (%)0.5 ( o)0.6 (f)0.6 ( p)0.5 (a)-9.4 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.6 ( a)0.6 (r)0.6 (e)0.5 ( i)0.6 (n)0.5 (j)0.6 (e)0.6 (c)0.5 (t)0.6 (i)0.5 (o)0.6 (n)0.6 ( s)0.6 (i)0.6 (t)0.5 (e)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
[(reactions,)37.2 ( inc)20.2 (luding er)-17.8 (ythema,)37.2 ( pruritus,)37.2 ( and rash.)]TJ
-0.01 Tc 0.047 Tw 0 -1.61 Td
[(Shifts from Grades 0-2 a)-9.8 (t baseline to Grades 2-3 abnormalities for selected labora)-9.7 (tor)-17.8 (y)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
[(tests in the COMMANDS trial are sho)-9.8 (wn in )37.2 (T)74.2 (able 9.)]TJ
ET
1 w 
/GS2 gs
q 1 0 0 1 36.0004 314.2358 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.2404 314.2358 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.6804 314.2358 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.1204 314.2358 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.5604 314.2358 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 138.2404 302.2939 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 213.1204 302.2939 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 137.9904 302.0439 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 138.2404 290.102 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 175.6804 302.0439 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.6804 290.102 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.1204 302.0439 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.5604 302.0439 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36.0004 289.852 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.2404 289.852 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.6804 289.852 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.2404 278.3801 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.6804 278.3801 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.1204 278.3801 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.2404 267.4082 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.6804 267.4082 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.1204 267.4082 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 36.0004 266.9082 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.2404 266.9082 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.6804 266.9082 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.1204 266.9082 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 36.0004 245.9963 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.2404 245.9963 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.6804 245.9963 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.1204 245.9963 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.5604 245.9963 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.5604 278.3801 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.5604 267.4082 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 250.5604 266.9082 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 213.1204 290.102 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 250.5604 290.102 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.1204 289.852 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.5604 289.852 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36.0004 326.3358 Tm
[(T)74.2 (able 9:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Selected T)74.2 (reatment-Emergent Laborator)-17.8 (y Abnormalities in COMMANDS)-12 ( )]TJ
0 -1.062 Td
[(T)74.2 (rial that Shift to Grades 2-3)-12 ( )]TJ
-0.017 Tc 0.017 Tw -0.01 -2.331 Td
[(P)24.2 (arameter)]TJ
11.674 0.762 Td
(REBLOZYL)Tj
0.048 Tw 9.541 0 Td
[(Epoetin Alf)20.2 (a)]TJ
0.017 Tw -10.485 -1.524 Td
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 157.8898 295.706 Tm
(a)Tj
7.6 0 0 8 160.4486 293.092 Tm
(\036)Tj
-0.017 Tc 0.048 Tw 3.423 0 Td
(n \(%\))Tj
0.017 Tw 5.503 0 Td
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 232.7047 295.706 Tm
( )Tj
EMC 
0.024 0 Td
(a)Tj
0 Tw 7.6 0 0 8 235.3937 293.092 Tm
(\036)Tj
-0.017 Tc 0.048 Tw 3.431 0 Td
(n \(%\))Tj
/T1_1 1 Tf
-29.667 -1.479 Td
[(T)74.2 (otal bilirubin)]TJ
0.017 Tw 15.213 0 Td
(171)Tj
0.048 Tw 4.336 0 Td
(38 \(22\))Tj
0.017 Tw 5.517 0 Td
(165)Tj
0.048 Tw 4.352 0 Td
(19 \(12\))Tj
0.017 Tw -29.418 -1.434 Td
(GFR)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 47.0081 272.4022 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 151.6192 269.7882 Tm
(171)Tj
0.048 Tw 4.336 0 Td
(60 \(35\))Tj
0.017 Tw 5.517 0 Td
(167)Tj
0.048 Tw 4.352 0 Td
(36 \(22\))Tj
0.017 Tw 5.04 0 0 5.6 36.0004 260.2103 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40.0004 257.5963 Tm
[(Number of pa)-9.7 (tients a)-9.7 (t Grades 0)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
11.332 0 Td
(-)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.319 0 Td
[(1 a)-9.8 (t baseline.)]TJ
0.017 Tw 5.04 0 0 5.6 36.0004 252.2103 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 40.0004 249.5963 Tm
(GFR)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.473 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
[(glomerular filtra)-9.8 (tion ra)-9.8 (te \(mL/min\).)]TJ
-0.023 Tc 0.034 Tw 8 0 0 8 36.0005 228.0442 Tm
[(Myelod)-10.2 (ysplastic Syndromes with Ring Sideroblasts or Myelod)-10.3 (ysplastic / Myeloprolifera)-10.2 (tive)-23 ( )]TJ
0.023 Tc 0.249 Tw 0 -1.07 Td
[(Neoplasm with Ring Sideroblasts and )37.1 (Thromboc)20 (ytosis )37.1 (Associa)-9.9 (ted )37.1 (Anemia in)23 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.07 Td
[(ESA-refractor)-17.8 (y or -intolerant pa)-9.8 (tients)]TJ
-0.013 Tc 0.032 Tw 0 -1.52 Td
[(The safety of REBLOZYL a)-9.8 (t the recommended dose and schedule was evalua)-9.9 (ted in 242)-13 ( )]TJ
-0.008 Tc 0.057 Tw 0 -1.07 Td
[(pa)-9.9 (tients with MDS with ring sideroblasts \(n)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
15.903 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.625 0 Td
(192\) or other myeloid neoplasms \(n)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.161 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.625 0 Td
[(50\))-8 ( )]TJ
-0.002 Tc 0.087 Tw -30.315 -1.07 Td
[(in the )0.5 (MEDALIST trial.)37.3 ( )37.4 (The safety popula)-9.7 (tion inc)20.2 (luded 63% males )0.5 (and 37% )0.5 (females)-2.1 ( )]TJ
0 Tc 0.096 Tw 0 -1.07 Td
[(of median a)-9.7 (ge 72 years \(range,)37.3 ( 30)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.409 0 Td
(\226)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.624 0 Td
[(95 years\); of these pa)-9.7 (tients,)37.3 ( 81% were )36.7 (White,)37 ( )]TJ
0 Tw 17.466 0 Td
( )Tj
-0.021 Tc -31.5 -1.07 Td
[(0.4% Black,)37.2 ( 0.4% Other)74.3 (,)37.2 ( and race was not reported in 18.2% of pa)-9.8 (tients.)37.2 ( )37.2 (The median time)-21 ( )]TJ
-0.011 Tc 0.043 Tw 0 -1.07 Td
[(on trea)-10 (tment with REBLOZYL was 50.4 weeks \(range,)37 ( 3)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
20.368 0 Td
(\226)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.603 0 Td
[(221 weeks\); 67% of pa)-10 (tients)-11 ( )]TJ
-0.017 Tc 0.012 Tw -20.971 -1.07 Td
[(were exposed for 6 months or longer and 49% were exposed for grea)-9.8 (ter than one year)74.2 (.)]TJ
-0.012 Tc 0.039 Tw 0 -1.61 Td
[(Among the 242 pa)-10.1 (tients trea)-10.1 (ted with REBLOZYL,)36.9 ( 5 \(2.1%\) had a fa)-10.2 (tal adverse reaction,)25 ( )]TJ
-0.011 Tc 0.041 Tw 0 -1.07 Td
[(11\036)-41.3 (\(4.5%\) discontinued due to an adverse reaction,)37.3 ( and 7 \(2.9%\) had a dose reduction)-11 ( )]TJ
0 Tc 0.099 Tw 0 -1.07 Td
[(due to an adverse reaction.)36.7 ( )36.8 (The most common \(\03510%\) all-grade adverse reactions )]TJ
0.001 Tc 0.101 Tw 0 -1.07 Td
[(inc)20.2 (luded fa)-9.7 (tigue,)37.3 ( musculoskeletal pain,)37.3 ( dizziness,)37.2 ( diarrhea,)37.3 ( nausea,)37.3 ( hypersensitivity)1 ( )]TJ
-0.021 Tc 0 Tw 0 -1.07 Td
[(reactions,)37.3 ( hypertension,)37.3 ( headache,)37.3 ( upper respira)-9.6 (tor)-17.6 (y tract infection,)37.3 ( bronchitis,)37.4 ( and urinar)-17.6 (y)-21 ( )]TJ
-0.009 Tc 0.055 Tw 0 -1.07 Td
[(tract infection.)36.7 ( )36.9 (The most common \(\0352%\) Grade \0353 adverse reactions inc)19.6 (luded fa)-10.4 (tigue,)28 ( )]TJ
-0.013 Tc 0.03 Tw 0 -1.07 Td
[(h)0.5 (y)0.5 (p)0.5 (e)0.5 (r)0.5 (t)0.5 (e)0.5 (n)0.5 (s)0.5 (i)0.5 (o)0.5 (n)0.5 (,)37.4 ( s)0.5 (y)0.5 (n)0.5 (c)0.5 (o)0.5 (p)0.5 (e)0.5 ( a)0.5 (n)0.5 (d)0.5 ( m)0.5 (u)0.5 (sc)0.5 (u)0.5 (l)0.5 (o)0.5 (s)0.5 (k)0.5 (e)0.5 (l)0.5 (e)0.5 (t)0.5 (a)0.6 (l p)0.5 (a)0.5 (i)0.5 (n)0.5 (.)37.5 ( S)0.5 (e)0.5 (l)0.5 (e)0.5 (c)0.5 (t)0.5 (e)0.5 (d)0.5 ( l)0.5 (a)0.5 (b)0.5 (o)0.5 (r)0.5 (a)-9.5 (t)0.5 (o)0.6 (r)-17.5 (y a)0.5 (b)0.5 (n)0.5 (o)0.5 (r)0.5 (m)0.5 (a)0.5 (l)0.5 (i)0.5 (t)0.5 (i)0.5 (e)0.5 (s)0.5 ( t)0.5 (h)0.5 (a)-9.5 (t)-13 ( )]TJ
-0.018 Tc 0 Tw 0 -1.07 Td
[(changed from Grade 0-1 a)-10 (t baseline to Grade \0352 a)-10 (t an)-10 (y time during the studies in a)-10 (t least)-18 ( )]TJ
-0.01 Tc 0.048 Tw 0 -1.07 Td
[(10% of pa)-9.9 (tients inc)20 (luded crea)-9.9 (tinine c)20.1 (learance decreased,)37 ( total bilirubin increased,)37 ( and)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.07 Td
(alanine aminotransferase increased.)Tj
0.018 Tw 0 -1.61 Td
[(T)74.2 (able 10 sho)-9.8 (ws the most common adverse reactions for pa)-9.8 (tients trea)-9.8 (ted with REBLOZYL)-17 ( )]TJ
0.012 Tw 0 -1.07 Td
[(or placebo through the \037rst 8 c)20.2 (yc)20.2 (les in the MEDALIST trial )]TJ
/T1_2 1 Tf
([see Clinical Studie)Tj
(s \(14.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
q 1 0 0 1 324 164.5361 cm
0 0 m
41.95 0 l
S
Q
/GS2 gs
q 1 0 0 1 538.56 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 673.7642 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.12 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 674.0142 cm
0 0 m
0 20.192 l
S
Q
1 w 
q 1 0 0 1 324 715.1481 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.12 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 715.1481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 715.1481 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 426.24 694.7061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 501.12 694.7061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 425.99 694.4561 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 426.24 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 463.68 694.4561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 501.12 674.0142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 426.24 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 673.7642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 651.0704 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 651.0704 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 651.0704 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 651.0704 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 628.1266 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 628.1266 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 628.1266 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 628.1266 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 582.2389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.68 582.2389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 582.2389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.56 582.2389 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.24 547.8232 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.68 547.8232 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 547.8232 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.56 547.8232 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 324 513.1574 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 513.1574 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 501.9355 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 513.1574 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 501.9355 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 513.1574 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 501.9355 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 513.1574 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 501.9355 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 478.9917 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 478.9917 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 478.9917 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 478.9917 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 456.0479 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 456.0479 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 456.0479 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 456.0479 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 433.354 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 463.68 433.354 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 501.12 433.354 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 538.56 433.354 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 324 421.3821 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 421.3821 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 409.9102 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.68 421.3821 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 409.9102 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 421.3821 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 409.9102 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.56 421.3821 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 409.9102 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.24 398.9383 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 398.9383 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 398.9383 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 398.9383 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 324 627.8766 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 627.8766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 627.8766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 627.8766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 627.8766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 581.9889 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 581.9889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 581.9889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 581.9889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 581.9889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 501.6855 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 501.6855 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 501.6855 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 501.6855 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 501.6855 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 490.2136 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 490.2136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 490.2136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 490.2136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 490.2136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 478.7417 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 478.7417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 478.7417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 478.7417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 478.7417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 467.2698 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 467.2698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 467.2698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 467.2698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 467.2698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 455.7979 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 455.7979 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 455.7979 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 455.7979 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 455.7979 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 444.3259 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 444.3259 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 444.3259 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 444.3259 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 444.3259 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 662.2923 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 662.2923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 662.2923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 662.2923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 662.2923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 570.517 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 570.517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 559.045 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.68 570.517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 559.045 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 570.517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 559.045 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.56 570.517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 559.045 cm
0 0 m
0 11.222 l
S
Q
1 w 
q 1 0 0 1 324 432.854 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 432.854 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 432.854 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 432.854 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 432.854 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 398.4383 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 398.4383 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 398.4383 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 398.4383 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 398.4383 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 324 377.5264 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 377.5264 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 377.5264 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 377.5264 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 377.5264 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 547.5732 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 547.5732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 547.5732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 547.5732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 547.5732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 650.8204 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 650.8204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 650.8204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 650.8204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 650.8204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 639.3485 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 639.3485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 639.3485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 639.3485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 639.3485 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 616.4047 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 616.4047 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.68 616.4047 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.12 616.4047 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.56 616.4047 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 604.9327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.24 593.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 463.68 593.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.12 593.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 538.56 593.4608 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 324 536.1013 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 536.1013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 524.8793 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 536.1013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 524.8793 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 536.1013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 524.8793 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 536.1013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 524.8793 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 324 524.6293 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 524.6293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 524.6293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 524.6293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 524.6293 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 323.9999 727.248 Tm
[(T)74.2 (able 10:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Adverse Reactions \(\0375%\) in P)24.2 (atients Receiving REBLOZYL with a)-12 ( )]TJ
0 -1.062 Td
[(Difference Between Arms of >2% in MED)34.2 (ALIST T)74.2 (rial Through Cyc)20.2 (le 8)]TJ
-0.017 Tc -4.737 -3.393 Td
(Body System/Adverse Reaction)Tj
0.017 Tw 16.401 1.825 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 706.1961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 451.7036 697.6961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(153\))Tj
0.017 Tw 8.456 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.2474 706.1961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 528.4672 697.6961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(76\))Tj
0.048 Tw -14.428 -1.524 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.472 1.062 Td
(Grade 3)Tj
0.454 -1.062 Td
(n \(%\))Tj
3.998 1.062 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.472 1.062 Td
[(Grade 3)-16.9 (\036)]TJ
0.454 -1.062 Td
(n \(%\))Tj
-29.65 -1.479 Td
(General disorders and administration site conditions)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
[(F)20.2 (a)-9.8 (tigue)]TJ
-0.198 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 343.688 656.3144 Tm
( )Tj
EMC 
0.024 0 Td
[(a,b)-17 (\036)]TJ
0.048 Tw 7.6 0 0 8 435.1302 653.7004 Tm
(63 \(41\))Tj
5.158 0 Td
(11 \(7\))Tj
4.695 0 Td
(17 \(22\))Tj
5.406 0 Td
(2 \(3\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Musculoskeletal and connective tissue disorders)Tj
/T1_1 1 Tf
0 -1.434 Td
(Musculoskeletal pain)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 380.839 633.3706 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 630.7566 Tm
(30 \(20\))Tj
5.389 0 Td
(3 \(2\))Tj
4.464 0 Td
(11 \(14\))Tj
5.406 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Ner)-17.8 (vous system disorders)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Dizziness/vertigo)Tj
0.048 Tw 14.622 0 Td
(28 \(18\))Tj
-0.198 Tw 5.085 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.665 0 Td
(5 \(7\))Tj
4.943 0 Td
(1 \(1\))Tj
0.017 Tw -29.881 -1.434 Td
(Headache)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 350.8075 598.9548 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 596.3408 Tm
(21 \(14\))Tj
5.389 0 Td
(0 \(0\))Tj
4.926 0 Td
(5 \(7\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Syncope/presyncope)Tj
0.048 Tw 15.085 0 Td
(8 \(5\))Tj
4.926 0 Td
(5 \(3\))Tj
4.926 0 Td
(0 \(0\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Gastrointestinal disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Nausea)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 344.176 564.5391 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 561.925 Tm
(25 \(16\))Tj
-0.198 Tw 5.085 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.434 0 Td
(8 \(11\))Tj
5.174 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Diarrhea)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 346.8708 553.0672 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 550.4532 Tm
(25 \(16\))Tj
5.389 0 Td
(0 \(0\))Tj
4.926 0 Td
(7 \(9\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Respirator)-17.8 (y)55.2 (,)37.2 ( thoracic and mediastinal disorder)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Dyspnea)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 347.2753 530.1234 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 527.5093 Tm
(20 \(13\))Tj
5.389 0 Td
(2 \(1\))Tj
4.926 0 Td
(4 \(5\))Tj
4.943 0 Td
(1 \(1\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Immune system disorders)Tj
/T1_1 1 Tf
0 -1.434 Td
(Hypersensitivity reactions)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 392.6778 507.1795 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
0 Tw 7.6 0 0 8 396.6201 504.5655 Tm
( )Tj
-0.017 Tc 0.048 Tw 5.067 0 Td
(15 \(10\))Tj
-0.198 Tw 5.085 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.665 0 Td
(5 \(7\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Renal and urinar)-17.7 (y disorders)]TJ
/T1_1 1 Tf
0 -1.434 Td
(Renal impairment)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 371.938 484.2357 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 436.8889 481.6217 Tm
(12 \(8\))Tj
5.158 0 Td
(3 \(2\))Tj
4.926 0 Td
(3 \(4\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Cardiac disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
[(T)74.2 (achycardia)]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 356.0394 461.2919 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 436.8889 458.6779 Tm
(12 \(8\))Tj
5.158 0 Td
(0 \(0\))Tj
4.926 0 Td
(1 \(1\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Injur)-17.8 (y poisoning and procedural complications)]TJ
/T1_1 1 Tf
0 -1.434 Td
[(Injection site reactions)-17 ( )]TJ
14.854 0 Td
(10 \(7\))Tj
5.158 0 Td
(0 \(0\))Tj
4.926 0 Td
(3 \(4\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Infections and infestations)Tj
/T1_1 1 Tf
0 -1.434 Td
[(Upper respira)-9.7 (tor)-17.8 (y tract infection)]TJ
14.854 0 Td
(10 \(7\))Tj
-0.198 Tw 4.854 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.665 0 Td
(2 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
-0.198 Tw -29.881 -1.434 Td
(Influenza)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
3.227 0 Td
(/)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.285 0 Td
[(influenza )-245.8 (like )-245.8 (illness)]TJ
0.048 Tw 11.573 0 Td
(9 \(6\))Tj
4.926 0 Td
(0 \(0\))Tj
4.926 0 Td
(2 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw 5.04 0 0 5.6 323.9999 391.7404 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 389.1264 Tm
[(Inc)20.2 (ludes asthenic conditions.)]TJ
0.017 Tw 5.04 0 0 5.6 323.9999 383.7404 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 381.1264 Tm
[(Reaction inc)20.2 (ludes similar/grouped terms.)]TJ
0.02 Tw 8 0 0 8 323.9999 361.4295 Tm
[(Other c)20.2 (linically relevant adverse reactions reported in <5% of pa)-9.7 (tients inc)20.2 (lude bronchitis,)20 ( )]TJ
0.012 Tw 0 -1.086 Td
[(urinar)-17.7 (y tract infection,)37.2 ( and hypertension )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.035 Tw 0 -1.626 Td
[(S)0.5 (h)0.5 (i)0.5 (f)0.5 (ts)0.5 ( f)0.5 (r)0.5 (o)0.5 (m)0.5 ( G)0.5 (r)0.5 (a)0.5 (d)0.5 (e)0.5 (s)0.5 ( 0)0.5 (-)0.5 (1)0.5 ( t)0.5 (o)0.5 ( G)0.5 (r)0.5 (a)0.5 (d)0.5 (e)0.5 (s 2)0.5 (-)0.5 (4)0.5 ( a)0.5 (b)0.5 (n)0.5 (o)0.5 (r)0.5 (m)0.5 (a)0.5 (l)0.5 (it)0.5 (i)0.5 (e)0.5 (s)0.5 ( f)0.5 (or)0.5 ( s)0.5 (e)0.5 (l)0.5 (e)0.5 (ct)0.5 (e)0.5 (d)0.5 ( l)0.5 (a)0.5 (bo)0.5 (r)0.5 (a)-9.5 (t)0.5 (o)0.5 (r)-17.5 (y)0.5 ( t)0.5 (e)0.5 (st)0.5 (s)0.5 ( d)0.5 (ur)0.5 (i)0.5 (n)0.5 (g)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.086 Td
[(the \037rst 8 c)20.2 (yc)20.2 (les in the MEDALIST trial are sho)-9.7 (wn in )37.2 (T)74.2 (able 11.)]TJ
ET
1 w 
/GS2 gs
q 1 0 0 1 323.9999 302.3901 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 302.3901 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 302.3901 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 302.3901 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 302.3901 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 426.2399 290.4482 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 501.1199 290.4482 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 425.9899 290.1982 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 426.2399 278.2563 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 463.6799 290.1982 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 278.2563 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 501.1199 290.1982 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 290.1982 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 278.0063 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 278.0063 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 278.0063 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.2399 266.5344 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.6799 266.5344 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 266.5344 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 255.0625 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 463.6799 255.0625 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 255.0625 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 243.5905 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 463.6799 243.5905 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 243.5905 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 232.6186 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.6799 232.6186 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.1199 232.6186 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 323.9999 232.1186 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 232.1186 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 232.1186 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 232.1186 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 211.2067 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 211.2067 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 211.2067 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 211.2067 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 211.2067 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 266.5344 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.5599 255.0625 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 538.5599 243.5905 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 538.5599 232.6186 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 538.5599 232.1186 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 501.1199 278.2563 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 538.5599 278.2563 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 501.1199 278.0063 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 278.0063 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 323.9999 314.4901 Tm
[(T)74.2 (able 11:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Selected Grades 2-4 T)74.2 (reatment-Emergent Laborator)-17.7 (y Abnormalities)-12 ( )]TJ
0 -1.062 Td
[(Through Cyc)20.2 (le 8 in the MED)34.2 (ALIST T)74.2 (rial)-12 ( )]TJ
-0.017 Tc 0.017 Tw -0.01 -2.331 Td
[(P)24.2 (arameter)]TJ
11.674 0.762 Td
(REBLOZYL)Tj
10.325 0 Td
(Placebo)Tj
-11.27 -1.524 Td
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 445.8893 283.8603 Tm
(a)Tj
7.6 0 0 8 448.4481 281.2463 Tm
(\036)Tj
-0.017 Tc 0.048 Tw 3.423 0 Td
(n \(%\))Tj
0.017 Tw 5.503 0 Td
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 520.7042 283.8603 Tm
( )Tj
EMC 
0.024 0 Td
(a)Tj
0 Tw 7.6 0 0 8 523.3932 281.2463 Tm
(\036)Tj
-0.017 Tc 0.048 Tw 3.431 0 Td
(n \(%\))Tj
/T1_1 1 Tf
-29.667 -1.479 Td
[(AL)94.2 (T eleva)-9.8 (ted)]TJ
0.017 Tw 15.213 0 Td
(151)Tj
0.048 Tw 4.567 0 Td
(13 \(9\))Tj
0.017 Tw 5.517 0 Td
(74)Tj
0.048 Tw 4.584 0 Td
(5 \(7\))Tj
-29.881 -1.434 Td
[(AST eleva)-9.8 (ted)]TJ
0.017 Tw 15.213 0 Td
(152)Tj
0.048 Tw 4.799 0 Td
(6 \(4\))Tj
0.017 Tw 5.285 0 Td
(76)Tj
0.048 Tw 4.584 0 Td
(0 \(0\))Tj
-29.881 -1.434 Td
[(T)74.2 (otal bilirubin eleva)-9.8 (ted)]TJ
0.017 Tw 15.213 0 Td
(140)Tj
0.048 Tw 4.336 0 Td
(17 \(12\))Tj
0.017 Tw 5.748 0 Td
(66)Tj
0.048 Tw 4.584 0 Td
(3 \(5\))Tj
-29.881 -1.434 Td
[(Crea)-9.7 (tinine c)20.2 (learance reduced)]TJ
0.017 Tw 15.213 0 Td
(113)Tj
0.048 Tw 4.336 0 Td
(30 \(27\))Tj
0.017 Tw 5.748 0 Td
(62)Tj
0.048 Tw 4.121 0 Td
(13 \(21\))Tj
0.017 Tw 5.04 0 0 5.6 323.9999 225.4207 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 222.8067 Tm
[(Number of pa)-9.7 (tients a)-9.7 (t Grades 0-1 a)-9.7 (t baseline.)]TJ
-0.115 Tw -0.556 -1 Td
[(AL)94.2 (T)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(alanine )-162.8 (aminotransferase; )-125.8 (AST)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(asparta)-9.8 (te )-162.8 (aminotransferase.)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 323.9999 191.7299 Tm
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
0.017 Tw -3.375 -1.716 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10.2 (y)]TJ
/T1_1 1 Tf
0.048 Tw -3.375 -1.558 Td
[(Risk Summar)-17.8 (y)]TJ
0.006 Tw 0 -1.536 Td
[(Based on \037ndings in animal reproduction studies,)37.2 ( REBLOZYL may cause fetal harm when)-17 ( )]TJ
-0.006 Tc 0.067 Tw 0 -1.086 Td
[(administered to a pregnant woman.)37.2 ( )36.7 (There are no a)-9.8 (vailable da)-9.9 (ta on REBLOZYL use in)-6 ( )]TJ
-0.008 Tc 0.059 Tw 0 -1.086 Td
[(pregnant women to inform a drug-associa)-10.2 (ted risk of major birth defects,)36.8 ( miscarria)-10.2 (ge,)29 ( )]TJ
-0.007 Tc 0.064 Tw 0 -1.086 Td
[(or adverse ma)-10.2 (ternal or fetal outcomes.)36.9 ( In animal reproduction studies,)36.9 ( administra)-10.1 (tion)-7 ( )]TJ
0.063 Tw 0 -1.086 Td
[(of luspa)-10 (tercept-aamt to pregnant ra)-10 (ts and rabbits during the period of organogenesis)-7 ( )]TJ
-0.017 Tc 0.02 Tw 0 -1.086 Td
[(resulted in adverse developmental outcomes inc)20.2 (luding embr)-17.8 (yo-fetal mortality)55.2 (,)37.2 ( altera)-9.8 (tions)-17 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.086 Td
[(to gro)-9.6 (wth,)37.3 ( and structural abnormalities a)-9.6 (t exposures \(based on area under the cur)-17.6 (ve)-5 ( )]TJ
0.001 Tc 0.103 Tw 0 -1.086 Td
[([AUC]\) above those occurring a)-10 (t the maximum recommended human dose \(MRHD\))1 ( )]TJ
0 Tc 0 Tw 0 -1.086 Td
(\()Tj
/T1_2 1 Tf
-0.017 Tc 0.012 Tw 0.224 0 Td
[(see Da)-9.7 (ta)]TJ
/T1_1 1 Tf
[(\).)37.2 ( )37.2 (Advise pregnant women of the potential risk to a fetus.)]TJ
-0.012 Tc 0.037 Tw -0.224 -1.626 Td
[(The )0.5 (estima)-9.7 (ted )0.5 (background )0.5 (risk )0.6 (of )0.5 (major )0.6 (birth )0.5 (defects )0.5 (and )0.5 (miscarria)-9.7 (ge )0.5 (for )0.6 (the )0.5 (indica)-9.7 (ted)-12 ( )]TJ
-0.01 Tc 0.045 Tw 0 -1.086 Td
[(p)0.5 (op)0.5 (ul)0.5 (a)-9.6 (t)0.5 (io)0.5 (n is)0.5 ( u)0.5 (nk)0.5 (no)-9.5 (wn)0.5 (.)37.4 ( )36.7 (Al)0.5 (l pr)0.5 (eg)0.5 (na)0.5 (nc)0.5 (ie)0.5 (s ha)-9.5 (ve)0.5 ( a)0.5 ( ba)0.5 (ck)0.5 (gr)0.5 (ou)0.5 (nd)0.5 ( r)0.5 (is)0.5 (k o)0.5 (f bir)0.5 (t)0.5 (h de)0.5 (fe)0.5 (ct)0.5 (,)37.4 ( lo)0.5 (s)0.5 (s,)37.4 ( or)-9.9 ( )]TJ
-0.017 Tc 0.011 Tw 0 -1.086 Td
[(other adverse outcomes.)37.2 ( In the U.S.)37.2 ( general popula)-9.8 (tion,)37.2 ( the estima)-9.8 (ted background risk of)-17 ( )]TJ
0.008 Tw 0 -1.086 Td
[(major birth defects and miscarria)-9.8 (ge in c)20.2 (linically recognized pregnancies is 2% to 4% and)-17 ( )]TJ
0.012 Tw 0 -1.086 Td
[(15% to 20%,)37.2 ( respectively)55.2 (.)]TJ
/T1_2 1 Tf
0 Tc 0 Tw -36 85.341 Td
(\()Tj
-0.017 Tc 0.017 Tw 0.224 0 Td
(Continued\))Tj
ET
endstreamendobj87 0 obj<</Length 38444>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 654.3281 cm
0 0 m
50.439 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.248 Tm
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Clinical T)74.2 (rials Experience)]TJ
/T1_1 1 Tf
-0.011 Tc 0.043 Tw -3.375 -1.512 Td
[(Because c)20 (linical trials are conducted under widely var)-18 (ying conditions,)36.9 ( adverse reaction)-11.1 ( )]TJ
-0.014 Tc 0.028 Tw 0 -1.062 Td
[(ra)-10 (tes obser)-17.9 (ved in the )0.5 (c)20 (linical trials of a drug cannot )0.5 (be )0.5 (directly )0.5 (compared to ra)-10 (tes )0.5 (in )0.5 (the)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(c)20.2 (linical trials of another drug and may not re\034ect the ra)-9.8 (tes obser)-17.8 (ved in practice.)]TJ
0.021 Tw 0 -1.602 Td
[(The da)-9.7 (ta in the )37.4 (W)18.2 (ARNINGS )37.4 (AND PRECAUTIONS re\034ect exposure )0.5 (to REBLOZYL as a )0.5 (single)-17 ( )]TJ
0.002 Tw 0 -1.062 Td
[(a)-9.8 (gent administered across a range of doses \(0.125 mg/kg to 1.75 mg/kg\) \in 571 pa)-9.8 (tients)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
(in 4 trials.)Tj
0.011 Tw 0 -1.625 Td
(Beta Thalassemia)Tj
-0.015 Tc 0.024 Tw 0 -1.512 Td
[(The safety of REBLOZYL in pa)-9.8 (tients with beta thalassemia was evalua)-9.9 (ted in the BELIEVE)-15 ( )]TJ
-0.012 Tc 0.012 Tw 0 -1.062 Td
(trial )Tj
/T1_2 1 Tf
0.04 Tw 1.616 0 Td
[([see )0.5 (Clinical )0.5 (Studies )0.5 (\(14.1\)])]TJ
/T1_1 1 Tf
[(.)36.8 ( )0.5 (Key )0.5 (eligibility )0.5 (criteria )0.5 (inc)19.7 (luded )0.5 (adult )0.5 (pa)-10.3 (tients )0.5 (with )0.5 (beta)-12 ( )]TJ
-0.003 Tc 0.08 Tw -1.616 -1.062 Td
[(t)0.5 (hal)0.5 (as)0.5 (se)0.5 (mi)0.5 (a \(w)0.5 (it)0.5 (h th)0.5 (e e)0.5 (xc)0.5 (ep)0.5 (ti)0.5 (on)0.5 ( o)0.5 (f p)0.5 (a)-9.6 (t)0.5 (ie)0.5 (nt)0.5 (s wi)0.5 (th h)0.5 (em)0.5 (og)0.5 (lo)0.5 (bi)0.5 (n S or)0.5 ( al)0.5 (pha)0.5 (-t)0.5 (ha)0.5 (la)0.5 (ss)0.5 (em)0.5 (ia)-3 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
[(disease\) without major organ dama)-10 (ge or recent DVT stroke and pla)-10.1 (telet counts less than)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
(or equal to 1000 x 10)Tj
0 Tc 0 Tw 5.6 0 0 5.6 97.165 611.842 Tm
(9)Tj
-0.017 Tc 0.017 Tw 8 0 0 8 99.7567 609.228 Tm
(/L.)Tj
-0.007 Tc 0.061 Tw -7.97 -1.602 Td
[(P)18.3 (a)-9.8 (tients received a starting dose of REBLOZYL 1 mg/kg subcutaneous injecti\on ever)-17.8 (y)-7 ( )]TJ
0.006 Tc 0.126 Tw 0 -1.062 Td
[(3 weeks.)37.3 ( Overall,)37.3 ( 53% of pa)-9.7 (tients had their dose increased to 1.25 mg/kg \(46%)6 ( )]TJ
0.008 Tc 0.136 Tw 0 -1.062 Td
[(REBLOZYL,)37.3 ( n)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.046 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.657 0 Td
[(223\) or placebo \(66%,)37.3 ( n)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.667 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.657 0 Td
[(109\).)37.3 ( )36.9 (The median dura)-9.7 (tion of trea)-9.7 (tment)8 ( )]TJ
-0.003 Tc 0.081 Tw -16.027 -1.062 Td
[(was similar between the REBLOZYL and placebo arms \(63.3 weeks vs.)37.3 ( 62.1 weeks,)34 ( )]TJ
-0.019 Tc 0 Tw 0 -1.062 Td
[(respectively\).)37 ( P)17.9 (er protocol,)36.9 ( pa)-10 (tients in the REBLOZYL and placebo arms were to remain on)-19 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(thera)-9.8 (py for a)-9.7 (t least 48 weeks in the double-blind phase of the trial.)]TJ
-0.006 Tc 0.069 Tw 0 -1.603 Td
[(Among pa)-10.1 (tients receiving REBLOZYL,)36.9 ( 94% were exposed for 6 months or longer and)-6 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.062 Td
[(72% were exposed for grea)-9.7 (ter than one year)74.2 (.)]TJ
-0.001 Tc 0.091 Tw 0 -1.602 Td
[(The median a)-9.7 (ge of pa)-9.6 (tients who received REBLOZYL was 30 years \(range:)37.3 ( 18,)37.3 ( 66\);)-1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.062 Td
[(59% female; 54% )37.2 (White and 36% )37.2 (Asian.)]TJ
-0.011 Tc 0.046 Tw 0 -1.602 Td
[(Serious )0.5 (adverse )0.5 (reactions occurred in )0.5 (3.6% )0.5 (of )0.5 (pa)-10.4 (tients on )0.5 (REBLOZYL.)36.5 ( )0.5 (Serious adverse)-11 ( )]TJ
0.001 Tc 0.104 Tw 0 -1.062 Td
[(reactions reported in 1% of pa)-10.1 (tients were cerebrovascular accident and deep vein)1 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.062 Td
[(thrombosis.)37.3 ( )37.3 (A fa)-9.6 (tal adverse reaction occurred in one pa)-9.7 (tient trea)-9.6 (ted with REBLOZYL who)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(died due to an uncon\037rmed case of )37.2 (AML \(M6\).)]TJ
-0.014 Tc 0.028 Tw 0 -1.602 Td
[(P)18 (ermanent discontinua)-10 (tion due to an adverse reaction \(Grades 1-4\) occurred in 5.4% of)-14 ( )]TJ
0.03 Tw 0 -1.062 Td
[(pa)-10.3 (tients who received REBLOZYL.)36.7 ( Most frequent adverse reactions requiring permanent)-14 ( )]TJ
-0.012 Tc 0.04 Tw 0 -1.062 Td
[(discontinua)-10.2 (tion )0.5 (in )0.5 (pa)-10.2 (tients )0.5 (who )0.5 (received REBLOZYL inc)19.8 (luded )0.5 (arthralgia \(1%\),)36.8 ( back pain)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(\(1%\),)37.2 ( bone pain \(<1%\),)37.2 ( and headache \(<1%\).)]TJ
0.009 Tw 0 -1.602 Td
[(Dosa)-9.7 (ge reductions due to an adverse reaction occurred in 2.7% of pa)-9.8 (tients who received)-17 ( )]TJ
-0.004 Tc 0.078 Tw 0 -1.062 Td
[(REBLOZYL.)37 ( Most frequent adverse reactions requiring dosa)-10 (ge reduction in >0.5% of)-4 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(pa)-9.8 (tients who received REBLOZYL inc)20.2 (luded hypertension and headache.)]TJ
-0.003 Tc 0.083 Tw 0 -1.602 Td
[(Dosa)-10 (ge interruptions due to an adverse reaction occurred in 15.2% of pa)-9.9 (tients who)-3 ( )]TJ
0.001 Tc 0.106 Tw 0 -1.062 Td
[(received REBLOZYL.)36.6 ( Most frequent adverse reactions requiring dosa)-10.4 (ge interruption)1 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.062 Td
[(in >1% of pa)-10.2 (tients who received REBLOZYL inc)19.8 (luded upper respira)-10.2 (tor)-18.2 (y tract infection,)28 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.062 Td
[(AL)94.2 (T increase,)37.2 ( and cough.)]TJ
-0.007 Tc 0.06 Tw 0 -1.602 Td
[(T)0.5 (he)0.5 ( m)0.5 (os)0.5 (t)0.5 ( c)0.5 (om)0.5 (m)0.5 (on)0.5 ( a)0.5 (dv)0.5 (e)0.5 (rs)0.5 (e)0.5 ( r)0.5 (ea)0.5 (ct)0.5 (i)0.5 (on)0.5 (s)0.5 ( \()0.5 (a)-9.6 (t)0.5 ( l)0.5 (ea)0.5 (s)0.5 (t 10)0.5 (%)0.5 ( f)0.5 (or)0.5 ( R)0.5 (EB)0.5 (L)0.5 (OZ)0.5 (YL)0.5 ( a)0.5 (n)0.5 (d 1)0.5 (%)0.5 ( m)0.5 (or)0.5 (e)0.5 ( t)0.5 (ha)0.5 (n)-7 ( )]TJ
0.004 Tc 0.118 Tw 0 -1.062 Td
[(placebo\) )0.5 (were )0.5 (headache )0.5 (\(26%\),)37 ( )0.5 (bone )0.5 (pain )0.5 (\(20%\),)37.1 ( )0.5 (arthralgia )0.5 (\(19%\),)37.1 ( )0.5 (fa)-9.9 (tigue )0.5 (\(14%\),)41 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.062 Td
[(cough \(14%\),)37.2 ( abdominal pain \(14%\),)37.1 ( diarrhea \(12%\),)37.2 ( and dizziness \(11%\).)]TJ
0 -1.602 Td
[(T)74.2 (able 6 summarizes the adverse reactions in BELIEVE.)]TJ
ET
/GS2 gs
q 1 0 0 1 250.56 266.1842 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 245.4923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 245.4923 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 213.12 245.4923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 266.1842 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 245.7423 cm
0 0 m
0 20.192 l
S
Q
1 w 
q 1 0 0 1 36 286.8761 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 213.12 286.8761 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 286.8761 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 286.8761 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 286.8761 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 138.24 266.4342 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 213.12 266.4342 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 137.99 266.1842 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 138.24 245.7423 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 175.68 266.1842 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 245.7423 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 213.12 245.7423 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 138.24 245.4923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 245.4923 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 234.0204 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 234.0204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 222.5485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 234.0204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 222.5485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 234.0204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 222.5485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 234.0204 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 222.5485 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 211.3266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 211.3266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 211.3266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 211.3266 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 36 211.0766 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 211.0766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 211.0766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 211.0766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 211.0766 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 199.6046 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 199.6046 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 188.1327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 199.6046 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 188.1327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 199.6046 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 188.1327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 199.6046 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 188.1327 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 176.9108 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 176.9108 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 176.9108 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 176.9108 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 153.717 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 153.717 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 153.717 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 153.717 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 142.4951 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 142.4951 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 142.4951 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 142.4951 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 119.5513 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 119.5513 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 119.5513 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 119.5513 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 138.24 84.8855 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 175.68 84.8855 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 213.12 84.8855 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 250.56 84.8855 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 138.24 73.6636 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 73.6636 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 73.6636 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 73.6636 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 138.24 50.7198 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 175.68 50.7198 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 213.12 50.7198 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 250.56 50.7198 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 36 176.6608 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 176.6608 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 176.6608 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 176.6608 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 176.6608 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 165.1889 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 165.1889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 165.1889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 165.1889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 165.1889 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 119.3013 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 119.3013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 119.3013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 119.3013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 119.3013 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 142.2451 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 142.2451 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 142.2451 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 142.2451 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 142.2451 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 130.7732 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 130.7732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 130.7732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 130.7732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 130.7732 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 107.8293 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 107.8293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 138.24 96.3574 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 175.68 107.8293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 96.3574 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 213.12 107.8293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 96.3574 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 250.56 107.8293 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 96.3574 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 36 50.4698 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 50.4698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 50.4698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 50.4698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 50.4698 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 73.4136 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 73.4136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 73.4136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 73.4136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 73.4136 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 36 61.9417 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 138.24 61.9417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 175.68 61.9417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 213.12 61.9417 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 250.56 61.9417 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.022 Tc 0.048 Tw 7.6 0 0 8 36 307.4761 Tm
[(T)64.2 (a)-9.8 (b)-9.8 (l)-9.8 (e)-9.8 ( )-9.8 (6)-9.8 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3 0 Td
( )Tj
EMC 
1.736 0 Td
[(Adverse Drug Reactions \(>5%\) in P)24.2 (atients with Beta Thalassemia)-22 ( )]TJ
0 -1.062 Td
[(Receiving REBLOZYL with a Difference Between Arms of 1% in)-22.1 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 255.4396 298.9761 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 72 290.4761 Tm
[(BELIEVE T)74.2 (rial)-22 ( )]TJ
-0.017 Tc -4.737 -2.862 Td
(Body System)Tj
0 Tc 0 Tw 7.6 0 0 8 74.1514 267.5783 Tm
( )Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 36 259.0783 Tm
( )Tj
EMC 
1.184 0 Td
(Adverse Reaction)Tj
0.017 Tw 15.217 2.356 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 190.7111 277.9242 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 163.5177 269.4242 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.6 ( )]TJ
EMC 
0.885 0 Td
(=)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
0.632 0 Td
(223\))Tj
0.017 Tw 8.432 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 262.2475 277.9242 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 238.5227 269.4242 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.6 ( )]TJ
EMC 
0.885 0 Td
(=)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
0.632 0 Td
(109\))Tj
0.048 Tw -14.221 -1.524 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
3.832 1.062 Td
[(Grades \037)-39.8 (3)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 208.0987 259.8463 Tm
(a)Tj
7.6 0 0 8 210.6575 257.2323 Tm
(\036)Tj
-0.017 Tc 0.048 Tw -3.184 -1.062 Td
(n \(%\))Tj
3.998 1.062 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.024 1.062 Td
(Grades \0373)Tj
0.903 -1.062 Td
(n \(%\))Tj
-29.65 -1.479 Td
(Musculoskeletal and connective tissue disorders)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Bone P)18.2 (ain)-17 (\036)]TJ
13.833 0 Td
(44 \(20\))Tj
5.389 0 Td
(3 \(1\))Tj
4.926 0 Td
(9 \(8\))Tj
4.943 0 Td
(0 \(0\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.881 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Arthralgia)Tj
0.048 Tw 13.833 0 Td
(43 \(19\))Tj
5.389 0 Td
(0 \(0\))Tj
4.464 0 Td
(13 \(12\))Tj
5.406 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Infections and infestation)Tj
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Influenza)Tj
0.048 Tw 14.064 0 Td
(19 \(9\))Tj
5.158 0 Td
(0 \(0\))Tj
4.926 0 Td
(6 \(6\))Tj
4.943 0 Td
(0 \(0\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-29.881 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Viral Upper Respira)-9.8 (tor)-17.7 (y Infection)]TJ
14.064 0 Td
(14 \(6\))Tj
4.815 0 Td
(1 \(0.4\))Tj
5.269 0 Td
(2 \(2\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Ner)-17.8 (vous system disorders)]TJ
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Headache)Tj
0.048 Tw 13.833 0 Td
(58 \(26\))Tj
-0.198 Tw 5.085 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.203 0 Td
(26 \(24\))Tj
5.406 0 Td
(1 \(1\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.881 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Dizziness)Tj
0.048 Tw 13.833 0 Td
(25 \(11\))Tj
5.389 0 Td
(0 \(0\))Tj
4.926 0 Td
(5 \(5\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(General disorders and administration site conditions)Tj
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(F)20.2 (a)-9.8 (tigue)]TJ
0.048 Tw 13.833 0 Td
(30 \(14\))Tj
5.389 0 Td
(0 \(0\))Tj
4.464 0 Td
(14 \(13\))Tj
5.406 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Gastrointestinal disorders)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
[(Abdominal P)18.2 (ain)]TJ
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 84.0137 101.8514 Tm
( )Tj
EMC 
0.024 0 Td
(b\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 147.1305 99.2374 Tm
(31 \(14\))Tj
5.389 0 Td
(0 \(0\))Tj
4.464 0 Td
(13 \(12\))Tj
5.406 0 Td
(0 \(0\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.881 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Diarrhea)Tj
0.048 Tw 13.833 0 Td
(27 \(12\))Tj
-0.198 Tw 5.085 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw 3.203 0 Td
(11 \(10\))Tj
5.406 0 Td
(0 \(0\))Tj
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.881 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Nausea)Tj
0.048 Tw 14.064 0 Td
(20 \(9\))Tj
5.158 0 Td
(0 \(0\))Tj
4.926 0 Td
(6 \(6\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(V)18.2 (ascular disorders)]TJ
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Hypertension)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 77.1388 55.9638 Tm
( )Tj
EMC 
0.024 0 Td
(c\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 148.8893 53.3498 Tm
(18 \(8\))Tj
5.158 0 Td
(4 \(2\))Tj
4.926 0 Td
(3 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 255.456 41.976 Tm
(\()Tj
-0.017 Tc 0.017 Tw 0.224 0 Td
(Continued\))Tj
ET
q 1 0 0 1 324 390.7393 cm
0 0 m
236.472 0 l
S
Q
/GS2 gs
q 1 0 0 1 538.56 685.9561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 665.2642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 665.2642 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.12 665.2642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 685.9561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 665.5142 cm
0 0 m
0 20.192 l
S
Q
1 w 
q 1 0 0 1 324 706.6481 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.12 706.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 706.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 706.6481 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 706.6481 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 426.24 686.2061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 501.12 686.2061 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 425.99 685.9561 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 426.24 665.5142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 463.68 685.9561 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 665.5142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 501.12 665.5142 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 426.24 665.2642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 665.2642 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.24 642.3204 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.68 642.3204 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.12 642.3204 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.56 642.3204 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 426.24 619.6266 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 463.68 619.6266 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 501.12 619.6266 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 538.56 619.6266 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 324 653.5423 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 653.5423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 653.5423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 653.5423 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 653.5423 cm
0 0 m
37.44 0 l
S
Q
1 w 
q 1 0 0 1 324 619.1266 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 619.1266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 619.1266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 619.1266 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 619.1266 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 324 590.2147 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 590.2147 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 590.2147 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 590.2147 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 590.2147 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 642.0704 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 642.0704 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 642.0704 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 642.0704 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 642.0704 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 324 630.5985 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.24 630.5985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.68 630.5985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.12 630.5985 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.56 630.5985 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.022 Tc 0.048 Tw 7.6 0 0 8 323.9999 727.248 Tm
[(T)64.2 (a)-9.8 (b)-9.8 (l)-9.8 (e)-9.8 ( )-9.8 (6)-9.8 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3 0 Td
( )Tj
EMC 
1.736 0 Td
[(Adverse Drug Reactions \(>5%\) in P)24.3 (atients with Beta Thalassemia)-22 ( )]TJ
0 -1.062 Td
[(Receiving REBLOZYL with a Difference Between Arms of 1% in)-22.1 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 543.4395 718.748 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 359.9999 710.248 Tm
[(BELIEVE T)74.2 (rial)-22 ( )]TJ
-0.017 Tc -4.737 -2.862 Td
(Body System)Tj
0 Tc 0 Tw 7.6 0 0 8 362.1513 687.3502 Tm
( )Tj
-0.017 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.6 0 0 8 323.9999 678.8502 Tm
( )Tj
EMC 
1.184 0 Td
(Adverse Reaction)Tj
0.017 Tw 15.217 2.356 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 697.6961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 451.5176 689.1961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.6 ( )]TJ
EMC 
0.885 0 Td
(=)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
0.632 0 Td
(223\))Tj
0.017 Tw 8.432 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.2474 697.6961 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 526.5226 689.1961 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.6 ( )]TJ
EMC 
0.885 0 Td
(=)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.5 ( )]TJ
EMC 
0.632 0 Td
(109\))Tj
0.048 Tw -14.221 -1.524 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
3.832 1.062 Td
[(Grades \037)-39.8 (3)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 496.0987 679.6182 Tm
(a)Tj
7.6 0 0 8 498.6575 677.0042 Tm
(\036)Tj
-0.017 Tc 0.048 Tw -3.184 -1.062 Td
(n \(%\))Tj
3.998 1.062 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.024 1.062 Td
(Grades \0373)Tj
0.903 -1.062 Td
(n \(%\))Tj
-29.65 -1.51 Td
(Metabolism and nutrition disorders)Tj
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Hyperuricemia)Tj
0.048 Tw 14.064 0 Td
(16 \(7\))Tj
5.158 0 Td
(6 \(3\))Tj
4.926 0 Td
(0 \(0\))Tj
4.943 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(Respirator)-17.8 (y)55.2 (,)37.2 ( thoracic and mediastinal disorders)]TJ
/T1_1 1 Tf
0.567 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
0.789 0 Td
(Cough)Tj
0.048 Tw 13.833 0 Td
(32 \(14\))Tj
5.389 0 Td
(0 \(0\))Tj
4.464 0 Td
(12 \(11\))Tj
5.406 0 Td
(0 \(0\))Tj
0.017 Tw 5.04 0 0 5.6 323.9999 612.4286 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 609.8146 Tm
(Limited to Grade 3 reactions with the exception of 4 events of Grade 4 h\yperuricemia.)Tj
0.017 Tw 5.04 0 0 5.6 323.9999 604.4286 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 601.8146 Tm
[(Grouped term inc)20.2 (ludes abdominal pain and abdominal pain upper)74.2 (.)]TJ
0.017 Tw 5.04 0 0 5.6 323.9999 596.4286 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.2 0 0 8 327.9999 593.8146 Tm
[(Grouped term inc)20.2 (ludes essential hypertension,)37.2 ( hypertension,)37.2 ( and hypertensive crisis.)]TJ
0.015 Tc 0.171 Tw 8 0 0 8 323.9999 574.3046 Tm
[(Clinically rele)0.5 (vant adverse )0.5 (re)0.5 (actions in <5% of p)0.5 (a)-9.6 (tients inc)20.4 (lude vertigo/v)0.5 (ertigo)15 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.062 Td
[(positional,)37.3 ( syncope/presyncope,)37.3 ( injection site reactions,)37.3 ( hypersensitivity)55.3 (,)37.3 ( extramedullar)-17.6 (y)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(hema)-9.7 (topoietic masses,)37.2 ( and spinal cord compression.)]TJ
0 -1.602 Td
[(Liver function abnormalities in the BELIEVE trial are sho)-9.8 (wn in )37.1 (T)74.3 (able 7.)]TJ
ET
1 w 
/GS2 gs
q 1 0 0 1 323.9999 516.0128 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 516.0128 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.1199 516.0128 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 426.2399 486.3508 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 501.1199 486.3508 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 323.9999 486.1008 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 486.1008 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.1199 486.1008 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 426.2399 474.6289 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 474.6289 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 463.157 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 463.157 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 451.6851 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 451.6851 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 440.2132 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 440.2132 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 429.2412 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.1199 429.2412 cm
0 0 m
0 10.972 l
S
Q
1 w 
q 1 0 0 1 323.9999 428.7412 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 428.7412 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.1199 428.7412 cm
0 0 m
74.88 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 407.8293 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 407.8293 cm
0 0 m
74.88 0 l
S
Q
q 1 0 0 1 501.1199 407.8293 cm
0 0 m
74.88 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 323.9999 528.1127 Tm
[(T)74.2 (able 7:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Liver Function Laborator)-17.8 (y Abnormalities in P)24.2 (atients with Beta)-12 ( )]TJ
0 -1.062 Td
[(Thalassemia in the BELIEVE T)74.2 (rial)]TJ
-0.017 Tc 0.017 Tw 11.664 -1.614 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 506.7008 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 453.8224 498.2008 Tm
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.581 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(223)Tj
0 Tc 0 Tw 7.6 0 0 8 473.5375 498.2008 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 455.7411 489.7008 Tm
(n \(%\))Tj
0.017 Tw 9.392 2.125 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.2474 506.7008 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 528.8273 498.2008 Tm
(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.581 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(109)Tj
0 Tc 0 Tw 7.6 0 0 8 548.5425 498.2008 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 530.7461 489.7008 Tm
(n \(%\))Tj
/T1_1 1 Tf
-27.203 -1.524 Td
[(AL)94.2 (T \035)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.036 0 Td
[(3 \327 ULN)-17 (\036)]TJ
15.049 0 Td
(26 \(12\))Tj
9.869 0 Td
(13 \(12\))Tj
-26.955 -1.434 Td
(AST \035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.186 0 Td
(3 \327 ULN)Tj
14.899 0 Td
(25 \(11\))Tj
10.332 0 Td
(5 \(5\))Tj
-27.417 -1.434 Td
(ALP \035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.148 0 Td
(2 \327 ULN)Tj
15.169 0 Td
(17 \(8\))Tj
-0.198 Tw 9.797 0 Td
[(1 )-245.8 (\(<)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.565 0 Td
(1\))Tj
0.048 Tw -28.678 -1.434 Td
[(T)74.2 (otal bilirubin \035)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.509 0 Td
(2 \327 ULN)Tj
11.345 0 Td
(143 \(64\))Tj
10.1 0 Td
(51 \(47\))Tj
-26.955 -1.434 Td
(Direct bilirubin \035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.937 0 Td
(2 \327 ULN)Tj
11.38 0 Td
(13 \(6\))Tj
10.1 0 Td
(4 \(4\))Tj
-0.198 Tw 7.2 0 0 8 323.9999 419.4293 Tm
(ALP)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.398 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
[(alkaline )-245.8 (phospha)-9.8 (tase; )-208.9 (AL)94.3 (T)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.248 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
[(alanine )-245.8 (aminotransferase;)]TJ
0.048 Tw -11.861 -1 Td
(AST)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
1.436 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
[(asparta)-9.8 (te aminotransferase; ULN)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
11.736 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(upper limit of normal.)Tj
8 0 0 8 323.9999 391.7393 Tm
[(T)74.2 (rea)-9.7 (tment of Myelod)-9.8 (ysplastic Syndromes )37.2 (Associa)-9.7 (ted )37.2 (Anemia in ESA-na\357ve P)18.2 (a)-9.8 (tients)]TJ
-0.013 Tc 0.035 Tw 0 -1.512 Td
[(The safety of REBLOZYL in pa)-10.3 (tients with ver)-18.3 (y lo)-10.3 (w- to intermedia)-10.2 (te-risk myelod)-10.2 (ysplastic)-13 ( )]TJ
-0.023 Tc -0.002 Tw 0 -1.062 Td
[(syndromes was evalua)-10.2 (ted in the COMMANDS trial in 356 randomized pa)-10.2 (tients )]TJ
/T1_2 1 Tf
([see Clinical)Tj
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.049 Tw -31.5 -1.062 Td
(Studies \(14.2\)])Tj
/T1_1 1 Tf
[(.)36.7 ( Key eligibility criteria inc)19.8 (luded adult pa)-10.2 (tients who were ESA-na\357ve with)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(endogenous sEPO levels of <500 U/L and who required regular RBC transfus\ions.)Tj
-0.014 Tc 0.03 Tw 0 -1.602 Td
[(The median time on trea)-10.4 (tment with REBLOZYL was 41.6 weeks \(range,)36.6 ( 0)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
26.46 0 Td
(\226)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.598 0 Td
[(165 weeks\);)-14 ( )]TJ
0 Tc 0.1 Tw -27.058 -1.062 Td
[(71.3% )0.5 (of )0.6 (pa)-10.2 (tients )0.5 (were )0.5 (exposed )0.5 (for )0.6 (24 )0.5 (weeks )0.5 (and )0.5 (45.5% )0.5 (completed )0.6 (48 )0.5 (weeks )0.5 (of )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
[(trea)-9.7 (tment.)]TJ
0 Tc 0.096 Tw 0 -1.602 Td
[(Amo)0.5 (ng )0.5 (the )0.5 (178 )0.5 (pa)-9.5 (tien)0.5 (ts )0.5 (trea)-9.5 (ted )0.5 (wit)0.5 (h )0.5 (REBLOZY)0.5 (L,)37.4 ( )0.5 (17 )0.5 (\(9.6%)0.5 (\) d)0.5 (iscon)0.5 (tinue)0.5 (d d)0.5 (ue )0.5 (to )0.5 (an )]TJ
-0.003 Tc 0.084 Tw 0 -1.062 Td
[(adverse reaction,)36.8 ( 48 \(27%\) had a dose interruption due to an adverse reaction,)36.8 ( and)-3 ( )]TJ
-0.01 Tc 0.05 Tw 0 -1.062 Td
[(5\036)-50 (\(2.8%\) had a dose reduction due to an adverse reaction.)36.6 ( )37.1 (The most common \(>10%\))-10 ( )]TJ
0.045 Tw 0 -1.062 Td
[(a)0.5 (l)0.6 (l)0.5 (-)0.5 (g)0.5 (r)0.5 (a)0.6 (d)0.5 (e)0.5 ( a)0.5 (d)0.5 (v)0.6 (e)0.5 (r)0.5 (s)0.5 (e)0.6 ( r)0.5 (e)0.5 (a)0.5 (c)0.6 (t)0.5 (i)0.5 (o)0.5 (n)0.6 (s)0.5 ( i)0.6 (n)0.5 (c)20.5 (l)0.5 (u)0.5 (d)0.6 (e)0.5 (d)0.5 ( d)0.5 (i)0.5 (a)0.5 (r)0.6 (r)0.5 (h)0.5 (e)0.6 (a)0.5 (,)37.5 ( f)0.5 (a)-9.5 (t)0.6 (i)0.5 (g)0.5 (u)0.5 (e)0.6 (,)37.5 ( h)0.6 (y)0.5 (p)0.5 (e)0.5 (r)0.5 (t)0.6 (e)0.5 (n)0.5 (s)0.6 (i)0.5 (o)0.5 (n)0.5 (,)37.5 ( e)0.5 (d)0.6 (e)0.5 (m)0.5 (a)0.6 ( p)0.5 (e)0.6 (r)0.5 (i)0.5 (p)0.5 (h)0.6 (e)0.5 (r)0.5 (a)0.5 (l)0.6 (,)27 ( )]TJ
-0.009 Tc 0.056 Tw 0 -1.062 Td
[(nausea,)36.6 ( and d)-10.4 (yspnea.)36.6 ( )37.4 (The most common \(>2%\) Grade >3 adverse reactions inc)19.5 (luded)-9 ( )]TJ
0.01 Tc 0.147 Tw 0 -1.062 Td
[(hypertension and d)-9.8 (yspnea.)37.2 ( Selected labora)-9.8 (tor)-17.8 (y abnormalities tha)-9.8 (t changed from)10 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.062 Td
[(Grade 0-2 a)-9.7 (t baseline to Grade >2 a)-9.7 (t an)-9.7 (y time during the studies in a)-9.7 (t least 10% of)-5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(pa)-9.8 (tients were glomerular \037ltra)-9.8 (tion ra)-9.8 (te and total bilirubin increased.)]TJ
-0.02 Tc 0 Tw 0 -1.602 Td
[(T)74.1 (able 8 sho)-9.9 (ws the most common adverse reactions for pa)-9.9 (tients trea)-9.9 (ted with REBLOZYL or)-20 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(epoetin alfa in the COMMANDS trial )Tj
/T1_2 1 Tf
([see Clinical Studie)Tj
(s \(14.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
/GS2 gs
q 1 0 0 1 538.5599 181.5155 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 160.8236 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 160.8236 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.1199 160.8236 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 181.5155 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 161.0736 cm
0 0 m
0 20.192 l
S
Q
1 w 
q 1 0 0 1 323.9999 202.2074 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 501.1199 202.2074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 202.2074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.2399 202.2074 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 202.2074 cm
0 0 m
37.44 0 l
S
Q
0.5 w 
q 1 0 0 1 426.2399 181.7655 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 501.1199 181.7655 cm
0 0 m
0 19.942 l
S
Q
q 1 0 0 1 425.9899 181.5155 cm
0 0 m
37.69 0 l
S
Q
q 1 0 0 1 426.2399 161.0736 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 463.6799 181.5155 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 161.0736 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 501.1199 161.0736 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 426.2399 160.8236 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 160.8236 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.2399 103.714 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.6799 103.714 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 103.714 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.5599 103.714 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 80.5202 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.6799 80.5202 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 80.5202 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.5599 80.5202 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 69.2983 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.6799 69.2983 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 69.2983 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.5599 69.2983 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 46.3545 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 463.6799 46.3545 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 501.1199 46.3545 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.5599 46.3545 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 323.9999 149.3517 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 149.3517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 426.2399 137.8798 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 463.6799 149.3517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 137.8798 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 501.1199 149.3517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 137.8798 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 538.5599 149.3517 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 137.8798 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 426.2399 126.4079 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 463.6799 126.4079 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 126.4079 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 538.5599 126.4079 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 426.2399 114.936 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 463.6799 114.936 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 501.1199 114.936 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 538.5599 114.936 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 323.9999 46.1045 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 46.1045 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 46.1045 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 46.1045 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 46.1045 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 103.464 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 103.464 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 103.464 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 103.464 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 103.464 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 91.9921 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 91.9921 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 91.9921 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 91.9921 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 91.9921 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 69.0483 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 69.0483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 69.0483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 69.0483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 69.0483 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 323.9999 57.5764 cm
0 0 m
102.24 0 l
S
Q
q 1 0 0 1 426.2399 57.5764 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 463.6799 57.5764 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 501.1199 57.5764 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 538.5599 57.5764 cm
0 0 m
37.44 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 323.9999 214.3074 Tm
[(T)74.2 (able 8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Adverse Reactions \(\0375%\) in P)24.2 (atients Receiving REBLOZYL in COMMANDS)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
[(T)74.2 (rial)]TJ
-0.017 Tc 0.048 Tw -4.737 -3.393 Td
(Body System/Adverse Reaction)Tj
0.017 Tw 16.401 1.824 Td
(REBLOZYL)Tj
0 Tc 0 Tw 7.6 0 0 8 478.7111 193.2555 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 451.7036 184.7555 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(178\))Tj
0.048 Tw 7.672 1.062 Td
[(Epoetin Alf)20.2 (a)]TJ
0 Tc 0 Tw 7.6 0 0 8 556.2095 193.2555 Tm
( )Tj
-0.017 Tc -0.198 Tw 7.6 0 0 8 526.7086 184.7555 Tm
(\(N)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.86 0 Td
(=)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.607 0 Td
(176\))Tj
0.048 Tw -14.197 -1.524 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.237 1.062 Td
(Grade \0373)Tj
0.689 -1.062 Td
(n \(%\))Tj
3.998 1.062 Td
(All Grades)Tj
0.928 -1.062 Td
(n \(%\))Tj
4.237 1.062 Td
(Grade \0373)Tj
0.689 -1.062 Td
(n \(%\))Tj
-29.65 -1.479 Td
(General disorders and administration site conditions)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
[(F)20.2 (a)-9.8 (tigue)]TJ
-0.198 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 343.688 143.3738 Tm
( )Tj
EMC 
0.024 0 Td
[(a,b)-17 (\036)]TJ
0.048 Tw 7.6 0 0 8 435.1302 140.7598 Tm
(38 \(22\))Tj
5.389 0 Td
(0 \(0\))Tj
4.695 0 Td
(12 \(7\))Tj
5.174 0 Td
(0 \(0\))Tj
-29.881 -1.434 Td
(Edema peripheral)Tj
14.622 0 Td
(23 \(13\))Tj
5.389 0 Td
(0 \(0\))Tj
4.695 0 Td
(12 \(7\))Tj
5.174 0 Td
(0 \(0\))Tj
-29.881 -1.434 Td
(Non-cardiac chest pain)Tj
15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(1 \(1\))Tj
4.926 0 Td
(6 \(3\))Tj
4.943 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Pyrexia)Tj
0.048 Tw 15.085 0 Td
(9 \(5\))Tj
4.926 0 Td
(1 \(1\))Tj
4.695 0 Td
(12 \(7\))Tj
5.174 0 Td
(1 \(1\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
(Gastrointestinal disorders)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Diarrhea)Tj
0.048 Tw 14.622 0 Td
(26 \(15\))Tj
5.389 0 Td
(0 \(0\))Tj
4.464 0 Td
(20 \(11\))Tj
5.406 0 Td
(0 \(0\))Tj
0.017 Tw -29.881 -1.434 Td
(Nausea)Tj
0.048 Tw 14.622 0 Td
(21 \(12\))Tj
5.389 0 Td
(0 \(0\))Tj
4.695 0 Td
(13 \(7\))Tj
5.174 0 Td
(0 \(0\))Tj
/T1_0 1 Tf
-29.881 -1.434 Td
[(V)18.2 (ascular disorders)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.434 Td
(Hypertension)Tj
0 Tc -0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.32 0 0 5.6 359.1384 51.5985 Tm
( )Tj
EMC 
0.024 0 Td
(a\036)Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 435.1302 48.9845 Tm
(25 \(14\))Tj
4.926 0 Td
(17 \(10\))Tj
5.158 0 Td
(13 \(7\))Tj
5.174 0 Td
(9 \(5\))Tj
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 543.456 37.584 Tm
(\()Tj
-0.017 Tc 0.017 Tw 0.224 0 Td
(Continued\))Tj
ET
1 w 4 M 
q 1 0 0 1 319.5 41.6519 cm
0 0 m
S
Q
BT
0 Tc 0 Tw 8 0 0 8 324 718.7401 Tm
(\()Tj
-0.017 Tc 0.017 Tw 0.224 0 Td
(Continued\))Tj
ET
endstreamendobj86 0 obj<</Length 24439>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 403.3012 cm
0 0 m
75.149 0 l
S
Q
q 1 0 0 1 36 107.077 cm
0 0 m
127.697 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(Dose Modi\037ca)-9.8 (tions for )37.2 (T)74.2 (oxicity)]TJ
/T1_1 1 Tf
-0.002 Tc 0.09 Tw 0 -1.519 Td
[(F)19.7 (or pa)-10.3 (tients experiencing Grade 3 or higher adverse reactions,)36.8 ( modify trea)-10.2 (tment as)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.069 Td
[(described in )37.2 (T)74.2 (able 4.)]TJ
ET
/GS2 gs
q 1 0 0 1 149.04 643.3479 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 149.04 655.0698 cm
0 0 m
0 22.462 l
S
Q
q 1 0 0 1 149.04 643.5979 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 36 643.3479 cm
0 0 m
113.04 0 l
S
Q
q 1 0 0 1 149.04 586.996 cm
0 0 m
0 56.102 l
S
Q
q 1 0 0 1 36 654.8198 cm
0 0 m
113.04 0 l
S
Q
q 1 0 0 1 149.04 654.8198 cm
0 0 m
138.96 0 l
S
Q
1 w 
q 1 0 0 1 36 586.496 cm
0 0 m
113.04 0 l
S
Q
q 1 0 0 1 149.04 586.496 cm
0 0 m
138.96 0 l
S
Q
0.5 w 
q 1 0 0 1 36 565.584 cm
0 0 m
113.04 0 l
S
Q
q 1 0 0 1 149.04 565.584 cm
0 0 m
138.96 0 l
S
Q
1 w 
q 1 0 0 1 36 678.0317 cm
0 0 m
113.04 0 l
S
Q
q 1 0 0 1 149.04 678.0317 cm
0 0 m
138.96 0 l
S
Q
BT
/GS1 gs
/T1_2 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 690.1317 Tm
[(T)74.2 (able 4:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(MDS Associated Anemia - REBLOZYL Dosing Modifications for Adverse)-12.1 ( )]TJ
0.012 Tw 0 -1.062 Td
[(Reactions)-12 ( )]TJ
-0.017 Tc 0.017 Tw 17.301 -1.569 Td
(REBLOZYL)Tj
0.048 Tw -3.019 -1.378 Td
(Dosing Recommendation*)Tj
/T1_1 1 Tf
-19.019 -1.479 Td
(Grade 3 or 4 hypersensitivity reactions)Tj
0.017 Tw 15.466 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
-16.65 -1.434 Td
(Other Grade 3 or 4 adverse reactions)Tj
0.017 Tw 15.466 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Interrupt trea)-9.8 (tment)]TJ
0.017 Tw -1.184 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(When the adverse reaction resolves to no)-17 ( )]TJ
0 -1.062 Td
[(more than Grade 1,)37.2 ( restart trea)-9.8 (tment a)-9.7 (t the)-17 ( )]TJ
0 -1.062 Td
[(next lo)-9.8 (wer dose level**)]TJ
0.017 Tw -1.184 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(If the dose delay is >12 consecutive weeks,)20 ( )]TJ
0 -1.062 Td
[(discontinue trea)-9.8 (tment)]TJ
0 Tc 0.031 Tw 5.04 0 0 5.6 36 579.7981 Tm
(  )Tj
0 Tw 7.84 0 0 7.84 38.7296 577.4137 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 41.3543 579.7981 Tm
( )Tj
EMC 
-0.017 Tc 0.048 Tw 7.2 0 0 8 43 577.1841 Tm
[(Grade 1 is mild,)37.2 ( Grade 2 is modera)-9.8 (te,)37.2 ( Grade 3 is severe,)37.2 ( and Grade 4 is life-threa)-9.7 (tening.)]TJ
0.017 Tw 7.84 0 0 7.84 36 569.4137 Tm
(**)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 41.2495 571.7981 Tm
( )Tj
EMC 
-0.017 Tc 0.048 Tw 7.2 0 0 8 43 569.1841 Tm
[(P)18.2 (er )37.2 (T)74.2 (able 3 dose reductions above.)]TJ
/T1_2 1 Tf
0.017 Tw 8 0 0 8 36 547.2859 Tm
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Preparation and Administration)Tj
/T1_1 1 Tf
0.012 Tw -3.375 -1.519 Td
(REBLOZYL should be reconstituted and administered by a healthcare profes\sional.)Tj
0 -1.609 Td
[(Reconstitute REBLOZYL with Sterile )37.2 (W)18.2 (a)-9.8 (ter for Injection,)37.2 ( USP only)55.2 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 515.561 252 -9.312 re
36 506.25 37.44 -29.192 re
73.44 506.25 88.56 -29.192 re
162 506.25 82.8 -29.192 re
244.8 506.25 43.2 -29.192 re
36 477.058 37.44 -11.472 re
73.44 477.058 88.56 -11.472 re
162 477.058 82.8 -11.472 re
244.8 477.058 43.2 -11.472 re
36 465.586 37.44 -11.472 re
73.44 465.586 88.56 -11.472 re
162 465.586 82.8 -11.472 re
244.8 465.586 43.2 -11.472 re
f
/GS2 gs
q 1 0 0 1 36 506.2495 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 73.44 506.2495 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 162 506.2495 cm
0 0 m
82.8 0 l
S
Q
q 1 0 0 1 244.8 506.2495 cm
0 0 m
43.2 0 l
S
Q
0.5 w 
q 1 0 0 1 73.44 477.3076 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 162 477.3076 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 244.8 477.3076 cm
0 0 m
0 28.442 l
S
Q
q 1 0 0 1 73.44 454.6138 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 162 454.6138 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 244.8 454.6138 cm
0 0 m
0 10.722 l
S
Q
1 w 
q 1 0 0 1 36 454.1138 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 73.44 454.1138 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 162 454.1138 cm
0 0 m
82.8 0 l
S
Q
q 1 0 0 1 244.8 454.1138 cm
0 0 m
43.2 0 l
S
Q
0.5 w 
q 1 0 0 1 36 477.0576 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 73.44 477.0576 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 73.44 465.8357 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 162 477.0576 cm
0 0 m
82.8 0 l
S
Q
q 1 0 0 1 162 465.8357 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 244.8 477.0576 cm
0 0 m
43.2 0 l
S
Q
q 1 0 0 1 244.8 465.8357 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 36 465.5857 cm
0 0 m
37.44 0 l
S
Q
q 1 0 0 1 73.44 465.5857 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 162 465.5857 cm
0 0 m
82.8 0 l
S
Q
q 1 0 0 1 244.8 465.5857 cm
0 0 m
43.2 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 509.8495 Tm
[(T)74.2 (able 5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Reconstitution V)24.2 (olumes)]TJ
-0.017 Tc -4.737 -1.569 Td
(Vial Size)Tj
5.518 0 Td
[(Amount of Sterile W)18.2 (ater)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 149.9426 497.2976 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 77.94 488.7976 Tm
[(for Injection,)37.2 ( USP required)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 156.4498 488.7976 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 77.94 480.2976 Tm
(for reconstitution)Tj
0.017 Tw 11.653 2.125 Td
(Final)Tj
0 Tc 0 Tw 7.6 0 0 8 180.5992 497.2976 Tm
( )Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 166.5 488.7976 Tm
(Concentration)Tj
10.895 1.062 Td
(Deliverable)Tj
0 Tc 0 Tw 7.6 0 0 8 281.7437 497.2976 Tm
( )Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 249.3 488.7976 Tm
[(V)24.2 (olume)]TJ
/T1_1 1 Tf
0.048 Tw -28.066 -2.541 Td
(25 mg vial)Tj
5.518 0 Td
(0.68 mL)Tj
11.653 0 Td
(25 mg/0.5 mL \(50 mg/mL\))Tj
10.895 0 Td
(0.5 mL)Tj
-28.066 -1.434 Td
(75 mg vial)Tj
5.518 0 Td
(1.6 mL)Tj
11.653 0 Td
(75 mg/1.5 mL \(50 mg/mL\))Tj
10.895 0 Td
(1.5 mL)Tj
-0.009 Tc 0.055 Tw 8 0 0 8 36 435.7057 Tm
[(Reconstitute the number of REBLOZYL vials to achieve the a)-10.3 (ppropria)-10.3 (te dose based on)-9 ( )]TJ
-0.014 Tc 0.027 Tw 0 -1.069 Td
[(the pa)-9.7 (tient\222)55.2 (s weight.)37.2 ( Use a syringe with suitable gradua)-9.7 (tions for reconstitution to ensure)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.069 Td
[(accura)-9.7 (te dosa)-9.8 (ge.)]TJ
0.048 Tw 0 -1.789 Td
(Reconstitution Instructions)Tj
-0.054 Tc 0.054 Tw 1.192 -1.429 Td
[(1)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.006 Tc 0.104 Tw 1.508 0 Td
[(Reconstitute with Sterile )37 (W)18 (a)-10 (ter for Injection,)37 ( USP using volumes described in)-6 ( )]TJ
-0.009 Tc 0.088 Tw 0 -1.069 Td
[(T)74.2 (able 5 \(Reconstitution )37.3 (V)18.2 (olumes\) with the stream directed onto the lyophilized)-9 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
[(po)-9.8 (wder)74.1 (.)37.3 ( )37.2 (Allo)-9.8 (w to stand for one minute.)]TJ
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(2)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.071 Tw 1.508 0 Td
[(D)0.5 (i)0.6 (s)0.5 (c)0.5 (a)0.6 (r)0.5 (d)0.5 ( t)0.6 (h)0.5 (e)0.5 ( n)0.5 (e)0.5 (e)0.6 (d)0.5 (l)0.5 (e)0.6 ( a)0.5 (n)0.6 (d)0.5 ( s)0.5 (y)0.6 (r)0.5 (i)0.5 (n)0.6 (g)0.5 (e)0.5 ( u)0.5 (s)0.5 (e)0.6 (d)0.5 ( f)0.5 (o)0.6 (r)0.5 ( r)0.6 (e)0.5 (c)0.6 (o)0.5 (n)0.5 (s)0.5 (t)0.6 (i)0.5 (t)0.5 (u)0.6 (t)0.5 (i)0.5 (o)0.6 (n)0.5 (.)37.5 ( )37.1 (T)0.6 (h)0.5 (e)0.5 ( n)0.5 (e)0.5 (e)0.6 (d)0.5 (l)0.5 (e)0.6 ( a)0.5 (n)0.6 (d)0.5 ( s)0.5 (y)0.6 (r)0.5 (i)0.5 (n)0.6 (g)0.5 (e)-12 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
(used for reconstitution should not be used for subcutaneous injections.)Tj
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(3)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.018 Tc 0.036 Tw 1.508 0 Td
[(Gently s)-10.2 (wirl the vial in a circular motion for 30 seconds.)36.8 ( Stop s)-10.2 (wirling and let the)-18 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
(vial sit in an upright position for 30 seconds.)Tj
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(4)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.017 Tc 0.052 Tw 1.508 0 Td
[(Inspect the vial for undissolved partic)20.2 (les in the solution.)37.2 ( If undissolved po)-9.8 (wder is)-17 ( )]TJ
0.048 Tw 0 -1.069 Td
[(obser)-17.7 (ved,)37.2 ( repea)-9.8 (t step 3 until the po)-9.8 (wder is completely dissolved.)]TJ
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(5)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.014 Tc 0.066 Tw 1.508 0 Td
[(Invert )0.6 (the )0.5 (vial )0.6 (and )0.5 (gently )0.6 (s)-10.3 (wirl )0.5 (in )0.5 (an )0.5 (inverted )0.5 (position )0.5 (for )0.5 (30 )0.6 (seconds.)36.7 ( )0.6 (Bring )0.6 (the)-14 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
[(vial back to the upright position,)37.2 ( and let it sit for 30 seconds.)]TJ
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(6)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.011 Tc 0.078 Tw 1.508 0 Td
[(Repea)-9.8 (t step 5 seven more times to ensure complete reconstitution of ma)-9.9 (terial)-11 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
(on the sides of the vial.)Tj
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(7)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.016 Tc 0.06 Tw 1.508 0 Td
[(P)17.7 (arenteral drug products should be inspected visually for particula)-10.3 (te ma)-10.2 (tter and)-16 ( )]TJ
-0.004 Tc 0.112 Tw 0 -1.069 Td
[(discolora)-9.7 (tion prior to administra)-9.7 (tion whenever solution and container permit.)33 ( )]TJ
-0.01 Tc 0.084 Tw 0 -1.069 Td
[(REBLOZYL is a colorless to slightly yello)-10.1 (w)37 (,)37 ( c)19.9 (lear to slightly opalescent solution)-10 ( )]TJ
-0.013 Tc 0.067 Tw 0 -1.069 Td
[(which is free of foreign particula)-9.6 (te ma)-9.6 (tter)74.3 (.)37.4 ( Do not use if undissolved product or)-13 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
[(foreign particula)-9.8 (te ma)-9.7 (tter are obser)-17.7 (ved.)]TJ
-0.054 Tc 0.054 Tw -1.508 -1.429 Td
[(8)-36.8 (.)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.017 Tc 0.048 Tw 1.508 0 Td
[(If the reconstituted solution is not used immedia)-9.8 (tely:)]TJ
0.017 Tw -0.068 -1.429 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.018 Tc 0.036 Tw 1.508 0 Td
[(Store a)-9.7 (t room tempera)-9.7 (ture a)-9.7 (t 20\260C to 25\260C \(68\260F to 77\260F\) in the original vial)-18 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.069 Td
[(for up to 8 hours.)37.2 ( Discard if not used within 8 hours of reconstitution.)]TJ
0.017 Tw -1.508 -1.429 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tc 0.193 Tw 1.508 0 Td
[(Alterna)-9.8 (tively)55.2 (,)37.2 ( store refrigera)-9.8 (ted a)-9.8 (t 2\260C to 8\260C \(36\260F to 46\260F\) for up)12 ( )]TJ
0.013 Tc 0.197 Tw 0 -1.069 Td
[(to 24 hours in the original vial.)37.4 ( Remove from refrigera)-9.6 (ted condition)13 ( )]TJ
-0.017 Tc 0.044 Tw 0 -1.069 Td
[(15-30 minutes prior to injection to allo)-9.7 (w solution to reach room tempera)-9.8 (ture)-17 ( )]TJ
-0.003 Tc 0.12 Tw 0 -1.069 Td
[(for a more comfortable injection.)36.9 ( Discard if not used within 24 hours of)-3 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.069 Td
(reconstitution.)Tj
-1.508 -1.429 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.508 0 Td
(Do not freeze the reconstituted solution.)Tj
-0.019 Tc 0 Tw -4.14 -1.519 Td
[(Discard an)-9.9 (y unused portion.)37.2 ( Do not pool unused portions from the vials.)37.2 ( Do not administer)-19 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.069 Td
[(more than 1 dose from a vial.)37.2 ( Do not mix with other medica)-9.8 (tions.)]TJ
0.048 Tw 0 -1.631 Td
[(Instructions for Subcutaneous )37.2 (Administra)-9.7 (tion)]TJ
0.012 Tw 0 -1.519 Td
[(Calcula)-9.8 (te the exact total dosing volume of 50 mg/mL solution required for the p\a)-9.8 (tient.)]TJ
-0.005 Tc 0.072 Tw 0 -1.609 Td
[(Slo)-9.8 (wly withdra)-9.7 (w the dosing volume of the reconstituted REBLOZYL solution from the)-5 ( )]TJ
-0.006 Tc 0.068 Tw 0 -1.069 Td
[(single-dose )0.5 (vial\(s\) )0.5 (into )0.5 (a )0.5 (syringe.)37.1 ( )0.5 (Divide )0.5 (doses )0.5 (requiring )0.5 (larger )0.5 (reconstituted )0.5 (volumes)-6 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.007 Tc 0.132 Tw -31.5 -1.069 Td
[(\(i.e.,)37.2 ( grea)-9.8 (ter than 1.2 mL\) into separa)-9.9 (te similar volume injections and inject into)7.1 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.069 Td
[(separa)-9.9 (te sites.)37 ( If multiple injections are required,)37.1 ( use a new syringe and needle for each)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.069 Td
(subcutaneous injection.)Tj
0 -1.609 Td
[(Administer the injection subcutaneously into the upper arm,)37.2 ( thigh,)37.2 ( and/or abdomen.)]TJ
/T1_2 1 Tf
0.017 Tw 36 86.406 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_1 1 Tf
0.017 Tw -3.375 -1.423 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.13 Tw 1.125 0 Td
[(F)19.8 (or injection:)36.7 ( 25 mg white to off-white lyophilized po)-10.2 (wder in a single-dose vial)-1 ( )]TJ
0 Tc 0 Tw 30.375 0 Td
( )Tj
-0.017 Tc 0.048 Tw -30.375 -1.062 Td
(for reconstitution.)Tj
0.017 Tw -1.125 -1.423 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.13 Tw 1.125 0 Td
[(F)19.8 (or injection:)36.7 ( 75 mg white to off-white lyophilized po)-10.2 (wder in a single-dose vial)-1 ( )]TJ
0 Tc 0 Tw 30.375 0 Td
( )Tj
-0.017 Tc 0.048 Tw -30.375 -1.062 Td
(for reconstitution.)Tj
/T1_2 1 Tf
0.017 Tw -1.125 -1.71 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
/T1_1 1 Tf
-3.375 -1.512 Td
(None.)Tj
/T1_2 1 Tf
0 -1.8 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.017 Tw -3.375 -1.512 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Thrombosis/Thromboembolism)Tj
/T1_1 1 Tf
-0.01 Tc 0.048 Tw -3.375 -1.513 Td
[(In )0.5 (adult pa)-9.9 (tients )0.5 (with beta thalassemia,)37.1 ( thromboembolic events \(TEE\) were )0.5 (reported in)-10 ( )]TJ
-0.017 Tc 0.005 Tw 0 -1.062 Td
[(8/223 \(3.6%\) REBLOZYL-trea)-9.8 (ted pa)-9.8 (tients.)37.2 ( Reported )36.8 (TEEs inc)20.2 (luded deep vein thromboses,)20 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.062 Td
[(p)0.5 (u)0.5 (l)0.5 (m)0.5 (o)0.5 (n)0.5 (a)0.5 (r)-17.5 (y)0.5 ( e)0.5 (m)0.5 (b)0.5 (o)0.5 (l)0.5 (u)0.5 (s)0.5 (,)37.5 ( p)0.5 (o)0.5 (r)0.5 (t)0.5 (a)0.5 (l)0.5 ( v)0.5 (e)0.6 (in)0.5 ( t)0.5 (hr)0.5 (o)0.5 (m)0.6 (bo)0.6 (si)0.5 (s)0.5 (,)37.5 ( a)0.6 (nd)0.5 ( i)0.5 (sc)0.5 (h)0.5 (e)0.5 (m)0.5 (i)0.5 (c)0.5 ( s)0.5 (t)0.5 (r)0.5 (o)0.6 (k)0.5 (e)0.5 (s)0.5 (.)37.4 ( P)18.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( k)0.5 (n)0.5 (o)-9.5 (w)0.5 (n)-12 ( )]TJ
-0.002 Tc 0.087 Tw 0 -1.062 Td
[(risk factors for thromboembolism,)37.3 ( e.g.)37.3 ( splenectomy or concomitant use of hormone)-2 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.062 Td
[(re)0.5 (pla)0.5 (cem)0.5 (ent )0.6 (th)0.5 (era)-9.5 (py)55.4 (,)37.4 ( )0.6 (ma)0.5 (y )0.6 (be )0.6 (a)-9.6 (t)0.5 ( )0.5 (fu)0.5 (rth)0.5 (er )0.6 (inc)0.5 (rea)0.5 (sed )0.6 (r)0.5 (isk )0.6 (of)0.5 ( )0.5 (t)0.5 (hrom)0.5 (boe)0.5 (mbo)0.5 (lic)0.5 ( )0.5 (co)0.5 (ndi)0.5 (tio)0.5 (ns.)32 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(Consider thromboprophylaxis in pa)-9.8 (tients with beta thalassemia a)-9.8 (t increased risk of )37.2 (TEE.)]TJ
0.024 Tw 0 -1.602 Td
[(Monitor pa)-10 (tients receiving REBLOZYL for signs and symptoms of thromboembolic event\s)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
[(and institute trea)-9.8 (tment promptly)55.2 (.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.782 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Hypertension)Tj
/T1_1 1 Tf
-0.003 Tc 0.082 Tw -3.375 -1.513 Td
[(Hypertension was reported in 63/554 \(11.4%\) of REBLOZYL-trea)-9.8 (ted pa)-9.8 (tients.)37.1 ( )36.8 (Across)-3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(c)20.2 (linical studies,)37.2 ( the incidence of Grade 3-4 hypertension ranged from 2% to 9.6%.)]TJ
-0.012 Tc 0.04 Tw 0 -1.602 Td
[(In adult pa)-10.3 (tients with beta thalassemia with normal baseline blood pressure,)36.7 ( 13 \(6.2%\))-12 ( )]TJ
-0.013 Tc 0.033 Tw 0 -1.062 Td
[(pa)-10 (tients developed systolic blood pressure \(SBP\) \035130 mm Hg and 33 \(\16.6%\) pa)-10 (tients)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(developed diastolic blood pressure \(DBP\) \03580 mm Hg.)Tj
-0.002 Tc 0.091 Tw 0 -1.602 Td
[(In )0.5 (ESA-refractor)-18.4 (y )0.5 (or )0.5 (-intolerant )0.5 (adult )0.5 (pa)-10.4 (tients )0.5 (with )0.5 (MDS )0.5 (with )0.5 (normal )0.6 (baseline )0.5 (blood)-2 ( )]TJ
0.006 Tc 0.127 Tw 0 -1.062 Td
[(pressure,)37.2 ( 26 \(30%\) pa)-9.8 (tients developed SBP \035130 mm Hg and 23 \(16%\) pa)-9.7 (tients)5.9 ( )]TJ
-0.014 Tc 0.025 Tw 0 -1.062 Td
[(d)0.5 (ev)0.5 (e)0.5 (lo)0.5 (pe)0.5 (d)0.5 ( D)0.5 (BP)0.5 ( \0358)0.5 (0 m)0.5 (m)0.5 ( H)0.5 (g.)37.5 ( I)0.5 (n)0.5 ( E)0.5 (S)0.5 (A-)0.5 (na)0.5 (\357v)0.5 (e)0.5 ( a)0.5 (d)0.5 (ul)0.5 (t)0.5 ( p)0.5 (a)-9.6 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s wi)0.5 (t)0.5 (h MD)0.5 (S)0.5 ( w)0.5 (it)0.5 (h)0.5 ( n)0.5 (or)0.5 (m)0.5 (al)0.5 ( ba)0.5 (s)0.5 (el)0.5 (in)0.5 (e)-14 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.062 Td
[(blood )0.5 (pressure,)36.8 ( )0.5 (23 )0.6 (\(36%\) )0.5 (pa)-10.2 (tients )0.5 (developed )0.5 (SBP )0.5 (\035140 )0.6 (mm )0.5 (Hg )0.6 (and )0.6 (11 )0.5 (\(6%\) )0.6 (pa)-10.2 (tients)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(developed DBP \03580 mm Hg.)Tj
-0.015 Tc 0.024 Tw 0 -1.603 Td
[(Monitor blood pressure prior to each administra)-10 (tion.)37 ( Mana)-10.1 (ge new-onset hypertension or)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(exacerba)-9.8 (tions of preexisting hypertension using anti-hypertensive a)-9.8 (gents.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.782 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Extramedullar)-17.8 (y Hematopoietic Masses)]TJ
/T1_1 1 Tf
0.004 Tc 0.116 Tw -3.375 -1.512 Td
[(In a)0.5 (dult pa)-9.5 (tients wi)0.5 (th tra)0.5 (nsfusion de)0.5 (pendent )0.5 (beta t)0.5 (halassemi)0.5 (a,)37.4 ( EMH )0.5 (masses )0.5 (were)4 ( )]TJ
-0.019 Tc 0 Tw 0 -1.062 Td
[(obser)-18.4 (ved in 3.2% of REBLOZYL-trea)-10.3 (ted pa)-10.3 (tients,)36.6 ( with spinal cord compression symptoms)-19 ( )]TJ
-0.008 Tc 0.059 Tw 0 -1.062 Td
[(due to EMH masses occurring in 1.9% of pa)-10.2 (tients \(BELIEVE and REBLOZYL long-term)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(follo)-9.8 (w-up stud)-9.8 (y\).)]TJ
-0.01 Tc 0.046 Tw 0 -1.602 Td
[(In a)0.5 ( stud)-9.6 (y of adult pa)-9.6 (tients with non-transfusion dependent beta thalassemia,)37.4 ( a higher)-10 ( )]TJ
-0.012 Tc 0.038 Tw 0 -1.062 Td
[(incidence of EMH masses was obser)-18.1 (ved in 6.3% of REBLOZYL-trea)-10.1 (ted pa)-10.1 (tients )]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
/T1_0 1 Tf
0.012 Tw 28.989 0 Td
(vs.)Tj
/T1_1 1 Tf
[(\036)-38.3 (2%)-12 ( )]TJ
0 Tc 0 Tw 2.511 0 Td
( )Tj
-0.001 Tc 0.092 Tw -31.5 -1.062 Td
[(of placebo-trea)-9.9 (ted pa)-9.8 (tients in the double-blind phase of the stud)-9.8 (y)55.1 (,)37.2 ( with spinal cord)-1 ( )]TJ
-0.004 Tc 0.08 Tw 0 -1.062 Td
[(compression due )0.5 (to EMH )0.5 (masses )0.5 (occurring )0.5 (in 1 pa)-10.2 (tient )0.5 (with )0.5 (a )0.5 (prior histor)-18.3 (y )0.5 (of EMH.)33 ( )]TJ
0.015 Tc 0.172 Tw 0 -1.062 Td
[(REBLOZYL is not indica)-9.8 (ted for use in pa)-9.8 (tients with non-transfusion dependent)15 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
(beta-thalassemia.)Tj
0.012 Tc 0.155 Tw 0 -1.603 Td
[(P)18.5 (o)0.6 (s)0.5 (s)0.5 (i)0.5 (b)0.6 (l)0.5 (e)0.6 ( r)0.6 (i)0.5 (s)0.5 (k)0.6 ( f)0.5 (a)0.5 (c)0.6 (t)0.5 (o)0.5 (r)0.6 (s)0.5 ( f)0.5 (o)0.6 (r)0.5 ( t)0.6 (h)0.5 (e)0.5 ( d)0.5 (e)0.6 (v)0.5 (e)0.6 (l)0.5 (o)0.5 (p)0.5 (m)0.6 (e)0.5 (n)0.6 (t)0.5 ( o)0.5 (f)0.6 ( E)0.5 (M)0.5 (H)0.5 ( m)0.6 (a)0.5 (s)0.5 (s)0.6 (e)0.5 (s)0.5 ( i)0.6 (n)0.5 ( p)0.5 (a)-9.4 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.6 ( w)0.6 (i)0.5 (t)0.6 (h)0.5 ( b)0.5 (e)0.5 (t)0.6 (a)12 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.062 Td
[(thalassemia inc)19.7 (lude histor)-18.2 (y of EMH masses,)36.7 ( splenectomy)54.7 (,)36.8 ( splenomegaly)54.7 (,)36.7 ( hepa)-10.2 (tomegaly)54.7 (,)23 ( )]TJ
-0.009 Tc 0.052 Tw 0 -1.062 Td
[(or lo)-9.7 (w baseline hemoglobin \(<8.5 g/dL\).)37.2 ( Signs and symptoms may var)-17.8 (y depending on)-9 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.062 Td
[(the ana)-10.2 (tomical loca)-10.2 (tion.)36.8 ( Monitor pa)-10.1 (tients with beta thalassemia a)-10.2 (t initia)-10.2 (tion and during)-11 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.062 Td
[(tr)0.5 (ea)-9.5 (tm)0.5 (ent)0.5 ( f)0.5 (or)0.5 ( sy)0.5 (mp)0.5 (tom)0.5 (s )0.5 (and)0.5 ( s)0.5 (ign)0.5 (s o)0.5 (r )0.5 (com)0.5 (pl)0.5 (ica)-9.5 (tio)0.5 (ns)0.5 ( r)0.5 (esu)0.5 (lti)0.5 (ng )0.5 (fr)0.5 (om)0.5 ( th)0.5 (e )0.5 (EMH)0.5 ( m)0.5 (ass)0.5 (es )0.5 (an)0.5 (d)-15 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.062 Td
[(trea)-10.1 (t according )0.5 (to c)19.9 (linical guidelines.)36.9 ( Discontinue trea)-10.1 (tment )0.5 (with REBLOZYL )0.5 (in case )0.5 (of)-9 ( )]TJ
-0.013 Tc 0.03 Tw 0 -1.062 Td
[(s)0.5 (e)0.6 (r)0.5 (i)0.5 (o)0.6 (u)0.5 (s)0.5 ( c)0.5 (o)0.6 (m)0.5 (p)0.6 (l)0.5 (i)0.5 (c)0.5 (a)-9.4 (t)0.5 (i)0.6 (o)0.5 (n)0.5 (s)0.6 ( d)0.6 (u)0.5 (e)0.5 ( t)0.5 (o)0.6 ( E)0.6 (M)0.5 (H)0.5 ( m)0.6 (a)0.5 (s)0.5 (s)0.6 (e)0.5 (s)0.5 (.)37.5 ( )37.2 (A)0.5 (v)0.6 (o)0.5 (i)0.5 (d)0.6 ( u)0.5 (s)0.5 (e)0.5 ( o)0.6 (f)0.5 ( R)0.5 (E)0.5 (B)0.6 (L)0.5 (O)0.5 (Z)0.5 (Y)0.6 (L)0.5 ( i)0.5 (n)0.6 ( p)0.6 (a)-9.5 (t)0.5 (i)0.6 (e)0.5 (n)0.5 (t)0.6 (s)0.5 ( r)0.5 (e)0.6 (q)0.5 (u)0.5 (i)0.6 (r)0.5 (i)0.5 (n)0.5 (g)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(trea)-9.7 (tment to control the gro)-9.8 (wth of EMH masses.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.782 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Embr)-17.8 (yo-F)20.2 (etal T)74.2 (oxicity)]TJ
/T1_1 1 Tf
-0.009 Tc 0.056 Tw -3.375 -1.512 Td
[(Based on )0.5 (\037ndings from animal reproductive )0.5 (studies,)36.5 ( REBLOZYL )0.5 (may cause fetal harm)-9 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.062 Td
[(when administered to a pregnant woman.)37.3 ( In animal reproduction studies,)37.3 ( administra)-9.7 (tion)-15 ( )]TJ
-0.001 Tc 0.095 Tw 0 -1.062 Td
[(of luspa)-10.3 (tercept-aamt to pregnant ra)-10.3 (ts and rabbits during organogenesis resulted in)-1 ( )]TJ
-0.014 Tc 0.026 Tw 0 -1.062 Td
[(adverse developmental outcomes inc)20.4 (luding increased embr)-17.6 (yo-fetal mortality)55.3 (,)37.4 ( altera)-9.7 (tions)-14 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.062 Td
[(to gro)-9.6 (wth,)37.3 ( and structural abnormalities a)-9.6 (t exposures \(based on area under the cur)-17.6 (ve)-5 ( )]TJ
-0.007 Tc 0.063 Tw 0 -1.062 Td
[([AUC]\) )0.5 (above )0.5 (those )0.5 (occurring )0.5 (a)-9.9 (t )0.5 (the )0.5 (maximum recommended )0.5 (human )0.5 (dose )0.5 (\(MRHD\) of)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(1.75 mg/kg.)Tj
-0.01 Tc 0.046 Tw 0 -1.602 Td
[(Advise pregnant women of the potential risk to a fetus.)37.3 ( )36.7 (Advise females of reproductive)-10 ( )]TJ
0.047 Tw 0 -1.062 Td
[(potential to use an effective method of contraception during trea)-9.8 (tment with REBLOZYL)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(and for a)-9.8 (t least 3 months after the \037nal dose )]TJ
/T1_0 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.7 (tions \(8)]TJ
[(.1,)37.2 ( 8.3\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.8 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.01 Tc 0.148 Tw -3.375 -1.513 Td
[(The )0.5 (follo)-9.9 (wing )0.5 (c)20.1 (linically )0.6 (significant )0.5 (adverse )0.5 (reactions )0.5 (are )0.6 (described )0.5 (elsewhere )0.5 (in)10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(the labeling:)Tj
0.017 Tw 1.192 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.508 0 Td
(Thrombosis/Thromboembolism )Tj
/T1_0 1 Tf
0.048 Tw 11.319 0 Td
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0.017 Tw -12.827 -1.423 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.508 0 Td
(Hypertension )Tj
/T1_0 1 Tf
0.048 Tw 4.894 0 Td
[([see )37.2 (W)18.2 (arnings and Precautions \(5.2\)])]TJ
/T1_1 1 Tf
0.017 Tw -6.402 -1.423 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.508 0 Td
[(Extramedullar)-17.8 (y Hema)-9.7 (topoietic Masses )]TJ
/T1_0 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.3\)])]TJ
ET
1 w 4 M 
q 1 0 0 1 319.5 551.96 cm
0 0 m
0 -131.76 l
S
Q
endstreamendobj84 0 obj<</Length 25119>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 750.2881 Tm
[(FULL PRESCRIBING INFORMA)55.1 (TION)]TJ
0.017 Tw 0 -1.98 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.017 Tw -3.375 -1.692 Td
(1.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Beta Thalassemia)Tj
/T1_1 1 Tf
-0.014 Tc 0.027 Tw -3.375 -1.512 Td
[(REBLOZYL \(luspa)-9.8 (tercept-aamt\) is indica)-9.8 (ted for the trea)-9.8 (tment of anemia in adult pa)-9.8 (tients)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(with beta thalassemia who require regular red blood cell \(RBC\) transfu\sions.)Tj
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(1.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Myelodysplastic Syndromes Associated Anemia)Tj
/T1_1 1 Tf
0 Tc 0.098 Tw -3.375 -1.512 Td
[(REBLOZYL is indica)-10 (ted for the trea)-10 (tment of anemia without previous er)-18 (ythropoiesis )]TJ
-0.009 Tc 0.052 Tw 0 -1.062 Td
[(stimula)-9.8 (ting a)-9.8 (gent use \(ESA-na\357ve\) in adult pa)-9.8 (tients with ver)-17.8 (y lo)-9.8 (w- to intermedia)-9.8 (te-risk)-9 ( )]TJ
0.008 Tc 0.139 Tw 0 -1.062 Td
[(myelod)-10.2 (ysplastic syndromes \(MDS\) who may require regular red blood cell \(RBC\\))8 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
(transfusions.)Tj
/T1_0 1 Tf
0 -1.782 Td
(1.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.081 Tw 3.375 0 Td
[(M)0.5 (y)0.5 (e)0.6 (l)0.5 (o)0.5 (d)0.5 (y)0.5 (s)0.5 (p)0.5 (l)0.5 (a)0.6 (s)0.5 (t)0.5 (i)0.5 (c)0.5 ( S)0.5 (y)0.5 (n)0.6 (d)0.5 (r)0.5 (o)0.5 (m)0.5 (e)0.5 (s)0.5 ( w)0.5 (i)0.6 (t)0.5 (h)0.5 ( R)0.5 (i)0.5 (n)0.5 (g)0.5 ( S)0.5 (i)0.5 (d)0.6 (e)0.5 (r)0.5 (o)0.5 (b)0.5 (l)0.5 (a)0.5 (s)0.5 (t)0.5 (s)0.6 ( o)0.5 (r)0.5 ( M)0.5 (y)0.5 (e)0.5 (l)0.6 (o)0.5 (d)0.5 (y)0.5 (s)0.5 (p)0.5 (l)0.5 (a)0.6 (s)0.5 (t)0.5 (i)0.5 (c)0.5 (/)-10 ( )]TJ
-0.016 Tc 0.06 Tw 0 -1.062 Td
[(Myeloproliferative Neoplasm with Ring Sideroblasts and Thromboc)9.8 (ytosis)-16 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
(Associated Anemia)Tj
/T1_1 1 Tf
-0.012 Tc 0.037 Tw -3.375 -1.512 Td
[(REBLOZYL is indica)-9.9 (ted for the trea)-9.8 (tment of anemia failing an er)-17.8 (ythropoiesis stimula)-9.8 (ting)-12 ( )]TJ
-0.009 Tc 0.05 Tw 0 -1.062 Td
[(a)-9.5 (ge)0.5 (n)0.5 (t)0.5 ( a)0.5 (n)0.5 (d r)0.5 (eq)0.5 (u)0.5 (ir)0.5 (i)0.5 (ng)0.5 ( 2)0.5 ( o)0.5 (r)0.5 ( mo)0.5 (r)0.5 (e)0.5 ( r)0.5 (e)0.5 (d)0.5 ( b)0.5 (l)0.5 (oo)0.5 (d)0.5 ( ce)0.5 (l)0.5 (l u)0.5 (ni)0.5 (t)0.5 (s o)0.5 (v)0.5 (er)0.5 ( 8 w)0.5 (e)0.5 (ek)0.5 (s)0.5 ( in)0.5 ( ad)0.5 (u)0.5 (lt)0.5 ( pa)-9.5 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s w)0.5 (it)0.5 (h)-9 ( )]TJ
0.009 Tc 0.145 Tw 0 -1.062 Td
[(ver)-18.3 (y lo)-10.3 (w- to intermedia)-10.3 (te-risk myelod)-10.3 (ysplastic syndromes with ring sideroblasts)9 ( )]TJ
-0.018 Tc 0 Tw 0 -1.062 Td
[(\(MDS-RS\) or with myelod)-10.1 (ysplastic/myeloprolifera)-10.1 (tive neoplasm with ring sideroblasts and)-18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(thromboc)20.2 (ytosis \(MDS/MPN-RS-T\).)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.782 Td
(1.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Limitations of Use)Tj
/T1_1 1 Tf
-0.011 Tc 0.042 Tw -3.375 -1.512 Td
[(REBLOZYL is not indica)-9.8 (ted )0.5 (for use )0.5 (as )0.5 (a substitute )0.5 (for RBC transfusions in pa)-9.8 (tients who)-11 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(require immedia)-9.7 (te correction of anemia.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.8 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
0.017 Tw -3.375 -1.692 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Recommended Dosage for Beta Thalassemia)Tj
/T1_1 1 Tf
0.002 Tc 0.109 Tw -3.375 -1.512 Td
[(The recommended starting dose of REBLOZYL is 1 mg/kg once ever)-18.1 (y 3 weeks by)2 ( )]TJ
0 Tc 0.099 Tw 0 -1.062 Td
[(subcutaneous )0.5 (injection )0.5 (for pa)-10.1 (tients )0.5 (with )0.5 (beta thalassemia.)36.9 ( Prior )0.5 (to each )0.5 (REBLOZYL )]TJ
-0.014 Tc 0.03 Tw 0 -1.062 Td
[(dose,)36.7 ( review the pa)-10.3 (tient\222)54.7 (s hemoglobin and transfusion record.)36.7 ( )37.4 (T)17.7 (itra)-10.2 (te the dose based on)-14 ( )]TJ
-0.017 Tc 0.023 Tw 0 -1.062 Td
[(responses )0.5 (according )0.5 (to )37.5 (T)74.2 (able )0.6 (1.)37.2 ( )0.5 (Interrupt )0.5 (trea)-9.8 (tment )0.5 (for )0.5 (adverse )0.5 (reactions )0.6 (as )0.5 (described )0.5 (in)-17 ( )]TJ
0.004 Tw 0 -1.062 Td
[(T)74.2 (able )0.6 (2.)37.2 ( )0.5 (Discontinue )0.5 (REBLOZYL )0.5 (if )0.6 (a )0.5 (pa)-9.8 (tient )0.5 (does )0.5 (not )0.5 (experience )0.5 (a )0.5 (decrease )0.5 (in )0.5 (transfusion)-17 ( )]TJ
0.001 Tw 0 -1.062 Td
[(burden after 9 weeks of trea)-9.8 (tment \(administra)-9.8 (tion of 3 doses\) a)-9.8 (t the maximum dose level)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
[(or if unacceptable toxicity occurs a)-9.8 (t an)-9.8 (y time.)]TJ
-0.014 Tc 0.03 Tw 0 -1.602 Td
[(If a planned administra)-10.3 (tion of REBLOZYL is delayed or missed,)36.7 ( administer REBLOZYL as)-14.1 ( )]TJ
-0.022 Tc 0 Tw 0 -1.062 Td
[(soon as possible and continue dosing as prescribed,)36.7 ( with a)-10.2 (t least 3 weeks between doses.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.048 Tw 0 -1.625 Td
[(Dose Modi\037ca)-9.8 (tions for Response)]TJ
/T1_1 1 Tf
-0.009 Tc 0.05 Tw 0 -1.512 Td
[(Ass)0.5 (ess)0.5 ( and)0.5 ( rev)0.5 (iew)0.5 ( h)0.5 (emo)0.5 (gl)0.5 (obi)0.5 (n res)0.5 (ult)0.5 (s pri)0.5 (or t)0.5 (o ea)0.5 (ch a)0.5 (dmi)0.5 (nis)0.5 (tra)-9.5 (tio)0.5 (n of)0.5 ( REBL)0.5 (OZY)0.5 (L.)37.4 ( If)0.5 ( an)-9 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.062 Td
[(RBC transfusion occurred prior to dosing,)36.6 ( use the pretransfusion hemoglobin for dose)-8 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
[(evalua)-9.8 (tion.)]TJ
-0.002 Tc 0.09 Tw 0 -1.602 Td
[(If a pa)-10.3 (tient does not achieve a reduction in RBC transfusion burden after a)-10.3 (t least 2)-2 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.062 Td
[(consecutive doses \(6 weeks\) a)-10.1 (t the 1 mg/kg starting dose,)36.9 ( increase the REBLOZYL dose)-15 ( )]TJ
-0.019 Tc 0 Tw 0 -1.062 Td
[(to 1.25 mg/kg.)36.9 ( Do not increase the dose beyond the maximum dose of 1.25 mg/kg.)36.9 ( In the)-19 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
[(absence of transfusions,)37.1 ( if hemoglobin increase is grea)-9.9 (ter than 2 g/dL within 3 weeks or)-17 ( )]TJ
-0.02 Tc 0 Tw 0 -1.062 Td
[(the predose hemoglobin is grea)-10.1 (ter than or equal to 11.5 g/dL,)37 ( reduce the dose or interrupt)-20 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(trea)-9.7 (tment with REBLOZYL as described in )37.2 (T)74.2 (able 1.)]TJ
0 -1.602 Td
[(Dose level modi\037ca)-9.8 (tions for response are provided in )37.2 (T)74.2 (able 1.)]TJ
ET
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 188.64 270.4442 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 188.64 270.6942 cm
0 0 m
0 22.462 l
S
Q
q 1 0 0 1 36 270.4442 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 259.2224 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 188.64 219.2785 cm
0 0 m
0 27.972 l
S
Q
q 1 0 0 1 188.64 199.3066 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 188.64 157.0228 cm
0 0 m
0 30.312 l
S
Q
q 1 0 0 1 188.64 98.9809 cm
0 0 m
0 57.542 l
S
Q
q 1 0 0 1 36 258.9724 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 258.9724 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 36 247.5004 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 247.5004 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 36 219.0285 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 219.0285 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 36 199.0566 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 199.0566 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 36 187.5847 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 187.5847 cm
0 0 m
99.36 0 l
S
Q
q 1 0 0 1 36 156.7728 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 156.7728 cm
0 0 m
99.36 0 l
S
Q
1 w 
q 1 0 0 1 36 98.4809 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 98.4809 cm
0 0 m
99.36 0 l
S
Q
0.5 w 
q 1 0 0 1 36 77.5689 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 77.5689 cm
0 0 m
99.36 0 l
S
Q
1 w 
q 1 0 0 1 36 293.6562 cm
0 0 m
152.64 0 l
S
Q
q 1 0 0 1 188.64 293.6562 cm
0 0 m
99.36 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 297.2562 Tm
[(T)74.2 (able 1:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Beta Thalassemia - REBLOZYL Dose T)18.2 (itration for Response)-12 ( )]TJ
-0.017 Tc 0.017 Tw 19.906 -1.569 Td
(REBLOZYL)Tj
0.048 Tw -3.019 -1.377 Td
(Dosing Recommendation*)Tj
-21.625 -1.479 Td
(Starting Dose)Tj
/T1_1 1 Tf
0.017 Tw 20.676 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(1 mg/kg ever)-17.7 (y 3 weeks)]TJ
/T1_0 1 Tf
-21.861 -1.434 Td
[(Dose Increases for Insufficient Response at Initiation of T)74.2 (reatment)]TJ
/T1_1 1 Tf
0 -1.434 Td
[(No reduction in RBC transfusion burden after a)-9.8 (t)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 167.3276 238.9085 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 36 230.4085 Tm
[(least 2 consecutive doses \(6 weeks\) a)-9.8 (t the 1 mg/kg)-17 ( )]TJ
0 -1.062 Td
(starting dose)Tj
0.017 Tw 20.676 1.594 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Increase the dose to)-16.9 ( )]TJ
0 -1.062 Td
[(1.25 mg/kg ever)-17.8 (y 3 weeks)]TJ
-21.861 -1.965 Td
[(No reduction in RBC transfusion burden after)-17 ( )]TJ
0 -1.062 Td
[(3\036)-47.8 (consecutive doses \(9 weeks\) a)-9.7 (t 1.25 mg/kg)]TJ
0.017 Tw 20.676 0.531 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
/T1_0 1 Tf
-21.861 -1.965 Td
(Dose Modifications for Predose Hemoglobin Levels or Rapid Hemoglobin Ris\e)Tj
/T1_1 1 Tf
0 -1.434 Td
[(Predose hemoglobin is grea)-9.8 (ter than or equal to)-17 ( )]TJ
0 -1.062 Td
(11.5 g/dL in the absence of transfusions)Tj
0.017 Tw 20.676 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Interrupt trea)-9.8 (tment)]TJ
0.017 Tw -1.184 -1.355 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Restart when the hemoglobin)-17 ( )]TJ
0 -1.062 Td
(is no more than 11 g/dL)Tj
-21.861 -1.434 Td
[(Increase in hemoglobin grea)-9.8 (ter than 2 g/dL within)-17 ( )]TJ
0 -1.062 Td
(3 weeks in the absence of transfusions and)Tj
0.017 Tw 1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 1.25 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 1 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 0.8 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 0.6 mg/kg)Tj
0 Tc 0 Tw 7.6 0 0 8 193.14 148.1808 Tm
( )Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 202.14 130.1008 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(Reduce dose to 1 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.042 Tw 1.184 0 Td
[(Reduce )0.5 (dose )0.5 (to )0.5 (0.8 )0.5 (mg/kg)]TJ
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.042 Tw 1.184 0 Td
[(Reduce )0.5 (dose )0.5 (to )0.5 (0.6 )0.5 (mg/kg)]TJ
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
0 Tc 0.031 Tw 5.04 0 0 5.6 36 91.7829 Tm
(  )Tj
0 Tw 7.84 0 0 7.84 38.7295 89.3985 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 41.3543 91.7829 Tm
( )Tj
EMC 
-0.007 Tc 0.097 Tw 7.2 0 0 8 43 89.1689 Tm
[(Do )0.6 (not)0.5 ( )0.5 (inc)0.5 (reas)0.5 (e )0.5 (t)0.5 (he )0.5 (d)0.5 (ose )0.6 (if )0.6 (the )0.6 (pa)-9.6 (t)0.5 (ient)0.5 ( )0.5 (is )0.6 (expe)0.5 (rie)0.5 (ncing)0.5 ( )0.5 (an )0.6 (adv)0.5 (erse)0.5 ( )0.5 (rea)0.5 (cti)0.5 (on )0.5 (a)0.5 (s )0.5 (de)0.5 (scri)0.5 (bed )0.6 (in)-7 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1 Td
[(T)74.2 (able 2.)]TJ
ET
4 M 
q 1 0 0 1 31.5 692.4601 cm
0 0 m
0 -47.88 l
S
Q
BT
/T1_2 1 Tf
8 0 0 8 324 727.248 Tm
[(Dose Modi\037ca)-9.8 (tions for )37.2 (T)74.2 (oxicity)]TJ
/T1_1 1 Tf
-0.002 Tc 0.09 Tw 0 -1.512 Td
[(F)19.7 (or pa)-10.3 (tients experiencing Grade 3 or higher adverse reactions,)36.8 ( modify trea)-10.2 (tment as)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(described in )37.2 (T)74.2 (able 2.)]TJ
ET
0.5 w 10 M 
/GS2 gs
q 1 0 0 1 450 612.6804 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 655.2142 cm
0 0 m
0 22.462 l
S
Q
q 1 0 0 1 450 643.7423 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 450 612.9304 cm
0 0 m
0 30.312 l
S
Q
q 1 0 0 1 324 612.6804 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 593.2085 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 324 654.9642 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 654.9642 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 324 643.4923 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 643.4923 cm
0 0 m
126 0 l
S
Q
1 w 
q 1 0 0 1 324 592.7085 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 592.7085 cm
0 0 m
126 0 l
S
Q
0.5 w 
q 1 0 0 1 324 579.7966 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 579.7966 cm
0 0 m
126 0 l
S
Q
1 w 
q 1 0 0 1 324 678.1761 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 450 678.1761 cm
0 0 m
126 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 690.2761 Tm
[(T)74.2 (able 2:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(Beta Thalassemia - REBLOZYL Dosing Modifications for Adverse)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Reactions)Tj
-0.017 Tc 0.017 Tw 18.154 -1.569 Td
(REBLOZYL)Tj
0.048 Tw -3.019 -1.378 Td
(Dosing Recommendation*)Tj
/T1_1 1 Tf
-19.872 -1.479 Td
(Grade 3 or 4 hypersensitivity reactions)Tj
0.017 Tw 17.171 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
-18.355 -1.434 Td
(Other Grade 3 or 4 adverse reactions)Tj
0.017 Tw 17.171 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Interrupt trea)-9.8 (tment)]TJ
0.017 Tw -1.184 -1.355 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Restart when the adverse reaction)-17 ( )]TJ
0 -1.062 Td
(resolves to no more than Grade 1)Tj
-18.355 -1.434 Td
[(Extramedullar)-17.7 (y hema)-9.7 (topoietic \(EMH\) masses)-17 ( )]TJ
0 -1.062 Td
[(causing serious complica)-9.7 (tions)]TJ
0.017 Tw 17.171 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
0 Tc 0 Tw 7.84 0 0 7.84 324 583.6262 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 326.6248 586.0106 Tm
( )Tj
EMC 
-0.017 Tc 0.048 Tw 7.2 0 0 8 328 583.3965 Tm
[(Grade 1 is mild,)37.2 ( Grade 2 is modera)-9.8 (te,)37.2 ( Grade 3 is severe,)37.2 ( and Grade 4 is life-threa)-9.7 (tening.)]TJ
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 8 0 0 8 324 562.4465 Tm
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.026 Tc 0.035 Tw 3.375 0 Td
(Recommended Dosage for Myelodysplastic Syndromes Associated Anemia)Tj
/T1_1 1 Tf
-0.004 Tc 0.075 Tw -3.375 -1.512 Td
[(T)0.5 (he)0.5 ( r)0.5 (e)0.5 (c)0.5 (om)0.5 (m)0.5 (e)0.5 (n)0.5 (de)0.5 (d)0.5 ( s)0.5 (t)0.5 (ar)0.5 (t)0.5 (i)0.5 (n)0.5 (g d)0.5 (o)0.5 (s)0.5 (a)-9.6 (g)0.5 (e)0.5 ( o)0.5 (f)0.5 ( R)0.5 (EB)0.5 (L)0.5 (O)0.5 (ZY)0.5 (L)0.5 ( i)0.5 (s 1)0.5 ( m)0.5 (g)0.5 (/)0.5 (kg)0.5 ( o)0.5 (n)0.5 (c)0.5 (e e)0.5 (v)0.5 (e)0.5 (r)-17.5 (y)0.5 ( 3)0.5 ( w)0.5 (e)0.5 (e)0.5 (k)0.5 (s b)0.5 (y)-4 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.062 Td
[(subcutaneous injection for the trea)-9.7 (tment of anemia of MDS.)37.3 ( Prior to each REBLOZYL)-5 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.062 Td
[(dose,)36.7 ( review the pa)-10.3 (tient\222)54.7 (s hemoglobin and transfusion record.)36.7 ( )37.4 (T)17.7 (itra)-10.2 (te the dose based on)-14 ( )]TJ
-0.017 Tc 0.023 Tw 0 -1.062 Td
[(responses )0.5 (according )0.5 (to )37.5 (T)74.2 (able )0.6 (3.)37.2 ( )0.5 (Interrupt )0.5 (trea)-9.8 (tment )0.5 (for )0.5 (adverse )0.6 (reactions )0.6 (as )0.5 (described )0.5 (in)-17 ( )]TJ
0.004 Tw 0 -1.062 Td
[(T)74.2 (able )0.6 (4.)37.2 ( )0.5 (Discontinue )0.5 (REBLOZYL )0.5 (if )0.6 (a )0.5 (pa)-9.8 (tient )0.5 (does )0.5 (not )0.5 (experience )0.5 (a )0.5 (decrease )0.5 (in )0.5 (transfusion)-17 ( )]TJ
-0.001 Tc 0.092 Tw 0 -1.062 Td
[(burden inc)20.2 (luding no increase from baseline hemoglobin after 9 weeks of trea)-9.8 (tment)-1 ( )]TJ
-0.013 Tc 0.035 Tw 0 -1.062 Td
[(\(administra)-10.3 (tion )0.5 (of )0.5 (3 )0.5 (doses\) )0.5 (a)-10.3 (t )0.5 (the )0.5 (maximum )0.5 (dose )0.5 (level )0.5 (\(1.75 )0.5 (mg/kg\),)36.7 ( )0.6 (or )0.5 (if )0.5 (unacceptable)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(toxicity occurs a)-9.7 (t an)-9.8 (y time.)]TJ
-0.014 Tc 0.03 Tw 0 -1.602 Td
[(If a planned administra)-10.3 (tion of REBLOZYL is delayed or missed,)36.7 ( administer REBLOZYL as)-14.1 ( )]TJ
-0.022 Tc 0 Tw 0 -1.062 Td
[(soon as possible and continue dosing as prescribed,)36.7 ( with a)-10.2 (t least 3 weeks between doses.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.048 Tw 0 -1.625 Td
[(Dose Modi\037ca)-9.8 (tions for Response)]TJ
/T1_1 1 Tf
-0.009 Tc 0.05 Tw 0 -1.512 Td
[(Ass)0.5 (ess)0.5 ( and)0.5 ( rev)0.5 (iew)0.5 ( h)0.5 (emo)0.5 (gl)0.5 (obi)0.5 (n res)0.5 (ult)0.5 (s pri)0.5 (or t)0.5 (o ea)0.5 (ch a)0.5 (dmi)0.5 (nis)0.5 (tra)-9.5 (tio)0.5 (n of)0.5 ( REB)0.5 (LOZY)0.5 (L.)37.4 ( If)0.5 ( an)-9 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.062 Td
[(RBC transfusion occurred prior to dosing,)36.6 ( use the pretransfusion hemoglobin for dose)-8 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
[(evalua)-9.8 (tion.)]TJ
0.006 Tw 0 -1.603 Td
[(If a pa)-9.8 (tient is not RBC transfusion-free after a)-9.8 (t least 2 consecutive doses \(6 weeks\) a)-9.8 (t the)-17 ( )]TJ
-0.02 Tc 0 Tw 0 -1.062 Td
[(1 mg/kg starting dose,)37.2 ( increase the REBLOZYL dose to 1.33 mg/kg \(T)74.2 (able 3\).)37.1 ( If a pa)-9.9 (tient is)-20 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.062 Td
[(not RBC transfusion-free after a)-9.8 (t least 2 consecutive doses \(6 weeks\) a)-9.8 (t the 1.33 mg/kg)-15 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.062 Td
[(d)0.5 (o)0.5 (s)0.5 (e)0.5 ( l)0.5 (e)0.5 (v)0.5 (e)0.5 (l)0.5 (,)37.5 ( i)0.5 (n)0.5 (c)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 ( th)0.5 (e)0.5 ( R)0.5 (E)0.5 (BL)0.6 (OZ)0.5 (Y)0.5 (L)0.5 ( d)0.5 (o)0.5 (se)0.5 ( t)0.5 (o)0.5 ( 1)0.5 (.)0.5 (75)0.5 ( m)0.5 (g)0.5 (/)0.5 (k)0.5 (g.)37.5 ( D)0.5 (o)0.5 ( n)0.5 (o)0.5 (t)0.5 ( i)0.5 (n)0.5 (c)0.5 (r)0.5 (e)0.5 (as)0.5 (e)0.5 ( t)0.5 (h)0.5 (e)0.5 ( do)0.5 (s)0.5 (e)0.5 ( m)0.5 (o)0.5 (r)0.5 (e)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(frequently than ever)-17.8 (y 6 weeks \(2 doses\) or beyond the maximum dose of 1.75 mg/kg.)]TJ
-0.003 Tc 0.084 Tw 0 -1.602 Td
[(In the absence of transfusions,)36.7 ( if hemoglobin increase is grea)-10.2 (ter than 2 g/dL within)-3 ( )]TJ
0.082 Tw 0 -1.062 Td
[(3 weeks or if the predose hemoglobin is grea)-9.7 (ter than or equal to 11.5 g/dL,)37.2 ( )0.5 (reduce)-3 ( )]TJ
-0.007 Tc 0.063 Tw 0 -1.062 Td
[(the dose or interrupt trea)-10 (tment with REBLOZYL as described in )36.7 (T)73.9 (able 3.)36.9 ( If,)36.9 ( upon dose)-7 ( )]TJ
0.008 Tc 0.137 Tw 0 -1.062 Td
[(reduction,)37.1 ( the pa)-9.9 (tient loses response \(i.e.,)37.1 ( requires a transfusion\) or hemoglobin)8 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.062 Td
[(concentra)-9.8 (tion drops by 1 g/dL or more in 3 weeks in the absence of transfusion,)37.2 ( increase)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
[(the dose by one dose level.)37.3 ( )37.1 (W)18.3 (ait a minimum of 6 weeks between dose increases.)]TJ
0 -1.602 Td
[(Dose modi\037ca)-9.8 (tions for response are provided in )37.2 (T)74.2 (able 3.)]TJ
ET
0.5 w 
/GS2 gs
q 1 0 0 1 475.1287 269.2827 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 475.1287 177.9232 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 475.1287 226.367 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 475.1287 206.3951 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 475.1287 269.5327 cm
0 0 m
0 22.462 l
S
Q
q 1 0 0 1 324 269.2827 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 258.0608 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 475.1287 226.617 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 324 226.367 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 206.6451 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 324 206.3951 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 178.1732 cm
0 0 m
0 27.972 l
S
Q
q 1 0 0 1 324 177.9232 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 68.2674 cm
0 0 m
0 67.122 l
S
Q
q 1 0 0 1 324 257.8108 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 257.8108 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 324 246.3389 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 246.3389 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 324 166.4512 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 166.4512 cm
0 0 m
100.871 0 l
S
Q
q 1 0 0 1 475.1287 135.8893 cm
0 0 m
0 30.312 l
S
Q
q 1 0 0 1 324 135.6393 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 135.6393 cm
0 0 m
100.871 0 l
S
Q
1 w 
q 1 0 0 1 324 67.7674 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 67.7674 cm
0 0 m
100.871 0 l
S
Q
0.5 w 
q 1 0 0 1 324 46.8555 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 46.8555 cm
0 0 m
100.871 0 l
S
Q
1 w 
q 1 0 0 1 324 292.4946 cm
0 0 m
151.129 0 l
S
Q
q 1 0 0 1 475.1287 292.4946 cm
0 0 m
100.871 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 296.0946 Tm
[(T)74.2 (able 3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
4.737 0 Td
[(MDS Associated Anemia - REBLOZYL Dose T)18.2 (itration for Response)-12 ( )]TJ
-0.017 Tc 0.017 Tw 19.807 -1.569 Td
(REBLOZYL)Tj
0.048 Tw -3.019 -1.377 Td
(Dosing Recommendation*)Tj
-21.525 -1.479 Td
(Starting Dose)Tj
/T1_1 1 Tf
0.017 Tw 20.477 0 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(1 mg/kg ever)-17.8 (y 3 weeks)]TJ
/T1_0 1 Tf
-21.662 -1.434 Td
[(Dose Increases for Insufficient Response at Initiation of T)74.2 (reatment)]TJ
/T1_1 1 Tf
0 -1.434 Td
[(Not RBC transfusion-free after a)-9.8 (t least 2 consecutive)-16.9 ( )]TJ
0 -1.062 Td
[(doses \(6 weeks\) a)-9.8 (t the 1 mg/kg starting dose)]TJ
0.017 Tw 20.477 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Increase the dose to)-16.9 ( )]TJ
0 -1.062 Td
[(1.33 mg/kg ever)-17.8 (y 3 weeks)]TJ
-21.662 -1.434 Td
[(Not RBC transfusion-free after a)-9.8 (t least 2 consecutive)-16.9 ( )]TJ
0 -1.062 Td
[(doses \(6 weeks\) a)-9.8 (t 1.33 mg/kg)-17 ( )]TJ
0.017 Tw 20.477 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Increase the dose to)-16.9 ( )]TJ
0 -1.062 Td
[(1.75 mg/kg ever)-17.8 (y 3 weeks)]TJ
-21.662 -1.434 Td
[(No reduction in RBC transfusion burden inc)20.2 (luding)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 459.9855 197.8032 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 189.3032 Tm
[(no increase from baseline hemoglobin after a)-9.7 (t least)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 466.3102 189.3032 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 324 180.8032 Tm
[(3 consecutive doses \(9 weeks\) a)-9.7 (t 1.75 mg/kg)]TJ
0.017 Tw 20.477 1.062 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
/T1_0 1 Tf
-21.662 -2.496 Td
(Dose Modifications for Predose Hemoglobin Levels or Rapid Hemoglobin Ris\e)Tj
/T1_1 1 Tf
0 -1.434 Td
[(Predose hemoglobin is grea)-9.8 (ter than or equal to)]TJ
0 -1.197 Td
(11.5 g/dL in the absence of transfusions)Tj
0.017 Tw 20.477 1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Interrupt trea)-9.8 (tment)]TJ
0.017 Tw -1.184 -1.355 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Restart when the hemoglobin)-17 ( )]TJ
0 -1.062 Td
(is no more than 11 g/dL)Tj
-21.662 -1.434 Td
[(Increase in hemoglobin grea)-9.8 (ter than 2 g/dL within)-17 ( )]TJ
0 -1.062 Td
(3 weeks in the absence of transfusions and)Tj
0.017 Tw 1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 1.75 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 1.33 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 1 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 0.8 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(current dose is 0.6 mg/kg)Tj
0 Tc 0 Tw 7.6 0 0 8 479.6287 127.0474 Tm
( )Tj
-0.017 Tc 0.017 Tw 7.6 0 0 8 488.6287 108.9674 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(Reduce dose to 1.33 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(Reduce dose to 1 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(Reduce dose to 0.8 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
(Reduce dose to 0.6 mg/kg)Tj
0.017 Tw -1.184 -1.197 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 1.184 0 Td
[(Discontinue trea)-9.8 (tment)]TJ
0 Tc 0 Tw 7.84 0 0 7.84 324 58.6851 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
5.04 0 0 5.6 326.6248 61.0695 Tm
( )Tj
EMC 
-0.005 Tc 0.11 Tw 7.2 0 0 8 328 58.4555 Tm
[(Do not increase the dose if the pa)-10 (tient is experiencing an adverse reaction as described in)-5 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1 Td
[(T)74.2 (able 4.)]TJ
ET
4 M 
q 1 0 0 1 319.5 569.412 cm
0 0 m
0 -82.512 l
S
Q
endstreamendobj85 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 310/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 20 0 R>>/Font<</T1_0 89 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 324 747.7531 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 453.1892 750.2881 Tm
(REBLOZYL)Tj
0 Tc 0 Tw 5.6 0 0 5.6 495.079 752.1521 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 499.5122 750.2881 Tm
[( \(luspater)18.3 (cept-aamt\))]TJ
ET
endstreamendobj89 0 obj<</BaseFont/CINJZY+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 90 0 R/LastChar 174/Subtype/Type1/ToUnicode 91 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 407 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 704 0 0 648 0 0 0 0 0 0 593 0 0 778 0 0 722 0 0 0 0 0 0 667 648 0 0 0 0 0 0 574 0 574 0 574 0 0 0 0 0 0 258 906 0 0 611 0 389 537 352 593 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj90 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/hyphen/B/E/L/O/R/Y/Z/a/c/e/l/m/p/r/s/t/u/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 92 0 R/FontName/CINJZY+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj91 0 obj<</Filter/FlateDecode/Length 333>>stream
Hâ\íœnÉ0∆Ôy
◊CEK¥BBtï8Ïè∆ˆ 41“Q†ﬁ~v\u“"ˇ¢ÿ_>ŸDU}™m?CÙÓG›‡]oç«iºyçp¡ko’6”Î˘~
_=¥NET‹,”åCmªQÂ9Dt9Õ~Åß“å\©ËÕÙΩΩ¬”W’¨ jnŒ˝‡ÄvÜÏHË•uØÌÄÖ≤umËæüó5’¸e|.!Á≠ò—£¡…µ}kØ®Ú≠Ú3≠B°5ˇÓ„X .ù˛nΩ cNﬁl(ÑÃG·#ÛI¯DºèS NÑÊJ∏b>ìÅ<ë¸ÑÛ—LX3)ÖK‚tòÒNx«,˙)Îß¢ü≤~*~Rˆìâˇå˝gÚV∆oe¢ì±N∂ﬁ3ãf∆öÂs`
‹®{G∏e4YxÃCﬂºßQÑÒáp˜{ãè?ƒç®ä∑˙` ¨
†Ôendstreamendobj92 0 obj<</Filter/FlateDecode/Length 1856/Subtype/Type1C>>stream
HâÑT}T◊üawﬂÚïXqfáı´X¿êäHDA*`‘ÍíFYewuYAçhkE?–TT4Dc?∞T(FE‡‰@ä’T”£¶äò&j,Q*GÀº˚Gﬂíòûˆ¥ßÛŒº˜Ó}˜˛Ó«ª˜±å“ÉaY64)%=u…‚Òs§¬b…i…3ßKk•¥¨Lg˛ƒô˘nΩ¨cÂ@•‚Àc⁄^]}ïßíóì∑˘wÜx.
`<‹0+Xgí}ızáeEÅS4∆Nù:ÅŒ±ëCsÙ1*22JLÃ∑ÁJbÊ˙"ßd-Slyv«jª√ÏîÚ√≈ƒ¬BqHπHtHEí£ÿÕ¸øàiõ›π~µ$Œ∂ÊŒ˘ ?≈%ZäD≥ËtòÛ%´Ÿ±J¥/ˇó~u%ú*≠∞PÁRæh±âŒIÃœÁQmN—lÀ≥~“ŒXæ‹í'1≠Êı"ÏﬂµÛ$á”LW;Öqà+◊:,E˘ñ<ß≈n+zn3[•ˇ‚Ö›!ZhÖﬁV$IˇdDrfñõàÛ•Â˝X∆ãÒf8f$3Üô»D2—L3çô…º…$3o1ÈÃ|&ì…b≤ôÖÃ	f8Ω* ú«î1mÃvªä}üΩÔë‡aı8†‡ŸääK PÂFe´*LµTuîDãÂ-Ú”ñŒ£ZÂJπlpû´å¿.Ï‡q:ÏS¡Ç"∂Ò‡&\ïj1Ìa:Rö»≠º{ánä√˚N*~5∫ÑmÉ“Ì|4jr0«i1≤£Ócà ﬁ$FY 
¢¥Q∆[&º÷ÎwÎ)1ïˇö!∆i!r1D≈B®Äﬁ‰é>ãQ•≈à4&¢HıñBpl¥+⁄†Äáv‡∞ùpOÀÅÉE0∏Ä`§ÓN¿a`‘ºÑb¯íáÚ≈ß∂ôâŸ%oÈ1û†9˙0¨F?Ã˘"ÊcΩFÓ™´ø|S#"ö©◊¯ê¿êÿXÚYkÈÏå\Gñ£	◊X¡êDçMÑ`ñZR‹í¡.û2˚®/}0Q~É“ßWJEÂª%Ø•* üÀw—H8Hÿ@è÷QÑ0 ¡ÙºxÃÖ åÖ5tA,‰B“◊–A˘X Ä1¸€¿¬ ¨}—}“%√R¶è¿Å∫¶NÉñ—π”pf»4›ú#π[ªr∆oÙ˚lO>jÚ§¥˝¸Œe∂˛yÌÌÈzV®Ôû>{ıÅò∏á(∏¯√üAn6Xìì$Î,=Œ ‹Á5≈É¶*)0T∫ë?!pDNSa°oI=NÉzŒ"pÿ5G5î,y!Ûò‹ß8$˜—ƒÑY#õT‡ÁÍƒ`¯á⁄•qôT‹ “ﬁ∏nÄﬁÄ”` 4d_X nãF≈≤‹™∂÷Ûáö˜Õ˚ZvØÒƒÙó¸g{Í?j◊µ4mIü∑+fì>zs¥Ω¥aYÚÏÍıÍãÕ∫ùvoÿÛÆ'å"õj∂^º®Öè‘‡á~«F°'˙‰·à_‘Ï <†∑`P»M-¡[P˘G‰t?}pFºDàÑêﬁ€zDè°$mãdN—EŸﬁ∫S˜›„ŒﬂŒﬂØÇ˛<ÿZ7R#8yà˛`2¸ﬂ‘°QDoå¿òÁ®Ñ)‡ıu+pÁıËOVmYV∞@ü”¯hõ˛ëÚ|≈âõèt7NIIUz˚HsEÎ√†	¥jZkäÂ)œ∆Å2Ä@Í`àÊ≤[⁄»Û?9˘h[rÜÄøßt£˙⁄°Î˜∫˜.HSJ˜©A=í≤sMV°À>ˇx™nNv·¬Â˙ÌD”}µjn7ÌJàß)y>–Nu∂“õËnßÌI˜;*»¢≥ù´ªt0˛Ì∆ŒÑ·8yn¶#À‚Üxzuj8ËäÁ#V›{†◊t?®ÎyÚ¯Ã‰XAÛtäuZ8Ì]`$x£7o-q–Tµª]/%ö⁄«Ánø®ÆŸ^V%h™ X≠©›µes≈Øt…≥L©k‹¯û¬s≥J{iï∞çTi.MN-ƒÛ∫ºL‡´onÜêÔ„Í¶’«ùVyE€tqÔÈ+M≥v†#†˘Â»TÈPÅƒÇ¡ë˜m˜◊Î˚◊vn|Gª¯Ìws3ﬂ˛∏kurﬂ˚¥ÅnÙ≤ﬂπü¶MÉ1<0b“Ñøbuß‰õìßvÓ>.ÄB]∂±t«F›/6∏§á˝/zG™π“RPé{&O
çˆ†ªäœ…› «âaÂ;”SM_pÅ“_™1∞a2åˇºÎd«9a—¨Kdo∏GÆÅ«µû{Ï·~—ë=¿ˆ+√+◊A
éÖ:R`,¨ÉLÅ1òCG
é¡°?à>‘˛@ﬂ=à £ètj–èVü˝¡Åﬂ≥[I?ŒV}ChMŒUuÌπT˜ïˆÒº3£HO*ì4\zœ¥®‡Ω•˙D¬m®4U„ ÉÛr’˚˚˜ªæ:®˛ëy¿NT˛Ω“ı∑^ﬁ`¯¿◊á|ﬂÄÀÅÚ˛ü ± endstreamendobj83 0 obj<</Length 17544>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55.2 (TION)]TJ
0.017 Tw 0 -1.558 Td
[(These highlights do not inc)20.2 (lude all the information needed to use REBLOZYL safely)-17 ( )]TJ
0.024 Tw 0 -1.062 Td
[(and effectively)55.2 (.)37.2 ( See full prescribing information for REBLOZYL.)]TJ
0.017 Tw 0 -1.647 Td
(REBLOZYL)Tj
0 Tc 0 Tw 5.6 0 0 5.6 67.1869 718.7621 Tm
(\256)Tj
-0.017 Tc 0.024 Tw 8 0 0 8 71.5705 716.1481 Tm
[( \(luspatercept-aamt\) for injection,)37.2 ( for subcutaneous use)]TJ
-4.446 -1.242 Td
[(Initial U.S.)37.2 ( Appro)-9.8 (v)16.3 (al: 2019)]TJ
0.017 Tw 0 -1.782 Td
(------------------------------)Tj
0.048 Tw 10.755 0 Td
(RECENT MAJOR CHANGES)Tj
-0.153 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
10.06 0 Td
(------------------------------)Tj
/T1_1 1 Tf
0.048 Tw -20.815 -1.648 Td
[(Indica)-9.7 (tions and Usa)-9.8 (ge \(1.2\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(8/2023)Tj
-28.908 -1.423 Td
[(Dosa)-9.7 (ge and )37.2 (Administra)-9.8 (tion \(2.2\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(8/2023)Tj
-28.908 -1.423 Td
[(W)18.2 (arnings and Precautions,)37.2 ( Hypertension \(5.2\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(8/2023)Tj
/T1_0 1 Tf
0.017 Tw -28.908 -1.962 Td
(-------------------------------)Tj
0.048 Tw 10.93 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.022 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(------------------------------)Tj
/T1_1 1 Tf
0.048 Tw -10.93 -1.647 Td
[(REBLOZYL is an er)-17.8 (ythroid ma)-9.8 (tura)-9.7 (tion a)-9.8 (gent indica)-9.8 (ted for the trea)-9.8 (tment of:)]TJ
0.017 Tw 0 -1.377 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.007 Tc 0.076 Tw 1.125 0 Td
[(Anemia in adult pa)-10.2 (tients with beta thalassemia who require regular red blood cell)-7.1 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
(\(RBC\) transfusions \(1.1\).)Tj
0.017 Tw -1.125 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.007 Tc 0.075 Tw 1.125 0 Td
[(Anemia without previous er)-18 (ythropoiesis stimula)-10 (ting a)-10 (gent use \(ESA-na\357ve\) in adult)-7 ( )]TJ
-0.011 Tc 0.056 Tw 0 -1.062 Td
[(pa)-10.1 (tients )0.5 (with )0.5 (ver)-18.1 (y )0.5 (lo)-10 (w- )0.5 (to intermedia)-10 (te-risk )0.5 (myelod)-10 (ysplastic )0.5 (syndromes )0.5 (\(MDS\) )0.5 (who)-11 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
(may require regular red blood cell \(RBC\) transfusions \(1.2\).)Tj
0.017 Tw -1.125 -1.333 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.036 Tw 1.125 0 Td
[(Anemia failing an er)-18.3 (ythropoiesis stimula)-10.3 (ting a)-10.2 (gent and requiring 2 or more RBC units)-17 ( )]TJ
-0.008 Tc 0.067 Tw 0 -1.062 Td
[(o)0.6 (v)0.5 (e)0.6 (r)0.5 ( 8)0.5 ( w)0.5 (e)0.6 (e)0.5 (k)0.6 (s)0.5 ( i)0.5 (n)0.6 ( a)0.6 (d)0.5 (u)0.6 (l)0.5 (t)0.6 ( p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.5 ( w)0.5 (i)0.6 (t)0.5 (h)0.6 ( v)0.6 (e)0.5 (r)-17.4 (y)0.6 ( l)0.5 (o)-9.4 (w)0.5 (-)0.6 ( t)0.6 (o)0.6 ( i)0.6 (n)0.5 (t)0.6 (e)0.5 (r)0.6 (m)0.5 (e)0.6 (d)0.5 (i)0.6 (a)-9.5 (t)0.6 (e)0.6 (-)0.5 (r)0.6 (i)0.5 (s)0.6 (k)0.5 ( m)0.5 (y)0.6 (e)0.5 (l)0.6 (o)0.5 (d)-9.4 (y)0.5 (s)0.6 (p)0.5 (l)0.6 (a)0.5 (s)0.6 (t)0.5 (i)0.6 (c)-8 ( )]TJ
-0.018 Tc 0 Tw 0 -1.062 Td
[(syndromes with ring sideroblasts \(MDS-RS\) or with myelod)-9.7 (ysplastic/myeloprolifera)-9.8 (tive)-17.9 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
[(neoplasm with ring sideroblasts and thromboc)20.2 (ytosis \(MDS/MPN-RS-T\) \(1.3\).)]TJ
0.017 Tw -1.125 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.005 Tc 0.133 Tw 1.125 0 Td
[(Limita)-9.7 (tions of Use:)37.3 ( REBLOZYL is not indica)-9.7 (ted for use as a substitute for RBC)5 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
[(transfusions in pa)-9.8 (tients who require immedia)-9.7 (te correction of anemia \(1.4\).)]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.917 Td
(---------------------------)Tj
0.048 Tw /Span<</ActualText<FEFF200A>>> BDC 
9.738 0 Td
( )Tj
EMC 
0.024 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
-0.112 Tw /Span<</ActualText<FEFF002D>>> BDC 
12 0 Td
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -21.762 -1.602 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.009 Tc 0.065 Tw 1.125 0 Td
[(The recommended starting dose is 1 mg/kg once ever)-17.9 (y 3 weeks by subcutaneous)-9 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.062 Td
[(injection \(2.1,)37.2 ( 2.2\).)]TJ
0.017 Tw -1.125 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(Review hemoglobin \(Hgb\) results prior to each administra)-9.8 (tion \(2.1,)37.2 ( 2.2\).)]TJ
0.017 Tw -1.125 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(See full prescribing informa)-9.8 (tion for prepara)-9.7 (tion and administra)-9.7 (tion instructions \(2.3\).)]TJ
/T1_0 1 Tf
0.017 Tw 34.875 35.455 Td
(--------------------------)Tj
0.048 Tw 9.291 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
-0.206 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.291 -1.604 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(F)20.2 (or injection:)37.2 ( 25 mg lyophilized po)-9.8 (wder in a single-dose vial for reconstitution \(3\))]TJ
0.017 Tw -1.125 -1.334 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(F)20.2 (or injection:)37.2 ( 75 mg lyophilized po)-9.8 (wder in a single-dose vial for reconstitution \(3\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.919 Td
(---------------------------------)Tj
11.731 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
8.025 0 Td
(---------------------------------)Tj
/T1_1 1 Tf
0.048 Tw -19.757 -1.649 Td
(None \(4\).)Tj
/T1_0 1 Tf
0.017 Tw 0 -1.964 Td
(----------------------------)Tj
0.048 Tw 9.871 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.021 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.871 -1.604 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.102 Tw 1.125 0 Td
[(T)0.5 (h)0.5 (ro)0.5 (m)0.5 (b)0.5 (o)0.5 (si)0.5 (s)0.5 (/)0.5 (T)0.5 (hr)0.5 (o)0.5 (m)0.5 (b)0.5 (o)0.5 (e)0.5 (mb)0.5 (o)0.5 (l)0.5 (i)0.5 (sm)0.5 (:)37.5 ( I)0.5 (nc)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 (d r)0.5 (i)0.5 (s)0.5 (k i)0.5 (n)0.5 ( p)0.5 (a)-9.5 (ti)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( be)0.5 (t)0.5 (a)0.5 ( t)0.5 (h)0.5 (al)0.5 (a)0.5 (s)0.5 (s)0.5 (e)0.5 (mi)0.5 (a)0.5 (.)36 ( )]TJ
-0.004 Tc 0.091 Tw 0 -1.064 Td
[(Monitor pa)-10.1 (tients for signs and symptoms of thromboembolic events and institute)-4 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.064 Td
[(trea)-9.7 (tment promptly \(5.1\).)]TJ
0.017 Tw -1.125 -1.334 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.035 Tw 1.125 0 Td
[(Hypertension:)37.2 ( Monitor blood pressure \(BP\) during trea)-9.8 (tment.)37.2 ( Initia)-9.8 (te anti-hypertensive)-17 ( )]TJ
0.024 Tw 0 -1.064 Td
[(trea)-9.7 (tment if necessar)-17.8 (y \(5.2\).)]TJ
0.017 Tw -1.125 -1.334 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.004 Tc 0.087 Tw 1.125 0 Td
[(E)0.5 (x)0.6 (t)0.6 (r)0.5 (a)0.6 (m)0.5 (e)0.6 (d)0.5 (u)0.6 (l)0.5 (l)0.5 (a)0.6 (r)-17.4 (y)0.5 ( H)0.5 (e)0.6 (m)0.5 (a)-9.4 (t)0.6 (o)0.5 (p)0.6 (o)0.5 (i)0.6 (e)0.5 (t)0.6 (i)0.5 (c)0.6 ( \()0.6 (E)0.5 (M)0.5 (H)0.6 (\))0.5 ( M)0.5 (a)0.6 (s)0.5 (s)0.6 (e)0.5 (s)0.6 (:)37.5 ( I)0.5 (n)0.6 (c)0.5 (r)0.6 (e)0.5 (a)0.6 (s)0.5 (e)0.6 (d)0.5 ( r)0.5 (i)0.6 (s)0.5 (k)0.6 ( i)0.6 (n)0.5 ( p)0.5 (a)-9.4 (t)0.5 (i)0.6 (e)0.5 (n)0.6 (t)0.5 (s)0.6 ( w)0.6 (i)0.5 (t)0.6 (h)0.5 ( b)0.5 (e)0.5 (t)0.6 (a)-4 ( )]TJ
-0.017 Tc 0.006 Tw 0 -1.064 Td
[(thalassemia.)37.2 ( Monitor pa)-9.8 (tients for symptoms and signs or complica)-9.8 (tions resulting from)-17 ( )]TJ
-0.012 Tc 0.047 Tw 0 -1.064 Td
[(t)0.5 (he)0.5 ( EM)0.5 (H)0.5 ( m)0.5 (a)0.5 (ss)0.5 (e)0.5 (s.)37.5 ( )36.7 (T)74.5 (re)0.5 (a)-9.5 (t)0.5 ( a)0.5 (c)0.5 (co)0.5 (r)0.5 (d)0.5 (in)0.5 (g)0.5 ( t)0.5 (o c)20.4 (l)0.5 (i)0.5 (ni)0.5 (c)0.5 (al)0.5 ( gu)0.5 (i)0.5 (de)0.5 (l)0.5 (in)0.5 (e)0.5 (s a)0.5 (nd)0.5 ( d)0.5 (i)0.5 (sc)0.5 (o)0.5 (nt)0.5 (i)0.5 (nu)0.5 (e)0.5 ( t)0.5 (r)0.5 (e)0.5 (a)-9.6 (t)0.5 (m)0.5 (e)0.5 (nt)0.5 ( i)0.5 (n)-12 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.064 Td
[(case of serious complica)-9.7 (tions due to EMH masses \(5.3\).)]TJ
0.017 Tw -1.125 -1.334 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.03 Tw 1.125 0 Td
[(Embr)-17.7 (yo-F)24.2 (etal )37.3 (T)74.2 (oxicity:)37.2 ( May cause fetal harm.)37.2 ( )37.2 (Advise females of reproductive potential)-17 ( )]TJ
0.024 Tw 0 -1.064 Td
[(of the potential risk to a fetus and use of effective contraception \(5.\4,)37.2 ( 8.1,)37.2 ( 8.3\).)]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.919 Td
(---------------------------------)Tj
0.048 Tw 11.651 0 Td
(ADVERSE REACTIONS)Tj
0.037 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------------)Tj
/T1_1 1 Tf
-0.014 Tc 0.064 Tw -11.651 -1.649 Td
[(The most common \(>10%\) adverse reactions were fa)-10 (tigue,)36.9 ( headache,)36.9 ( musculoskeletal)-14.1 ( )]TJ
-0.007 Tc 0.099 Tw 0 -1.064 Td
[(pain,)37 ( arthralgia,)37 ( dizziness/vertigo,)37 ( nausea,)37 ( diarrhea,)36.9 ( cough,)37 ( abdominal pain,)37 ( d)-10 (yspnea,)30 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.064 Td
[(COVID-19,)37.2 ( edema peripheral,)37.2 ( hypertension,)37.2 ( and hypersensitivity \(6.1\).)]TJ
/T1_0 1 Tf
0.002 Tc 0.147 Tw 0 -1.424 Td
[(T)73.6 (o report SUSPECTED ADVERSE REACTIONS,)36.6 ( contact Bristol-Myers Squibb at)2.1 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.064 Td
[(1-888-423-5436 or FD)34.2 (A at 1-800-FD)34.3 (A-1088 or www)37.2 (.fda.go)-9.8 (v/medwatch.)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
27.508 0 Td
( )Tj
EMC 
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -27.508 -1.964 Td
(---------------------------)Tj
0.048 Tw 9.838 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
-0.012 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.048 Tw -9.838 -1.649 Td
[(Lacta)-9.8 (tion:)37.2 ( )37.2 (Advise not to breastfeed \(8.2\).)]TJ
/T1_0 1 Tf
-0.024 Tc 0.036 Tw 0 -2.031 Td
[(See 17 for P)53.9 (A)54.9 (TIENT COUNSELING INFORMA)54.9 (TION and FD)33.9 (A-appro)-10.1 (ved P)23.8 (atient Labeling.)]TJ
-0.017 Tc 0.048 Tw 25.371 -1.536 Td
(Revised: 5/2024)Tj
-61.371 -5.782 Td
[(FULL PRESCRIBING INFORMA)55.1 (TION: CONTENTS*)]TJ
0.017 Tw 0 -1.805 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(1.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
(Beta Thalassemia)Tj
0.017 Tw -3.125 -1.387 Td
(1.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
[(Myelod)-9.8 (ysplastic )-36.8 (Syndromes Associa)-9.8 (ted Anemia)]TJ
0.017 Tw -3.125 -1.387 Td
(1.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Myelod)-9.8 (ysplastic Syndromes with Ring Sideroblasts or)-17 ( )]TJ
0 -1.062 Td
[(Myelod)-9.8 (ysplastic)-19.8 (/)-19.8 (Myeloprolifera)-9.8 (tive Neoplasm with Ring Sideroblasts)-17 ( )]TJ
0.011 Tw 0 -1.062 Td
[(and Thromboc)20.2 (ytosis Associa)-9.8 (ted Anemia)]TJ
0.017 Tw -3.125 -1.387 Td
(1.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Limita)-9.8 (tions of Use)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.405 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Recommended Dosa)-9.8 (ge for Beta )37.2 (Thalassemia)]TJ
0.017 Tw -3.125 -1.386 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Recommended Dosa)-9.8 (ge for Myelod)-9.8 (ysplastic Syndromes )37.2 (Associa)-9.8 (ted)-17 ( )]TJ
0.017 Tw 0 -1.062 Td
(Anemia)Tj
-3.125 -1.387 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
[(Prepara)-9.8 (tion )-36.7 (and Administra)-9.8 (tion)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.405 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.017 Tw -3.125 -1.423 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
-3.125 -1.423 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8.0947 61 234.5675 Tm
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Thrombosis)-19.8 (/)-19.8 (Thromboembolism)]TJ
-3.125 -1.383 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Hypertension)Tj
-3.125 -1.383 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Extramedullar)-17.7 (y Hema)-9.7 (topoietic Masses)]TJ
0.017 Tw -3.125 -1.383 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
[(Embr)-17.7 (yo-F)24.2 (etal T)74.2 (oxicity)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 189.7538 Tm
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.017 Tw 8 0 0 8.0947 61 178.4172 Tm
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
[(Clinical T)74.1 (rials )-36.8 (Experience)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 168.1129 Tm
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
/T1_1 1 Tf
0.017 Tw 8 0 0 8.0947 61 156.7763 Tm
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Pregnanc)20.2 (y)]TJ
-3.125 -1.383 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Lacta)-9.8 (tion)]TJ
-3.125 -1.383 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(F)24.2 (emales and Males of Reproductive P)18.2 (otential)]TJ
0.017 Tw -3.125 -1.383 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(P)18.2 (edia)-9.7 (tric Use)]TJ
0.017 Tw -3.125 -1.383 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Geria)-9.7 (tric Use)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324 394.1962 Tm
(9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(DR)-9.8 (UG ABUSE AND DEPENDENCE)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(9.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(Controlled Substance)Tj
0.017 Tw -3.125 -1.387 Td
(9.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Abuse)Tj
/T1_0 1 Tf
-6.25 -1.405 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DESCRIPTION)Tj
-3.125 -1.423 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
[(Mechanism )-36.8 (of Action)]TJ
0.017 Tw -3.125 -1.387 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Pharmacod)-9.8 (ynamics)]TJ
-3.125 -1.387 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Pharmacokinetics)Tj
-3.125 -1.387 Td
(12.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Immunogenicity)Tj
/T1_0 1 Tf
-6.25 -1.405 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Carcinogenesis,)37.2 ( Muta)-9.8 (genesis,)37.2 ( Impairment of F)24.2 (ertility)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.405 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL STUDIES)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.125 0 Td
(Beta Thalassemia)Tj
0.017 Tw -3.125 -1.387 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(T)74.2 (rea)-9.7 (tment of Myelod)-9.8 (ysplastic Syndromes with )37.2 (Associa)-9.8 (ted )37.2 (Anemia)-17 ( )]TJ
0 Tc 0 Tw 23.707 0 Td
( )Tj
-0.017 Tc 0.048 Tw -23.707 -1.062 Td
[(in ESA-na\357ve P)18.2 (a)-9.8 (tients)]TJ
0.017 Tw -3.125 -1.387 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Myelod)-9.8 (ysplastic Syndromes with Ring Sideroblasts or)-17 ( )]TJ
0 -1.062 Td
[(Myelod)-9.8 (ysplastic)-19.8 (/)-19.8 (Myeloprolifera)-9.8 (tive Neoplasm with Ring Sideroblasts)-17 ( )]TJ
0.011 Tw 0 -1.062 Td
[(and Thromboc)20.2 (ytosis Associa)-9.8 (ted Anemia )-36.8 (in )-36.7 (ESA-refractor)-17.8 (y )-36.8 (or)-16.9 ( )]TJ
0 Tc 0 Tw 21.7 0 Td
( )Tj
-0.017 Tc 0.048 Tw -21.7 -1.062 Td
[(-intolerant P)18.3 (a)-9.8 (tients)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.405 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.405 Td
(16.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(Ho)-9.8 (w Supplied)]TJ
0.017 Tw -3.125 -1.387 Td
(16.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Stora)-9.7 (ge)]TJ
/T1_0 1 Tf
-6.25 -1.405 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION)]TJ
/T1_1 1 Tf
-3.125 -2.143 Td
[(*Sections or subsections omitted from the full prescribing informa)-9.8 (tion are not listed.)]TJ
ET
0 0 0 1 K
4 M 
q 1 0 0 1 36 434.994 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 35.28 91.8325 cm
0 0 m
540 0 l
S
Q
endstreamendobj93 0 obj<</CreationDate(D:20240521063933-04'00')/Creator(Adobe InDesign 19.4 \(Macintosh\))/ModDate(D:20240521063934-04'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 94
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000008564 00000 n
0000000000 00000 f
0000336761 00000 n
0000337690 00000 n
0000338805 00000 n
0000339990 00000 n
0000341175 00000 n
0000008814 00000 n
0000010001 00000 n
0000011199 00000 n
0000012386 00000 n
0000008624 00000 n
0000008713 00000 n
0000013574 00000 n
0000014689 00000 n
0000313322 00000 n
0000173674 00000 n
0000061090 00000 n
0000224494 00000 n
0000226034 00000 n
0000225280 00000 n
0000311725 00000 n
0000220540 00000 n
0000283439 00000 n
0000244331 00000 n
0000244443 00000 n
0000187713 00000 n
0000173787 00000 n
0000067082 00000 n
0000067911 00000 n
0000067345 00000 n
0000038872 00000 n
0000015842 00000 n
0000067211 00000 n
0000061201 00000 n
0000039404 00000 n
0000039909 00000 n
0000040162 00000 n
0000040564 00000 n
0000061238 00000 n
0000143792 00000 n
0000143817 00000 n
0000126133 00000 n
0000126158 00000 n
0000095452 00000 n
0000095699 00000 n
0000068470 00000 n
0000068723 00000 n
0000069244 00000 n
0000096241 00000 n
0000126570 00000 n
0000126853 00000 n
0000126922 00000 n
0000127188 00000 n
0000127284 00000 n
0000144415 00000 n
0000144872 00000 n
0000144941 00000 n
0000145201 00000 n
0000145307 00000 n
0000221277 00000 n
0000221788 00000 n
0000222151 00000 n
0000222553 00000 n
0000237583 00000 n
0000237708 00000 n
0000238421 00000 n
0000231314 00000 n
0000231423 00000 n
0000232016 00000 n
0000226493 00000 n
0000226576 00000 n
0000227047 00000 n
0000227588 00000 n
0000232663 00000 n
0000239130 00000 n
0000311892 00000 n
0000311983 00000 n
0000312258 00000 n
0000312567 00000 n
0000480665 00000 n
0000451767 00000 n
0000476938 00000 n
0000427276 00000 n
0000388780 00000 n
0000342360 00000 n
0000477448 00000 n
0000477959 00000 n
0000478322 00000 n
0000478724 00000 n
0000498261 00000 n
trailer<</Size 94/Root 1 0 R/Info 93 0 R/ID[<04FC676DDD624A50A5436AE599D4F8CB><47A78D0DC64B4A9F99CC050E26006DD1>]>>startxref498443%%EOF1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R/DisplayDocTitle true>>>>endobj2 0 obj<</Length 10732/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-05-21T06:39:33-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-05-21T09:43:03-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-05-21T09:43:03-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.4 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:8b038bbb-3970-1342-b4b6-89811632caa9</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:6d344d5b-79aa-4918-a565-1501a7a8fd1f</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:27ecfd10-d87b-45c2-8283-f74195d413a8</stRef:instanceID>
            <stRef:documentID>xmp.did:c7c909c9-c228-44e9-82ad-1781f5cf7544</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.4 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-05-21T06:39:33-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">REBLOZYL U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2162960759</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2162960759</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1117836794</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1117836794</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.010</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj94 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20240521063933-04'00')/Creator(Adobe InDesign 19.4 \(Macintosh\))/ModDate(D:20240521094303-04'00')/Producer(Adobe PDF Library 17.0)/Title(REBLOZYL U.S. Prescribing Information)/Trapped/False>>endobjxref
0 3
0000000000 65535 f
0000500475 00000 n
0000500604 00000 n
94 1
0000511413 00000 n
trailer<</Size 95/Root 1 0 R/Info 94 0 R/ID[<04FC676DDD624A50A5436AE599D4F8CB><484E02C701474FAF9E20876A83BE1B3B>]/Prev 498443>>startxref511669%%EOF